

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 August 2001 (02.08.2001)

PCT

(10) International Publication Number
WO 01/55317 A2

(51) International Patent Classification ⁷ :	C12N	60/226,279	18 August 2000 (18.08.2000)	US	
		60/226,868	22 August 2000 (22.08.2000)	US	
(21) International Application Number:	PCT/US01/01329	60/226,681	22 August 2000 (22.08.2000)	US	
		60/227,182	22 August 2000 (22.08.2000)	US	
(22) International Filing Date:	17 January 2001 (17.01.2001)	60/227,009	23 August 2000 (23.08.2000)	US	
		60/228,924	30 August 2000 (30.08.2000)	US	
(25) Filing Language:	English	60/229,344	1 September 2000 (01.09.2000)	US	
		60/229,345	1 September 2000 (01.09.2000)	US	
(26) Publication Language:	English	60/229,343	1 September 2000 (01.09.2000)	US	
		60/229,287	1 September 2000 (01.09.2000)	US	
		60/229,513	5 September 2000 (05.09.2000)	US	
(30) Priority Data:		60/229,509	5 September 2000 (05.09.2000)	US	
60/179,065	31 January 2000 (31.01.2000)	US	60/230,438	6 September 2000 (06.09.2000)	US
60/180,628	4 February 2000 (04.02.2000)	US	60/230,437	6 September 2000 (06.09.2000)	US
60/184,664	24 February 2000 (24.02.2000)	US	60/231,413	8 September 2000 (08.09.2000)	US
60/186,350	2 March 2000 (02.03.2000)	US	60/231,242	8 September 2000 (08.09.2000)	US
60/189,874	16 March 2000 (16.03.2000)	US	60/231,244	8 September 2000 (08.09.2000)	US
60/190,076	17 March 2000 (17.03.2000)	US	60/231,414	8 September 2000 (08.09.2000)	US
60/198,123	18 April 2000 (18.04.2000)	US	60/232,080	8 September 2000 (08.09.2000)	US
60/205,515	19 May 2000 (19.05.2000)	US	60/232,081	8 September 2000 (08.09.2000)	US
60/209,467	7 June 2000 (07.06.2000)	US	60/231,243	8 September 2000 (08.09.2000)	US
60/214,886	28 June 2000 (28.06.2000)	US	60/231,968	12 September 2000 (12.09.2000)	US
60/215,135	30 June 2000 (30.06.2000)	US	60/232,400	14 September 2000 (14.09.2000)	US
60/216,647	7 July 2000 (07.07.2000)	US	60/232,399	14 September 2000 (14.09.2000)	US
60/216,880	7 July 2000 (07.07.2000)	US	60/232,401	14 September 2000 (14.09.2000)	US
60/217,487	11 July 2000 (11.07.2000)	US	60/232,397	14 September 2000 (14.09.2000)	US
60/217,496	11 July 2000 (11.07.2000)	US	60/233,064	14 September 2000 (14.09.2000)	US
60/218,290	14 July 2000 (14.07.2000)	US	60/233,063	14 September 2000 (14.09.2000)	US
60/220,963	26 July 2000 (26.07.2000)	US	60/233,065	14 September 2000 (14.09.2000)	US
60/220,964	26 July 2000 (26.07.2000)	US	60/232,398	14 September 2000 (14.09.2000)	US
60/225,757	14 August 2000 (14.08.2000)	US	60/234,274	21 September 2000 (21.09.2000)	US
60/225,758	14 August 2000 (14.08.2000)	US	60/234,223	21 September 2000 (21.09.2000)	US
60/225,447	14 August 2000 (14.08.2000)	US	60/234,997	25 September 2000 (25.09.2000)	US
60/225,267	14 August 2000 (14.08.2000)	US	60/234,998	25 September 2000 (25.09.2000)	US
60/224,518	14 August 2000 (14.08.2000)	US	60/235,484	26 September 2000 (26.09.2000)	US
60/225,270	14 August 2000 (14.08.2000)	US	60/235,834	27 September 2000 (27.09.2000)	US
60/224,519	14 August 2000 (14.08.2000)	US	60/235,836	27 September 2000 (27.09.2000)	US
60/225,268	14 August 2000 (14.08.2000)	US	60/236,369	29 September 2000 (29.09.2000)	US
60/225,759	14 August 2000 (14.08.2000)	US	60/236,327	29 September 2000 (29.09.2000)	US
60/225,213	14 August 2000 (14.08.2000)	US	60/236,368	29 September 2000 (29.09.2000)	US
60/225,214	14 August 2000 (14.08.2000)	US	60/236,367	29 September 2000 (29.09.2000)	US
60/225,266	14 August 2000 (14.08.2000)	US	60/236,370	29 September 2000 (29.09.2000)	US

[Continued on next page]

WO 01/55317 A2

(54) Title: NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES

(57) Abstract: The present invention relates to novel testes related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "testicular antigens", and the use of such testicular antigens for detecting disorders of the testes, particularly the presence of testicular cancer and testicular cancer metastases. More specifically, isolated testicular associated nucleic acid molecules are provided encoding novel testes associated polypeptides. Novel testicular polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human testes associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the testes, including testicular cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.



60/237,038	2 October 2000 (02.10.2000)	US	60/251,030	5 December 2000 (05.12.2000)	US
60/237,039	2 October 2000 (02.10.2000)	US	60/251,988	5 December 2000 (05.12.2000)	US
60/237,037	2 October 2000 (02.10.2000)	US	60/256,719	5 December 2000 (05.12.2000)	US
60/236,802	2 October 2000 (02.10.2000)	US	60/251,479	6 December 2000 (06.12.2000)	US
60/237,040	2 October 2000 (02.10.2000)	US	60/251,869	8 December 2000 (08.12.2000)	US
60/239,937	13 October 2000 (13.10.2000)	US	60/251,868	8 December 2000 (08.12.2000)	US
60/239,935	13 October 2000 (13.10.2000)	US	60/251,856	8 December 2000 (08.12.2000)	US
60/241,809	20 October 2000 (20.10.2000)	US	60/251,990	8 December 2000 (08.12.2000)	US
60/241,785	20 October 2000 (20.10.2000)	US	60/251,989	8 December 2000 (08.12.2000)	US
60/240,960	20 October 2000 (20.10.2000)	US	60/254,097	11 December 2000 (11.12.2000)	US
60/241,787	20 October 2000 (20.10.2000)	US	60/259,678	5 January 2001 (05.01.2001)	US
60/241,808	20 October 2000 (20.10.2000)	US			
60/241,221	20 October 2000 (20.10.2000)	US			
60/241,786	20 October 2000 (20.10.2000)	US			
60/241,826	20 October 2000 (20.10.2000)	US			
60/244,617	1 November 2000 (01.11.2000)	US			
60/246,532	8 November 2000 (08.11.2000)	US			
60/246,474	8 November 2000 (08.11.2000)	US			
60/246,475	8 November 2000 (08.11.2000)	US			
60/246,476	8 November 2000 (08.11.2000)	US			
60/246,525	8 November 2000 (08.11.2000)	US			
60/246,528	8 November 2000 (08.11.2000)	US			
60/246,477	8 November 2000 (08.11.2000)	US			
60/246,526	8 November 2000 (08.11.2000)	US			
60/246,613	8 November 2000 (08.11.2000)	US			
60/246,609	8 November 2000 (08.11.2000)	US			
60/246,478	8 November 2000 (08.11.2000)	US			
60/246,524	8 November 2000 (08.11.2000)	US			
60/246,523	8 November 2000 (08.11.2000)	US			
60/246,527	8 November 2000 (08.11.2000)	US			
60/246,611	8 November 2000 (08.11.2000)	US			
60/246,610	8 November 2000 (08.11.2000)	US			
60/249,299	17 November 2000 (17.11.2000)	US			
60/249,216	17 November 2000 (17.11.2000)	US			
60/249,210	17 November 2000 (17.11.2000)	US			
60/249,218	17 November 2000 (17.11.2000)	US			
60/249,245	17 November 2000 (17.11.2000)	US			
60/249,244	17 November 2000 (17.11.2000)	US			
60/249,217	17 November 2000 (17.11.2000)	US			
60/249,208	17 November 2000 (17.11.2000)	US			
60/249,213	17 November 2000 (17.11.2000)	US			
60/249,212	17 November 2000 (17.11.2000)	US			
60/249,207	17 November 2000 (17.11.2000)	US			
60/249,297	17 November 2000 (17.11.2000)	US			
60/249,211	17 November 2000 (17.11.2000)	US			
60/249,215	17 November 2000 (17.11.2000)	US			
60/249,264	17 November 2000 (17.11.2000)	US			
60/249,214	17 November 2000 (17.11.2000)	US			
60/249,209	17 November 2000 (17.11.2000)	US			
60/249,300	17 November 2000 (17.11.2000)	US			
60/249,265	17 November 2000 (17.11.2000)	US			
60/250,391	1 December 2000 (01.12.2000)	US			
60/250,160	1 December 2000 (01.12.2000)	US			

(71) Applicant (for all designated States except US): **HUMAN GENOME SCIENCES, INC.** [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ROSEN, Craig, A.** [US/US]; 22400 Rolling Hill Lane, Laytonsville, MD 20882 (US). **BARASH, Steven, C.** [US/US]; 111 Watkins Pond Blvd. #301, Rockville, MD 20850 (US). **RUBEN, Steven, M.** [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US).

(74) Agents: **HOOVER, Kenley, K.** et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Nucleic Acids, Proteins, and Antibodies

[001] This application refers to a "Sequence Listing" that is provided only on electronic media in computer readable form pursuant to Administrative Instructions Section 801(a)(i). The Sequence Listing forms a part of this description pursuant to Rule 5.2 and Administrative Instructions Sections 801 to 806, and is hereby incorporated in its entirety.

[002] The Sequence Listing is provided as an electronic file (PA120PCT_seqList.txt, 7,005,066 bytes in size, created on January 12, 2001) on four identical compact discs (CD-R), labeled "COPY 1," "COPY 2," "COPY 3," and "CRF." The Sequence Listing complies with Annex C of the Administrative Instructions, and may be viewed, for example, on an IBM-PC machine running the MS-Windows operating system by using the V viewer software, version 2000 (see World Wide Web URL: <http://www.fileviewer.com>).

Field of the Invention

[003] The present invention relates to novel testes related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "testicular antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such testicular polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the male reproductive system, particularly disorders of the testes, including, but not limited to, the presence of testicular cancer and testicular cancer metastases. More specifically, isolated testicular nucleic acid molecules are provided encoding novel testicular polypeptides. Novel testicular polypeptides and antibodies that bind to these polypeptides are provided.

Also provided are vectors, host cells, and recombinant and synthetic methods for producing human testicular polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the testes, including testicular cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

Background of the Invention

[004] The two primary functions of the testes are 1) production of testosterone and 2) production of sperm. Testosterone produced in the testes is released into the blood stream, where it travels to and acts on a wide range of tissues and organs within the male body. Disorders resulting from testosterone deficiency are manifested in the male reproductive system typically by symptoms of hypogonadism, which is the failure to go through puberty. Specifically, erectile function is impaired, as well as libido and sperm production.

[005] Known dysfunctions of sperm production include aspermia (the failure to produce an ejaculate), asthenospermia (the production of an ejaculate in which less than 50% of spermatozoa are motile), azoospermia (the production of an ejaculate devoid of spermatozoa), oligospermia (production of an ejaculate containing less than 20x100 spermatozoa per milliliter of semen), and teratospermia (the production of an ejaculate in which more than 50% of the spermatozoa are of abnormal shape), all of which result in reduced fertility. Improper sperm formation may result from a variety of factors, including congenital defects, genetic abnormalities, injury, and infection. For example, contraction of the mumps virus early in male adolescence can infect the testicles, leading to permanent complications in sperm production.

[006] Sperm formation may also be impaired by disorders of the epididymus, a labyrinthine tube system located in each testis where sperm mature. Common disorders include infections (e.g., *Neisseria gonorrhoea*, *Pseudomonas*,

Enterobacteriaceae, and *Chlamydia trachomatis*), cyst formation or other obstructions, or enlargement of spermatoceles (liquid filled cavities in the epididymus).

[007] During fetal development, the testes mature within the abdominal cavity and descend through the inguinal canal into the scrotum prior to birth. It is well known that the testicles reside in the scrotum because it is cooler than other places within the body cavity, and even minor temperature differences can have a dramatic influence on the ability of the testicle to make sperm. An undescended testicle, sometimes called a cryptorchid testicle, is a fairly common problem in male babies. Typically, testicles undescended at birth will move into the scrotum within the first year of life, however in a small percentage of cases, this migration does not occur. Early correction of this problem is crucial in preserving the fertility of the male, as the testicles begin to lose the ability to make sperm very early in life if they are not properly stored in the scrotum. Additionally, testicles that are undescended have a much higher risk of developing testicular cancer than testicles that descended spontaneously. Testicular cancer is the most common solid tumor in males aged 18 to 35. It typically is extremely aggressive and spreads early. A tumor of the testicle often shows itself by a fast enlargement of the testicle. Bringing the testes into the scrotum will allow for easier and more accurate examination of the testes, hopefully resulting in earlier detection of tumors. Undescended testicles are also associated with a greater risk of hernia.

[008] Disorders of the scrotal pouch commonly involve the small amount of fluid lining the pouch that allows for small movements and cushioning of the testicles. Several causes, such as testicular torsion, trauma, or tumors, may lead to an increase of the amount of liquid, causing the scrotal pouch to bulge. While this condition is harmless, it may cause irritation and discomfort if the bulge becomes too large.

[009] Another harmless, yet irritating disease of the testes is varicocele, a disorder of the small veins that run the blood from the testicle back toward the heart. Small valves are present in these veins to prevent blood from flowing back toward the testicles. Sometimes, these valves malfunction, causing backflow and subsequent enlargement of the small vessel network in the scrotal sac. This gives rise to dull pain and an uncomfortable "bag of worms" feeling around the scrotum. There is currently considerable debate as to whether this phenomenon contributes to decreased fertility.

[010] Thus, the discovery of new human testicular associated polynucleotides, the polypeptides encoded by them, and antibodies that immunospecifically bind these polypeptides, satisfies a need in the art by providing new compositions which are useful in the diagnosis, treatment, prevention and/or prognosis of disorders of the testes, including, but not limited to, cryptorchid testicle, varicocele, azoospermia, testicular cancers, and those described in the "Reproductive System Disorders" section below.

Summary of the Invention

[011] The present invention relates to novel testes related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "testicular antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such testicular polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the male reproductive system, particularly disorders of the testes, including, but not limited to, the presence of testicular cancer and testicular cancer metastases. More specifically, isolated testicular nucleic acid molecules are provided encoding novel testicular polypeptides. Novel testicular polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human testicular polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the testes, including testicular cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

Detailed Description

Tables

[012] Table 1A summarizes some of the polynucleotides encompassed by the invention (including cDNA clones related to the sequences (Clone ID NO:Z), contig sequences (contig identifier (Contig ID:) and contig nucleotide sequence identifier (SEQ ID NO:X)) and further summarizes certain characteristics of these polynucleotides and the polypeptides encoded thereby. The first column provides a unique clone identifier, "Clone ID NO:Z", for a cDNA plasmid related to each testes associated contig sequence disclosed in Table 1A. The second column provides a unique contig identifier, "Contig ID:" for each of the contig sequences disclosed in Table 1A. The third column provides the sequence identifier, "SEQ ID NO:X", for each of the contig polynucleotide sequences disclosed in Table 1A. The fourth column, "ORF (From-To)", provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:X that delineate the preferred open reading frame (ORF) shown in the sequence listing and referenced in Table 1A as SEQ ID NO:Y (column 5). Column 6 lists residues comprising predicted epitopes contained in the polypeptides encoded by each of the preferred ORFs (SEQ ID NO:Y). Identification of potential immunogenic regions was performed according to the method of Jameson and Wolf (CABIOS, 4:181-186 (1988)); specifically, the Genetics Computer Group (GCG) implementation of this algorithm, embodied in the program PEPTIDESTRUCTURE (Wisconsin Package v10.0, Genetics Computer Group (GCG), Madison, Wisc.). This method returns a measure of the probability that a given residue is found on the surface of the protein. Regions where the antigenic index score is greater than 0.9 over at least 6 amino acids are indicated in Table 1A as "Predicted Epitopes." In particular embodiments, testes associated polypeptides of the invention comprise, or alternatively consist of, one, two, three, four, five or more of the predicted epitopes described in Table 1A. It will be appreciated that depending on the analytical criteria used to predict antigenic determinants, the exact address of the determinant may vary slightly. Column 7, "Tissue Distribution" shows the expression profile of tissue, cells, and/or cell line libraries which express the polynucleotides of the invention. The first number in column 7 (preceding the colon), represents the

tissue/cell source identifier code corresponding to the code and description provided in Table 4. Expression of these polynucleotides was not observed in the other tissues and/or cell libraries tested. For those identifier codes in which the first two letters are not "AR", the second number in column 7 (following the colon), represents the number of times a sequence corresponding to the reference polynucleotide sequence (e.g., SEQ ID NO:X) was identified in the tissue/cell source. Those tissue/cell source identifier codes in which the first two letters are "AR" designate information generated using DNA array technology. Utilizing this technology, cDNAs were amplified by PCR and then transferred, in duplicate, onto the array. Gene expression was assayed through hybridization of first strand cDNA probes to the DNA array. cDNA probes were generated from total RNA extracted from a variety of different tissues and cell lines. Probe synthesis was performed in the presence of ^{33}P dCTP, using oligo(dT) to prime reverse transcription. After hybridization, high stringency washing conditions were employed to remove non-specific hybrids from the array. The remaining signal, emanating from each gene target, was measured using a Phosphorimager. Gene expression was reported as Phosphor Stimulating Luminescence (PSL) which reflects the level of phosphor signal generated from the probe hybridized to each of the gene targets represented on the array. A local background signal subtraction was performed before the total signal generated from each array was used to normalize gene expression between the different hybridizations. The value presented after "[array code]:" represents the mean of the duplicate values, following background subtraction and probe normalization. One of skill in the art could routinely use this information to identify normal and/or diseased tissue(s) which show a predominant expression pattern of the corresponding polynucleotide of the invention or to identify polynucleotides which show predominant and/or specific tissue and/or cell expression. Column 8, "Cytologic Band," provides the chromosomal location of polynucleotides corresponding to SEQ ID NO:X. Chromosomal location was determined by finding exact matches to EST and cDNA sequences contained in the NCBI (National Center for Biotechnology Information) UniGene database. Given a presumptive chromosomal location, disease locus association was determined by comparison with the Morbid Map, derived from Online Mendelian Inheritance in Man (Online Mendelian Inheritance in Man,

OMIM™. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD) 2000. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>. If the putative chromosomal location of the Query overlapped with the chromosomal location of a Morbid Map entry, an OMIM identification number is provided in column 9 labeled "OMIM Disease Reference(s)".

A key to the OMIM reference identification numbers is provided in Table 5.

[013] Table 1B summarizes additional polynucleotides encompassed by the invention (including cDNA clones related to the sequences (Clone ID NO:Z), contig sequences (contig identifier (Contig ID:) contig nucleotide sequence identifiers (SEQ ID NO:X)), and genomic sequences (SEQ ID NO:B). The first column provides a unique clone identifier, "Clone ID NO:Z", for a cDNA clone related to each contig sequence. The second column provides the sequence identifier, "SEQ ID NO:X", for each contig sequence. The third column provides a unique contig identifier, "Contig ID:" for each contig sequence. The fourth column, provides a BAC identifier "BAC ID NO:A" for the BAC clone referenced in the corresponding row of the table. The fifth column provides the nucleotide sequence identifier, "SEQ ID NO:B" for a fragment of the BAC clone identified in column four of the corresponding row of the table. The sixth column, "Exon From-To", provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:B which delineate certain polynucleotides of the invention that are also exemplary members of polynucleotide sequences that encode polypeptides of the invention (e.g., polypeptides containing amino acid sequences encoded by the polynucleotide sequences delineated in column six, and fragments and variants thereof).

[014] Table 2 summarizes homology and features of some of the polypeptides of the invention. The first column provides a unique clone identifier, "Clone ID NO:Z", corresponding to a cDNA disclosed in Table 1A. The second column provides the unique contig identifier, "Contig ID:" corresponding to contigs in Table 1A and allowing for correlation with the information in Table 1A. The third column provides the sequence identifier, "SEQ ID NO:X", for the contig polynucleotide sequences. The fourth column provides the analysis method by which the homology/identity disclosed in the row was determined. Comparisons were made between polypeptides

encoded by the polynucleotides of the invention and either a non-redundant protein database (herein referred to as "NR"), or a database of protein families (herein referred to as "PFAM") as further described below. The fifth column provides a description of PFAM/NR hits having significant matches to a polypeptide of the invention. Column six provides the accession number of the PFAM/NR hit disclosed in the fifth column. Column seven, "Score/Percent Identity", provides a quality score or the percent identity, of the hit disclosed in column five. Columns 8 and 9, "NT From" and "NT To" respectively, delineate the polynucleotides in "SEQ ID NO:X" that encode a polypeptide having a significant match to the PFAM/NR database as disclosed in the fifth column. In specific embodiments, polypeptides of the invention comprise, or alternatively consist of, an amino acid sequence encoded by the polynucleotides in SEQ ID NO:X as delineated in columns 8 and 9, or fragments or variants thereof.

[015] Table 3 provides polynucleotide sequences that may be disclaimed according to certain embodiments of the invention. The first column provides a unique clone identifier, "Clone ID NO:Z", for a cDNA clone related to testes associated contig sequences disclosed in Table 1A. The second column provides the sequence identifier, "SEQ ID NO:X", for contig polynucleotide sequences disclosed in Table 1A. The third column provides the unique contig identifier, "Contig ID", for contigs disclosed in Table 1A. The fourth column provides a unique integer 'a' where 'a' is any integer between 1 and the final nucleotide minus 15 of SEQ ID NO:X, represented as "Range of a", and the fifth column provides a unique integer 'b' where 'b' is any integer between 15 and the final nucleotide of SEQ ID NO:X, represented as "Range of b", where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:X, and where b is greater than or equal to a + 14. For each of the polynucleotides shown as SEQ ID NO:X, the uniquely defined integers can be substituted into the general formula of a-b, and used to describe polynucleotides which may be preferably excluded from the invention. In certain embodiments, preferably excluded from the polynucleotides of the invention (including polynucleotide fragments and variants as described herein and diagnostic and/or therapeutic uses based on these polynucleotides) are at least one, two, three, four, five, ten, or more of the polynucleotide sequence(s) having the accession number(s) disclosed in the sixth column of this Table (including for example, published sequence in connection with a

particular BAC clone). In further embodiments, preferably excluded from the invention are the specific polynucleotide sequence(s) contained in the clones corresponding to at least one, two, three, four, five, ten, or more of the available material having the accession numbers identified in the sixth column of this Table (including for example, the actual sequence contained in an identified BAC clone).

[016] Table 4 provides a key to the tissue/cell source identifier code disclosed in Table 1A, column 7. Column 1 provides the key to the tissue/cell source identifier code disclosed in Table 1A, Column 7. Columns 2-5 provide a description of the tissue or cell source. Codes corresponding to diseased tissues are indicated in column 6 with the word "disease". The use of the word "disease" in column 6 is non-limiting. The tissue or cell source may be specific (e.g. a neoplasm), or may be disease-associated (e.g., a tissue sample from a normal portion of a diseased organ). Furthermore, tissues and/or cells lacking the "disease" designation may still be derived from sources directly or indirectly involved in a disease state or disorder, and therefore may have a further utility in that disease state or disorder. In numerous cases where the tissue/cell source is a library, column 7 identifies the vector used to generate the library.

[017] Table 5 provides a key to the OMIM™ reference identification numbers disclosed in Table 1A, column 9. OMIM reference identification numbers (Column 1) were derived from Online Mendelian Inheritance in Man (Online Mendelian Inheritance in Man, OMIM™. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine, (Bethesda, MD) 2000. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>). Column 2 provides diseases associated with the cytologic band disclosed in Table 1A, column 8, as determined from the Morbid Map database.

[018] Table 6 summarizes ATCC Deposits, Deposit dates, and ATCC designation numbers of deposits made with the ATCC in connection with the present application.

[019] Table 7 shows the cDNA libraries sequenced, tissue source description, vector information and ATCC designation numbers relating to these cDNA libraries.

[020] Table 8 provides a physical characterization of clones encompassed by the invention. The first column provides the unique clone identifier, "Clone ID NO:Z", for certain cDNA clones of the invention, as described in Table 1A. The second

column provides the size of the cDNA insert contained in the corresponding cDNA clone.

Definitions

[021] The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

[022] In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide. The term "isolated" does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide sequences of the present invention.

[023] As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence encoding SEQ ID NO:Y or a fragment or variant thereof; a nucleic acid sequence contained in SEQ ID NO:X (as described in column 3 of Table 1A) or the complement thereof; a cDNA sequence contained in Clone ID NO:Z (as described in column 1 of Table 1A and contained within a library deposited with the ATCC); a nucleotide sequence encoding the polypeptide encoded by a nucleotide sequence in SEQ ID NO:B as defined in column 6 of Table 1B or a fragment or variant thereof; or a nucleotide coding sequence in SEQ ID NO:B as defined in column 6 of Table 1B or the complement thereof. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having an amino acid sequence encoded by a polynucleotide of the invention as broadly defined (obviously excluding poly-Phenylalanine or poly-Lysine peptide

sequences which result from translation of a polyA tail of a sequence corresponding to a cDNA).

[024] As used herein, a "testicular antigen" refers collectively to any polynucleotide disclosed herein (e.g., a nucleic acid sequence contained in SEQ ID NO:X or the complement thereof, or cDNA sequence contained in Clone ID NO:Z, or a nucleotide sequence encoding the polypeptide encoded by a nucleotide sequence in SEQ ID NO:B as defined in column 6 of Table 1B, or a nucleotide coding sequence in SEQ ID NO:B as defined in column 6 of Table 1B or the complement thereof and fragments or variants thereof as described herein) or any polypeptide disclosed herein (e.g., an amino acid sequence contained in SEQ ID NO:Y, an amino acid sequence encoded by SEQ ID NO:X, or the complement thereof, an amino acid sequence encoded by the cDNA sequence contained in Clone ID NO:Z, an amino acid sequence encoded by SEQ ID NO:B, or the complement thereof, and fragments or variants thereof as described herein). These testicular antigens have been determined to be predominantly expressed in testicular tissues, including normal or diseased tissues (as shown in Table 1A column 7 and Table 4).

[025] In the present invention, "SEQ ID NO:X" was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X is deposited at Human Genome Sciences, Inc. (HGS) in a catalogued and archived library. As shown, for example, in column 1 of Table 1A, each clone is identified by a cDNA Clone ID (identifier generally referred to herein as Clone ID NO:Z). Each Clone ID is unique to an individual clone and the Clone ID is all the information needed to retrieve a given clone from the HGS library. Furthermore, certain clones disclosed in this application have been deposited with the ATCC on October 5, 2000, having the ATCC designation numbers PTA 2574 and PTA 2575; and on January 5, 2001, having the depositor reference numbers TS-1, TS-2, AC-1, and AC-2. In addition to the individual cDNA clone deposits, most of the cDNA libraries from which the clones were derived were deposited at the American Type Culture Collection (hereinafter "ATCC"). Table 7 provides a list of the deposited cDNA libraries. One can use the Clone ID NO:Z to determine the library source by reference to Tables 6 and 7. Table 7 lists the deposited cDNA libraries by name and links each library to an ATCC

Deposit. Library names contain four characters, for example, "HTWE." The name of a cDNA clone (Clone ID NO:Z) isolated from that library begins with the same four characters, for example "HTWEP07". As mentioned below, Table 1A correlates the Clone ID NO:Z names with SEQ ID NO:X. Thus, starting with an SEQ ID NO:X, one can use Tables 1, 6 and 7 to determine the corresponding Clone ID NO:Z, which library it came from and which ATCC deposit the library is contained in. Furthermore, it is possible to retrieve a given cDNA clone from the source library by techniques known in the art and described elsewhere herein. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposits were made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure.

[026] In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

[027] A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, or the complement thereof (e.g., the complement of any one, two, three, four, or more of the polynucleotide fragments described herein), the polynucleotide sequence delineated in columns 8 and 9 of Table 2 or the complement thereof, and/or cDNA sequences contained in Clone ID NO:Z (e.g., the complement of any one, two, three, four, or more of the polynucleotide fragments, or the cDNA clone within the pool of cDNA clones deposited with the ATCC, described herein) and/or the polynucleotide sequence delineated in column 6 of Table 1B or the complement thereof. "Stringent hybridization conditions" refers to an overnight incubation at 42

degree C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65 degree C.

[028] Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency), salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH₂PO₄; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 µg/ml salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

[029] Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

[030] Of course, a polynucleotide which hybridizes only to polyA⁺ sequences (such as any 3' terminal polyA⁺ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

[031] The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-

stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

[032] The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization,

selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth. Enzymol. 182:626-646 (1990); Rattan et al., Ann. N.Y. Acad. Sci. 663:48-62 (1992).)

[033] "SEQ ID NO:X" refers to a polynucleotide sequence described, for example, in Tables 1 or 2, while "SEQ ID NO:Y" refers to a polypeptide sequence described in column 5 of Table 1A. SEQ ID NO:X is identified by an integer specified in column 3 of Table 1A. The polypeptide sequence SEQ ID NO:Y is a translated open reading frame (ORF) encoded by polynucleotide SEQ ID NO:X. "Clone ID NO:Z" refers to a cDNA clone described in column 1 of Table 1A.

[034] "A polypeptide having biological activity" refers to a polypeptide exhibiting activity similar to, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention).

[035] Table 1A summarizes some of the polynucleotides encompassed by the invention (including contig sequences (SEQ ID NO:X) and clones (Clone ID NO:Z) and further summarizes certain characteristics of these polynucleotides and the polypeptides encoded thereby.

Polynucleotides and Polypeptides

TABLE 1A

Clone ID NO: Z	Contig ID:	SEQ ID NO: X	ORF (From-To)	AA SEQ ID NO: Y	Predicted Epitopes	Tissue Distribution Library code: count (see Table IV for Library Codes)	Cytologic Band	OMIM Disease Reference(s):
H7MDC49	722780	11	125 - 3	995		S0284: 2 and L0758: 1.		
H7MDD72	847688	12	100 - 510	996	Glu-9 to Gly-22, Lys-50 to Lys-69, Gly-91 to Arg-107, Pro-113 to Ile-129, Tyr-131 to Gln-137.	AR054: 6, AR050: 2, AR051: 1, AR089: 1, AR061: 0 S0284: 2		
HCDMB01	887805	985	3 - 824	1969				
HCDMB16	915613	13	3 - 125	997		S0398: 2		
HCDMB60	835781	14	2 - 181	998		S0398: 2		
	726339	15	22 - 120	999	Thr-6 to Leu-12, Tyr-19 to Lys-28.	S0398: 2		
HCDMC01	915239	16	2 - 901	1000	Ser-10 to Gly-23.	L0758: 13, H0253: 4, H0618: 3, H0038: 1, L0779: 1 and S0398: 1.		
HCDMD23	676799	17	2 - 184	1001		S0398: 2		
HEEAD64	741305	18	1 - 159	1002	Glu-21 to Lys-30, Gly-33 to Ser-39.	H0549: 2		
HEEAH07	851219	19	1 - 150	1003	Pro-44 to Phe-50.	H0549: 2		
HEEAJ58	785121	20	246 - 1	1004	Lys-25 to Gly-34, Pro-42 to Trp-57, Lys-71 to Asp-82.	H0549: 2		
HEEAJ76	887321	21	3 - 332	1005		AR054: 10, AR051:		

									9, AR050: 8 H0549: 2			
HEEAK22	673904	22	140 - 253	1006					H0549: 2			
HEEAK84	780838	23	167 - 283	1007					H0549: 2			
HEEAN24	676721	24	1 - 147	1008					H0549: 2			
HEEAS58	735620	25	3 - 278	1009					H0549: 2			
HEEAU79	706935	26	1 - 228	1010					H0549: 2 and L0600: 1.			
HEEAW01	851213	27	55 - 195	1011					H0549: 2			
HEEAW13	656299	28	28 - 168	1012					H0549: 2			
HEGAA24	676716	29	1 - 204	1013					H0550: 2			
HEGAA73	767284	30	150 - 425	1014					H0550: 2			
HEGAB84	823900	31	1 - 351	1015					AR089: 13, AR061: 8 H0618: 2 and H0550: 1.			
HEGAC69	754344	32	281 - 475	1016					H0550: 2 and L0750: 1.			
HEGAK04	887299	33	54 - 305	1017					AR054: 16, AR051: 5, AR050: 3 H0550: 2 and L0749: 1.			
HEGAO83	780837	34	3 - 326	1018					AR089: 9, AR061: 7 H0550: 1 and H0253: 1.			
HEGAP31	697419	35	59 - 319	1019					H0550: 2			

							Arg-69 to Asp-75, Ser-82 to Ser-87.				
HEGAP36	706951	36	117 - 239	1020			Tyr-36 to Thr-41.	H0550: 2			
HEGAY32	699906	37	1 - 195	1021			Leu-22 to Ser-28, Lys-36 to Lys-43, His-56 to Pro-65.	H0550: 2			
HEGAY52	726316	38	1 - 204	1022			His-32 to Trp-37, Pro-39 to Thr-53.	H0550: 2			
HEGAZ61	950033	39	12 - 560	1023			Leu-45 to Lys-50, Gln-55 to Glu-74, Thr-114 to Ile-119.	AR050: 66, AR054: 55, AR051: 37, AR089: 11, AR061: 6 H0549: 1 and H0550: 1.			
HEPAA44	509456	40	91 - 204	1024			Ala-6 to Gln-12.	H0150: 2			
HEPAB70	557149	41	90 - 353	1025			Ser-7 to Asp-20, Thr-30 to Phe-41, Gly-55 to Gly-61.	H0150: 2			
HEPAD09	888726	42	3 - 176	1026			Ala-20 to Gln-36, Pro-38 to Asn-50.	AR050: 154, AR051: 146, AR054: 141 H0150: 3	16q24.3	155555, 155555, 227650, 253000, 602783	
HEPAD40	509002	43	132 - 257	1027				H0150: 2			
HEPAD82	509452	44	3 - 113	1028			Ile-14 to Leu-22.	H0150: 3 and L0763: 1.			
HEPAJ70	586843	45	1 - 75	1029			His-1 to Thr-9.	H0150: 2	9q34.2- q34.3	120215, 120215, 190198	

HEPAK01	518331	46	73 - 309	1030	Asn-1 to Lys-7, Leu-27 to His-32, Arg-34 to Pro-50.	H0150: 2		
HEPAK41	925146	47	284 - 583	1031	Pro-4 to Arg-13, Val-34 to Asp-40.	H0549: 1, H0150: 1, L0761: 1 and L0764: 1.		
HEPAM29	508706	48	2 - 154	1032	Ser-9 to Leu-20, Thr-38 to Thr-44.	H0150: 2		
HEPAN19	508694	49	250 - 360	1033	Leu-13 to Lys-21.	L0758: 3, H0150: 2, L0803: 1 and L0779: 1.		
HEPAP02	926914	50	3 - 167	1034		H0150: 2	2p12	147200, 178640, 216900
HEPAP12	968771	51	105 - 284	1035		H0150: 2		
HEPAS44	884083	52	3 - 260	1036		H0150: 2, L0369: 1 and L0532: 1.		
HEPBA39	919875	53	3 - 518	1037	His-1 to Met-10.	AR061: 44, AR089: 13 H0150: 10, H0549: 5, H0176: 1, L0790: 1 and L0779: 1.		
HEPBB24	508684	54	42 - 179	1038		H0150: 3		
HEPBB60	855597	55	72 - 323	1039		H0150: 4		
HEPBG26	967921	56	4 - 204	1040		H0150: 2		
HEPBG35	508686	57	92 - 229	1041	Asp-15 to Gly-21, Gln-32 to Lys-45.	H0150: 2 and L0717: 1.		
HEPBH28	508673	58	171 - 290	1042	Glu-7 to Gln-12.	H0150: 2, L0809: 1, L0731: 1 and L0758: 1.		
HEPBH38	707524	59	99 - 257	1043		H0150: 2		

HEPBH45	508696	60	193 - 312	1044			H0150: 3		
HEPBO69	888697	61	112 - 216	1045			H0150: 5		
HEPBQ47	713836	62	91 - 291	1046		Pro-4 to Ser-12.	H0150: 2		
HEPBQ69	888693	63	272 - 460	1047		His-25 to Ile-31.	AR050: 7, AR054: 1 H0150: 3		
HEPBS10	968665	64	123 - 296	1048		Ala-1 to Asp-7.	H0150: 2		
HEPBX43	715685	65	2 - 445	1049		Pro-12 to Gly-22.	H0549: 2 and H0150: 2.		
HEPCE25	529343	66	2 - 121	1050			H0150: 2		
HEPCO59	761094	67	19 - 117	1051			H0150: 2		
HEPCT32	947081	68	227 - 685	1052		Ser-20 to Lys-30, Ala-43 to Ser-48, Ser-65 to Thr-72, Thr-112 to Thr-118, Ala-139 to Arg-147.	AR051: 15, AR054: 2, AR050: 0 H0150: 4, H0038: 3, L0758: 3 and L0779: 2.		
HEPCU32	931824	69	448 - 975	1053		Arg-57 to Arg-64, Arg-106 to Arg-116, Gln-128 to Pro-135.	AR051: 9, AR054: 8, AR050: 1, AR061: 0, AR089: 0 H0150: 2, H0270: 1, H0032: 1, H0212: 1 and L0779: 1.		
	946975	986	345 - 872	1970		Arg-57 to Arg-64, Arg-106 to Arg-116, Gln-128 to Pro-135.			
HTEAA54	923070	70	34 - 513	1054		Gln-1 to Met-10, Met-16 to Lys-21, Thr-26 to Met-32.	H0618: 2, H0038: 1 and H0616: 1.		
HTEAB52	537136	71	1 - 315	1055		Pro-53 to Asn-59.	H0038: 3		

HTEAD32	504353	72	50 - 187	1056	Arg-16 to Thr-28.	H0038: 2		
HTEAD95	961232	73	1 - 246	1057	Cys-5 to Ser-11, Pro-13 to Thr-18, His-28 to Arg-33, Arg-40 to Arg-45, Pro-52 to Arg-57, His-66 to Gln-71.	H0038: 3, L0747: 2, H0618: 1, L0665: 1, L0779: 1 and L0758: 1.		
HTEAF07	835805	74	87 - 326	1058		L0758: 6, H0038: 3, H0616: 1, L0659: 1 and L0779: 1.		
	954433	987	330 - 91	1971	Arg-1 to Pro-9.			
HTEAF26	537271	75	238 - 116	1059	Thr-5 to Glu-11.	H0038: 11, L0758: 7, L0753: 2 and H0616: 1.		
HTEAG50	787500	76	199 - 104	1060	Val-6 to Lys-13.	H0038: 1 and H0616: 1.		
HTEAK57	536769	77	423 - 202	1061		H0038: 12, H0616: 6, 10p12- H0593: 1, L0439: 1 and p11.2 L0756: 1.	600964, 602026	
HTEAL28	963538	78	3 - 626	1062	Gln-11 to Lys-24, His-60 to Leu-67, Arg-85 to Ser-92.	H0038: 11, L0758: 7, L0753: 2 and H0616: 1.		
HTEAP91	966113	79	10 - 324	1063	Glu-13 to Trp-29, Thr-31 to Thr-44, Arg-54 to Ser-71.	H0616: 4, L0758: 2 and H0038: 1.		
HTEAR84	783328	80	2 - 130	1064		H0038: 1 and H0616: 1.		
HTEAV43	927010	81	368 - 520	1065	Lys-17 to Lys-26.	L0758: 3, H0616: 2 and H0038: 1.		

HTEAY67	679390	82	280 - 143	1066	Tyr-14 to Ser-19.	L0758: 3, H0038: 2, L0794: 2 and L0779: 1.		
HTEAZ54	793441	83	286 - 501	1067		H0038: 2 and H0616: 1.		
HTEBD35	967959	84	13 - 252	1068	Asn-28 to Cys-34.	H0038: 2		
HTEBD40	779134	85	3 - 152	1069	Pro-44 to Ser-50.	H0038: 2 and H0616: 1.		
HTEBJ78	779265	86	3 - 971	1070	Ser-86 to Thr-97, Gln-104 to Pro-116, Glu-168 to Ser-182, Thr-190 to Ser-198, Glu-208 to Tyr-213, Ser-230 to Val-237.	H0038: 7, H0253: 1, H0616: 1 and L0151: 1.		
HTEBS30	693377	87	185 - 334	1071	Ser-39 to Val-49.	H0038: 2 and H0616: 2.		
HTEBS77	953904	88	106 - 552	1072	Lys-1 to Asn-14.	H0038: 1 and H0616: 1.		
HTEBS80	854052	89	201 - 359	1073	Lys-24 to Val-32.	H0038: 2, H0040: 2 and L0758: 1.		
HTEBX62	508150	90	250 - 417	1074		H0038: 2		
HTEBY08	960427	91	3 - 356	1075	Ile-11 to Trp-17, Arg-52 to Glu-65.	AR061: 1, AR089: 0 H0038: 4		
HTEBY15	526281	92	1 - 231	1076	Lys-66 to Thr-72.	H0038: 2		
HTEBY28	923026	93	1 - 546	1077	Arg-1 to Phe-12, Met-34 to Lys-39, Lys-46 to Ser-56, Pro-72 to Lys-79, Lys-101 to Asp-107,	H0616: 3 and H0038: 2.		

HTEBY41	711523	94	106 - 243	1078	Trp-139 to Lys-148.	H0038: 2 and H0616: 1.		
HTEBY61	967340	95	1 - 435	1079	Glu-9 to Arg-24, Arg-32 to Thr-40.	H0253: 1, H0038: 1 and L0758: 1.		
HTEBZ21	958381	96	2 - 121	1080		H0038: 2 and H0616: 1.		
HTECA13	507053	97	1 - 204	1081	His-27 to Leu-39.	H0038: 4 and H0616: 1.		
HTECA16	764416	98	111 - 389	1082	Glu-8 to Lys-17.	H0038: 2 and L0779: 1.		
HTECA21	911369	99	1 - 387	1083	Asn-1 to His-6, Arg-117 to Cys-126.	AR061: 596, AR089: 427 H0038: 2, H0616: 1 and L0439: 1.		
HTECA32	947605	100	792 - 406	1084		AR061: 49, AR089: 45 H0038: 2		
HTECA51	708860	101	96 - 248	1085		H0038: 2, L0748: 2, L0749: 2, L0769: 1, L0776: 1, L0659: 1 and L0663: 1.		
HTECA83	870692	102	3 - 311	1086	Arg-22 to Tyr-28, Ser-78 to Arg-87.	H0038: 2		
HTECB21	921070	103	32 - 271	1087	Tyr-1 to Arg-6, Ile-49 to Val-55.	H0038: 3		
HTECC13	971673	104	61 - 270	1088		H0253: 1 and H0038: 1.		

HTECC20	963353	105	763 - 1005	1089	Arg-1 to Arg-11, Arg-55 to Ser-70, Ser-76 to Gly-81.	H0038: 2 and H0616: 2.		
HTECC37	508143	106	1 - 147	1090		H0038: 1 and H0616: 1.		
HTECC38	844558	107	203 - 463	1091	Arg-15 to Leu-21, Ala-29 to Glu-34.	H0038: 4, H0616: 3, L0758: 3 and L0779: 1.		
HTECC66	790937	108	84 - 287	1092	Asn-9 to Asn-16, Asp-60 to Lys-68.	H0038: 2 and H0616: 1.		
HTECC80	796820	109	37 - 459	1093	Gln-18 to Trp-29, Arg-46 to Val-52.	H0038: 2 and H0616: 1.		
HTECC85	508138	110	1 - 297	1094	Ala-10 to Thr-17, Glu-19 to Glu-28, Thr-36 to Trp-44, Ile-47 to Gly-54, Ala-61 to Pro-69.	H0038: 2		
HTECC96	959874	111	138 - 491	1095	Pro-6 to Cys-11, Pro-77 to His-92.	H0038: 2		
HTECD17	508108	112	154 - 411	1096		H0038: 2		
HTECD18	973163	113	2 - 508	1097	Arg-1 to Ala-35, Gly-41 to Lys-61.	H0616: 14, H0038: 12, H0618: 6, H0253: 5, L0758: 5, L0768: 4, H0411: 2, L0779: 2, L0151: 1, L0697: 1 and S0398: 1.		
HTECD36	518124	114	1 - 141	1098	Val-9 to His-36.	H0038: 2		
HTECD62	527207	115	3 - 161	1099	His-8 to Arg-15, Lys-19 to Lys-36.	H0038: 2, L0794: 2, L0779: 2, H0616: 1 and L0758: 1.		

HTECD75	727422	116	3 - 275	1100	Gly-2 to Ala-8, Pro-10 to Thr-18, Pro-23 to Ser-34, Pro-45 to Asp-55.	H0616: 4, H0038: 2 and L0758: 1.		
HTECE09	620494	117	2 - 286	1101	Ile-1 to Gly-9.	H0038: 2		
HTECE44	764830	118	2 - 286	1102	Ser-29 to Gly-35, Asp-85 to Val-92.	H0038: 8, L0758: 5, L0794: 4, H0616: 2, L0763: 1 and L0777: 1.		
HTECE45	790894	119	2 - 352	1103		L0766: 2, H0038: 1 and H0616: 1.		
HTECE69	522983	120	2 - 253	1104	Ile-1 to Arg-13, Glu-25 to Leu-31.	H0038: 2		
HTECE91	522984	121	3 - 296	1105		H0038: 2		
HTEDF13	522964	122	123 - 257	1106	Glu-1 to Thr-6, Glu-30 to Met-43.	H0038: 2		
HTEDF23	522966	123	3 - 164	1107	Gly-2 to Arg-19, Arg-24 to Gly-29, Lys-48 to Arg-54.	H0038: 2		
HTEDF57	964734	124	2 - 418	1108	Asn-37 to Val-42, Lys-82 to Glu-95, Glu-100 to Leu-105, Tyr-114 to Ser-120, Leu-129 to Lys-134.	H0616: 2 and H0038: 1.		
HTEDF76	522973	125	141 - 329	1109		H0038: 2		
HTEDG16	925527	126	1 - 423	1110	Gln-61 to Cys-76, Ile-95 to Asp-111.	H0038: 2		
HTEDG34	761752	127	169 - 324	1111		H0616: 2 and H0038: 1.		

HTEDH21	522764	128	3 - 170	1112	Arg-1 to Glu-9, Thr-42 to Arg-49.	H0038: 3		
HTEDH22	522765	129	33 - 206	1113		H0038: 2, H0616: 2, L0769: 1, L0794: 1, L0779: 1 and L0758: 1.		
HTEDH54	957762	130	1 - 411	1114	Asn-1 to Ser-14, Glu-103 to Gly-108.	H0038: 1 and H0616: 1.		
HTEDI02	921243	131	121 - 705	1115	Glu-7 to Lys-13, Asp-29 to Leu-34, His-83 to Pro-91, Ser-106 to Thr-111.	AR061: 14, AR089: 12 H0618: 2, H0634: 2, H0038: 1, H0616: 1 and L0758: 1.		
HTEDI16	932292	132	65 - 544	1116	Lys-18 to Arg-24, Pro-30 to Thr-35.	H0038: 2, H0616: 2, L0740: 1 and L0758: 1.		
HTEDI82	536477	133	274 - 549	1117	Pro-20 to Thr-29.	H0038: 3		
HTEDJ04	519940	134	43 - 165	1118		H0038: 2		
HTEDM08	960303	135	3 - 257	1119	Pro-31 to Ala-40.	H0038: 2 and H0616: 1. 8p12-pl1.2	136350, 152760, 173370, 180100, 182900, 185430, 270800, 277700, 600617	
HTEDO31	870711	136	101 - 271	1120	Pro-1 to Trp-9, Pro-25 to Lys-31.	H0038: 2		
HTEDO51	530592	137	3 - 164	1121	Arg-8 to Ser-20.	H0038: 2		
HTEDP15	870675	138	1 - 321	1122		H0038: 4		

HTEDP31	870548	139	68 - 337	1123		H0038: 1 and H0616: 1.		
HTEDP32	839532	140	152 - 322	1124	Ser-9 to Ala-15.	H0038: 2		
HTEDP83	536821	141	1 - 345	1125		H0038: 2		
HTEDQ30	530589	142	3 - 206	1126		AR061: 7, AR089: 3 L0758: 4, H0038: 2 and H0616: 1.		
HTEDQ72	795332	143	53 - 475	1127	Pro-11 to Cys-28, Ser-41 to Leu-55, Pro-58 to Asn-63, Phe-67 to Ser-77.	H0616: 2, H0038: 1 and L0758: 1.		
HTEDQ83	530586	144	318 - 494	1128		H0038: 2		
HTEDR71	761585	145	88 - 171	1129		L0070: 2, H0038: 1 and H0616: 1.		
HTEDR91	530451	146	53 - 238	1130	Ala-25 to Thr-32, Lys-46 to Gly-52.	H0038: 2		
HTEDU45	870708	147	137 - 706	1131	Ile-2 to Gly-8.	L0731: 6, L0758: 3, H0618: 1, H0038: 1 and L0794: 1.		
HTEDU48	932315	148	2 - 730	1132	Lys-16 to Ser-22.	H0038: 2 and H0616: 2.		
HTEDV02	921114	149	3 - 164	1133		H0038: 2		
HTEDX22	523959	150	324 - 566	1134	Phe-37 to Ser-49.	H0038: 3, L0438: 2, H0616: 1 and L0439: 1.		
HTEDX55	530452	151	172 - 357	1135	Arg-1 to Asn-13, Met-37 to Pro-47.	H0038: 2		
HTEDY38	771505	152	3 - 140	1136	Lys-28 to Lys-41.	H0616: 2 and H0038: 1.		

HTEDY54	922964	153	151 - 762	1137	Asp-67 to Asn-72, Pro-113 to Gly-121.	H0616: 3, L0759: 3, H0038: 1, L0774: 1 and L0777: 1.		
HTEDY57	530580	154	189 - 326	1138	Glu-11 to Gln-18.	H0038: 2		
HTEEB18	523962	155	271 - 549	1139	Gln-9 to Asn-26.	H0038: 2 and L0779: 1.		
HTEEB33	924818	156	100 - 615	1140	His-19 to Lys-55, Pro-72 to Ser-84, Ser-92 to Gly-104, Ser-111 to Asp-124, Thr-129 to His-141.	H0038: 5 and H0618: 1.		
HTEEC10	968517	157	1 - 216	1141	Ser-1 to Gly-14, Lys-28 to Ser-37.	H0038: 2 and H0616: 1.		
HTEEE65	530157	158	202 - 384	1142		H0038: 2, L0758: 2 and L0779: 1.		
HTEEF31	924840	159	88 - 345	1143	Pro-5 to Gln-13, Thr-40 to Arg-45, Thr-52 to Gln-57, Phe-59 to Gly-64.	H0038: 2		
HTEEH31	507814	160	72 - 215	1144	Glu-9 to Val-15, Glu-24 to Pro-30.	H0038: 3		
HTEEU23	524059	161	2 - 328	1145	Pro-8 to Leu-13.	H0038: 2		
HTEEU52	530199	162	128 - 343	1146	Pro-32 to Asp-39, Lys-57 to Gly-65.	H0038: 1 and H0616: 1.		
HTEEU88	698315	163	106 - 240	1147	Ser-1 to Ser-8, Ser-11 to Trp-19.	H0038: 3		
HTEEU92	960127	164	136 - 393	1148	Asn-2 to Lys-8, Lys-16 to Asp-23,	H0038: 2 and L0779: 1.		

HTEEV53	523957	165	48 - 311	1149	Arg-28 to His-51.			
HTEEW73	917206	166	55 - 507	1150	Pro-24 to Ala-38.	H0038: 2		
HTEEZ95	530095	167	1 - 147	1151		H0038: 4, L0779: 2, L0758: 2 and L0618: 1.		
HTEFJ53	935982	168	103 - 222	1152		H0038: 2		
HTEFM31	771355	169	298 - 429	1153		H0616: 2 and H0038: 1.		
HTEFN15	959854	170	266 - 493	1154		H0038: 2 and H0616: 1.		
HTEFO32	529272	171	150 - 73	1155	Phe-3 to Val-24.	H0038: 2		
HTEFO76	770270	172	240 - 416	1156		H0038: 1 and H0616: 1.		
HTEFP14	659369	173	3 - 260	1157		H0038: 4 and H0616: 1.		
HTEFP50	507219	174	124 - 321	1158	Met-41 to Ile-46.	L0776: 3 and H0038: 2.		
HTEFP61	711399	175	119 - 352	1159	Arg-1 to Gln-22.	H0038: 3		
HTEFS60	836010	176	1 - 168	1160		H0038: 1 and H0616: 1.		
HTEFU46	920604	177	118 - 195	1161		H0038: 2		
HTEFW55	787550	178	273 - 662	1162		H0616: 4 and H0038: 1.		
HTEFW56	528019	179	35 - 358	1163	Arg-1 to Asp-7, Trp-24 to Cys-29, Ser-68 to Ile-73.	H0038: 2 and H0616: 1.		
HTEFW78	961061	180	1 - 279	1164	Arg-3 to Leu-10, Gln-34 to Glu-41,	H0038: 1 and H0616: 1.		

HTEFX53	842047	181	268 - 35	1165	Ile-48 to Ser-53.			
HTEGA13	656077	182	2 - 139	1166	Lys-1 to Thr-6.	H0038: 3		
HTEGA17	964198	183	2 - 1519	1167	Val-11 to Ser-19.	H0038: 3	2q37.3	
HTEGA43	715583	184	190 - 306	1168	Lys-7 to Tyr-19.	H0038: 15, L0758: 5, H0618: 1, H0253: 1, L0151: 1 and L0768: 1.		
HTEGA47	503300	185	2 - 298	1169	Lys-6 to Lys-16, Arg-44 to Gln-51, Asn-57 to Phe-63, Ser-84 to Trp-89.	H0038: 2		
HTEGD11	967698	186	190 - 468	1170	Gln-6 to Ser-11, Ser-15 to Gly-31, Ser-69 to Lys-93.	H0038: 2, L0779: 2 and L0758: 2.		
HTEGE44	528017	187	2 - 334	1171	Asn-1 to Pro-9.	H0038: 1 and H0616: 1.		
HTEGF78	614242	188	210 - 407	1172	Thr-1 to Ala-7.	H0038: 2		
HTEGF95	796660	189	76 - 267	1173	Glu-25 to Trp-31, Lys-49 to Ser-54.	H0038: 1 and H0616: 1.		
HTEGG07	954115	190	144 - 335	1174		H0038: 2		
HTEGG61	528007	191	2 - 217	1175		H0038: 2		
HTEGK51	520046	192	3 - 143	1176	Pro-13 to Lys-25.	H0038: 2		
HTEGM38	675087	193	84 - 263	1177	Ala-15 to Tyr-24, His-32 to Asp-39.	AR089: 1, AR061: 0 H0038: 2	11q25	602782
HTEGN63	520037	194	1 - 183	1178	Asn-38 to Glu-47.	H0038: 2		
HTEGO05	932583	195	3 - 884	1179	Pro-12 to Tyr-21.	AR089: 1, AR061: 0 H0038: 2, L0745: 2 and H0616: 1.		
HTEGQ21	923059	196	134 - 433	1180	Lys-28 to Lys-34,	L0794: 15, H0616: 13,		

					Glu-42 to Ser-48, Ser-53 to Phe-63.	H0038: 7, H0253: 1 and L0758: 1.		
HTEGQ74	573865	197	2 - 187	1181	Val-3 to Ser-8, Cys-35 to Lys-45.	H0038: 2		
HTEGR56	959871	198	23 - 196	1182	Glu-8 to Ile-22.	H0038: 2		
HTEGR88	871611	199	160 - 402	1183		H0038: 3		
HTEGS16	527914	200	131 - 352	1184		H0038: 2		
HTEGS93	506653	201	155 - 355	1185		H0038: 2		
HTEGT29	870638	202	200 - 367	1186	Arg-1 to Thr-11.	H0038: 3 and L0758: 1.		
HTEGT33	716783	203	170 - 463	1187		H0038: 2 and L0758: 2.		
HTEGU13	520041	204	2 - 205	1188	Ala-1 to Tyr-14, Thr-28 to Ser-60.	H0038: 3 and H0616: 1.		
HTEGU32	524053	205	39 - 506	1189	Asn-44 to Asp-49, Ala-91 to Thr-97.	H0253: 8, H0038: 2, H0179: 1, L0151: 1 and L0758: 1.		
HTEGU62	573885	206	3 - 98	1190		H0038: 2 and H0616: 1.		
HTEGU93	764831	207	194 - 595	1191		H0038: 8, L0758: 5, L0794: 4, H0616: 2, L0763: 1 and L0777: 1.		
HTEGV08	959888	208	220 - 399	1192	Thr-14 to Gln-20, Cys-23 to Glu-31.	H0038: 2		
HTEGV60	822954	209	80 - 418	1193	Tyr-12 to Phe-17, Pro-32 to Asp-39.	H0038: 1 and H0616: 1.		
HTEGV84	870240	210	234 - 449	1194		L0758: 8, H0038: 3, H0618: 2, H0616: 2		

HTEGW41	573880	211	1 - 243	1195	Ser-24 to Gln-30, Asn-38 to Leu-44, Pro-46 to Glu-59.	and H0253: 1. H0038: 2	20q13.2- q13.3	118504, 118504, 131242, 139320, 139320, 139320, 139320, 139320, 602025, 602235
HTEGW94	794350	212	1 - 351	1196	Gly-1 to Ile-7, Pro-76 to Ala-82, Asn-86 to Ile-91.	H0038: 3 and H0616: 2.		
HTEGX74	783829	213	200 - 556	1197	Asn-1 to Asp-9, Pro-17 to Cys-23.	L0758: 5, H0038: 3, H0618: 1, H0616: 1, L0768: 1 and L0794: 1.		
HTEGY01	917214	214	2 - 388	1198	Arg-87 to Tyr-92.	H0038: 1 and H0616: 1.		
HTEGY85	573849	215	91 - 312	1199		H0038: 2		
HTEHB07	870707	216	90 - 350	1200	Gly-23 to Lys-29.	H0038: 5		
HTEHC20	526704	217	198 - 326	1201		H0038: 3		
HTEHC47	973071	218	719 - 84	1202	Ser-32 to Thr-37, Ser-161 to Cys-167.	AR050: 13, AR051: 13, AR061: 3, AR054: 1, AR089: 1 L0758: 5, H0616: 2 and H0038: 1.		
HTEHC60	965998	219	74 - 358	1203	Thr-44 to Ala-49, Pro-60 to Arg-67, Asp-83 to Lys-95.	H0616: 3 and H0038: 2.		

HTEHC78	573882	220	2 - 256	1204	Ala-1 to Leu-9, Thr-11 to Gly-19, Arg-31 to Thr-39, Gln-44 to Ser-58. Glu-57 to Pro-63.	H0038: 2		
HTEHE60	795264	221	2 - 223	1205		H0038: 1 and H0616: 1.		
HTEHE67	784926	222	143 - 652	1206	Ala-2 to Asn-7, Glu-47 to Ile-62, Pro-71 to Trp-81, Gly-83 to Glu-88.	H0616: 2, H0038: 1 and L0794: 1.		
HTEHE78	932312	223	194 - 301	1207	Ser-1 to Arg-6, Gly-16 to Glu-26.	H0038: 3 and L0519: 1.		
HTEHE91	790342	224	3 - 329	1208	Gln-1 to Asp-17, Ser-51 to Arg-63, Pro-70 to Asp-78, Val-86 to Asn-93, Pro-100 to Asp-105.	H0038: 2		
HTEHF13	667224	225	201 - 332	1209		H0038: 2 and H0616: 1.		
HTEHF66	836999	226	2 - 436	1210	Ala-1 to Tyr-6, Ala-88 to Asp-95.	H0038: 4		
HTEHG44	933624	227	57 - 695	1211		H0618: 1, L0023: 1, H0038: 1, H0616: 1 and L0758: 1.		
HTEHI06	935984	228	262 - 534	1212	His-16 to Ser-22, Ala-77 to Glu-83.	L0758: 3, H0038: 2 and L0747: 1.		
HTEHI14	526687	229	216 - 458	1213		AR089: 5, AR061: 5 H0038: 4		
HTEHI54	533960	230	3 - 350	1214	Arg-1 to Gly-9,	H0038: 2		

НТЕНН62	922559	231	1 - 282	1215	Pro-50 to Ala-56.	H0038: 2 and H0616: 1.		
НТЕНН93	870629	232	1 - 330	1216	Lys-9 to Pro-14.	H0038: 3		
НТЕНН64	530749	233	136 - 249	1217		H0038: 2		
НТЕНН40	660875	234	2 - 301	1218	Thr-16 to Met-39.	H0038: 4		
НТЕНН70	771432	235	2 - 274	1219		H0038: 2		
НТЕНН81	573866	236	73 - 231	1220	Gln-2 to Leu-8, Asp-42 to Gly-47.	H0038: 2		
НТЕНН96	573859	237	3 - 404	1221	Glu-17 to Trp-27, Leu-29 to Phe-34, Leu-56 to Arg-61, Asn-74 to Gly-83.	H0038: 2		
НТЕНН02	920625	238	66 - 215	1222	Glu-13 to Pro-27, Leu-30 to Arg-37.	H0038: 2 and H0616: 2.		
НТЕНН20	967443	239	37 - 285	1223	Lys-5 to Glu-14, Arg-53 to Lys-60, Met-77 to Gln-83.	L0758: 3, H0038: 2, H0616: 2 and L0794: 1.		
НТЕНН50	531505	240	7 - 126	1224	Arg-2 to Arg-17.	H0038: 3		
НТЕНН60	573853	241	210 - 434	1225	Glu-18 to Ser-26.	H0038: 2		
НТЕНН67	751866	242	1 - 135	1226		H0616: 2, H0038: 1 and L0758: 1.		
НТЕНН80	573830	243	3 - 320	1227	His-1 to Ser-8, Asp-15 to Gln-50, Val-54 to Ser-67, Glu-76 to Lys-86, Ala-90 to Arg-105.	H0038: 2		
НТЕНН83	573841	244	3 - 197	1228	Phe-43 to Glu-49.	H0038: 2		

HTEHS19	529280	245	1 - 237	1229	Gly-70 to Gly-75.	AR061: 5, AR089: 2 H0038: 2		
HTEHU20	573813	246	61 - 234	1230		H0038: 2, H0616: 2 and L0758: 2.		
HTEHU68	786378	247	109 - 294	1231	Lys-1 to Arg-6, Glu-23 to Arg-29.	H0038: 1 and H0616: 1.		
HTEHU73	870083	248	76 - 276	1232		H0038: 2		
HTEHV86	785652	249	2 - 466	1233	Ala-1 to Gly-8, Ser-52 to Lys-58, Leu-81 to Asn-86.	H0038: 1 and H0616: 1.		
HTEHW03	924832	250	181 - 453	1234		H0038: 2		
HTEHW21	760552	251	2 - 163	1235		H0038: 3, L0740: 2 and L0748: 1.		
HTEHX03	924826	252	15 - 410	1236	Pro-4 to Lys-14, Thr-17 to His-22, Glu-25 to Arg-49, Pro-78 to Gly-85, Pro-120 to Phe-126.	H0616: 3, H0038: 2 and L0758: 1.		
HTEHX32	772643	253	3 - 215	1237	Arg-19 to Asn-24, Gly-30 to Gln-47.	L0758: 5, H0616: 3, H0038: 2, L0794: 2 and H0253: 1.		
HTEHX51	668553	254	84 - 212	1238		H0038: 2		
HTEHX92	527167	255	17 - 292	1239		H0038: 3		
HTEIA60	859130	256	2 - 343	1240		H0618: 2, H0038: 1 and L0783: 1.	16q24.1	256850
HTEIA80	721831	257	10 - 225	1241		H0038: 3		
HTEIF40	958355	258	173 - 457	1242	His-16 to Ser-21, Ser-33 to Gly-60,	H0038: 4 and H0616: 4.		

HTEIF68	573828	259	139 - 249	1243	Asp-87 to Glu-95.				
HTEIG32	699470	260	135 - 326	1244	Ser-5 to Ile-17.			H0038: 2	
HTEIH70	573826	261	58 - 192	1245	Leu-41 to Arg-55.			H0038: 3	
HTEIJ17	520113	262	3 - 311	1246				H0038: 2	
					Thr-65 to Thr-71, Arg-92 to Glu-99.			H0038: 3 and H0616: 1.	
HTEIJ41	712520	263	1 - 186	1247	Ser-7 to Ile-13, Arg-21 to His-26, Met-33 to Ser-49.			H0038: 1, H0616: 1 and L0731: 1.	
HTEIJ73	958241	264	40 - 255	1248	Pro-38 to Gln-54.			H0038: 1 and H0616: 1.	
HTEIJ77	772402	265	1 - 69	1249				H0038: 1 and H0616: 1.	
HTEIK70	530454	266	2 - 121	1250	Thr-24 to Thr-39.			H0038: 2	
HTEIK90	789121	267	104 - 292	1251	Thr-41 to Lys-46, Arg-57 to Trp-62.			H0038: 1 and H0616: 1.	
HTEIL07	953803	268	42 - 443	1252	Glu-13 to Thr-27.			AR061: 1, AR089: 0 L0758: 4, L0617: 2, L0794: 2, H0253: 1, H0038: 1, H0616: 1, L0789: 1 and L0779: 1.	
HTEIL48	523681	269	83 - 271	1253				H0038: 3	
HTEIL70	520045	270	2 - 331	1254	Lys-15 to Lys-29, Lys-36 to Thr-42, Val-48 to Thr-55, Gln-61 to Glu-80.			H0038: 2	
HTEIL71	760551	271	1 - 246	1255	Gly-1 to Gly-6, Leu-28 to Asn-33.			H0616: 2 and H0038: 1.	

HTEIN68	753210	272	74 - 346	1256	Gly-1 to Gly-6, Pro-12 to Pro-17, Arg-27 to Pro-40.	H0038: 2		
HTEIN95	839884	273	159 - 545	1257	Asn-28 to Asn-33.	H0038: 1 and H0616: 1.		
HTEIO02	920622	274	3 - 347	1258	His-1 to Arg-11.	H0038: 2 and H0616: 1.		
HTEIO12	653244	275	152 - 334	1259	Phe-27 to Glu-39.	H0038: 3		
HTEIO28	573803	276	159 - 356	1260		H0038: 2		
HTEIP88	941155	277	1 - 252	1261	Met-23 to Thr-30.	AR089: 1, AR061: 0 H0038: 2 and H0253: 1.		
HTEIP92	523892	278	194 - 370	1262		H0038: 4		
HTEIQ74	765794	279	232 - 462	1263	Lys-1 to Trp-10.	H0038: 1 and H0616: 1.		
HTEIR33	928058	280	41 - 472	1264	Arg-24 to Glu-38, Arg-46 to Ser-52, Pro-74 to Glu-80, Pro-118 to Ser-126.	H0616: 5, H0038: 2 and H0253: 1.		
HTEIS65	573775	281	300 - 458	1265	Glu-15 to Lys-29.	H0038: 2		
HTEIU75	779163	282	305 - 547	1266		H0038: 1 and H0616: 1.		
HTEIU92	870652	283	1 - 339	1267	Asp-5 to Arg-13, Thr-37 to Ser-45.	AR061: 3, AR089: 1 H0038: 3		
HTEIV54	922027	284	2 - 712	1268	Ala-1 to Arg-9, Thr-14 to Trp-20, Arg-46 to His-53, Pro-58 to Glu-67.	H0616: 8, L0751: 6, L0753: 6, L0776: 4, L0758: 4, H0038: 3, L0759: 2, S0222: 1,		

HTEIV86	784657	285	1 - 231	1269	Tyr-80 to Pro-86, Ile-151 to Pro-160.	L0770: 1, L0779: 1, L0731: 1 and L0608: 1.		
HTEIW27	829698	286	124 - 423	1270	Arg-16 to Ser-23, Cys-30 to Arg-35, Arg-51 to Arg-57, Gly-62 to Thr-68.	L0779: 2, H0038: 1 and H0616: 1.		
HTEIW37	573891	287	68 - 352	1271		H0038: 6 and H0616: 1.		
HTEIX85	864251	288	2 - 226	1272		H0038: 2		
HTEIY52	963536	289	58 - 216	1273	Gly-43 to Ser-48.	H0038: 1 and H0616: 1.		
HTEIY69	577783	290	2 - 355	1274	Pro-7 to Pro-20, Pro-33 to Leu-49.	H0038: 2		
HTEIY80	955242	291	188 - 460	1275	Thr-7 to Glu-16, Lys-24 to Asp-34, Thr-40 to Glu-48, Leu-52 to Lys-57.	H0038: 3 and L0758: 1.		
HTEIZ76	523764	292	144 - 386	1276	Leu-5 to Gly-13.	H0038: 3, H0616: 1 and L0758: 1.		
HTEJB20	528015	293	115 - 348	1277		H0038: 2		
HTEJB25	530590	294	216 - 377	1278		H0038: 2		
HTEJB81	870644	295	3 - 269	1279	Gly-47 to Ile-53.	H0038: 2		
HTEJC28	573774	296	167 - 304	1280	Trp-14 to Glu-21, Gly-29 to Arg-36.	H0038: 2 and H0616: 1.		
HTEJC95	772989	297	156 - 377	1281		H0616: 2 and H0038: 1.		
HTEJE15	908360	298	2 - 319	1282		AR061: 4, AR089: 1		

HTEJE50	520049	299	2 - 424	1283	Lys-9 to Lys-23, Lys-30 to Lys-35.	L0758: 7, L0794: 4, H0038: 2 and L0791: 1. H0038: 2		
HTEJF45	942476	300	122 - 643	1284	Ser-11 to Ala-19, Glu-24 to Leu-33, Pro-37 to Pro-45.	AR089: 21, AR061: 15 H0038: 2 H0038: 2		
HTEJG24	526278	301	79 - 276	1285		H0038: 2		
HTEJJ43	774243	302	148 - 384	1286		H0038: 2 and H0616: 1.		
HTEJL21	573742	303	415 - 173	1287	Gly-1 to Leu-9, Cys-15 to Arg-26, Pro-44 to Arg-50.	L0758: 12, L0794: 6, H0038: 2, L0789: 2, L0752: 2, L0803: 1 and L0779: 1.		
HTEJM56	952255	304	115 - 294	1288	Thr-17 to Ala-24.	H0038: 1 and H0616: 1.		
HTEJN10	958389	305	63 - 368	1289	Thr-1 to Trp-9, Glu-12 to Arg-17, Pro-23 to Gln-40.	H0038: 2 and H0616: 1.		
HTEJN49	558383	306	1 - 126	1290		H0038: 2		
HTEJN96	573845	307	169 - 354	1291	Thr-13 to Asn-19.	H0038: 2		
HTEJP10	914785	308	2 - 418	1292	His-1 to Cys-7.	H0038: 2		
HTEJP66	916481	309	475 - 645	1293		H0038: 1 and H0616: 1.		
HTEJT37	530596	310	3 - 194	1294	His-1 to Ser-15, Glu-29 to Lys-46, Pro-51 to Gln-63.	H0038: 2 and L0747: 1.		
HTEJT74	676254	311	1 - 450	1295	Pro-14 to Ser-31.	H0038: 2		

HTEJU30	573823	312	1 - 219	1296	Lys-1 to Ser-6, Glu-22 to Ser-28, Ser-48 to Arg-56.	H0038: 2 and H0616: 1.		
HTEJV62	694525	313	23 - 337	1297	Gly-11 to Thr-17.	H0038: 2		
HTEJX78	806395	314	2 - 388	1298	Glu-2 to Thr-11, Asn-35 to Gly-41, Thr-57 to Asn-63, Pro-73 to Glu-88, Pro-101 to Phe-110.	H0038: 2		
HTEJY27	685272	315	1 - 252	1299	Arg-3 to Ala-10, Asp-25 to Trp-31.	L0758: 4, L0779: 3 and H0038: 2.		
HTEJZ26	523818	316	2 - 121	1300	Ala-1 to Pro-7, Arg-13 to Ser-22.	H0038: 2 and H0616: 1.		
HTEKC07	920925	317	76 - 402	1301	Arg-1 to Pro-12, Trp-42 to Thr-47.	H0038: 2		
HTEKC12	815975	318	1 - 291	1302	Gly-1 to Trp-6, Pro-12 to Ser-20.	H0038: 2		
HTEKD04	519938	319	147 - 338	1303	Arg-7 to Ser-12, Trp-36 to Pro-60.	H0038: 5		
HTEKE41	974044	320	103 - 315	1304	Glu-29 to Ser-36, Cys-49 to Thr-71.	H0616: 2 and H0038: 1.		
HTEKE46	870084	321	753 - 1043	1305	Pro-22 to His-28.	H0038: 2 and H0618: 1.		
HTEKE80	790381	322	130 - 438	1306	Glu-19 to Tyr-36, Glu-48 to Lys-53.	H0616: 3 and H0038: 2.		
HTEKF04	774260	323	1 - 594	1307	Phe-1 to Gly-19, Gln-21 to Glu-31, Arg-79 to Lys-92.	L0758: 5, H0616: 3 and H0038: 2.		

HTEKF24	573750	324	103 - 267	1308	Ser-135 to Leu-145. Arg-43 to Phe-48.	H0038: 2	1p13	102770, 188540, 600234, 601414, 601691, 601691, 601691, 601691, 601691, 601718, 602094
HTEKF35	573749	325	27 - 233	1309	Pro-28 to Gly-33, Asp-35 to Leu-51, Leu-61 to Thr-69.	H0038: 2		
HTEKF68	772997	326	1 - 291	1310	Glu-12 to Glu-19.	H0038: 2 and H0616: 1.		
HTEKI01	917176	327	3 - 344	1311		H0038: 2		
HTEKI70	503039	328	257 - 682	1312	Ala-24 to Tyr-31, Gln-38 to Lys-43.	H0038: 3, L0758: 2, H0253: 1, H0616: 1, L0794: 1, L0803: 1, L0745: 1 and L0588: 1.		
HTEKI48	530588	329	2 - 247	1313	Pro-7 to Gln-16, Arg-19 to Gly-32, Pro-34 to Glu-45, Phe-56 to Leu-65.	H0038: 2		
HTEKM14	745257	330	1 - 264	1314	Lys-34 to Ala-42.	H0038: 3 and H0616: 1.		
HTEKO49	723148	331	3 - 251	1315	Pro-8 to Thr-14.	H0038: 1 and H0616: 1.		

HTEKQ26	870627	332	31 - 165	1316		H0038: 2		
HTEKQ85	784444	333	348 - 569	1317	Lys-62 to Ser-67.	H0038: 1 and H0616: 1.		
HTEKR75	870555	334	139 - 318	1318		H0038: 1 and H0616: 1.		
HTEKS15	529273	335	290 - 427	1319		H0038: 2		
HTEKS20	846714	336	3 - 569	1320	Pro-9 to Arg-14, Phe-34 to Ile-39, Arg-41 to Lys-47, Leu-49 to Gly-55, Lys-104 to Lys-110, Asp-119 to Gly-124.	AR061: 2, AR089: 1 L0758: 14, H0038: 5, L0779: 4, L0794: 2 and H0616: 1.		
HTEKS21	506651	337	113 - 346	1321	Val-1 to Val-8, Arg-36 to Pro-41, Thr-50 to Leu-55.	H0618: 3, H0253: 1 and H0038: 1.		
HTEKS76	767658	338	166 - 399	1322	Ser-9 to Ser-17, Leu-48 to Cys-54.	H0038: 1 and H0616: 1.		
HTEKX06	935945	339	87 - 263	1323	Gly-46 to Glu-58.	H0038: 1 and H0616: 1.		
HTEKX08	959876	340	118 - 375	1324	Glu-37 to Asp-46.	L0758: 10, H0038: 3, L0794: 2, H0618: 1, H0253: 1 and H0616: 1.		
HTEKX28	920927	341	108 - 257	1325		H0038: 2 and L0758: 1.		
HTEKX70	573700	342	68 - 259	1326		H0038: 2		
HTEKZ50	524054	343	98 - 280	1327	Ile-9 to Asn-20, Ala-22 to Asp-29.	H0038: 2		

HTELA50	774268	344	49 - 195	1328	Lys-8 to Lys-14.	H0616: 4, L0803: 1 and L0731: 1.		
HTELD47	934272	345	165 - 536	1329		H0616: 3 and L0519: 2.		
HTELD82	779315	346	79 - 267	1330	Arg-1 to Ser-6.	H0616: 2		
HTELE10	963563	347	157 - 438	1331		H0616: 3		
HTELE41	791743	348	260 - 475	1332	Ala-8 to Ser-13.	H0616: 5		
HTELG47	757740	349	279 - 455	1333	Pro-2 to Asp-7.	H0038: 1 and H0616: 1.		
HTELG57	870621	350	1 - 318	1334	Val-17 to Val-23, Phe-34 to Tyr-46, Thr-62 to His-67.	H0616: 2 and H0038: 1.		
HTELG80	773018	351	3 - 107	1335	Val-1 to Thr-12.	H0616: 2		
HTELG44	766462	352	351 - 542	1336	Gln-9 to His-21.	H0038: 1, H0616: 1 and L0745: 1.		
HTELI03	923071	353	421 - 588	1337	Glu-27 to Thr-34.	H0038: 1 and H0616: 1.		
HTELI51	806403	354	318 - 554	1338		H0616: 2 and L0749: 1.		
HTELI89	966134	355	86 - 361	1339	Asn-1 to Gln-7, Phe-27 to Gly-38, Pro-61 to Gly-68.	H0616: 4 and L0758: 3.		
HTELK14	794339	356	3 - 449	1340		H0038: 1 and H0616: 1.		
HTELK50	870552	357	9 - 239	1341	Arg-21 to Phe-28.	H0616: 2		
HTELK68	923055	358	107 - 349	1342		H0616: 2		
HTELL48	783824	359	181 - 294	1343		H0616: 4		
HTELL51	952267	360	394 - 648	1344		H0616: 2		

HTELL90	952269	361	357 - 626	1345	Asn-56 to Ser-66.	H0616: 3 and L0779: 1.		
HTELM89	786268	362	75 - 302	1346	Asp-19 to Lys-24.	H0038: 2 and H0616: 18		
HTELO20	926910	363	117 - 434	1347	Leu-21 to Gly-26, His-101 to Trp-106.	H0616: 11 and H0038: 1.		
HTELO51	931120	364	2 - 166	1348	Ser-21 to Ser-29, Ala-43 to Asn-49.	H0616: 4		
HTELO73	761806	365	56 - 232	1349	Lys-1 to Cys-7, Lys-16 to Glu-21, Ser-23 to Thr-37, Pro-40 to Ser-47, Glu-49 to Arg-59.	H0038: 1 and H0616: 1.		
HTELO93	934344	366	1 - 204	1350	Asn-6 to Ser-12.	H0616: 2		
HTELP27	921621	367	3 - 470	1351	Pro-1 to Val-16, Lys-22 to Asp-30, Asn-47 to Ala-61, Arg-89 to Leu-94.	H0616: 2, H0038: 1 and L0754: 1.		
HTELQ41	922634	368	97 - 462	1352		H0616: 3		
HTELQ87	761768	369	36 - 344	1353	Tyr-1 to Leu-7, Phe-51 to Asp-60.	H0616: 2 and H0038: 1.		
HTELR90	826531	370	2 - 451	1354	Arg-29 to Leu-40, Gly-50 to Gln-55, Thr-73 to Ile-83, Lys-90 to Lys-95.	H0616: 2		
HTELT72	761598	371	2 - 235	1355	Thr-7 to Asn-12, Leu-20 to Ile-29, Ser-54 to Ser-64, Met-66 to Gly-77.	H0616: 4, L0774: 2, H0618: 1, L0665: 1 and L0747: 1.		

HTELT83	780619	372	3 - 521	1356	Lys-50 to Glu-55.	H0616: 4	
HTELU01	915339	373	3 - 173	1357	Lys-1 to Lys-9.	H0616: 2	
HTELV06	934302	374	37 - 240	1358	Lys-57 to Gly-63.	H0616: 2 and L0758: 1.	
HTELV10	963576	375	106 - 270	1359	Asp-1 to Trp-11, Ser-49 to Lys-55.	H0616: 2	
HTELV26	796832	376	172 - 303	1360	Thr-17 to Leu-22.	L0758: 16, H0038: 1 and H0616: 1.	
HTELV43	870615	377	2 - 448	1361	Gly-2 to Ile-19, Lys-22 to Ala-31, Asp-49 to Asn-56.	H0038: 1 and H0616: 1.	
HTELV86	910946	378	1 - 927	1362	Thr-5 to Ser-11, Asp-78 to His-85, Ser-153 to Ser-162, Glu-221 to Ala-234, Gly-247 to Glu-252.	AR089: 7, AR061: 6, H0616: 4, H0038: 1, L0745: 1 and L0779: 1.	
HTELV29	952241	379	3 - 293	1363	Ala-21 to Trp-26, Arg-64 to Val-83.	H0616: 4, H0038: 2, L0768: 1 and L0779: 1.	
HTELV62	870596	380	71 - 271	1364	Cys-2 to Glu-9.	H0616: 2 and L0758: 1.	
HTELV52	963506	381	3 - 302	1365	Gln-3 to Gln-13.	H0616: 2	
HTELV72	761599	382	25 - 117	1366		H0038: 1 and H0616: 1.	
HTELV64	764834	383	140 - 283	1367	Thr-18 to Gly-25.	H0616: 2	
HTELV07	952268	384	94 - 312	1368	Lys-32 to His-41.	H0038: 1 and H0616: 1.	
HTELV89	786424	385	171 - 353	1369	Ser-46 to Thr-53.	H0616: 2	
HTEMA54	911666	386	22 - 1167	1370	Gly-23 to Asn-30,	AR089: 19, AR061: 9q31	109400,

					Arg-45 to Lys-50.	13	H0618: 14, H0253: 12, H0038: 11, H0616: 2, L0794: 1, L0779: 1 and L0758: 1.		132800, 132800, 186855, 223900, 253800, 253800, 278700, 602088
HTEMB26	827055	387	75 - 143	1371	Thr-6 to Lys-23.		H0616: 2		
HTEMB28	870614	388	103 - 342	1372	Tyr-4 to Tyr-11, Ala-20 to Ser-28, Val-44 to Arg-54.		H0616: 3		
HTEMB34	870589	389	141 - 371	1373	Leu-25 to Asn-32, Ala-49 to Phe-56, Arg-60 to Lys-69.		H0616: 3		
HTEMB72	761602	390	1 - 306	1374			H0038: 1 and H0616: 1.		
HTEMB83	775593	391	2 - 292	1375	Lys-49 to Lys-56.		L0758: 9, L0794: 3, H0038: 2, H0616: 2, L0790: 1 and L0779: 1.		
HTEMC18	924727	392	1 - 453	1376	Gln-16 to Gly-27, Glu-59 to Gly-65, Ser-107 to Arg-113.		H0253: 3, H0618: 2 and H0616: 1.		
HTEMC75	848193	393	58 - 240	1377	Gln-15 to Arg-21.		H0038: 1 and H0616: 1.		
HTEMD10	963546	394	1 - 270	1378	Gly-1 to Glu-8, Glu-16 to Ser-22, Asp-43 to Gly-49, His-65 to Met-70,		H0616: 2 and L0758: 2.		

HTEMD73	761783	395	2 - 310	1379	Lys-79 to Gln-90. Ala-20 to Thr-44.	H0038: 2 and H0616: 2.		
HTEMF08	958386	396	3 - 116	1380		H0616: 2		
HTEMJ34	786377	397	248 - 496	1381		H0616: 6 and L0758: 1.		
HTEMI54	963531	398	388 - 570	1382		H0616: 4, H0038: 1 and L0748: 1.		
HTEMK03	923066	399	45 - 359	1383	Pro-11 to Gly-21, Pro-65 to Ser-71.	H0038: 1 and H0616: 1.		
HTEMM80	888686	400	353 - 631	1384	Pro-32 to Gly-40, His-54 to Glu-74.	H0616: 5, H0038: 2, L0779: 1 and L0758: 1.		
HTEMN08	958374	401	10 - 96	1385	Tyr-16 to Ser-25.	H0616: 2		
HTEMN95	789113	402	54 - 251	1386		H0038: 1 and H0616: 1.		
HTEMO14	880634	403	2 - 319	1387		H0616: 2 and H0038: 1.		
HTEMO85	771434	404	166 - 276	1388	Phe-7 to Glu-12, Leu-22 to Tyr-28.	H0616: 3		
HTEMP48	767863	405	1 - 159	1389	Gln-29 to Gly-34.	H0616: 3 and H0038: 1.		
HTEMP49	932319	406	3 - 629	1390	Arg-8 to Ser-15, Ser-21 to Trp-40, Glu-63 to Trp-74, Ser-76 to Ser-81, Asp-83 to Asp-96, Glu-125 to Ser-131, Leu-198 to Leu-206.	H0038: 10, L0758: 7, L0768: 6, H0253: 4, H0616: 2, L0772: 1, L0773: 1, L0779: 1 and L0731: 1.		

HTEMS10	963527	407	102 - 371	1391	Arg-1 to Arg-8, Leu-44 to Ala-50, Ser-58 to Ile-68.	H0038: 1, H0616: 1 and L0758: 1.		
HTEMS48	832506	408	45 - 203	1392	Ser-16 to His-24.	H0038: 1 and H0616: 1.		
HTEMT06	934338	409	2 - 268	1393	Ile-14 to Asp-22, Pro-28 to Gln-43, Pro-49 to Arg-56, Pro-62 to Ser-78, Thr-81 to Glu-89.	L0758: 4, H0038: 1, H0616: 1 and L0779: 1.		
HTEMT89	922999	410	2 - 160	1394	Glu-36 to Val-53.	L0758: 3 and H0616: 2.		
HTEMU17	789623	411	112 - 273	1395	Arg-21 to Pro-26.	H0616: 2, L0749: 2 and H0038: 1.		
HTEMU54	870618	412	43 - 189	1396	Arg-18 to Lys-24, Thr-29 to Ile-34.	H0616: 3		
HTEMX92	913795	413	23 - 514	1397	Gly-82 to Lys-89.	AR061: 6, AR089: 3 H0616: 2 and H0038: 1.		
HTEMY30	870662	414	46 - 231	1398	Arg-32 to Gly-37.	H0038: 1, H0616: 1 and L0759: 1.		
HTEMZ04	927021	415	162 - 377	1399		H0616: 2		
HTENA22	870601	416	1 - 294	1400	Pro-20 to Ala-32, Arg-46 to Val-51.	H0038: 1 and H0616: 1.		
HTENB03	923050	417	24 - 338	1401	Ser-29 to Val-39.	H0616: 3		
HTENC22	775544	418	243 - 497	1402	Gln-29 to Leu-34, Arg-36 to Leu-44, Glu-58 to Ser-64,	H0616: 2 and L0109: 1.		

HTENF08	958378	419	380 - 574	1403	Ser-67 to Pro-85. Ala-6 to Ala-12.	H0038: 1 and H0616: 1.			
HTENG66	840151	420	3 - 308	1404	Asn-2 to Glu-14, Pro-17 to Lys-27, Gly-42 to Ser-59, Cys-70 to Lys-81.	H0253: 3, H0038: 1 and H0616: 1.			
HTENG93	967432	421	1 - 102	1405	His-7 to Ser-12.	H0038: 1 and H0616: 1.			
HTENH86	784798	422	182 - 436	1406	Ile-28 to Ser-36.	H0616: 2, H0038: 1 and L0758: 1.			
HTENI58	917213	423	41 - 589	1407	Asn-17 to Asn-30, Glu-37 to Lys-56, Asp-64 to Gln-69, Gly-77 to Ser-95, Lys-109 to Asn-114, Arg-158 to Ser-183.	AR089: 30, AR061: 13 L0794: 25, L0758: 4, H0038: 3, H0616: 2, L0779: 2, L0768: 1 and L0790: 1.			
HTENJ28	968135	424	1 - 948	1408	Thr-6 to Arg-17.	H0038: 7, H0124: 1, H0040: 1, H0616: 1 and L0779: 1.			
HTENJ76	767838	425	3 - 443	1409	Thr-17 to Ala-25, Pro-40 to Glu-46, Asn-76 to Glu-81, Gln-90 to Lys-104.	H0253: 1 and H0616: 1. 1.	11q13.2- q13.3	133780, 151400, 602078	
HTENK06	835851	426	249 - 566	1410	Gly-23 to Pro-32.	H0616: 3 and H0618: 1.			
HTENK69	844557	427	192 - 509	1411	Arg-15 to Leu-21, Ala-29 to Glu-34, Pro-40 to Trp-49,	H0038: 4, H0616: 3, L0758: 3 and L0779: 1.			

HTENO12	917032	428	76 - 1467	1412	Ser-82 to Ala-97. Gly-29 to Glu-39, Gly-105 to Lys-117, Gln-135 to Leu-142, Pro-180 to Ser-186, Gln-202 to Ser-207, Gln-214 to Asp-220, Gly-246 to Thr-255.	H0616: 6, H0618: 3, H0253: 3 and H0038: 3.		
HTENO50	969213	429	190 - 618	1413	Asn-1 to Glu-6, Gln-9 to Gly-15, Gln-18 to Arg-40.	H0038: 1 and H0616: 1.		
HTENP54	787535	430	17 - 208	1414	Arg-13 to Leu-18.	H0616: 17 and L0758: 1.		
HTENP80	775387	431	2 - 496	1415	Asp-16 to Leu-22, Met-37 to Thr-42, Glu-55 to Gly-68.	H0038: 1 and H0616: 1.		
HTENQ05	928244	432	1 - 654	1416	His-23 to Ser-34, His-77 to Glu-82.	H0038: 2, H0616: 1 and L0758: 1.		
HTENR10	963530	433	24 - 380	1417	Gly-40 to Ala-45, Arg-65 to Thr-75.	H0038: 1 and H0616: 1.		
HTENR74	764828	434	1 - 456	1418	Gly-1 to Pro-15.	H0038: 2 and H0616: 1.		
HTENS22	785996	435	3 - 440	1419	Met-2 to Asn-16, Gln-30 to Gln-35, Met-42 to Gln-48, Ser-54 to His-60, Pro-63 to Ser-69, Leu-101 to Gln-118, Gly-139 to Pro-146.	H0038: 1, H0616: 1 and L0748: 1.		

HTENS43	784936	436	226 - 756	1420			H0616: 5, H0038: 3, H0253: 1, L0769: 1, L0794: 1, H0521: 1, L0748: 1, L0779: 1 and L0758: 1.		
HTENS91	870515	437	387 - 725	1421	Trp-1 to Gln-10.		H0616: 2 and L0517: 1.		
HTENV57	944416	438	99 - 617	1422	Gly-5 to Arg-10, Arg-18 to Ser-24, Glu-35 to Asn-42, Lys-72 to Gln-82, Tyr-90 to Lys-96, Lys-112 to Arg-123, Asp-141 to Met-146.		AR061: 7, AR089: 3 H0616: 5 and H0038: 1.		
HTENW53	907717	439	1 - 243	1423	Arg-6 to Asp-13, Lys-70 to Trp-76.		H0038: 2, H0616: 2 and L0758: 2.		
HTENX77	771409	440	168 - 359	1424	Glu-1 to Lys-11.		L0758: 10, L0439: 6, H0616: 2, L0803: 2, L0756: 2, L0455: 1, H0038: 1 and L0438: 1.		
HTENY21	870587	441	383 - 553	1425	Ala-17 to Ser-22.		H0038: 1 and H0616: 1.		
HTENY35	884043	442	2 - 1009	1426	Gln-1 to Ser-19, Glu-29 to Lys-35, Leu-58 to Phe-68, Cys-100 to Arg-107, Cys-113 to Cys-119, Phe-124 to Asn-139, Leu-157 to Glu-163,		H0616: 3		

						Ile-174 to Ile-180, Pro-195 to Pro-204, Gly-228 to Glu-250, Ile-260 to Asp-266, Thr-273 to His-279, Cys-281 to Gly-291.				
HTENZ33	870591	443	102 - 377	1427		Gln-24 to Glu-34, Ala-58 to Ser-64.	1.	H0038: 1 and H0616:		
HTENZ72	773024	444	2 - 400	1428		Met-56 to Pro-67, Ser-82 to Tyr-87, Pro-111 to Ala-121.	1.	H0616: 2 and H0038:		
HTEOA90	787516	445	24 - 329	1429		Arg-20 to Gln-27, Arg-37 to His-42, Pro-46 to His-55.	1.	H0038: 1 and H0616:		
HTEOD34	812307	446	129 - 428	1430		Tyr-3 to Cys-9, Thr-20 to Ile-25, Gly-60 to Arg-67.	1.	H0616: 2 and H0038:		
HTEOE61	918635	447	247 - 411	1431			1.	H0616: 2 and H0038:		
HTEOF31	793202	448	258 - 632	1432		Gly-2 to Glu-13, Val-40 to Cys-79.	1.	H0038: 1 and H0616:		
HTEOF80	847224	449	2 - 262	1433		Val-17 to Arg-23, Tyr-28 to Ser-34, Thr-41 to Cys-47.		AR061: 7, AR089: 3 H0616: 3	Xp22	300000, 300066, 300077, 300310, 301220, 302350, 304050, 304110,

										306100, 309530, 309585, 312040
HTEOF91	918571	450	27 - 164	1434	Arg-31 to Asp-37.				H0616: 2	
HTEOI36	870575	451	3 - 410	1435	Pro-17 to Ala-25, Lys-33 to Arg-40, Arg-62 to Lys-68, Ala-79 to Val-93, Lys-106 to Asp-113.				AR089: 36, AR061: 21 H0038: 7, H0618: 1, H0253: 1 and H0616: 1.	
HTEOI53	810333	452	11 - 295	1436	Arg-1 to Ile-8, Tyr-12 to Gly-29, Lys-34 to Ala-64, Lys-77 to Glu-91.				H0038: 1 and H0616: 1.	
HTEOK02	918590	453	121 - 408	1437					H0616: 2 and H0038: 1.	
HTEON29	815852	454	2 - 520	1438	Pro-27 to Ala-35.				AR061: 6, AR089: 3 H0038: 4, L0758: 3, H0616: 2, L0794: 2, L0747: 2, L0803: 1, L0789: 1 and L0590: 1.	
HTEON67	954114	455	107 - 271	1439					H0038: 2 and H0616: 1.	
HTEOU45	915138	456	320 - 529	1440					H0616: 22	
HTEOV90	870532	457	22 - 438	1441	Pro-14 to Phe-23, Lys-111 to Lys-133.				L0766: 5, L0803: 3, H0616: 2, L0777: 2, L0470: 1, L0761: 1, L0764: 1, L0804: 1, L0805: 1, L0776: 1,	

HTEOW02	918475	458	3 - 266	1442	Ser-30 to His-36, Arg-54 to Arg-59.	L0789: 1 and L0750: 1. H0616: 2		
HTEOW39	870566	459	2 - 445	1443	Gly-38 to Val-44.	AR089: 17, AR061: 14 H0616: 2		
HTEOW85	969682	460	2 - 490	1444	Arg-1 to Ala-13, Arg-99 to Arg-104, Thr-117 to Gln-124, Asn-132 to Gln-137, Thr-145 to His-155.	H0618: 3, H0616: 2 and H0253: 1.		
HTEPA08	958391	461	147 - 605	1445	Tyr-34 to Glu-43.	L0758: 9, H0038: 1, H0616: 1 and S0042: 1.		
HTEPA27	872923	462	43 - 393	1446	Pro-77 to Ser-83.	H0616: 3, L0747: 2, L0794: 1, L0803: 1 and L0779: 1.		
HTEPB66	772949	463	204 - 515	1447	Asp-35 to Gly-40.	H0616: 3, L0758: 2, L0794: 1 and L0366: 1.		
HTEPB84	782248	464	161 - 568	1448	Leu-2 to Gly-11.	H0616: 2 and H0038: 1.		
HTEPC76	767824	465	140 - 328	1449	Pro-10 to Asn-16, Asn-38 to Arg-44.	H0616: 4, L0779: 1 and L0758: 1.		
HTEPC87	883021	466	126 - 497	1450	Cys-5 to Thr-14.	H0616: 2		
HTEPD06	933299	467	2 - 193	1451	His-7 to Gly-17, Gly-25 to Leu-36.	H0616: 4, L0756: 2 and H0038: 1.		
HTEPG15	812303	468	3 - 395	1452	Gln-1 to Asn-9, Pro-14 to Leu-20, Leu-42 to Gly-47.	L0752: 3, H0618: 1, H0616: 1, L0769: 1, L0803: 1, L0789: 1,		

						Gln-56 to Arg-61, Pro-109 to Ser-114, Lys-119 to Thr-131.	L0439: 1, L0758: 1 and L0698: 1.		
HTEPH01	915301	469	25 - 477	1453		Thr-2 to Ser-12, Arg-60 to Leu-67, Ala-72 to Thr-77, Pro-82 to Lys-91, Gly-96 to Ser-101, Glu-110 to Pro-118, Gln-124 to Leu-129, Gln-132 to Ser-138.	H0616: 3 and H0038: 1.		
HTEPJ09	956200	470	305 - 1216	1454		Arg-1 to Asn-11, His-40 to Arg-45.	H0616: 2 and L0758: 1.		
HTEPJ19	918599	471	37 - 345	1455		Arg-1 to Ser-9.	H0616: 2		
HTEPJ79	774212	472	27 - 122	1456			H0038: 1 and H0616: 1.		
HTEPK40	939675	473	209 - 631	1457		Gly-5 to Pro-15, Ser-23 to His-32.	H0616: 5, L0758: 5 and H0038: 1.		
HTEPM33	870561	474	1 - 735	1458		Pro-8 to Gly-26, Cys-54 to Cys-66, Gly-73 to His-85.	AR061: 25, AR089: 5 L0758: 3, H0616: 2, H0038: 1 and L0779: 1.		
HTEPM52	806471	475	171 - 326	1459			H0616: 2		
HTEPN07	952243	476	3 - 311	1460		Leu-12 to Pro-17, Pro-24 to Gly-29, Ser-34 to Gly-39.	H0616: 2 and H0038: 1.		
HTEPP23	836572	477	1 - 192	1461		Asn-6 to Asp-16.	H0616: 2, L0779: 2, H0038: 1 and L0758: 1.		
HTEPP29	917207	478	1 - 372	1462		Gly-33 to Gly-38, Gln-61 to His-66.	H0038: 1 and H0616: 1.		

HTEPP30	947107	479	12 - 641	1463	Ala-35 to Glu-41, Ile-54 to Glu-74, Lys-80 to Leu-87.	H0616: 3 and H0038: 1.		
HTEPP32	785803	480	3 - 866	1464	Gln-8 to Cys-17, Cys-20 to Gln-26, Thr-61 to Lys-68, His-75 to Gly-83, Asn-88 to Gln-104, Pro-118 to Leu-126, Gln-131 to Glu-138.	H0616: 4 and H0038: 3.		
HTEPP92	790869	481	3 - 545	1465	Lys-86 to Lys-91, Lys-107 to Lys-139, Leu-155 to Asn-162.	H0038: 1 and H0616: 1.		
HTEPR90	787499	482	1 - 168	1466		H0038: 2 and H0616: 2.		
HTEPT25	870509	483	2 - 238	1467	Gly-42 to Gly-47.	H0616: 2		
HTEPT75	870637	484	42 - 518	1468	Pro-66 to Ser-74.	H0616: 2 and H0038: 1.		
HTEPU01	915134	485	533 - 670	1469		H0616: 2		
HTEPV02	917406	486	1 - 471	1470	Ser-9 to Ser-17, Phe-21 to Leu-45.	AR061: 6, AR089: 2 H0616: 3, L0758: 2, L0768: 1, L0792: 1 and L0779: 1.		
HTEPX32	870698	487	91 - 699	1471	Ser-10 to Gly-15, Pro-20 to Ser-27, Glu-34 to Gly-41, Ala-45 to Trp-50, Pro-79 to Gly-88.	AR089: 11, AR061: 2 H0038: 6, H0616: 6, L0794: 4, L0768: 1 and L0758: 1.		
HTEPZ10	963433	488	274 - 543	1472	Pro-9 to Ser-19.	H0616: 2 and L0758:		

HTEPZ18	888470	489	50 - 502	1473	Pro-51 to Asp-57. Lys-2 to Gly-11.	2. H0618: 1 and H0616: 1.			
HTEQB03	922941	490	2 - 151	1474	Pro-30 to Cys-35, Thr-41 to Ser-47.	H0616: 4			
HTEQD40	915198	491	2 - 490	1475	Met-11 to Lys-28.	L0758: 7, H0618: 1, H0616: 1, L0794: 1 and L0779: 1.			
HTEQD69	918579	492	133 - 321	1476	Thr-39 to Asn-45.	H0616: 2 and H0038: 1.			
HTEQE87	958354	493	205 - 633	1477	His-16 to Ser-21, Val-30 to Asn-40, Leu-54 to Pro-64.	H0038: 2 and H0616: 1.			
HTEQG56	881004	494	10 - 426	1478	Pro-31 to Glu-45, Ala-52 to Lys-58, Met-78 to Lys-89.	H0616: 3 and H0038: 1.			
HTEQI54	853971	495	189 - 422	1479	Thr-1 to Asn-6, Pro-11 to Phe-19, Arg-21 to Asn-27.	H0616: 2, L0803: 1 and L0774: 1.			
HTEQJ14	870525	496	158 - 424	1480		H0038: 2 and H0616: 1.			
HTEQJ42	806495	497	90 - 308	1481	Gln-4 to Ser-9, Ala-23 to Glu-29, Phe-65 to Ser-71.	H0038: 1 and H0616: 1.			
HTEQO81	806504	498	1 - 144	1482		H0038: 1 and H0616: 1.			
HTEQP45	966141	499	1 - 141	1483	Lys-1 to Phe-10.	H0616: 4			
HTEQQ82	932301	500	254 - 24	1484	Asp-5 to Asp-14.	H0616: 3 and L0758:			

HTEQR15	939641	501	108 - 590	1485	Thr-17 to Leu-22.	1. AR089: 10, AR061: 3 H0253: 8, H0038: 4, H0616: 3, H0618: 2, L0758: 2 and L0779: 1.		
HTEQR94	966486	502	77 - 388	1486	Asn-83 to Ser-88.	L0758: 6, H0616: 2 and L0794: 2.		
HTEQT63	924799	503	193 - 1311	1487		L0758: 3, H0038: 1 and H0616: 1.		
HTLAB19	530577	504	3 - 281	1488	Asp-32 to Gln-37.	H0253: 2		
HTLAB44	530579	505	3 - 266	1489	Ala-6 to Gly-25.	H0618: 4 and H0253: 3.		
HTLAB73	575019	506	1 - 333	1490	Gly-42 to Arg-47.	H0253: 2		
HTLAC81	679414	507	2 - 163	1491	Leu-2 to Cys-8, Gly-32 to Arg-39.	H0253: 3		
HTLAC87	546469	508	23 - 154	1492	Ala-1 to Arg-6, Met-14 to Thr-32.	H0038: 164, H0253: 42, H0150: 2, H0549: 1 and S0042: 1.		
HTLAD21	761758	509	2 - 298	1493	Ser-5 to Asn-12, Leu-63 to Gly-71.	L0758: 4, H0253: 2, H0616: 2, L0649: 1, L0666: 1, L0663: 1 and L0780: 1.		
HTLAD38	421550	510	86 - 529	1494	Phe-12 to Leu-22, Ser-26 to Tyr-32, Phe-53 to Asn-59, Tyr-68 to Leu-73, Gln-96 to Gly-102.	L0758: 5, H0253: 4, L0794: 4, H0618: 2, H0038: 1, H0616: 1 and L0768: 1.		
HTLAF84	836390	511	1 - 444	1495	Pro-32 to Thr-48,	H0253: 2 and L0777:		

							Arg-102 to Pro-109.	1.				
HTLAV67	530742	512	36 - 221	1496			Ser-39 to Gly-45.	H0253: 3				
HTLBD12	506739	513	2 - 331	1497			Ala-2 to Pro-8, Pro-57 to Trp-67, Cys-69 to Gly-74.	H0253: 2				
HTLBE55	967408	514	2 - 232	1498			Glu-6 to Thr-15, Ser-21 to His-34, Arg-53 to Ala-64.	H0253: 1, H0038: 1 and H0616: 1.				
HTLBE82	780116	515	209 - 481	1499			Ser-1 to Gly-8, Thr-15 to Thr-23, Pro-45 to Pro-53.	L0366: 3, H0618: 2, H0253: 1 and L0754: 1.	9q31-q34		109400, 125270, 125270, 128100, 132800, 132800, 132800, 137350, 186855, 191100, 215700, 223360, 223900, 253800, 253800, 268900, 278700, 601850, 602088	
HTLBF14	971661	516	3 - 590	1500			Glu-21 to Gln-27, Ser-30 to Lys-37.	H0616: 2, H0618: 1 and H0253: 1.				
HTLBG83	527942	517	96 - 200	1501				H0253: 2				

HTLCA95	911655	518	38 - 1096	- 1502		AR061: 373, AR089: 188 H0253: 3, H0618: 2, H0038: 2, H0616: 1 and L0758: 1.		
HTLCG77	772644	519	2 - 112	1503	Gly-1 to Ile-6, Gly-12 to Ile-27.	L0758: 5, H0616: 3, H0038: 2, L0794: 2 and H0253: 1.		
HTLCX76	767667	520	2 - 277	1504	Leu-58 to Arg-68.	H0253: 2		
HTLCY54	908832	521	134 - 934	1505	Arg-1 to Arg-6, Ala-49 to Tyr-58, Pro-67 to Lys-80, Ser-92 to Trp-108.	AR061: 5, AR089: 5 H0253: 4, H0618: 3, L0758: 3, L0779: 2 and L0794: 1.		
HTLCZ48	572959	522	1 - 162	1506	His-1 to Gly-6.	H0253: 2		
HTLCZ96	815897	523	17 - 286	1507		L0758: 4, L0794: 2, L0617: 1, H0253: 1, H0038: 1, L0789: 1 and L0779: 1.		
HTLDA58	828115	524	2 - 271	1508	Ser-6 to Ser-11.	H0253: 2		
HTLDE53	780842	525	72 - 497	1509	Asn-1 to Glu-6, Gly-17 to His-28, Glu-33 to Ser-39, Pro-41 to Lys-51, Pro-56 to Glu-69, Ser-83 to Lys-90, Thr-97 to Ser-103, Arg-121 to Asp-131.	L0758: 11, H0253: 3, H0550: 1 and H0616: 1.		
HTLDE64	908613	526	83 - 427	1510	Glu-15 to Leu-20, Leu-24 to Ser-47.	AR089: 25, AR061: 11		

									H0253: 2 and H0618: 1.		
HTLDE95	616724	527	86 - 298	1511					H0253: 2		
HTLDG55	911645	528	1 - 192	1512	Gly-1 to Arg-10.				H0253: 2		
HTLDI90	835850	529	248 - 472	1513					H0618: 1 and H0253: 1.		
HTLDP77	920546	530	1 - 573	1514	Gly-1 to Gly-9, Gln-15 to Arg-20, Cys-53 to Arg-59, Arg-84 to Glu-89, Pro-105 to Glu-113.				H0253: 3 and H0618: 2.		
HTLDQ25	870057	531	1 - 834	1515	Ser-3 to Ser-16.				H0618: 11, H0253: 10, H0616: 6, L0758: 5, H0038: 4, L0768: 2 and H0090: 1.		
HTLDS55	891322	532	2 - 1171	1516	Ala-1 to Gln-13, Pro-19 to Leu-27, Asp-34 to Pro-40, Ser-45 to Ser-52, Lys-105 to Pro-112, Pro-146 to Trp-158, Arg-181 to Arg-189, Arg-241 to Arg-248, Asp-285 to Asn-291, Gln-328 to Ile-333, Gln-369 to Thr-375, Arg-380 to Phe-390.			AR061: 7, AR089: 2, AR054: 2, AR051: 2, AR050: 2 H0618: 5, L0758: 4, H0038: 3, H0253: 2, H0553: 1, H0616: 1, L0789: 1, L0663: 1 and L0779: 1.			
HTLDT05	909752	533	2 - 328	1517	Gly-3 to Ser-8.				AR089: 11, AR061: 7 H0253: 2, L0439: 1		

HTLDT81	952265	534	1 - 465	1518	Pro-3 to Pro-8, Glu-22 to Gln-29.	and L0599: 1. H0253: 2 and H0618: 1.		
HTLDU05	911649	535	2 - 469	1519	Pro-89 to Ala-97.	AR061: 8, AR089: 7 H0253: 3, H0618: 1 and L0758: 1.	109400, 132800, 132800, 186855, 223900, 253800, 253800, 278700, 602088	
HTLDX88	791684	536	148 - 636	1520	Pro-5 to Gly-10, Gly-24 to Ala-33, Pro-88 to Pro-95, Pro-106 to His-114.	H0618: 2 and H0253: 1.		
HTLDY85	573746	537	3 - 425	1521	Lys-50 to Ala-55, Thr-99 to Glu-104, Arg-116 to Arg-122, Lys-129 to Thr-136.	H0038: 2 and H0253: 1.		
HTLDZ14	573401	538	174 - 347	1522		H0253: 2		
HTLEB14	573464	539	1 - 414	1523	Gly-63 to Arg-71.	H0618: 4 and H0253: 3.		
HTLED72	906989	540	102 - 287	1524	Leu-1 to Pro-7.	H0253: 2		
HTLEF94	870258	541	33 - 239	1525		H0253: 2		
HTLEG65	870154	542	177 - 1181	1526		AR051: 12, AR054: 10, AR050: 8 H0616: 6, H0618: 2, H0253: 2 and H0038:		

HTLEG91	870257	543	1 - 111	1527		2.			
HTLEH30	934287	544	1 - 528	1528	Gly-1 to His-8, Glu-26 to Gly-33.	H0253: 2			
HTLEI47	573460	545	124 - 417	1529	Glu-58 to Thr-63.	H0253: 3			
HTLEJ11	973302	546	2 - 802	1530	Tyr-52 to Gln-60, Phe-86 to Ala-94, Lys-111 to Arg-118, His-193 to Tyr-198.	AR061: 3, AR089: 1 H0618: 3 and H0253: 1.	15q13-qter		
HTLEJ93	960314	547	2 - 307	1531	His-22 to Lys-36, Asp-51 to Lys-59, Gln-68 to Leu-83.	H0253: 5 and H0618: 3.			
HTLEK64	506747	548	2 - 331	1532	Ala-1 to Cys-13, Arg-32 to Ala-37.	H0253: 2			
HTLEL01	917022	549	2 - 202	1533	Pro-3 to Gly-9.	H0253: 1 and H0616: 1.			
HTLEL03	575080	550	2 - 106	1534		H0253: 2	3p21.3	116806, 120120, 120120, 120120, 120120, 120436, 120436, 120436, 138320, 168468, 182280, 600163	
HTLEL31	669950	551	3 - 143	1535	Pro-6 to Glu-13, Arg-18 to Pro-30.	H0253: 2	7q22	126650, 126650,	

									154276, 173360, 173360, 602136, 602136, 602136, 602447
HTLEM46	719160	552	1 - 456	1536				H0253: 2, L0777: 2 and L0759: 1.	
HTLEO50	506649	553	2 - 265	1537	Ser-2 to Pro-10.			H0253: 1 and H0038: 1.	
HTLEP16	574942	554	3 - 443	1538				H0253: 2, L0794: 2 and S0042: 1.	
HTLEQ07	953706	555	3 - 605	1539	His-7 to Ile-32, Glu-82 to Glu-87, Lys-103 to Gly-108.			H0618: 2 and H0253: 1.	
HTLES43	573403	556	49 - 216	1540				H0253: 2	
HTLES54	574884	557	1 - 282	1541	Pro-10 to Gln-19, Pro-46 to Ile-59, Thr-64 to Leu-70.			H0038: 2 and H0253: 1.	
HTLET56	911654	558	95 - 826	1542	Ser-54 to Lys-61, Pro-118 to Lys-128, Thr-208 to Ser-213, Ser-218 to Ala-227, Pro-230 to Ser-236, Pro-238 to Ser-244.			AR061: 6, AR089: 5 H0253: 18, H0618: 7, L0794: 3, H0038: 1, H0616: 1, L0788: 1 and L0758: 1.	
HTLET78	836820	559	2 - 826	1543	Leu-11 to Lys-18, Phe-107 to Gly-114, Glu-121 to Asn-128,			AR061: 4, AR089: 2 H0618: 10, H0253: 5, L0758: 5, L0664: 1,	

						Met-146 to Pro-153.	L0756: 1, L0779: 1 and L0698: 1.		
HTLET93	573454	560	1 - 111	1544			H0253: 2		
HTLEV33	527956	561	1 - 273	1545		Ala-8 to Gly-17, Pro-25 to His-34.	L0794: 5, H0253: 3, H0618: 2, H0616: 2, L0758: 2 and L0787: 1.		
HTLEV95	883332	562	52 - 414	1546		His-1 to Thr-6, His-14 to Cys-58, Cys-70 to Ala-77, Pro-85 to Cys-109, Pro-116 to Glu-121.	H0616: 14, H0618: 8, L0779: 4, H0253: 3, H0038: 3, L0790: 1 and L0758: 1.		
HTLEW21	573458	563	3 - 197	1547			H0253: 2		
HTLEY11	967309	564	2 - 130	1548		Arg-1 to Gly-21, Gln-38 to Asp-43.	H0253: 2		
HTLEY91	775310	565	5 - 226	1549		Pro-38 to Trp-43, Pro-47 to Lys-54, Gly-62 to Arg-72.	H0253: 2		
HTLEZ14	791662	566	2 - 334	1550		Asn-18 to Pro-44, Val-64 to Phe-70.	H0618: 4 and H0253: 3.		
HTLEZ15	934288	567	3 - 251	1551		Pro-5 to His-12, Glu-30 to Thr-36.	H0618: 2 and H0253: 2.		
HTLEZ32	870261	568	3 - 209	1552			H0253: 2		
HTLFA74	934172	569	279 - 707	1553		Ser-20 to Glu-26, Gly-31 to Ala-46, Thr-62 to His-67, Arg-72 to Pro-81.	H0253: 2 and H0618: 1.		
HTLFC20	917128	570	409 - 1041	1554		Ala-4 to Trp-10, Glu-27 to Gln-32.	H0618: 3 and H0253: 3.		

HTLFE01	917033	571	98 - 313	1555	Gly-115 to Gly-122. Asn-7 to Val-12, Leu-15 to Ser-23.	H0253: 4 and H0038: 1.			
HTLFE05	954984	572	3 - 812	1556	His-1 to Cys-6, Glu-24 to Gly-29, Gln-53 to Asp-59, Gly-80 to Pro-86, Glu-142 to Ser-148, Ser-154 to Val-160, Pro-163 to Gln-180, Val-195 to Pro-200, Lys-205 to Ser-213, Ala-222 to Glu-228, Asp-239 to Gly-270.	H0253: 5, H0618: 4, H0038: 1 and H0616: 1.	7q22	126650, 126650, 154276, 173360, 173360, 602136, 602136, 602136, 602447	
HTLFE20	934278	573	80 - 475	1557	Gly-11 to Val-29, Gly-31 to Glu-38, Ala-40 to Arg-48, Gly-55 to Val-65, Leu-70 to Thr-76.	H0253: 8 and H0618: 7.			
HTLFI28	775392	574	2 - 430	1558	Pro-24 to Arg-31, Ile-66 to Leu-72, Asp-90 to Glu-98.	H0253: 3 and H0038: 2.			
HTLFI39	953730	575	2 - 622	1559	Ala-15 to Asp-23, Thr-44 to Tyr-52.	AR089: 19, AR061: 13 H0618: 8 and H0253: 4.	7q22	126650, 126650, 154276, 173360, 173360, 602136, 602136,	

HTLFI83	781303	576	19 - 513	1560	Asp-13 to Leu-26, Val-38 to Val-76.	H0253: 1 and H0038: 1.	602136, 602447
HTLFI39	573462	577	2 - 343	1561	Gln-7 to Phe-13, Leu-24 to Val-37, Pro-50 to Leu-65.	H0253: 2	
HTLGD25	870136	578	28 - 600	1562	Gly-3 to Gly-9, Leu-51 to Gln-58, Leu-67 to Ser-74, His-100 to Pro-106, Arg-132 to Arg-138.	AR061: 3, AR089: 1 H0618: 4, H0253: 4, H0616: 2, L0758: 2 and H0038: 1.	
HTLGD69	835493	579	287 - 652	1563	His-27 to Ser-39, His-47 to Pro-55.	L0758: 2, H0618: 1, H0253: 1, H0616: 1 and L0779: 1.	
HTLGC36	789656	580	2 - 574	1564	Thr-13 to Ser-21, Arg-26 to His-44, Ala-85 to Cys-91, Thr-104 to Thr-121, Gly-156 to Arg-163.	H0618: 4, L0779: 1 and L0758: 1.	
HTLGM02	964878	581	62 - 766	1565	Lys-1 to Gly-12, Glu-32 to Phe-41, Arg-69 to Leu-81, Pro-188 to Ile-195.	H0618: 2	
HTLGM07	952254	582	3 - 761	1566	Arg-1 to Glu-6, Ile-15 to Phe-23, Gly-59 to Phe-72, Pro-95 to Trp-112, Phe-117 to Pro-129.	AR089: 21, AR061: 16 H0618: 32, H0253: 13, H0616: 6, L0758: 3, H0038: 2, L0794: 2,	

								H0009: 1, H0688: 1, L0769: 1, L0372: 1, L0646: 1, L0363: 1, L0766: 1, L0790: 1, L0665: 1, H0670: 1 and L0779: 1.			
HTLGT62	918606	583	2 - 547	1567		Asn-4 to Thr-10, Pro-46 to Asp-51.		H0618: 9, H0253: 1 and L0758: 1.			
HTLGW17	958208	584	1 - 768	1568		Arg-39 to Asn-44, Arg-55 to Gly-62, Arg-98 to Ile-103.		H0618: 3 and H0253: 3.			
HTLGX90	870528	585	61 - 906	1569		Pro-41 to Gly-57, Leu-76 to Gly-83, Pro-87 to Ser-95, Glu-97 to Pro-106, Ile-122 to Glu-128, Gln-152 to Arg-166, Thr-180 to Arg-187, Leu-191 to Pro-199, Glu-231 to Cys-241, Val-248 to Asp-255.		L0748: 4, H0618: 3, L0751: 3, L0749: 2, L0777: 2, H0038: 1, H0616: 1, L0772: 1 and L0775: 1.			
HTLHC14	908428	586	3 - 503	1570		Gly-38 to Phe-51, Pro-74 to Trp-91, Phe-96 to Ala-127, Glu-130 to Gly-148.		AR061: 7, AR089: 4 H0618: 32, H0253: 13, H0616: 6, L0758: 3, H0038: 2, L0794: 2, H0009: 1, H0688: 1, L0769: 1, L0372: 1, L0646: 1, L0363: 1, L0766: 1, L0790: 1,			

HTLHE72	963471	587	62 - 508	1571			L0665: 1, H0670: 1 and L0779: 1.			
HTLHL82	958334	588	186 - 1103	1572	Gln-1 to Trp-27.		H0618: 3 and H0253: 1.			
HTLHO94	968685	589	298 - 164	1573	Lys-36 to Glu-45.		H0253: 11, H0618: 8, L0779: 3, L0758: 3 and L0768: 1.			
HTLHP32	933335	590	87 - 455	1574	Phe-6 to Ala-12, Arg-24 to Arg-35, Leu-66 to Phe-84.		H0038: 2, L0747: 2, H0618: 1, L0665: 1, L0779: 1 and L0758: 1.			
HTLHP52	926980	591	11 - 181	1575	Glu-37 to Gln-42.		AR089: 35, AR061: 7, H0618: 2			
HTLHP80	870156	592	350 - 604	1576			H0618: 2			
HTLHT15	946586	593	1 - 381	1577	Tyr-31 to Arg-42, Met-63 to Leu-69, Tyr-114 to His-123.		H0618: 2			
HTLHT24	870254	594	21 - 893	1578	Pro-1 to Ala-10, Val-27 to Gly-42, Asp-61 to Asp-66, Ser-81 to Ala-88.		H0618: 26, H0253: 20 and L0758: 1.			
HTLHU04	926950	595	2 - 943	1579	Gln-10 to Ile-18, Arg-41 to Ala-59, His-115 to Lys-128, Lys-143 to Glu-151, Thr-164 to Glu-169.		L0758: 8, H0618: 4, H0253: 1, H0038: 1 and L0769: 1.			
HTLHV67	936139	596	2 - 700	1580	Glu-2 to Thr-7, Arg-64 to Lys-72,		H0618: 3	15q23-q25	118485, 151670,	

70

HTLIU76	946300	604	46 - 609	1588	Val-102 to Lys-108, Gly-125 to Glu-130, Leu-138 to Asp-144, Arg-149 to Arg-158. Pro-13 to Ala-18, His-30 to Gln-37, Gly-49 to Ala-66, Ala-80 to Lys-92, Glu-98 to Asp-103, His-119 to Thr-126.	AR089: 9, AR061: 8 L0758: 12, H0618: 6, H0038: 3, H0253: 1, H0050: 1, L0151: 1 and L0768: 1.			
HTLIV78	947234	605	618 - 97	1589	Pro-18 to Asp-23, Arg-110 to Gln-122.	AR089: 9, AR061: 7 L0758: 10, L0794: 3, H0618: 2, H0038: 2, H0253: 1, L0768: 1 and L0789: 1.			
HTLIY52	942161	606	1 - 1368	1590		AR061: 0, AR089: 0 H0618: 64, H0253: 52, L0758: 6, L0779: 2, H0392: 1, H0038: 1, L0761: 1, L0803: 1, L0806: 1 and L0697: 1.			
HTLJA23	953729	607	2 - 814	1591	Thr-50 to Tyr-58, Gly-155 to Gln-161, Thr-164 to Gln-175.	H0618: 8 and H0253: 7q22 4.			126650, 126650, 154276, 173360, 173360, 602136, 602136, 602136,

HTLJA24	934279	608	3 - 572	1592	Ile-1 to Trp-9, Gly-35 to Val-53, Gly-55 to Glu-62, Ala-64 to Arg-72, Gly-79 to Arg-85.	H0618: 2	602447
HTLJC71	922923	609	3 - 1355	1593	His-1 to Phe-9, Cys-13 to Thr-18, Pro-35 to Gly-48, Glu-61 to Pro-68, Lys-105 to Ala-136, Thr-144 to Gln-154, Leu-163 to Gly-171, Thr-205 to Gln-222, Pro-251 to Gln-257.	AR061: 7, AR089: 5 H0618: 12, H0253: 8, H0038: 6, L0758: 6, L0779: 5, H0616: 3, T0041: 1, L0776: 1, S0274: 1 and H0543: 1.	
HTLJD35	967336	610	1 - 192	1594	Cys-5 to Ser-15, Pro-36 to Pro-44.	H0618: 1 and H0253: 1.	
HTLJD88	953714	611	161 - 760	1595	Arg-15 to Glu-25, Lys-35 to Val-41, Gln-70 to Pro-100.	H0253: 5 and H0618: 2.	
HTLJJ75	924755	612	1 - 921	1596	Gln-1 to Thr-12.	AR089: 11, AR061: 9 H0253: 7, H0618: 6, L0794: 2, L0779: 2, L0595: 2, H0687: 1, L0438: 1, L0741: 1 and L0758: 1.	
HTLJL23	922994	613	2 - 619	1597	Leu-9 to Ser-14.	H0618: 3, H0038: 3, H0616: 3 and H0253: 2.	

HTTAD55	835652	614	132 - 245	1598			H0040: 3		
HTTAE49	723331	615	74 - 160	1599			H0040: 2		
HTTAH87	509574	616	2 - 232	1600			H0040: 2		
HTTAJ50	509657	617	1 - 261	1601			H0040: 2		
HTTAN57	509453	618	29 - 274	1602		Gly-21 to Gly-27, Pro-38 to Gly-49, Ser-68 to Asp-73.	H0040: 2		
HTTAS96	961057	619	91 - 255	1603		Arg-7 to Cys-13, Ser-16 to Arg-21, Ala-28 to Gly-33.	H0040: 2		
HTTAU82	797726	620	61 - 309	1604		Pro-6 to Asn-13, Thr-25 to Gly-34.	H0040: 2		
HTTBE25	509128	621	1 - 156	1605			H0040: 2		
HTTBH54	530563	622	114 - 266	1606			H0040: 2		
HTTB194	530564	623	3 - 263	1607		Thr-3 to Arg-14.	AR061: 4, AR089: 3 H0040: 2		
HTTBN67	578085	624	54 - 176	1608			H0040: 2		
HTTCA15	869705	625	2 - 262	1609		Glu-74 to Tyr-79.	H0040: 2		
HTTCD03	925390	626	248 - 391	1610		Asn-1 to Ser-13.	H0040: 2		
HTTCD71	530393	627	3 - 101	1611			H0040: 2		
HTTCL35	529672	628	72 - 185	1612			H0040: 2, L0766: 1 and L0758: 1.		
HTTCT34	973210	629	3 - 1049	1613		Phe-86 to Tyr-94, Val-149 to Lys-155, Trp-169 to Asn-179, Thr-189 to Glu-197.	AR061: 5, AR089: 2 H0040: 3		
HTTDF50	526385	630	191 - 298	1614			H0040: 2		
HTTDF90	917155	631	78 - 260	1615			H0040: 3		

HTTDG36	968131	632	26 - 280	1616	Gly-13 to Gly-19, Pro-38 to Gly-50, Glu-67 to Gly-73.	H0040: 2		
HTTDI21	869686	633	3 - 188	1617		H0040: 1 and H0634: 1.		
HTTDJ65	973307	634	155 - 364	1618	Ser-2 to Val-16, Pro-50 to Trp-56.	H0040: 3		
HTTDL38	573641	635	47 - 136	1619		H0040: 2		
HTTDL45	523452	636	3 - 89	1620		H0040: 3 and L0792: 1.		
HTTDL89	959837	637	183 - 341	1621		H0040: 2		
HTTDL40	734318	638	52 - 387	1622	Gln-8 to Ser-13, Asp-20 to Tyr-27.	H0040: 2		
HTTDL85	783444	639	89 - 313	1623		H0040: 2		
HTTDO19	908937	640	1 - 333	1624	Thr-3 to Lys-9, Gly-14 to His-26, His-30 to Lys-37, Lys-43 to Ser-49.	AR089: 16, AR061: 9 H0040: 2		
HTTDR91	790336	641	110 - 280	1625	Ile-3 to Lys-9.	H0040: 2 and L0766: 1.		
HTTDR92	573666	642	190 - 330	1626	Gly-8 to His-21.	H0040: 2		
HTTDS02	920589	643	217 - 387	1627		H0040: 2		
HTTDX84	921100	644	1 - 480	1628	Pro-33 to Arg-43, Ala-48 to Tyr-57.	H0253: 3, L0758: 2, H0618: 1, H0038: 1 and H0040: 1.		
HTTDZ54	692608	645	125 - 298	1629		H0040: 2		
HTTDZ91	523206	646	2 - 313	1630	Ser-11 to Ala-19, Lys-27 to Ala-33.	H0618: 1 and H0040: 1.		

HTTEB33	573719	647	227 - 349	1631			H0040: 2			
HTTEH58	747943	648	149 - 286	1632			H0040: 2			
HTTEL50	745985	649	102 - 209	1633			H0040: 2			
HTTEU68	967819	650	2 - 766	1634		Lys-8 to Val-20, Ser-72 to Ala-77, Ala-84 to Ser-92, Leu-110 to Lys-119.	H0040: 2, L0439: 2, L0438: 1 and L0747: 1.			
HTTEV62	573614	651	85 - 285	1635		Ser-1 to Gln-7, Arg-9 to Glu-14, Pro-16 to Val-24, Arg-35 to Asp-40.	H0040: 2, H0616: 1, L0794: 1, L0779: 1 and L0758: 1.			
HTTEY64	974107	652	207 - 464	1636			H0040: 4			
HTTEZ34	771602	653	168 - 329	1637		Arg-40 to Asn-45.	H0040: 2			
HTTFB60	869666	654	2 - 220	1638			H0040: 2			
HTTFG35	778426	655	1 - 183	1639		Asp-14 to Gln-22.	H0040: 5			
HTTFH70	757358	656	139 - 285	1640			H0040: 2			
HTTFK90	787599	657	36 - 263	1641		Arg-25 to Trp-32.	H0040: 2, L0794: 2, L0659: 1, L0809: 1, L0779: 1 and L0752: 1.			
HTTFL89	974346	658	99 - 419	1642		Gly-15 to Gly-21, Pro-31 to Pro-46.	H0040: 3			
HTTFM17	750942	659	52 - 219	1643			H0040: 2, L0805: 1 and L0758: 1.	17q		
HTTFM66	950051	660	141 - 1079	1644			AR061: 6, AR089: 2 H0040: 2			
HTTFS59	825922	661	1 - 273	1645			H0040: 2, L0748: 2, L0749: 2 and L0766: 1.	11p11.2- p11.1	133701, 168500, 171650,	

HTTFT08	934460	662	34 - 207	1646	Asn-23 to Gln-29, Arg-37 to Asn-43.	H0040: 3	176930, 176930, 600623, 600811, 600958
HTTFV93	925544	663	47 - 169	1647	Asp-36 to Lys-41.	H0040: 2	
HTTFZ70	974066	664	114 - 329	1648	Lys-20 to Lys-27.	H0040: 2 and H0634: 1.	
HTTHH05	931004	665	436 - 606	1649	Tyr-12 to Gly-17.	H0634: 2	
HTTIG04	926752	666	2 - 235	1650	His-54 to Ser-61.	H0634: 2	
HTTIH23	869636	667	2 - 247	1651	Lys-47 to Asp-56.	H0634: 2	
HTTIH80	869635	668	32 - 226	1652		H0040: 1 and H0634: 1.	
HTTIL06	934089	669	547 - 717	1653		H0040: 1, H0634: 1 and L0485: 1.	
HTTIN23	869634	670	338 - 553	1654	Gln-15 to Thr-20.	H0634: 2	
HTTIU05	931015	671	158 - 430	1655	Ala-17 to Gln-28, Pro-73 to Thr-83.	H0634: 2	
HTTIW81	922817	672	294 - 446	1656		H0634: 3	
HTTIZ05	930994	673	112 - 354	1657	Ser-60 to Pro-69.	H0634: 2	
HTTJA11	839725	674	13 - 240	1658	Glu-54 to Lys-60, Pro-65 to Gly-74.	H0040: 1, H0634: 1 and L0803: 1.	
HTTJA47	869618	675	18 - 356	1659	Glu-61 to Lys-66, Met-76 to Asn-83.	H0040: 1 and H0634: 1.	
HTTJH13	869615	676	3 - 182	1660	Gln-11 to Gly-17, Glu-26 to Ser-36,	H0634: 2	

HTTJM01	913799	677	137 - 283	1661	Arg-53 to Ala-60.				
HTTJQ06	934130	678	61 - 177	1662	Pro-14 to Pro-20.	H0634: 2			
HTTJX68	974063	679	1 - 147	1663	Arg-29 to Arg-41.	H0040: 1 and H0634: 1.			
HTTJY08	958170	680	169 - 276	1664		H0634: 2			
HTTKD44	948750	681	2 - 448	1665	Lys-13 to Arg-21, Gly-26 to Thr-36.	H0549: 1 and H0634: 1.			
HTTKF89	960928	682	1 - 189	1666		H0040: 2 and H0634: 1.			
HTTKG34	915033	683	56 - 181	1667		H0634: 2			
HTTKK06	974311	684	210 - 383	1668		H0634: 3			
HTTKL80	974316	685	228 - 362	1669		H0634: 3			
HTTKN21	974310	686	354 - 509	1670		H0634: 3			
HTTKP07	911390	687	2 - 337	1671	Thr-15 to Asp-25, Glu-69 to Leu-89.	AR089: 1, AR061: 1			
HTTKS13	926795	688	65 - 484	1672	Ala-12 to Gly-22, Pro-38 to Ser-45, Ala-77 to Pro-83, Ala-88 to Gly-93.	H0634: 2			
HTTKV17	830008	689	2 - 193	1673	Thr-1 to Gln-7, Gly-13 to Gln-37.	H0634: 2			
HUDAM29	529157	690	3 - 224	1674		S0042: 2			
HUDBZ78	739638	691	2 - 163	1675		H0038: 1 and S0042: 1.			
HUDBZ01	869026	692	213 - 533	1676	Arg-7 to Arg-13, Asn-31 to Ser-37.	AR050: 75, AR054: 59, AR051: 51			

	915945	988	191 - 3	1972			S0042: 1		
HUDBK39	886368	693	77 - 487	1677	Gly-43 to Leu-48, Ser-57 to Lys-67.		AR054: 2, AR051: 0, AR050: 0 S0042: 1		
HUDBE95	795796	694	147 - 248	1678			S0042: 1		
HUDBE64	746508	695	56 - 286	1679			S0042: 1		
HUDBE48	869034	696	39 - 368	1680	Glu-17 to Ala-30, Gly-42 to Thr-56.		S0042: 1		
HUDBE28	686520	697	3 - 374	1681	Glu-1 to Leu-6, Cys-10 to Asn-28, Lys-41 to Tyr-50, Gln-53 to Ser-60, Pro-67 to His-78.		S0042: 1		
HUDBE02	917361	698	3 - 137	1682	Phe-2 to Arg-7, Asn-23 to Asn-32, Gln-39 to Asn-45.		S0042: 1		
HUDAK54	899753	699	18 - 710	1683	Thr-14 to Phe-26, Gln-46 to Arg-52, Leu-74 to Tyr-84, Glu-125 to Glu-132, Tyr-180 to Ser-186, Leu-216 to Pro-222, Val-226 to His-231.		AR051: 32, AR050: 31, AR054: 25 S0042: 1		
HUDAK19	671974	700	109 - 234	1684	Glu-27 to Glu-33.		L0783: 1, L0439: 1, L0731: 1 and S0042: 1.		
HTTKG12	969547	701	1 - 171	1685	Thr-1 to Ser-10.		H0634: 1 and L0593: 1		

HTTKC85	956206	702	380 - 240	1686			H0634: 1, L0662: 1 and L0766: 1.		
HTTJV79	869602	703	61 - 213	1687			H0634: 1 and L0766: 1.		
HTTJN26	869612	704	132 - 497	1688	Glu-53 to Gln-62, Gly-80 to Val-86.		L0770: 3, L0777: 3, L0518: 2, L0779: 2, L0758: 2, L0608: 2, H0634: 1, L0764: 1, L0803: 1, L0749: 1 and L0752: 1.		
HTTJK06	934094	705	2 - 577	1689	Gln-1 to Trp-16, Asp-18 to Gly-25, Leu-38 to Pro-43, Trp-146 to Gly-153.		H0634: 1 and L0565: 1.		
HTTIX05	931024	706	395 - 532	1690			H0634: 1, L0803: 1, L0749: 1 and L0779: 1.		
HTTIR33	974323	707	136 - 345	1691	Lys-11 to Glu-18.		H0634: 1		
HTTIR04	926772	708	86 - 235	1692			H0634: 1, L0766: 1 and L0588: 1.		
HTTIN11	965920	709	452 - 625	1693			L0745: 2 and H0634: 1.		
HTTIE08	958169	710	195 - 329	1694	Ala-10 to Thr-16.		H0634: 1 and L0731: 1.		
HTTIB12	969568	711	1 - 216	1695	Pro-25 to Thr-31, Pro-59 to Gly-72.		H0634: 1 and L0748: 1.		
HTTHJ56	944914	712	87 - 218	1696	Asn-1 to Arg-11, Val-23 to Ser-28, Asp-35 to Tyr-44.		L0157: 1 and H0634: 1.		

HTTFG12	751809	713	128 - 373	1697	Leu-21 to Gly-30.	H0040: 1		
HTTEZ61	742004	714	146 - 301	1698	Ser-24 to His-34.	H0040: 1 and L0439: 1.		
HTTEQ59	739445	715	57 - 230	1699		H0040: 1, L0766: 1 and L0748: 1.		
HTTEQ01	917156	716	2 - 205	1700	Pro-28 to Thr-38, Gly-47 to Arg-52.	H0040: 1, L0803: 1, L0439: 1 and L0777: 1.		
HTTEO59	900662	717	1 - 153	1701	Gly-1 to Asp-8, Leu-15 to Cys-20, Gly-24 to Ser-29.	AR061: 5, AR089: 5 H0040: 1		
HTTEO53	728344	718	396 - 545	1702	Arg-2 to Ile-8, Ser-34 to Cys-44.	H0040: 1, L0740: 1 and L0747: 1.		
HTTEJ56	573669	719	1 - 339	1703	Pro-1 to Glu-7, Thr-29 to Gly-35, Glu-63 to Ile-68, Glu-89 to Asn-95, Glu-98 to Leu-105.	AR050: 2, AR051: 1, AR054: 0 L0439: 3 and H0040: 1.		
HTTEB05	932294	720	1 - 387	1704	Arg-10 to Asp-15.	L0483: 1 and H0040: 1.		
HTTDO59	744438	721	511 - 747	1705	Arg-1 to Trp-9, Pro-13 to Gly-19, Gly-24 to Pro-32.	L0754: 2 and H0040: 1.	1q21	104770, 107670, 110700, 135940, 145001, 146790, 152445, 152445, 159001, 174000,

									179755, 182860, 182860, 182860, 191315, 230800, 230800, 266200, 600897, 601105, 601412, 601652, 602491
HTTDM42	460948	722	177 - 401	1706				AR061: 5, AR089: 5 L0748: 2 and H0040: 1.	
HTTDL81	694222	723	2 - 241	1707	Ala-4 to Pro-22.			H0040: 1 and L0748: 1.	
HTTDL75	766551	724	41 - 178	1708	Gly-10 to Cys-16, Arg-25 to Trp-31, Pro-39 to Pro-46.			H0040: 1, L0742: 1 and L0592: 1.	
HTTDA85	784537	725	3 - 392	1709	Arg-83 to Arg-88.			H0040: 1 and L0748: 1.	
HTTCQ95	796674	726	2 - 241	1710	Cys-19 to Pro-29.			H0040: 1 and L0755: 1.	
HTTCJ39	709581	727	63 - 266	1711	Ala-50 to Asp-55.			L0745: 2 and H0040: 1.	
HTTCD06	960599	728	162 - 413	1712	Lys-15 to Asn-23, Asp-75 to Val-82.			L0754: 2 and H0040: 1.	

HTTCB87	524841	729	3 - 236	1713	Pro-7 to Ala-26.	H0040: 1 and L0748: 1.		
HTTBR42	714220	730	3 - 272	1714		H0040: 1 and L0592: 1.		
HTTBP62	932997	731	1 - 615	1715	Arg-12 to Gly-20, His-102 to Ser-108, Ala-132 to Gln-137.	L0764: 2 and H0040: 1.		
HTTBO82	780164	732	367 - 170	1716	Asn-24 to Asp-32.	H0040: 1 and L0748: 1.		
HTTBM03	925409	733	11 - 202	1717	Arg-18 to Trp-29.	H0040: 1 and L0753: 1.		
HTTBI80	781590	734	3 - 203	1718	Asp-1 to Gln-14, Phe-18 to Gly-33.	H0040: 1 and L0766: 1.		
HTTBH95	530559	735	125 - 256	1719	Tyr-1 to Tyr-12.	H0040: 1		
HTTBH75	767520	736	175 - 435	1720		H0040: 1 and L0439: 1.		
HTTBH36	530567	737	186 - 311	1721		H0040: 1		
HTTAQ60	742377	738	367 - 627	1722	Asn-1 to Cys-12, Asp-20 to Trp-37.	L0748: 3 and H0040: 1.		
HTTAP45	717736	739	65 - 262	1723		H0040: 1		
	869717	989	151 - 342	1973				
HTTAP21	671488	740	632 - 787	1724		L0747: 2 and H0040: 1.		
HTTAP09	826343	741	252 - 440	1725		H0040: 1 and L0591: 1.		
HTTAN34	509454	742	111 - 230	1726	Ser-4 to Lys-12.	L0595: 2, H0040: 1 and L0794: 1.		
HTTAJ93	791413	743	220 - 420	1727		L0748: 2 and H0040: 1.		

HTTAH03	965134	744	73 - 294	1728	Ile-15 to Phe-21, Pro-31 to Cys-39, Pro-41 to Pro-49, Leu-69 to Pro-74.	1. L0769: 2 and H0040: 1.		
HTTAC77	772735	745	435 - 632	1729		L0752: 2, H0040: 1 and L0756: 1.		
HTTAA94	793001	746	2 - 271	1730	Asn-14 to Leu-20, Gln-30 to Pro-46.	L0749: 2, H0040: 1, L0748: 1 and L0591: 1.		
HTTAA39	710355	747	298 - 137	1731		H0040: 1 and L0731: 1.		
HTLIP06	934207	748	20 - 241	1732		H0618: 1, L0751: 1 and L0758: 1.		
HTLID06	974047	749	318 - 491	1733	Gln-10 to Ser-16.	H0618: 1		
HTLHV59	965808	750	41 - 277	1734	Pro-8 to Ala-15, Arg-23 to Glu-35, Pro-41 to Val-49.	H0618: 1 and L0731: 1.		
HTLHU81	870150	751	1 - 345	1735		L0591: 2 and H0618: 1.		
HTLHU63	870147	752	219 - 527	1736	Glu-33 to Arg-40.	L0439: 3 and H0618: 1.		
HTLHS69	870152	753	144 - 593	1737	Lys-34 to Pro-40, Glu-51 to Gly-56, Glu-117 to Gly-124.	H0618: 1 and L0770: 1.		
HTLHS05	933720	754	724 - 113	1738	Pro-42 to Ser-47, Ala-51 to Arg-68, Leu-109 to Gly-117.	H0618: 1 and L0771: 1.		
HTLHK57	894863	755	736 - 1140	1739	Phe-10 to Pro-19,	AR054: 35, AR051:		

					Gly-107 to Arg-112, Thr-128 to Lys-135.	24, AR050: 10, AR061: 8, AR089: 3 H0618: 1, L0766: 1 and L0749: 1.		
	946914	990	1342 - 1788	1974	Ser-49 to Lys-58, Glu-75 to Pro-91.			
HTLHJ51	865399	756	165 - 878	1740	Gln-3 to Arg-10, Leu-74 to Arg-80, Pro-87 to Cys-92, Ser-144 to Pro-158.	H0618: 1, L0749: 1 and L0759: 1.		
HTLHB93	945862	757	1 - 375	1741	Glu-1 to Glu-6.	AR061: 1, AR089: 1 H0618: 1 and L0758: 1.		
HTLHA63	870172	758	243 - 566	1742		H0618: 1 and L0779: 1.		
HTLGS10	963458	759	1 - 483	1743	Ser-25 to Asn-32, His-40 to Glu-45.	L0769: 2 and H0618: 1.		
HTLGR32	928245	760	657 - 950	1744	Arg-14 to Gly-29.	L0779: 3, L0758: 3, H0618: 1 and L0600: 1.		
HTLGP84	782194	761	1 - 393	1745	Ser-1 to Lys-12, Met-22 to Gly-29, Pro-62 to Gly-69.	L0439: 3, L0753: 3, H0618: 1, L0741: 1, L0745: 1 and L0746: 1.		
HTLGK08	958304	762	182 - 388	1746	Glu-35 to Ile-51.	H0618: 1 and L0758: 1.		
HTLGC43	870228	763	3 - 350	1747	Glu-1 to His-15, Gly-21 to Cys-26, Thr-34 to Pro-42, Pro-49 to Glu-57.	L0794: 2, H0618: 1 and L0768: 1.		
HTLEQ92	932882	764	3 - 305	1748		L0439: 3 and H0253:		

HTLEP21	671151	765	3 - 416	1749	Val-25 to Ala-31.	1. H0253: 1 and L0767:		
HTLEN77	772363	766	90 - 422	1750	Ala-1 to Ala-35.	1. AR089: 33, AR061: 18 L0748: 2 and H0253: 1.		
HTLEM92	573400	767	1 - 429	1751	Gly-1 to Arg-13, Phe-19 to Arg-33.	H0253: 1		
	792812	991	360 - 599	1975	Glu-28 to Val-34, Trp-58 to Ser-64.			
HTLEL16	384492	768	2 - 355	1752	Thr-30 to Glu-35, Asp-101 to Gly-106, Ser-112 to Ser-117.	H0253: 1 and L0439: 1.		
HTLEG67	751842	769	138 - 317	1753	Thr-6 to Ser-11.	L0748: 2 and H0253: 1.		
HTLDZ81	778180	770	3 - 296	1754	Ser-5 to Arg-17.	H0253: 1		
HTLDW27	961353	771	197 - 601	1755	His-1 to Cys-8, His-35 to Phe-40.	H0253: 1, L0761: 1, L0649: 1 and L0805: 1.		
HTLDO01	913669	772	3 - 308	1756	Glu-63 to Ala-68, Gly-84 to Tyr-102.	L0758: 3 and H0253: 1.		
HTLDG43	715439	773	1 - 132	1757	Ala-28 to Trp-33.	H0253: 1		
HTLDB18	868533	774	2 - 448	1758	Ser-13 to Gly-19, Leu-22 to Asn-36, Asn-57 to Ser-68, Pro-82 to Trp-107.	H0253: 1 and L0439: 1.		
HTLCZ79	572853	775	1 - 285	1759	Asp-72 to Leu-78.	H0253: 1		
HTLCX66	578921	776	23 - 199	1760	Gly-6 to Thr-12,	H0253: 1		

HTLCO02	921045	777	152 - 382	1761	Pro-28 to Arg-34, Asn-39 to Asn-47. Arg-50 to Trp-58.	H0253: 1 and L0768: 1.		
HTLCG65	413333	778	3 - 143	1762	Ala-14 to Asn-22.	H0253: 1		
HTLCG59	530039	779	6 - 218	1763		H0253: 1		
HTLCA03	870290	780	50 - 250	1764		H0253: 1		
HTLBH67	751985	781	1 - 282	1765		AR061: 2, AR089: 1 L0752: 3, L0747: 2, H0294: 1, H0253: 1, H0046: 1, H0040: 1, H0063: 1, H0494: 1, S0352: 1, L0769: 1, L0766: 1, L0804: 1, L0805: 1, L0791: 1, H0521: 1, L0779: 1, L0780: 1, L0731: 1 and L0758: 1.		
HTLBC07	954111	782	259 - 408	1766		L0758: 2 and H0253: 1.		
HTLBB72	766270	783	3 - 590	1767	His-1 to Trp-11, Lys-13 to Ser-27, Glu-33 to Ser-38.	H0253: 1, L0745: 1 and L0750: 1.		
HTLAI30	690936	784	133 - 492	1768		L0439: 3, L0438: 2, H0253: 1 and L0769: 1.		
HTLAF33	870300	785	1 - 228	1769	Phe-2 to Arg-12.	H0253: 1		
HTLAC61	683247	786	28 - 165	1770		H0253: 1	6p25-pter	
HTLAC39	575343	787	74 - 226	1771	Ala-1 to Trp-18.	H0253: 1		

HTLAB55	732480	788	3 - 320	1772	Gln-32 to Leu-37, Gln-65 to Val-70, Thr-73 to Pro-79.	H0253: 1 and L0439: 1.		
HTLAB29	879168	789	133 - 426	1773	Gly-1 to Thr-9.	H0253: 1 and L0747: 1.		
HTFBE02	920507	790	1 - 363	1774	Asp-28 to Leu-35, Asp-52 to Cys-57.	AR089: 1, AR061: 0 L0439: 2, L0021: 1, H0372: 1, L0769: 1, L0649: 1, L0748: 1, L0485: 1, L0604: 1 and L0361: 1.		
HTEQS95	972746	791	311 - 496	1775	Ser-37 to Ser-43.	H0616: 1		
HTEQS90	973426	792	86 - 388	1776	Pro-45 to Pro-50, Arg-64 to Ser-77, Ile-88 to Ala-101.	H0616: 1		
HTEQP03	870516	793	129 - 596	1777	Pro-71 to Cys-82.	H0616: 1 and L0794: 1.		
HTEQN83	908528	794	3 - 293	1778	Met-12 to Met-24, Pro-46 to Tyr-52, Arg-92 to Lys-97.	AR061: 4, AR089: 1 L0758: 2 and H0616: 1.		
HTEQB08	958291	795	147 - 437	1779	Val-48 to Gly-54, Asp-63 to Arg-74, Gly-87 to Leu-92.	L0748: 2, H0616: 1 and L0747: 1.		
HTEPY28	870559	796	263 - 412	1780	Ala-1 to Met-6, Gly-9 to Ser-15.	L0758: 3 and H0616: 1.		
HTEPV63	870549	797	614 - 931	1781	Leu-47 to Thr-59, Pro-73 to Pro-87.	H0616: 1, L0519: 1, L0748: 1 and L0779: 1.		
HTEPE35	948475	798	839 - 78	1782	Tyr-1 to Lys-8, Phe-19 to Ser-24,	AR061: 4, AR089: 1 L0758: 7, L0768: 2,		

HTEOY82	948845	799	159 - 392	1783	Thr-28 to Ser-34, Pro-54 to Trp-70.	H0616: 1 and L0151: 1.			
HTEOO83	836721	800	1 - 318	1784	Lys-22 to Asp-27.	H0616: 1 and L0779: 1.			
HTEOE28	870581	801	18 - 296	1785	Leu-80 to Lys-86.	H0616: 1 and L0774: 1.			
HTENY44	870588	802	3 - 191	1786	Asp-16 to Arg-23, Leu-40 to Asp-47.	H0616: 1 and L0779: 1.			
HTENV06	933294	803	133 - 390	1787	Glu-1 to Ser-10.	L0758: 3, H0616: 1, L0794: 1, L0791: 1 and L0779: 1.			
HTENS74	773925	804	3 - 329	1788	Arg-30 to Arg-37, Asn-40 to Glu-46, Leu-56 to Arg-64, Ala-85 to Arg-102.	H0616: 1 and L0755: 1.			
HTENR26	870595	805	15 - 146	1789	Thr-12 to Ile-17.	L0755: 2 and H0616: 1.	17p13.3	113721, 247200, 600059, 601545	
HTENQ92	790908	806	54 - 494	1790	Ala-6 to Trp-19, Leu-34 to Gln-39, Asp-63 to Arg-76, Thr-94 to Gly-105, Asp-108 to Phe-113, Lys-122 to Phe-128, Asn-131 to Glu-136, Arg-142 to Gly-147.	H0616: 1 and L0768: 1.			
HTENP08	958382	807	58 - 447	1791	Tyr-2 to His-7.	L0731: 3, H0616: 1 and L0750: 1.			
						H0616: 1 and L0794: 1.			

HTENL95	795314	808	149 - 322	1792	Pro-43 to Ile-51.	L0748: 2, H0616: 1, L0439: 1 and L0740: 1.		
HTENL73	974363	809	109 - 426	1793	Pro-29 to Thr-34, Cys-42 to Ser-47, Gln-52 to His-58, Pro-68 to Cys-80.	H0616: 1		
HTENA08	958380	810	60 - 206	1794		H0616: 1 and L0758: 1.		
HTEMY05	880592	811	1 - 363	1795	Cys-18 to Lys-43, Ser-45 to Leu-52, Ser-63 to Ser-68, Lys-75 to Arg-80, His-113 to Lys-121.	H0616: 1 and L0362: 1.		
HTEMV66	813038	812	1 - 318	1796	Ser-38 to Pro-45.	AR061: 5, AR089: 1 H0616: 1 and L0758: 1.		
HTEMU66	944419	813	454 - 963	1797	Ala-1 to Gln-7, Lys-24 to Ser-30, Pro-44 to Asn-53, Glu-104 to Asp-112, Leu-152 to Ser-157.	AR061: 7, AR089: 5 H0616: 1		
HTEMS01	915308	814	21 - 197	1798	Glu-3 to Cys-9, Gln-32 to Asp-45.	L0758: 4 and H0616: 1.		
HTEMO58	964769	815	77 - 361	1799		H0616: 1 and L0758: 1.		
HTEMN80	775543	816	51 - 137	1800		H0616: 1 and L0439: 1.		
HTEMM91	938396	817	58 - 378	1801	His-15 to Arg-22.	H0616: 1 and L0747: 1.		

HTEMI51	870613	818	283 - 573	1802	Arg-24 to Pro-30.	H0616: 1, L0779: 1 and L0758: 1.		
HTEMB57	849214	819	198 - 374	1803	His-44 to Phe-49, Pro-53 to Pro-58.	H0616: 1 and L0758: 1.		
HTELY90	787549	820	2 - 250	1804		H0616: 1 and L0748: 1.		
HTELV29	806421	821	33 - 641	1805	Pro-28 to His-34, Lys-51 to Arg-59, Arg-66 to Phe-82, Thr-92 to Gln-100, Ala-106 to Gln-118, Pro-123 to Leu-133, Ala-137 to Glu-147, Arg-185 to Leu-190.	H0616: 1 and L0594: 1.		
HTELP07	952274	822	102 - 296	1806	Thr-15 to Lys-28, Gly-47 to Thr-54.	H0616: 1, L0764: 1, L0779: 1 and L0758: 1.		
HTELM71	954982	823	63 - 329	1807	Pro-24 to Asn-37, Asp-43 to Thr-49, Leu-63 to Gln-72.	L0758: 2 and H0616: 1.		
HTELA02	918699	824	185 - 451	1808	Ala-48 to Lys-57, Ser-75 to Phe-84.	L0794: 2, H0616: 1 and L0758: 1.		
HTEKU62	754010	825	43 - 657	1809	His-1 to Lys-7.	H0038: 1 and L0439: 1.		
HTEKI62	812862	826	68 - 286	1810	Pro-43 to Asn-48.	L0766: 2, H0038: 1, L0637: 1, L0750: 1 and L0590: 1.		
HTEKH17	942526	827	83 - 391	1811		AR051: 29, AR050: 21, AR054: 21, AR089: 11, AR061:		

							11 H0038: 1			
HTEKD77	772397	828	105 - 428	1812	Ala-5 to Arg-15.		H0038: 1 and L0756: 1.			
HTEJV94	793039	829	92 - 241	1813	Pro-19 to Phe-28.		L0758: 2 and H0038: 1.			
HTEJO46	717850	830	282 - 401	1814	Ser-5 to Cys-16, Glu-20 to Ile-25.		H0038: 1 and L0743: 1.			
HTEJN12	653252	831	1 - 279	1815			H0038: 1 and L0595: 1.	Xp22	300000, 300066, 300077, 300310, 301220, 302350, 304050, 304110, 306100, 309530, 309585, 312040	
HTEJL30	696784	832	23 - 301	1816			L0748: 2 and H0038: 1.	15q21.1- q21.2	107910, 107910, 109700, 114240, 134797, 134797, 134797, 151670, 600839,	

HTEJC70	490772	833	601 - 380	1817				H0038: 1 and L0748: 1.		601780, 602099
	870649	992	1 - 330	1976	Arg-1 to Arg-6, Pro-17 to Ala-23, Gly-33 to Gln-40, Arg-45 to Arg-73.					
HTEJB07	953801	834	79 - 264	1818	Thr-1 to Glu-7, Cys-35 to Gly-51.			L0779: 3, L0758: 2 and H0038: 1.		
HTEIS34	887112	835	383 - 135	1819	Cys-33 to Asn-38.			H0038: 1 and L0366: 1.		
HTEIS25	870660	836	3 - 299	1820	Pro-31 to Arg-37, Phe-39 to Ala-55.			L0758: 4 and H0038: 1.		
HTEIN26	684711	837	178 - 417	1821	Gly-1 to Glu-9, Ile-12 to Lys-30, Cys-34 to Lys-39, Glu-55 to Gln-62, Val-66 to Lys-72.			H0038: 1 and L0754: 1.		
HTEIL36	708304	838	69 - 395	1822				H0038: 1, L0768: 1, L0438: 1 and L0779: 1.		
HTEIJ58	491030	839	379 - 179	1823	Asp-19 to Ser-25.			H0038: 1		
	870667	993	3 - 281	1977	Ile-1 to Phe-9, Gly-73 to Gly-82.					
HTEID15	395868	840	44 - 151	1824	Gln-1 to Leu-6.			H0038: 1		
HTEIB38	839966	841	39 - 296	1825	His-1 to Asp-9, Lys-37 to Glu-45.			H0038: 1 and L0779: 1.		
HTEIB37	870671	842	19 - 264	1826	Gln-11 to Cys-18.			H0038: 1		

HTEIB03	921926	843	35 - 235	1827	Pro-2 to Thr-13.	H0038: 1		
HTEIA57	734983	844	1 - 225	1828	Glu-1 to Ser-18.	L0748: 2 and H0038: 1.		
HTEHXS7	734976	845	279 - 446	1829	Gly-14 to Val-21, Thr-25 to Leu-32.	H0038: 1, L0740: 1 and L0754: 1.		
HTEHV11	967439	846	59 - 361	1830	Gln-9 to Ala-21, Thr-24 to Thr-29.	H0038: 1, L0779: 1 and L0758: 1.		
HTEHS17	664436	847	15 - 233	1831	Lys-30 to Leu-39, Glu-42 to Ser-53.	L0758: 3, L0151: 2, H0038: 1 and L0779: 1.		
HTEHJ11	964956	848	147 - 254	1832	Gly-10 to Arg-19.	L0163: 1 and H0038: 1.		
HTEGW02	920628	849	64 - 747	1833	Lys-1 to Arg-27, Thr-42 to Met-57, Gln-89 to Ala-95, Asp-113 to Ser-119, Thr-128 to Thr-156, Phe-179 to Ser-187.	L0758: 3, L0776: 2, L0779: 2 and H0038: 1.		
HTEGU55	931017	850	173 - 388	1834	Ala-1 to Lys-10, Pro-29 to Ser-36, Gly-46 to Ser-58, Ile-62 to Cys-67.	L0439: 2 and H0038: 1.	20q13.12	602025
HTEGS24	932987	851	130 - 600	1835	Glu-13 to Ser-20, Pro-33 to Phe-38, Ser-41 to Lys-49.	H0038: 1 and L0766: 1.		
HTEGJ74	765901	852	3 - 452	1836		AR089: 3, AR061: 2, L0439: 2 and H0038: 1.		
HTEGJ56	732630	853	272 - 457	1837	Asp-26 to Trp-35.	H0038: 1 and L0755: 1.		

HTEGI38	709420	854	74 - 325	1838			H0038: 1 and L0749: 1.		
HTEGH60	545137	855	3 - 221	1839	Gly-5 to Gly-12.		H0038: 1		
HTEGC30	690998	856	2 - 97	1840			H0038: 1 and L0756: 1.		
HTEFX90	887616	857	3 - 581	1841			AR050: 9, AR051: 3, AR054: 1 H0038: 1, L0750: 1 and L0755: 1.		
HTEFU18	666920	858	3 - 353	1842	Leu-25 to Asp-35, Ser-41 to Tyr-47, Trp-72 to Pro-77, Lys-106 to Arg-112.		H0038: 1, L0766: 1, L0789: 1 and L0749: 1.		
HTEFO46	719280	859	133 - 408	1843	Pro-28 to Tyr-38, Thr-40 to Lys-48, Val-61 to Thr-68, Glu-74 to Gln-82.		L0591: 2, H0038: 1, L0381: 1, L0779: 1 and L0758: 1.		
HTEFO28	685383	860	150 - 464	1844	Thr-6 to Gln-12.		H0038: 1, L0744: 1 and L0756: 1.		
HTEEU78	530196	861	2 - 256	1845	Ile-1 to Ala-7, Arg-26 to Gly-38.		H0038: 1		
HTEEU35	707717	862	2 - 115	1846			H0038: 1		
HTEEU27	575476	863	99 - 227	1847	Glu-15 to Ser-20.		H0038: 1		
HTEEU18	530203	864	2 - 280	1848	Ser-14 to Ser-25, Leu-42 to Glu-62, Ala-75 to Thr-84.		H0038: 1 and L0758: 1p21 1.	102770, 120280, 120280, 166600, 170995, 232400,	

									232400, 600309, 601414, 601691, 601691, 601691, 601691, 601691, 601718, 602094
HTEEU17	530200	865	76 - 303	1849				Pro-40 to Leu-50, Ser-64 to Gln-74.	H0038: 1
HTEET22	675071	866	206 - 373	1850				Thr-20 to His-29, Pro-31 to Ser-38.	H0038: 1, L0756: 1 and L0758: 1.
HTEEF25	677513	867	123 - 341	1851					H0038: 1, L0794: 1 and L0758: 1.
HTEEB82	780161	868	151 - 288	1852				Ser-11 to Arg-19.	L0748: 2 and H0038: 1.
HTEDX39	530201	869	123 - 260	1853					H0038: 1
HTEDX04	927850	870	114 - 344	1854					H0038: 1
HTEDX03	925353	871	1 - 204	1855					H0038: 1
HTEDW96	881958	872	86 - 511	1856				Thr-48 to Ser-53, Gly-63 to Arg-68, Gly-77 to Trp-85, Gln-99 to Gly-112, Arg-131 to Arg-142.	L0601: 2 and H0038: 1.
HTEDW59	530448	873	1 - 213	1857				Gly-17 to Glu-29.	H0038: 1
HTEDV86	785818	874	86 - 322	1858				Ser-47 to Phe-57.	H0038: 1 and L0749: 1.

HTEDU53	727362	875	2 - 253	1859	Gly-22 to Arg-28.	H0038: 1 and L0756: 1.		
HTEDS40	934047	876	147 - 509	1860		H0038: 1		
HTEDS06	960645	877	625 - 170	1861		H0038: 1 and L0779: 1.		
HTEDO75	767024	878	60 - 197	1862		H0038: 1		
HTEDK72	766343	879	137 - 283	1863		H0038: 1 and L0740: 1.		
HTEDI92	522827	880	3 - 143	1864		H0038: 1		
HTEDJ63	508086	881	29 - 322	1865		H0038: 1		
HTEDI09	522969	882	233 - 409	1866		H0038: 1		
HTEDI01	961028	883	92 - 229	1867		H0038: 1		
HTEDH90	909165	884	3 - 311	1868	Phe-1 to Pro-7, Trp-32 to Thr-39.	AR061: 3, AR089: 1 H0038: 1		
HTEDH76	522940	885	3 - 170	1869	Gly-2 to Ile-13.	H0038: 1		
HTEDH42	615250	886	18 - 353	1870	Leu-56 to Leu-63, Gly-103 to Arg-108.	AR061: 6, AR089: 4 H0038: 1		
HTEDH30	522936	887	1 - 249	1871	Asn-1 to Gly-17.	H0038: 1		
HTEDH17	522938	888	80 - 385	1872	Pro-67 to Gly-75.	H0038: 1		
HTEDH06	869427	889	2 - 361	1873	Ile-1 to Lys-9, Pro-88 to Lys-100.	H0038: 1		
HTEDG75	890715	890	162 - 371	1874	Arg-43 to Thr-50.	AR050: 42, AR054: 35, AR051: 33 H0038: 1		
HTEDG26	519947	891	1 - 396	1875	Asn-1 to Arg-8, Leu-18 to Asp-23, Glu-84 to His-89.	H0038: 1		
HTEDF96	614726	892	1 - 174	1876	Leu-22 to Arg-34.	H0038: 1	19q13.3	113900,

HTEDF70	522977	893	2 - 277	1877	Ile-1 to Gln-11.	H0038: 1	126340, 126391, 130410, 134790, 138570, 160900, 173850, 258501, 600040, 602225, 602225
HTEDF60	742368	894	1 - 369	1878	Glu-1 to Gln-7, Arg-16 to Asp-30, Pro-35 to Asn-43.	H0038: 1	
HTEDF22	908406	895	1 - 303	1879	Pro-2 to Trp-7, His-28 to Gly-35, Pro-37 to Gly-56, Gly-68 to Lys-75.	AR061: 8, AR089: 3 L0758: 2 and H0038: 1.	
HTECE66	522997	896	26 - 196	1880	Gly-36 to Gly-52.	H0038: 1	
HTECE62	523002	897	1 - 369	1881	Ala-22 to Gly-30, Asn-36 to Ala-43.	H0038: 1	
HTECE61	789732	898	85 - 471	1882	Ser-30 to Arg-36.	H0038: 1 and L0750: 1.	
HTECE51	870723	899	85 - 282	1883	Leu-30 to Arg-40.	H0038: 1	
HTECE39	650885	900	63 - 401	1884	Ser-37 to Gly-49.	H0038: 1	
HTECE31	508104	901	33 - 203	1885		H0038: 1	
HTECE08	960428	902	2 - 154	1886	Ile-1 to Ser-8, Pro-13 to Ser-19,	H0038: 1	

HTECD94	527210	903	1 - 330	1887	Gly-31 to Ile-41. Val-28 to Cys-55, Arg-71 to Cys-90, Pro-102 to Pro-107.	H0038: 1	7q11-q22	126650, 126650, 154276, 173360, 173360, 602136, 602136, 602136, 602447
HTECD88	527214	904	246 - 356	1888		H0038: 1		
HTECD70	527203	905	2 - 211	1889	Ala-28 to Ser-43, Ala-57 to Tyr-64.	H0038: 1		
HTECD65	533795	906	144 - 341	1890		H0038: 1		
HTECD56	527209	907	3 - 119	1891	Ala-10 to Thr-18.	H0038: 1		
HTECD15	523029	908	3 - 251	1892	Pro-23 to Val-32, Ala-54 to Ala-60, Thr-68 to Gly-73.	H0038: 1		
HTECC71	508142	909	3 - 173	1893	Glu-39 to Cys-57.	H0038: 1		
HTECC45	508124	910	20 - 142	1894	Phe-1 to Gly-10, Leu-32 to Cys-39.	H0038: 1		
HTECC26	508144	911	74 - 202	1895	Ser-21 to Ser-29, Ala-31 to Thr-37.	H0038: 1		
HTECC09	678659	912	3 - 365	1896	Arg-1 to Pro-6.	AR089: 39, AR061: 19		
HTECC08	960439	913	2 - 151	1897		H0038: 1		
HTECA44	508135	914	56 - 439	1898	Ile-4 to Lys-23,	H0038: 1		

HTECA39	508132	915	105 - 236	1899	Arg-87 to Cys-103. Gly-9 to Leu-17, Arg-38 to Glu-44.	H0038: 1		
HTEBP54	728811	916	559 - 744	1900		L0754: 2 and H0038: 1.		
HTEBO43	715704	917	3 - 266	1901	Gly-42 to Gln-53, Leu-67 to Glu-76.	H0038: 1		
HTEBM87	503275	918	78 - 230	1902	Glu-16 to Lys-21, Met-25 to Tyr-32.	H0038: 1		
HTEBL53	578544	919	110 - 367	1903	Pro-7 to Cys-13, Glu-41 to Trp-46, Ser-60 to Gln-65.	H0038: 1		
HTEBJ02	921321	920	123 - 299	1904		H0038: 1 and L0748: 1.		
HTEBH09	870732	921	23 - 346	1905	Glu-7 to Gly-14.	H0038: 1 and L0758: 1.		
HTEAX06	960792	922	134 - 394	1906	Ala-7 to Val-13, Pro-15 to Val-21.	L0758: 3, L0666: 2, L0021: 1, H0038: 1 and L0665: 1.		
HTEAV22	679394	923	151 - 462	1907		L0439: 2, L0717: 1, H0038: 1, L0769: 1, L0772: 1, L0800: 1, L0666: 1, L0758: 1 and L0601: 1.		
HTEAU39	503295	924	371 - 144	1908	Ser-8 to Asn-19.	L0439: 4 and H0038: 1.		
HTEAT17	667184	925	45 - 311	1909		L0758: 5, H0038: 1 and L0768: 1.		

HTEAS02	921323	926	79 - 324	1910		H0038: 1 and L0758: 1.		
HTEAR93	503298	927	373 - 230	1911	Ser-19 to Trp-27.	H0038: 1		
HTEAQ55	732562	928	3 - 398	1912	Asn-14 to Gln-20, Arg-28 to Glu-40.	L0740: 3, L0731: 3, L0748: 2, L0757: 2 and H0038: 1.		
HTEAJ96	503533	929	216 - 434	1913	Phe-10 to Ser-16, Ser-24 to Gly-50.	H0038: 1		
HTEAH75	503546	930	145 - 336	1914		H0038: 1		
HTEAG47	503623	931	146 - 268	1915	Ala-15 to Leu-24, Pro-32 to Cys-41.	L0748: 2 and H0038: 1.		
HTEAG08	960469	932	17 - 172	1916		H0038: 1 and L0766: 1.		
HTEAB50	724751	933	7 - 324	1917	Ser-17 to Cys-23, Pro-25 to Ala-32.	H0038: 1 and L0758: 1.		
HTEAA04	925522	934	106 - 348	1918	Arg-20 to Tyr-28, Phe-31 to Arg-38, Asp-44 to Arg-51.	L0758: 2 and H0038: 1.		
HEPCB04	941270	935	72 - 305	1919	Ser-1 to Gln-9, Ser-16 to Cys-22, Ser-33 to Ser-38, Ser-58 to Trp-66.	L0777: 4, H0150: 1 and L0757: 1.		
HEPBO92	952996	936	146 - 349	1920	Arg-10 to Ser-18, Leu-37 to Arg-48.	H0150: 1 and L0747: 1.		
HEPBO85	783362	937	1 - 240	1921		L0754: 2 and H0150: 1.		
HEPAY26	825778	938	29 - 193	1922		H0150: 1 and L0743: 1.		

HEPAX40	535627	939	2 - 172	1923		L0744: 2, L0731: 2 and H0150: 1.		
HEPAX16	667665	940	1 - 330	1924		L0766: 3, L0776: 2, H0150: 1, L0371: 1, L0761: 1, L0764: 1, L0662: 1, L0655: 1, L0748: 1, L0754: 1, L0749: 1 and L0779: 1.	11p15.5	125852, 126452, 126452, 141900, 141900, 141900, 141900, 141900, 142000, 142000, 142200, 142250, 142270, 176730, 176730, 176730, 190020, 191290, 192500, 192500, 194071, 194071, 204500, 600856, 601680, 602631,

HEPAQ35	707533	941	245 - 511	1925			L0748: 2, L0756: 2, L0777: 2, H0150: 1, L0789: 1, L0666: 1 and L0758: 1.		602631
HEPAP34	703336	942	369 - 623	1926	Pro-17 to Val-26, His-34 to Lys-41, Pro-54 to Phe-66.		H0150: 1 and L0777: 1.		
HEPAN05	932893	943	223 - 489	1927	Lys-15 to Leu-29, Lys-45 to Glu-55, Lys-82 to Lys-89.		H0150: 1 and L0780: 1.		
HEPAK04	933039	944	4 - 177	1928	Leu-42 to Gly-54.		H0150: 1 and L0763: 1.		
HEPAJ14	657440	945	55 - 243	1929	His-1 to Ser-10, Pro-22 to Gly-38, Asn-55 to Ser-60.		H0150: 1 and L0743: 1.		
HEPAJ04	933091	946	71 - 367	1930	Thr-1 to Arg-16, Ala-45 to Gln-50, Pro-63 to Ala-68, Ala-80 to Asp-93.		H0150: 1, L0779: 1 and L0758: 1.		
HEPAE58	509130	947	174 - 353	1931	Gly-38 to Asp-56.		H0150: 1 and L0743: 1.		
HEPAE02	921389	948	3 - 107	1932	Leu-15 to Lys-24.		H0150: 1 and L0522: 1.		
HEGBC03	922550	949	2 - 304	1933			H0550: 1 and L0646: 1.		
HEGBB67	751233	950	95 - 352	1934	Val-6 to Glu-11, Phe-22 to Cys-29.		H0550: 1 and L0745: 1.		

HEGBA01	915596	951	217 - 372	1935		H0550: 1 and L0605: 1.			
HEGAX04	927260	952	3 - 230	1936	Lys-18 to Glu-23, Gln-60 to Ala-67.	H0550: 1 and L0766: 1.			
HEGAQ91	789940	953	1 - 273	1937		H0550: 1, L0748: 1 and L0749: 1.	Xq22.3	300067, 300067, 300121, 300121, 301201, 301835, 311850	
HEGAL55	731654	954	153 - 359	1938	Lys-5 to Gly-11.	H0550: 1, L0745: 1 and L0731: 1.			
HEGAJ08	959216	955	344 - 511	1939	Pro-7 to Val-13.	L0731: 2, L0597: 2, H0550: 1, L0783: 1 and L0439: 1.			
HEGAC02	918992	956	2 - 196	1940	Ser-7 to Cys-21, Ile-59 to Gly-64.	H0550: 1 and L0758: 1.			
HEEAY84	782706	957	222 - 383	1941	Asn-1 to Lys-14.	H0549: 1 and L0748: 1.			
HEEAX09	912065	958	2 - 328	1942	Arg-65 to Arg-72.	AR051: 4, AR050: 2, AR054: 2 H0549: 1			
HEEAW40	710655	959	222 - 398	1943	Asn-45 to Thr-50, Pro-52 to Arg-57.	H0549: 1, L0589: 1 and L0366: 1.	6q25.2-q27	152200, 167000, 180020, 600320, 600883, 602544	

HEEAP59	738892	960	249 - 413	1944	Leu-32 to Leu-38.	H0549: 1 and L0594: 1.		
HEEAM25	677599	961	101 - 784	1945		L0794: 6, L0806: 2, L0752: 2, H0549: 1, L0796: 1, L0766: 1, L0380: 1, L0803: 1, L0804: 1, L0807: 1, L0789: 1, L0663: 1, L0755: 1, L0596: 1 and L0485: 1.		
HEEAH94	794257	962	114 - 344	1946		H0549: 1 and L0599: 1.		
HEEAH76	769950	963	16 - 213	1947	Val-21 to Gly-26, Leu-29 to Gly-38.	H0549: 1 and L0748: 1.		
HEEAH57	734488	964	219 - 404	1948	Pro-3 to Phe-9, Ser-17 to Ala-24, Val-52 to Lys-62.	H0549: 1 and L0601: 1.		
HEEAH16	661827	965	15 - 344	1949	Ser-45 to Ser-50, Tyr-103 to Phe-110.	H0549: 1 and L0747: 1.		
HEEAG51	930810	966	1 - 423	1950	Glu-61 to Val-77, Phe-81 to Ser-88.	H0549: 1 and L0605: 1.		
HEEAG12	724929	967	266 - 36	1951	Thr-29 to Pro-49, Asp-65 to Glu-77.	AR050: 66, AR054: 64, AR051: 63, AR089: 13, AR061: 3 H0549: 1		
HEEAD13	887048	994	429 - 295	1978				
	470886	968	1 - 195	1952		H0549: 1 and L0756: 1.		
HEEAB40	710668	969	128 - 310	1953	Val-15 to Ala-23,	H0549: 1 and L0748: 1.		

HCDMF96	796196	970	86 - 286	1954	Pro-30 to Ser-35. Gly-12 to Cys-27.	1. L0752: 1 and S0398: 1.			
HCDME32	863374	971	147 - 473	1955	Glu-8 to Met-22, Pro-104 to Pro-109.	L0777: 1, L0758: 1, L0697: 1 and S0398: 1.			
HCDMC86	785134	972	160 - 330	1956	Glu-12 to Leu-20.	S0398: 1			
HCDMC25	677627	973	47 - 283	1957	Gln-9 to Val-17, Phe-38 to Glu-45.	L0439: 1 and S0398: 1.			
HCDMC23	675490	974	116 - 271	1958		S0398: 1			
HCDMC22	672815	975	2 - 241	1959		S0398: 1			
HCDMC06	934663	976	28 - 183	1960		S0398: 1			
HCDMB91	789551	977	185 - 289	1961		S0398: 1			
HCDMB42	713300	978	128 - 244	1962	Gly-12 to His-19.	S0398: 1			
HCDMB41	711996	979	2 - 202	1963	Gly-13 to Asn-22.	L0587: 1 and S0398: 1.			
HCDMB27	682389	980	23 - 148	1964		S0398: 1			
HCDMB12	968918	981	418 - 627	1965	Pro-7 to Gly-24.	AR050: 93, AR054: 62, AR051: 57 S0398: 1			
HCDMB08	958542	982	115 - 267	1966	Gly-38 to Gly-51.	L0753: 1 and S0398: 1.			
HCDMB03	923316	983	88 - 252	1967	Cys-20 to His-27, Glu-35 to Lys-54.	S0398: 1			
HCDMA20	669201	984	3 - 92	1968		L0438: 1, L0439: 1 and S0398: 1.			

- [036] The first column in Table 1A provides a unique "Clone ID NO:Z" for a cDNA clone related to each contig sequence disclosed in Table 1A. This clone ID references the cDNA clone which contains at least the 5' most sequence of the assembled contig, and at least a portion of SEQ ID NO:X was determined by directly sequencing the referenced clone. The reference clone may have more sequence than described in the sequence listing or the clone may have less. In the vast majority of cases, however, the clone is believed to encode a full-length polypeptide. In the case where a clone is not full-length, a full-length cDNA can be obtained by methods known in the art and/or as described elsewhere herein.
- [037] The second column in Table 1A provides a unique "Contig ID" identification for each contig sequence. The third column provides the "SEQ ID NO:X" identifier for each of the testes associated contig polynucleotide sequences disclosed in Table 1A. The fourth column, "ORF (From-To)", provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence "SEQ ID NO:X" that delineate the preferred open reading frame (ORF) shown in the sequence listing and referenced in Table 1A, column 5, as SEQ ID NO:Y. Where the nucleotide position number "To" is lower than the nucleotide position number "From", the preferred ORF is the reverse complement of the referenced polynucleotide sequence.
- [038] The fifth column in Table 1A provides the corresponding SEQ ID NO:Y for the polypeptide sequence encoded by the preferred ORF delineated in column 4. In one embodiment, the invention provides an amino acid sequence comprising, or alternatively consisting of, a polypeptide encoded by the portion of SEQ ID NO:X delineated by "ORF (From-To)". Also provided are polynucleotides encoding such amino acid sequences and the complementary strand thereto.
- [039] Column 6 in Table 1A lists residues comprising epitopes contained in the polypeptides encoded by the preferred ORF (SEQ ID NO:Y), as predicted using the algorithm of Jameson and Wolf, (1988) Comp. Appl. Biosci. 4:181-186. The Jameson-Wolf antigenic analysis was performed using the computer program PROTEAN (Version 3.11 for the Power MacIntosh, DNASTAR, Inc., 1228 South Park Street Madison, WI). In specific embodiments, polypeptides of the invention comprise, or alternatively consist of, at least one, two, three, four, five or more of the predicted epitopes as described in Table 1A. It will be appreciated that depending on

the analytical criteria used to predict antigenic determinants, the exact address of the determinant may vary slightly.

[040] Column 7 in Table 1A provides an expression profile and library code: count for each of the contig sequences (SEQ ID NO:X) disclosed in Table 1A, which can routinely be combined with the information provided in Table 4 and used to determine the normal or diseased tissues, cells, and/or cell line libraries which predominantly express the polynucleotides of the invention. The first number in column 7 (preceding the colon), represents the tissue/cell source identifier code corresponding to the code and description provided in Table 4. For those identifier codes in which the first two letters are not "AR", the second number in column 7 (following the colon) represents the number of times a sequence corresponding to the reference polynucleotide sequence was identified in the tissue/cell source. Those tissue/cell source identifier codes in which the first two letters are "AR" designate information generated using DNA array technology. Utilizing this technology, cDNAs were amplified by PCR and then transferred, in duplicate, onto the array. Gene expression was assayed through hybridization of first strand cDNA probes to the DNA array. cDNA probes were generated from total RNA extracted from a variety of different tissues and cell lines. Probe synthesis was performed in the presence of ^{33}P dCTP, using oligo(dT) to prime reverse transcription. After hybridization, high stringency washing conditions were employed to remove non-specific hybrids from the array. The remaining signal, emanating from each gene target, was measured using a Phosphorimager. Gene expression was reported as Phosphor Stimulating Luminescence (PSL) which reflects the level of phosphor signal generated from the probe hybridized to each of the gene targets represented on the array. A local background signal subtraction was performed before the total signal generated from each array was used to normalize gene expression between the different hybridizations. The value presented after "[array code]:" represents the mean of the duplicate values, following background subtraction and probe normalization. One of skill in the art could routinely use this information to identify normal and/or diseased tissue(s) which show a predominant expression pattern of the corresponding polynucleotide of the invention or to identify polynucleotides which show predominant and/or specific tissue and/or cell expression. The sequences disclosed herein have been determined to be predominantly expressed in testicular

tissues, including normal and diseased testicular tissues (See Table 1A, column 7 and Table 4).

[041] Column 8 in Table 1A provides a chromosomal map location for certain polynucleotides of the invention. Chromosomal location was determined by finding exact matches to EST and cDNA sequences contained in the NCBI (National Center for Biotechnology Information) UniGene database. Each sequence in the UniGene database is assigned to a "cluster"; all of the ESTs, cDNAs, and STSs in a cluster are believed to be derived from a single gene. Chromosomal mapping data is often available for one or more sequence(s) in a UniGene cluster; this data (if consistent) is then applied to the cluster as a whole. Thus, it is possible to infer the chromosomal location of a new polynucleotide sequence by determining its identity with a mapped UniGene cluster.

[042] A modified version of the computer program BLASTN (Altschul et al., J. Mol. Biol. 215:403-410 (1990), and Gish et al., Nat. Genet. 3:266-272 (1993)) was used to search the UniGene database for EST or cDNA sequences that contain exact or near-exact matches to a polynucleotide sequence of the invention (the 'Query'). A sequence from the UniGene database (the 'Subject') was said to be an exact match if it contained a segment of 50 nucleotides in length such that 48 of those nucleotides were in the same order as found in the Query sequence. If all of the matches that met this criteria were in the same UniGene cluster, and mapping data was available for this cluster, it is indicated in Table 1A under the heading "Cytologic Band". Where a cluster had been further localized to a distinct cytologic band, that band is disclosed; where no banding information was available, but the gene had been localized to a single chromosome, the chromosome is disclosed.

[043] Once a presumptive chromosomal location was determined for a polynucleotide of the invention, an associated disease locus was identified by comparison with a database of diseases which have been experimentally associated with genetic loci. The database used was the Morbid Map, derived from OMIM™ (*supra*). If the putative chromosomal location of a polynucleotide of the invention (Query sequence) was associated with a disease in the Morbid Map database, an OMIM reference identification number was noted in column 9, Table 1A, labeled "OMIM Disease

Reference(s)". Table 5 is a key to the OMIM reference identification numbers (column 1), and provides a description of the associated disease in Column 2.

TABLE 1B

Clone ID NO:Z	SEQ ID NO:X	CONTIG ID:	BAC ID: A	SEQ ID NO:B	EXON From-To
HCDMB01	13	915613	AC012484	1979	1-355
HCDMC01	16	915239	AC005789	1980	1-48 1051-2390 2839-3458
HCDMC01	16	915239	AC005789	1981	1-1721 2187-3101 3194-3363 4200-4903 5310-5493 6194-6294 7366-7482 7598-7676 8092-8778 8869-9496
HCDMD23	17	676799	AC018743	1982	1-801
HCDMD23	17	676799	AC018630	1983	1-413
HCDMD23	17	676799	AC018743	1984	1-138
HCDMD23	17	676799	AC018630	1985	1-177
HEEAD64	18	741305	AC011457	1986	1-795 2400-2512
HEEAD64	18	741305	AC006116	1987	1-795 2400-2512
HEEAD64	18	741305	AC011457	1988	1-391
HEEAD64	18	741305	AC006116	1989	1-391
HEEAH07	19	851219	AC019039	1990	1-112
HEEAK84	23	780838	AC004549	1991	1-570
HEEAK84	23	780838	AC004549	1992	1-873
HEEAN24	24	676721	AC073835	1993	1-519
HEEAN24	24	676721	AC012366	1994	1-656
HEEAN24	24	676721	AC012366	1995	1-633 782-1160
HEEAN24	24	676721	AC073835	1996	1-379
HEEAS58	25	735620	AC022730	1997	1-562
HEEAU79	26	706935	AC069419	1998	1-744
HEEAU79	26	706935	AC011311	1999	1-744
HEEAU79	26	706935	AC011311	2000	1-316
HEEAU79	26	706935	AC011311	2001	1-500 3112-3179 3264-3366

					4303-4458 5803-5999 6173-6605 7699-7818 8085-8264 12380-13064 13449-14180 14198-14750 15016-15543 15578-15659 16183-16694 17010-19286
HEEAW01	27	851213	AC003117	2002	1-384
HEEAW01	27	851213	AC003117	2003	1-289
HEEAW13	28	656299	AC005344	2004	1-1022
HEEAW13	28	656299	AC005344	2005	1-612
HEEAW13	28	656299	AC005344	2006	1-569
HEGAA24	29	676716	AC015818	2007	1-416
HEGAA24	29	676716	AC022319	2008	1-416
HEGAA24	29	676716	AC022596	2009	1-429
HEGAA24	29	676716	AC005324	2010	1-419
HEGAA24	29	676716	AL353996	2011	1-429
HEGAA24	29	676716	AC015818	2012	1-435
HEGAA24	29	676716	AC022596	2013	1-435
HEGAA24	29	676716	AC022319	2014	1-435
HEGAA24	29	676716	AC005324	2015	1-435
HEGAA24	29	676716	AL353996	2016	1-434
HEGAB84	31	823900	AC007040	2017	1-750 1028-1687 2050-2327 3305-3352
HEGAB84	31	823900	AC007040	2018	1-513
HEGAB84	31	823900	AC007040	2019	1-745 1107-1335
HEGAK04	33	887299	AP001319	2020	1-790
HEGAK04	33	887299	AP000485	2021	1-789
HEGAK04	33	887299	AP001319	2022	1-471 761-1159 2076-2471 3129-4172 5710-6153
HEGAK04	33	887299	AP000485	2023	1-471
HEGAK04	33	887299	AP001319	2024	1-106
HEGAK04	33	887299	AP000485	2025	1-106
HEGAO83	34	780837	AC024009	2026	1-880 1967-2289 2746-2890

					3236-3284
HEGAO83	34	780837	AC040991	2027	1-880 1967-2288 2745-2889 3235-3283
HEGAO83	34	780837	AC040991	2028	1-176
HEGAP31	35	697419	U73167	2029	1-462 537-572 1142-1632 1720-2993 3778-4687 5675-5764 5875-6565
HEGAP31	35	697419	U90094	2030	1-462 537-572 1142-1632 1720-2993 3778-4687 5675-5764 5875-6565
HEGAP31	35	697419	U73167	2031	1-47 235-1145
HEGAP31	35	697419	U73167	2032	1-463 947-1439 1459-1899 1984-2068 2160-2287 2366-3007 3094-3248 3517-3657 3744-3873 3944-4147 4183-4867
HEGAP31	35	697419	U90094	2033	1-463 947-1439 1459-1899 1984-2068 2160-2287 2366-3007 3094-3248 3517-3657 3744-3873 3944-4147 4183-4867
HEGAP31	35	697419	U90094	2034	1-47 235-1145
HEGAP36	36	706951	AL160314	2035	1-558

HEGAP36	36	706951	AC023226	2036	1-558
HEGAP36	36	706951	AL160314	2037	1-316
HEGAP36	36	706951	AC023226	2038	1-194
HEGAY32	37	699906	AP000759	2039	1-156 199-2013
HEGAY52	38	726316	AC004863	2040	1-272 2151-2257 4711-4808 5669-5932
HEGAY52	38	726316	AC004863	2041	1-517
HEGAY52	38	726316	AC004863	2042	1-307
HEPAA44	40	509456	AP002440	2043	1-554
HEPAD40	43	509002	AC022486	2044	1-599
HEPAD40	43	509002	AC007379	2045	1-599
HEPAD40	43	509002	AC068541	2046	1-599
HEPAD82	44	509452	AC012054	2047	1-199
HEPAD82	44	509452	AC012054	2048	1-367
HEPAK41	47	925146	AL355987	2049	1-1171 2141-2215 2661-2998 3515-3894
HEPAK41	47	925146	AL355987	2050	1-412
HEPAM29	48	508706	AC068515	2051	1-403
HEPAM29	48	508706	AC012256	2052	1-629
HEPAN19	49	508694	AC018422	2053	1-656
HEPAN19	49	508694	AC018422	2054	1-488
HEPAP02	50	926914	AC005041	2055	1-68 87-493 711-838 997-1167 2227-2960 3326-4641 4768-5786
HEPAP02	50	926914	AC005041	2056	1-2920 3439-3667 3839-4332
HEPAP02	50	926914	AC005041	2057	1-143
HEPAP12	51	968771	AC022123	2058	1-704
HEPAS44	52	884083	AC005042	2059	1-526 2088-2310 2826-3158 3165-3449 3645-4062 5680-6042 9261-9489 9723-10014 10575-10710

					12839-14011 17421-17570 17625-17808 19953-20102 20972-21402 21801-22496 23146-23452 25891-26147 27915-28163 36900-37086 40102-40222 40334-40438 41262-41858 42042-42215 44623-45334 45461-45648 47989-48685 52151-52529 52651-52771 55505-56703 57348-57424 58261-58444 58449-58644 58759-59136 59195-60637
HEPAS44	52	884083	AC005042	2060	1-505
HEPBB24	54	508684	AC010862	2061	1-649
HEPBB24	54	508684	AC010862	2062	1-345
HEPBB60	55	855597	AC021139	2063	1-570
HEPBB60	55	855597	AC021139	2064	1-373
HEPBG26	56	967921	AL117692	2065	1-362
HEPBG26	56	967921	AL117692	2066	1-680
HEPBG35	57	508686	AL390242	2067	1-235
HEPBG35	57	508686	AC073965	2068	1-758
HEPBG35	57	508686	AL357055	2069	1-522
HEPBG35	57	508686	AC006286	2070	1-759
HEPBG35	57	508686	AL357055	2071	1-307
HEPBG35	57	508686	AC073965	2072	1-308
HEPBG35	57	508686	AC006286	2073	1-307
HEPBH38	59	707524	AC021881	2074	1-353
HEPBO69	61	888697	AC004464	2075	1-565
HEPBQ47	62	713836	AC015624	2076	1-243
HEPBQ47	62	713836	AC011743	2077	1-94 853-988 2270-2334 3850-4276 4554-4835

					5824-5974 7894-8034 9229-9353 10526-10939 11126-11250 12266-13223
HEPBQ47	62	713836	AC009948	2078	1-125 1141-2098
HEPBQ47	62	713836	AC011743	2079	1-238
HEPBQ47	62	713836	AC009948	2080	1-414
HEPBQ47	62	713836	AC011743	2081	1-914
HEPBQ47	62	713836	AC009948	2082	1-914
HEPBQ69	63	888693	AC011799	2083	1-573
HEPBQ69	63	888693	AC011799	2084	1-413
HEPCE25	66	529343	AL121747	2085	1-823
HEPCE25	66	529343	AL034548	2086	1-823
HEPCE25	66	529343	AL121747	2087	1-277
HEPCE25	66	529343	AL034548	2088	1-277
HEPCE25	66	529343	AL121747	2089	1-2350
HEPCE25	66	529343	AL034548	2090	1-2350
HEPCO59	67	761094	AC025879	2091	1-1719
HEPCO59	67	761094	AC025879	2092	1-457
HEPCT32	68	947081	AC010458	2093	1-95
HTEAD95	73	961232	AC006445	2094	1-1321
HTEAF26	75	537271	AC022988	2095	1-319
HTEAG50	76	787500	AC026462	2096	1-310
HTEAG50	76	787500	AC026462	2097	1-250
HTEAR84	80	783328	AL133353	2098	1-222 225-361 2796-2928 4044-4119 5719-5962 7512-7571 10952-11165 11840-11870 15055-15191 17157-17497 18170-18193 19594-20180 20819-21289 21499-22434 22520-23934
HTEAR84	80	783328	AL133353	2099	1-200 456-609 5860-5998 6526-6629 8425-8724

					9151-9625 12117-12252 15026-15571 15654-16121 16221-16852 19264-19592 21596-21794 22707-22795 23248-23407 23487-23890 25183-26429 26561-27890 28380-28908 28953-29430 29490-32385 32577-35455 36789-37427 37736-38206 38250-38308 38867-39048 39075-39236 39491-39811 39971-40302 40401-40871 41105-41186 41719-41801 43440-43567 43732-44141 44689-44855 46395-46619 47357-47643 47700-47887 48174-48294 48469-48728 50284-50469 52382-52845
HTEAR84	80	783328	AL133353	2100	1-445
HTEAV43	81	927010	AL365184	2101	1-577
HTEAZ54	83	793441	AC024644	2102	1-521
HTEAZ54	83	793441	AC008555	2103	1-797 1423-1942 2185-2716 2806-4251
HTEAZ54	83	793441	AC024644	2104	1-97
HTEBD35	84	967959	AC072024	2105	1-317
HTEBD35	84	967959	AL353796	2106	1-317
HTEBD35	84	967959	AL360172	2107	1-317

HTEBJ78	86	779265	AP001177	2108	1-1021 3487-4086 4668-5157 5193-5665 5913-7625
HTEBJ78	86	779265	AC016186	2109	1-1021
HTEBJ78	86	779265	AC016127	2110	1-1021 2300-2622 3488-4067
HTEBJ78	86	779265	AP001164	2111	1-1021 2463-2587 3494-4093 4675-5164 5200-5672 5920-7633
HTEBJ78	86	779265	AC023989	2112	1-1021 2300-2622 3488-4067
HTEBJ78	86	779265	AP001164	2113	1-340
HTEBJ78	86	779265	AC023989	2114	1-340
HTEBJ78	86	779265	AC016186	2115	1-340
HTEBJ78	86	779265	AC016127	2116	1-340
HTEBJ78	86	779265	AC023989	2117	1-490
HTEBX62	90	508150	AC068620	2118	1-584
HTEBX62	90	508150	AC068620	2119	1-2496 2639-3538
HTEBY15	92	526281	AL117259	2120	1-260
HTEBY41	94	711523	AL357093	2121	1-229
HTEBY41	94	711523	AL157736	2122	1-229
HTEBY41	94	711523	AL357093	2123	1-142
HTEBY41	94	711523	AL357093	2124	1-455
HTEBY41	94	711523	AL157736	2125	1-142
HTEBY41	94	711523	AL157736	2126	1-455
HTEBY61	95	967340	AC020663	2127	1-150 1916-2097 3254-3396 4731-5065 5605-5801 5830-6113 6544-6716 7594-8121 8494-8612 8752-9291 9401-9505 10308-10582 11826-11970 12379-12478

					12796-13085 13942-14925
HTEBY61	95	967340	AC020663	2128	1-265
HTEBZ21	96	958381	AL390764	2129	1-101 236-1007 1038-1344 1353-1493 1641-1750 1837-2006 2542-2700 3557-3720 4326-9299 9617-10008 10623-11068 11238-11714 11800-11992 12001-12566 13314-15677 15882-16457 16614-17442 17850-18427 19713-19802
HTEBZ21	96	958381	AL135843	2130	1-32 1420-1543 2122-2266 2730-3022 3914-4068 4197-4968 4999-5305 5314-5454 5602-5711 5798-5967 6503-6661 7518-7681 8287-13260 13578-13969 14584-15029 15199-15675 15761-15953 15962-16527 17275-19638 19843-20418 20575-21403
HTEBZ21	96	958381	AL136105	2131	1-576
HTEBZ21	96	958381	AL359921	2132	1-703 1021-1412 2027-2470

					2640-3116 3202-3394 3403-3968 4716-7079 7284-7859 8016-8844 9252-9829 11115-11204
HTEBZ21	96	958381	AL136105	2133	1-32 1420-1543 2122-2266 2730-3022 3914-4068 4197-4968 4999-5305 5314-5454 5602-5711 5798-5967 6503-6661 7518-7681 8287-13260 13578-13969 14584-15029 15199-15675 15761-15953 15962-16527 17275-19638 19843-20418 20575-21403 21811-22388 23674-23763
HTEBZ21	96	958381	AL136105	2134	1-311
HTEBZ21	96	958381	AL390764	2135	1-287
HTEBZ21	96	958381	AL135843	2136	1-302
HTEBZ21	96	958381	AL136105	2137	1-1122
HTEBZ21	96	958381	AL359921	2138	1-347 661-1203 1533-2057 2287-2445 3335-3716 5741-6053
HTEBZ21	96	958381	AL136105	2139	1-347 661-1203 1533-2057 2287-2445 3335-3716 5729-6044

HTEBZ21	96	958381	AL136105	2140	1-302
HTECA16	98	764416	AC011726	2141	1-470
HTECA16	98	764416	AC022911	2142	1-470
HTECA16	98	764416	AC011726	2143	1-500
HTECA16	98	764416	AC022911	2144	1-500
HTECA51	101	708860	AL035450	2145	1-93 1880-3178
HTECA51	101	708860	AL035450	2146	1-105
HTECC13	104	971673	AC018638	2147	1-252 3348-3556 3720-3822 3877-4004 4927-5181 5226-5736
HTECC13	104	971673	AC018638	2148	1-130
HTECC37	106	508143	AC073270	2149	1-416
HTECC37	106	508143	AC022202	2150	1-416
HTECC80	109	796820	AC016767	2151	1-35 784-988 1186-1254 1854-2737
HTECC80	109	796820	AL353608	2152	1-140 1348-1579 1810-2502 2585-2694 2831-3054 3202-3273 3513-3903 4019-4053 4802-5008 5205-5273 5873-6756
HTECC80	109	796820	AL078621	2153	1-35 784-988 1187-1255 1855-2739
HTECC80	109	796820	AC016767	2154	1-103
HTECC96	111	959874	AC025977	2155	1-1286
HTECC96	111	959874	AC040170	2156	1-1286
HTECC96	111	959874	AC013513	2157	1-1286
HTECD17	112	508108	AC013812	2158	1-700
HTECD17	112	508108	AL136360	2159	1-707
HTECD17	112	508108	AL132868	2160	1-712
HTECD17	112	508108	AL136360	2161	1-263
HTECD17	112	508108	AL132868	2162	1-1166
HTECD36	114	518124	AL132780	2163	1-562 736-1855

					1931-2051 2232-2897 3495-3673 3759-3882 3968-4030 4121-4203 4369-4532 5620-6405 7007-7151 7615-7702 7882-8106 8655-8942
HTECD36	114	518124	AL132780	2164	1-1058 1452-2073
HTECE44	118	764830	AC026957	2165	1-198 2840-3137 3146-3524 3811-4890 6360-6479 7798-8125 13068-13250 14052-14252
HTECE44	118	764830	AC026957	2166	1-626 1734-2270
HTECE44	118	764830	AC026957	2167	1-514
HTECE91	121	522984	AC021586	2168	1-1460 4600-4966 5827-6179 6596-7246 8893-9973 9991-10696 10851-11246 11352-11783 11934-12787 12926-13555
HTECE91	121	522984	AC021586	2169	1-310
HTECE91	121	522984	AC021586	2170	1-227
HTEDF13	122	522964	AL133499	2171	1-370
HTEDF13	122	522964	AP001579	2172	1-370
HTEDF13	122	522964	AL133499	2173	1-373
HTEDF13	122	522964	AP001579	2174	1-373
HTEDF76	125	522973	AC073612	2175	1-445
HTEDF76	125	522973	AC011601	2176	1-445
HTEDF76	125	522973	AC073612	2177	1-1099
HTEDF76	125	522973	AC011601	2178	1-1099
HTEDG16	126	925527	AC008547	2179	1-196 5138-6241

HTEDG16	126	925527	AC008547	2180	1-615
HTEDI82	133	536477	AL359455	2181	1-396 561-837 2703-2900 3015-3099
HTEDI82	133	536477	AL359455	2182	1-99 404-514 597-985
HTEDJ04	134	519940	AL359767	2183	1-363 411-960
HTEDJ04	134	519940	AL139377	2184	1-363 411-960
HTEDJ04	134	519940	AL359767	2185	1-1831
HTEDJ04	134	519940	AL359767	2186	1-430
HTEDJ04	134	519940	AL139377	2187	1-27 318-1304 2398-3171 3518-4027 4716-4919 6801-6956 9618-9892 9938-10400 10485-11629 14162-18670 18980-19880 20136-20686 21997-22089 23839-23999 24083-24175 25513-26022 27060-27487 27557-28168 28906-29445 31090-31363 31403-31488 31669-33499
HTEDJ04	134	519940	AL139377	2188	1-430
HTEDM08	135	960303	AF215848	2189	1-170 294-404
HTEDM08	135	960303	AC009314	2190	1-171 295-405
HTEDM08	135	960303	AF215848	2191	1-317
HTEDM08	135	960303	AC009314	2192	1-319
HTEDO31	136	870711	AC066613	2193	1-279
HTEDO31	136	870711	AC021238	2194	1-279
HTEDO51	137	530592	AL390816	2195	1-67 5510-5778

HTEDP15	138	870675	AC008119	2196	1-129 1226-2057 3894-4078 4353-5054 5261-6347 6614-7200 9168-9576 10127-10285 11014-11729 11817-12350 12430-12511 12645-12705 13644-13859 15181-15386 16010-16997 17664-18577 18904-19074 20351-20663 20725-20760 22661-23119 23379-23760 24351-24525 24708-25559 25582-29154 29209-29484 29561-30822 31196-31337 31407-31850 31943-32302 33856-33927
HTEDP15	138	870675	AC008119	2197	1-254
HTEDP31	139	870548	AC004674	2198	1-660
HTEDP31	139	870548	AC004674	2199	1-139
HTEDQ30	142	530589	AC011181	2200	1-683
HTEDQ30	142	530589	AC011181	2201	1-443
HTEDQ30	142	530589	AC011181	2202	1-275
HTEDQ83	144	530586	AC018935	2203	1-491
HTEDR71	145	761585	AJ239328	2204	1-367 884-2043 2287-2859 4457-4512 4780-6360 9237-9407 10873-11661
HTEDR71	145	761585	AP000219	2205	1-367 884-2043 2287-2859

					4457-4512 4780-6360 9237-9407 10903-11691
HTEDR71	145	761585	AP000341	2206	1-367 884-2043 2287-2859 4457-4512 4780-6360 9237-9407 10903-11691
HTEDR71	145	761585	AJ239328	2207	1-241
HTEDR71	145	761585	AP000219	2208	1-241
HTEDR71	145	761585	AP000341	2209	1-241
HTEDU48	148	932315	AC026083	2210	1-1222
HTEDU48	148	932315	AC026083	2211	1-416
HTEDU48	148	932315	AC026083	2212	1-442
HTEEE65	158	530157	AC011830	2213	1-164 2053-2094 2375-2846
HTEEE65	158	530157	AC018502	2214	1-164 2053-2094 2375-2846
HTEEE65	158	530157	AC018499	2215	1-164 2053-2094 2375-2846
HTEEE65	158	530157	AC018502	2216	1-2058
HTEEU23	161	524059	AL355801	2217	1-359 3545-3632 6187-6329 7609-7687
HTEEU23	161	524059	AL355801	2218	1-939 1454-1932 2912-3240 3284-3953
HTEEW73	166	917206	AL355377	2219	1-83 578-621 1159-1219 2182-2285 2508-2616 6024-6598
HTEFJ53	168	935982	AC019031	2220	1-710
HTEFJ53	168	935982	AC019031	2221	1-405
HTEFO32	171	529272	AL133264	2222	1-190 1330-1629 2351-5250 5255-5600

					5635-9271 9938-10152 10897-11597 11951-12840 13095-13296 13340-13626 13704-14430 14536-14639 15282-15909 16437-16561 18269-18449 20662-21446 21484-22073
HTEFO76	172	770270	AC055733	2223	1-160 888-1009 1771-2022
HTEFO76	172	770270	AC025148	2224	1-322 946-1105 1827-1948 2710-2961
HTEFO76	172	770270	AC025148	2225	1-924 1228-1751 1793-2057 2224-2959 3239-3297 4754-4965 5736-6035 8675-9217 10252-11580 11720-11844 12753-13021
HTEFS60	176	836010	Z84469	2226	1-640
HTEFW55	178	787550	AL138975	2227	1-703
HTEFW55	178	787550	AC011190	2228	1-703
HTEFW55	178	787550	AL162171	2229	1-118 600-642 4987-5103 8034-8072 8978-9174 9525-9958 10048-10357 10648-11468 11642-12760 12786-12888 13913-14249 14931-15063 15738-16168

					16205-16345 17103-17538 20097-20865 21389-21912 24378-24502 24644-25083 27767-28008 28873-29360 31358-32060 36985-37295 38992-39029 39774-40017 44189-44310 44400-44530 46199-46350 46476-46750 47107-47593 47781-48000 48185-48492 48689-50784
HTEFW55	178	787550	AL162171	2230	1-1502
HTEFW55	178	787550	AL162171	2231	1-294 309-744
HTEFX53	181	842047	AC019054	2232	1-1177
HTEFX53	181	842047	AC019054	2233	1-272
HTEGA13	182	656077	AC016366	2234	1-124 250-1075 1645-1784 3488-3903 4325-4378 5000-5066 5729-5862
HTEGA13	182	656077	AC005237	2235	1-129 864-968 2110-2704 2874-3374 3897-4026 4152-4977 5547-5686 7392-7807 8227-8285 8903-8970 9633-9766 10230-10642 10754-10917 13200-13823 15685-15784

					16202-16302 16342-16496 16754-16865 17467-17820 20203-20289 25130-25260 26385-26486 28046-28566 28884-28989 30114-30820 33068-33452
HTEGA13	182	656077	AC005237	2236	1-592
HTEGF95	189	796660	AC023097	2237	1-1019 1110-1237 1879-2520 2630-2722 2971-3623 3632-3799 4789-5451 5681-5917 6015-6176 7511-7632 7814-8250 9336-9535 9998-11067 12025-12474 14608-14706 15489-15605 16481-16607
HTEGF95	189	796660	AC023097	2238	1-600
HTEGF95	189	796660	AC023097	2239	1-388
HTEGG07	190	954115	AC011842	2240	1-486
HTEGG07	190	954115	AC011842	2241	1-606
HTEGG61	191	528007	AC009220	2242	1-627
HTEGG61	191	528007	AC009220	2243	1-303
HTEGG61	191	528007	AC009220	2244	1-123
HTEGK51	192	520046	AC008555	2245	1-797 1423-1942 2185-2716 2806-4251
HTEGU13	204	520041	AC036208	2246	1-388 3367-3638 4217-4390 4594-4868 6530-6680 7892-7971 9392-9567

					10136-10429
HTEGU13	204	520041	AC036208	2247	1-156
HTEGU62	206	573885	AC036238	2248	1-402
HTEGU62	206	573885	AC036238	2249	1-256
HTEGU62	206	573885	AC036238	2250	1-150
HTEGU93	207	764831	AC026957	2251	1-198 2840-3137 3146-3524 3811-4890 6360-6479 7798-8125 13068-13250 14052-14252
HTEGU93	207	764831	AC026957	2252	1-626 1734-2270
HTEGU93	207	764831	AC026957	2253	1-514
HTEGV60	209	822954	AC013414	2254	1-138 550-714 2702-3122 3973-4262 4649-4745 5363-7228
HTEGV60	209	822954	AC016171	2255	1-127 1017-1306 1693-1789 2407-5049
HTEGV60	209	822954	AC016171	2256	1-4710
HTEGV84	210	870240	AC027120	2257	1-1730
HTEGV84	210	870240	AC023877	2258	1-1730
HTEGV84	210	870240	AC027120	2259	1-85
HTEGV84	210	870240	AC023877	2260	1-85
HTEGW41	211	573880	AL135939	2261	1-541
HTEGW94	212	794350	AC022672	2262	1-1334 1951-2103
HTEGW94	212	794350	AC022672	2263	1-5446
HTEGX74	213	783829	AC027396	2264	1-95 227-318 546-654 669-792 1355-1766
HTEGX74	213	783829	AC027396	2265	1-1730
HTEGY01	214	917214	AC009061	2266	1-123 4295-4489 5148-5404 5536-5632
HTEGY01	214	917214	AC009061	2267	1-101
HTEHB07	216	870707	AC020575	2268	1-625

					1178-1625
HTEHB07	216	870707	AC027000	2269	1-625 1177-1624
HTEHC60	219	965998	AC007343	2270	1-695
HTEHC60	219	965998	AC018553	2271	1-695
HTEHC60	219	965998	AC007343	2272	1-494
HTEHC60	219	965998	AC018553	2273	1-494
HTEHE60	221	795264	AC007114	2274	1-738
HTEHE60	221	795264	AC007114	2275	1-359
HTEHE78	223	932312	AC022621	2276	1-419
HTEHE78	223	932312	AC022621	2277	1-634
HTEHE78	223	932312	AC022621	2278	1-398
HTEHF66	226	836999	AL109657	2279	Γ-67 611-694 1472-1552 7387-7447 7998-8086 10739-10859
HTEHI93	232	870629	AL121926	2280	1-402
HTEHX32	253	772643	AL049742	2281	1-694
HTEIA80	257	721831	AC021473	2282	1-258
HTEIA80	257	721831	AC016310	2283	1-257
HTEIA80	257	721831	AC021473	2284	1-114
HTEIA80	257	721831	AC016310	2285	1-114
HTEIF40	258	958355	AL157687	2286	1-40 249-903 1489-1913 2058-2116 2558-2733 2737-2876 3462-3623 5522-5820 5917-6004
HTEIF40	258	958355	AL161668	2287	1-40 249-903 1489-1913 2058-2116 2558-2892 3479-3633 5532-5830 5927-6014
HTEIF40	258	958355	AL157687	2288	1-307
HTEIF40	258	958355	AL161668	2289	1-307
HTEIF68	259	573828	AP001887	2290	1-311
HTEIF68	259	573828	AP002008	2291	1-311
HTEIF68	259	573828	AP001887	2292	1-107
HTEIF68	259	573828	AP002008	2293	1-357

HTEIF68	259	573828	AP001887	2294	1-357
HTEIF68	259	573828	AP002008	2295	1-107
HTEIH70	261	573826	AC020908	2296	1-85 759-1469 2611-2787 3133-3229 3908-3972 4076-4239 5908-6009 6780-6924 8969-9104 9180-9480 9730-10047 10173-10906 12607-13024
HTEIH70	261	573826	AC020908	2297	1-183
HTEIK90	267	789121	AL161442	2298	1-380
HTEIK90	267	789121	AL161442	2299	1-185 1241-1480 3780-4356 5514-5666 6203-6495 6752-7126 7461-7946 10053-10148 10892-10967 12645-13553
HTEIK90	267	789121	AL161442	2300	1-323
HTEIL48	269	523681	AC026861	2301	1-38 601-692 1658-1810 2194-2275
HTEIO02	274	920622	AC010632	2302	1-38 1512-1878 2899-2944 3751-4080
HTEIO02	274	920622	AC010632	2303	1-523
HTEIO02	274	920622	AC010632	2304	1-394
HTEIO28	276	573803	AC067839	2305	1-489
HTEIO28	276	573803	AC007898	2306	1-489
HTEIO28	276	573803	AL359508	2307	1-346
HTEIP88	277	941155	AC068659	2308	1-51 583-821 4529-4916 5879-6079 6298-6442 7345-7447

					7836-8136 8423-8833 12525-12677 13528-13727 14268-14602 14605-14655 15410-15666 17282-18408
HTEIP88	277	941155	AC012183	2309	1-51 583-821 4528-4915 5878-6078 6297-6441 7344-7446 7835-8135 8422-8832 12525-12677 13529-13728 14269-14603 14606-14656 15410-15666 17282-18408
HTEIP88	277	941155	AC068659	2310	1-482
HTEIP88	277	941155	AC012183	2311	1-482
HTEIP88	277	941155	AC068659	2312	1-1254
HTEIP88	277	941155	AC012183	2313	1-1254
HTEIP92	278	523892	AC013252	2314	1-368
HTEIP92	278	523892	AC013252	2315	1-952
HTEIP92	278	523892	AC013252	2316	1-413
HTEIQ74	279	765794	AC055815	2317	1-681
HTEIQ74	279	765794	AC026801	2318	1-681
HTEIQ74	279	765794	AC008690	2319	1-681
HTEIQ74	279	765794	AC055815	2320	1-435
HTEIQ74	279	765794	AC026801	2321	1-435
HTEIQ74	279	765794	AC008690	2322	1-435
HTEIR33	280	928058	AL139130	2323	1-164 346-423 545-673 1188-1349 3339-3655 4129-4219 6133-6265 8323-8553
HTEIR33	280	928058	AL139130	2324	1-196 418-529 695-927 1596-1660

					1751-1803 2056-2085 2710-2770 3176-4018 5037-5258
HTEIU75	282	779163	AL390863	2325	1-51 469-1032
HTEIU75	282	779163	AL136370	2326	1-51 469-1032
HTEIV86	285	784657	AC021467	2327	1-44 1339-1503 2150-2290 3993-4708
HTEIV86	285	784657	AC009761	2328	1-112 759-899 2602-3318
HTEIX85	288	864251	AL161614	2329	1-2924 3023-4030 5001-5171 7210-7434 7618-7734 9610-9764 10165-10247 11951-12426 12489-12966 12976-14097 14682-14894 15043-15480 15790-16240 18111-18240 19064-19538 21727-21871 22803-22927
HTEIY52	289	963536	AC067940	2330	1-358
HTEIY52	289	963536	AC067940	2331	1-304
HTEIY69	290	577783	AC013615	2332	1-1089
HTEIY69	290	577783	AC019281	2333	1-1089
HTEIY69	290	577783	AC013615	2334	1-386
HTEIY69	290	577783	AC019281	2335	1-386
HTEJB81	295	870644	AC005230	2336	1-267 506-723 867-1915 24366-24674 28859-29337 45854-46053
HTEJB81	295	870644	AC005230	2337	1-505
HTEJC28	296	573774	AL358214	2338	1-298

HTEJE15	298	908360	AC016632	2339	1-220 361-469 1509-2194
HTEJE15	298	908360	AC016639	2340	1-220 362-470 1510-2195
HTEJE15	298	908360	AC008914	2341	1-220 361-469 1512-2197
HTEJG24	301	526278	AL139237	2342	1-430
HTEJG24	301	526278	AC025004	2343	1-430
HTEJG24	301	526278	AC021540	2344	1-430
HTEJJ43	302	774243	AC018519	2345	1-214 309-383 1911-2211 2693-2983 3679-4166 4899-4949 9474-9544
HTEJJ43	302	774243	AC018519	2346	1-611
HTEJM56	304	952255	AC025036	2347	1-148
HTEJM56	304	952255	AC027300	2348	1-158
HTEJM56	304	952255	AC016327	2349	1-165
HTEJM56	304	952255	AC016327	2350	1-195
HTEJN49	306	558383	AL354888	2351	1-250
HTEJN49	306	558383	AC067884	2352	1-250
HTEJN49	306	558383	AL033527	2353	1-250
HTEJN49	306	558383	AL354888	2354	1-391
HTEJN49	306	558383	AC067884	2355	1-391
HTEJN49	306	558383	AL033527	2356	1-392
HTEJT37	310	530596	AC011318	2357	1-170 4244-4812
HTEJT37	310	530596	AC027296	2358	1-404
HTEJT37	310	530596	AC012340	2359	1-404
HTEJX78	314	806395	AL136373	2360	1-131 694-1754
HTEJX78	314	806395	AL357392	2361	1-112 675-1735
HTEJX78	314	806395	AC013593	2362	1-131 694-1754
HTEJX78	314	806395	AL357392	2363	1-3661 5981-6371 6517-7301 8141-8268 9332-9897 11527-11603 11625-11713

					13194-13546 14430-14533 16668-16939
HTEJX78	314	806395	AL136373	2364	1-217
HTEJX78	314	806395	AC013593	2365	1-3662 5982-6372 6518-7302 8142-8269 9333-9446 9450-9898 11528-11604 11626-11714 13195-13547 14428-14534 16669-16940 18704-20067 20193-20457 20794-22689
HTEKC07	317	920925	AL359708	2366	1-546
HTEKC07	317	920925	AL139318	2367	1-546
HTEKD04	319	519938	AC026525	2368	1-1001 1500-1654 1958-2325
HTEKF35	325	573749	AC016878	2369	1-152 2683-2792
HTEKF35	325	573749	AC023911	2370	1-152 2683-2792
HTEKF35	325	573749	AC011272	2371	1-152 2681-2790
HTEKF35	325	573749	AC023911	2372	1-128
HTEKF35	325	573749	AC011272	2373	1-128
HTEKF68	326	772997	AL357117	2374	1-634
HTEKF68	326	772997	AC023219	2375	1-634
HTEKI70	328	503039	AC009648	2376	1-230 1002-1211 1349-1470 2451-2575 2924-3218 3509-3805
HTEKI70	328	503039	AC009648	2377	1-103 188-274 326-447 2665-2749 3400-4013
HTEKO49	331	723148	AC021527	2378	1-159 330-389 747-1508

					1628-1889 2484-3286
HTEKO49	331	723148	AC006211	2379	1-159 330-389 747-1508 1628-1889 2484-3286
HTEKO49	331	723148	AC021527	2380	1-233
HTEKO49	331	723148	AC006211	2381	1-233
HTEKQ26	332	870627	AC069404	2382	1-343
HTEKQ85	333	784444	AP000879	2383	1-39 770-842 2822-3250 3862-4296
HTEKQ85	333	784444	AP000879	2384	1-355
HTEKS20	336	846714	AL137023	2385	1-1052
HTEKS20	336	846714	AL137023	2386	1-868 1143-1650
HTEKS76	338	767658	AC073366	2387	1-121 756-1172
HTEKS76	338	767658	AC012683	2388	1-121 756-1172
HTEKS76	338	767658	AC069546	2389	1-121 756-1172
HTEKX06	339	935945	AC020603	2390	1-434
HTEKX06	339	935945	AC020603	2391	1-89
HTEKX08	340	959876	AC064835	2392	1-2215
HTEKX28	341	920927	AC027120	2393	1-1730
HTEKX28	341	920927	AC069399	2394	1-1153
HTEKX28	341	920927	AC023877	2395	1-1730
HTEKX28	341	920927	AC027120	2396	1-85
HTEKX28	341	920927	AC023877	2397	1-85
HTEKZ50	343	524054	AC008552	2398	1-424
HTEKZ50	343	524054	AC008385	2399	1-424
HTEKZ50	343	524054	AC008385	2400	1-435
HTELD47	345	934272	AC017113	2401	1-883 888-1012 1959-2108 2538-3546 5010-5154 6554-6734
HTELD47	345	934272	AL109804	2402	1-885 890-1014 1960-2109 2553-3562 5027-5172 6576-6756

HTELD47	345	934272	AC017113	2403	1-1019
HTELD47	345	934272	AL109804	2404	1-493 810-1071 1154-2175
HTELG47	349	757740	AC024231	2405	1-377 458-535
HTELG47	349	757740	AC016891	2406	1-377 458-535
HTELG47	349	757740	AC024231	2407	1-533
HTELG47	349	757740	AC016891	2408	1-533
HTELG57	350	870621	AL356494	2409	1-2375 2863-3250 3804-3987
HTELG57	350	870621	AL353662	2410	1-2375 2863-3250 3804-3987
HTELG57	350	870621	AL356494	2411	1-538
HTELG57	350	870621	AL356494	2412	1-85 637-1181
HTELG57	350	870621	AL353662	2413	1-538
HTELG57	350	870621	AL353662	2414	1-85 637-1181
HTELH44	352	766462	AC006480	2415	1-266 1371-2150
HTELH44	352	766462	AC006480	2416	1-369
HTELI03	353	923071	AC068698	2417	1-587
HTELI03	353	923071	AC005157	2418	1-587
HTELI03	353	923071	AC068698	2419	1-276
HTELI03	353	923071	AC068698	2420	1-427
HTELI03	353	923071	AC005157	2421	1-427
HTELI03	353	923071	AC005157	2422	1-273
HTELJ89	355	966134	AL023585	2423	1-117 211-466
HTELJ89	355	966134	AC024690	2424	1-123 217-474
HTELJ89	355	966134	AL358783	2425	1-123 217-474
HTELJ89	355	966134	AL023585	2426	1-122 217-474
HTELJ89	355	966134	AL022101	2427	1-123 217-474
HTELK14	356	794339	Z99716	2428	1-56 2209-2313 3622-3727 3907-4268 5968-6088 6723-7099

HTELK14	356	794339	Z99716	2429	1-291
HTELK14	356	794339	Z99716	2430	1-100 161-616 2777-2861 3555-3660 5314-5769
HTELK50	357	870552	AC025953	2431	1-75 1003-1162
HTELK50	357	870552	AL355516	2432	1-77 1002-1161
HTELK50	357	870552	AC015873	2433	1-77 1002-1161
HTELK68	358	923055	AL110504	2434	1-658
HTELK68	358	923055	AL110504	2435	1-346
HTELK68	358	923055	AL110504	2436	1-420
HTELL48	359	783824	AC027195	2437	1-649
HTELL48	359	783824	AC027195	2438	1-105
HTELL48	359	783824	AC027195	2439	1-729
HTELO20	363	926910	AL031597	2440	1-346 524-615
HTELO73	365	761806	AL078613	2441	1-96 242-666
HTELO93	366	934344	AC012391	2442	1-400
HTELO93	366	934344	AC023283	2443	1-270
HTELO93	366	934344	AC012308	2444	1-400
HTELO93	366	934344	AC023283	2445	1-314 1245-1274
HTELO93	366	934344	AC012308	2446	1-317
HTELO93	366	934344	AC012308	2447	1-235
HTELQ87	369	761768	AC024958	2448	1-404 2868-3192
HTELQ87	369	761768	AC018422	2449	1-404 2868-3192
HTELT72	371	761598	AC011237	2450	1-633 697-899 1405-1529 1983-2165 2371-2490 4239-4353 6793-6880 6993-8390 8442-8767 9115-9434
HTELT72	371	761598	AF214633	2451	1-633 697-899 1405-1529 1983-2165

					2371-2490 4239-4353 6793-6880 6993-8387 8439-8764 9112-9431
HTELT72	371	761598	AC011237	2452	1-2683 2788-2900 3022-3162 3429-3503 3651-3777 4664-5070 5348-5888 6053-6296 6742-6875 7101-7249 7462-8011 8400-9118 9860-10566 10670-11294
HTELT72	371	761598	AF214633	2453	1-2685 2790-2902 3024-3164 3431-3505 3653-3779 4666-5072 5351-5891 6056-6299 6745-6878 7104-7252 7465-8014 8403-9121 9863-10569 10673-11487 12212-12665 12994-13576 14033-14265 14998-15123
HTELT72	371	761598	AC011237	2454	1-367
HTELT72	371	761598	AF214633	2455	1-367
HTELU01	373	915339	AL033517	2456	1-375
HTELV10	375	963576	AC010339	2457	1-256
HTELV10	375	963576	AC008674	2458	1-256
HTELV10	375	963576	AC008674	2459	1-95
HTELW29	379	952241	AC009131	2460	1-780
HTELW29	379	952241	AC009131	2461	1-246
HTELW29	379	952241	AC009131	2462	1-270

HTELX52	381	963506	AL390858	2463	1-70 733-1332
HTELX52	381	963506	AC026025	2464	1-70 733-1332
HTELX52	381	963506	AL390858	2465	1-457
HTELX52	381	963506	AC026025	2466	1-457
HTELX72	382	761599	AC009682	2467	1-263
HTELX72	382	761599	AL358940	2468	1-263
HTELY64	383	764834	AL356056	2469	1-445
HTELY64	383	764834	AL136982	2470	1-445
HTELY64	383	764834	AL356056	2471	1-328
HTELY64	383	764834	AL356056	2472	1-371
HTELY64	383	764834	AL136982	2473	1-78 179-861
HTELY64	383	764834	AL136982	2474	1-371
HTEMA54	386	911666	AL359692	2475	1-1487
HTEMB26	387	827055	AC004900	2476	1-112
HTEMB26	387	827055	AC004900	2477	1-2372 2882-2974 3048-3578 4547-4806 5624-6285 7400-7547 10800-11164 11907-12010 16372-16542 17325-17552 19368-19662 22876-23302 28256-28683 31524-31990 35872-36237 36287-36728 37997-38535 38707-38829 39160-39466 40178-40339 40353-40480 40782-41520 42009-42538
HTEMB26	387	827055	AC004900	2478	1-1968
HTEMB34	389	870589	AL354940	2479	1-649
HTEMB34	389	870589	AL157708	2480	1-649
HTEMB34	389	870589	AL359554	2481	1-649
HTEMB83	391	775593	AL050341	2482	1-294 621-1371 3345-3753

HTEMC75	393	848193	AC074117	2483	1-93 317-475 850-1162 1511-2098 2194-4316 4373-4717 4836-5053 5192-5313 5403-5497 5798-6033 6121-6210 6370-6841 7244-7310 7582-7935 8489-8606 9212-9266
HTEMC75	393	848193	AC074117	2484	1-70 485-599 880-966 1279-1414 2072-2489 3066-3209 3281-4159 4400-4694 4931-6271
HTEMD10	394	963546	AC005858	2485	1-655
HTEMJ34	397	786377	AC021491	2486	1-124 290-781 1447-1562 1650-1767 2309-2417 3273-3466 3935-4120 5213-5358 6216-6605 7621-7744 8491-8761 9044-9175 9353-9523 9966-10843 11395-11839
HTEMJ34	397	786377	AC021491	2487	1-228 3662-4225
HTEMJ54	398	963531	AC026334	2488	1-1272 1874-2420 4782-5167 5373-5502

					5508-5671 5752-6010 6478-6836 7094-7292 7526-8820 9237-9731
HTEMJ54	398	963531	AC060226	2489	1-1272
HTEMJ54	398	963531	AC060226	2490	1-547
HTEMJ54	398	963531	AC026334	2491	1-424
HTEMJ54	398	963531	AC060226	2492	1-424
HTEMN08	401	958374	AP001016	2493	1-248
HTEMN08	401	958374	AC011077	2494	1-248
HTEMN08	401	958374	AP002381	2495	1-248
HTEMN08	401	958374	AC011077	2496	1-339
HTEMN08	401	958374	AP001016	2497	1-339
HTEMN08	401	958374	AP002381	2498	1-339
HTEMN95	402	789113	AC005540	2499	1-157 1565-1735
HTEMP48	405	767863	AL121747	2500	1-181 315-683 1416-1776 1804-2673 2940-3611 3880-4030 4596-4924 5925-6032 6514-6965 7032-7135 7196-7771 8229-8385 9347-9435 11732-13123
HTEMP48	405	767863	AL049761	2501	1-573 2229-2431 2486-2797 3011-3299 3434-3924 4487-4614 5864-6151 6385-6768 6786-7099 7437-7594 7761-8029 8318-9645 9767-10324 10882-10944 11032-11505

					12853-13033 13167-13535 14268-14627 14656-15525 15792-16463 16731-16911 17448-17776 18777-18886 19366-19817 19884-19987 20048-20606 21085-21248 22199-22289 24584-25975
HTEMP48	405	767863	AL121747	2502	1-1738
HTEMP48	405	767863	AL049761	2503	1-1738
HTEMP48	405	767863	AL049761	2504	1-267
HTEMP49	406	932319	AC005848	2505	1-50 276-606 3099-3179 3390-3458 4162-4388
HTEMU17	411	789623	AL159141	2506	1-210 345-515 4335-4446 9330-9443 9841-9904 11140-12334 12776-13144 13501-13916 17369-18981
HTEMU17	411	789623	AL118559	2507	1-369
HTEMU17	411	789623	AL159141	2508	1-318
HTEMU17	411	789623	AL118559	2509	1-416
HTEMU17	411	789623	AL118559	2510	1-231
HTEMZ04	415	927021	AC068707	2511	1-102 574-851
HTEMZ04	415	927021	AC068707	2512	1-202
HTENB03	417	923050	AL157814	2513	1-490
HTENB03	417	923050	AL157814	2514	1-30 1784-1887 2320-2867
HTENB03	417	923050	AL157814	2515	1-550
HTENC22	418	775544	AC069539	2516	1-890 999-1314 1794-4625
HTENC22	418	775544	AC069539	2517	1-416

HTENC22	418	775544	AC069539	2518	1-129
HTENF08	419	958378	AC018682	2519	1-752
HTENF08	419	958378	AC018682	2520	1-252
HTENI58	423	917213	AL121980	2521	1-716
HTENI58	423	917213	AL121980	2522	1-179 373-573
HTENK69	427	844557	AC063919	2523	1-696 1146-1317 1506-1768
HTENK69	427	844557	AC073439	2524	1-696 1146-1317 1506-1768
HTENO50	429	969213	AC009874	2525	1-315 1284-1411 1668-1749 3993-4056 4183-4346 5547-6161 6198-6612 6660-6806 7328-7394 7459-7881 8005-8503 8700-8977 9207-9362 10056-10514 12312-12436
HTENO50	429	969213	AC009874	2526	1-1809 1985-2077 2851-7606
HTENP80	431	775387	AL035453	2527	1-408 4407-4511
HTENP80	431	775387	AL035453	2528	1-342
HTENQ05	432	928244	AC024952	2529	1-126 1960-2212 2845-2947 6326-6450 9966-10000 12088-12311 13031-13145 13786-13869 14356-14874
HTENQ05	432	928244	AC018638	2530	1-123 666-828 4839-5113 6402-6995 7727-7910

					9744-9996 10630-10732 14112-14236 17737-17771 19858-20081 20801-20915 21556-21640 22127-22645
HTENQ05	432	928244	AC024952	2531	1-368
HTENQ05	432	928244	AC018638	2532	1-368
HTENQ05	432	928244	AC018638	2533	1-374
HTENS22	435	785996	AP001034	2534	1-964 1560-2151
HTENS22	435	785996	AC015840	2535	1-965 1070-1278 1561-2152
HTENS22	435	785996	AC015840	2536	1-422
HTENS43	436	784936	AC011959	2537	1-189 439-1562
HTENS43	436	784936	AF131216	2538	1-188 440-1562
HTENS91	437	870515	AC016771	2539	1-688
HTENS91	437	870515	AC048382	2540	1-1000
HTENS91	437	870515	AC016771	2541	1-53 468-636 1619-1744 2423-2651 2790-3043 4364-4636 7345-7727
HTENS91	437	870515	AC048382	2542	1-255
HTENX77	440	771409	AP000484	2543	1-1719
HTENX77	440	771409	AP000484	2544	1-255
HTENX77	440	771409	AP000484	2545	1-103 2060-2420 4856-5151
HTENY35	442	884043	AC006208	2546	1-1385 1465-3044 3323-3377 3821-3917 4057-4165 4748-4778 4805-5177 5224-5464 5956-6173 6207-7085 8138-8296

					8758-9056 9162-9263 9638-9764 10225-10392 10853-11247 11548-12281 12417-12970
HTEY35	442	884043	AC006208	2547	1-1425 1603-1678 1783-1875 2028-3154 3258-3740 3768-4488 4764-4913 5252-5382 5827-5905 6172-6319 6397-6466 6957-7076 7473-7606 8554-8608 8714-8741 8840-8984
HTEOF91	450	918571	AL133387	2548	1-1187
HTEOF91	450	918571	AL135794	2549	1-1189
HTEOF91	450	918571	AL133387	2550	1-47 231-264 355-857
HTEOF91	450	918571	AL135794	2551	1-146
HTEOF91	450	918571	AL133387	2552	1-140
HTEOF91	450	918571	AL135794	2553	1-47 231-264 355-857
HTEOK02	453	918590	AL136084	2554	1-486
HTEOK02	453	918590	AL136084	2555	1-181 2911-3377
HTEON67	455	954114	AC004533	2556	1-347
HTEOU45	456	915138	AC016309	2557	1-708
HTEOU45	456	915138	AC016309	2558	1-1634
HTEOV90	457	870532	AL359092	2559	1-116
HTEOV90	457	870532	AC009453	2560	1-143
HTEOV90	457	870532	AC025036	2561	1-148
HTEOV90	457	870532	AC011953	2562	1-126
HTEOV90	457	870532	AC027300	2563	1-158
HTEOV90	457	870532	AC022231	2564	1-151
HTEOV90	457	870532	AC023242	2565	1-86
HTEOV90	457	870532	AC048342	2566	1-130

HTEOV90	457	870532	AL121656	2567	1-2346 2487-3703 3832-4167
HTEOV90	457	870532	AC048342	2568	1-118
HTEOW39	459	870566	AL356464	2569	1-142 570-728 1523-1638 1741-1926
HTEOW39	459	870566	AL356797	2570	1-142 570-728 1523-1638 1741-1926
HTEOW39	459	870566	Z98304	2571	1-142 570-728 1523-1638 1742-1926
HTEOW39	459	870566	AL356464	2572	1-538
HTEOW39	459	870566	AL356464	2573	1-437
HTEOW39	459	870566	AL356797	2574	1-136
HTEOW39	459	870566	AL356797	2575	1-437
HTEOW39	459	870566	Z98304	2576	1-538
HTEOW39	459	870566	Z98304	2577	1-437
HTEPA08	461	958391	AL133480	2578	1-918 1739-2284 2588-2821
HTEPA08	461	958391	AC021645	2579	1-918 1739-2284 2588-2821
HTEPA08	461	958391	AL133480	2580	1-640
HTEPA08	461	958391	AL133480	2581	1-331
HTEPA08	461	958391	AC021645	2582	1-331
HTEPA08	461	958391	AC021645	2583	1-640
HTEPC76	465	767824	AC008403	2584	1-270 797-964 1044-1123 1229-1342 1467-1845 2640-2987 3113-4431 4439-4555 5060-5233 5373-5488 6011-6410 6946-7068 7284-7513 8720-8791 8874-9044

					9864-10381 10706-10846 12118-12821 12983-13117 13377-14044 14066-15218 16961-17324
HTEPC76	465	767824	AC008403	2585	1-1468
HTEPC76	465	767824	AC008403	2586	1-583
HTEPJ79	472	774212	AC073569	2587	1-370
HTEPJ79	472	774212	AC073595	2588	1-371
HTEPJ79	472	774212	AC007949	2589	1-371
HTEPM33	474	870561	AL132776	2590	1-42 1020-1195 2173-2338 6839-7029 11880-12103
HTEPM33	474	870561	AL132776	2591	1-173
HTEPM33	474	870561	AL132776	2592	1-791
HTEPM52	475	806471	AC022744	2593	1-600
HTEPM52	475	806471	AC009588	2594	1-600
HTEPM52	475	806471	AC022744	2595	1-197
HTEPM52	475	806471	AC009588	2596	1-86 404-641 1062-1413 1506-1869 2725-3045 3625-4106
HTEPP29	478	917207	AC064831	2597	1-467
HTEPP29	478	917207	AC023103	2598	1-470
HTEPP29	478	917207	AC036199	2599	1-470
HTEPT25	483	870509	AC074256	2600	1-408
HTEPZ10	488	963433	AC011028	2601	1-543
HTEQB03	490	922941	AC023331	2602	1-393
HTEQB03	490	922941	AL358236	2603	1-391
HTEQB03	490	922941	AL359374	2604	1-391
HTEQB03	490	922941	AL358236	2605	1-220
HTEQB03	490	922941	AC023331	2606	1-292
HTEQB03	490	922941	AL359374	2607	1-116 130-210
HTEQB03	490	922941	AL359374	2608	1-290
HTEQD40	491	915198	AL121906	2609	1-158 414-924 975-1601
HTEQD40	491	915198	AL121906	2610	1-776 856-949 1390-1468

					1591-2048 2412-2463 2503-2918 3174-3270
HTEQD40	491	915198	AL121906	2611	1-411
HTEQD69	492	918579	AL157399	2612	1-712
HTEQD69	492	918579	AC018476	2613	1-712
HTEQD69	492	918579	AC007949	2614	1-711
HTEQD69	492	918579	AC018476	2615	1-922 1159-1246 1288-1481 1547-1649 1673-1758 2026-2482 2668-3297
HTEQD69	492	918579	AC018476	2616	1-145 541-677 1557-1852
HTEQD69	492	918579	AC007949	2617	1-145 541-677 1555-1850
HTEQD69	492	918579	AC007949	2618	1-314
HTEQJ42	497	806495	AC007405	2619	1-510
HTEQO81	498	806504	AC010766	2620	1-198 316-378 3441-3601
HTEQO81	498	806504	AL163636	2621	1-198 316-378 3442-3602
HTEQO81	498	806504	AL163195	2622	1-198 316-378 3442-3602
HTEQO81	498	806504	AC010766	2623	1-301
HTEQO81	498	806504	AC010766	2624	1-591
HTEQO81	498	806504	AL163636	2625	1-591
HTEQO81	498	806504	AL163636	2626	1-177
HTEQO81	498	806504	AL163195	2627	1-293
HTEQO81	498	806504	AL163195	2628	1-591
HTEQR94	502	966486	AC010980	2629	1-1047
HTEQT63	503	924799	AC026410	2630	1-1820
HTLAB44	505	530579	AC006549	2631	1-530
HTLAB44	505	530579	AC000097	2632	1-530
HTLAB44	505	530579	AC006547	2633	1-530
HTLAB44	505	530579	AC006549	2634	1-42 147-212 380-436 699-747

					821-1197
HTLAB44	505	530579	AC006549	2635	1-311
HTLAB44	505	530579	AC000097	2636	1-42 147-212 380-436 699-747 821-1197
HTLAB44	505	530579	AC000097	2637	1-311
HTLAB44	505	530579	AC006547	2638	1-42 147-212 380-436 699-747 821-1197
HTLAB44	505	530579	AC006547	2639	1-314
HTLAB73	506	575019	AC000078	2640	1-341 2484-3046 3397-3489 4877-5165 5231-5303 5477-5578 6429-7030 7187-7509 7842-8148
HTLAB73	506	575019	AC000078	2641	1-507
HTLAC81	507	679414	AC019258	2642	1-200
HTLAC81	507	679414	AP002807	2643	1-204
HTLAC81	507	679414	AC034259	2644	1-204
HTLAD21	509	761758	AC024029	2645	1-37 1140-1255 2004-2115 2586-2801 3347-3460 4242-4320 4959-5284
HTLAD21	509	761758	AC019121	2646	1-37 1140-1249 2584-2799 3342-3460 4243-4321 4956-5281
HTLAD21	509	761758	AC019121	2647	1-336
HTLAD21	509	761758	AC024029	2648	1-336
HTLAV67	512	530742	AC005258	2649	1-326
HTLAV67	512	530742	AC005258	2650	1-278
HTLAV67	512	530742	AC005258	2651	1-89
HTLBF14	516	971661	AC018638	2652	1-252 3348-3556

					3720-3822 3877-4004 4927-5181 5226-5736
HTLBF14	516	971661	AC018638	2653	1-130
HTLBG83	517	527942	AP002840	2654	1-102 1010-1888 2064-2785
HTLBG83	517	527942	AC016056	2655	1-290
HTLBG83	517	527942	AC009466	2656	1-94 1419-1520 2428-3306 3482-4203
HTLBG83	517	527942	AP000880	2657	1-94 1419-1520 2428-3306 3482-4203
HTLBG83	517	527942	AC009466	2658	1-998
HTLBG83	517	527942	AP002840	2659	1-368
HTLBG83	517	527942	AP000880	2660	1-368
HTLBG83	517	527942	AC009466	2661	1-368
HTLBG83	517	527942	AP000880	2662	1-996
HTLCA95	518	911655	AC012616	2663	1-1151
HTLCA95	518	911655	AC012616	2664	1-284
HTLCX76	520	767667	AC011736	2665	1-97 612-718 913-1065 5655-5767 6173-6351 6803-6954 9565-9706 13178-13360 13963-14058 17351-17653 19337-19476 22288-22405 22711-22769 24564-24601 25844-25947 26983-27370 28050-28233 29000-29163
HTLCX76	520	767667	AC027618	2666	1-97 612-718 913-1065 5657-5768 6174-6352

					6807-6958 9568-9709 13178-13216
HTLCX76	520	767667	AC027618	2667	1-89
HTLCX76	520	767667	AC011736	2668	1-152
HTLCX76	520	767667	AC027618	2669	1-40 3350-3648 7546-7581
HTLCZ48	522	572959	AC015497	2670	1-402
HTLCZ48	522	572959	AL353695	2671	1-405
HTLCZ48	522	572959	AC015497	2672	1-140
HTLCZ48	522	572959	AL353695	2673	1-140
HTLCZ96	523	815897	AL118498	2674	1-160 1685-1871 2742-2910 5414-5599 6883-6914 8226-8271 9277-9733 11311-11543
HTLDE64	526	908613	AC005087	2675	1-207 524-773 945-1056 3251-3659
HTLDE64	526	908613	AC005087	2676	1-232
HTLDE64	526	908613	AC005087	2677	1-232
HTLDQ25	531	870057	AL355315	2678	1-1401
HTLDQ25	531	870057	AL359388	2679	1-1401
HTLDQ25	531	870057	AL355315	2680	1-636
HTLDQ25	531	870057	AL355315	2681	1-112 128-185
HTLDQ25	531	870057	AL359388	2682	1-112 128-185
HTLDQ25	531	870057	AL359388	2683	1-636
HTLDS55	532	891322	AC020663	2684	1-64 584-868 2241-2367 2459-2539 4278-4416 4580-4698 4790-4886 8560-8662 9190-9487 10204-10263 10348-10678
HTLDS55	532	891322	AC020663	2685	1-309
HTLDS55	532	891322	AC020663	2686	1-304

					849-1240 2947-3164
HTLDZ14	538	573401	AL133318	2687	1-403
HTLDZ14	538	573401	AL133318	2688	1-353
HTLDZ14	538	573401	AL133318	2689	1-381
HTLEB14	539	573464	AL353647	2690	1-1046 1485-1639
HTLEB14	539	573464	AL138784	2691	1-1046 1485-1639
HTLEB14	539	573464	AC022786	2692	1-1046 1485-1639
HTLEB14	539	573464	AL353647	2693	1-116
HTLEB14	539	573464	AL138784	2694	1-116
HTLED72	540	906989	AC011442	2695	1-281
HTLEG65	542	870154	AC026083	2696	1-1655
HTLEG91	543	870257	AL031406	2697	1-114
HTLEG91	543	870257	Z94160	2698	1-114
HTLEG91	543	870257	AL031406	2699	1-945
HTLEG91	543	870257	Z94160	2700	1-945
HTLEI47	545	573460	AC025959	2701	1-307 650-751 1100-1209
HTLEI47	545	573460	AC009451	2702	1-307 650-751 1100-1209
HTLEI47	545	573460	AC025963	2703	1-307 650-751 1100-1209
HTLEL01	549	917022	AC024631	2704	1-496 699-1081 1222-1331 1385-1614 1658-1771 1784-2779 3025-3737
HTLEL01	549	917022	AC053481	2705	1-84 142-371 415-528 541-1535 1780-2492 3204-3300 3678-5015
HTLEL01	549	917022	AC027821	2706	1-50 213-300 859-1126 1195-1903 2104-2487

					2628-2737 2791-3020 3064-3182 3190-4185 4433-5145 5857-5953 6331-7971 7973-8232 8452-8515
HTLEL01	549	917022	AC036181	2707	1-84 141-370 414-532 540-1535 1776-2488 3200-3296 3674-5593 5809-6696
HTLEL01	549	917022	AC036181	2708	1-524 687-774 1333-1600 1669-2377 2578-2962 3103-3212 3266-3495 3539-3657 3665-4659 4905-5617 6332-6428 6806-8442 8444-8703 8918-9805
HTLEL01	549	917022	AC023133	2709	1-524 688-775 1333-1600 1669-2321 2574-2957 3098-3207 3261-3490 3534-3652 3660-4655 4896-5608 6320-6416 6792-8432 8434-8693 8908-9796
HTLEL01	549	917022	AC067923	2710	1-104 267-354

					913-1180 1249-1956 2157-2540 2681-2790 2844-3073 3117-3235 3243-4238 4484-5196 5908-6004 6382-8301 8517-9404
HTLEL01	549	917022	AC015818	2711	1-940
HTLEL01	549	917022	AC003976	2712	1-524 688-775 1334-1601 1670-2378 2579-2962 3103-3212 3266-3495 3539-3657 3665-4659 4905-5617 6332-6428 6806-8442 8444-8703 8918-9804
HTLEL01	549	917022	AC021317	2713	1-529
HTLEL01	549	917022	AC036181	2714	1-358
HTLEL01	549	917022	AC053481	2715	1-297
HTLEL01	549	917022	AC036181	2716	1-371
HTLEL01	549	917022	AC036181	2717	1-371
HTLEL01	549	917022	AC023133	2718	1-243
HTLEL01	549	917022	AC036181	2719	1-243
HTLEL01	549	917022	AC023133	2720	1-371
HTLEL01	549	917022	AC067923	2721	1-371
HTLEL01	549	917022	AC015818	2722	1-527
HTLEL01	549	917022	AC015818	2723	1-554 559-639
HTLEL01	549	917022	AC003976	2724	1-371
HTLEL01	549	917022	AC003976	2725	1-243
HTLEL01	549	917022	AC021317	2726	1-1419 1443-1741 1748-2500
HTLEL01	549	917022	AC021317	2727	1-103
HTLEL31	551	669950	AF053356	2728	1-71 234-304 320-826

					878-1099 1233-1683 2077-3297
HTLEL31	551	669950	AF053356	2729	1-434
HTLEL31	551	669950	AF053356	2730	1-152
HTLEQ07	555	953706	AC009485	2731	1-159 352-455 634-742 1105-1433
HTLEQ07	555	953706	AC009485	2732	1-550
HTLES54	557	574884	AC007732	2733	1-694
HTLES54	557	574884	AC007732	2734	1-102
HTLES54	557	574884	AC007732	2735	1-1969
HTLET56	558	911654	AL356984	2736	1-1371
HTLET78	559	836820	AC048358	2737	1-64 135-253 439-619 880-1007 1334-1548 1691-2473
HTLET78	559	836820	AC027307	2738	1-64 135-253 439-619 880-1007 1335-1549 1692-2474
HTLET78	559	836820	AC027307	2739	1-80
HTLET93	560	573454	AC021744	2740	1-105
HTLEV33	561	527956	AC024257	2741	1-1156
HTLEV33	561	527956	AC024257	2742	1-496
HTLEV33	561	527956	AC024257	2743	1-529
HTLEW21	563	573458	AC008392	2744	1-80 1758-1900 3780-4202 4434-4597 4677-4747
HTLEW21	563	573458	AC027218	2745	1-80 1754-1896 3776-4198 4430-4593 4673-4743
HTLEW21	563	573458	AC027218	2746	1-872
HTLEW21	563	573458	AC008392	2747	1-872
HTLEY11	564	967309	AC036174	2748	1-88 1369-1453 2944-3069 3655-4026

HTLEZ14	566	791662	AC006549	2749	1-530
HTLEZ14	566	791662	AC000097	2750	1-530
HTLEZ14	566	791662	AC006547	2751	1-530
HTLEZ14	566	791662	AC006549	2752	1-42 147-212 380-436 699-747 821-1197
HTLEZ14	566	791662	AC006549	2753	1-311
HTLEZ14	566	791662	AC000097	2754	1-42 147-212 380-436 699-747 821-1197
HTLEZ14	566	791662	AC000097	2755	1-311
HTLEZ14	566	791662	AC006547	2756	1-42 147-212 380-436 699-747 821-1197
HTLEZ14	566	791662	AC006547	2757	1-314
HTLEZ15	567	934288	AC021163	2758	1-212 773-858 1055-1178
HTLEZ15	567	934288	AC011495	2759	1-210 774-859 1056-1155
HTLEZ15	567	934288	AC021163	2760	1-150
HTLEZ15	567	934288	AC021163	2761	1-334
HTLEZ15	567	934288	AC011495	2762	1-150
HTLEZ15	567	934288	AC011495	2763	1-325
HTLFC20	570	917128	AL354944	2764	1-116 1049-1279 1947-2369 2924-3064 3498-9096 10048-10150 10917-11052 11221-11920 12125-12310 12501-12633 12868-13122 13980-14176 16118-16486 16537-17101 17616-18267 18312-19168

					20650-20901 21433-21866 23387-23568 23660-23748
HTLFC20	570	917128	AL354944	2765	1-259
HTLFC20	570	917128	AL354944	2766	1-101
HTLGD25	578	870136	AC025865	2767	1-1491
HTLGD25	578	870136	AC019225	2768	1-1491
HTLGD25	578	870136	AL160006	2769	1-1491
HTLGD25	578	870136	AC019225	2770	1-480
HTLGD25	578	870136	AC025865	2771	1-481
HTLGD25	578	870136	AL160006	2772	1-481
HTLGD69	579	835493	AC013713	2773	1-1128
HTLGD69	579	835493	AL157875	2774	1-1128
HTLGD69	579	835493	AC013713	2775	1-362 5379-5440
HTLGD69	579	835493	AC013713	2776	1-493
HTLGD69	579	835493	AL157875	2777	1-362 5379-5440
HTLGM07	582	952254	AC003688	2778	1-81 236-691 773-1054 1662-1893 2248-2282 3053-3219 3774-4061 4238-4344 4469-4939 5460-5564 5664-6980
HTLGM07	582	952254	AC003688	2779	1-85 509-995 1324-1425 1574-1640
HTLGM07	582	952254	AC003688	2780	1-265
HTLHE72	587	963471	AL353608	2781	1-510
HTLHE72	587	963471	AL353608	2782	1-628
HTLHE72	587	963471	AL353608	2783	1-907
HTLHL82	588	958334	AL162377	2784	1-246 3348-4249
HTLHO94	589	968685	AC006445	2785	1-1321
HTLHP80	592	870156	AL132868	2786	1-784
HTLHP80	592	870156	AL132868	2787	1-135
HTLIK11	600	966043	AC008649	2788	1-504 1236-1319 2515-2917 4549-4998

					5053-5186 5694-5778 6477-6722 9052-9536 9591-9714 9993-10115
HTLIK11	600	966043	AC008649	2789	1-370 376-776
HTLIP19	601	958351	AC067784	2790	1-74 3587-3742 4069-4200 4639-4740 5740-5808 6262-6401
HTLIP19	601	958351	AC018595	2791	1-147 393-578 1688-1771 4090-4246 4573-4704 5143-5249 6244-6312 6446-6554 6763-6903
HTLIP19	601	958351	AC018595	2792	1-140
HTLIY52	606	942161	AC011448	2793	1-194 424-1198 1938-2018 3137-3317 5423-5732 5894-6019 6299-6608 7425-7771 8216-8713 9697-9815 9872-9959 10811-11127 11264-11754 11867-12454 12539-13980 14020-14373 14522-15107 15641-15786 18585-22176 22246-22801 24994-25641 26099-26401 28795-29074

					29176-29432 29653-29854 31298-31468 31507-32203 32864-33359 34805-34936 35464-35750 35878-36319 36610-37065 37680-38123 38902-39124 42685-42993 43593-43745 47682-47911 48694-49237 49352-49706 52310-52618 53725-54348 54650-55016 56425-56525 56655-57164 58248-59197 59662-60112 60732-61475 62024-62173 69325-69730
HTLIY52	606	942161	AC011448	2794	1-544
HTLIY52	606	942161	AC011448	2795	1-293
HTLJA24	608	934279	AC006237	2796	1-77 1994-2263 3098-3450 3551-4203
HTLJA24	608	934279	AC006237	2797	1-1048 1633-2065 2080-2333 2374-2524 4212-4459 5299-5463 7313-7346
HTLJA24	608	934279	AC006237	2798	1-101
HTLJC71	609	922923	AC009516	2799	1-2009
HTLJC71	609	922923	AC007957	2800	1-1747
HTLJC71	609	922923	AC018751	2801	1-2009
HTLJC71	609	922923	AC023490	2802	1-2009
HTLJC71	609	922923	AC009516	2803	1-375
HTLJC71	609	922923	AC009516	2804	1-494
HTLJC71	609	922923	AC007957	2805	1-205

HTLJC71	609	922923	AC018751	2806	1-494
HTLJC71	609	922923	AC023490	2807	1-375
HTLJC71	609	922923	AC018751	2808	1-375
HTLJJ75	612	924755	AL354888	2809	1-1283
HTLJJ75	612	924755	AL033527	2810	1-448 451-1733
HTLJJ75	612	924755	AL354888	2811	1-699
HTLJJ75	612	924755	AL033527	2812	1-696
HTLJL23	613	922994	AL031587	2813	1-151 441-552 1214-1667 1820-2290 2375-2664 4552-5062 5224-5492 6136-6319 6684-7594 7786-8096 8297-8930 8932-10855
HTLJL23	613	922994	AL031587	2814	1-135 2617-2705 3232-3371 5671-5793
HTTAD55	614	835652	AC021558	2815	1-260
HTTAD55	614	835652	AC021558	2816	1-599
HTTAE49	615	723331	AC023266	2817	1-491
HTTAE49	615	723331	AC023266	2818	1-276
HTTAE49	615	723331	AC023266	2819	1-1777
HTTAJ50	617	509657	AC022148	2820	1-287
HTTAJ50	617	509657	AC022148	2821	1-392
HTTAN57	618	509453	AC010299	2822	1-304
HTTAS96	619	961057	AC074073	2823	1-254
HTTAS96	619	961057	AC022621	2824	1-320
HTTAS96	619	961057	AC022621	2825	1-272
HTTAS96	619	961057	AC022621	2826	1-195
HTTAU82	620	797726	AC009618	2827	1-342
HTTAU82	620	797726	AL390022	2828	1-510
HTTAU82	620	797726	AC006517	2829	1-191 443-741 2568-2781 3248-3544 3716-3884
HTTAU82	620	797726	AC006927	2830	1-191 443-741 2568-2778 3317-3427

					3717-3885
HTTAU82	620	797726	AC009618	2831	1-731
HTTAU82	620	797726	AL390022	2832	1-728
HTTAU82	620	797726	AC006517	2833	1-115
HTTAU82	620	797726	AL390022	2834	1-383
HTTAU82	620	797726	AC006517	2835	1-76 848-890 1618-2210
HTTAU82	620	797726	AC006927	2836	1-89
HTTAU82	620	797726	AC006927	2837	1-76 848-890 1618-2210
HTTBH54	622	530563	AC013443	2838	1-305
HTTBJ94	623	530564	AC012306	2839	1-371 2517-2948 3269-3389 4036-4139 4655-4747 6026-6302 6920-7056 7205-7304 8993-12574
HTTBN67	624	578085	AF235102	2840	1-227
HTTBN67	624	578085	AF235102	2841	1-117 290-371 1962-2328
HTTCA15	625	869705	AC005833	2842	1-412
HTTCA15	625	869705	AC005833	2843	1-559
HTTCD71	627	530393	AL049844	2844	1-74 381-637 1227-1614 1677-3333 4088-4213 4220-4876 5053-5406 5474-5917 6045-6442
HTTCD71	627	530393	AL049844	2845	1-263
HTTCD71	627	530393	AL049844	2846	1-885
HTTCL35	628	529672	AC024375	2847	1-253 1273-1795
HTTCL35	628	529672	AC024375	2848	1-418
HTTDF50	630	526385	AC022335	2849	1-1306
HTTDF50	630	526385	AC022335	2850	1-156
HTTDI21	633	869686	AC074236	2851	1-485
HTTDI21	633	869686	AC009269	2852	1-192 206-468

					1229-1713 2228-2407 2998-3211 3314-3817 4343-4938 5571-5768
HTTDI21	633	869686	AC009269	2853	1-104
HTTDI21	633	869686	AC009269	2854	1-559
HTTDL45	636	523452	AC007390	2855	1-75 417-583 1679-1765 2788-3466 4413-4490 4941-5105 5400-5517 6071-6185 8399-8718 9893-10500
HTTDL45	636	523452	AC007390	2856	1-803
HTTDL45	636	523452	AC007390	2857	1-186 901-2187 2559-2605 2853-4188 4215-6320 6739-7105 7892-8398 8852-9356 9561-10277 10360-10560 12504-12595 13356-13552 13845-13905 15014-15064 15377-15953 16401-16466 16831-17031 17378-18339 18502-18552 19127-19426 19501-19804 20934-21502 21567-21695 21900-21988 22836-23379 23660-23743 23890-24076 24682-24916

					26831-27787 28708-30551 32927-33109
HTTDL89	637	959837	AC004803	2858	1-376
HTTDL89	637	959837	AC004765	2859	1-376 471-1538 2707-3361
HTTDL89	637	959837	AC004803	2860	1-1068
HTTDL89	637	959837	AC004803	2861	1-2019 3153-3257 3637-3880 4449-4655 4695-4983 5401-6067 7497-7573 8470-8588 8874-9327 9904-10065 11619-11681 12466-12581 12911-13213 14830-14911 16048-17861 17889-18018 18305-18362 18566-18740 19076-19167
HTTDL89	637	959837	AC004765	2862	1-264
HTTDN85	639	783444	AC078852	2863	1-442
HTTDN85	639	783444	AC022763	2864	1-443
HTTDN85	639	783444	AC078852	2865	1-538
HTTDN85	639	783444	AC022763	2866	1-538
HTTDR91	641	790336	AC005740	2867	1-176 1646-1818 4524-4697 5747-5899 8660-9945 10558-10883 11064-11295 11314-11646 14324-14496 15739-15886 16611-16794 18676-21241 22938-23085 23224-24224 24447-24843

					25199-25490 25515-27062
HTTDR91	641	790336	AC005740	2868	1-540
HTTDR91	641	790336	AC005740	2869	1-398
HTTDR92	642	573666	AC023098	2870	1-368
HTTDR92	642	573666	AC003046	2871	1-368
HTTDR92	642	573666	AC023098	2872	1-368
HTTDR92	642	573666	AC023098	2873	1-62 1717-2020 2315-2432 3271-3381 4686-4832
HTTDR92	642	573666	AC003046	2874	1-62 1728-2020 2315-2432 3271-3381 4686-4832
HTTDR92	642	573666	AC003046	2875	1-368
HTTDS02	643	920589	AL139100	2876	1-309 2987-3113 4207-4877 5573-5677 5684-5845 9382-9495 11034-11269 14694-14786 16010-16116 16799-17013 17078-17196 18023-18134 19046-19565 20157-20645
HTTDS02	643	920589	AL139100	2877	1-121
HTTDX84	644	921100	AC016912	2878	1-137 839-1199 4679-4860
HTTDX84	644	921100	AC018682	2879	1-137 840-1200 4680-4861
HTTDZ91	646	523206	AL137229	2880	1-145 572-661 4888-5112 6942-7339 7820-7914 8041-8423 8957-9106 11434-11806

					11986-12491 13542-13680 14277-16062
HTTDZ91	646	523206	AL137229	2881	1-1790
HTTEH58	648	747943	AC068781	2882	1-387
HTTEH58	648	747943	AC068365	2883	1-387
HTTEH58	648	747943	AC073466	2884	1-387
HTTEH58	648	747943	AC068365	2885	1-813
HTTEH58	648	747943	AC073466	2886	1-813
HTTEH58	648	747943	AC068781	2887	1-813
HTTEL50	649	745985	AL359551	2888	1-443
HTTEL50	649	745985	AL360010	2889	1-227 3577-4019 4331-4797
HTTEL50	649	745985	AL360010	2890	1-556
HTTEV62	651	573614	AC018706	2891	1-120 327-596
HTTEY64	652	974107	AL121759	2892	1-457
HTTEY64	652	974107	AL121759	2893	1-182 1815-1886
HTTEY64	652	974107	AL121759	2894	1-413
HTTEZ34	653	771602	AL356116	2895	1-508
HTTEZ34	653	771602	AC017067	2896	1-244 4587-5158 5672-6138
HTTEZ34	653	771602	AL356116	2897	1-467
HTTFB60	654	869666	AC023818	2898	1-2041 2271-2442 2475-6107
HTTFB60	654	869666	AC023818	2899	1-353
HTTFB60	654	869666	AC023818	2900	1-120
HTTFG35	655	778426	AC019205	2901	1-231 428-607
HTTFG35	655	778426	AL133336	2902	1-231 428-607
HTTFG35	655	778426	AC068247	2903	1-231 428-607
HTTFG35	655	778426	AC019205	2904	1-974
HTTFG35	655	778426	AL133336	2905	1-974
HTTFG35	655	778426	AC068247	2906	1-974
HTTFL89	658	974346	AC005551	2907	1-436
HTTFL89	658	974346	AC005551	2908	1-135 1535-1715 2043-2114 5528-6140
HTTFM17	659	750942	AC009994	2909	1-422

					658-1260 2947-3758
HTTFM17	659	750942	AC009994	2910	1-155
HTTFS59	661	825922	AP001332	2911	1-1736 1937-2284 2596-2760 3034-3162 4857-4934 5196-5338 6131-6244 6276-6756 7170-7308 7537-7569 7659-7709
HTTFS59	661	825922	AC013606	2912	1-1738 1938-2285 2478-2580 2594-2758 3036-3160
HTTFS59	661	825922	AC015685	2913	1-1737
HTTFS59	661	825922	AC013606	2914	1-489
HTTFS59	661	825922	AC015685	2915	1-487
HTTFT08	662	934460	AC013726	2916	1-43 317-418 1097-2127 2193-2346 2456-2503 2713-3159 3231-6093
HTTFT08	662	934460	AC013726	2917	1-536
HTTFV93	663	925544	AL139410	2918	1-1222 1338-1532
HTTFV93	663	925544	AL353760	2919	1-1222 1338-1532
HTTFZ70	664	974066	AL355594	2920	1-115 207-368 516-876 1441-1565 2014-2187 2404-2951 3705-5973 6008-8387
HTTFZ70	664	974066	AL033383	2921	1-1004 2982-3105 3372-3514 4034-4609 5643-5817

					9019-9176 10736-10817 12053-12475 13292-13391 14259-14546 15423-15497 16340-16660 17244-17630 17683-17864 17981-18128 18264-18585 18678-18767 20206-20356 20955-21122 22834-23358 23679-23944 24217-24406 24565-24684 25085-25439 26585-26758 26975-27139 28275-30550 30582-33232 36611-37091 37344-38113 46301-46465 55718-55969 66431-66687
HTTFZ70	664	974066	AL138831	2922	1-1004 2982-3105 3372-3514 4034-4609 5643-5817 9019-9176 10736-10817 12053-12475 13292-13391 14259-14546 15423-15497 16340-16660 17244-17630 17683-17864 17981-18128 18264-18585 18678-18767 20206-20356 20955-21122

					22836-23360 23681-23946 24219-24408 24567-24686 24778-24939 25087-25441 26585-26758 26975-27139 28275-30550 30582-33232 36611-37091 37344-38113 46301-46465 55718-55969 66431-66687
HTTFZ70	664	974066	AL033383	2923	1-375
HTTFZ70	664	974066	AL355594	2924	1-266 539-728
HTTFZ70	664	974066	AL033383	2925	1-205
HTTFZ70	664	974066	AL138831	2926	1-375
HTTFZ70	664	974066	AL138831	2927	1-205
HTTIG04	666	926752	AC012609	2928	1-458
HTTIG04	666	926752	AC026406	2929	1-458
HTTIG04	666	926752	AC012609	2930	1-661
HTTIG04	666	926752	AC026406	2931	1-661
HTTIH23	667	869636	AC040970	2932	1-1041 1186-1881 2845-2973
HTTIH23	667	869636	AC011676	2933	1-1041 1185-1880 2844-2972 5523-5631 6840-7111 7196-7890 8274-9038 9916-10234
HTTIH23	667	869636	AC040970	2934	1-740
HTTIH23	667	869636	AC011676	2935	1-400
HTTIH80	668	869635	AC006443	2936	1-385
HTTIH80	668	869635	AC006443	2937	1-201
HTTIN23	670	869634	AC002549	2938	1-566
HTTIU05	671	931015	AC008663	2939	1-461 3399-3527 4652-5129 5447-6031 6123-6401 6651-7418

					8095-9142
HTTIU05	671	931015	AC010339	2940	1-76 1203-1680 1998-2582 2674-2952 3202-3969 4646-5693
HTTIU05	671	931015	AC022259	2941	1-585
HTTIU05	671	931015	AC008663	2942	1-101
HTTIU05	671	931015	AC008663	2943	1-130
HTTIU05	671	931015	AC010339	2944	1-130
HTTIU05	671	931015	AC022259	2945	1-478
HTTIU05	671	931015	AC022259	2946	1-280
HTTIW81	672	922817	AL357149	2947	1-433
HTTIW81	672	922817	AL357149	2948	1-399
HTTIZ05	673	930994	AC012246	2949	1-443
HTTIZ05	673	930994	AC012246	2950	1-646
HTTJA11	674	839725	AC068403	2951	1-440
HTTJA11	674	839725	AC067775	2952	1-440
HTTJA11	674	839725	AC068403	2953	1-288
HTTJA11	674	839725	AC067775	2954	1-288
HTTJA47	675	869618	AP002091	2955	1-276 3023-3207
HTTJA47	675	869618	AP002091	2956	1-149
HTTJA47	675	869618	AP002091	2957	1-179
HTTJH13	676	869615	AC013436	2958	1-324
HTTJH13	676	869615	AC004859	2959	1-324
HTTJH13	676	869615	AC013436	2960	1-209
HTTJH13	676	869615	AC013436	2961	1-65 191-304 339-660 712-888
HTTJH13	676	869615	AC004859	2962	1-209
HTTJH13	676	869615	AC004859	2963	1-65 191-304 339-660 712-888
HTTJM01	677	913799	AC009469	2964	1-310 383-487
HTTJQ06	678	934130	AC022202	2965	1-1086
HTTJQ06	678	934130	AL136969	2966	1-308 973-1308 4938-4961 8196-8326 11508-12593 13039-13501

					15003-15234 17040-17530 20304-20729 25068-25578 25828-26705 26728-26816 26831-27320 28927-29311 29405-29614 30437-31474
HTTJQ06	678	934130	AC022202	2967	1-461
HTTJQ06	678	934130	AL136969	2968	1-98
HTTJQ06	678	934130	AL136969	2969	1-377
HTTJX68	679	974063	AC026318	2970	1-312 987-1439 3651-3801
HTTJX68	679	974063	AC023910	2971	1-453
HTTJX68	679	974063	AC026318	2972	1-241
HTTJX68	679	974063	AC026318	2973	1-128
HTTJY08	680	958170	AL355586	2974	1-453
HTTJY08	680	958170	AL355307	2975	1-453
HTTJY08	680	958170	AL023584	2976	1-453
HTTJY08	680	958170	AL355586	2977	1-349
HTTJY08	680	958170	AL355307	2978	1-349
HTTJY08	680	958170	AL023584	2979	1-349
HTTKF89	682	960928	AL035425	2980	1-524
HTTKF89	682	960928	AL035425	2981	1-133
HTTKF89	682	960928	AL035425	2982	1-418
HTTKK06	684	974311	AC046137	2983	1-1282 1645-2164 3070-3680 3888-3943 3999-4329 5064-5333 6343-6658 6733-6987 7096-7247 7432-7831 8006-8123 8293-8756 9804-9858
HTTKK06	684	974311	AL138965	2984	1-1284 1646-2165 3071-3681 3889-3944 4000-4499 5065-5333

					6343-6662 6733-6987 7096-7247 7432-7831 8006-8123 8293-8756 9803-9857
HTTKL80	685	974316	AC027572	2985	1-495
HTTKN21	686	974310	AC024563	2986	1-495
HTTKN21	686	974310	AC010318	2987	1-495
HTTKN21	686	974310	AC008626	2988	1-495
HTTKN21	686	974310	AC024563	2989	1-276
HTTKN21	686	974310	AC010318	2990	1-276
HTTKN21	686	974310	AC008626	2991	1-276
HTTKS13	688	926795	AC023593	2992	1-494
HTTKS13	688	926795	AC012406	2993	1-195 510-647 1298-1791 2210-2419 2689-2911 3871-4132 4236-4418 5740-5922 9461-9715 10556-10634
HTTKS13	688	926795	AC023593	2994	1-207 480-702 1662-1923
HTTKS13	688	926795	AC012406	2995	1-87
HTTKV17	689	830008	AC005027	2996	1-993 2319-3110 3184-3327 3609-3791 4475-4927 8332-9120 9164-9583 10780-11193 12543-14416
HTTKV17	689	830008	AC005027	2997	1-2780
HUDAM29	690	529157	AL161451	2998	1-354
HUDAM29	690	529157	AL161451	2999	1-238
HUDBZ78	691	739638	AC018638	3000	1-123 666-828 4839-5113 6402-6995 7727-7910 9744-9996

					10630-10732 14112-14236 17737-17771 19858-20081 20801-20915 21556-21640 22127-22645
HUDBZ78	691	739638	AC018638	3001	1-368
HUDBZ78	691	739638	AC018638	3002	1-374
HUDBE95	694	795796	AC019073	3003	1-780 5430-5615 7641-7685 10826-10887 11255-11332 12359-12669 13590-13776 16097-16197 16225-16569 17409-17588 17614-18145 18212-18277 20025-20135 21203-21289 21668-21798 22067-22836 22902-23233 23289-24983
HUDBE95	694	795796	AC009079	3004	1-780 1966-2659 5432-5617 7643-7687 10830-10891 11259-11336 12363-12673 13594-13780 16101-16201 16229-16573 17510-17593 17618-18149 18216-18281 20020-20130 21198-21284 21663-21793 22060-22829 22895-23226 23282-24977
HUDBE95	694	795796	AC019073	3005	1-464

HUDBE95	694	795796	AC009079	3006	1-454
HUDAK19	700	671974	AC024249	3007	1-882 1119-1964
HTTKC85	702	956206	AC007246	3008	1-445
HTTKC85	702	956206	AC007246	3009	1-653
HTTKC85	702	956206	AC007246	3010	1-766
HTTJN26	704	869612	AC010761	3011	1-545 730-2324 2733-2817 2910-2993 3334-3705 4186-4362
HTTJN26	704	869612	AC010761	3012	1-158
HTTJN26	704	869612	AC010761	3013	1-244
HTTIX05	706	931024	AL138955	3014	1-492 646-1277 1480-2938
HTTIX05	706	931024	AL136104	3015	1-493 647-1278 1481-2939
HTTIX05	706	931024	AL136104	3016	1-124
HTTIN11	709	965920	AC073580	3017	1-815
HTTIN11	709	965920	AL109916	3018	1-815
HTTIN11	709	965920	AC073580	3019	1-436
HTTIN11	709	965920	AC073580	3020	1-228
HTTIN11	709	965920	AL109916	3021	1-436
HTTIN11	709	965920	AL109916	3022	1-228
HTTIE08	710	958169	AC026405	3023	1-4307
HTTIE08	710	958169	AC020566	3024	1-575
HTTIE08	710	958169	AC016901	3025	1-6684
HTTIE08	710	958169	AC020566	3026	1-34 1050-1364
HTTIE08	710	958169	AC016901	3027	1-131 1868-2214 2273-2385 3084-3172
HTTIB12	711	969568	AC026576	3028	1-715
HTTHJ56	712	944914	AC013715	3029	1-241 407-704 1629-1750 3363-3439 6942-7140 7436-7629 11318-11960
HTTFG12	713	751809	AC068289	3030	1-1168
HTTFG12	713	751809	AC068289	3031	1-104
HTTEQ59	715	739445	AC018654	3032	1-113

					608-2226 2955-3217 3366-4135 4148-4842
HTTEQ59	715	739445	AC022073	3033	1-113 608-2226 2955-3217 3366-4135 4148-4842
HTTEQ01	716	917156	Z83845	3034	1-684
HTTEQ01	716	917156	Z83845	3035	1-504 658-707 1786-3045 3351-4099
HTTEO59	717	900662	AC046168	3036	1-2879
HTTEO53	718	728344	AC074116	3037	1-280 905-4002
HTTEO53	718	728344	AL162722	3038	1-280 905-3688
HTTEO53	718	728344	AC074116	3039	1-99
HTTEO53	718	728344	AL162722	3040	1-99
HTTEJ56	719	573669	AC068707	3041	1-134 1054-1276 1688-1740 2572-2856 2936-3012 3748-3941 4846-4969 5395-5467 5675-6158
HTTEJ56	719	573669	AC068707	3042	1-1098
HTTEB05	720	932294	AL031672	3043	1-1512
HTTEB05	720	932294	AL031672	3044	1-489
HTTEB05	720	932294	AL031672	3045	1-692 4641-5166 6143-6251 8784-8849 11398-11796 11851-12038 13499-13858 14606-14716 17177-17863 19079-19195 19315-19699 20154-20572 22216-22455 22597-23544

HTTDO59	721	744438	AL160282	3046	1-671 781-2678 2858-2994 3178-3347 3426-3693
HTTDM42	722	460948	AC073619	3047	1-421 704-793 1909-2043
HTTDM42	722	460948	AL354745	3048	1-421 704-793 1910-2044 2204-2966 3204-4359
HTTDM42	722	460948	AL354745	3049	1-904
HTTDM42	722	460948	AL354745	3050	1-233
HTTDL81	723	694222	AL022328	3051	1-481 729-828 1094-1193 1289-1396 1553-1617 1798-1929 2089-2152 2247-4100 4146-4381 4518-4577 4865-4961 5157-5580 5725-6072
HTTDL81	723	694222	AL022328	3052	1-723
HTTDL81	723	694222	AL022328	3053	1-81 162-241 315-880 1024-1324 1365-1937 2215-2794
HTTDL75	724	766551	AC068013	3054	1-384
HTTDL75	724	766551	AC068471	3055	1-697
HTTDL75	724	766551	AC074378	3056	1-697
HTTDL75	724	766551	AC074378	3057	1-495
HTTCQ95	726	796674	AC026065	3058	1-100 772-894 1216-1581 1841-2015 2108-2519 3025-3350 3659-4132 6075-6743

HTTBR42	730	714220	AL157409	3059	1-570 4245-4986
HTTBR42	730	714220	AL157409	3060	1-312
HTTBO82	732	780164	AC044902	3061	1-436 477-893
HTTBO82	732	780164	AC009595	3062	1-436 477-893
HTTBO82	732	780164	AC044902	3063	1-256
HTTBM03	733	925409	AC031984	3064	1-766 2180-2586 3286-3634 3651-3858 3895-4311
HTTBM03	733	925409	AL050318	3065	1-766 2178-2584 3284-3632 3649-3856 3893-4309 4861-5005 7178-7361 11400-11880 12124-12392 13017-13267 15332-15583 15793-16031 16947-17288 18668-18837 19381-19764 21255-21574 22689-22887 23670-23952 27931-28039 28646-28948 29548-29705 30258-32335
HTTBM03	733	925409	AL390374	3066	1-766 2178-2584 3284-3632 3649-3856 3893-4309 4861-5005 7178-7362 11063-11173 11400-11880 12124-12392 13017-13268 15332-15583

					15795-16033 16952-17289 18674-18843 19387-19770 21261-21580 22695-22893 23676-23958 27937-28045 28652-28954 29556-29713 30266-32343
HTTBM03	733	925409	AC031984	3067	1-145
HTTBM03	733	925409	AL050318	3068	1-151
HTTBM03	733	925409	AL050318	3069	1-195
HTTBM03	733	925409	AL390374	3070	1-195
HTTBI80	734	781590	AC008628	3071	1-162 1001-1703
HTTBI80	734	781590	AC010226	3072	1-162 1001-1703
HTTBH95	735	530559	AL121759	3073	1-182 1815-1886
HTTBH95	735	530559	AL121759	3074	1-457
HTTAQ60	738	742377	AC055720	3075	1-643 842-1218
HTTAQ60	738	742377	AC024145	3076	1-643 842-1223
HTTAQ60	738	742377	AC055720	3077	1-679
HTTAQ60	738	742377	AC024145	3078	1-679
HTTAQ60	738	742377	AC024145	3079	1-135
HTTAP21	740	671488	AL023803	3080	1-198 4122-4247 8722-8781 12640-12742 15684-15778 17532-17609 17745-18841 19072-19205 20937-21397 21427-21993 22264-22342 24544-24618 28047-28160 30396-30560 32340-33565
HTTAP21	740	671488	AL023803	3081	1-293
HTTAP21	740	671488	AL023803	3082	1-414
HTTAP09	741	826343	AC023593	3083	1-437

HTTAP09	741	826343	AC012406	3084	1-437
HTTAP09	741	826343	AC012406	3085	1-786 1865-1938
HTTAP09	741	826343	AC023593	3086	1-787 1865-1938
HTTAC77	745	772735	AC021291	3087	1-779
HTTAA94	746	793001	AL031255	3088	1-908
HTTAA94	746	793001	AL031255	3089	1-480
HTTAA39	747	710355	AC016691	3090	1-526 564-1577
HTTAA39	747	710355	AC015719	3091	1-1149
HTTAA39	747	710355	AC016691	3092	1-496
HTTAA39	747	710355	AC016691	3093	1-106
HTTAA39	747	710355	AC015719	3094	1-840
HTLIP06	748	934207	AL162586	3095	1-2160 2297-2470
HTLIP06	748	934207	AL162426	3096	1-2160 2297-2472 3211-3477 3629-4087
HTLIP06	748	934207	AC007430	3097	1-2160 2297-2472 3211-3477 3629-4087
HTLIP06	748	934207	AL162586	3098	1-136 294-491 2350-2692 3660-3898
HTLIP06	748	934207	AL162426	3099	1-136 294-491 2351-2693 3661-3899
HTLIP06	748	934207	AC007430	3100	1-136 294-491 2351-2693 3661-3899
HTLIP06	748	934207	AL162426	3101	1-118
HTLIP06	748	934207	AC007430	3102	1-118
HTLHS69	753	870152	AC009095	3103	1-220 227-466 573-1448
HTLHS05	754	933720	AL121753	3104	1-77 91-640 2531-2639 3380-3625 3692-4433 4677-4862

					5043-5355 5532-5893 6299-10579 12966-13230 14676-15242 15749-15996 16066-16393 16675-17238 17381-17885 18029-18260 19347-19477 20064-20199 20849-21010
HTLHS05	754	933720	AL356652	3105	1-77 91-640 2531-2639 3380-3625 3692-4433 4677-4862 5043-5355 5532-5893 6299-10590 12979-13243 14689-15255 15762-16052 16079-16406 16688-17251 17394-17898 18042-18273 19363-19509 20088-20188 20863-21024
HTLHS05	754	933720	AL121753	3106	1-437
HTLHS05	754	933720	AL121753	3107	1-638 793-854
HTLHS05	754	933720	AL356652	3108	1-437
HTLHS05	754	933720	AL356652	3109	1-638 793-854
HTLHJ51	756	865399	AC027421	3110	1-146 1403-3399
HTLHJ51	756	865399	AC025860	3111	1-146 1402-3398
HTLHJ51	756	865399	AL353622	3112	1-146 1402-3398
HTLHB93	757	945862	AL161656	3113	1-585
HTLHB93	757	945862	AL035460	3114	1-585
HTLHB93	757	945862	AL161656	3115	1-29

					92-459 544-844
HTLHB93	757	945862	AL161656	3116	1-754
HTLHB93	757	945862	AL035460	3117	1-29 92-459 544-844
HTLHB93	757	945862	AL035460	3118	1-754
HTLGS10	759	963458	AC055863	3119	1-34 227-316 895-1294 1518-1678 1917-2553
HTLGR32	760	928245	AC013403	3120	1-1399
HTLGR32	760	928245	AC013403	3121	1-391
HTLGR32	760	928245	AC013403	3122	1-126
HTLGP84	761	782194	AC020934	3123	1-58 591-853 900-1357
HTLGC43	763	870228	AL118524	3124	1-903 936-2052
HTLGC43	763	870228	AL118524	3125	1-497
HTLEQ92	764	932882	AC009109	3126	1-303 1003-1241 2173-2763
HTLEQ92	764	932882	AC010531	3127	1-303 1003-1241 2173-2763 2907-3967 4804-4849 4950-7755
HTLEQ92	764	932882	AC009109	3128	1-722
HTLEQ92	764	932882	AC010531	3129	1-1592
HTLEP21	765	671151	AC016774	3130	1-138 467-569 810-930 1056-1149 1553-1686 1774-2544
HTLEP21	765	671151	AC010789	3131	1-138 468-570 811-931 1057-1150 1554-1687 1775-2546
HTLEP21	765	671151	AC016774	3132	1-594 1023-1155 1772-2162

					2448-2739 2975-3438 3681-4096 4814-4865 5289-5389 5443-5627 7000-7166 7396-8248 8876-9167 10516-10689 11193-11857 12200-12372 12455-12745 13874-14148 14398-14684 15738-15861 16053-16243 17510-17938 18019-18179 18259-18528 18587-18676 18960-19577 19606-20010 20036-21667 22067-26217 26261-26631 26869-27524 27631-28143 28212-28560 29119-29156 29687-30245 30256-31203 31798-33971
HTLEP21	765	671151	AC010789	3133	1-595 1024-1156 1773-2165 2447-2738 2974-3437 3680-4095 4813-4864 5288-5388 5442-5626 6999-7165 7395-8247 8875-9166 10515-10688 11192-11856

					12199-12371 12454-12755 13981-14147 14397-14683 15737-15860 16052-16242 17509-17937 18018-18178 18258-18527 18586-18675 18959-19576 19605-20009 20035-21666 22243-26224 26240-26630 26868-27523 27630-28149 28212-28560 29119-29156 29688-30247 30269-31205 31800-33973
HTLDO01	772	913669	AC002056	3134	1-1300
HTLDO01	772	913669	AC000036	3135	1-1300 2362-2937
HTLDO01	772	913669	AC002056	3136	1-375
HTLDO01	772	913669	AC000036	3137	1-829 1755-2331 3054-3393 5260-5322
HTLDO01	772	913669	AC000036	3138	1-375
HTLCZ79	775	572853	AC004064	3139	1-285
HTLCZ79	775	572853	AL161939	3140	1-285
HTLCZ79	775	572853	AL118502	3141	1-285
HTLCZ79	775	572853	AC004064	3142	1-97
HTLCZ79	775	572853	AC004064	3143	1-471 571-1561
HTLCZ79	775	572853	AL161939	3144	1-471 571-1561
HTLCZ79	775	572853	AL118502	3145	1-471 571-1561
HTLCO02	777	921045	AC066588	3146	1-242 2043-2258
HTLCG65	778	413333	AC015549	3147	1-167
HTLCG65	778	413333	AC006060	3148	1-171 3245-3475 3590-3742

					4110-4269 5242-5535 6465-6516
HTLCG59	779	530039	AC027712	3149	1-46 3805-3943 5188-5370 6708-6843 7531-7689 8008-8127 8669-8788 9234-9406 9698-10187 10689-15514
HTLCG59	779	530039	AL356097	3150	1-46 3805-3943 5188-5370 6709-6844 7530-7688 8007-8126 8668-8787 9234-9406 9698-10187 10693-15517
HTLCG59	779	530039	AC027113	3151	1-46 3805-3944 5189-5371 6709-6844 7530-7688 8007-8126 8668-8787 9233-9405 9697-10186 10692-15518
HTLCG59	779	530039	AC027712	3152	1-595
HTLCG59	779	530039	AL356097	3153	1-595
HTLCG59	779	530039	AC027113	3154	1-595
HTLBH67	781	751985	AC008439	3155	1-62 293-400 452-976 1016-1058 1463-1534 1886-2026 2110-2249 2401-2463 3324-4027 4192-4288 4694-5330

					5485-5650 5813-6262 6273-6401 6475-6559 6728-6847 6979-7205 7573-7676 7730-8146 8334-8866 8885-9392
HTLBH67	781	751985	AC008781	3156	1-85 254-371 505-731 1098-1201 1255-1671 1718-2387 2408-2915 3113-3244 3382-4278 4504-4538 4650-5645
HTLBH67	781	751985	AC022420	3157	1-62 295-403 455-979 1019-1061 1466-1537 1890-2030 2114-2253 2405-2467 3328-4030 4195-4291 4697-5333 5488-5653 5816-6265 6276-6404 6478-6562 6731-6850 6982-7208 7575-7678 7732-8148 8195-8864 8885-9392 9590-9721 9859-10754 10980-11014 11126-12121
HTLBH67	781	751985	AC005368	3158	1-64

					294-399 451-975 1015-1057 1462-1533 1885-2025 2109-2248 2400-2462 3323-4026 4191-4287 4693-5329 5484-5649 5812-6264 6275-6403 6477-6561 6730-6849 6981-7207 7575-7678 7732-8148 8201-8868 8887-9394 9592-9723 9861-10759 10985-11019 11131-12126
HTLBH67	781	751985	AC008781	3159	1-292
HTLBH67	781	751985	AC022420	3160	1-323 1372-1431 1657-1821 2377-2485 4488-4700 4954-5061 6224-6547 6819-6965 7268-7333 8088-8593 9897-10068 10109-10623 10645-10680 10812-10871 10982-11123 11345-11383 11877-12000 12310-13467
HTLBH67	781	751985	AC022420	3161	1-292
HTLBH67	781	751985	AC005368	3162	1-292
HTLBC07	782	954111	AC015841	3163	1-668
HTLBC07	782	954111	AC018617	3164	1-672

HTLBC07	782	954111	AC004586	3165	1-672
HTLBC07	782	954111	AC015841	3166	1-124
HTLBC07	782	954111	AC018617	3167	1-124
HTLBC07	782	954111	AC004586	3168	1-514 681-994 1116-1732 1974-2431 2451-3123 3603-3698 4469-4606 5033-5496 6293-6890 6965-8015 8053-8130
HTLBC07	782	954111	AC004586	3169	1-77 3689-3807 3960-4294 4692-4820 5674-5809 6237-6334 7138-7247 8211-8309 8720-8861 9797-10087 10098-10215 10448-11237 11311-11550 11566-11654 12306-12914 12929-13575 13587-13703 14256-14391 14535-14763 17193-17450
HTLAB29	789	879168	AC026362	3170	1-389 508-653 1079-1226 1867-2043 2136-2239 2359-3327 3438-3958 4003-5312
HTLAB29	789	879168	AC026362	3171	1-336
HTFBE02	790	920507	AC022536	3172	1-31 340-421 1097-1262 2446-2621

					3069-3161 3571-3791 4947-5076 5905-6987
HTFBE02	790	920507	AC022536	3173	1-102
HTEQS95	791	972746	AL133284	3174	1-1005
HTEQS95	791	972746	AL133284	3175	1-258
HTEQS90	792	973426	AP000635	3176	1-692
HTEQS90	792	973426	AP000610	3177	1-691
HTEQS90	792	973426	AP001547	3178	1-691
HTEQS90	792	973426	AP000635	3179	1-543
HTEQS90	792	973426	AP000610	3180	1-197
HTEQS90	792	973426	AP001547	3181	1-197
HTEQS90	792	973426	AP000610	3182	1-543
HTEQS90	792	973426	AP001547	3183	1-543
HTEQP03	793	870516	AC018931	3184	1-238 672-970 6605-6665
HTEQP03	793	870516	AC018931	3185	1-323 373-560
HTEQB08	795	958291	AL139106	3186	1-831
HTEQB08	795	958291	AL162721	3187	1-831
HTEQB08	795	958291	AL139106	3188	1-324
HTEQB08	795	958291	AL162721	3189	1-261 805-1128
HTEOE28	801	870581	AL139243	3190	1-1106
HTENY44	802	870588	AC027544	3191	1-197 710-864 1263-1380 2382-2706 3184-3394 3970-4082
HTENY44	802	870588	AC027544	3192	1-570
HTENY44	802	870588	AC027544	3193	1-322
HTENV06	803	933294	AL121753	3194	1-498
HTENV06	803	933294	AL356652	3195	1-498
HTENV06	803	933294	AL121753	3196	1-116
HTENV06	803	933294	AL356652	3197	1-104
HTENL95	808	795314	AC022930	3198	1-32 79-745 880-1680 1782-2276 2861-3730 4861-5265
HTENL95	808	795314	AC069217	3199	1-32 79-745

					880-1679
HTENL95	808	795314	AF238376	3200	1-32 79-745 880-1680
HTENL95	808	795314	AC022930	3201	1-150 215-626 662-1438 2351-2999
HTENL95	808	795314	AC022930	3202	1-297
HTENL95	808	795314	AC069217	3203	1-297
HTENL95	808	795314	AF238376	3204	1-297
HTENL95	808	795314	AC069217	3205	1-495
HTENL95	808	795314	AF238376	3206	1-495
HTENA08	810	958380	Z97985	3207	1-460 851-1242 1372-1475 2276-2373
HTENA08	810	958380	Z97985	3208	1-264
HTEMY05	811	880592	AC019326	3209	1-734 1378-6434
HTEMY05	811	880592	AF129408	3210	1-734 1378-7065
HTEMY05	811	880592	AC019326	3211	1-579
HTEMY05	811	880592	AF129408	3212	1-756
HTEMU66	813	944419	AC006510	3213	1-1150
HTEMU66	813	944419	AL022167	3214	1-1796
HTEMU66	813	944419	AC018903	3215	1-631
HTEMU66	813	944419	AC068470	3216	1-706
HTEMU66	813	944419	AL049186	3217	1-912
HTEMU66	813	944419	AC022305	3218	1-686
HTEMU66	813	944419	AL049186	3219	1-87
HTEMN80	816	775543	AP001386	3220	1-2970 3001-4307
HTEMN80	816	775543	AP002785	3221	1-2974 3005-4311
HTEMN80	816	775543	AP001386	3222	1-300
HTEMN80	816	775543	AP002785	3223	1-236
HTEMI51	818	870613	AL365214	3224	1-94 3508-4007
HTELV29	821	806421	AC068938	3225	1-643
HTELV29	821	806421	AC073407	3226	1-2055 3690-3915 3928-4379 4421-5222 7704-8003 11303-11530

					12021-12259 12917-14410
HTELV29	821	806421	AC073407	3227	1-350
HTELP07	822	952274	AC041014	3228	1-118 490-918
HTELP07	822	952274	AC041014	3229	1-332
HTELA02	824	918699	AC021688	3230	1-687 1014-1336
HTEKI62	826	812862	AC005848	3231	1-164 343-428 578-2903 3020-3168 4072-4415 5074-5526 5547-5780
HTEKI62	826	812862	AC005848	3232	1-863 1241-1590 1666-2167 2328-2424 2500-2950 3000-3341 3351-3962 3976-3995 4276-5430 5485-5585 5616-5892 6622-6727 7156-8018
HTEKD77	828	772397	AC018865	3233	1-1638
HTEJV94	829	793039	AC058807	3234	1-946
HTEJV94	829	793039	AC003669	3235	1-946
HTEJN12	831	653252	AL096763	3236	1-118 1052-1310 3744-4364 4488-4515 5291-5447 6507-7124 7157-7605 7842-8575
HTEJL30	832	696784	AC012379	3237	1-2084
HTEJL30	832	696784	AC009697	3238	1-2084
HTEJL30	832	696784	AC012379	3239	1-142
HTEJL30	832	696784	AC009697	3240	1-719
HTEJL30	832	696784	AC012379	3241	1-719
HTEJL30	832	696784	AC009697	3242	1-142
HTEJB07	834	953801	AC073625	3243	1-494 2402-2532

HTEJB07	834	953801	AC007394	3244	1-430
HTEJB07	834	953801	AC073625	3245	1-1712 1727-2677
HTEJB07	834	953801	AC007394	3246	1-1712 1727-2677
HTEIS34	835	887112	AC069257	3247	1-635 725-895 1011-1169 1645-2361 2527-3215 3399-3766 3842-4045
HTEIS34	835	887112	AC026308	3248	1-635 725-895 1011-1169 1645-2361 2527-3215 3399-3766 3842-4045
HTEIS34	835	887112	AC069257	3249	1-165
HTEIS34	835	887112	AC069257	3250	1-380
HTEIS34	835	887112	AC026308	3251	1-381
HTEIS34	835	887112	AC026308	3252	1-486
HTEIS25	836	870660	AC053512	3253	1-252 304-440 462-606 851-994
HTEIS25	836	870660	AL360086	3254	1-253 305-441 463-607 852-995
HTEHX57	845	734976	AC023756	3255	1-91 1173-1400 3751-4383 4431-4890 5497-5769 5920-6396
HTEHX57	845	734976	AP001152	3256	1-452 1059-1331 1482-1958
HTEHX57	845	734976	AC011007	3257	1-79 3753-3901 9145-9297 9344-9538 13689-14081 14559-14683 15765-15992

					17822-18243 18342-18974 19022-19481 20088-20360 20511-20987
HTEHX57	845	734976	AC023756	3258	1-1701 1831-4730
HTEHX57	845	734976	AP001152	3259	1-1702 1835-4742
HTEHX57	845	734976	AC011007	3260	1-1701
HTEHV11	846	967439	AL021331	3261	1-569
HTEHV11	846	967439	AL021331	3262	1-690
HTEHS17	847	664436	AC010255	3263	1-184 308-529 2761-3109
HTEHS17	847	664436	AC010255	3264	1-502
HTEHS17	847	664436	AC010255	3265	1-130 310-1003 1040-1331
HTEGU55	850	931017	Z98752	3266	1-2035
HTEGU55	850	931017	Z98752	3267	1-465
HTEGU55	850	931017	Z98752	3268	1-415
HTEGC30	856	690998	AC073079	3269	1-504
HTEFO46	859	719280	AC068790	3270	1-31 136-656
HTEFO46	859	719280	AC024438	3271	1-31 136-942 1083-4020
HTEFO28	860	685383	AC023123	3272	1-119 151-982 1019-1286 1442-1755 1908-2137 2256-2608 2974-3413 4977-5488 5507-8584 8676-10198
HTEFO28	860	685383	AC006534	3273	1-119 151-982 1019-1286 1442-1755 1986-2137 2256-2608 2974-3413 4977-5488 5507-8584

					8676-10198
HTEFO28	860	685383	AC023123	3274	1-546 601-659
HTEFO28	860	685383	AC006534	3275	1-230 234-264
HTEFO28	860	685383	AC023123	3276	1-237 239-272
HTEFO28	860	685383	AC006534	3277	1-546 601-659
HTEET22	866	675071	AC022930	3278	1-649 1562-2338 2374-2785 2850-2999
HTEET22	866	675071	AC069217	3279	1-777 813-1224 1289-1366
HTEET22	866	675071	AF238376	3280	1-38 1258-1452 3186-3304 3555-3746 6146-6232 8111-8262 9292-9751 10190-10839 11752-12528 12564-12975 13040-13189
HTEET22	866	675071	AC022930	3281	1-460
HTEET22	866	675071	AC022930	3282	1-405 1536-2405 2990-3484 3586-4386 4521-5187 5234-5265
HTEET22	866	675071	AC069217	3283	1-402
HTEET22	866	675071	AF238376	3284	1-408
HTEEF25	867	677513	AC012330	3285	1-344
HTEEF25	867	677513	AC008132	3286	1-344
HTEEF25	867	677513	AC023491	3287	1-344
HTEEF25	867	677513	AC008103	3288	1-583 683-2302 5090-5245 5708-5746 5973-6045
HTEEF25	867	677513	AC023490	3289	1-582 682-2297
HTEEF25	867	677513	AC008079	3290	1-583

					683-2302 4878-5241 5704-5742 5969-6041
HTEEF25	867	677513	AC007325	3291	1-583 683-2306 4881-5244 5707-5745 5972-6044
HTEEF25	867	677513	AC007708	3292	1-582 682-2297
HTEEF25	867	677513	AC007324	3293	1-582 682-2301 5089-5244 5707-5745 5972-6044
HTEEF25	867	677513	AC008018	3294	1-582 682-2301 4877-5240 5703-5741 5968-6040
HTEEF25	867	677513	AC007981	3295	1-340
HTEEF25	867	677513	AC008103	3296	1-603
HTEEF25	867	677513	AC008103	3297	1-233
HTEEF25	867	677513	AC023490	3298	1-603
HTEEF25	867	677513	AC008079	3299	1-452 1155-1470 1497-1744 6815-7114 8000-8325 8749-9359 10364-10577 10586-10884 11714-12079 14576-14752 16955-17117 17240-17567 21365-21630 23483-23784 23982-24078 24280-24312 25597-25744 25952-26024 26254-26692 27187-27493 27543-27657 27931-28344

					31056-31145 31243-31541 31698-31846 33652-33750 34559-34729 34936-35276 36328-36748 36956-37092 37601-37650 38741-38979 40580-41206
HTEEF25	867	677513	AC008079	3300	1-233
HTEEF25	867	677513	AC007325	3301	1-603
HTEEF25	867	677513	AC007325	3302	1-235
HTEEF25	867	677513	AC007708	3303	1-603
HTEEF25	867	677513	AC007324	3304	1-234
HTEEF25	867	677513	AC007324	3305	1-603
HTEEF25	867	677513	AC008018	3306	1-233
HTEEF25	867	677513	AC008018	3307	1-603
HTEEF25	867	677513	AC007981	3308	1-488
HTEEB82	868	780161	AC026140	3309	1-81 1974-2064 2695-2852 2934-3354 4059-4360 4682-4800
HTEEB82	868	780161	AL033531	3310	1-81 1974-2064 2695-2852 2934-3354 4059-4845
HTEEB82	868	780161	AC026140	3311	1-212
HTEEB82	868	780161	AL033531	3312	1-669
HTEEB82	868	780161	AL033531	3313	1-212
HTEDX39	869	530201	AC005726	3314	1-257
HTEDX39	869	530201	AC005726	3315	1-124
HTEDX39	869	530201	AC005726	3316	1-81 754-902 1011-1476 1836-2127 3328-3518 3715-3773 4307-4426 4516-4946 5049-5097 5496-5623 6425-6598

HTEDX04	870	927850	AF111169	3317	1-136 1693-1823 1913-2092 2493-2707 4607-4680
HTEDX04	870	927850	AF111169	3318	1-347
HTEDX03	871	925353	AC005300	3319	1-202
HTEDX03	871	925353	AC006946	3320	1-202
HTEDX03	871	925353	AC006946	3321	1-168
HTEDW96	872	881958	AC017028	3322	1-477 786-1004
HTEDW96	872	881958	AC017028	3323	1-867
HTEDW59	873	530448	AC025868	3324	1-217
HTEDW59	873	530448	AC025868	3325	1-264 363-446
HTEDV86	874	785818	AL356801	3326	1-763
HTEDV86	874	785818	AL356801	3327	1-142
HTEDO75	878	767024	AL049541	3328	1-910
HTEDJ92	880	522827	AL390815	3329	1-295
HTEDI01	883	961028	AC019205	3330	1-224
HTEDH30	887	522936	AL049697	3331	1-57 1807-1921 2559-2625
HTEDH30	887	522936	AL049697	3332	1-365 381-1034
HTEDH17	888	522938	AC026124	3333	1-413
HTEDH17	888	522938	AC012597	3334	1-413
HTEDH06	889	869427	AC006251	3335	1-718 767-1512 1639-2023 2398-2655 2926-2990 3300-3357 4357-4395 5163-5275 5927-6337 6945-7074 7156-7444
HTEDH06	889	869427	AC006251	3336	1-163 460-673 787-898 4433-4791 6955-7223 7246-7642 11004-11548 12185-12593 13374-13482

					14491-14587 15381-16043 16395-16546 18407-18623 19528-19762 19852-20715 21495-21936
HTEDH06	889	869427	AC006251	3337	1-400
HTEDF96	892	614726	AC021163	3338	1-540 655-1021 1053-1143 1354-1536 1692-1762 1924-2030 2867-2962 3191-4078 4135-4228 4365-4458 4565-4675 4747-4815 4901-4977 5232-5675 6013-6910
HTEDF96	892	614726	AC006942	3339	1-541 656-1023 1055-1145 1356-1538 1694-1764 1926-2032 3194-4081 4138-4231 4368-4461 4568-4678 4750-4818 4904-4980 5235-5678 6016-6914 7138-7281 7453-7737 7813-8322 8835-9123 9152-10108 10204-10288 10387-10448 11252-11414 11496-11676 11746-12218

					12336-12436 13243-13426 13626-13767 13891-14067 14442-14596 15655-15742 16852-17292 17660-17764 18610-18921 19197-19405 19407-19499 20302-20404 20510-20780 21329-21458
HTEDF96	892	614726	AC021163	3340	1-288
HTEDF96	892	614726	AC006942	3341	1-288
HTEDF22	895	908406	AL138891	3342	1-822
HTEDF22	895	908406	AC002418	3343	1-823
HTEDF22	895	908406	AC004386	3344	1-823
HTEDF22	895	908406	AL138891	3345	1-155
HTEDF22	895	908406	AC002418	3346	1-142
HTECE66	896	522997	AL159160	3347	1-61 5520-5850
HTECE66	896	522997	AL390071	3348	1-61 620-770 5508-5838
HTECE66	896	522997	AL390071	3349	1-259
HTECE62	897	523002	AC069401	3350	1-158 259-547 1614-2136
HTECE62	897	523002	AC005232	3351	1-158 259-547 1614-2136
HTECE51	899	870723	AC016976	3352	1-301
HTECE51	899	870723	AC058805	3353	1-301
HTECE51	899	870723	AC027764	3354	1-301
HTECE51	899	870723	AC016976	3355	1-425
HTECE51	899	870723	AC027764	3356	1-425
HTECE31	901	508104	AC069360	3357	1-283
HTECE31	901	508104	AC023850	3358	1-283
HTECE31	901	508104	AC069360	3359	1-409
HTECE31	901	508104	AC023850	3360	1-409
HTECD94	903	527210	AC025959	3361	1-58 828-1050 2944-3114 3238-3330
HTECD94	903	527210	AC025963	3362	1-127

					951-1008 1778-2000 3894-4064 4188-4280
HTECD94	903	527210	AC009451	3363	1-127 951-1008 1781-2003 3897-4067 4191-4283
HTECD94	903	527210	AC025959	3364	1-151
HTECD94	903	527210	AC025963	3365	1-151
HTECD94	903	527210	AC009451	3366	1-151
HTECD88	904	527214	AC024631	3367	1-560
HTECD88	904	527214	AC017098	3368	1-560
HTECD88	904	527214	AC024631	3369	1-263
HTECD88	904	527214	AC017098	3370	1-869 1451-4175
HTECD88	904	527214	AC024631	3371	1-869 1451-4174
HTECD88	904	527214	AC017098	3372	1-263
HTECD70	905	527203	AC013471	3373	1-243 3350-3433
HTECD65	906	533795	AL157899	3374	1-119 4379-4589
HTECD65	906	533795	AL137800	3375	1-119 4380-4590
HTECD65	906	533795	AL157899	3376	1-489 540-886
HTECD65	906	533795	AL137800	3377	1-489 540-2889
HTECD15	908	523029	AC019082	3378	1-405
HTECD15	908	523029	AC019082	3379	1-136 545-583 824-1177
HTECC71	909	508142	AC060234	3380	1-364
HTECC45	910	508124	AC034305	3381	1-320
HTECC45	910	508124	AC034305	3382	1-539
HTECC26	911	508144	AL158090	3383	1-168 2574-2660 3463-3623
HTECC09	912	678659	AC069004	3384	1-91 238-330 1468-1597 1773-1835 2685-2851 2987-3081 3275-3440

					4518-4928 6204-6550 6951-7273 7923-8577
HTECC09	912	678659	AC069004	3385	1-816
HTECC08	913	960439	AC008397	3386	1-436
HTECC08	913	960439	AC008397	3387	1-314
HTECC08	913	960439	AC008397	3388	1-555
HTECA39	915	508132	AC036150	3389	1-412
HTECA39	915	508132	AP001883	3390	1-412
HTECA39	915	508132	AC036150	3391	1-496 541-1674
HTECA39	915	508132	AP001883	3392	1-461
HTECA39	915	508132	AC036150	3393	1-461
HTECA39	915	508132	AP001883	3394	1-496 541-1674
HTEBJ02	920	921321	AL031727	3395	1-1383
HTEBJ02	920	921321	AL031727	3396	1-576
HTEAX06	922	960792	AC015559	3397	1-949
HTEAX06	922	960792	AC015559	3398	1-65 86-509 733-1178 2992-3574 4191-4337 4759-4850 6000-6163 6241-6337 6731-6852 6932-7048 7138-7271 8386-8513 9167-9300 9384-9468 9527-9830 10006-10582 11005-11153 11315-11469 11660-11810 14929-15256 15410-15569 16041-16200 16626-16799 17095-17498 17712-18272
HTEAX06	922	960792	AC015559	3399	1-188 1981-2138 3446-3545

					3751-3867 3900-4028 4262-4369
HTEAV22	923	679394	AC016757	3400	1-1823
HTEAV22	923	679394	AC016757	3401	1-1229 2106-2702 3129-4275
HTEAR93	927	503298	AC009967	3402	1-411 1914-2289 2844-2962 3628-4209 4664-4925 5258-5353
HTEAR93	927	503298	AC009967	3403	1-241 348-492 1563-1872 1875-2138
HTEAR93	927	503298	AC009967	3404	1-315
HTEAG47	931	503623	AL139384	3405	1-939
HTEAG47	931	503623	AL162711	3406	1-939 1988-2462 5032-5242
HTEAG47	931	503623	AC011695	3407	1-939
HTEAG47	931	503623	AL139384	3408	1-475
HTEAG47	931	503623	AL162711	3409	1-310
HTEAG47	931	503623	AL139384	3410	1-198
HTEAG47	931	503623	AL162711	3411	1-198
HTEAG47	931	503623	AC011695	3412	1-198
HTEAG47	931	503623	AC011695	3413	1-475
HTEAG08	932	960469	AC069236	3414	1-329
HTEAG08	932	960469	AC069236	3415	1-454
HTEAB50	933	724751	AL391056	3416	1-162 524-688 735-874 1577-1774 2049-2216 2395-2540 3191-3424
HTEAB50	933	724751	AC007779	3417	1-162 524-688 749-849 1579-1776 2050-2217 2396-2541 3192-3425
HTEAB50	933	724751	AC007779	3418	1-130
HEPCB04	935	941270	AL023581	3419	1-394

					541-679
HEPBO85	937	783362	AC010192	3420	1-1410
HEPBO85	937	783362	AC010192	3421	1-844
HEPAX40	939	535627	AP000872	3422	1-919
HEPAX40	939	535627	AP001316	3423	1-918
HEPAX40	939	535627	AC020735	3424	1-918
HEPAX40	939	535627	AP000872	3425	1-239
HEPAX40	939	535627	AP001316	3426	1-239
HEPAX40	939	535627	AC020735	3427	1-239
HEPAP34	942	703336	AC023500	3428	1-861 1078-1553 1584-2086 2457-5820 5956-6035 6220-6390 6480-6573
HEPAP34	942	703336	AC023500	3429	1-90 204-285 394-540 757-840 1060-1090
HEPAP34	942	703336	AC023500	3430	1-44 976-1138 1382-1480 1506-1645 2208-2505 2848-2978 3094-3276 4404-4939 5843-5881
HEPAJ14	945	657440	AL158843	3431	1-749
HEPAJ14	945	657440	AL158843	3432	1-548
HEPAJ04	946	933091	AC078837	3433	1-358
HEPAJ04	946	933091	AC015937	3434	1-295 1964-2131 2295-2696
HEPAJ04	946	933091	AC007993	3435	1-295 1964-2131 2295-2696
HEPAJ04	946	933091	AC015937	3436	1-152 343-406 656-852
HEPAJ04	946	933091	AC007993	3437	1-152 343-406 656-852
HEPAE58	947	509130	AL356017	3438	1-422 489-1010

					1016-1105 4311-4768 4930-5657 12468-12775 12982-13085 17810-19506 19953-20359 20615-20935 21563-21594 21625-21685 21806-22238
HEPAE58	947	509130	AL117187	3439	1-422 489-1009 1015-1104 4310-4767 4929-5656 12467-12774 12981-13084 17809-19505 19952-20358 20614-20934 21562-21593 21624-21684 21805-22237
HEPAE02	948	921389	AC004887	3440	1-573
HEGBA01	951	915596	AC006333	3441	1-164
HEGBA01	951	915596	AC006333	3442	1-1132
HEGBA01	951	915596	AC006333	3443	1-106
HEGAQ91	953	789940	AL031319	3444	1-429 1170-1866 7200-7527 8540-8925
HEGAL55	954	731654	AL133367	3445	1-51 740-1103 3374-3642 5341-6839
HEGAL55	954	731654	AL139300	3446	1-51 740-1103 3374-3642 5340-6838
HEGAL55	954	731654	AL133367	3447	1-680
HEGAL55	954	731654	AL139300	3448	1-535
HEGAL55	954	731654	AL139300	3449	1-680
HEGAJ08	955	959216	AC013472	3450	1-162 207-664 1217-1396 1663-1842

					2264-3540 3892-4029
HEGAC02	956	918992	Z93016	3451	1-154 1660-2193 4376-4518 4613-4754 5136-5690
HEGAC02	956	918992	Z93016	3452	1-196
HEEAY84	957	782706	AC058792	3453	1-366 744-1196
HEEAY84	957	782706	AC024408	3454	1-366 744-1196
HEEAY84	957	782706	AL136091	3455	1-366 744-1196
HEEAY84	957	782706	AC024408	3456	1-379
HEEAY84	957	782706	AL136091	3457	1-379
HEEAY84	957	782706	AC058792	3458	1-379
HEEAX09	958	912065	AL355987	3459	1-380 897-1234 1680-1754 2724-3894
HEEAX09	958	912065	AL355987	3460	1-412
HEEAW40	959	710655	AL132982	3461	1-475 741-1367
HEEAP59	960	738892	AC019120	3462	1-389 915-1330
HEEAP59	960	738892	AC019120	3463	1-520
HEEAH94	962	794257	AC044789	3464	1-596
HEEAH94	962	794257	AC009877	3465	1-621
HEEAH94	962	794257	AC039056	3466	1-618
HEEAH94	962	794257	AC009877	3467	1-185
HEEAH94	962	794257	AC009877	3468	1-358
HEEAH94	962	794257	AC039056	3469	1-358
HEEAH94	962	794257	AC039056	3470	1-185
HEEAH76	963	769950	AC010600	3471	1-835 1917-2695
HEEAH76	963	769950	AC010600	3472	1-427
HEEAH76	963	769950	AC010600	3473	1-516
HEEAH57	964	734488	AC069029	3474	1-561 661-1152
HEEAH57	964	734488	AC069029	3475	1-150
HEEAG51	966	930810	U73637	3476	1-456 624-1143 1468-3366 5719-5910 11252-11421 16310-16521

					16547-16574 18633-20907
HEEAG51	966	930810	AF015416	3477	1-456 677-1130 1469-3367 5720-5912 6136-6235 11254-11423 16312-16523 16549-16576 18636-19929
HEEAG51	966	930810	AF015416	3478	1-727
HEEAG51	966	930810	U73637	3479	1-280
HEEAG51	966	930810	AF015416	3480	1-280
HEEAD13	968	470886	AC020558	3481	1-162 5477-5629 8588-8704 8974-9372 9931-10402 11053-11250 11813-11910 12288-12575
HEEAD13	968	470886	AC073621	3482	1-153 3113-3228 3498-3896 4455-4926 5578-5775 6338-6435 6813-7100 10158-10763 11954-11987
HEEAD13	968	470886	AC073621	3483	1-428
HCDMF96	970	796196	AC004676	3484	1-80 563-871 1053-1408 1467-2070 4385-4481 4889-4977 5408-5903 6173-6232 6875-7016 9420-10150 11107-11627
HCDMF96	970	796196	AC004676	3485	1-126
HCDMF96	970	796196	AC004676	3486	1-323
HCDMC86	972	785134	AC007337	3487	1-74 578-1317

HCDMC86	972	785134	AC009039	3488	1-74 579-1318
HCDMC86	972	785134	AC007337	3489	1-278
HCDMC86	972	785134	AC009039	3490	1-278
HCDMC22	975	672815	AC012204	3491	1-74
HCDMB91	977	789551	AL358472	3492	1-348
HCDMB42	978	713300	AC024971	3493	1-274
HCDMB42	978	713300	AL078591	3494	1-283
HCDMB41	979	711996	AC024481	3495	1-588
HCDMB27	980	682389	AC027783	3496	1-298
HCDMB27	980	682389	AC027576	3497	1-298
HCDMB03	983	923316	AL030997	3498	1-325
HCDMB03	983	923316	AL030997	3499	1-340
HCDMB03	983	923316	AL030997	3500	1-268
HCDMA20	984	669201	AC016874	3501	1-72 1460-2583
HCDMA20	984	669201	AC016721	3502	1-72 1460-2583
HCDMA20	984	669201	AC016874	3503	1-98
HCDMA20	984	669201	AC016721	3504	1-454
HCDMA20	984	669201	AC016874	3505	1-458
HCDMA20	984	669201	AC016721	3506	1-98

[044] Table 1B summarizes additional polynucleotides encompassed by the invention (including cDNA clones related to the sequences (Clone ID NO:Z), contig sequences (contig identifier (Contig ID:) contig nucleotide sequence identifiers (SEQ ID NO:X)), and genomic sequences (SEQ ID NO:B). The first column provides a unique clone identifier, "Clone ID NO:Z", for a cDNA clone related to each contig sequence. The second column provides the sequence identifier, "SEQ ID NO:X", for each contig sequence. The third column provides a unique contig identifier, "Contig ID:" for each contig sequence. The fourth column, provides a BAC identifier "BAC ID NO:A" for the BAC clone referenced in the corresponding row of the table. The fifth column provides the nucleotide sequence identifier, "SEQ ID NO:B" for a fragment of the BAC clone identified in column four of the corresponding row of the table. The sixth column, "Exon From-To", provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:B which delineate certain polynucleotides of the invention that are also exemplary members of polynucleotide sequences that encode polypeptides of the invention (e.g., polypeptides containing amino acid sequences encoded

by the polynucleotide sequences delineated in column six, and fragments and variants thereof).

TABLE 2

Clone ID NO:Z	Contig ID:	SEQ ID NO:X	Analysis Method	PFam/NR Description	PFam/NR Accession Number	Score/ Percent Identity	NT From	NT To
H7MDD72	847688	12	blastx.2	(AF034780) lysosphingolipid receptor Edg5 [Homo sapiens]	gb AAC98919.1	95%	597	7
H7MDD72	887805	985	HMMER 1.8	PFAM: 7 transmembrane receptor (rhodopsin family)	PF00001	118	75	668
HEEAH07	851219	19	blastx.2	(AL137469) hypothetical protein [Homo sapiens]	emb CAB70754.1	100%	178	270
HEEAJ58	785121	20	blastx.2	(AF080470) pallid [Homo sapiens]	gb AAF08343.1 AF080470_1	100% 100% 66%	169 90 169	258 170 252
HEEAJ76	887321	21	blastx.2	truncated protein [Saccharomyces cerevisiae]	gb AAB31222.1	87%	94	23
HEEA W01	851213	27	blastx.2	(AK000385) unnamed protein product [Homo sapiens]	dbj BAA91131.1	72%	371	210
HEGAB84	823900	31	HMMER 2.1.1	PFAM: Ank repeat	PF00023	36.9	205	315
HEGAO83	780837	34	blastx.2 HMMER 1.8	ankyrin 3 [Mus musculus] PFAM: IG (immunoglobulin) superfamily	gb AAB01605.1 PF00047	37% 9.4	28 234	348 305
HEGAZ61	950033	39	HMMER 2.1.1	PFAM: Reprolysin family propeptide	PF01562	141.4	276	560
			blastx.2	epididymal apical protein I-	emb CAA46929.1	92%	60	560

HEPAB70	557149	41	blastx.2	precursor [Macaca fascicularis] ORF_ID:o209#7 [Escherichia coli]					
					dbj BAA35540.1	83%	99	329	
						87%	43	141	
						90%	326	355	
HEPAP02	926914	50	blastx.2	WW domain binding protein-1 [Homo sapiens]	gb AAD10950.1	100%	59	163	
					PF00061	26.73	117	509	
HEPBA39	919875	53	HMMER 1.8	PFAM: lipocalins					
			blastx.2	(AF109472) epididymal protein 52 [Oryctolagus cuniculus]	gb AAC98311.1	42%	314	66	
HEPBH38	707524	59	blastx.2	(AK000385) unnamed protein product [Homo sapiens]	dbj BAA91131.1	53%	319	146	
HEPCT32	947081	68	blastx.2	(AJ243311) matrix metalloproteinase-2 [Equus caballus]	emb CAB46656.1	32%	262	636	
						39%	262	477	
						32%	24	269	
						27%	18	275	
HEPCU32	931824	69	HMMER 1.8	PFAM: lipocalins	PF00061	11.52	508	627	
			blastx.14	mE-RABP minor form protein [Mus musculus]	gi 3241966 gb AA C24316.1	30%	502	630	
						20%	336	482	
						60%	279	308	
HEPCU32	946975	986	HMMER 1.8	PFAM: lipocalins	PF00061	11.52	405	524	
			blastx.14	mE-RABP minor form protein [Mus musculus]	gi 3241966 gb AA C24316.1	30%	399	527	
						20%	233	379	
						60%	176	205	

HTEAL28	963538	78	blastx.14	(AL080154) hypothetical protein [Homo sapiens]	gi 526261 emb CAB45745.1	36%	234	413
HTEBY08	960427	91	HMMER 2.1.1	PFAM: Protein phosphatase 2A regulatory subunit PR55	PF01240	92.8	63	251
			blastx.14	protein phosphatase 2A1 B gamma subunit [Oryctolagus cuniculus]	gi 619215 gb AA58956.1	97% 87%	63 231	197 254
HTECA21	911369	99	HMMER 2.1.1	PFAM: PDZ domain (Also known as DHR or GLGF).	PF00595	57.6	100	354
			blastx.14	tyrosine phosphatase [Homo sapiens]	gi 1486367 emb CAA56124.1	57% 51%	85 467	351 652
HTEDI02	921243	131	HMMER 2.1.1	PFAM: Leucine Rich Repeat	PF00560	36.2	346	414
			blastx.14	densin-180 [Rattus norvegicus]	gi 1657758 gb AAC52881.1	36% 32% 34% 30% 33% 26% 29% 36% 36% 24% 26% 40% 29% 29% 31% 29%	220 214 220 241 214 214 214 268 463 220 214 463 220 463 463 463 463	450 450 456 450 453 441 450 450 612 453 453 588 606 606 606 603

HTEDQ30	530589	142	HMMER 2.1.1	PFAM: Ferritins	PF00210	24%	463	612
HTEDU48	932315	148	blastx.14	(AF176069) ubiquilin [Homo sapiens]	gi 5733824 gb AA D49751.1 AF176 069_1	104.6	9	164
HTEDY38	771505	152	HMMER 1.8	PFAM: Zinc-binding metalloprotease domain	PF00099	66%	11	118
HTEDY54	922964	153	blastx.14	lysozyme [Gallus gallus]	gi 63426 emb CA A43319.1	46%	305	454
HTEGM38	675087	193	HMMER 2.1.1	PFAM: DnaI domain	PF00226	55%	587	688
HTEGO05	932583	195	HMMER 2.1.1	PFAM: Eukaryotic protein kinase domain	PF00069	57%	452	535
HTEHC47	973071	218	blastx.14	male germ cell-associated kinase (mak) [Rattus norvegicus]	gi 205278 gb AA A41562.1	24%	251	472
						28%	293	388
						26%	332	502
						15%	311	490
						24%	569	679
						32%	184	267
						25%	329	436
						2.19	9	44
						46%	696	457
						41%	405	220
						61%	234	181
						65.2	93	197
						50.8	3	233
						85%	3	395
						64%	489	761
						85%	768	848
						38%	1023	1100
						29%	112	612

HTEHI14	526687	229	HMMER 2.1.1	PFAM: lactate/malate dehydrogenase	PF00056	50.6	222	371
HTEHS19	529280	245	HMMER 2.1.1	PFAM: 7 transmembrane receptor (Secretin family)	PF00002	19.3	16	135
HTEIF40	958355	258	blastx.14	(AF132972) CGI-38 protein [Homo sapiens]	gi4680715 gb AA D27747.1 AF132 972_1	64%	117	275
HTEIL07	953803	268	HMMER 1.8	PFAM: EF hand	PF00036	11.27	192	263
HTEIP88	941155	277	HMMER 2.1.1	PFAM: Transmembrane amino acid transporter protein	PF01490	34.7	1	216
HTEIU92	870652	283	HMMER 2.1.1	PFAM: Transketolase	PF00456	70.1	1	225
HTEIV54	922027	284	blastx.14	p18H-rev 107 [Rattus norvegicus]	gi433963 emb C AA53991.1	40% 65%	359 251	682 364
HTEIY80	955242	291	blastx.14	(AF146793) protein B [Mus musculus]	gi4836805 gb AA D30564.1 AF146 793_1	91% 74% 83% 31%	320 453 111 257	454 569 203 322
HTEJE15	908360	298	HMMER 1.8	PFAM: Helicases conserved C-terminal domain	PF00271	14.92	5	52
HTEJF45	942476	300	blastx.14	vasa-like gene protein, RVLG protein=putative DEAD 1 [Rattus sp.]	gi806464 gb AA B33364.1	73% 84% 65%	2 242 188	190 319 265
			HMMER 1.8	PFAM: Zinc-binding metalloprotease domain	PF00099	2.28	593	637
			blastx.2	(AB017800) nolp [Homo]	dbj BAA34576.1	69%	135	299

HTEJP10	914785	308	HMMER 1.8	sapiens]			53%	290	487
				PFAM: Heat shock hsp90 proteins		PF00183	77%	523	549
HTEJP66	916481	309	blastx.14	(AF151885) CGI-127 protein [Homo sapiens]		gi 4929723 gb AA D34122.1 AF151 885 1	37%	540	629
							13.29	110	214
HTEKS20	846714	336	HMMER 2.1.1	PFAM: EF hand		PF00036	100%	499	639
HTELE10	963563	347	blastx.14	integrumentary mucin B.1 [Xenopus laevis]		gi 1184035 emb C AA64795.1	62%	626	706
HTELJ89	966134	355	HMMER 1.8	PFAM: Zinc-binding metalloprotease domain		PF00099	75%	339	244
							2.6	290	316
HTELV86	910946	378	HMMER 1.8	PFAM: Fibronectin type III domain		PF00041	77.22	400	669
				neural cell adhesion protein BIG-2 precursor [Rattus norvegicus]		gi 1016012 gb AA C52262.1	96%	1	918
			blastx.14				68%	960	1025
							92%	926	967
							66%	22	75
							28%	1	171
							55%	1	54
							28%	286	399
							42%	10	93
							44%	280	354
							33%	274	390
							33%	286	357
							100%	1028	1054
							42%	184	225

HTEMA54	911666	386	HMMER 2.1.1	PFAM: Actin		100%	1057	1077
			blastx.14	actin [Girardia tigrina]	PF00022	28%	658	741
HTEMK03	923066	399	blastx.14	(AF116463) unknown [Streptomyces lincolnensis]	gi4204812 gb AA D11530.1	42%	253	849
						44%	955	1161
HTEMP49	932319	406	blastx.14	(AL117564) hypothetical protein [Homo sapiens]	gi4455041 gb AA D21045.1	55%	1232	1360
			blastx.14	120 kDa style glycoprotein [Nicotiana glauca]	gi2653671 gb AA C15893.1	48%	847	927
HTEMT06	934338	409	HMMER 2.1.1	PFAM: BTB/POZ domain	PF00651	58%	1169	1204
			blastx.14	(AF086831) leukemia/lymphoma related factor cLRF [Gallus gallus]	gi3599513 gb AA C35368.1	37%	302	216
HTEMX92	913795	413	HMMER 2.1.1	PFAM: HMG (high mobility group) box	PF00505	53%	171	127
			blastx.14			47%	348	292
HTENI58	917213	423	HMMER 2.1.1			53%	55	17
						35%	231	181
						42%	190	134
						42%	134	78
						58%	43	8
						91%	12	629
						28%	50	280
						37%	240	383
						32%	80	226
						62.3	122	319
						47%	143	337
						32%	331	450
						118.2	308	514

			blastx.14	HMG-X protein [Xenopus laevis]	gi 639691 dbj BA A06440.1	43%	269	514
HTENP54	787535	430	HMMER 1.8	PFAM: Bacterial regulatory proteins, luxR family	PF00196	43%	101	319
HTENP80	775387	431	HMMER 1.8	PFAM: TPR Domain	PF00515	26%	89	214
HTENR10	963530	433	blastx.14	protein kinase related to Raf protein kinases; 1	gi 1171248 gb AA C50354.1	57%	446	487
HTENY35	884043	442	HMMER 1.8	PFAM: Zinc finger, C3HC4 type (RING finger)	PF00097	6.37	107	199
HTEOF80	847224	449	HMMER 1.8	PFAM: EGF-like domain	PF00008	11.77	83	166
HTEOI36	870575	451	HMMER 1.8	PFAM: HMG (high mobility group) box	PF00505	82%	10	132
HTEON29	815852	454	HMMER 1.8	PFAM: EF hand	PF00036	6.56	449	592
HTEOV90	870532	457	HMMER 1.8	PFAM: Core histones H2A, H2B, H3 and H4	PF00125	14.65	20	100
HTEOW39	870566	459	HMMER 1.8	PFAM: C-type lysozymes and alpha-lactalbumin	PF00062	15.44	69	236
HTEPA08	958391	461	blastx.14	(AF004430) hD54+ins2 isoform [Homo sapiens]	gi 2895085 gb AA C98478.1	22.29	266	349
HTEPM33	870561	474	HMMER 2.1.1	PFAM: LIM domain containing proteins	PF00412	11.37	358	435
HTEPN07	952243	476	blastx.14	WW domain binding protein-2 [Homo sapiens]	gi 4205086 gb AA D10951.1	126.92	59	295
						47%	225	482
						67%	483	575
						95.6	4	180
						54%	174	311
						42%	9	158

HTEPP30	947107	479	blastx.14	(AF081947) tektin [Mus musculus]	gi 4235350 gb AA D13183.1	73%	30	689
HTEPV02	917406	486	HMMER 2.1.1	PFAM: Ank repeat	PF00023	21%	72	590
			blastx.14	alt. ankyrin (variant 2.2) [Homo sapiens]	gi 747710 emb C AA34611.1	30.4	343	435
HTEPX32	870698	487	HMMER 1.8	PFAM: Double-stranded RNA binding motif	PF00035	41%	247	411
HTEQD40	915198	491	blastx.14	(AC004877) sco-spondin-mucin-like; similar to P98167 1 sapiens]	gi 3638957 gb AA C36301.1	36	508	699
						30%	278	171
						33%	266	195
						43%	188	141
						45%	506	447
						54%	110	78
						42%	121	65
						25%	260	177
HTEQE87	958354	493	blastx.14	(AF132972) CGI-38 protein [Homo sapiens]	gi 4680715 gb AA D27747.1 AF132 972 1	50%	334	645
						58%	149	349
HTEQP45	966141	499	HMMER 1.8	PFAM: HMG (high mobility group) box	PF00505	5.99	7	48
HTEQR15	939641	501	HMMER 1.8	PFAM: 4 transmembrane segments integral membrane proteins	PF00335	32.9	174	455
			blastx.2	(AF133424) tetraspanin TM4-B [Homo sapiens]	gb AAF08363.1 AF133424 1	74%	141	698
HTEQT63	924799	503	HMMER 1.8	PFAM: Bacterial mufT protein	PF00293	3.53	472	501
HTLCA95	911655	518	HMMER 2.1.1	PFAM: Actin	PF00022	345.2	170	1096

			blastx.14	actin 2 [Echinococcus granulosus]	gi 290399 gb AA C80574.1	50% 42% 53% 45% 63%	170 761 677 593 2	568 1096 760 652 34
HTLCY54	908832	521	HMMER 2.1.1	PFAM: DnaJ domain	PF00226	119.8	245	445
			blastx.14	(AB014888) MRJ [Homo sapiens]	gi 3402485 dbj B AA32209.1	67% 78% 47% 40%	239 797 632 611	616 934 694 691
HTLDE64	908613	526	HMMER 2.1.1	PFAM: Zinc finger, C2H2 type	PF00096	47.6	197	271
			blastx.2	Kruppel-like factor LKLF [Mus musculus]	gb AAA86728.1	61% 42%	179 57	355 176
HTLDG55	911645	528	blastx.14	actin [Trypanosoma brucei]	gi 161963 gb AA A30151.1	48% 58%	95 28	199 63
HTLDS55	891322	532	HMMER 2.1.1	PFAM: Cell division protein	PF00735	454.7	233	1069
			blastx.2	(AJ250723) septin-like protein Sint1 [Mus musculus]	emb CAB59833.1	63%	131	1054
HTLDT05	909752	533	HMMER 2.1.1	PFAM: PH domain	PF00169	36.9	59	271
			blastx.2	(AK000004) FLJ00004 protein [Homo sapiens]	dbj BAA92229.1	77%	47	487
HTLDU05	911649	535	HMMER 1.8	PFAM: Actins	PF00022	141.45	125	469

HTLEH30	934287	544	blastx.14	(AF113908) actin-related protein [Emericella nidulans]	gi 4731565 gb AA D28502.1 AF113 908_1	30% 33%	2 451	469 540
HTLEJ11	973302	546	blastx.14 HMMER 2.1.1	(AF025310) tssk-1 and tssk-2 kinase substrate [Mus musculus] PFAM: Eukaryotic protein kinase domain	gi 2739052 gb AA C03366.1	90% 58% 81%	205 343 306	270 429 338
HTLET56	911654	558	blastx.14 HMMER 1.8	(AF144573) Mx-interacting protein kinase PKM [Mesocricetus auratus] PFAM: Actins	gi 4868443 gb AA D31319.1 AF144 573_1 PF00022	69% 40% 42% 38% 262.03	35 437 293 877 134	268 592 397 939 703
HTLET78	836820	559	blastx.14 HMMER 2.1.1	actin [Filobasidiella neoformans] PFAM: Proprotein convertase P-domain	gi 508701 gb AA C49074.1 PF01483	52% 33% 53% 52% 216.9	143 787 721 966 38	715 963 804 1022 433
HTLEV95	883332	562	HMMER 1.8	PFAM: Phorbol esters / diacylglycerol binding domain	PF00130	1.97	172	225
HTLEY11	967309	564	blastx.14	(AC004877) sco-spondin-mucin-like; similar to P98167 1 sapiens]	gi 3638957 gb AA C36301.1	66%	267	250
HTLFE05	954984	572	blastx.14	(AJ007798) nuclear protein SA3 [Homo sapiens]	gi 5834580 emb C AB55312.1	86% 65%	12 589	731 924
HTLFI39	953730	575	blastx.2	(AF053356) ORF4 [Homo sapiens]	gb AAC78801.1	100%	77	256

				sapiens]			100%	3	77
HTLGD25	870136	578	HMMER 1.8	PFAM: Ubiquitin family	PF00240		100%	376	420
HTLGM07	952254	582	HMMER 2.1.1 blastx.14	PFAM: 'Cold-shock' DNA- binding domain (AF096834) germ cell specific Y-box binding protein [Homo sapiens]	PF00313		83.86	79	324
							70.2	3	158
							90%	3	323
					gi 4837737 gb AA D30662.1		100%	393	485
							100%	549	614
							100%	711	761
							36%	661	750
							28%	637	720
							34%	117	203
							40%	475	519
							63%	487	519
HTLGT62	918606	583	blastx.14	a6(IV) collagen [Homo sapiens]	gi 1850097 dbj B AA09791.1		48%	187	261
							38%	379	456
							61%	503	541
							40%	113	178
							80%	232	261
							61%	181	219
							53%	229	273
							37%	196	276
							42%	14	70
							66%	181	207
HTLGX90	870528	585	HMMER 2.1.1	PFAM: UBX domain	PF00789		20.1	637	846
HTLHC14	908428	586	HMMER 2.1.1	PFAM: 'Cold-shock' DNA- binding domain	PF00313		36.8	9	95

HTLHP32	933335	590	HMMER 1.8	(AF096834) germ cell specific Y-box binding protein [Homo sapiens]	gi 4837737 gb AA D30662.1	88% 92% 62% 100% 37% 34% 50% 70% 28% 23% 34% 37% 30% 30%	3 330 424 539 539 397 519 584 509 342 54 460 256 402	260 443 528 577 625 483 572 613 634 479 140 531 363 479
HTLHT15	946586	593	blastx.14	PFAM: RNA recognition motif. (aka RRM, RBD, or RNP domain) (AL032626) cDNA EST EMBL:D70654 comes from this 1 1 1 yk377b8.3 comes f	gi 3925211 emb C AA21539.1	43% 66% 50% 58% 39%	1 287 402 235 240	243 358 455 270 308
HTLHV67	936139	596	blastx.14	(AF005038) secretory carrier membrane protein [Homo sapiens]	gi 5230678 gb AA B62723.2	83% 60% 96% 66%	152 591 465 2	475 749 542 46
HTLHZ10	963475	598	blastx.14	circumsporozoite protein [Plasmodium vivax]	gi 482882 gb AA _C46499.1	37% 35% 33%	3 3 3	137 137 137

[illegible]

HTLJA23	953729	607	blastx.2	(AF053356) ORF4 [Homo sapiens]	gb AAC78801.1	100%	2	274
HTLJC71	922923	609	HMMER 1.8	PFAM: Src homology domain 3	PF00018	100%	394	438
			blastx.2	(AL133030) hypothetical protein [Homo sapiens]	emb CAB61362.1	9.14	1152	1340
HTLJD88	953714	611	blastx.14	(AF025310) tssk-1 and tssk-2 kinase substrate [Mus musculus]	gi 2739052 gb AA C03366.1	94%	3	1355
HTLJJ75	924755	612	HMMER 2.1.1	PFAM: Coenzyme A transferase	PF01144	83%	3	206
			blastx.14	succinyl-CoA:alpha-ketoacid coenzyme A transferase [Sus scrofa]	gi 164423 gb AA A31019.1	74%	554	715
						95%	263	391
						72%	516	548
						77%	468	494
						63%	510	542
						32%	260	334
						60%	21	50
HTTBJ94	530564	623	HMMER 2.1.1	PFAM: Protein of unknown function	PF01871	317.7	445	813
HTTCT34	973210	629	HMMER 2.1.1	PFAM: Divalent cation transporter	PF01769	85%	448	813
			blastx.2	(AK000480) unnamed protein product [Homo sapiens]	dbj BAA91192.1	65%	37	405
						80%	813	977
						79%	980	1096
HTTDO19	908937	640	HMMER 2.1.1	PFAM: Zinc finger, C2H2 type	PF00096	63.2	18	254
						46.7	93	251
						89%	466	972
						96%	105	491
						58%	861	1049
						42.8	22	90

			blastx.2	zinc finger protein [Homo sapiens]	emb CAA55529.1	76%	1	129
						72%	1	129
						45%	1	237
						67%	1	129
						44%	1	237
						67%	1	129
						50%	13	234
						63%	125	190
						36%	180	287
						71%	149	190
						90%	161	190
						36%	180	287
						36%	180	287
						57%	180	221
						50%	180	227
HTTEU68	967819	650	blastx.14	glycosyl-phosphatidyl-inositol-anchored protein homolog [Mus musculus]	gi 1098569 gb AA82599.1	36%	26	190
						52%	536	649
						32%	197	352
						52%	759	827
						43%	377	424
HTTFM66	950051	660	blastx.2	(AK001269) unnamed protein product [Homo sapiens]	dbj BAA91592.1	84%	195	1124
HTTKP07	911390	687	HMMER 1.8	PFAM: Src homology domain 3	PF00018	15.82	47	196
			blastx.2	(AL049683) hypothetical protein [Homo sapiens]	emb CAB41255.1	51%	8	289
				cDNA EST yk338f6.5 comes from this gene;	emb CAB04553.1	56%	292	450
HTTJN26	869612	704	blastx.2			35%	587	345
						50%	666	589

HTTIR04	926772	708	blastx.14	cDNA EST EMBL:D75296 comes from this gene [Caenorhabditis elegans] (AF092091) cp431 [Rattus norvegicus] PFAM: KRAB box	gi 3851160 gb AA C72234.1 PF01352	45% 26% 79.1	462 195 282	163 118 401
HTTDM42	460948	722	HMMER 2.1.1					
HTTBP62	932997	731	blastx.14	(AF036705) Similar to phytoene desaturase; coded for 1 1 1 coded for	gi 2749982 gb AA B95172.1	69% 68%	64 373	336 468
HTLHK57	946914	990	blastx.14	acetylcholine receptor alpha 9 subunit [Rattus rattus]	gi 595481 gb AA A56720.1	76% 71%	783 586	938 720
HTLHB93	945862	757	blastx.2	(AJ006692) ultra high sulfur keratin [Homo sapiens]	emb CAA07188.1 	40% 39%	21 21	272 272
HTLGS10	963458	759	blastx.14	pro-alpha-2(I) collagen [Mus musculus]	gi 50489 emb CA A41205.1	34% 50% 26% 53%	108 380 186 302	212 433 320 340
HTLEQ92	932882	764	blastx.14	(AL117444) hypothetical protein [Homo sapiens]	gi 5911890 emb C AB55929.1	100% 100% 36%	6 203 213	107 256 269
HTLEN77	772363	766	HMMER 1.8	PFAM: EF hand	PF00036	26.93	294	380
HTLDZ81	778180	770	HMMER 1.8	PFAM: Tubulin	PF00091	12.29	156	245
HTLDW27	961353	771	blastx.14	(AF014461) EXO70 protein [Mus musculus]	gi 2352998 gb AA B69345.1	95% 100% 88% 76%	239 186 76 1	601 236 126 51

HTLBH67	751985	781	HMMER 1.8	PFAM: Src homology domain 3	PF00018	63%	36	68
HTFBE02	920507	790	HMMER 2.1.1	PFAM: Isopenentenyl- diphosphate delta-isomerase	PF01772	37.78	16	162
HTEQN83	908528	794	HMMER 2.1.1	PFAM: KRAB box	PF01352	95.6	103	291
HTEPE35	948475	798	blastx.14	(AL080125) hypothetical protein [Homo sapiens]	gi 5262560 emb C AB45723.1	62%	75	251
			HMMER 2.1.1	PFAM: Phosphatidylinositol- specific phospholipase C, Y domain	PF00387	66%	39	74
			blastx.2	1-phosphatidylinositol-4,5- biphosphate phosphodiesterase 1	pir S14113 S1411 3	163.8	839	507
HTEOY82	948845	799	blastx.14	(AJ010949) calcium channel alpha-2-delta-C subunit [Mus musculus]	gi 4186073 emb C AA09423.1	48%	1	750
HTEMV66	813038	812	HMMER 2.1.1	PFAM: Eukaryotic protein kinase domain	PF00069	97%	165	374
HTEMU66	944419	813	HMMER 1.8	PFAM: Eukaryotic protein kinase domain	PF00069	27.8	154	315
HTEMO58	964769	815	blastx.2	MEK Kinase 3 [Mus musculus]	gb AAB03535.1	114.85	613	963
			blastx.14	casein kinase 1 gamma 1 isoform [Rattus norvegicus]	gi 854733 gb AA C52200.1	49%	604	948
						29%	209	340
						82%	395	195
						65%	482	423
						87%	424	401

HTEKH17	942526	827	blastx.2	(AF016184) putative pheromone receptor [Rattus norvegicus]	gb AAC53331.1	77%	214	188
HTEGJ74	765901	852	HMMER 2.1.1	PFAM: Tudor domain	PF00567	70% 53% 52%	300 602 85	88 378 29
HTEDH90	909165	884	HMMER 2.1.1	PFAM: BTB/POZ domain	PF00651	38.5	6	167
HTEDH42	615250	886	blastx.14	(AF097916) HIV-1 inducer of short transcripts binding protein [Homo sapiens]	gi 3860089 gb AA C72973.1	45% 39%	150 348	308 416
HTEDF22	908406	895	HMMER 2.1.1	PFAM: ADP-ribosylation factor family	PF00025	156.4	42	353
			HMMER 1.8	PFAM: Zinc finger, CCHC class	PF00098	20.37	250	297
			blastx.2	nucleic acid binding protein [Mus sp.]	gb AAA89198.1	46%	52	303
HTECC09	678659	912	HMMER 1.8	PFAM: Zinc finger, C3HC4 type (RING finger)	PF00097	14.18	261	338
			blastx.2	(AF151048) HSPC214 [Homo sapiens]	gb AAF36134.1 AF151048.1	85%	111	332
HEPCB04	941270	935	blastx.14	(AF153605) androgen induced protein [Homo sapiens]	gi 5231135 gb AA D41087.1 AF153 605.1	97%	524	387
HEPAJ04	933091	946	blastx.14	(AL034368) predicted using hexExon; L779.3, 1	gi 4760337 emb C AB39078.2	44% 87% 50% 50%	95 302 201 1	148 325 236 42

HEGBC03	922550	949	blastx.14	similar to collagen [Caenorhabditis elegans]	gi 3873667 emb C AA94874.1	45%	230	262
HEEAX09	912065	958	HMMER 1.8	PFAM: lipocalins	PF00061	12.2	86	205
			blastx.14	epididymal secretory protein I (ESP I) [Rattus norvegicus]	gi 56117 emb CA A42493.1	39% 39% 33%	86 8 206	208 76 259
HEEAG51	930810	966	blastx.14	(AF083108) sirtuin type 3 [Homo sapiens]	gi 5225322 gb AA D40851.1 AF083 108.1	82% 75%	94 260	282 295
HCDMC22	672815	975	HMMER 1.8	PFAM: Core histones H2A, H2B, H3 and H4	PF00125	9.49	182	241

[045] Table 2 further characterizes certain encoded polypeptides of the invention, by providing the results of comparisons to protein and protein family databases. The first column provides a unique clone identifier, "Clone ID NO:", corresponding to a cDNA clone disclosed in Table 1A. The second column provides the unique contig identifier, "Contig ID:" which allows correlation with the information in Table 1A. The third column provides the sequence identifier, "SEQ ID NO:X", for the contig polynucleotide sequences. The fourth column provides the analysis method by which the homology/identity disclosed in the row was determined. The fifth column provides a description of PFam/NR hits having significant matches identified by each analysis. Column six provides the accession number of the PFam/NR hit disclosed in the fifth column. Column seven, "Score/Percent Identity", provides a quality score or the percent identity, of the hit disclosed in column five. Comparisons were made between polypeptides encoded by polynucleotides of the invention and a non-redundant protein database (herein referred to as "NR"), or a database of protein families (herein referred to as "PFam"), as described below.

[046] The NR database, which comprises the NBRF PIR database, the NCBI GenPept database, and the SIB SwissProt and TrEMBL databases, was made non-redundant using the computer program nrdb2 (Warren Gish, Washington University in Saint Louis). Each of the polynucleotides shown in Table 1A, column 3 (e.g., SEQ ID NO:X or the 'Query' sequence) was used to search against the NR database. The computer program BLASTX was used to compare a 6-frame translation of the Query sequence to the NR database (for information about the BLASTX algorithm please see Altschul et al., J. Mol. Biol. 215:403-410 (1990), and Gish et al., Nat. Genet. 3:266-272 (1993)). A description of the sequence that is most similar to the Query sequence (the highest scoring 'Subject') is shown in column five of Table 2 and the database accession number for that sequence is provided in column six. The highest scoring 'Subject' is reported in Table 2 if (a) the estimated probability that the match occurred by chance alone is less than $1.0e-07$, and (b) the match was not to a known repetitive element. BLASTX returns alignments of short polypeptide segments of the Query and Subject sequences which share a high degree of similarity; these segments are known as High-Scoring Segment Pairs or HSPs. Table 2 reports the degree of similarity between the Query and the Subject for each HSP as a percent identity in Column 7.

The percent identity is determined by dividing the number of exact matches between the two aligned sequences in the HSP, dividing by the number of Query amino acids in the HSP and multiplying by 100. The polynucleotides of SEQ ID NO:X which encode the polypeptide sequence that generates an HSP are delineated by columns 8 and 9 of Table 2.

[047] The PFam database, PFam version 5.2, (Sonnhammer et al., Nucl. Acids Res., 26:320-322, (1998)) consists of a series of multiple sequence alignments; one alignment for each protein family. Each multiple sequence alignment is converted into a probability model called a Hidden Markov Model, or HMM, that represents the position-specific variation among the sequences that make up the multiple sequence alignment (see, e.g., R. Durbin et al., *Biological sequence analysis: probabilistic models of proteins and nucleic acids*, Cambridge University Press, 1998 for the theory of HMMs). The program HMMER version 1.8 (Sean Eddy, Washington University in Saint Louis) was used to compare the predicted protein sequence for each Query sequence (SEQ ID NO:Y in Table 1A) to each of the HMMs derived from PFam version 5.2. A HMM derived from PFam version 5.2 was said to be a significant match to a polypeptide of the invention if the score returned by HMMER 1.8 was greater than 0.8 times the HMMER 1.8 score obtained with the most distantly related known member of that protein family. The description of the PFam family which shares a significant match with a polypeptide of the invention is listed in column 5 of Table 2, and the database accession number of the PFam hit is provided in column 6. Column 7 provides the score returned by HMMER version 1.8 for the alignment. Columns 8 and 9 delineate the polynucleotides of SEQ ID NO:X which encode the polypeptide sequence which shows a significant match to a PFam protein family.

[048] As mentioned, columns 8 and 9 in Table 2, "NT From" and "NT To", delineate the polynucleotides of "SEQ ID NO:X" that encode a polypeptide having a significant match to the PFam/NR database as disclosed in the fifth column of Table 2. In one embodiment, the invention provides a protein comprising, or alternatively consisting of, a polypeptide encoded by the polynucleotides of SEQ ID NO:X delineated in columns 8 and 9 of Table 2. Also provided are polynucleotides encoding such proteins, and the complementary strand thereto.

[049] The nucleotide sequence SEQ ID NO:X and the translated SEQ ID NO:Y are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, the nucleotide sequences of SEQ ID NO:X are useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in Clone ID NO:Z. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling immediate applications in chromosome mapping, linkage analysis, tissue identification and/or typing, and a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used to generate antibodies which bind specifically to these polypeptides, or fragments thereof, and/or to the polypeptides encoded by the cDNA clones identified in, for example, Table 1A.

[050] Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

[051] Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X, and a predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing cDNA Clone ID NO:Z (deposited with the ATCC on October 5, 2000, and receiving ATCC designation numbers PTA 2574 and PTA 2575; deposited with the ATCC on January 5, 2001, having the depositor reference numbers TS-1, TS-2, AC-1, and AC-2; and/or as set forth, for example, in Table 1A, 6 and 7). The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. Further, techniques known in the art can be used to verify the nucleotide sequences of SEQ ID NO:X.

[052] The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

RACE Protocol For Recovery of Full-Length Genes

[053] Partial cDNA clones can be made full-length by utilizing the rapid amplification of cDNA ends (RACE) procedure described in Frohman, M.A., et al., Proc. Nat'l. Acad. Sci. USA, 85:8998-9002 (1988). A cDNA clone missing either the 5' or 3' end can be reconstructed to include the absent base pairs extending to the translational start or stop codon, respectively. In some cases, cDNAs are missing the start codon of translation. The following briefly describes a modification of this original 5' RACE procedure. Poly A⁺ or total RNA is reverse transcribed with Superscript II (Gibco/BRL) and an antisense or complementary primer specific to the cDNA sequence. The primer is removed from the reaction with a Microcon Concentrator (Amicon). The first-strand cDNA is then tailed with dATP and terminal deoxynucleotide transferase (Gibco/BRL). Thus, an anchor sequence is produced which is needed for PCR amplification. The second strand is synthesized from the dA-tail in PCR buffer, Taq DNA polymerase (Perkin-Elmer Cetus), an oligo-dT primer containing three adjacent restriction sites (XhoI, SalI and ClaI) at the 5' end and a primer containing just these restriction sites. This double-stranded cDNA is PCR amplified for 40 cycles with the same primers as well as a nested cDNA-specific antisense primer. The PCR products are size-separated on an ethidium bromide-agarose gel and the region of gel containing cDNA products the predicted size of missing protein-coding DNA is removed. cDNA is purified from the agarose with the Magic PCR Prep kit (Promega), restriction digested with XhoI or SalI, and ligated to a plasmid such as pBluescript SKII (Stratagene) at XhoI and EcoRV sites. This DNA is transformed into bacteria and the plasmid clones sequenced to identify the correct protein-coding inserts. Correct 5' ends are confirmed by comparing this sequence with the putatively identified homologue and overlap with the partial cDNA clone. Similar

methods known in the art and/or commercial kits are used to amplify and recover 3' ends.

[054] Several quality-controlled kits are commercially available for purchase. Similar reagents and methods to those above are supplied in kit form from Gibco/BRL for both 5' and 3' RACE for recovery of full length genes. A second kit is available from Clontech which is a modification of a related technique, SLIC (single-stranded ligation to single-stranded cDNA), developed by Dumas et al., *Nucleic Acids Res.*, 19:5227-32 (1991). The major differences in procedure are that the RNA is alkaline hydrolyzed after reverse transcription and RNA ligase is used to join a restriction site-containing anchor primer to the first-strand cDNA. This obviates the necessity for the dA-tailing reaction which results in a polyT stretch that is difficult to sequence past.

[055] An alternative to generating 5' or 3' cDNA from RNA is to use cDNA library double-stranded DNA. An asymmetric PCR-amplified antisense cDNA strand is synthesized with an antisense cDNA-specific primer and a plasmid-anchored primer. These primers are removed and a symmetric PCR reaction is performed with a nested cDNA-specific antisense primer and the plasmid-anchored primer.

RNA Ligase Protocol For Generating The 5' or 3' End Sequences To Obtain Full Length Genes

[056] Once a gene of interest is identified, several methods are available for the identification of the 5' or 3' portions of the gene which may not be present in the original cDNA plasmid. These methods include, but are not limited to, filter probing, clone enrichment using specific probes and protocols similar and identical to 5' and 3' RACE. While the full length gene may be present in the library and can be identified by probing, a useful method for generating the 5' or 3' end is to use the existing sequence information from the original cDNA to generate the missing information. A method similar to 5' RACE is available for generating the missing 5' end of a desired full-length gene. (This method was published by Fromont-Racine et al., *Nucleic Acids Res.*, 21(7):1683-1684 (1993)). Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcript. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest, is

used to PCR amplify the 5' portion of the desired full length gene which may then be sequenced and used to generate the full length gene. This method starts with total RNA isolated from the desired source, poly A RNA may be used but is not a prerequisite for this procedure. The RNA preparation may then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase, if used, is then inactivated and the RNA is treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase. This modified RNA preparation can then be used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction can then be used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the testicular antigen of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the relevant testicular antigen.

[057] The present invention also relates to vectors or plasmids, which include such DNA sequences, as well as the use of the DNA sequences. The material deposited with the ATCC (deposited with the ATCC on October 5, 2000, and receiving ATCC designation numbers PTA 2574 and PTA 2575; deposited with the ATCC on January 5, 2001, having the depositor reference numbers TS-1, TS-2, AC-1, and AC-2; and/or as set forth, for example, in Tables 1A, 6 and 7) is a mixture of cDNA clones derived from a variety of human tissue and cloned in either a plasmid vector or a phage vector, as shown, for example, in Table 7. These deposits are referred to as "the deposits" herein. The tissues from which some of the clones were derived are listed in Table 7, and the vector in which the corresponding cDNA is contained is also indicated in Table 7. The deposited material includes cDNA clones corresponding to SEQ ID NO:X described, for example, in Table 1A (Clone ID NO:Z). A clone which is isolatable from the ATCC Deposits by use of a sequence listed as SEQ ID NO:X, may include the entire coding region of a human gene or in other cases such clone may include a substantial portion of the coding region of a human gene. Furthermore, although the sequence listing may in some instances list only a portion of the DNA

sequence in a clone included in the ATCC Deposits, it is well within the ability of one skilled in the art to sequence the DNA included in a clone contained in the ATCC Deposits by use of a sequence (or portion thereof) described in, for example Tables 1A or 2 by procedures hereinafter further described, and others apparent to those skilled in the art.

[058] Also provided in Table 7 is the name of the vector which contains the cDNA clone. Each vector is routinely used in the art. The following additional information is provided for convenience.

[059] Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128,256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., *Nucleic Acids Res.* 16:7583-7600 (1988); Altting-Mees, M. A. and Short, J. M., *Nucleic Acids Res.* 17:9494 (1989)) and pBK (Altting-Mees, M. A. et al., *Strategies* 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Phagemid pBS may be excised from the Lambda Zap and Uni-Zap XR vectors, and phagemid pBK may be excised from the Zap Express vector. Both phagemids may be transformed into *E. coli* strain XL-1 Blue, also available from Stratagene.

[060] Vectors pSport1, pCMVSport 1.0, pCMVSport 2.0 and pCMVSport 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into *E. coli* strain DH10B, also available from Life Technologies. See, for instance, Gruber, C. E., et al., *Focus* 15:59- (1993). Vector lafmid BA (Bento Soares, Columbia University, New York, NY) contains an ampicillin resistance gene and can be transformed into *E. coli* strain XL-1 Blue. Vector pCR[®]2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into *E. coli* strain DH10B, available from Life Technologies. See, for instance, Clark, J. M., *Nuc. Acids Res.* 16:9677-9686 (1988) and Mead, D. et al., *Bio/Technology* 9: (1991).

[061] The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, and/or the deposited clone (Clone ID NO:Z). The corresponding gene

can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

[062] Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of testes associated genes corresponding to SEQ ID NO:X or the complement thereof, polypeptides encoded by SEQ ID NO:X or the complement thereof, and/or the cDNA contained in Clone ID NO:Z, using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

[063] The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

[064] The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

[065] The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, *Gene* 67:31-40 (1988). Polypeptides of the invention also can be purified from natural, synthetic or recombinant sources using techniques described herein or otherwise known in the art,

such as, for example, antibodies of the invention raised against the testicular polypeptides of the present invention in methods which are well known in the art.

[066] The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or the cDNA sequence contained in Clone ID NO:Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X or a complement thereof, a polypeptide encoded by the cDNA contained in Clone ID NO:Z, and/or the polypeptide sequence encoded by a nucleotide sequence in SEQ ID NO:B as defined in column 6 of Table 1B. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of, the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X, a polypeptide encoded by the cDNA contained in Clone ID NO:Z and/or a polypeptide sequence encoded by a nucleotide sequence in SEQ ID NO:B as defined in column 6 of Table 1B are also encompassed by the invention. The present invention further encompasses a polynucleotide comprising, or alternatively consisting of, the complement of the nucleic acid sequence of SEQ ID NO:X, a nucleic acid sequence encoding a polypeptide encoded by the complement of the nucleic acid sequence of SEQ ID NO:X, and/or the cDNA contained in Clone ID NO:Z.

[067] Moreover, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in Table 1B column 6, or any combination thereof. Additional, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in Table 1B column 6, or any combination thereof. In further embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in Table 1B, column 6, and have a nucleic acid sequence which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table 1B, column 5). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in Table 1B, column 6, and have a nucleic acid sequence which is different from that published for the BAC clone identified as BAC ID NO:A (see Table 1B, column 4). In

additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in Table 1B, column 6, and have a nucleic acid sequence which is different from that contained in the BAC clone identified as BAC ID NO:A (see Table 1B, column 4). Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides and polypeptides are also encompassed by the invention.

[068] Further, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in column 6 of Table 1B which correspond to the same Clone ID NO:Z (see Table 1B, column 1), or any combination thereof. Additional, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in column 6 of Table 1B which correspond to the same Clone ID NO:Z (see Table 1B, column 1), or any combination thereof. In further embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table 1B which correspond to the same Clone ID NO:Z (see Table 1B, column 1) and have a nucleic acid sequence which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table 1B, column 5). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table 1B which correspond to the same Clone ID NO:Z (see Table 1B, column 1) and have a nucleic acid sequence which is different from that published for the BAC clone identified as BAC ID NO:A (see Table 1B, column 4). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table 1B which correspond to the same Clone ID NO:Z (see Table 1B, column 1) and have a nucleic acid sequence which is different from that contained in the BAC clone identified as BAC ID NO:A (see Table 1B, column 4). Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also

encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides and polypeptides are also encompassed by the invention.

[069] Further, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in column 6 of Table 1B which correspond to the same contig sequence identifier SEQ ID NO:X (see Table 1B, column 2), or any combination thereof. Additional, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in column 6 of Table 1B which correspond to the same contig sequence identifier SEQ ID NO:X (see Table 1B, column 2), or any combination thereof. In further embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table 1B which correspond to the same contig sequence identifier SEQ ID NO:X (see Table 1B, column 2) and have a nucleic acid sequence which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table 1B, column 5). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table 1B which correspond to the same contig sequence identifier SEQ ID NO:X (see Table 1B, column 2) and have a nucleic acid sequence which is different from that published for the BAC clone identified as BAC ID NO:A (see Table 1B, column 4). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table 1B which correspond to the same contig sequence identifier SEQ ID NO:X (see Table 1B, column 2) and have a nucleic acid sequence which is different from that contained in the BAC clone identified as BAC ID NO:A (See Table 1B, column 4). Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides and polypeptides are also encompassed by the invention.

[070] Moreover, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or

more of the sequences delineated in the same row of Table 1B column 6, or any combination thereof. Additional, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in the same row of Table 1B column 6, or any combination thereof. In preferred embodiments, the polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in the same row of Table 1B column 6, wherein sequentially delineated sequences in the table (i.e. corresponding to those exons located closest to each other) are directly contiguous in a 5' to 3' orientation. In further embodiments, above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in the same row of Table 1B, column 6, and have a nucleic acid sequence which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table 1B, column 5). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in the same row of Table 1B, column 6, and have a nucleic acid sequence which is different from that published for the BAC clone identified as BAC ID NO:A (see Table 1B, column 4). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in the same row of Table 1B, column 6, and have a nucleic acid sequence which is different from that contained in the BAC clone identified as BAC ID NO:A (see Table 1B, column 4). Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.

[071] In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in column 6 of Table 1B, and the polynucleotide sequence of SEQ ID NO:X (e.g., as defined in Table 1B, column 2) or fragments or variants thereof. Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.

- [072] In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in column 6 of Table 1B which correspond to the same Clone ID NO:Z (see Table 1B, column 1), and the polynucleotide sequence of SEQ ID NO:X (e.g., as defined in Table 1A or 1B) or fragments or variants thereof. In preferred embodiments, the delineated sequence(s) and polynucleotide sequence of SEQ ID NO:X correspond to the same Clone ID NO:Z. Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.
- [073] In further specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in the same row of column 6 of Table 1B, and the polynucleotide sequence of SEQ ID NO:X (e.g., as defined in Table 1A or 1B) or fragments or variants thereof. In preferred embodiments, the delineated sequence(s) and polynucleotide sequence of SEQ ID NO:X correspond to the same row of column 6 of Table 1B. Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.
- [074] In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1B and the 5' 10 polynucleotides of the sequence of SEQ ID NO:X are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.
- [075] In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides

of one of the sequences delineated in column 6 of Table 1B and the 5' 10 polynucleotides of a fragment or variant of the sequence of SEQ ID NO:X are directly contiguous Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[076] In specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of the sequence of SEQ ID NO:X and the 5' 10 polynucleotides of the sequence of one of the sequences delineated in column 6 of Table 1B are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[077] In specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of a fragment or variant of the sequence of SEQ ID NO:X and the 5' 10 polynucleotides of the sequence of one of the sequences delineated in column 6 of Table 1B are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally,

fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides, are also encompassed by the invention.

[078] In further specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1B and the 5' 10 polynucleotides of another sequence in column 6 are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[079] In specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1B and the 5' 10 polynucleotides of another sequence in column 6 corresponding to the same Clone ID NO:Z (see Table 1B, column 1) are directly contiguous. Nucleic acids which hybridize to the complement of these 20 lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[080] In specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of one sequence in column 6 corresponding to the same contig sequence identifier SEQ ID NO:X (see Table 1B, column 2) are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or

nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[081] In specific embodiments, polynucleotides of the invention comprise, or alternatively consist of a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1B and the 5' 10 polynucleotides of another sequence in column 6 corresponding to the same row are directly contiguous. In preferred embodiments, the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1B is directly contiguous with the 5' 10 polynucleotides of the next sequential exon delineated in Table 1B, column 6. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[082] Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. Accordingly, for each contig sequence (SEQ ID NO:X) listed in the third column of Table 1A, preferably excluded are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 and the final nucleotide minus 15 of SEQ ID NO:X, b is an integer of 15 to the final nucleotide of SEQ ID NO:X, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:X, and where b is greater than or equal to a + 14. More specifically, preferably excluded are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a and b are integers as defined in columns 4 and 5, respectively, of Table 3. In specific

embodiments, the polynucleotides of the invention do not consist of at least one, two, three, four, five, ten, or more of the specific polynucleotide sequences referenced by the Genbank Accession No. as disclosed in column 6 of Table 3 (including for example, published sequence in connection with a particular BAC clone). In further embodiments, preferably excluded from the invention are the specific polynucleotide sequence(s) contained in the clones corresponding to at least one, two, three, four, five, ten, or more of the available material having the accession numbers identified in the sixth column of this Table (including for example, the actual sequence contained in an identified BAC clone). In no way is this listing meant to encompass all of the sequences which may be excluded by the general formula, it is just a representative example. All references available through these accessions are hereby incorporated by reference in their entirety.

TABLE 3

Clone ID NO: Z	SEQ ID NO: X	Contig ID:	EST Disclaimer		Accession #'s
			Range of a	Range of b	
H7MDC49	11	722780	1 - 148	15 - 162	AI139000, AA884996, AA889649, and AA724461.
H7MDD72	12	847688	1 - 592	15 - 606	AW182856, AI218191, AA834537, AA804628, AA827835, AF034780, and E07989.
HCDMB01	13	915613	1 - 430	15 - 444	AL042428.
HCDMB16	14	835781	1 - 261	15 - 275	
HCDMB60	15	726339	1 - 107	15 - 121	AI590413, AI869343, AI955933, AA593639, AI886450, AA576909, AI371486, AI971730, AA602301, AI421322, AI383426, AI371487, AW059533, AA858249, C00365, Z41784, F17104, AI200274, AW166558, AW337598, AA232052, AA280665, AA731352, AA729138, AW206613, AW241202, M62039, AI932508, AA769242, AI865740, AI866738, AI858186, H12707, AA434237, AI863089, AI874192, N22963, AI349363, AI161110, AA622939, AI625498, AA280821, AW264859, AW198004, AI689114, AI298884, AI311832, W93266, AW152359, AA905965, AA280666, AA044299, H20483, AW273322, AW117633, AA872094, AI811143, AW268474, AA838719, AI858578, AW303327, AW081605, N63438, AI744276, AI992061, AA603101, AI189379, T78004, H62603, AW291643, R72899, H53116, AW193894, H52807, H42028, AI521005, AA745254, AI819014, AI624624, AI859693, AI613489, AI473536, AI696603, AI284013, T69241, AA831128, AI818562, AI674627, AA102339, AL042193, AF106657, AF184965, AL137488, AF060866, X69026, AS8545, AL137284, AF076633, AC010077, AL137657, AL080154, AL050155, AL137480, and AJ005690.
HCDMC01	16	915239	1 - 1444	15 - 1458	AI201296, AA421493, AI015515, AA401557, AA693498, AA815294, AA609724, AA608961, AA705839, AI016248, AA400144, AA971327, AI656796, AA383127, AA725026, AA815293, AA609137, AA421507, AI024165, and AC005789.
HCDMD23	17	676799	1 - 171	15 - 185	
HEEAD64	18	741305	1 - 328	15 - 342	AI041541, and AC006116.
HEEAH07	19	851219	1 - 329	15 - 343	AI343204, R92902, AW138732, AC011331, AL137469, AB007899, Z84480, AP000228, AP000140, U95090, AP000078, AL050067, AC010168, AC004741, AC002426, AC005668, AL022164, AC005034,

						AD000685, AL035701, AC005307, AC005067, AC005572, AC003663, AC007056, AF099810, AC004472, AF061779, AL022399, AC000025, AC005527, AL022238, AC005529, AC005280, AP000088, AC007298, AC004964, AC002991, AL021026, AC002287, AF181449, AL008725, AL118516, AC006271, Z94044, and AL031985.
HEEAJ58	20	785121	1 - 340	15 - 354		AA206618, AA204795, W38480, AA431939, AA587180, and AF080470.
HEEAJ76	21	887321	1 - 535	15 - 549		AW088322, D80133, D80522, D80248, D80251, C14389, D51060, D81026, D59610, D51022, D80366, D80188, D59859, D51423, D80166, D59619, D80210, D51799, D80240, D58283, D80253, D80241, D81030, D80269, D50979, D80024, D80212, D80195, D80043, D80022, C14331, D80219, AW377671, D50995, D59467, D80391, D80164, D59275, D59787, D80227, D59502, D57483, D59889, D80196, AA305409, AA305578, D59927, C15076, D80038, D80193, C06015, D80045, C14014, D80378, D80268, D59373, AW177440, AA514186, AA514188, D80439, C14429, AW360811, AW178893, D80302, D59627, D80247, C75259, AW178983, T03269, AW375405, AW179328, AW378532, D80258, C05695, AW366296, AW360844, D58253, AW360817, D80132, AW375406, AW378534, AW178906, D51759, AW179332, AW177501, AW377672, AW179023, D80157, AW178905, AW177511, D80134, D51103, AW178762, AW378528, D51250, T11417, AW176467, AW352171, AW377676, AW352170, AW360834, AW177731, AW178775, AW178907, AW369651, AW179019, AW179024, AW367967, AW352158, AW177505, AW360841, AW352117, AW179020, D59653, AW178909, AW177456, AW179329, D59503, AW178980, AW178914, AW177733, AW178908, AW178754, AW179018, T48593, D51213, D81111, D80064, AW378525, D51079, AW179004, AW178774, C14227, D45260, AW179012, AW352120, AW352163, T02974, AI910186, AW352174, AW378543, AW179009, AI905856, H67854, C14407, AW177728, AW178911, AW378540, AW177722, D58246, F13647, D51221, AW367950, H67866, AA514184, C03092, AW177508, AA809122, AW178781, Z21582, D80228, AI525923, AW177497, AI535850, D60010, AI525917, D80014, AI557774, AW178986, D59474, T03116, C14957, C14298, AW177723, AW179011, D59317, AW378533, C14973, D58101, D45273,

HEEAK22	22	673904	1 - 312	15 - 326	AW378539, AI525920, C14344, T03048, D50981, AI525235, AI557751, AW177734, D80168, AI525227, AI535959, AI535686, AA285331, D59551, AI525912, D51097, C14046, D60214, AI535961, D52291, AI525215, D80949, AW378542, AI525242, AI525925, AI525222, D59695, C16955, C05763, Z33452, AW360855, H67858, AI525237, D51053, C04682, Z30160, T02868, A62298, AR018138, AR008278, AJ132110, A84916, A62300, AF058696, AB028859, A82595, X67155, Y17188, D26022, A25909, AR060385, Y12724, A67220, D89785, A78862, D34614, AB002449, A94995, D88547, AR008443, I50126, I50132, I50128, I50133, AR066488, X82626, AR016514, AR060138, A45456, A26615, AR052274, AR016808, Y09669, A43192, A43190, AR038669, AR025207, AR066487, A30438, I14842, AR054175, D50010, AR066490, Y17187, I18367, AR008277, AR008281, A63261, A70867, AR008408, AR062872, AR016691, AR016690, U46128, AB012117, D13509, A64136, A68321, AR060133, X68127, I79511, A85396, D88507, AR066482, A44171, A85477, I19525, A86792, X93549, U79457, AF123263, AR032065, and AR008382.
HEEAK84	23	780838	1 - 293	15 - 307	AC004549.
HEEAK24	24	676721	1 - 335	15 - 349	
HEEAS58	25	735620	1 - 496	15 - 510	
HEEAU79	26	706935	1 - 430	15 - 444	H64999, and AC011311.
HEEAW01	27	851213	1 - 372	15 - 386	AA368329, AI281622, AA935827, AA581317, AI350189, AW177224, AI859906, AI039257, AA385094, H29593, F35789, AI267450, AI267356, AI245693, AA493533, AI668566, AA364199, AL039515, AW151848, AI733523, AI732911, AI336771, AA614647, AI338575, AA354695, H48017, R70883, AA736713, AI249688, AI982994, AA197089, AA496941, AI671077, AL040360, AA834798, AI038304, AW023975, AA354677, AI003391, AI754567, AI569100, AW192599, AI754105, AI755214, R70884, AA351893, AI080307, F23268, AA813203, AA456149, AA525332, AA557945, AA077637, AA533660, N55076, AW301855, AA504951, AI342863, H65213, AI459879, AW089395, AA155817, AA363311, AI270280, AI624038, H43183, AI905494, AI859744, W61253, AI791227, AL041681, AL041682, AA847341, AA522864, AA601378, AA077247, T10579, AL047645,

HEEAW13	28	656299	1 - 357	15 - 371	AC004760, AC005856, AC004900, AL031659, AC002072, AL035706, AC005874, AF134471, Z84497, AC004242, AC004542, AC005694, AC005747, AL031680, AL031311, AC004081, AC006020, AL008630, AF001549, AL031295, AC006017, AL133500, M92069, AF139813, AC005081, AC008282, K03431, AL031984, M69197, AP000115, AP000692, AC004686, AC005544, AP000030, AL020997, AL033527, AC007666, AC007240, AC009028, AF200465, AF196779, AC004004, AC004883, U82668, AC006254, AC002350, AC006088, Z70224, U95742, AC006455, Z97055, AC004762, AF126403, AD000833, AL049591, AP000152, AC004106, AL033397, AL031588, AC006132, AL034553, AC005722, AC004099, AC002299, AL022398, AL009179, AC003013, AC004975, AL049761, AC004228, AC005702, AL109963, AC007277, Z82176, AL021368, Z95115, AC008056, AC005399, AC004882, Z95116, AC007216, AC004812, AC004491, and AC005519. AC005344.
HEGAA24	29	676716	1 - 407	15 - 421	AC005324.
HEGAA73	30	767284	1 - 411	15 - 425	
HEGAB84	31	823900	1 - 339	15 - 353	AI222155, and AC007040.
HEGAC69	32	754344	1 - 600	15 - 614	W21047, and AW364581.
HEGAK04	33	887299	1 - 502	15 - 516	AA707670.
HEGAO83	34	780837	1 - 314	15 - 328	AR064011.
HEGAP31	35	697419	1 - 454	15 - 468	U73167, and U90094.
HEGAP36	36	706951	1 - 536	15 - 550	
HEGAY32	37	699906	1 - 182	15 - 196	R55547, H12557, H27260, H00825, R23780, AA747653, H12800, T50030, H42368, and AW361580.
HEGAY52	38	726316	1 - 190	15 - 204	AL137660.
HEGAZ61	39	950033	1 - 547	15 - 561	X66139, and X66140.
HEPAA44	40	509456	1 - 313	15 - 327	AA335025, and AA335496.
HEPAB70	41	557149	1 - 341	15 - 355	
HEPAD09	42	888726	1 - 268	15 - 282	AA335337, AA336174, AA335376, AW406878, AI541216, AI525220, AI525710, and AL022318.
HEPAD40	43	509002	1 - 254	15 - 268	AA335399, and AA335663.
HEPAD82	44	509452	1 - 185	15 - 199	AA335412, AA335243, AA335606, and AA507007.
HEPAJ70	45	586843	1 - 61	15 - 75	AA335523, and AA335948.

HEPAK01	46	518331	1 - 297	15 - 311	AA335526, and AA347833.
HEPAK41	47	925146	1 - 571	15 - 585	AA524859, AI366999, AW274554, AW085032, AA897153, AA335550, AA405462, and AW305246.
HEPAM29	48	508706	1 - 389	15 - 403	AA335591, and AA335639.
HEPAN19	49	508694	1 - 395	15 - 409	AA335593, AI247347, AA335892, AI700468, AI014987, AA629210, AI700878, and X66139.
HEPAP02	50	926914	1 - 351	15 - 365	T31859, AI452722, AI810976, AA039492, AW166142, T34621, AA887990, AA526699, AI491944, AI291744, AA971270, AI291429, AI147212, AI191377, AI282167, AW194181, AI382209, AI819092, AI125991, AI291350, AA635803, AI076763, AI025483, AW054812, AW026209, AI872247, AA446939, AA393844, AA595299, AA588205, AA635837, AA580350, W42714, AA652370, AI205639, AI346541, AI299347, AA618584, AA041546, AI190326, AI589781, AI038728, AA747482, AI374991, AI186987, AI272049, AA968514, AA781105, AA719399, AI745517, AI479431, AW005070, AI760672, AI828575, AI653887, AI983727, AI950052, AI681964, AA953968, R60201, AW001576, R43919, AI568018, AI445351, R88422, HI4119, AI588901, T67080, H20066, Z38557, AA069378, N95318, HI9689, R88071, AA069325, AW340398, AA532555, AA742707, AI095816, AI261987, T31864, AA224332, AI089055, AI192912, T29995, AI690936, AA490233, AA425662, AW178914, H52718, AW178908, AI198749, AI277302, AW178907, N75536, AW178911, AI336808, AW178912, AW050516, N91860, AW178906, AI354778, HI9688, AI925482, T31898, AA308975, AA393826, HI9728, AW439026, AA362297, AA308974, AA427787, AW178913, AA375056, AI028636, AI281040, AI955663, AA350360, AI372759, AA328758, AA223799, W23910, R88070, AA536032, U79457, and AC005041.
HEPAPI2	51	968771	1 - 298	15 - 312	AO1447, and E00237.
HEPAS44	52	884083	1 - 371	15 - 385	AA335822, AA335497, AA605142, AA493490, and AC005042.
HEPBA39	53	919875	1 - 696	15 - 710	AW291560, AA335715, AA897741, and AI559166.
HEPBB24	54	508684	1 - 206	15 - 220	AA335914, AA335921, and AA335993.
HEPBB60	55	855597	1 - 351	15 - 365	AA335668, AA336011, AA335983, and AA335973.
HEPBG26	56	967921	1 - 344	15 - 358	AA336199.
HEPBG35	57	508686	1 - 221	15 - 235	AA335799, AA336205, and AA653622.

HEPBH28	58	508673	1 - 390	15 - 404	AI208794, AA336191, AA150459, AI620599, and AC003090.
HEPBH38	59	707524	1 - 325	15 - 339	AA335435, AI078409, AA384480, AI635196, AI445373, AA515224, AA363957, AA551548, AI793032, AF053356, AF111167, AC006511, AC004106, AP000044, AP000112, AF001549, D00596, AC005531, AL080241, AC002310, AL049694, AC005043, AL049643, AL034421, AC002350, AL022334, AL133243, AC004770, AC009225, AC005231, AC005031, AC004134, AP000475, U80017, AL049569, Z82206, AC004000, AC007358, AC002400, AB002325, AC005618, AC005730, AL049745, AF176815, D88268, AC005632, AC006137, AC002126, AD000812, Z82190, AL035460, AC004223, AC002477, AL050318, AC005071, AC004692, AC004531, AF060568, AC007055, AF015262, AJ229043, AC005261, AL022322, AC004675, AL133245, AC001228, Z93023, AC005529, AL121973, AF134726, AC006965, AC006285, AL008718, Z49236, Z99943, AL035086, and Z93930.
HEPBH45	60	508696	1 - 312	15 - 326	AA336047, and AA335600.
HEPBO69	61	888697	1 - 335	15 - 349	AA335535, AA335244, AA335394, and AC004464.
HEPBQ47	62	713836	1 - 327	15 - 341	AA336176, AW204786, AI094626, AW246712, AI935606, and H92959.
HEPBQ69	63	888693	1 - 448	15 - 462	AA335278.
HEPBS10	64	968665	1 - 391	15 - 405	
HEPBX43	65	715685	1 - 431	15 - 445	AI827693.
HEPCE25	66	529343	1 - 202	15 - 216	AL034548.
HEPCO59	67	761094	1 - 150	15 - 164	AI198719, AI381368, AI695853, AI620570, AA564802, and AA456099.
HEPCT32	68	947081	1 - 843	15 - 857	AA913839, AA429491, AA428554, AA724454, AA868848, AA336014, AI190145, and AI125345.
HEPCU32	69	931824	1 - 1512	15 - 1526	
HTEAA54	70	923070	1 - 694	15 - 708	AA382253, AI806382, and AI478870.
HTEAB52	71	537136	1 - 582	15 - 596	AA382333, AA382331, H52860, and AL040167.
HTEAD32	72	504353	1 - 362	15 - 376	AA382382, AA382236, and AC006305.
HTEAD95	73	961232	1 - 451	15 - 465	AA382376, AA382242, AA860376, and AC006445.
HTEAF07	74	835805	1 - 312	15 - 326	AA382453.
HTEAF26	75	537271	1 - 301	15 - 315	H53354, AA758164, AA448168, AI025042, AI829657, AA382854, AA382293, AA400727, AA442764, and AA812451.
HTEAG50	76	787500	1 - 297	15 - 311	AA382498.
HTEAK57	77	536769	1 - 411	15 - 425	H09661, AW196402, AA760720, AA432259, AI539284, AI805310,

HTEAL28	78	963538	1 - 666	15 - 680	AA781214, AW268890, AI797250, AW235912, AA993321, AI017538, AW274549, AA884002, AI017535, AI217337, AW014623, AA868679, AI808721, AI769073, N62418, AI364253, AA909554, AA382799, AI917688, AA485055, AL080136, and AF079363.
HTEAP91	79	966113	1 - 746	15 - 760	AA429726, AA398189, H53400, AA382855, AA382294, AA383397, AA382295, AA382880, and Z58143.
HTEAR84	80	783328	1 - 237	15 - 251	AA411883, AW444833, AA382955, AA889519, AI217183, and AA781849.
HTEAV43	81	927010	1 - 583	15 - 597	AA382996, AA180840, AI929073, AL133353, AF132966, and X66366.
HTEAY67	82	679390	1 - 433	15 - 447	AA770016, AW195558, AA757200, AW340425, AW182241, AA383009, and AI191751.
HTEAZ54	83	793441	1 - 499	15 - 513	AA383288, AL044302, AA398247, AI916926, AI970265, AA399313, AI806241, AI208574, AA994365, AA382290, and AL137385.
HTEBD35	84	967959	1 - 303	15 - 317	AA383257, AA812455, and AL137538.
HTEBD40	85	779134	1 - 457	15 - 471	AA383417, and AA383322.
HTEBJ78	86	779265	1 - 1003	15 - 1017	AA383323, AI950478, and AL121757.
HTEBS30	87	693377	1 - 326	15 - 340	AA383746, AF012361, AI918814, AI638690, and AF088868.
HTEBS77	88	953904	1 - 592	15 - 606	AA102609, AA903522, AA810166, AI887877, AA928872, AI912645, AI628759, AI652056, AA372813, AA326308, AA313595, AA252658, AA491058, AA205648, AW375850, AA252657, and AA082983.
HTEBS80	89	854052	1 - 381	15 - 395	AA399558.
HTEBX62	90	508150	1 - 404	15 - 418	AL133028, and AB033037.
HTEBY08	91	960427	1 - 344	15 - 358	M78063, AI560292, H50301, AA340759, AA340760, H45375, U09355, and AF096153.
HTEBY15	92	526281	1 - 252	15 - 266	
HTEBY28	93	923026	1 - 609	15 - 623	AB033083.
HTEBY41	94	711523	1 - 230	15 - 244	
HTEBY61	95	967340	1 - 421	15 - 435	AA725713, AL040570, R48431, and AC020663.
HTEBZ21	96	958381	1 - 340	15 - 354	AF193806.
HTECA13	97	507053	1 - 393	15 - 407	AA382976.
HTECA16	98	764416	1 - 482	15 - 496	AI017997.
HTECA21	99	911369	1 - 688	15 - 702	R20356, H09898, and R13239.
HTECA32	100	947605	1 - 779	15 - 793	

HTECA51	101	708860	1 - 414	15 - 428	AI479803, R89200, AA382300, AA700729, and AL035450.
HTECA83	102	870692	1 - 446	15 - 460	
HTECB21	103	921070	1 - 359	15 - 373	
HTECC13	104	971673	1 - 301	15 - 315	
HTECC20	105	963353	1 - 993	15 - 1007	AI521186, AI287890, AW006015, AI739342, AI536021, AI915154, D59412, AI382968, AA723799, C14160, and R58305.
HTECC37	106	508143	1 - 317	15 - 331	
HTECC38	107	844558	1 - 553	15 - 567	AL042436, AI125824, AA437087, AI028669, AI024321, AW241753, AA400083, AA953011, AA972296, AI674705, and AL042437.
HTECC66	108	790937	1 - 409	15 - 423	AW375961, H12646, N46186, AI114644, AI133382, AA314626, T92864, AA482645, AA203566, W20194, AA878228, W80608, AA699466, AA482495, Z25122, AA490161, AA939181, AI635552, and AF113691.
HTECC80	109	796820	1 - 446	15 - 460	AL079435, AW070333, AA868621, AI024608, AI208541, AA644440, AA992264, AI219709, and AL078621.
HTECC85	110	508138	1 - 337	15 - 351	AA219332, and AW274715.
HTECC96	111	959874	1 - 547	15 - 561	AL039822.
HTECD17	112	508108	1 - 397	15 - 411	Z68165.
HTECD18	113	973163	1 - 614	15 - 628	T36107, T19204, AF012359, and T36109.
HTECD36	114	518124	1 - 421	15 - 435	AL079683, T69495, AA377984, AA411067, W19966, AL135463, AA152011, AI080369, AI928496, AI969686, AW150086, AW162108, AW245409, AW245596, AW087350, AI660688, AW025370, AI986318, AA417624, AW073180, R65681, AA609692, AI568566, AF015913, and AF167572.
HTECD62	115	527207	1 - 242	15 - 256	AI018016, AA927826, AA781742, AI206323, and AI699610.
HTECD75	116	727422	1 - 410	15 - 424	AA770236.
HTECE09	117	620494	1 - 363	15 - 377	AA074745, AA311579, AW369123, AW377808, AW369199, AA305128, AA279742, AA382491, AA457232, AA350374, and AF119664.
HTECE44	118	764830	1 - 349	15 - 363	AI016755, AA626104, AI215071, AI968379, AA506126, AI340264, AI214879, AI653073, AI208052, AW235456, and AA609852.
HTECE45	119	790894	1 - 349	15 - 363	AA702149, AI760177, W87526, AL042666, AA721639, AA721643, and R55626.
HTECE69	120	522983	1 - 340	15 - 354	AA209512, and AF084521.

HTECE91	121	522984	1 - 283	15 - 297	
HTEDF13	122	522964	1 - 370	15 - 384	
HTEDF23	123	522966	1 - 319	15 - 333	
HTEDF57	124	964734	1 - 467	15 - 481	AA206531, AA205273, AF134584, AF133655, R57172, AA370673, AL049834, AF144487, and AF144488.
HTEDF76	125	522973	1 - 371	15 - 385	
HTEDG16	126	925527	1 - 1246	15 - 1260	AI341284, AA954970, AA971333, AI656306, AI341232, AI962769, AI970130, AI015246, AI149570, A W236864, AI187784, AI824998, AI699532, A W087767, AA776716, AA758202, H75549, AI282907, and AC003691.
HTEDG34	127	761752	1 - 601	15 - 615	A65985.
HTEDH21	128	522764	1 - 307	15 - 321	A W237166, and AI806759.
HTEDH22	129	522765	1 - 412	15 - 426	AA884595, AI004070, AI652358, AI933335, and AC006012.
HTEDH54	130	957762	1 - 398	15 - 412	AI142272, A W303480, and AL117355.
HTEDI02	131	921243	1 - 693	15 - 707	A W166305.
HTEDI16	132	932292	1 - 830	15 - 844	AI200759, N35603, and AI806635.
HTEDI82	133	536477	1 - 536	15 - 550	
HTEDI04	134	519940	1 - 151	15 - 165	
HTEDM08	135	960303	1 - 243	15 - 257	AA383292, and AA010475.
HTEDO31	136	870711	1 - 279	15 - 293	
HTEDO51	137	530592	1 - 336	15 - 350	
HTEDP15	138	870675	1 - 309	15 - 323	AC008119.
HTEDP31	139	870548	1 - 526	15 - 540	AC004674.
HTEDP32	140	839532	1 - 412	15 - 426	
HTEDP83	141	536821	1 - 391	15 - 405	AA382559.
HTEDQ30	142	530589	1 - 192	15 - 206	AA470110.
HTEDQ72	143	795332	1 - 463	15 - 477	AA424209.
HTEDQ83	144	530586	1 - 493	15 - 507	
HTEDR71	145	761585	1 - 303	15 - 317	AJ003479, AJ003512, AJ003478, AJ239328, and AP000219.
HTEDR91	146	530451	1 - 363	15 - 377	AA778548.
HTEDU45	147	870708	1 - 1168	15 - 1182	AA401417, AI654822, AA131789, AA401393, AA040136, AA030057, AA040089, A W002428, AA131796, AI809387, AI208853, AI798677, AI808134, AA028977, AA131846, and AI468240.
HTEDU48	148	932315	1 - 718	15 - 732	

HTEDV02	149	921114	1 - 152	15 - 166	
HTEDX22	150	523959	1 - 552	15 - 566	T64832, Z45475, and F12119.
HTEDX55	151	530452	1 - 345	15 - 359	AL035450.
HTEDY38	152	771505	1 - 128	15 - 142	
HTEDY54	153	922964	1 - 845	15 - 859	AI141062, AA779725, AA451707, AA453324, and AA954529.
HTEDY57	154	530580	1 - 314	15 - 328	
HTEEB18	155	523962	1 - 537	15 - 551	AA995142, AC005661, and Z65242.
HTEEB33	156	924818	1 - 601	15 - 615	AL049780, and AC007055.
HTEEC10	157	968517	1 - 353	15 - 367	
HTEEE65	158	530157	1 - 372	15 - 386	AI243357, AI126440, AI693753, and AA783013.
HTEEF31	159	924840	1 - 333	15 - 347	
HTEEH31	160	507814	1 - 279	15 - 293	
HTEEU23	161	524059	1 - 314	15 - 328	
HTEEU52	162	530199	1 - 331	15 - 345	AL040261, AI525252, and AI025700.
HTEEU88	163	698315	1 - 355	15 - 369	
HTEEU92	164	960127	1 - 471	15 - 485	AA383576, T04917, T35202, AI422683, AI694269, AW341450, AW172298, AI253197, AI392973, AI817020, AI675030, AW149563, AI830691, AI288333, AI420397, AI768573, AW300444, AW271819, AI862664, AW165982, AI761400, AI826256, AI368689, AI697857, AI889625, AI972408, AI357436, AI421517, AI651095, AI283759, AI634398, AI523543, AI948511, AW196914, AI992087, AI417903, AI827278, AI927043, AW237591, AI831948, AI831197, AI830712, AW085599, AI375540, AI300150, AI936396, AI082343, AI190058, AI369782, AA937125, AI926819, AA872799, AI831516, AA502373, AI823952, AI262912, and AL035461.
HTEEV53	165	523957	1 - 298	15 - 312	AI005426.
HTEEW73	166	917206	1 - 862	15 - 876	
HTEEZ95	167	530095	1 - 134	15 - 148	AI125404, AI247364, AI208217, AA910021, AI915307, and T11495.
HTEFJ53	168	935982	1 - 210	15 - 224	
HTEFM31	169	771355	1 - 449	15 - 463	AL137385.
HTEFN15	170	959854	1 - 480	15 - 494	
HTEFO32	171	529272	1 - 137	15 - 151	
HTEFO76	172	770270	1 - 404	15 - 418	
HTEFPI4	173	659369	1 - 289	15 - 303	AL080239, and AL030997.

HTEPP50	174	507219	1 - 398	15 - 412	A1733211, AA977235, and A1793144.
HTEPP61	175	711399	1 - 339	15 - 353	
HTEFS60	176	836010	1 - 308	15 - 322	Z84469.
HTEFU46	177	920604	1 - 182	15 - 196	
HTEFW55	178	787550	1 - 720	15 - 734	Z20330.
HTEFW56	179	528019	1 - 344	15 - 358	
HTEFW78	180	961061	1 - 327	15 - 341	AA416708.
HTEFX53	181	842047	1 - 301	15 - 315	
HTEGA13	182	656077	1 - 260	15 - 274	AA304950, and AC005237.
HTEGA17	183	964198	1 - 1718	15 - 1732	AA861754, AI041049, AA974148, AI025824, AI015271, AA973722, AI262750, AF012394, H44966, H45019, H65081, H65127, H65128, H65081, N30790, N32825, N41565, AA021000, AA037708, AA158991, AA158990, AA522704, AA581540, AA583387, AA594383, AA568601, AA639650, AA962753, AI076864, C01177, C17452, AA610069, AA677739, AA678002, Z17891, Z17844, Z17858, D29489, D31204, D31401, D31430, AI147272, AI348141, AI434148, AI446782, AI401705, AI473505, AI475244, AI560742, AI565331, AI479120, AI567547, AI569204, AI570723, AI571642, AI521092, AI587097, AI619824, AI619826, AI683822, AI745345, AI700348, AI862997, AI891040, AI805378, AI805561, AI814808, AI917522, AI924990, AI925791, AI925824, AI926709, AI932677, AW008971, AW025107, AW028354, AW028895, and AW044371.
HTEGA43	184	715583	1 - 293	15 - 307	
HTEGA47	185	503300	1 - 305	15 - 319	AA469976, and AA382993.
HTEGD11	186	967698	1 - 454	15 - 468	
HTEGE44	187	528017	1 - 460	15 - 474	AI739081.
HTEGF78	188	614242	1 - 394	15 - 408	
					AA320491, AA461257, T96959, AA620998, AI803092, AI598264, AI802911, AA613500, AI701066, AA873354, AA976002, AI337726, AI401363, AA889162, AW449691, AA460950, AI435494, T91835, N47591, T08650, AI672896, AI015106, AI122076, AF082179, AF173643, and AF088884.
HTEGF95	189	796660	1 - 264	15 - 278	AI809182, and AI014526.
HTEGG07	190	954115	1 - 450	15 - 464	
HTEGG61	191	528007	1 - 203	15 - 217	

HTEGK51	192	520046	1 - 137	15 - 151	AA496105, AL038451, AA020916, AA214222, AL038833, AW239553, AL038903, AL036026, W94506, H11258, H19187, T09424, AW163336, AA084982, AA853848, AA852612, AA134785, T30709, T31235, R13838, T30596, T31277, T32509, F08351, T30996, R61645, A1002404, AA281162, N33973, W63690, AA056138, AA400554, AA224046, AW160678, AA252722, AA308905, H37946, AA159207, AA337592, H15180, N36548, T78050, A1214139, H45908, AL036764, AL038918, AA486190, N99529, AA176166, T29922, AA173378, A1929392, AA993699, T32147, W92551, AA314753, W20343, A1028519, W52361, R12459, R17656, D30841, D56168, AA018894, AW375983, AA318870, R57052, AA083038, AA018506, AA401854, W94711, H82178, AB014888, AB015799, AF075601, AF060703, AB015798, AF080569, AB028854, and AF035962.
HTEGN63	194	520037	1 - 196	15 - 210	AB007131, AP001052, and AP001051.
HTEGO05	195	932583	1 - 1086	15 - 1100	AA059465, AA059211, AA731209, AA236961, T86500, T87461, AL024498, and M35862.
HTEGQ21	196	923059	1 - 419	15 - 433	AA382826, AA382492, A1917341, A1967930, A1990328, A1041198, AW135194, A1936466, A1990195, A1336861, A1825657, AA609860, A1652939, A1950262, and A1968690.
HTEGQ74	197	573865	1 - 358	15 - 372	
HTEGR56	198	959871	1 - 186	15 - 200	
HTEGR88	199	871611	1 - 405	15 - 419	AL133660.
HTEGS16	200	527914	1 - 340	15 - 354	
HTEGS93	201	506653	1 - 395	15 - 409	
HTEGT29	202	870638	1 - 463	15 - 477	AA610046, AA725767, AA609763, AA694482, A1674115, and A122344.
HTEGT33	203	716783	1 - 505	15 - 519	AA459933, and AA460208.
HTEGU13	204	520041	1 - 380	15 - 394	AA725598, AA437008, AA758847, and AA383617.
HTEGU32	205	524053	1 - 492	15 - 506	A1208922, AF012358, AC000359, AF176024, and AC000357.
HTEGU62	206	573885	1 - 307	15 - 321	
HTEGU93	207	764831	1 - 721	15 - 735	AL037365, A1968379, AA397716, A1016755, A1340264, AA626104, AA435927, AA506126, and AL133624.
HTEGV08	208	959888	1 - 425	15 - 439	AP000275, AP000105, AP000037, and AC002452.

HTEGV60	209	822954	1 - 484	15 - 498	AA210913.
HTEGV84	210	870240	1 - 759	15 - 773	AI809518, AA725632, AA400546, AW303510, AA621301, AA400438, AI184200, AI016652, AI698674, AA758091, AA757258, AA725799, and AA705799.
HTEGW41	211	573880	1 - 406	15 - 420	AF169385, and AF149310.
HTEGW94	212	794350	1 - 526	15 - 540	
HTEGX74	213	783829	1 - 544	15 - 558	AA789286, AI339366, AI656082, AA861573, AA416690, AI808240, AA889130, and AI216654.
HTEGY01	214	917214	1 - 438	15 - 452	
HTEGY85	215	573849	1 - 300	15 - 314	AL080197, AP000346, and AL022324.
HTEHB07	216	870707	1 - 336	15 - 350	AA383326, and AI672505.
HTEHC20	217	526704	1 - 313	15 - 327	Z98752.
HTEHC47	218	973071	1 - 723	15 - 737	AA436088, AI149899, AI002083, AA411806, AA470059, AA781801, AA416972, AA435988, AA758635, and AA707529.
HTEHC60	219	965998	1 - 610	15 - 624	
HTEHC78	220	573882	1 - 332	15 - 346	
HTEHE60	221	795264	1 - 551	15 - 565	AI018790, AA885492, AI377750, AW340453, and AC007114.
HTEHE67	222	784926	1 - 677	15 - 691	AA421403, AA411967, AA412565, AI825585, AW136990, AI962705, AI825455, and AA889516.
HTEHE78	223	932312	1 - 357	15 - 371	AA642104, AA664126, N66948, AI753334, N70325, AA601713, AA320178, H53040, AA577770, H53039, AA515742, AI222360, AA837716, AL109628, AC006064, AL022721, AP001052, AC004694, AL109801, AL117258, AL109759, AC004884, AC005476, Z95116, AL022159, AC005015, AC003101, AL035086, Z99943, U91323, U91318, AC007773, AC005261, AC002350, AL031289, AC005081, AC005529, U73640, AC005552, AC007040, AL133244, AC006163, AC007285, AC007057, AL121655, AC006324, AR036572, AP000092, AC005829, AL132777, AP000512, AC000025, AF107257, AC005520, AF107258, AP000236, AC004814, AC006581, AC010168, AC005790, AL049759, AC005519, AL022316, AC004100, AL031427, AC007688, AL031584, AC009516, AC006449, AC006441, AC005387, AP000501, AL121652, AP000510, AL049539, U91321, AC003071, AC004908, AC005921, AD001527, AC005800, Z92542, AL034548, AF196969, AC004552, AC009181, AC005971, AC004966, AC004815, AL031681,

HTEHE91	224	790342	1 - 520	15 - 534	AC007617, AF196779, AC004707, AB023050, Z83844, AC002312, Z82190, AC007172, AC004990, AC002565, AC007386, AF134726, AL034549, Z82208, Z95329, AC005037, AC007637, AC005162, AL031680, AL022165, AF026069, Z97184, AC006966, and AC003086.
HTEHF13	225	667224	1 - 319	15 - 333	AI653740, AI223017, AA393574, AP000346, AL022324, and AL080197.
HTEHF66	226	836999	1 - 424	15 - 438	AL137678, and AL109657.
HTEHG44	227	933624	1 - 682	15 - 696	AA446074, AJ224924, and AA868166.
HTEHI06	228	935984	1 - 817	15 - 831	AA394226, AA398139, AA025620, AA451812, AA454022, and AC012599.
HTEHI14	229	526687	1 - 444	15 - 458	
HTEHI54	230	533960	1 - 338	15 - 352	R19058, Z44007, F06961, and F05366.
HTEHI62	231	922559	1 - 390	15 - 404	AI202243, AA687318, and AI184808.
HTEHI93	232	870629	1 - 317	15 - 331	
HTEHI64	233	530749	1 - 235	15 - 249	
HTEHK40	234	660875	1 - 317	15 - 331	
HTEHK70	235	771432	1 - 430	15 - 444	
HTEHK81	236	573866	1 - 414	15 - 428	
HTEHL96	237	573859	1 - 390	15 - 404	AA926746.
HTEHP02	238	920625	1 - 429	15 - 443	
HTEHP20	239	967443	1 - 379	15 - 393	AA393345, AI018421, AI018412, and AI621296.
HTEHP50	240	531505	1 - 219	15 - 233	
HTEHP60	241	573853	1 - 439	15 - 453	
HTEHP67	242	751866	1 - 425	15 - 439	AA429653, and AL137385.
HTEHP80	243	573830	1 - 354	15 - 368	AL042482.
HTEHR83	244	573841	1 - 260	15 - 274	AW117582, and AW275130.
HTEHS19	245	529280	1 - 324	15 - 338	
HTEHU20	246	573813	1 - 345	15 - 359	AA625735, and AI205755.
HTEHU68	247	786378	1 - 362	15 - 376	AI808748, and AA868749.
HTEHU73	248	870083	1 - 377	15 - 391	
HTEHV86	249	785652	1 - 454	15 - 468	AB007926.
HTEHW03	250	924832	1 - 439	15 - 453	
HTEHW21	251	760552	1 - 286	15 - 300	H99838, AL037447, H98172, R99332, and N73909.

HTEHX03	252	924826	1 - 502	15 - 516	AI198906, AI743542, AI807563, AI392615, AI813744, AI150517, and AI150519.
HTEHX32	253	772643	1 - 440	15 - 454	AI699984, AA470157, AI018717, AI917728, AA398746, AA393334, AI216704, AA868127, and AL049742.
HTEHX51	254	668553	1 - 200	15 - 214	AC004148.
HTEHX92	255	527167	1 - 477	15 - 491	
HTEIA60	256	859130	1 - 442	15 - 456	AA594897, Z46029, AA316462, T27008, AA306099, F12789, R05542, AA635902, T75086, T35592, AW378962, R28411, AA740171, T52620, AL021707, and AJ236698.
HTEIA80	257	721831	1 - 265	15 - 279	
HTEIF40	258	958355	1 - 578	15 - 592	AI806847, AA431560, AI219847, AA913948, AI633873, AI638029, AW003193, AI990760, AA861291, AI190550, and AI187284.
HTEIF68	259	573828	1 - 263	15 - 277	
HTEIG32	260	699470	1 - 313	15 - 327	AA383150.
HTEIH70	261	573826	1 - 186	15 - 200	
HTEIJ17	262	520113	1 - 425	15 - 439	AF088868.
HTEIJ41	263	712520	1 - 347	15 - 361	AA037622, AA151557, AA884833, and AI027960.
HTEIJ73	264	958241	1 - 322	15 - 336	
HTEIJ77	265	772402	1 - 55	15 - 69	
HTEIK70	266	530454	1 - 107	15 - 121	
HTEIK90	267	789121	1 - 383	15 - 397	AL133625, and AL050310.
HTEIL07	268	953803	1 - 445	15 - 459	H55431, and AL031843.
HTEIL48	269	523681	1 - 302	15 - 316	
HTEIL70	270	520045	1 - 515	15 - 529	AA383469, and AW340027.
HTEIL71	271	760551	1 - 418	15 - 432	AW374031, AI376865, AA610337, AL031277, AC004159, AL035073, Z83838, AC011422, and AL031286.
HTEIN68	272	753210	1 - 333	15 - 347	
HTEIN95	273	839884	1 - 602	15 - 616	AI638483.
HTEIO02	274	920622	1 - 365	15 - 379	AW188204, and AL078587.
HTEIO12	275	653244	1 - 322	15 - 336	
HTEIO28	276	573803	1 - 344	15 - 358	
HTEIP88	277	941155	1 - 253	15 - 267	
HTEIP92	278	523892	1 - 356	15 - 370	
HTEIQ74	279	765794	1 - 576	15 - 590	AA905565.

HTEIR33	280	928058	1 - 504	15 - 518	A1041198, A W135194, A1336861, A1917341, A1825657, A1936466, A1967930, A1990195, A1990328, AA609860, A1652939, A1950262, A1968690, A W043968, A1695938, A1918858, A1207159, A1961172, A1635425, AA382492, AA382826, and Z54930.
HTEIS65	281	573775	1 - 444	15 - 458	
HTEIU75	282	779163	1 - 535	15 - 549	
HTEIU92	283	870652	1 - 390	15 - 404	
HTEIV54	284	922027	1 - 859	15 - 873	AA608560, A W119083, A1805320, A W241508, AA478132, A1935179, AA478131, A W241453, A1148017, AA496125, A1159761, A1290727, AA757496, A1039534, AA410246, A W015244, AA991785, A1299213, A1191790, F32781, H53433, AA708313, AA757725, AA987362, A1018579, A1824880, A1989666, A1950419, H53434, A1703120, AA436358, AA410593, AA410594, A1205656, AA404329, AA404331, A1147261, AA935676, AA708988, and AF163095.
HTEIV86	285	784657	1 - 476	15 - 490	AA884237, and Z66028.
HTEIW27	286	829698	1 - 790	15 - 804	AL040266, AA045127, H71355, AA070703, AA036715, AA325559, AA043642, AA196645, H94227, AA305440, AA383234, H61672, H06121, R60099, AL042836, A1016643, A W410572, AL042837, and A1018804.
HTEIW37	287	573891	1 - 340	15 - 354	
HTEIX85	288	864251	1 - 364	15 - 378	A1143096, AA476476, AF112968, and AF133914.
HTEIY52	289	963536	1 - 365	15 - 379	
HTEIY69	290	577783	1 - 342	15 - 356	AA860220, AA373213, AA095300, AA294896, AA056395, A W369291, AA081316, AA081068, AA258633, AA491648, T78543, A1565548, T68394, D81309, AA303509, C02623, AA552624, C15625, W65448, and H56519.
HTEIY80	291	955242	1 - 640	15 - 654	A1206714, A1962380, A W139167, A1341507, A W197295, AF146793, and AC004673.
HTEIZ76	292	523764	1 - 373	15 - 387	
HTEJB20	293	528015	1 - 336	15 - 350	A W119138, AA508616, and AC000386.
HTEJB25	294	530590	1 - 364	15 - 378	A1804160, A1287878, AA400787, A1003207, AF176315, AF042089, AC007040, AC000385, and AC004967.
HTEJB81	295	870644	1 - 326	15 - 340	AC005230, and AL031230.
HTEJC28	296	573774	1 - 292	15 - 306	

HTEJC95	297	772989	1 - 412	15 - 426	
HTEJE15	298	908360	1 - 577	15 - 591	AI217144, AA399611, AA398976, AI025074, AA758412, AW449170, AI953070, AI337133, AI654417, AA608877, AI969018, AA400066, AA401568, AL137462, and S75275.
HTEJE50	299	520049	1 - 410	15 - 424	AA383469.
HTEJF45	300	942476	1 - 704	15 - 718	AA927155, AI989936, AI870479, AW196902, and AW137017.
HTEJG24	301	526278	1 - 432	15 - 446	
HTEJJ43	302	774243	1 - 505	15 - 519	
HTEJL21	303	573742	1 - 460	15 - 474	AA913820, AW138390, W37338, AI139797, AW135343, AA776708, AA621016, AW274952, AI623224, AI125250, AA778537, AI208106, AI637631, AW341652, AA776715, AI204215, AA609761, AI671266, AI023591, AI950399, AA758819, AW104292, AI188024, AW058598, AA460183, AI969065, W37337, and AA824405.
HTEJM56	304	952255	1 - 392	15 - 406	AL042395, AA504349, AI693474, AI125391, AL041671, AW168041, AA838043, AI990015, AI864457, AI149664, AI738586, AL041569, AW294188, AI805280, AA579771, AW273185, AI653680, AW197733, AI138789, AI699335, AI475427, AA883961, AI203057, AI968077, AA383594, AA976749, AI648684, AI952360, AI680162, AI590021, AW076093, AW264516, AI073952, AI568870, AI564719, AI623828, AA808060, AI683684, AI866457, AI628292, AW196868, AW075413, AI590686, AI867042, AI922365, AW081255, AI285586, AI249375, AI610293, AW103878, AI915576, AW403717, AI475455, AI811860, AI282903, AI539808, AI873644, AI174394, AI469811, AI831140, AI872910, AI690585, AI539829, AI863191, AI613270, AI625464, AI281660, AI870187, AI886022, AI269862, AI624293, AI920833, AI680498, AI934259, AI610114, AW193026, AL121270, AI289337, AW075657, AI364788, AI383919, AW168723, AI922901, AI636719, AW073697, AI863321, AI270055, AI633073, AI624543, AI610645, AI702433, AI611743, AI690312, AL039276, AI689420, AL045500, AW080992, AI687065, AI432040, AL048656, AI819326, AW238730, AI445976, AI744256, AA572758, AL045163, AI627880, AI866741, AI805385, AI612721, AL119791, AW079159, AI343059, AI619716, AI828731, AI612759, AW089179, AW151729, AI696819, AI870192, AI567351, AI349933, AI934011, AI280661, AI699011, AI537617, AI919345, AI251830, AW088899, AI366549, AI539153, AW088144,

AL036214, A1866608, A1859464, A1866585, A1499986, AW149236, AW083804, A1862144, AW170734, A1696626, AL040241, A1554821, A1589993, AW059713, A1921082, AL038445, AW168425, A1345111, A1446373, A1358701, AL036638, A1537677, A1621179, A1433157, AL041150, A1537837, A1159837, A1874351, AL038882, A1520785, A1609059, A1344817, A1539771, A1798258, A1922577, A1471361, A1500659, A1288285, A1889168, A1344935, A1866573, AW068845, AW103228, AL045620, A1476109, A1815232, A1801325, A1500523, A1573060, AW302965, AA640779, A1345608, A1582932, A1284517, AA613907, A1500706, A1445237, A1491776, A1758613, AW151138, AL042628, A1521560, A1889189, A1500662, A1284509, A1439452, A1857724, AW148320, A1633493, AW169653, A1434256, A1344785, A1249962, AL041772, A1609677, A1888661, A1811344, A1284513, A1620284, A1888118, A1349614, A1872051, A1589273, A1866510, A1569583, AW302992, A1801112, AW088903, A1440252, A1800152, A1963068, A1569632, A1274769, A1348854, AL036664, AW023590, A1608676, A1345471, AW088134, AA579232, AA494167, AW075084, A1468872, AA420722, A1537307, AL120853, AL040243, A1251205, A1924971, A1287489, A1698401, A1524607, A1683714, AL043632, AL043326, A1538342, N71180, A1433976, AC003688, AF096834, AF073955, AF073954, AL117585, S68736, A08916, A08910, AR000496, U39656, A08909, I48978, I89947, A08913, U72620, I89931, I49625, AL049382, AF090896, AL080060, I26207, AL137556, AL137283, AF113676, AL137538, AF104032, AB019565, A93350, X93495, AF158248, AL122093, AL137527, AL050393, AL122121, I48979, AF119337, U35846, AL122123, AL137557, I33392, AJ242859, X84990, E07108, AL050138, AF113689, I03321, AF118070, U00763, AR059958, AF026124, AF090903, AL133568, AL080124, A08912, AL117583, E15569, AL050116, AL050146, AL117435, Y14314, AL049452, U67958, AL122098, AF185576, AL080137, AJ012755, A93016, AF078844, E03348, Y11587, I42402, AL110221, AF125949, AF113013, AL137463, AF081195, AL122110, I09360, AL133093, AL137648, AJ238278, AF017152, AL080127, AL133077, AL050108, A12297, AL133104, AF113690, AL049466, Y16645, AL050024, AL110196, AJ000937, AL133080, AL122050, AL049430, X70685,				
---	--	--	--	--

					AL049314, E02349, AL137550, AL117457, AL133016, S78214, AF177401, AL117440, AL110225, AL117394, AL133606, AF079765, X63574, X96540, AL133560, AF111112, AF113019, X82434, AF090934, AF067728, A65341, A77033, A77035, AF087943, AF113699, AL137560, AL137271, Z82022, AF183393, AF090901, AL133072, X65873, A03736, AL137521, U91329, AF106862, AL050277, AL133067, AL122049, A90832, U96683, AF113691, AF017437, AF097996, Y11254, AL080159, AL133640, AL133557, AL133075, AL050149, AF125948, AF146568, U80742, AL133113, AL133565, AL049464, AR011880, A58524, A58523, AF113694, AF113677, AF118064, AF111851, AL137459, AL096744, AF061943, AF026816, AF091084, AF003737, AR038854, AL049300, AF118094, AF090943, Y10080, AL117460, Y09972, L31396, AL133014, U42766, L31397, X72889, E07361, AL049938, AL049283, AL122111, AF153205, AF090900, AL110280, X98834, E08263, E08264, A1006417, I00734, AL110197, AF132676, E00617, E00717, E00778, AF162270, S61953, AF061836, AL050172, AL137705, U58996, M86826, X92070, A08908, L30117, A07647, E02221, AL080074, Z72491, A18777, AF106827, AL133098, E08631, AF008439, Y10655, AR038969, AF051325, AL137523, M30514, AF079763, AF057300, AF057299, AL137476, AL137526, A45787, X62580, AF210052, I17767, AF081197, AL137429, E05822, AL122045, AL133031, I96214, AR034830, AL122118, I41145, AL080086, AR013797, AL137273, E04233, AF111849, U68387, U78525, AL137480, S76508, X87582, Z37987, AL137533, and Y07905.
HTEJN10	305	958389	1 - 412	15 - 426	AA397714, and AL688816.
HTEJN49	306	558383	1 - 244	15 - 258	AL033527.
HTEJN96	307	573845	1 - 341	15 - 355	
HTEJP10	308	914785	1 - 406	15 - 420	AA173098, AA330453, N72370, AA382609, D82507, AA305139, AA376308, AA319043, AA360655, AA204809, N47351, L48818, T97397, H74112, AA303102, N98390, T85235, R92534, A1400282, W78773, AA226439, N77177, AA135383, AA089951, N28003, AA094694, AA036797, and D82374.
HTEJP66	309	916481	1 - 697	15 - 711	AW402599, AA402458, N28458, W04863, AA683291, C17218, AA452695, AA321934, AA325890, AA148436, AA083939, W95796,

						AA203350, AA373216, H87410, R96313, N29206, W60562, N55788, W32702, N40125, AA319796, T27329, AA360583, H49227, AA402577, AA027923, AA115050, AA150348, AA496191, W05840, N35260, AA382795, AA210879, AA346660, A1902181, AFI72940, AFI51885, and AC007298.
HTEJT37	310	530596	1 - 339	15 - 353		A1092208.
HTEJT74	311	676254	1 - 438	15 - 452		AA393248, AA393292, A1796754, AA293815, AA459841, A1075905, AW137492, A1652522, A1217933, A1150346, A1694956, AA399502, AA398164, A1024099, AA719008, AA629029, AA861041, AA402463, AA435622, R24468, R66361, AA688372, AF081250, and AF081249.
HTEJU30	312	573823	1 - 304	15 - 318		AC000093.
HTEJV62	313	694525	1 - 325	15 - 339		AA813665, A1025041, and A1215603.
HTEJX78	314	806395	1 - 411	15 - 425		AA496111, AW138142, AA306268, AA417106, AA382596, A1027705, AA383788, A1824924, AA382469, AA812546, AA382920, A1183592, AA383156, and A1828862.
HTEJY27	315	685272	1 - 239	15 - 253		AA853991, AA778707, AW182416, AA634398, and AA609856.
HTEJZ26	316	523818	1 - 262	15 - 276		AW247046, AA401701, and AA398161.
HTEKC07	317	920925	1 - 389	15 - 403		AW087802.
HTEKC12	318	815975	1 - 345	15 - 359		A1539455, A1218279, A1348415, AW408773, AW340548, A1368160, AA894774, AA937067, and AW364691.
HTEKD04	319	519938	1 - 418	15 - 432		
HTEKE41	320	974044	1 - 735	15 - 749		A1091681, AC009405, AC003683, A1239321, AC007253, AL009173, AL030995, Z99572, and AL109853.
HTEKE46	321	870084	1 - 1112	15 - 1126		A1125483, W77994, A1161017, W73951, A1250771, AA777158, W94063, AA912611, AA339877, A1265865, and AA339786.
HTEKE80	322	790381	1 - 523	15 - 537		
HTEKF04	323	774260	1 - 732	15 - 746		AA609512, AW074860, AW119172, AA626238, AA759162, AA609090, AA421396, AW070485, AA421292, AW303549, and AC007999.
HTEKF24	324	573750	1 - 412	15 - 426		AF001846.
HTEKF35	325	573749	1 - 253	15 - 267		
HTEKF68	326	772997	1 - 567	15 - 581		AW263561, AW183891, A1005584, A1216442, AA983878, AA815385, AA868890, and A1004495.
HTEKI01	327	917176	1 - 416	15 - 430		
HTEKI70	328	503039	1 - 686	15 - 700		A1830436, AA187445, AA383192, H91927, A1640587, and A1989949.

HTEKJ48	329	530588	1 - 235	15 - 249	
HTEKM14	330	745257	1 - 312	15 - 326	
HTEKO49	331	723148	1 - 383	15 - 397	AA69599, AI275162, N27054, R09201, and AC006211.
HTEKQ26	332	870627	1 - 314	15 - 328	
HTEKQ85	333	784444	1 - 555	15 - 569	
HTEKR75	334	870555	1 - 412	15 - 426	
HTEKS15	335	529273	1 - 414	15 - 428	
HTEKS20	336	846714	1 - 1063	15 - 1077	AI936596, AA868353, AI797296, AA725553, AI221970, AA429551, AA428462, AA629305, AA629047, AA431190, AI073397, AW235895, AI123443, AI808267, AA609412, AI914363, AA933895, AI214385, AA431516, AA911681, AA781953, AI825106, AA298758, AI215028, AA909534, AA723768, DI0393, and S63991.
HTEKS21	337	506651	1 - 333	15 - 347	
HTEKS76	338	767658	1 - 495	15 - 509	AI990484, AI917746, AW182169, AI216456, AA723888, AI018419, and AA969884.
HTEKX06	339	935945	1 - 426	15 - 440	
HTEKX08	340	959876	1 - 490	15 - 504	AL042392, AI147451, AA758821, AW450252, AA399310, AI656343, AI636668, AI190733, AA725709, AI025812, AA398244, AA723645, AA382463, AA709253, AI139837, AA401777, and A57391.
HTEKX28	341	920927	1 - 286	15 - 300	AA393705.
HTEKX70	342	573700	1 - 304	15 - 318	
HTEKZ50	343	524054	1 - 304	15 - 318	H89084, AA296876, AL023876, AC011422, AP000962, AL020989, AL049563, AL022575, AL031183, AL009028, AL031391, and AC002487.
HTELA50	344	774268	1 - 497	15 - 511	AI670826, AA058736, and Z99297.
HTELD47	345	934272	1 - 1005	15 - 1019	AA229071, and AA229024.
HTELD82	346	779315	1 - 510	15 - 524	
HTELE10	347	963563	1 - 495	15 - 509	AI377684, H03750, H84635, AA625639, and R22878.
HTELE41	348	791743	1 - 601	15 - 615	
HTELG47	349	757740	1 - 442	15 - 456	AI684943, AW117611, AI418517, and AI418516.
HTELG57	350	870621	1 - 441	15 - 455	
HTELG80	351	773018	1 - 251	15 - 265	
HTELA44	352	766462	1 - 658	15 - 672	AW341441, AI651145, AI919149, AI247339, AA412289, AI218635, AI650567, AW340087, AA709187, AW118140, and AW183314.
					AI298565, H92427, AW452904, AI361759, AW449414, AA004711,

HTELJ03	353	923071	1 - 575	15 - 589	R75764, F04362, AC006480, AL035414, AL133404, AC004486, and AL035072.
HTELJ51	354	806403	1 - 654	15 - 668	AC005157.
HTELJ89	355	966134	1 - 376	15 - 390	AI022339, and Z99127.
HTELK14	356	794339	1 - 453	15 - 467	AA397525, AA399055, AA758883, and AL022101.
HTELK50	357	870552	1 - 227	15 - 241	Z99716.
HTELK68	358	923055	1 - 646	15 - 660	AL078475.
HTELJ48	359	783824	1 - 515	15 - 529	
HTELL51	360	952267	1 - 635	15 - 649	
HTELL90	361	952269	1 - 940	15 - 954	
HTELM89	362	786268	1 - 288	15 - 302	AA913156, AI221124, AA305153, and AF106564.
HTELO20	363	926910	1 - 420	15 - 434	AI591200, AA102066, AI867662, AW088720, and D26018.
HTELO51	364	931120	1 - 378	15 - 392	AL031597.
HTELO73	365	761806	1 - 514	15 - 528	AI540890, AI557426, AI557082, AI541027, AI547225, and AI541056.
HTELO93	366	934344	1 - 249	15 - 263	AL078613.
HTELP27	367	921621	1 - 564	15 - 578	
HTELQ41	368	922634	1 - 449	15 - 463	R80089, X85707, and X85708.
HTELQ87	369	761768	1 - 449	15 - 463	AA310475, AI536833, AA319470, AA278518, AA319408, W20004, AI611260, AA418173, AI968286, AW182252, AA315267, AA491655, AW170378, and AI904985.
HTELR90	370	826531	1 - 437	15 - 451	AI125340, AI125684, AI377949, AA884214, AI126470, AI218351, AI243952, AA723933, AI240603, AI143979, and AI187742.
HTELT72	371	761598	1 - 447	15 - 461	AA652491, and AFI52924.
HTELT83	372	780619	1 - 699	15 - 713	AI827560, AI336053, AA873745, AA451732, AI436724, AA923591, AA055247, AW189536, AA747873, and Z40977.
HTELU01	373	915339	1 - 367	15 - 381	AA746627, AA398848, AA435892, AI208905, AI024568, AA861337, AA861875, and AA910621.
HTELV06	374	934302	1 - 457	15 - 471	AL033517.
HTELV10	375	963576	1 - 256	15 - 270	AI799028, AW263660, AA861674, and AA993711.
HTELV26	376	796832	1 - 435	15 - 449	AI198878, AI190586, AI018804, AL042837, AI208256, AA725583, AI016643, AA833661, AA626323, AA993365, AI018351, AA718913, AA725636, AA992718, AI183840, AA403023, AI911045, R60037, AA398422, AW410573, AA749431, AI128961, AI077415, AI198777,

HTELV43	377	870615	1 - 434		AI439996, AI934676, AI199096, AA682387, H92998, AI200368, AA778651, AA045098, AW157530, AW250790, AA587915, AW188549, AI819989, AI951978, AW007464, AI951992, AI376410, AI677931, AA778720, AI364379, AA584288, AW162769, AI040155, AA150015, AI187131, AA977318, AI373112, AI000432, AI038499, AI076148, AI278114, W94564, AA513466, AA946608, AI279549, AI758476, AW103741, AA836837, AI700221, AI253749, AI913907, AA057355, AI038357, AI758826, H71311, AW004637, AW273537, AA186980, AI885648, AA824341, W70033, T35014, AI262733, AI693026, AA196549, AI868298, AI090830, T16464, AL042836, AI887548, AW025276, AI139138, and AA150080.
HTELV86	378	910946	1 - 1086		AC007746.
HTELW29	379	952241	1 - 768		AI272244, AA382531, AI809639, U35371, and X99043.
HTELW62	380	870596	1 - 486		AW117507, AW105238, AW105158, AA969617, AI692859, AA934716, AA383047, and AI917691.
HTELX52	381	963506	1 - 345		AA393684, AA813816, and AI700752.
HTELX72	382	761599	1 - 216		AI220445.
HTELY64	383	764834	1 - 437		
HTELZ07	384	952268	1 - 535		
HTELZ89	385	786424	1 - 451		
HTEMA54	386	911666	1 - 1484		
HTEMB26	387	827055	1 - 130		AI954673, AI220421, AA813119, AA382989, AI024406, AF113526, AB023063, and AF113519.
HTEMB28	388	870614	1 - 402		AC004900.
HTEMB34	389	870589	1 - 533		
HTEMB72	390	761602	1 - 294		
HTEMB83	391	775593	1 - 370		
HTEMCI8	392	924727	1 - 447		AA778498, AI337034, AA609166, AA625857, AI201263, AA437287, AI678062, AI961118, AI203907, AI917789, AA626247, AA927799, AI187708, AA442366, AW294301, and AL050341.
HTEMC75	393	848193	1 - 296		AI813375.
HTEMD10	394	963546	1 - 673		M78994, R86687, T08961, AW402241, R46318, AA349761, AA350295, AA354235, H15340, AI909793, D31764, and AF037332.
					AA625914, AA416795, and AC005858.

HTEMD73	395	761783	1 - 430	15 - 444	A1026681, AA609997, AA382092, AA789295, and T12649.
HTEMF08	396	958386	1 - 494	15 - 508	
HTEMJ34	397	786377	1 - 550	15 - 564	A1142370.
HTEMJ54	398	963531	1 - 558	15 - 572	H59039.
HTEMK03	399	923066	1 - 347	15 - 361	
HTEMM80	400	888686	1 - 869	15 - 883	AA759198, and AA968427.
HTEMN08	401	958374	1 - 232	15 - 246	
HTEMN95	402	789113	1 - 311	15 - 325	
HTEMO14	403	880634	1 - 407	15 - 421	
HTEMO85	404	771434	1 - 485	15 - 499	AA804990.
HTEMP48	405	767863	1 - 348	15 - 362	AL049761.
HTEMP49	406	932319	1 - 774	15 - 788	AA933702, AL036538, AA928649, AA393559, AW104883, AA974777, AA587615, AA594505, AI351083, AA406036, AI004273, AI217923, AA923027, AA435495, AI128197, AA496058, AI187946, AI026847, AA865921, AA383556, AA927439, and AL117564.
HTEMS10	407	963527	1 - 386	15 - 400	AW082687, AA774543, AW195592, AW274057, AA460327, AA382893, AI126206, AI198578, AA682221, AW183102, and AA911099.
HTEMS48	408	832506	1 - 341	15 - 355	AA045732, AA412195, T70810, T85978, H26344, AA293873, AI343622, and AC004231.
HTEMT06	409	934338	1 - 636	15 - 650	AI016782, AI149777, AA448011, AA448155, and AI285926.
HTEMT89	410	922999	1 - 630	15 - 644	AW003548, AA757091, AW014801, AA813302, AA437209, AP000220, and AP000084.
HTEMU17	411	789623	1 - 335	15 - 349	W90717, and W90708.
HTEMU54	412	870618	1 - 436	15 - 450	AP000470.
HTEMX92	413	913795	1 - 525	15 - 539	
HTEMY30	414	870662	1 - 219	15 - 233	AL048534, AA403281, N78348, and AL031255.
HTEMZ04	415	927021	1 - 363	15 - 377	
HTENA22	416	870601	1 - 720	15 - 734	AL080132, ACO11594, AC006238, R38805, R49132, R49132, H06801, N66174, N98697, AA043641, AA146965, AA147010, AA259116, AA259155, AA534491, AA570283, AA687335, AA766643, AA910635, AA948152, AA401719, AA609258, AA626320, AA644562, AA680291, AA757030, AA758747, AA888971, AI023819, AI032507, AI088947, AI274536, AI345946, AI431770, AI192387, AI214901, and AI217881.

HTENB03	417	923050	1 - 476	15 - 490		
HTENC22	418	775544	1 - 560	15 - 574		AW195712, D44825, AI124542, and AB032984.
HTENF08	419	958378	1 - 743	15 - 757		
HTENG66	420	840151	1 - 295	15 - 309		
HTENG93	421	967432	1 - 91	15 - 105		
HTENH86	422	784798	1 - 601	15 - 615		
HTENI58	423	917213	1 - 636	15 - 650		AA393073, AI139819, AA860114, AA412161, and AA868102. AI970129, AW237169, AI621267, AI653036, AI797400, AI797725, AW182923, AI961057, AI970364, AI191623, AL036577, AW188292, AI341330, AI655836, AA918201, AI202983, AI825213, AI824962, AI990770, AA890172, AI982569, AI918790, AI205504, AI611043, AI969360, AW293674, AI203082, AI828842, AI634070, AI962396, AA757981, AI917843, AI867911, AI824830, AA903616, AI968361, AA781952, AL036578, and AA629230.
HTENJ28	424	968135	1 - 1014	15 - 1028		AI240133, and AF032967.
HTENJ76	425	767838	1 - 431	15 - 445		AF012383, AI307797, AW270088, and U86074.
HTENK06	426	835851	1 - 552	15 - 566		AB020719.
HTENK69	427	844557	1 - 899	15 - 913		AL042436, AL042437, AI674705, AA400083, AW241753, AA401372, AI218464, AA953011, AA972296, AA812520, AI125824, AA437087, AI028669, and AI024321.
HTENO12	428	917032	1 - 1454	15 - 1468		
HTENO50	429	969213	1 - 635	15 - 649		AA905347, AA371108, T20204, Z43158, and AA151400.
HTENP54	430	787535	1 - 494	15 - 508		AA496169, and AC009411.
HTENP80	431	775387	1 - 482	15 - 496		AL035453.
HTENQ05	432	928244	1 - 641	15 - 655		AA393064.
HTENR10	433	963530	1 - 575	15 - 589		
HTENR74	434	764828	1 - 444	15 - 458		AI823791, and AF069682.
HTENS22	435	785996	1 - 532	15 - 546		H83100, AL044519, and AL137391.
HTENS43	436	784936	1 - 1079	15 - 1093		AI971582, H58143, AI499833, AI393537, and AA973074.
HTENS91	437	870515	1 - 720	15 - 734		AA225153, AA629286, AA225136, AI272649, AA909816, AA070899, AI866377, AA229443, R67086, AA084212, AW243884, H59093, AA158549, AC002086, AL133304, AC000004, AL049830, AC006050, AC007270, AL031846, AC006125, D43727, AL031670, AC002470, AL050318, AC007114, AF001549, AP000329, AL135959, AC003070, AL034420, AL031286, AC007226, AL049694, AC004143, AL022476,

HTENV57	438	944416	1 - 605	15 - 619	Z93244, Z68284, AP000359, AC005015, AL034429, AC000394, AC006120, AC003029, AL031589, AC004782, and AL035072.
HTENW53	439	907717	1 - 806	15 - 820	
HTENX77	440	771409	1 - 521	15 - 535	AA429691, AA429515, AC007114, Z61140, and AC004156.
HTENY21	441	870587	1 - 705	15 - 719	AA781188, AA460513, AA860910, AA781845, AI027285, AI208471, AA889700, N73782, H08088, R38703, F03385, AI830535, AI474644, R41444, AA459870, AI023552, and AA421081.
HTENY35	442	884043	1 - 1011	15 - 1025	AI743533, AI424822, AW082413, and AI915340.
HTENZ33	443	870591	1 - 616	15 - 630	AJ223811, X85630, T36006, AA382232, Z21393, AA383107, N78092, T36070, T36050, Z21341, Z21392, AA459806, Z21315, AF012377, Z21111, AI827647, AW340665, AA280976, Z21340, T85719, AL043525, AL043526, R82847, AC006208, and AL137671.
HTENZ72	444	773024	1 - 564	15 - 578	AA383398.
HTEOA90	445	787516	1 - 489	15 - 503	AI632084, AI221893, AA383392, AA759214, AW137663, AI269516, and AA923222.
HTEOD34	446	812307	1 - 552	15 - 566	AA383437.
HTEOE61	447	918635	1 - 548	15 - 562	AI990671, and AI990110.
HTEOF31	448	793202	1 - 619	15 - 633	
HTEOF80	449	847224	1 - 506	15 - 520	AL031283.
HTEOF91	450	918571	1 - 237	15 - 251	AFI86084, and AL117610.
HTEOI36	451	870575	1 - 516	15 - 530	
HTEOI53	452	810333	1 - 422	15 - 436	AA298760, AA298759, AA298601, and AL133073.
HTEOK02	453	918590	1 - 395	15 - 409	AW206247, AI400618, AI671128, AW237084, AI811276, AI337166, AI341186, AI360596, AW235137, AI183637, AI654814, AI654771, AI969744, AI954759, AA417208, AI969746, AW087480, AA417104, AW182372, AA723770, AW241414, AW003345, AW241474, AW183339, AA432142, and AA757062.
HTEON29	454	815852	1 - 978	15 - 992	
HTEON67	455	954114	1 - 335	15 - 349	AW004028, AI968030, AW237673, AA432290, AW138422, AA112090, AA428635, AI143780, AI143791, and AA861634.
HTEOU45	456	915138	1 - 639	15 - 653	AC004533.
HTEOV90	457	870532	1 - 425	15 - 439	AW204420, AW058611, AI767863, AI433866, AI671711, AI802010, AI935766, AA280379, AI808931, AA523871, AI193461, AA827208,

AA418269, AI302010, AA280200, AA251664, AI637584, AI932794, AI564719, AI677796, AI538716, AI633125, AI862139, AI433157, AI702073, AI476046, AW050522, AI924971, AW151786, AW198090, AI569583, AI591420, AI590227, AI619502, AW102785, AI826225, AI648663, AI863240, AI886753, AW075381, AI480118, AI270183, AI097248, AI567351, AW152182, AI434468, AW104724, AI863321, AI612759, AI679916, AI271796, AI922365, AI890833, AI926790, AI802542, AI799199, AI636719, AI241819, AI280637, AI696612, AI828731, AI873644, AA833760, AI915291, AI445992, AI874261, AI804983, AI923357, AI670009, AI560099, AI613017, AL036187, AI572787, AI570807, AW026882, AI536638, AI620003, AI624548, AI537244, AA449768, AI433023, AI934026, AW104827, AI537303, AI274508, AI273142, AI955906, AL041772, AI811785, AI796743, AI446248, AA857306, AI863382, AI554427, AI445025, AI274013, AI520702, AI446003, AI889376, AW051258, AW150453, AI699865, AI925156, AW151136, AI923370, AW148320, AI619716, AI539808, AI869367, AI689248, AW075413, AI619607, AI499285, AW029611, AI698391, AI249962, AI680498, AI567814, AI889189, AI554821, AI539153, AI554218, AI784252, AW170635, AI608936, AI569945, AI635464, AI432040, AI537273, AI817552, AI564723, AI612852, AI681985, AI432969, AI828367, AI559296, AI702433, AW075667, AI432030, AI366900, AW148408, AI436644, AI633308, AW169527, AW090550, AI569328, AI627909, AI800411, AI612920, AI919534, AI921176, AI280661, AI499381, AI469112, AI580984, AI934259, AI539687, AI567128, AW193530, AW073270, AI648502, AI783861, AI610690, AI889306, AW169653, AI648684, AW081036, AI491775, AI801523, AW054964, AI469532, AI702068, AW148363, AI819976, AW080992, AW152469, AI273839, AI687127, AW192652, AI249877, AW087207, AI655932, AI680377, AI453322, AI439452, AI439762, AI648509, AI579901, AI818980, AI439717, AW235482, AW243820, AI357316, AI285735, AI497733, AI696606, AW193236, AI687362, AI589273, AI921464, AI623396, AW190042, AI280747, AI963216, AI284020, AI816010, AI628205, AI365256, AI758512, AI619737, AI886206, AW087534, AI352497, AI625079, AI813919, AW129916, AW129722, AI868204, AI587114, AW128841, AI610086, AI683173,					
---	--	--	--	--	--

						AF079763, AC006222, X80340, AL137476, AF003737, US8996, AL023657, AL137533, X87582, A45787, AL050155, S61953, AR013797, AL117440, AR038969, AL137526, A90832, I66342, AL080074, AF162270, AL133067, E05822, AF111849, AL050092, AF061981, AF000145, E04233, Z72491, U78525, AF106657, E06743, AF051325, M30514, U96683, AJ006417, AL137292, AF008439, AF177767, U49908, L30117, AF061573, L19437, AL122118, AL137488, I96214, AF132676, AF061836, AP000020, E08631, U68387, E02221, S79832, Z37987, AF210052, I17767, AL022147, and AR020905.
HTEOW02	458	918475	1 - 596	15 - 610		Z98304.
HTEOW39	459	870566	1 - 488	15 - 502		AI684621.
HTEOW85	460	969682	1 - 649	15 - 663		AI041556, AL042783, AA834968, AA789271, A1032390, AA400082, AA757197, AW206997, AA416988, AW235392, A1028342, A1024253, AI015964, AL040413, and AA411964.
HTEPA08	461	958391	1 - 1054	15 - 1068		AI765491, A1469067, A1870585, A1870612, A1652881, AA055971, AI763357, AA036000, AA358708, AA889873, A1701794, N56631, AL042137, A1825129, AW297101, and AB018353.
HTEPA27	462	872923	1 - 589	15 - 603		AW449288, A1147992, A1142275, A1654490, A1002885, A1743450, and AW103158.
HTEPB66	463	772949	1 - 610	15 - 624		A1688792, AA504908, AL138425, AA908950, A1208672, and AF081466.
HTEPB84	464	782248	1 - 580	15 - 594		
HTEPC76	465	767824	1 - 526	15 - 540		
HTEPC87	466	883021	1 - 514	15 - 528		
HTEPD06	467	933299	1 - 341	15 - 355		N47565, N47576, C14331, D80227, D80269, D80378, C14429, D51799, C14389, AW118681, D80391, D59787, D59467, D80196, D80038, D59927, D50995, D58283, D59859, D80022, D80166, D80195, D51423, D59619, D80210, D80164, D59275, D80240, D80253, D80043, D59502, D81030, D81026, D51022, D80212, AA305578, D80188, D59610, D80219, AA514186, AA514188, C15076, D57483, D80024, D80366, AA305409, D50979, D59889, D80193, D80045, C14407, D80133, AW360811, D80241, D80248, D80522, D51060, AW177440, C14014, D80251, AW178893, AW375405, T03269, AW179328, C75259, AW366296, AW377671, AW360844, AW375406, AW360817, AW378534, AW179332, AW377672, AW179023, AW178905, D80268,

					<p>AW378532, D80132, C05695, AW352171, AW177501, AW177511, D80302, D80134, D80439, AW377676, AW352170, AW177731, AI557751, AW178907, AW178762, D58253, AW179019, AW179024, AI535686, D80247, D51250, AW369651, AW177505, AW178906, AW352174, AW179020, AW178775, AW360841, AW178909, D59373, AW177456, AW179329, FI3647, AW178980, AW177733, AW378528, AW178908, AW178754, D52291, C14227, AW179018, AW352158, AW352117, AW176467, T11417, AW179004, AW367967, AW179012, AW178914, AW378525, D51103, D80168, AA926689, AA809122, AI910186, D80157, C14344, AW177728, C06015, AW179009, D51759, D58246, D81111, AW178774, AW178911, AW378543, AW177722, AW352163, C14298, D80064, AI905856, D59503, AW178983, AW178781, T48593, D58101, AW360834, Z21582, AW177723, AW378540, AW352120, D59627, D59653, D80258, AI535850, AW378533, D45260, D51097, C14975, Z33452, AW367950, D80014, AA285331, AW177508, H67854, C03092, H67866, AI525920, AI525923, D51213, AW177497, D80228, AW178986, C14973, D50981, D45273, N66429, T03116, AI525917, D59317, AW177734, D51221, D59474, D60010, AA514184, D59551, C14957, D60214, T03048, AI525235, AI535961, AI525227, C14046, AI557774, AI525242, AI525912, AW378542, AI525925, AW378539, AI525215, A62298, A84916, A62300, AR018138, Y17188, A82595, AB028859, AJ132110, AF058696, AR008278, Y17187, X82626, X67155, D26022, Y12724, A25909, A67220, D89785, A78862, D34614, D88547, A94995, AR060385, AB002449, AR008443, A30438, I50126, I50128, I50133, AR025207, AR066488, X64588, AR016514, X68127, AR060138, A45456, A26615, AR052274, AR066490, Y09669, A43192, A43190, AR038669, I18367, AR066487, AR008277, AR008281, U46128, I14842, AR054175, AR016691, AR016690, AR062872, AB012117, D50010, A63261, AR008408, X93549, A85396, A70867, D88507, AR066482, A44171, U79457, A85477, I19525, A86792, I79511, D13509, A64136, A68321, AR060133, AF123263, AR032065, and AR008382.</p>
HTEPGI5	468	812303	1 - 533	15 - 547	<p>AI937640, T18881, R24582, AA412546, AI083751, AF079564, AF079565, AF106658, AF106659, AF202454, AF202453, and Z63351.</p>

HTEPH01	469	915301	1 - 618	15 - 632	AA399486, T69681, and AC007537.
HTEPJ09	470	956200	1 - 1202	15 - 1216	AA394192.
HTEPJ19	471	918599	1 - 453	15 - 467	T18597, D59751, A1557262, A1525556, Z33559, A1540903, Z32887, D50992, A1557533, A1536138, A1535660, A1541205, D59436, A1526078, A1535639, A1541321, A1541075, C14228, A1557864, A1557238, AA058620, A1557808, A1525500, A1557082, H65400, A1525653, A1535828, A1557809, A1541356, A1557602, A1541365, A1557731, A1525302, A1525316, A1535813, A1546829, A1525757, A1540974, A1557312, A1557317, A1541154, R29657, A1536150, A1541034, A1557852, A1525856, A1535994, A1541353, A1541027, A1541048, A1557258, A1557543, A1525666, A1557041, A1557426, A1536070, A1557039, A1557810, A1525656, A1547177, D30843, A1557408, AR050070, A62298, A82595, A82593, U94592, Z30183, A62300, AF006072, and AR025466.
HTEPJ79	472	774212	1 - 359	15 - 373	
HTEPK40	473	939675	1 - 619	15 - 633	A1075905, A1796754, AW137492, A1652522, AA393248, A1217933, AA459841, A1150346, AA293815, A1694956, AA435622, AA393292, AA719008, AA629029, A1024099, AA861041, AA398164, AA402463, AA399502, R24468, R66361, AA688372, AF081250, and AF081249.
HTEPM33	474	870561	1 - 816	15 - 830	AA824347, AA889787, A1425084, AA868962, A1190895, A1132776, and AF083394.
HTEPM52	475	806471	1 - 444	15 - 458	
HTEPN07	476	952243	1 - 307	15 - 321	Z99716.
HTEPP23	477	836572	1 - 327	15 - 341	A1150152, A1216505, AW103179, and AC006017.
HTEPP29	478	917207	1 - 458	15 - 472	
HTEPP30	479	947107	1 - 732	15 - 746	AF191546.
HTEPP32	480	785803	1 - 963	15 - 977	AA402763.
HTEPP92	481	790869	1 - 596	15 - 610	
HTEPR90	482	787499	1 - 155	15 - 169	
HTEPT25	483	870509	1 - 393	15 - 407	
HTEPT75	484	870637	1 - 630	15 - 644	A1283483, A1873282, and A1827738.
HTEPU01	485	915134	1 - 704	15 - 718	
HTEPV02	486	917406	1 - 489	15 - 503	
HTEPX32	487	870698	1 - 1349	15 - 1363	A1217947, AW237109, A1918745, A1968403, AA934788, and X84693.

HTEPZ10	488	963433	1 - 529	15 - 543	AI217204, AW183426, and AA759358.
HTEPZ18	489	888470	1 - 560	15 - 574	AA397836, AI139919, AW162347, AI223276, AI879324, AI200822, AI150592, AI028601, AI200868, AI879701, AI138943, AI652314, AI377443, AA868111, AW160551, and AF177398.
HTEQB03	490	922941	1 - 396	15 - 410	AI624244, AI120897, AI121756, AC007099, Z99496, AC004584, AC002418, AP000248, AC004386, AL050305, AC002483, AL022315, AL034452, AC004638, AC005899, AC000353, AC004623, Z84476, and U91323.
HTEQD40	491	915198	1 - 543	15 - 557	AI623182, AA776747, AW082325, AW273819, AI3393350, AI810085, AI125567, AI221672, AI200770, AI204194, AW263528, AI240146, AA437189, AA758317, AI192035, AA709217, AA992316, AA758401, AA961979, AI217262, and Z66485.
HTEQD69	492	918579	1 - 607	15 - 621	
HTEQE87	493	958354	1 - 729	15 - 743	AA913948, AI633873, AI638029, AI990760, AI806847, AW003193, AI190550, AA4431560, AI187284, AI915840, AI286045, AI243468, AA719044, AA448281, AI219847, AW135537, AA861812, AA861291, AI969788, AA812901, AI187727, AI286137, and AI942348.
HTEQG56	494	881004	1 - 577	15 - 591	
HTEQI54	495	853971	1 - 603	15 - 617	AW299627, AA917835, AA758010, AI989828, AW103119, and AW241908.
HTEQJ14	496	870525	1 - 496	15 - 510	
HTEQJ42	497	806495	1 - 496	15 - 510	AA383039.
HTEQO81	498	806504	1 - 375	15 - 389	AA382997, and AA397859.
HTEQP45	499	966141	1 - 127	15 - 141	
HTEQQ82	500	932301	1 - 590	15 - 604	AA609033, AA293870, AA382673, AW263657, and U51244.
HTEQR15	501	939641	1 - 756	15 - 770	AI979286, AA382595, and AF133424.
HTEQR94	502	966486	1 - 556	15 - 570	AI990882, AA447560, AI201149, AI341615, AW002367, AI651854, AA437021, AI149956, AI140621, AW292211, AA620811, AW196416, AA757082, AA993629, AA932499, N92273, AA448543, AI458277, AA398159, AW004057, AI918824, AI635506, AA401699, AA994466, and AI016246.
HTEQT63	503	924799	1 - 1298	15 - 1312	AI142296, AA417385, and AI148005.
HTLAB19	504	530577	1 - 347	15 - 361	
HTLAB44	505	530579	1 - 253	15 - 267	AC006549, AC000097, and AC006547.

HTLAB73	506	575019	1 - 320	15 - 334	AC000078.
HTLAC81	507	679414	1 - 192	15 - 206	AF038406.
HTLAC87	508	546469	1 - 226	15 - 240	
HTLAD21	509	761758	1 - 490	15 - 504	AI217166, AI184534, AI150079, AI142754, AI697160, AI811701, AI214713, and AW188915.
HTLAD38	510	421550	1 - 517	15 - 531	
HTLAF84	511	836390	1 - 558	15 - 572	AA418228, AF045454, D63648, and E13935.
HTLAV67	512	530742	1 - 208	15 - 222	AC005258.
HTLBD12	513	506739	1 - 319	15 - 333	AL121757.
HTLBE55	514	967408	1 - 293	15 - 307	AL036680, AA421020, AW151136, R66759, AL037558, AL045421, AA830821, AW149876, AI571529, AI355008, AI567582, A W089006, AI471361, A W023338, A W020095, AL041150, A W167924, AI829990, AI345224, AI079736, AL046463, AI311892, A W162194, AI697324, T99953, A W243637, AI921167, AA291456, AI539771, AI873638, AI473451, AI805688, AI888621, AI828574, A W022682, A W239367, AI540606, AI689420, AI336662, AL038575, AA464646, A W020693, AI890887, AI590423, AI570966, AI307507, AI916419, AI611728, AI470293, AI929108, AI538850, AI610667, AA572758, AI648567, A W088899, AI805638, AI366549, AI799195, AI866082, AI636719, AI539153, AI620093, AI866608, AI636619, AL120853, AI340603, AI537677, AI611743, A W083804, AI349598, AI582912, A W172723, AI539800, AI696626, AI349256, A W075207, AI589993, AI866573, AI312152, AI365256, AA579232, AA807088, AI343037, AI345735, A W085786, A W265004, A W075084, AI310925, AL038564, AI472536, AI312399, AI677797, A W082600, AI349937, AI567944, AI345688, AI334884, AI307543, AI494201, N71199, AI345251, A W071412, AI307210, AI307708, N29277, AI312325, A W071395, AL036631, AI538885, AI249946, AI244380, AI340659, AI589267, A W071377, A W129230, AI802240, A W161579, AI313320, AI955906, AI340644, AI805769, AI434242, AI313352, AI335363, AI307503, AI539707, AI334930, AI309443, AI623682, AL039086, AI307736, A W161402, AI307520, AI623736, AI446124, A W084097, AI349266, AI349787, AI334452, AI340664, AI310592, AI344938, AI312146, AI866786, AI309431, AI312339, AI340537, A W301300, AI345739, A W161202, AI345674, AI345258, AI538764, AI312143, AI307459, AI349637,

AA635382, AI273179, N74355, AI312428, AI499974, AI310927, AI110306, AI311604, AI307578, AA420722, AW162189, AI436429, AI349955, AW189933, AW075093, AI312432, AI120300, AA580663, AI349269, AI312357, AI590943, AI358701, AW021588, AI310945, AI040241, AW088903, AW151714, AI036638, AI636581, AI583445, AW059713, AI648408, AI312237, AI922901, AI446373, AW263716, AI251830, AI343059, AI917963, AI573026, AI349933, AW193467, AW268261, AW082623, AI249877, AI047422, AI133741, AA493923, AI345253, AW409775, AI119836, AI345677, AW167918, AA494167, AW191003, AI633402, AI119791, AW071362, AW021373, AI345608, N98606, AW191844, AI336513, AI357599, AI433968, AI499581, AA848053, AI554821, AW264719, AI046618, AI348895, AI345347, AW269097, AI866465, AI310575, AI589428, AI349226, AI046595, AI040694, AA493647, AI537837, AW403717, AA974049, AI036718, AI037454, AI824360, AW058233, AI046466, AI569328, AI434833, AI038605, AW163834, AI886055, AF065135, I48978, Z72491, AF113690, AI035458, AI133104, AF158248, AI050172, AF090934, Y16645, AI8777, S78214, AI049382, AF090886, AF113691, A08916, AR000496, U39656, X70685, M86826, I89947, A08913, A08910, I26207, AI117585, I89931, A08909, A08912, Y11587, I49625, AI122118, AF036941, AI080074, AR038854, AF132676, AF061836, AF090900, A08908, AR011880, AI110171, AF090943, X84990, AI133016, AI122110, AF097996, AF118070, AI122050, AI137538, AI117457, AI133568, AF102578, AF028823, A65340, A07647, I48979, X53587, AI080060, AF114170, AF118064, AI133081, AJ238278, AF017790, AI122098, U68233, I92592, AI137712, AI080137, AI117394, E01614, E13364, A03736, M92439, AB016226, AF113677, I42402, AI050108, AI137705, AF067790, I89934, AF087943, E02221, AB019565, A65341, X62580, AI122111, AF210052, AI137574, AF125949, U68387, S68736, AF003737, I89944, AI133093, AI049466, Z37987, AI137658, U58996, AI050092, X87582, AJ000937, AF069506, AF118090, AF192557, AI096744, U78525, Y08769, X63574, A21103, S76508, AF113019, AI133558, AF215669, E02253, AI137560, AI133640, X52128, AF177401, AI080148, AI133565, AF104032, AF113013, AI049465, AI137300, I00734, S77771, I41145, AF012536,					
---	--	--	--	--	--

					AL137429, AF113689, AL049300, E05822, AL137478, AL133645, U95114, AF176651, AB007812, E06743, AL080158, AF017152, AF026124, U96683, AL110221, S69510, AF113676, E00617, E00717, E00778, AL137656, D16301, AL137527, Y07905, AL050393, AL117435, AL137548, AL122121, AL110280, AL137463, AF111112, S61953, AL080086, AF078844, AL122049, E04233, X80340, AL117583, AL133098, AL117460, X72387, AL133557, X92070, AF090903, AL050116, AL122045, AJ003118, U49434, AL133014, U80742, AL133113, U91329, AJ005690, AL137479, U72620, D83032, AF162270, AL133560, AF126247, I09360, AL049938, X79812, AL122106, AL133075, AL122093, AL137294, U42766, AL117432, AF113694, AL137526, AL133080, AL117649, AL080127, AL133077, AF061573, U00763, AC002467, AL080124, AR068751, Y10655, S75997, AL049464, D89079, AL133067, AL137556, Y16258, Y16257, E02756, Y16256, X06146, AL137557, AL050024, U67958, AL049314, E01314, E07108, M27260, AL050149, A45787, AL133072, AL137273, AF106657, AF030513, AL050138, X93495, X65873, AL137665, E15569, A58524, A18788, A58523, E03348, AL050277, U92068, AL110196, E03349, AR038969, L30117, AJ242859, AR059958, and Y09972.
HTLBE82	515	780116	1 - 467	15 - 481	H03896, AA788921, AA985315, and AL133595.
HTLBF14	516	971661	1 - 728	15 - 742	
HTLBG83	517	527942	1 - 187	15 - 201	AA132777, AA809070, and A1799864.
HTLCA95	518	911655	1 - 1148	15 - 1162	AI028227, A1798166, A1968058, and A1962770.
HTLCG77	519	772644	1 - 98	15 - 112	
HTLCX76	520	767667	1 - 265	15 - 279	AL045710, and AL096749.
HTLCY54	521	908832	1 - 1050	15 - 1064	AA453366, A1188219, A1638044, AA983750, A1219830, AA453365, and AA912820.
HTLCZ48	522	572959	1 - 399	15 - 413	
HTLCZ96	523	815897	1 - 459	15 - 473	AW139921, AA725842, A1971598, A1651885, AA453466, AL110422, AI027229, AI026797, AA778573, A1279962, A1073425, A1208767, H55405, and AL118498.
HTLDA58	524	828115	1 - 259	15 - 273	AA948538.
HTLDE53	525	780842	1 - 610	15 - 624	AA400498, AA400590, AA861265, AA398875, A1149809, A1198885, AA435582, AA460749, AA460151, AA889548, A1015434, and

HTLDE64	526	908613	1 - 838	15 - 852	AA815269.
HTLDE95	527	616724	1 - 285	15 - 299	AA566051, AA52211, AA393552, AA418209, H05646, H06920, R34733, AA293017, Z42496, A1743990, and AA280537.
HTLDG55	528	911645	1 - 196	15 - 210	
HTLDI90	529	835850	1 - 458	15 - 472	AB020719.
HTLDP77	530	920546	1 - 638	15 - 652	AC002128.
HTLDQ25	531	870057	1 - 1220	15 - 1234	AA399278, AA889597, AA758803, AW117336, AA398195, AA729781, AA889586, and AA922590.
HTLDS55	532	891322	1 - 1302	15 - 1316	A1890919, A1018797, AA913452, A1797580, A1809012, A1187382, AA448485, A1554914, AW137847, A1393577, AA382830, AA432050, AA609003, and AC020663.
HTLDT05	533	909752	1 - 473	15 - 487	R59447, R17647, T62170, and A1439348.
HTLDT81	534	952265	1 - 480	15 - 494	AA398001, AA399683, AW177623, AA809773, and AL137531.
HTLDU05	535	911649	1 - 589	15 - 603	AA437044, AF113527, AB023062, and AF113520.
HTLDX88	536	791684	1 - 686	15 - 700	
HTLDY85	537	573746	1 - 481	15 - 495	
HTLDZ14	538	573401	1 - 334	15 - 348	
HTLEB14	539	573464	1 - 402	15 - 416	
HTLED72	540	906989	1 - 273	15 - 287	
HTLEF94	541	870258	1 - 309	15 - 323	
HTLEG65	542	870154	1 - 1167	15 - 1181	
HTLEG91	543	870257	1 - 99	15 - 113	Z94160.
HTLEH30	544	934287	1 - 542	15 - 556	
HTLEI47	545	573460	1 - 463	15 - 477	
HTLEI11	546	973302	1 - 956	15 - 970	M62294.
HTLEI93	547	960314	1 - 294	15 - 308	AL044506.
HTLEK64	548	506747	1 - 318	15 - 332	AA442457, AA601393, AC005625, and AC005789.
HTLEL01	549	917022	1 - 515	15 - 529	AC003976, AC005702, AC005562, and AL117394.
HTLEL03	550	575080	1 - 93	15 - 107	AF042793, AB011130, AF042792, AF040709, and Z84492.
HTLEL31	551	669950	1 - 131	15 - 145	AA250913, W56681, R24109, H01291, AA161334, AW160808, and AF053356.
HTLEM46	552	719160	1 - 443	15 - 457	A1760165, A1341569, AW241888, AW135684, A1624778, AA883817, A1494564, AA722107, AA521079, and AA405142.

HTLEO50	553	506649	1 - 335	15 - 349	Z68869.
HTLEP16	554	574942	1 - 567	15 - 581	AA305510, AA099550, A1917501, A1631488, A1142135, AW391262, AA305581, N39659, A1829757, and AF151810.
HTLEQ07	555	953706	1 - 592	15 - 606	AL133071.
HTLES43	556	573403	1 - 203	15 - 217	
HTLES54	557	574884	1 - 312	15 - 326	A1207997, and AW172597.
HTLET56	558	911654	1 - 1096	15 - 1110	A1968198, A1655275, AA397903, AL044119, AW003563, AL044118, and Z74696.
HTLET78	559	836820	1 - 812	15 - 826	AL041695, AA454137, T19069, D31497, and AL133566.
HTLET93	560	573454	1 - 99	15 - 113	
HTLEV33	561	527956	1 - 261	15 - 275	A1808336, AW013835, A1624717, and A1650408.
HTLEV95	562	883332	1 - 574	15 - 588	AA776758, A1808140, AA884694, AA909615, AA904970, AA909196, AW294544, AA723919, and A1525608.
HTLEW21	563	573458	1 - 311	15 - 325	AL122083.
HTLEY11	564	967309	1 - 336	15 - 350	
HTLEY91	565	775310	1 - 212	15 - 226	AC005343.
HTLEZ14	566	791662	1 - 322	15 - 336	AC000097, AC006547, AP000344, and AC006549.
HTLEZ15	567	934288	1 - 368	15 - 382	D51002, A1541205, A1541321, A1557082, A1535660, A1557238, A1557258, A1557602, A1525500, Z33559, T18597, A1557533, A1557731, A1525556, A1557262, H65400, A1557234, A1525757, C14322, D50992, A1525856, A1557241, A1541027, A1525852, A1535639, AA058620, A1540903, A1541365, A1557084, A1541048, N71206, A1557312, A1526078, A1557474, A1525302, Z33585, A1541075, A1541034, A1541346, A1541353, A1541154, A1557039, A1557041, A1557222, A1557317, A1525656, A1546829, A1536070, A1535813, A1525666, A1541056, A1535994, AF025310, Z30183, U45328, AR050070, U94592, A82595, A82593, A63903, A62298, and A62300.
HTLEZ32	568	870261	1 - 512	15 - 526	AC005899.
HTLFA74	569	934172	1 - 695	15 - 709	AA398001, AA399683, AW177623, AA809773, and AL137531.
HTLFC20	570	917128	1 - 1029	15 - 1043	AA356490, R05624, AA262044, and AL138430.
HTLFE01	571	917033	1 - 591	15 - 605	
HTLFE05	572	954984	1 - 1305	15 - 1319	AW275845, A1830267, A1572906, A1439086, AA766499, AA723111, AA836614, AA453028, AA747738, AA483838, AA077798, AA077483, AW302599, AA215573, AA077013, AA009576, AA078283, AA323484,

HTLFE20	573	934278	1 - 463	15 - 477	AA077510, AJ007798, and AC005071.
HTLFI28	574	775392	1 - 423	15 - 437	AC006237.
HTLFI39	575	953730	1 - 616	15 - 630	AC003963.
HTLFI83	576	781303	1 - 501	15 - 515	AF053356, and AF174604.
HTLFI39	577	573462	1 - 329	15 - 343	AL117491, AB007913, AL137693, and AL110281.
HTLGD25	578	870136	1 - 1477	15 - 1491	AI001797, and AJ910520.
HTLGD69	579	835493	1 - 1010	15 - 1024	AA608970, and AA758832.
HTLGG36	580	789656	1 - 561	15 - 575	AA403179, AA398239, AW339857, and AA952990.
HTLGM02	581	964878	1 - 752	15 - 766	AW269804, AA781852, AW104592, AI239999, AI698249, and AC005821.
HTLGM07	582	952254	1 - 1194	15 - 1208	C02944, C03248, AI807681, AA095819, AI797565, AI333238, AI863457, HS3759, AW138808, AW451889, AW138004, AW207397, AW184023, and AC005216.
HTLGT62	583	918606	1 - 533	15 - 547	AI693474, AL042395, AL041671, AW168041, AI738586, AA504349, AI125391, AI990015, AA838043, AI149664, AL041569, AI864457, AA579771, AW273185, AW294188, AW197733, AI805280, AA383594, AI699335, AI138789, AI653680, AI738485, AA383400, AI475427, AA976749, AI203057, AA883961, AI968077, AF096834, AF073954, AF073955, AC003688, and L07578.
HTLGW17	584	958208	1 - 794	15 - 808	AL040693.
HTLGX90	585	870528	1 - 1358	15 - 1372	AA399144, AJ982647, AA394141, AA234366, AA405404, AA034080, AA644012, AA234434, T86343, AI344623, R02436, T86344, AA707052, R02333, and Z98257.
HTLHC14	586	908428	1 - 752	15 - 766	AI738485, AI738586, AF096834, AC003688, AF073955, and AF073954.
HTLHE72	587	963471	1 - 494	15 - 508	AL078621, Z63130, and Z63232.
HTLHL82	588	958334	1 - 1159	15 - 1173	AA459835, AI286187, AA742548, AI187289, AI392611, AA922025, AI138515, AA884337, and AI936608.
HTLHO94	589	968685	1 - 460	15 - 474	AI632413, AA026276, AA382241, AA936327, AI026815, AA382375, AA026275, AA860376, and AC006445.
HTLHP32	590	933335	1 - 615	15 - 629	AA405738, AA116025, AA102802, AA211814, D63260, AA306027, H97316, T78952, X93817, AW136521, AI659011, AW382734, AW374638, AL022316, Z93241, and AF151854.

HTLHP52	591	926980	1 - 569	15 - 583	AA483387, AA065093, AA126035, AA126051, AI871722, AA164944, AA199708, AL044904, Z69651, AP000337, and AC002425.
HTLHP80	592	870156	1 - 590	15 - 604	T85616.
HTLHT15	593	946586	1 - 560	15 - 574	AA402128.
HTLHT24	594	870254	1 - 1191	15 - 1205	AI869974, AA405686, AI199718, AI969027, AW086198, AL045468, AW082694, AA399273, AW136449, AI933024, AA412383, AA300675, AA405951, AA412243, AL045467, AI150480, AA889135, and AI217882.
HTLHU04	595	926950	1 - 998	15 - 1012	H44302, R50303, AA341701, AA179217, T60490, AA478857, R47809, AA234882, AA302994, AI797287, F12041, T66192, H81762, AW403784, AA171826, AI417037, AI906347, AI436806, AA298718, AI906396, and AF005038.
HTLHV67	596	936139	1 - 735	15 - 749	AC005971.
HTLHZ08	597	958321	1 - 663	15 - 677	AC003662.
HTLHZ10	598	963475	1 - 677	15 - 691	
HTLID36	599	945891	1 - 521	15 - 535	
HTLJK11	600	966043	1 - 471	15 - 485	
HTLIP19	601	958351	1 - 941	15 - 955	AA431834, AA412657, AA399262, AI970493, AI026627, AA412489, AA431430, AA383405, AL042749, and AI696044.
HTLIQ09	602	931046	1 - 630	15 - 644	
HTLIR30	603	870115	1 - 709	15 - 723	
HTLIU76	604	946300	1 - 829	15 - 843	AA393092, AA453482, AF012388, and AF002992.
HTLIV78	605	947234	1 - 685	15 - 699	AA846864, AI125243, AA446154, AW003474, AI200764, AW137061, AA992083, AI139618, AA429664, AA991813, AA923010, AI150169, AI825677, AI917106, AA429514, AW029457, AW264822, AI800160, AW085654, AI445992, AI660211, AA761545, AW084368, AI633009, AA113768, AI863191, AL048875, AW117746, AI874189, AI583982, AI634707, AW149869, AI537989, AI140134, AI680138, AL035460, and AF185576.
HTLIY52	606	942161	1 - 1354	15 - 1368	AI827749, AI819667, AI580407, AI025487, AI223109, AI150036, AW087713, AI024234, T18864, AI479322, AA883975, AW341589, AA860213, AI831802, AA913074, AA608857, AI050685, AA860223, AA948538, and AI075930.
HTLJA23	607	953729	1 - 943	15 - 957	AF053356, AF174604, and AF083655.

HTLJA24	608	934279	1 - 560	15 - 574	AC006237.
HTLJC71	609	922923	1 - 1738	15 - 1752	AL039539, AL045443, A1336919, AA406128, AA405229, AL042307, AA431504, AA311249, AW086440, AA813520, A1240644, AA897733, AW268487, AA782009, AW172455, A1301209, A1014598, AA969918, AL041043, AA431178, AL039540, AA973051, A1221826, AL133030, AC009516, AP000552, AP000556, AP000557, and AL117509.
HTLJD35	610	967336	1 - 518	15 - 532	
HTLJD88	611	953714	1 - 865	15 - 879	AL041339, AF025310, and AF200923.
HTLJJ75	612	924755	1 - 1137	15 - 1151	AA889705, AA224167, AW263624, A1627392, AA907369, AA224175, H41231, A1392654, A1223199, A1208705, A1825010, AL033527, and Z66397.
HTLJL23	613	922994	1 - 1787	15 - 1801	W02882, A1017323, AW118900, AA912672, A1208003, AA909041, A1765407, A1765419, AA609441, Z33510, A1016233, A1657083, A1339208, A1991437, AA781685, AA860425, AA382780, Z21333, AA357733, Z21332, AA256011, N74515, AL031587, and AF006501.
HTTAD55	614	835652	1 - 246	15 - 260	AA301270, AA301379, and AA301366.
HTTAE49	615	723331	1 - 269	15 - 283	AA301335, AA301157, W27731, AA525760, AA449997, AW088581, F07155, AW337237, A1536857, A1524371, AA737106, AA056569, AA491298, AA953587, A1857836, AA515753, AW080777, AA491681, A1766408, A1278972, T39494, R97104, N55508, A1376747, AW081296, A1311647, A1923333, A1207465, F08230, AA531412, A1183976, AA601355, AA953228, AA165505, N73610, AA598927, N72717, A1620992, H72530, AA970967, A1809745, A1923052, A1674840, A1341654, AA648942, T07769, H84675, AA602727, A1950671, H70076, A1270675, R49657, A1908093, AL021939, AL022238, AC004526, AC007546, AL121748, Z98051, AC005368, Z83846, AC004000, L78810, AL021368, AC004447, AL031667, AL049552, AF059650, AL008707, AC004833, AL049745, AC006344, AC006387, AL034419, Z98884, AC004805, AC004996, AL022326, AL035046, AP000080, M31061, M33764, X16277, M81740, U73636, AL031668, AL121658, AC006271, AL133382, AC009286, AC003041, AC007461, AL031587, Z98742, AC005953, AP000557, D87009, AL031311, AC002312, AP000023, AC002350, AL137100, AL022721, AC007051, U07562, AC010209, AC006160, AC007919, AL118510, AC007559, M97911, AC007564, AC004799, AC005067, AC002369, AC005227, AC008122,

HTTAH87	616	509574	1 - 304	15 - 318	AL096763, Z95116, AC004947, AC004841, AC003049, AC004655, AC004838, Z85986, AP001053, AC005962, AC008015, AL035086, AC004098, AC005384, AC006115, AC009405, AC006239, AC003684, AP000171, AP000056, AC004477, AC007934, AC003669, AL035078, Z75888, AL049589, AP000967, AC004757, AF106564, U47924, AL078472, AC003038, AC004686, AC004966, AL050318, AC005803, AC005726, AC004228, AC006449, AC004492, AC003091, AC005179, AC004905, AC006552, AF200465, AL049835, AL080242, AL035682, AC005230, AC005484, Z92547, AL031283, AL049759, AL009181, AC004938, AC004008, AF030453, Z98946, AC005088, AC007014, U91318, Z98304, AL133245, AP000556, AB020871, AL031845, AL023575, AC005212, AC005857, AL035530, AP000467, AL031864, AL034417, AP000563, AP000211, AP000133, AL022330, AC003093, AL035417, AC005043, AC004032, AL049646, AC005180, Z75887, AC005251, AC004895, AL049554, AC006130, AL031056, AP000330, AC006270, AC006101, AC005884, Z83856, AP000257, and AP000256. AA301200.
HTTAJ50	617	509657	1 - 249	15 - 263	AA300966, and AA301128.
HTTAN57	618	509453	1 - 292	15 - 306	AA300600, and AA301000.
HTTAS96	619	961057	1 - 247	15 - 261	AA300802, AA300767, and AC004559.
HTTAU82	620	797726	1 - 296	15 - 310	AA300687, AA286758, AL139165, and Z70227.
HTTBE25	621	509128	1 - 256	15 - 270	AA300493, AA300591, AF059569, and AL049778.
HTTBH54	622	530563	1 - 302	15 - 316	
HTTBH94	623	530564	1 - 311	15 - 325	AL046237, and AL045777.
HTTBN67	624	578085	1 - 163	15 - 177	
HTTCA15	625	869705	1 - 413	15 - 427	AC005833.
HTTCD03	626	925390	1 - 378	15 - 392	
HTTCD71	627	530393	1 - 112	15 - 126	AL049844.
HTTCL35	628	529672	1 - 239	15 - 253	AA505142.
HTTCT34	629	973210	1 - 1295	15 - 1309	AW192348, AA081773, H06122, C75208, W38676, AA302953, AI907561, AA311414, AA151050, AW411262, AA226372, AA297279, T50005, AA938031, AI276055, AI433141, AI814125, AA689289, AI264581, AI650824, AW235148, AI273243, AA340545, T50069, AW340759, AW088730, AI093394, W44759, W73928, AI242558,

HTTDF50	630	526385	1 - 293	15 - 307	AI800707, AA421100, AA243847, AW265034, AA226593, AW294446, AI097360, AI302409, AI298574, AA770396, AI418623, AI122285, AI150958, R31691, AI969750, AI168830, AW236726, AI459694, AA936951, AA422134, AA150960, AA029400, AW305179, AA046886, AA226401, AI935787, AW118839, R24074, AI803011, AI564140, AI797634, AI671022, AA084054, AA031539, AI831233, AA046979, H79028, H05830, AA033515, AW296225, N70304, R31733, AW296783, H28027, AA334000, F32723, H54170, AA031538, AI826552, AA421099, AW766234, D60652, AI696661, AA913310, AW383613, AI077484, AW383609, AW236130, AA652326, AI191597, H77423, AI435580, AI302073, AI675809, H54014, AI973084, AW383535, AW239479, AA496314, AI971370, AA233111, and AA629153.
HTTDF90	631	917155	1 - 427	15 - 441	AA301144.
HTTDG36	632	968131	1 - 347	15 - 361	AW052029.
HTTDJ21	633	869686	1 - 341	15 - 355	
HTTDJ65	634	973307	1 - 406	15 - 420	AC006030, AP000513, AB023052, and AC006140.
HTTDL38	635	573641	1 - 289	15 - 303	
HTTDL45	636	523452	1 - 291	15 - 305	AW292800, and AC007390.
HTTDL89	637	959837	1 - 328	15 - 342	W22023, AC004765, and AB002342.
HTTDN40	638	734318	1 - 373	15 - 387	AA182963, W39759, AA132990, H69405, R94355, T66121, H68623, H68650, N36314, R14722, AA166770, R70624, AA923755, AW385783, R69735, AA190899, R19750, T10743, H07954, H93885, AA164319, and AC005876.
HTTDN85	639	783444	1 - 435	15 - 449	AL137653.
HTTDO19	640	908937	1 - 320	15 - 334	
HTTDR91	641	790336	1 - 549	15 - 563	AA252780, T84947, and AC005740.
HTTDR92	642	573666	1 - 326	15 - 340	AC003046, AC002366, and AC003685.
HTTDS02	643	920589	1 - 418	15 - 432	
HTTDX84	644	921100	1 - 668	15 - 682	AA432195, AA435548, and AA431175.
HTTDZ54	645	692608	1 - 286	15 - 300	AW163244, H89834, W06845, N42782, N42829, N31946, and AI190785.
HTTDZ91	646	523206	1 - 300	15 - 314	AI762137, AW242639, AA044752, AA884207, AA235512, AI870472, D80100, D59403, W88874, AA481286, N92013, D31111, D31113,

HTTEB33	647	573719	1 - 336	15 - 350	AI167596, R10048, AA906542, AW087683, R49500, AI361492, AF155112, and AL137478.
HTTEH58	648	747943	1 - 307	15 - 321	
HTTEL50	649	745985	1 - 196	15 - 210	
HTTEU68	650	967819	1 - 1207	15 - 1221	AA134604, AA187575, T75572, AA083163, W42892, AI092672, T97891, Z44468, R34642, R14267, AI078644, AA354837, R48102, AA362636, R55924, AA497072, AW044159, AW377397, R17450, T78498, AA625142, R56338, AA258076, and R99732.
HTTEV62	651	573614	1 - 272	15 - 286	AI828837, AI015418, and AA953392.
HTTEY64	652	974107	1 - 450	15 - 464	
HTTEZ34	653	771602	1 - 498	15 - 512	
HTTFB60	654	869666	1 - 208	15 - 222	AW298813.
HTTFG35	655	778426	1 - 254	15 - 268	AA581033.
HTTFH70	656	757358	1 - 342	15 - 356	H64973, AA659316, AA649530, AI636734, AA047057, AA664924, AA157876, AA046906, AI940546, AW028376, H57802, AA420703, AI306717, AA019793, AA385652, AA359194, AA713538, AA713930, AA639056, AA837006, AI679759, AA135988, AA084148, AW019964, AA908682, W27084, AA602458, AA083850, AI679486, C75332, H62123, AA338238, AA055647, W85818, AI634466, AI890283, AC003973, AC006263, AF196971, AC007793, AF039907, U80017, AL049779, AC006530, AL022238, Z83820, AP000221, AL136295, AF011889, AP000084, AL049709, AC006142, AF109907, AL022721, AC004617, AL049780, AL049831, AL020997, AC004462, AC006211, AL049761, Z83826, AL031255, AL024498, AL133216, AC005529, AC006030, AC000134, AC004999, AC004934, AC007390, AL139054, AF111167, AC002314, U85195, AL109758, I59642, L77570, AC005346, AC002492, Z83822, AC006261, AE000658, L39891, AC007993, AC006064, AC005969, AC006950, U91327, AC007664, AL049759, Z97180, Z98949, AC007462, AC005484, AF045555, AC005821, AC006581, AC004659, AC002039, AP000355, AL035684, AC007157, AP000552, AC012099, AF001549, AL022316, AC006162, Z98044, AC005874, AF134471, AC005179, AC005527, AC007688, AC003086, AL049697, AL109984, AL078584, AP000550, AL049760, AC006023, AC004996, AP000692, AC001231, AC007022, AC002040, AC009288,

					AC007066, AC004876, AC005730, AC008018, AC005320, AL022394, Z82198, AC004148, Z75890, AL023281, AC005037, AC008039, AC006273, AC005516, AC009248, AP000299, AL079342, AC007684, AB023049, AC005031, AC004686, AC002366, AL022398, AC004019, AC006960, AC006417, AC003048, AL031577, AF038458, AC006079, Z81364, D87675, AC002310, AC005740, AC004913, AL096701, AC003071, AC000003, AC004491, AC005744, AL035587, AC004253, AL050307, AC005180, AC001478, AL117351, AC004890, AL031848, AC006241, Z98051, AC003982, AP000114, AC005722, Z97056, AL031432, AL050318, AC006538, AC005089, AC004750, AL049713, AC002070, AL096761, AP000353, and AL133163.
HTTFK90	657	787599	1 - 551	15 - 565	AI637920, AI657055, AA772352, AW316972, AI676064, AA904483, TI1417, D59503, D81111, D80014, D58283, D58246, D80258, D80043, CI4227, D80064, D80247, AA809122, D80251, C06015, AI535686, D80253, D58101, D59502, AA514184, C03092, C14407, D80366, AI557751, D80522, D80022, C14331, H67866, C14389, D50995, D59610, D51423, H67854, D80157, D80439, AA305578, D59859, D80166, C14014, F13647, D80195, D59467, D59619, D51022, D80210, D51799, D80391, D80164, D59275, D80240, D80038, D59787, D80227, AA305409, D80188, C14344, D81030, D45260, D80248, D50979, D81026, D80269, AW178893, D80212, D80268, D80196, D80219, D51759, D80241, D59927, D80024, C15076, AI557774, D51060, D57483, D59889, D80193, D80133, D80045, D80168, AA514186, AA514188, D60010, D80302, D51103, D80378, C14429, D59317, AW177440, C14298, C14973, C14957, D59627, D59653, AW360834, T03116, D51213, D51221, D59474, AI525917, C14046, C16955, AW360817, AI525920, AW377671, AW375405, AW360811, AI525235, D60214, C05695, C75259, D59551, D52291, AW178907, AI525227, AW178908, D59373, AW178906, AW378533, D45273, AI535959, AW360844, AI525923, AA285331, T03269, AW179328, D51079, D59695, D80949, T48593, AW375406, AW378534, AW179332, AW360841, AW377672, AW179023, AW178905, AW366296, AW177731, AI525912, AI525215, AW378528, AW178762, AW179019, AI525242, AW352170, AW378532, Z33452, T02974, AW352120, AW352117, AI525925, T03048, AW178914, AW378539, AW378542,

					Z21582, AW367950, AW360855, AW176467, C05763, AW378525, D80228, AW179020, AW378540, AW377676, AW352171, AW178774, AW177733, AW179024, AW179018, AW378543, AIS25237, AW177505, AW178781, H67858, D51250, AW352163, D51053, C04682, AW177456, C13958, AW178911, C14077, AIS25222, AW178775, T02868, AW178909, F13796, AW179004, AW179329, AW178980, AW177728, AW178986, AW178754, AW369651, AW352158, Z30160, AIS35961, D31458, AW177734, AA305720, AI910186, N66429, AW177508, T11191, AW179009, AW179012, AW177497, AW177722, AIS25928, AIS25216, AIS25228, D80654, AB028859, AI132110, AF058696, A62300, AR018138, AR008278, A84916, A62298, A82595, AR060385, AR054175, I14842, AB002449, I50126, I50132, I50128, I50133, A70867, AR008277, AR008281, AR062872, AR016808, AR016514, X64588, X67155, Y17187, AR060138, A45456, Y17188, A94995, D26022, A26615, AR052274, A43192, Y12724, A63261, A43190, AR038669, A25909, A64136, A68321, AR066488, Y09669, AR066487, A67220, D89785, A78862, D34614, A30438, I79511, AR008443, X68127, AF123263, AR016691, AR016690, U46128, D88547, AR032065, D50010, AR008408, and AR060133.
HTTFL89	658	974346	1 - 405	15 - 419	AC005551.
HTTFM17	659	750942	1 - 430	15 - 444	AI457366, and AI023804.
HTTFM66	660	950051	1 - 1145	15 - 1159	AA085574, AA490803, AA147472, AI239866, and AL049745.
HTTFS59	661	825922	1 - 842	15 - 856	AA228367, AA176965, AA228376, AA004521, AA251249, R00504, AA303183, AW136898, AA448887, R00605, AA229970, H50956, AA345572, AA040486, AA004604, AA177117, AW247896, T74926, AA566080, and AF045584.
HTTFT08	662	934460	1 - 441	15 - 455	
HTTFV93	663	925544	1 - 393	15 - 407	AA301328, and H78684.
HTTFZ70	664	974066	1 - 357	15 - 371	
HTTHH05	665	931004	1 - 592	15 - 606	AC004067.
HTTIG04	666	926752	1 - 390	15 - 404	
HTTIH23	667	869636	1 - 472	15 - 486	AW401826, AW408670, AA488824, and AB020677.
HTTIH80	668	869635	1 - 328	15 - 342	AC006443.

HTTIL06	669	934089	1 - 765	15 - 779	Z25007, A1758350, D80247, D50979, AA305578, C14389, D59275, D52291, D80195, D59502, D80164, D80193, D80439, D59467, D58283, A1525903, D80227, D81026, D80269, D59859, C15076, D80022, D51799, C14331, D80166, D80248, D80253, D81030, D59695, D51423, D59619, D80043, D80210, D80391, D80240, D80366, D80038, D59787, AA305409, C14014, D80212, D80188, D80196, D51022, D80045, D80522, D57483, D80219, D59627, D59927, H67858, D50995, D59610, A1525922, D51060, AA514188, D59889, D80024, D80302, D80268, D80133, D80378, D80251, D80168, D59474, D51103, C14298, AA514186, D80241, Z21582, D59317, D51213, D80157, T03116, D80258, AA809122, C75259, D80064, D31458, D59503, D45273, D59551, D59373, C06015, A1525914, F13647, H67854, C05695, C16955, T02974, C14077, T11417, T03048, H67866, D58246, A1525912, C03092, D80014, C14407, C14973, Z33452, C14227, T02868, A1535686, C14344, D52317, C13958, D51221, D81111, A1525907, C14957, Z30160, C14046, D51759, D59653, D45260, D58101, A1525242, A1557774, D60010, A1557751, A1525227, D51053, A1525235, A1525920, A1525917, N66429, A1525923, AA514184, A1525215, A1525216, A1525228, A1525238, A1525925, A1525237, A1525222, A1525969, A1535961, AR016808, AB028859, A84916, AJ132110, A62298, A62300, A82595, AR060385, AR008278, AR018138, AF058696, AB002449, X64588, I82448, I79511, I14842, AR054175, AR008277, AR008281, and AR060382.
HTTIN23	670	869634	1 - 539	15 - 553	AC002549.
HTTIU05	671	931015	1 - 573	15 - 587	
HTTIW81	672	922817	1 - 434	15 - 448	
HTTIZ05	673	930994	1 - 418	15 - 432	
HTTJA11	674	839725	1 - 406	15 - 420	A1522185, and A1889003.
HTTJA47	675	869618	1 - 417	15 - 431	
HTTJH13	676	869615	1 - 297	15 - 311	AC004859.
HTTJM01	677	913799	1 - 271	15 - 285	
HTTIQ06	678	934130	1 - 397	15 - 411	AL046690, AL046714, AA301225, AW405562, AC005027, AL132774, AC005050, AC004409, AC006059, AC007785, AC004673, Z99496, AL033397, and AC002488.
HTTJX68	679	974063	1 - 375	15 - 389	

HTTJY08	680	958170	1 - 430	15 - 444	AL023584.
HTTKD44	681	948750	1 - 434	15 - 448	AA300492, R69716, AA377913, AA096018, and AC003688.
HTTKF89	682	960928	1 - 411	15 - 425	AA301180, AA300961, and AL035425.
HTTKG34	683	915033	1 - 378	15 - 392	
HTTKK06	684	974311	1 - 584	15 - 598	
HTTKL80	685	974316	1 - 464	15 - 478	
HTTKN21	686	974310	1 - 504	15 - 518	
HTTKP07	687	911390	1 - 562	15 - 576	AI640500, AA035703, AF130247, and AF165138.
HTTKS13	688	926795	1 - 470	15 - 484	
HTTKV17	689	830008	1 - 416	15 - 430	AC005027.
HUDAM29	690	529157	1 - 214	15 - 228	
HUDBZ78	691	739638	1 - 366	15 - 380	AI799013, AW173341, AW072440, AI910986, AA620943, AA977595, AA913759, AI208578, and H56769.
HUDBZ01	692	869026	1 - 519	15 - 533	AC000070.
HUDBK39	693	886368	1 - 474	15 - 488	N88782, N88601, AA247964, N84855, H58760, N83168, AA095359, N89520, N83991, AA096046, AA247827, N83992, N55698, N84048, AA095641, AA096066, N88518, N84718, N86694, N83993, N84712, AA471338, N84830, N87989, N84829, S78798, U48696, AF103726, AR066487, AF039698, AF045432, AF102850, AF032922, AJ243486, and U39066.
HUDBE95	694	795796	1 - 316	15 - 330	
HUDBE64	695	746508	1 - 348	15 - 362	
HUDBE48	696	869034	1 - 423	15 - 437	AI651392, AI912649, AI690582, AA101690, H02616, AI139898, AA731894, AW269260, AW248051, C04885, AW137058, AI597917, R41929, AI401381, AI125561, AA394302, AI884475, AI913287, AI915152, AI753690, AA295249, AW088536, AI380436, AI632150, and AB020861.
HUDBE28	697	686520	1 - 360	15 - 374	AI697533, AW204092, and AI963731.
HUDBE02	698	917361	1 - 123	15 - 137	AA585476, T18597, R28735, R29445, R45895, R28967, AA170832, R29218, AA585325, N86592, R28895, AA283326, R28965, R28892, R29179, AA585098, R29657, R29177, C16293, AA585101, D61254, C16315, Z28355, AI546875, AI557734, AI557864, AI525306, D53472, C16300, D57491, D60844, R29262, R29172, Z32822, D60765, AI526140, AI546971, AI541365, AI557763, D59751, AI546999,

					AI547250, AA585439, AI557262, CI5406, D53447, D54897, CI5120, D53161, D52835, AI541383, AI541374, AI541356, D59436, D61185, CI6292, AI557740, AA585155, D55233, Z32887, AI526184, AI546945, AI525500, AI525431, AI546921, CI6305, CI5069, D57186, AI541517, AI547006, CI6294, CI5762, AI540967, AA092643, CI6290, TI9407, AI526194, AI541205, AI541535, Z30131, AI526078, AI525316, AI541013, CI5737, AI557731, AI526073, D60730, AI541523, AI557787, AA585356, AI546996, AI547039, AI526191, AI541307, AI525556, AI557758, CI6296, AI557727, AI546891, T41289, CI4208, AI526016, AI541346, AA174170, AI541527, AI525320, AA514191, AI557807, AI525339, CI4723, CI4322, CI4391, T41329, AI547202, AI557264, AI557155, AI547196, AI557084, AA585117, AI525286, AI557799, AI557408, AI547137, AI526113, AI557718, AI540920, AI541034, AI557809, AI526180, AI536138, AI526158, AI535639, AI526109, AI526024, AA585430, AI556967, AI557602, AI524890, AI541514, AI535660, AI540974, AA585453, AI557808, AI540903, AI546828, AI541390, AI541321, AI541506, AI541415, AI546829, Z33559, N87188, AI557279, AI526112, AI525332, AI541508, D54850, AI540882, AI546954, AI547189, AI526195, AI557796, AI541345, AI557039, N88113, AI657485, AI541422, AI546831, N88337, AI524904, D59458, AI557533, AI541515, AI541017, AI526117, AI546901, AI525656, N85682, AI557786, AI557802, N88532, AI557852, AI541027, AI557238, AI547071, AI540944, AI557285, AA585434, AI541410, AI525114, AI046024, D61060, AI547026, AI541492, AI048523, AI557041, AI557082, AI525168, AI557317, AI557810, AI525076, AJ243486, D50010, D13509, AR062872, AR062873, AR038855, AR062871, A25909, A20702, A20700, AF082186, Y09813, AJ244005, Y16359, AR054723, Z32836, AR038762, AJ244004, X81969, D78345, A43189, A43188, AR017907, AJ244003, X55486, AR018815, AC005913, A98420, A98423, A98432, A98436, A98417, A98427, AF045432, X82786, A98767, A93963, A93964, I63120, AJ244006, X76012, U39066, AR003381, U48697, and U48696.
HUDAK54	699	899753	1 - 822	15 - 836	AA247964, N88601, N89520, N88782, N84718, H58760, N84855, N83992, N83168, N83991, AA095359, AA247827, N84048, AA093224, AA096046, AA095641, AA096066, N83993, N86694, N84712.

						AA471338, N55698, N84830, N88518, N84829, AF154415, AF164678, AF165161, S78798, AF045432, AF103726, U48696, AF102850, AF039698, AR066487, AF032922, AJ243486, and U39066.
HUDAK19	700	671974	1 - 444	15 - 458		HI6933, AA149496, and AA531296.
HTTKG12	701	969547	1 - 461	15 - 475		AA172361, AI537800, AI791659, AW272815, AI355103, F23338, F34506, AI934307, AI246996, AI242614, AW407220, AL045476, H51835, AI869797, AA503258, AW238341, AI805261, F23327, AI587583, AI587565, AI720141, AI471455, AA808725, AI865980, AW151761, AA342238, AI246192, AA524800, AI927275, AW265688, AI281474, AL046416, AI687343, AW270619, AW023111, AW372037, R34070, AI310464, AI521525, C14014, AI539024, AA743811, AW069227, AA657835, AI801563, AA484892, AA947369, AA992877, AI249688, T71936, AA468923, AW020150, AI537368, N71619, H79308, AI280266, AA364082, AA218684, AA533463, AI251436, AA084320, AW302017, AA351840, AA610433, AA936718, AI858165, AA350644, AA904275, AA714011, AA298365, AW272389, AI445216, H59856, AW275719, AA719433, AA720582, AW104163, T07451, AL118980, AI880889, AA583386, AA550959, AA292254, AA018923, AI935827, AW419389, AA846923, R73744, AA128592, AL134441, AA714110, R56485, AA809104, AI821945, AI587349, AW439703, AI536625, AA533054, AI223968, AI568659, AA992126, F32248, AW274078, T39390, AI205181, AA630122, AI367473, T48723, AI024339, AA774794, AA632765, AC006511, AC005740, AC002059, U47924, AC002985, AL031985, AC006538, AC005102, AF196779, AL031281, AP000065, AC004797, I34294, Z84469, AL022721, AL022322, AC004611, AJ006216, AC005914, AL009174, AC005189, AC004941, Z84487, AC004955, AC007450, Y15994, AF001552, AC002115, AL034549, AC004675, U95739, AL080243, AF088219, AC005378, Z93023, AC005520, AC005089, AC005015, AC005324, AC005212, AC004087, Z98257, AC004913, AL049709, AB023050, AC006512, AB001523, AC005632, AP000014, AC004491, Z97054, AP000514, AC006211, AC007225, AC004531, AC006958, AP000355, AL136295, AL008718, AC004024, AP000240, AL050318, AC004905, AL122020, AC004134, AC002546, Z85987, AL035400, AC005566, Z99128, AC002549, AL109984, AC006515, AL049569, Z97184,

HTTKC85	702	956206	1 - 436	15 - 450	U85195, AC005529, AL035587, AC002347, AC005386, AL121655, AC000025, AC005591, AC004791, AL034418, AC006544, AB014540, AC005899, AC004659, AC005519, AL049643, Z82195, AE000658, AC007551, AC006371, AC007546, Z83844, Z98047, AC006285, AC006115, AC003043, AC005531, AC007032, AC005342, AC005264, AC006271, AC005670, AC005379, AL031291, AC005237, AF053356, AL035249, AC002536, Z84481, AC006197, AC009516, AC005730, AC008039, AC003962, AL034553, AL023575, AC009247, AL035683, Z96074, AC004216, AC020663, AC004655, L48038, AC003003, AC004158, AC005516, AC005280, AC004929, AC007541, Z93017, AL009179, AC005940, Z86090, Z93020, AC007731, AL021453, AC007055, AC003007, AF001548, AJ229043, AL049766, AL031602, AC004417, AL049699, AC004079, AL031005, AP000348, AC005082, AC007686, AL109798, AC004150, AC007842, AC000026, AC007387, AL117354, Z93024, AC005358, AC007371, AP001053, AC004896, AC005996, AC007226, AC005332, AL031594, AP000359, AL031431, AC004671, AC005274, AC005844, AC003101, AL117258, AL109628, Y18000, AC005017, AC007435, AC006530, AL049636, AC004912, AL035455, AL032821, AC007444, AL009181, AL031729, AC004139, AL121652, AL009051, AC007676, AC006124, AL031737, AC004167, AC005500, AF222686, AC006088, AC007283, AC005233, AR036572, U91328, AL049712, AL035460, AC006213, AC004890, AL035086, AL022302, AL035457, AC005746, U52112, AC005778, AL033527, AL031588, AF060568, AC007707, AC015853, AC009263, AC005043, U91323, AC006057, AC005913, AC005690, AC006270, AC005003, AC005071, U91321, AC007538, AF134726, AJ003147, AC007690, AL133238, AC004253, AL133445, AL121578, AC004834, M37551, and U02047.
HTTKC85	702	956206	1 - 436	15 - 450	AI224604, AA279200, AA258999, and W37285.
HTTJV79	703	869602	1 - 434	15 - 448	AA825972.
HTTJN26	704	869612	1 - 891	15 - 905	AI356567, N90525, AA232991, AI148171, AI022165, AA233101, AA573721, AA448133, AI306380, AA447991, AA127550, AA127551, AW016855, AA243852, AI473237, AI005068, AA554071, AA570256, AA906902, AW014761, and AI359627.
HTTJK06	705	934094	1 - 564	15 - 578	AA853292, AL117470, and AB023143.

HTIX05	706	931024	1 - 520	15 - 534	A1493098, AW024745, AA921917, W90789, and A1915946.
HTIR33	707	974323	1 - 341	15 - 355	AC004491, AL050307, AP000023, AC004884, AL078472, AL008715, AC007227, AC005180, and Z98304.
HTIR04	708	926772	1 - 557	15 - 571	AA083298, AA829975, and AB014535.
HTIN11	709	965920	1 - 801	15 - 815	AL133824, H86873, and H86809.
HTIE08	710	958169	1 - 427	15 - 441	AW052126, and AA101833.
HTIB12	711	969568	1 - 336	15 - 350	R92571.
HTIHJ56	712	944914	1 - 258	15 - 272	D81882, AA193637, AA234876, T83136, H11688, AA258658, AA306506, and AA252212.
HTIFG12	713	751809	1 - 359	15 - 373	AA169457, AA172190, and A1636076.
HITEZ61	714	742004	1 - 539	15 - 553	R13891, A1150008, and A1198021.
HTEQS9	715	739445	1 - 550	15 - 564	AA237056, AA491051, H78425, and R92491.
HTEQ01	716	917156	1 - 458	15 - 472	A1827837, A1142441, A1086379, AA813388, AA253028, H17296, AA613757, A1474835, and Z83845.
HTEO59	717	900662	1 - 148	15 - 162	
HTEOS3	718	728344	1 - 763	15 - 777	W74401, Z45510, H79976, D81436, D53762, and D61200.
HTESJ6	719	573669	1 - 492	15 - 506	R54109, A1884701, Z39259, R41821, and AW075808.
HTEB05	720	932294	1 - 373	15 - 387	C74999, T90424, AB023197, and AL031672.
HTIDO59	721	744438	1 - 734	15 - 748	R82651, R82700, AA372368, N79122, AA033606, A1546974, AL133016, AL122061, AB021868, AF034080, and AF032872.
HTTDM42	722	460948	1 - 389	15 - 403	R95162, and H91087.
HTTDL81	723	694222	1 - 392	15 - 406	AA485538, H74053, N43924, N43932, AA280231, AA613434, and AL022328.
HTTDL75	724	766551	1 - 356	15 - 370	AA199666, AL120288, and H18766.
HTTDA85	725	784537	1 - 408	15 - 422	N46977.
HTTCQ95	726	796674	1 - 310	15 - 324	N57049, and AW078548.
HTTCJ39	727	709581	1 - 469	15 - 483	AA012877, AA021074, AC007450, AC009533, and AC008013.
HTTCD06	728	960599	1 - 483	15 - 497	R22892, R30952, AA767622, D80460, D60956, A1800613, D60394, A1750009, A1453046, C15178, R81201, and D59944.
HTTCB87	729	524841	1 - 224	15 - 238	H80337, AA769820, R16729, A1091785, and AW273500.
HTTBR42	730	714220	1 - 329	15 - 343	AA164855.
HTTBP62	731	932997	1 - 601	15 - 615	AA341024, and AA249649.
HTTBO82	732	780164	1 - 422	15 - 436	N59547.
HTTBM03	733	925409	1 - 193	15 - 207	R96101, and AL050318.

HTTB180	734	781590	1 - 229	15 - 243	AA256038, and AA768241.
HTTBH95	735	530559	1 - 244	15 - 258	
HTTBH75	736	767520	1 - 422	15 - 436	
HTTBH36	737	530567	1 - 299	15 - 313	R21404, AC006987, and AFI46191.
HTTAQ60	738	742377	1 - 615	15 - 629	H73605, R92625, AA300822, and T77356.
HTTAP45	739	717736	1 - 384	15 - 398	AA300727
HTTAP21	740	671488	1 - 802	15 - 816	W94307, W79130, AA300911, AL023803, and AF086439.
HTTAP09	741	826343	1 - 427	15 - 441	AA189122, and AA300969.
HTTAN34	742	509454	1 - 455	15 - 469	AA252276, AA227154, AI656990, AA301077, AA301076, AL042627, AC004593, AL023574, and AC007536.
HTTAJ93	743	791413	1 - 406	15 - 420	R01464, AA300985, T87497, and Z75742.
HTTAH03	744	965134	1 - 282	15 - 296	AI198425, AI480040, AW054766, AI564875, AI359129, AI359233, AI422375, AI651642, AI056060, AA301255, T84917, T85537, T86503, AI954689, AI962153, T92050, AI742287, AA421072, AI244008, AA379174, AW135598, H84990, AA045378, H86604, AI580336, AA731146, R99375, H86921, AA007586, AA128609, AA062583, T85467, AA453722, H55168, AI200967, AA383353, T10083, and AA919169.
HTTAC77	745	772735	1 - 764	15 - 778	AI694695, AA913353, AW236100, AA846529, AW301152, N62629, AI366198, AA449338, AA694442, AI620459, W39523, AI521787, AA977228, AA600876, AA724335, AW078557, AA995242, AA860876, AW235851, W15410, AA456019, AA301436, AL122078, and AF198338.
HTTAA94	746	793001	1 - 555	15 - 569	AA191546, W91892, AA486427, AA694339, AA416561, AI140707, AA417297, H77647, H77648, W95110, AA303182, T19870, H26488, and AL031255.
HTTAA39	747	710355	1 - 284	15 - 298	AI800489, AW105035, AI480088, AW299975, AA303221, AI670831, and AA135748.
HTLIP06	748	934207	1 - 330	15 - 344	AI820928, AA405805, AI821678, AA813084, AA410617, AI821566, AA235536, AW302988, AI344933, AI344928, AW161579, AW268220, AI610756, AI537677, AA225339, AL036361, AI251221, AW103371, AI498579, AI683340, AI610645, AL041772, AW150578, AL038445, AI860537, AL036736, AI554245, AL119791, AL036403, AI815855, AA572758, AI627988, AI336592, AL039086, AI340603, AI866002,

AL079963, AI950664, AI349004, AW074869, AI633419, AI312428, AI859464, AI521012, AI251205, AI308032, AI344785, AI783504, AI284517, AI434281, AW081255, AI922901, AI888944, AI308035, AW023590, AI345347, AW129106, AL119748, AL038605, AW117882, AA427700, AL036274, AL040241, AI349933, AI800453, AI800433, AW059837, AW238730, AI433976, AI636719, AW169653, AW268251, AL042628, AI923768, AL121365, AI491852, AI572418, AI252023, AL119863, AI923989, AL042551, AI318280, AA508692, AI828731, AI564719, AW190042, AI281772, AI889376, AI681985, AI524671, AI345608, AW268768, AW051258, AW117746, AI921248, AI611738, AI590120, AI829327, AI619502, AI677796, AI306613, AI632408, AI802542, AL043981, AI497733, AA658033, AI499285, AW088134, AI886753, AI1174394, AI933589, AW026882, AI539153, AI269696, AL045266, AI620284, AI340582, AW002342, AI468872, AA640779, AI868831, AI539028, AW020693, AI334450, AA613907, AI335209, AI698401, AI445165, AI670009, AI862144, AI433157, AI702073, AL036802, AI873644, AW068845, AI648684, AI539771, AW403717, AI567351, AI340519, AI874166, AW071417, AI284509, AI633125, AL119049, AW103893, AI561299, AI476109, AI608676, AI446373, AI446003, AI922676, AI648663, AI036396, AW074993, AI349614, AI866608, AI888953, AI886124, AI250663, AL120853, AI224992, AI554218, AL042627, AI963216, AW301409, AW082594, AI571909, AI521560, AW149227, AI282326, AI343059, AW079159, AL036631, AI619716, AI284131, AL042544, AI312152, AI687065, AI612759, AW268072, AW089179, AI554425, AI926790, AI801325, AI500523, AI867042, AI696819, AA493647, AW075084, AI932794, AI280661, AI349937, AI699011, AW300889, AI349645, AI680498, AI537617, AI919345, AW088903, AI364788, AI500706, AI348897, AI307708, AI500662, AI251830, AI569583, AI866573, AI269862, AI366549, AL048871, AW118512, AI340627, AI916419, AL044207, AW073994, AI952217, AI569616, AI133559, AI611743, AI335449, AW151138, AI680162, AW083804, AW302973, AI696626, AI349967, AW268060, AW148716, AW005858, AI589993, AI250369, AL045997, AA494167, AW163464, AW022808, AW162071, AI608936, AI702406, AI689420, AI805603, AL049085, AL040456, AI289937, AI525669, AI436644,					
--	--	--	--	--	--

AW022682, AI869367, AW081797, AW080402, AL049314, I48978, I48979, AF113694, A08916, I89947, A08913, A08910, AL122121, AL122110, AJ242859, AL122098, U80742, AL050108, X65873, A08909, I89931, I49625, AL110197, AF113676, AL122093, S78214, AB019565, U72620, AF125948, AF146568, AL137550, U42766, Y16645, A65341, AL049283, Z82022, U00763, AR059938, X84990, AL133560, AF177401, AF106862, AR011880, AF118064, AL137557, AL122050, AL133557, AL110225, AF090896, AL117394, A12297, AF125949, AF158248, AF104032, AF113019, AF113689, Y11587, AF118070, S68736, X63574, AL080060, U67958, AL133080, A77033, A77035, AL050277, AL117460, AL137463, AF090901, AL050393, AL133565, X98834, AL122123, AL049466, E03348, AJ000937, AF113699, AF017152, AF113690, AL050146, AL049452, AF090934, Y11254, AL049382, AF111851, AF113013, AF113691, E07108, AL117457, AL137527, AF078844, X82434, AL110196, I33392, X70685, AL137271, E02349, AL117583, AL137459, AF183393, AL110221, AL133075, AF090903, AL050149, AL133016, AL080124, AL117435, U35846, A58524, A58523, AF113677, AL133093, AL133640, AL050116, AL080137, AF079765, A03736, A93016, AL137648, AL117585, AL133606, AF090943, A050024, AL049430, AL137538, AL080127, AL133113, X72889, AF097996, AF090900, AL050138, AF091084, I03321, AF017437, AF118094, AF087943, A08912, AL049464, AJ238278, L31396, AL096744, L31397, X96540, AL049300, AL049938, X93495, U91329, E07361, AL080159, I42402, AL137521, I09360, AL133072, AL137283, I26207, AF061943, I00734, E00617, E00717, E00778, AL133568, E15569, AF067728, M30514, AF119337, AL133077, AL050172, AJ012755, AR038969, AL133104, A93350, AL122049, AL137560, AF111112, AF003737, AR000496, U39656, AL133014, AF026124, A07647, S61953, AL137556, AL137526, E08263, E08264, U96683, I09499, AF026816, Y14314, AL137476, U58996, AL110280, Y09972, AF185576, AF057300, AF057299, AL137523, AF111849, Z72491, AF153205, E08631, U49908, AF162270, I17767, E02221, AL133098, AJ006417, A45787, AL117440, AF106827, AF079763, AR038854, AR013797, AL133067, L30117, Y07905, AL137429, X87582, X62580, AL133081, AL122111, X53587,
--

HTLID06	749	974047	1 - 648	15 - 662	AF132676, AF061836, AL080074, E05822, A90832, AF210052, AL137533, U68387, E04233, AL122118, AL110222, AL137480, AL137292, AC006371, AF081197, U62317, X92070, AF008439, AL137478, M86826, Z37987, E12747, AL080086, U78525, AL137294, AF067790, Y10655, L19437, A08911, U68233, I92592, and AL023657.
					AW238325, AA513916, AW169687, AI344844, AA371311, AI357551, D53046, AI880168, AW270284, AA554293, AA526514, AA371410, AI884861, D55004, D51877, AA317144, AI298977, D54301, D51997, D55588, AA384911, D51927, D56450, AI885465, R81453, AA365548, AW438916, AA364488, F13749, AI345654, AL135643, AI751162, AW162288, AI696793, AI565581, AA714140, R66997, AW128881, AI590404, AA586433, AW102955, AI914558, AA304790, H38817, AA295893, AA295899, AL040462, T06292, H41462, AA493829, AI214510, R48980, AW327597, AI359368, AI869786, AA572967, AW090629, AW327555, AL137946, AL137954, AW175641, AA583978, H21488, AI907629, AA373861, AW151727, AA658235, AA247731, N43757, AI630283, AI557323, AA435854, AA745560, AI761471, AA745431, AI053672, AA450199, AI801600, AA665293, AI345522, AA655002, R63239, AI921649, AI334443, AI859742, AW081359, AI376100, AI345459, AI336660, AA192740, AA178953, AI340453, AL043756, AW074059, AI064952, AI356904, AI922654, AI564284, Z96530, Z98884, AC004814, AC000114, AL135960, AI131016, AC007450, AC004382, AC007878, AC005034, AC006398, AE000658, AL031643, AL008627, AC006210, AC005370, AL031430, AC005386, AL021808, AC006965, AC006952, AC005822, AC004671, AC008134, AC004593, Z99570, Z84487, AC007970, AL034370, AC004074, AC000027, AC006548, AC004659, D87014, AC004552, AC003101, AC006213, AF011889, AC004616, AL132777, AC012331, AC006030, AL078593, AL008708, AI011930, AL133353, AL079305, AP000959, AL078476, AC004222, AC006544, and AL049829.
HTLHV59	750	965808	1 - 530	15 - 544	AA036821, AA877774, AA845452, AA902976, AW027037, AW245073, AI857490, AA948226, AA977183, AI819768, AW085596, AA363071, AA528041, AI804187, AW376089, AI763409, AI524117, AA622713, AW090272, AA973857, AI361156, AA515276, AI686841, AA971889, AI953946, AA595152, AI209096, AI474502, AA918802, AA581475,

HTLHU81	751	870150	1 - 863	15 - 877	AI888756, AI129507, AA371872, AW304826, AA632326, AI274834, AI799750, AI206384, AI290279, AI590567, AI340981, AI683971, AI802753, AA352552, AI739258, AA524697, AA417825, AI147766, AA018444, R49435, AW167804, AI281446, AW008926, AI570321, AI143414, AA648251, AA768690, AI468510, T91019, and T34395. AA488434, N76166, AA085536, AW390492, AA488573, AA375937, N39974, AA401426, AA307647, W05791, N64758, AI148945, C17327, C16676, C17892, AI200786, AI148951, T11417, D80258, C14227, D59503, D81111, D58246, AI535686, C06015, D80014, D80064, D80247, AA809122, C14389, D58101, D80195, AA514184, D80043, D59467, D80391, D59787, D80164, D59502, D58283, D51423, D80022, D81026, C14407, D80196, AI557774, C03092, D80168, D80227, C14014, AA305578, D57483, D59275, D80038, D80251, D80188, D50979, D80157, C15076, D80253, D80269, D80439, F13647, D80302, AI57751, D80166, D51103, D80193, D59619, D80210, D80240, D80045, D59859, C14331, AA305409, D80133, D51799, D50995, D80366, D81030, D60214, D80024, D59627, D59889, D80522, D80212, D80219, AW178893, D59610, D80268, AA400102, D51060, D51022, D80248, AA514188, H67866, D59927, H67854, AA514186, D51759, D80378, C14344, T03116, D59317, C14298, D45260, D80241, AW177440, D59653, D59551, D51221, AW360834, C14973, AI525242, AI525227, D59474, C14429, AI525917, AW360817, C14957, D60010, D59695, AI525923, D51213, AI525920, AW377671, AW375405, D45273, D52291, AW360811, C05695, C75259, T03048, Z21582, AW178907, D59373, AW178908, D51079, AI525235, AW352117, Z33452, C14046, C16955, AI525925, D80949, AI525237, AI525215, AW178906, AW360844, AA285331, AI535959, T03269, AW179328, T48593, AW375406, AW378534, AW179332, AW360841, AW377672, AW179023, AW178905, AW366296, AW177731, AW378528, AW178762, AW179019, AW378533, AW378532, AI525912, AW377676, AW352120, AW378539, AW178914, D80228, AW378542, AW367950, AW360855, AW176467, C05763, T02974, AW178909, AW179020, AW177505, AW352171, AW352170, AW178774, AW177733, AW179024, C13958, AW179018, T02868, AW178781, D51053, D51250, AW378543, AW378525, AW352163, C04682,
---------	-----	--------	---------	----------	---

HTLHU63	752	870147	1 - 515	15 - 529	AW177456, AW178911, AW378540, AW177734, A1525222, AW178775, AW179004, AW179329, AW178980, D31458, AW177728, AW178986, A1525228, AW178754, AW369651, Z30160, AW352158, C14077, N66429, H67858, AI910186, A1525928, AW177508, AR018138, AB002449, A82595, AR060385, AB028859, AJ132110, A84916, I14842, A62300, A62298, AR008278, AF058696, AR054175, I50126, I50132, I50128, I50133, AR008277, AR008281, AR016808, AR062872, X64588, AR016514, X67155, Y17187, A70867, AR060138, A45456, Y17188, A94995, D26022, A26615, AR052274, A43192, Y12724, A63261, A43190, AR038669, A25909, I79511, AF123263, A64136, A68321, AR066488, Y09669, AR066487, A67220, D89785, A78862, D34614, A30438, AR008443, X68127, I82448, AR016691, AR016690, U46128, AR032065, D50010, D88547, X72378, A63887, AR008408, Z82022, and AR060133.
HTLHS69	753	870152	1 - 659	15 - 673	R51662, H17203, R13772, R17328, and AF176701.
HTLHS05	754	933720	1 - 712	15 - 726	AW166505, A1085633, A1830616, A1948664, A1817701, AW183365, AW082276, A1471025, AA843215, W31421, AW439937, AA843291, A1476729, AA781027, and W04559.
HTLHK57	755	894863	1 - 1127	15 - 1141	A1348086, A1928156, A1074858, AW136076, AW243178, A1262696, AA627913, A1810972, AA595104, A1858055, AW043820, A1582191, AW001777, A1804955, A1798900, A1242330, A1887909, AW001248, A1813670, AW028151, A1336325, AW243042, A1299745, A1805058, A1923922, A1949719, A1741492, A1304384, M62028, A1276119, A1269740, A1684429, A1183994, A1401041, A1580934, A1097473, AA321296, AA480684, A1200633, A1719036, N42455, AA480650, W68465, A1348656, AA365138, AA335996, AW263563, T48387, A1648474, N66329, AA527274, AA863058, AA642939, A1277482, A1971175, AA884197, A1347141, A1863828, AA367149, A1474817, W68353, W25028, A1262960, A1054319, A1700621, H27099, AW205513, AA987972, A1015046, Z39325, W46985, R60687, T66319, F04561, A1656572, A1026748, F09789, F01927, F04682, A1521950, A1498629, H12192, A1214318, A1580497, H11935, AA136297, T15701, A1161214, A1890045, A1948515, A1866509, A1423812, T07980, and AB021226.
					AA504779, AA491394, AA699349, AA004906, AA778225, AA005001,

HTLHJ51	756	865399	1 - 1017	15 - 1031	and AA806914. AA418490, AA418620, AI922829, AI264627, AW002386, AI080674, R61294, AI424861, AI610381, AI263843, AA004548, AW075751, AW080659, AI275462, AA570113, AW271292, W60463, AA453156, AA599740, H09296, H23133, AI473729, AA454079, AA054336, T35266, T35000, AI54231, AW078913, AA502766, AW151599, Z45311, Z38523, N84063, T66912, T31030, R44925, AA363400, R49157, AI521799, AI348847, AI344931, AI038456, AI628833, AW196097, AI345114, AI307494, AI345677, AI340627, AI349622, AI310606, AI345370, AI307446, AI828705, AI312271, AI824648, AI349814, AW081242, AI561087, AI862144, AI312261, AI345224, AI340644, AI311892, AI345026, AI952217, AI582871, AW082033, AW268261, AI553669, AW074869, AI491904, AI241678, AI307210, AI336513, AI336662, AI307569, AI345253, AI344935, AI348895, AI345736, AI313320, AI343091, AI310575, AI336495, AI310920, AI313352, AI307503, AI307736, AI335235, AW029349, AI336585, AI349266, AI34452, AI349787, AI340533, AI344938, AI036215, AI312146, AI590423, AI309431, AI312339, AI340537, AI345258, AI348854, AW148590, AI345471, AI307459, AI334895, AI636595, AI307507, AI348879, AI349245, AI311604, AI349805, AI343131, AI310930, AI349269, AI312333, AW168503, AI310945, AI312431, AI439089, AI038775, AW071380, AI573085, AW020381, AI335363, AI742068, AI311159, AI620093, AI348897, AI345397, AW054972, AI334930, AI307520, AI887775, AI340664, AI307542, AW132104, AA848053, AI349637, AI866465, AI334902, N75771, AW150804, AI336488, AI336565, AI311440, AI345737, AI345396, AI874109, AI922756, AI860694, AI349971, AW268253, AI047422, AI348969, N71180, AI567971, AI366959, AI358042, AI343140, AI366992, AW059828, AI349276, AI539690, AI345315, AA468418, AW274192, AI349645, AI345735, AI349246, AI242736, AI307708, AI865116, AI335476, F31233, F36033, AI345745, AI340659, AW071377, AI050666, AI345005, AI633061, AA427700, AI309443, AI343030, AI619754, AI690930, AW058233, AW021373, AI040694, AI271234, AI623736, AI349186, AI349279, AI310592, AI312325, AW071395, AI345739, AI345674, AI312143, AI340511, AI334920, AI446405,
---------	-----	--------	----------	-----------	--

AI345014, AI345251, AI923357, AI310927, AI307578, AI436429, AI345608, AI349955, AI307456, AW075093, AI312432, AI635690, AI811840, AI581048, AF104032, AL035067, AI8777, S77771, X98834, E12580, A08910, A08907, A08909, M19658, AR068466, A08908, I09360, A08912, AR038969, AL133016, A08911, L13297, AF085809, AL137547, X63574, S76508, I89931, A08913, AR000496, U39656, AR053103, I89934, I89944, X69026, I49625, AL133606, AR034830, I96214, AL110225, A21101, AR038854, AP000130, AP000208, AL050024, AL050108, AL117394, AL137648, AL133098, AC002471, AC005374, AF177767, E12579, AJ242859, AF159615, A12297, AF118090, AF143957, AF185614, AL080057, AJ006417, I77092, AC009501, E01573, E02319, E02152, E15582, Y13653, AL049465, AL136884, AF031903, AF141315, E05822, M30514, AL133557, AL137471, Y09972, U62966, AL133112, A08916, AB022159, AC006313, I48978, AL080086, AR054987, AF118064, AF013249, AL122111, I36502, AL049460, AL080127, U87620, AF090896, AL137527, AF182215, U51587, A17115, A18079, AC002382, E08516, U67813, AL050143, AL137526, AF061836, AF125949, U68387, E03671, AF132676, AL137523, AF061836, AF125949, U68387, AL137656, AJ012582, AL096751, AL137555, AL133072, E01963, AF061573, X83508, U88966, A57389, U36585, AL133093, U92068, U02475, AL137640, X62580, U91329, I18355, U57715, AF106827, AB025103, E01812, I17767, AL080158, I34392, Y10080, S68736, AL110222, X62773, X96540, I89947, AL080118, A70386, AF022813, AL137461, M96857, AR060156, Z37987, AL050116, S69407, Y08616, AF180525, AB030279, AF019298, Z82206, AC006197, AC006112, AC007869, AF172930, AF100781, AF076464, A20553, AF090923, X99257, X70685, AL117583, AF017790, AL133075, X99717, AL096720, AF114168, D16301, I08319, AL049276, I29004, X66417, I41145, AL080060, AL137429, AL122049, AF175903, AL137557, Y11587, U67958, AL133080, A76335, AF210052, X89102, AL137554, X84990, I61429, AL117649, A91160, E07108, AL137712, AL117443, AL110224, AF139986, AL137659, A91162, AF081197, AF081195, AL110218, AF126372, L19437, AL133085, U00763, X57961, X72387, AF106945, S61953, D89079, AF114818, AF036941, X55446, AL117585,					
---	--	--	--	--	--

						X92070, AF017152, AL137281, E08631, AF205861, AL122045, AL133077, AL050146, U49434, AL133014, A27171, AF146568, AL137705, AL050393, AF079765, AF098162, I68732, X59414, A90832, AL117629, U77594, AL137300, AL110159, M84133, AF111112, AB019565, A92311, AF012536, AL133104, AL137556, Y16258, and AF114170.
HTLHB93	757	945862	1 - 361	15 - 375		AI828062, AI028564, AW173227, AW102657, and AL035460.
HTLHA63	758	870172	1 - 554	15 - 568		AI218545.
HTLGS10	759	963458	1 - 470	15 - 484		AI560769, AI857497, AW151454, AW298056, AW007781, AW166326, and AW339468.
HTLGR32	760	928245	1 - 943	15 - 957		AI126041, AA812952, AA770544, N26185, AI222967, AA813689, AA815395, AW119183, and AA912724.
HTLGP84	761	782194	1 - 534	15 - 548		AA709009, AI570570, AA708887, AA062549, AI871015, AA757855, R41916, H80820, AA719341, AA701030, H30641, AA063144, AA757876, AA063046, R87769, H79988, AI003643, AW138067, R12796, and AA758374.
HTLGK08	762	958304	1 - 463	15 - 477		AA813640, AI766152, and AW403165.
HTLGC43	763	870228	1 - 484	15 - 498		AI653373, AI917476, AI650958, AI684722, AI632004, AI962304, AI341785, AW195932, AI653363, AI672453, AA778499, AA613494, AW197798, AI968944, AW001758, AA813413, and AA279933.
HTLEQ92	764	932882	1 - 296	15 - 310		AI962454, AI432386, AI087321, T08978, T77035, R12108, AI093960, R51395, AW196322, and AL117444.
HTLEP21	765	671151	1 - 402	15 - 416		AA737807, AW296355, AI694694, AI950417, AA448944, AI341643, AW083848, AA316241, AW076055, AI341859, AI950236, AW452665, AI796355, AI338467, AI367080, AF081280, AF079325, and U67172.
HTLEN77	766	772363	1 - 410	15 - 424		T89583.
HTLEM92	767	573400	1 - 419	15 - 433		AC005695, AR049867, and U75586.
HTLEL16	768	384492	1 - 425	15 - 439		R21318.
HTLEG67	769	751842	1 - 305	15 - 319		AI149770, AI809937, AA644408, AI808767, AI913293, R06443, and R06497.
HTLDZ81	770	778180	1 - 351	15 - 365		
HTLDW27	771	961353	1 - 587	15 - 601		AI479021, AW339781, AW276999, AI369304, AW392460, AI391729, AW392463, AW392466, AW392459, AW392461, AW392468, AW392462, AW372446, AI903603, AB028990, AF014461, and

HTLDO01	772	913669	1 - 703	15 - 717	AF032667.
HTLDG43	773	715439	1 - 123	15 - 137	AI198827, AA397596, AA435832, AC002036, and AC000036.
HTLDB18	774	868533	1 - 436	15 - 450	
HTLCZ79	775	572853	1 - 273	15 - 287	R18251, and C06467.
HTLCX66	776	578921	1 - 318	15 - 332	
HTLCO02	777	921045	1 - 429	15 - 443	AI360679, and AI217856.
HTLCG65	778	413333	1 - 129	15 - 143	AA420979, and AC006060.
HTLCG59	779	530039	1 - 205	15 - 219	AB007918, and AF202893.
HTLCA03	780	870290	1 - 236	15 - 250	
HTLBH67	781	751985	1 - 432	15 - 446	W19592, and AC005368.
HTLBC07	782	954111	1 - 662	15 - 676	AA626715, AA403001, and AW003923.
HTLBB72	783	766270	1 - 711	15 - 725	AW401867, H88137, W19173, AW390017, AI088172, AI970225, AW134697, AW390006, AI971802, AA991241, AA906307, AI808864, AA781530, AI918830, AA742991, AA936350, AI478204, AI523622, AA808091, and AA923464.
HTLAI30	784	690936	1 - 562	15 - 576	R40037, R60927, AW005925, Z41798, and F01644.
HTLAF33	785	870300	1 - 432	15 - 446	
HTLAC61	786	683247	1 - 153	15 - 167	T27009, Y18503, and Y18504.
HTLAC39	787	575343	1 - 214	15 - 228	AA323644, T94592, AA298192, N55287, AW162762, AA525407, AA167549, AI459879, N99245, AA522864, AA579082, F00937, W69639, AA132445, F04838, AL133906, AL133902, AA745302, AA297698, AI253376, AA457230, AL046416, N22837, AA568390, N35492, AI207476, AA657910, AI354233, AA523833, AA584756, T73021, AA155817, AA365056, AA363890, AL047480, H87756, AA831997, AA368329, R99076, AI636734, AA338216, AA847427, AW028179, AA357979, AI653783, AW057873, AA809179, AL138091, N34258, AW245354, AI073735, AA847508, AA553830, W52705, AA653291, AA629852, AA632765, F34605, R93224, AI471467, AA668711, AA302763, AA467740, AA654293, AI471455, AA468135, AI734119, AA352521, AI732720, H43183, AI475294, AI687343, AA368201, AW392414, AA133013, AI733856, AC005914, AP000501, AC002111, AC004862, AL132987, AC005547, Z74617, AP000359, Z92845, AL031985, AC005332, AC011456, AC006992, AC007225,

AC005412, AL009174, AC005399, AC002375, AC002299, AC000070, AC006197, U52111, AL050337, AC009946, AL022721, AB023049, U24498, AC005300, AL031283, U95740, L39891, AL022163, AL035541, Z86090, AC004531, Z99716, AC004673, AL035534, AC006512, AL035089, U47924, AL078581, AP000141, AL035413, AP000088, AL035405, AC002470, D87675, AC002565, AP000344, AL034420, Z98044, AF111168, AC005821, AL031293, AC005235, AC005670, AC002425, AC006130, AC005796, AC009516, AC005058, AP000556, AP000557, AL049692, AL033504, AC005379, AL133382, AC002077, AL031295, AC004587, AP000495, AC002483, AC005702, AC006101, AC007388, AL133371, AC007151, AC005057, AC000035, AC007731, AL022313, Z98941, X64467, Z83838, AC004148, AL022238, AL049869, AL035072, AC005998, AL022326, AL121748, AC002302, AL035587, AP000065, AL049814, AC002472, AC003043, AC006023, AL136295, AD000092, D63861, AL030996, AL033381, AC006116, AC004098, AC005014, AP000343, AL022322, AP000114, AP000046, AC004242, Z97053, AC005899, AL049569, AC004893, AC006146, AL022316, AC003086, AL109801, AC004816, AL049553, AC004383, AC004813, U72790, AC000025, AC005089, AL050319, AL031662, AC006543, AL031587, AC007387, AC006544, AC000085, AC002326, AC005527, AC004079, AC005500, AL109963, AP000493, AC004882, AC007216, AC004858, AC003687, AL122023, AC004491, AF109907, AC004883, AL137549, AF020662, AC004790, AC005265, AL049653, Z98750, AL023575, AC007868, AC006141, AC004466, Z81365, AC008115, AC006210, AC005669, AL049570, AP000513, AP000353, AC009263, AP000550, AC002314, AL133163, AC006080, AC004985, AC004841, AC006486, AR036572, U91328, AL021878, AC002511, AC005272, AL034344, AC005826, AC006379, AC005800, AC008018, AL031007, AP000352, AC004849, AC006449, AL080243, Z93244, U80017, AC006538, AC006011, AC004106, AC005529, AC005160, AC007565, AC003972, AC004792, AC007546, AC005182, AC007746, AL031984, AC005005, AC009247, AF196779, AC008078, AC006312, AC009731, U82828, Z83836, AC005324, AL031729, Z99129, AC003108, Z93017, AF047825, U07000, AC005066, and AC005839.					
---	--	--	--	--	--

HTLAB55	788	732480	1 - 451	15 - 465	T65363, and F11993.
HTLAB29	789	879168	1 - 432	15 - 446	AA023022, H51019, AI309636, AI569285, AI431902, R90861, AI740858, and R23430.
HTFBE02	790	920507	1 - 571	15 - 585	R92414, AA197116, F00607, AI923217, AI814569, AI804663, AI762903, AI804682, AI143304, AI082030, AI139520, AI911904, AW274978, AW450838, AI216343, AI183410, AA680119, W93273, R92413, W93272, AI918971, T51116, AI823928, C15320, R42713, T51024, T96094, AI422647, AI216344, T96093, AI936703, AI869077, F00114, AI741425, C00216, Z66165, and Z56024.
HTEQS95	791	972746	1 - 654	15 - 668	
HTEQS90	792	973426	1 - 667	15 - 681	
HTEQP03	793	870516	1 - 584	15 - 598	AI652668, AW196588, AI611041, and AI696211.
HTEQN83	794	908528	1 - 331	15 - 345	AA442506, AA436703, AA080897, AA219287, AA214213, AA332559, AA356572, AW197626, W86428, AA083980, AW239273, AL042822, AW137277, AW197400, AW197285, AA772083, AW206752, AA854258, AI934409, AL096747, AB021642, AB021644, and AB033024.
HTEQB08	795	958291	1 - 711	15 - 725	AI144505, T83402, AW439340, and T81586.
HTEPY28	796	870559	1 - 682	15 - 696	AA412612, AA412499, AA719038, and AI149873.
HTEPV63	797	870549	1 - 917	15 - 931	AI217359, AA229749, AI990822, T80962, AI393339, AA935552, AC005844, and AC006205.
HTEPE35	798	948475	1 - 825	15 - 839	AI935040, AA861064, AA933697, AA707583, AA872105, AA398866, AA609626, AA620685, AA435866, AA812556, AA781805, AA993718, AF012362, AI217888, and AA824315.
HTEOY82	799	948845	1 - 489	15 - 503	AA724785, AW341727, AI990635, AW138616, and AJ010949.
HTEOO83	800	836721	1 - 720	15 - 734	AA885943, AI807908, AI214900, AI810745, AA725810, F31353, and H91431.
HTEOE28	801	870581	1 - 846	15 - 860	AI222323, AW274395, AW104230, and AA917623.
HTENY44	802	870588	1 - 320	15 - 334	AA860344, AW449340, AI188119, AW241563, AI218844, AA725683, AA860397, H48932, AA398488, AA416572, AI654971, AA719259, AI797656, AI337070, AA416676, H52862, AA402604, and AL137366.
HTENV06	803	933294	1 - 479	15 - 493	NA1901.
HTENS74	804	773925	1 - 544	15 - 558	NA1653, AI879320, AI879319, AW249274, AI928959, N33827, AA701980, AA156930, AA777363, AL047958, AL048281, H95107,

HTENR26	805	870595	1 - 292		W68434, AI015217, AA364327, W68552, AA909383, W32502, AI188322, AA906240, AI741757, AA021053, AA329553, R16958, AW401707, AA281392, H00750, AA032085, W25157, N88679, AA534002, AI142442, AA552483, T85967, T75519, H94009, AI985732, AW248852, AI362972, AI240796, AI929211, AI129518, W84587, W84606, AI708380, AA156806, AA954310, AI369295, AA745783, AW291743, AI096816, W88714, AA301938, AI167203, AA356672, F23466, AA666297, W60290, AA922513, W37200, W02166, W60381, AA090596, AI040943, AA535548, AA628365, AI937756, AA576306, AW206638, AA927434, AI565666, AW292178, AI266717, AA181912, AI078402, AA429252, N24950, AA430649, AI189422, AI348358, AI690429, R55029, AL047959, AI811153, AA430402, AI741768, AA774634, AI567256, AI400297, AI004611, AA488479, N93305, AW406490, AA582428, AI554548, AI048282, AW193651, T79324, H54744, AA321085, AI866522, AA037421, W79170, AI239605, AA352112, AI439069, W74366, AA096370, F37003, F33844, AA649533, AI300497, AA995088, F13662, AA632491, AA86406, N83253, AW272778, AA721011, AA744603, and AC004148.
HTENQ92	806	790908	1 - 639		AW374010, AI360575, AI018337, AW188121, and AC005879.
HTENP08	807	958382	1 - 433		AW188190, AI026684, AA861425, AI656213, AI656331, AI148424, AI597882, AA978263, AI806072, AI560944, AA609392, AW103266, W19795, AW341673, AA135775, AA131502, AI274049, AI559891, AA131402, AI797927, and AA135731.
HTENL95	808	795314	1 - 652		AW293376, AW002918, AI206147, AW235254, and AI968897.
HTENL73	809	974363	1 - 705		R95033, H98000, H15506, H54108, Z43087, and F07410.
HTENA08	810	958380	1 - 193		AW368483, AC004671, AB015617, and AB029004.
HTEMY05	811	880592	1 - 349		AW118931, and AI205921.
HTEMV66	812	813038	1 - 456		AA074939, X85715, and AA193675.
HTEMU66	813	944419	1 - 1078		AA430250.
					AL039924, AL045794, AW013814, AL036630, T02921, AL044412, T24119, AL044364, T24112, AW450335, AL039476, D51250, D80253, D80043, AL040992, AL039109, AL038531, AL037726, AL039629, AL039625, AL039648, AL038837, AL039074, AL039678, AL039108, AL039538, AL039564, AL039156, AL039659, AL039566, AL039509,

AL039521, H00069, AL039128, AL044407, AL036973, AL045337, AL037051, AL045353, AL039386, AL039423, AL045341, AL042909, AL039410, D59787, AL039150, AL044530, AL038821, AL038025, D80219, AL036725, AL043422, D59275, AL043445, AL039459, AI535983, D80227, AL043586, AL043423, D80240, AL043441, D80210, D51423, T23947, AL036650, D80134, AL036196, D59619, D80391, AL037639, D80193, AW451070, AL037615, D80196, AL036767, C14227, AL039085, AI535783, D80949, AL036117, D80366, D59927, AL037526, AL042334, AW452756, D80168, R47228, AL036238, AL036679, AL037601, T11051, D81026, AL039504, C14014, D50995, C75259, AL039842, AL036964, D80045, AL036733, AL036158, AL037027, AL036924, AL037054, D59889, AL036765, T23659, AI557751, AL038851, T23658, AL037177, AL036998, D80022, AL037047, AL044413, AW293068, AL037643, AL036227, AL036418, AL036133, D80038, T11417, AL037082, AL036163, D58283, D80195, AL036207, AL037124, D81030, D80188, AL037021, AL036191, AL036167, AL036132, AL037049, AL037679, AL036190, AL037600, D51799, AL036139, D80378, F13647, D80522, T03269, AL036152, T23656, C14429, T48598, D50979, D80212, AL036900, Z21582, AL037178, AA514190, AL048425, AA285331, AW451416, D59502, AL043613, D58253, AL039555, AL043585, D80166, D59859, AL037085, D80268, D80269, Z25782, AL037569, D80024, D52291, C14331, AL036174, AL036808, AL036953, D57483, Z99396, D59610, AW450376, AL044178, D80241, AL036150, D81111, AI910186, D80164, D59627, C14389, H00072, C15076, D59467, D51060, AA305409, AL036268, AW178893, D51213, D51079, C14298, AL038043, N47620, D80251, AW177440, D51022, C14407, AL044447, AW179328, D80014, AW178775, AL037077, AW378532, AA305578, D80064, AW352158, D80248, D59695, AI905856, AW369651, D51097, AL043840, AL037002, AW178762, AA514188, AW177501, AW177511, AA514186, D80133, AW360834, AL039417, AW360811, C05695, Z25783, AI557774, AW135155, D80258, T02974, AW352117, AW176467, AW375405, AW378540, AW377671, AA809122, AW366296, A25909, A85396, A86792, A44171, A85477, X68127, AR062871, A84772, A84776, A84773, A84775, A84774, AR037157,

				AR017907, AR062872, AR062873, AR067731, AR067732, A58522, A91750, A20702, A43189, A43188, A98767, AR031374, I56772, I95540, AR038762, A95117, A38214, A98767, AR031374, I56772, I95540, AR018924, A97700, A63067, A51047, A63064, AR018923, A48774, A63072, A95052, A48775, AR068507, A18053, AR068506, A93963, A93964, A23334, A75888, I70384, AR043602, AR015960, AR043603, AR043601, A58521, AR000007, AR015961, A18050, A60111, A23633, A10361, A23998, AR007512, AR020969, I60241, I60242, I63120, AR054109, I03343, AR031375, AR022240, A58524, A58523, A81878, A24783, A24782, E12615, AR035193, A92133, E14304, A27396, AR027100, I28266, A49045, E16678, A82653, E16636, I06859, A93016, I25027, AR000006, I26929, E13740, I44515, I26928, I26930, I26927, A58525, I49890, I44516, A58526, A91753, AJ244003, AR025207, I18371, E06034, AF156296, A13038, A29289, AR029417, AF156294, AR067733, AR029418, AR067734, A64081, AR028669, AR028668, AR028667, AR028670, AR017908, A68112, A68104, A98467, I62368, AR031488, I13521, I52048, I44531, A84746, A17115, AR028672, A18079, AR038066, I50882, I15353, I66495, I66494, I66498, I66497, I66496, I66486, I66487, A71440, A71435, A67220, I13349, A07699, E08322, I74623, A60109, AJ244004, U87250, I00081, A70040, AR028564, A83643, A98420, A98423, A98432, A98436, A98417, A98427, A83151, I01968, A13388, E00974, A02228, E00954, E00952, E00953, E00955, I08049, I43960, AR021440, E03165, E02221, E13364, A10360, E02679, E02104, E02098, A92666, E02001, E01718, E02003, E02102, E03550, A28163, E02100, E01997, A58998, E02291, E02292, E02293, E01999, E02396, E02327, E01563, E02431, E01693, E01696, A92668, AR005163, AR005154, AR005157, AR005160, I09250, AR005153, A92667, E01024, AR050583, AR050584, E02430, E01148, E12527, E01503, AR005165, E12523, E02432, A49701, A62009, E01216, I77211, A95096, I70974, I31847, I31848, AR060673, AR060676, A95106, A95105, A80476, A91965, E01324, I08638, A80474, A94048, A94061, A80477, AR035224, A80475, A94046, A94054, I63560, AR031529, A49428, I63561, I63563, and E16036. AW182380, AI016150, AA436052, AI016144, AA459652, AI110776, AC007227, AC004536, and AL049761.
HTEMS01	814	915308	1 - 576	15 - 590

HTEM058	815	964769	1 - 475	15 - 489	AI026760, H54090, W90174, AI016127, and U22296.
HTEMN80	816	775543	1 - 301	15 - 315	T80539, and AI719083.
HTEMM91	817	938396	1 - 378	15 - 392	AI655972, AI809237, AI872211, AI377032, AI381901, AA523409, AI150552, AI248517, AW328508, AA523391, AI241274, AA609120, W92335, AW194863, AA580479, AI912966, AW243314, Z25384, AI217725, AA531424, AI142666, AW137703, W56565, W56787, AI678791, FI7380, R95131, AW057531, and AI825787.
HTEMI51	818	870613	1 - 583	15 - 597	AI149866, and AA918162.
HTEMB57	819	849214	1 - 456	15 - 470	AA398093.
HTELY90	820	787549	1 - 356	15 - 370	AI022425, and T86122.
HTELV29	821	806421	1 - 627	15 - 641	AA083981, AL043302, AL050276, AF194030, and AF185576.
HTELP07	822	952274	1 - 550	15 - 564	AI005651, AA502325, and AI005304.
HTELM71	823	954982	1 - 509	15 - 523	AA843728, AW303661, and AA813137.
HTELA02	824	918699	1 - 602	15 - 616	AI651239, AW268856, AI024356, AI016924, AI016923, AI698585, AA609414, AA620951, AW072208, AI696034, and AI340253.
HTEKU62	825	754010	1 - 713	15 - 727	RI3043, AA402245, W03238, and AA293855.
HTEKI62	826	812862	1 - 472	15 - 486	AA741257, W23913, AA769417, AI923864, AA099994, AA113016, AI633572, AI129921, AI740509, AI087861, AI198728, AA451698, AA811514, AW328432, AI345992, AW135872, AI865582, AA769447, AA716235, AA946657, AI818126, AA742292, AW025858, AI092084, AI864067, AI992065, AW027054, AI129952, AW105702, AA527064, AW166911, AI969997, AW263370, TI2481, AI571406, AW243885, AA192190, AW134596, AI143876, AI143870, AW136628, AW009874, AI475650, AA063520, F21628, AA781441, F37014, AW074003, AI928446, AA736768, N91862, AA774271, AI611242, AW363815, F33207, AW328431, AI470616, H39778, W76151, W72588, AW444846, AW368798, AI479056, AI861919, AI223368, AI760686, AA973718, AA991724, AA804626, AW449436, AI217528, AI246328, AI391628, AA977169, AI222649, AI453599, AI825699, AI968087, AA910938, AW294100, N74597, AI587076, AI738417, AI818572, AI347378, and C00207.
HTEKH17	827	942526	1 - 643	15 - 657	
HTEKD77	828	772397	1 - 414	15 - 428	N47372, AA029276, AW173125, T51928, AW197647, AA436376, N56847, AI142573, AA885319, W26719, AI961121, R52187, AI032543,

HTEJV94	829	793039	1 - 381	15 - 395	AW009278, T51718, AA992217, W37315, A1370687, AA495856, AI073556, AL041264, AF147339, and AP000533.
HTEJO46	830	717850	1 - 388	15 - 402	AI628611, AA416585, AA420969, AW271467, AI831883, AI928360, AA421125, AW001638, AA397955, AI656005, AW016672, AW003460, AL110224, and AC003669.
HTEJN12	831	653252	1 - 443	15 - 457	R72953.
HTEJL30	832	696784	1 - 386	15 - 400	AA223373, AL096763, and Y18004.
					R92318, R97141, D61526, W58524, R13204, AA333107, AW163212, R55599, H23092, D52777, AI929587, C05240, R19781, D61319, AA150352, Z46053, AA355121, AA296708, AA323111, D53669, R26633, H08329, AA317832, AA322876, W01316, AA973604, AA374431, R49663, AA296782, H23093, H85812, AA149563, AA318184, AI368381, AW088920, AI253781, R40292, AI928933, AI857794, AI452755, AI160425, AA975568, AA961868, AI718865, AA776210, AA025635, AA337795, AI191849, W73632, N79435, AA679726, AA865487, W78161, AW339133, AI582690, W58412, AI744177, AA902205, H97698, AI338657, AI338667, AW452422, AI187166, AA330474, AA333363, AA976009, AA126618, AJ239435, AI572582, AA085720, R55362, AA360533, AW166355, AI879369, AW163740, AI752339, AI302066, AI954021, AA355733, T57729, T60002, AA332269, AW160676, AW403792, AA111927, D61306, N31004, AA064830, W79204, D53612, AA961222, AA845309, AA186387, W07796, W73680, N58648, AA642523, AA151815, AI805801, T30103, D54012, T36033, AA393418, AF092135, and AL109701.
HTEJC70	833	490772	1 - 587	15 - 601	R94482, and AI004651.
HTEJB07	834	953801	1 - 451	15 - 465	AA993947, AW134645, AA884829, AI004532, AI150514, and AI239661.
HTEIS34	835	887112	1 - 371	15 - 385	AI002739.
HTEIS25	836	870660	1 - 390	15 - 404	AI208897, AI187424, AA682756, and AI187850.
HTEIN26	837	684711	1 - 403	15 - 417	R72964, W76526, R64535, and U82396.
HTEJL36	838	708304	1 - 425	15 - 439	AA417003, AA835058, AI424995, AI220270, AA694436, AW182313, R20520, AI382131, AI004786, AA418740, AA418795, AI190974, Z39070, AA742556, and AI809322.
HTEJL58	839	491030	1 - 528	15 - 542	N71729, N71226, AP000041, AP000109, and AP000285.

HTEID15	840	395868	1 - 247	15 - 261	
HTEIB38	841	839966	1 - 318	15 - 332	AA724539, and AA960890.
HTEIB37	842	870671	1 - 336	15 - 350	
HTEIB03	843	921926	1 - 223	15 - 237	
HTEIA57	844	734983	1 - 489	15 - 503	N38963, and R92356.
HTEHX57	845	734976	1 - 442	15 - 456	AW451115, AI863336, AW104507, AI692981, AI652017, AI827145, AI017283, AI955549, N33485, R76560, AW409808, AI207003, AI202422, and AI927281.
HTEHV11	846	967439	1 - 561	15 - 575	AA916546, AI204535, and AI021331.
HTEHS17	847	664436	1 - 391	15 - 405	AA424196, AA846387, AI797455, AA778547, AW340809, AI217364, AI188208, AI150580, AI123441, AI027637, AA770175, AI150190, AF012356, AA909271, AF012355, and AA442327.
HTEHJ11	848	964956	1 - 242	15 - 256	C04728, AA381098, N45678, AA480568, W69682, AA397755, AA476511, AA476550, AI860245, AW024421, AW382036, AW382039, AA838817, AW382042, AW382037, AW381999, AW382041, AW381961, AW382000, AW381997, AA934010, AI363359, W69923, AW190384, N36268, W44317, AA181315, AI864889, AA130883, AI745226, AI934734, AA187057, W38774, AW382054, N26942, AI469219, AI380284, AI380273, W45689, AI057575, AA725447, AI360479, N48961, and AI057565.
HTEGW02	849	920628	1 - 1006	15 - 1020	AI288698, AI914273, AI203577, AI696478, AA913934, AA812691, AI573252, AI936975, AI015501, AI280024, AW054753, AA975903, AI371833, AI160502, AA844728, AA687959, AA393300, F34643, AA813782, T53463, AI091343, AA435624, AA595143, T53462, AI364294, and AI217827.
HTEGU55	850	931017	1 - 376	15 - 390	R61288, R05576, AA778664, AA280073, AB014581, and Z98752.
HTEGS24	851	932987	1 - 598	15 - 612	AA256743, AI374955, AI123527, AA251700, AA455406, AA429834, AA618437, Z28611, AI433315, AA331686, AI498096, AW203957, AI377211, AA770064, AA808245, AA828466, AA098810, AA331825, AA814045, AA101241, AI078061, AA625885, H53435, AA357747, and D42054.
HTEGJ74	852	765901	1 - 474	15 - 488	RI3795, and RI4717.
HTEGJ56	853	732630	1 - 607	15 - 621	N32789, AA992305, AI829630, AI453589, AI037906, AA490671, N47354, AF106857, and AF026169.

HTEG138	854	709420	1 - 356	15 - 370	W87922, and AA694342.
HTEGH60	855	545137	1 - 207	15 - 221	AI125270, AI025275, AI017509, AA724721, AA970833, AA904629, and AC002128.
HTEGC30	856	690998	1 - 463	15 - 477	N51343, AI341075, AI967945, AL035252, Z79996, AL031775, AL021978, AC002384, and AC002455.
HTEFX90	857	887616	1 - 568	15 - 582	N41791, AI734225, W21309, AF026169, and AF106857.
HTEFU18	858	666920	1 - 623	15 - 637	AA011636, AW136535, AA641738, AI242200, AA972854, AI357112, AI252660, AI919234, AI732405, and AW379801.
HTEFO46	859	719280	1 - 537	15 - 551	AA188885, AA189066, AA834951, AA971947, AW389450, AA856992, and AA189065.
HTEFO28	860	685383	1 - 470	15 - 484	N78395, and H45135.
HTEEU78	861	530196	1 - 327	15 - 341	AL044999.
HTEEU35	862	707717	1 - 102	15 - 116	AC004259, and AC004600.
HTEEU27	863	575476	1 - 275	15 - 289	
HTEEU18	864	530203	1 - 348	15 - 362	AA442512, AA002017, N68854, AF122013, AF064102, AF000367, and AF064103.
HTEEU17	865	530200	1 - 371	15 - 385	
HTEET22	866	675071	1 - 395	15 - 409	N55308, AI201311, and AA709195.
HTEEF25	867	677513	1 - 329	15 - 343	AA461517, AL040379, AI825108, AL040378, AC007981, AC011718, AC008103, AC012330, AC007708, AC007324, AC009288, AC008079, AP000550, AC007325, AP000552, AC008018, and AC008132.
HTEEB82	868	780161	1 - 326	15 - 340	H53320, R97852, AI032585, H53321, R97802, AL033351, and AL034424.
HTEDX39	869	530201	1 - 246	15 - 260	AC005726.
HTEDX04	870	927850	1 - 330	15 - 344	AF111169.
HTEDX03	871	925353	1 - 190	15 - 204	AW002847, AC005300, and AC006946.
HTEDW96	872	881958	1 - 539	15 - 553	AA101046, AA860334, AI240068, AI381744, AA064659, M79124, AB006626, AF132607, and A86973.
HTEDW59	873	530448	1 - 201	15 - 215	AI139615, and AL117627.
HTEDV86	874	785818	1 - 497	15 - 511	W87362.
HTEDU53	875	727362	1 - 443	15 - 457	N75217, AI827641, and AI313263.
HTEDS40	876	934047	1 - 496	15 - 510	N64316, and AA418089.
HTEDS06	877	960645	1 - 839	15 - 853	AA557354, AA004230, AA702179, AI671185, AI924143, AI609113, AI056239, AI638795, AI337375, AA634413, AW250803, AA417152,

HTEDO75	878	767024	1 - 184	15 - 198	AL135398, AA478510, AA195614, AA190630, AI814763, AA827285, AI091408, AI638180, AI080126, AA632206, AI379107, AI288872, AI263619, AA626405, AI679151, AI754325, AI769841, AI559213, AI679722, AA417030, AA552345, W93249, AA007263, AI969543, AA766364, AA534494, AI038181, AA960978, AA449336, AA573241, AW043937, AA725439, AI291838, N73539, AA189108, AI699813, N73585, AW104716, AW166044, D19671, AW192890, AA454518, AA621586, H73339, N54283, AA910989, H14801, H05808, N56013, H75580, AI038699, AA248270, AA149737, H70079, AA808510, AI806228, AI806407, AI628327, AL079833, W93248, AA478509, and AF044588.
HTEDK72	879	766343	1 - 339	15 - 353	AI693509, and H95965.
HTEDJ92	880	522827	1 - 294	15 - 308	
HTEDJ63	881	508086	1 - 310	15 - 324	Z98257.
HTEDI09	882	522969	1 - 397	15 - 411	AI797509.
HTEDI01	883	961028	1 - 230	15 - 244	AC006960, AC005015, AL035249, and AL049569.
HTEDH90	884	909165	1 - 403	15 - 417	R79137, AA314329, AA323430, U69560, AC007731, and AC005500.
HTEDH76	885	522940	1 - 208	15 - 222	AC004945.
HTEDH42	886	615250	1 - 459	15 - 473	C03196, C03292, F00515, AA361228, AW003009, AA626353, AW403239, W67213, AA314421, W05346, W63719, AI346486, W24987, D12319, D11537, AA423922, N45183, AR053393, and AF092130.
HTEDH30	887	522936	1 - 237	15 - 251	AL049697.
HTEDH17	888	522938	1 - 371	15 - 385	
HTEDH06	889	869427	1 - 392	15 - 406	AC006251.
HTEDG75	890	890715	1 - 358	15 - 372	
HTEDG26	891	519947	1 - 384	15 - 398	AW246994, AA421090, AA421091, AA397662, AA375279, R83399, AI638717, AA306667, AA747622, and AC000378.
HTEDF96	892	614726	1 - 323	15 - 337	AA242852, AA252186, AI129391, AA743400, AI934605, AA531278, AA705950, AA418351, AA834128, and AC006942.
HTEDF70	893	522977	1 - 294	15 - 308	AC004983.
HTEDF60	894	742368	1 - 356	15 - 370	AI656191, Z21349, and Z21348.
HTEDF22	895	908406	1 - 291	15 - 305	AC002418, Z83843, and AC004386.

HTECE66	896	522997	1 - 403	15 - 417	AW241925, and AC005232. N80927, AA400153, AI027600, W58447, AA813400, AA746206, AI139801, AA828177, AW375643, AI279610, AI359755, AA444123, AA443944, AA569017, AA451805, AI089230, AI632987, AI338403, AI262825, AA767495, AI005034, AA453635, AA454013, AI560993, AW250814, T30813, AW149100, AW327945, AW207031, AA629893, AI342923, AA922333, F37015, AI745194, AA676942, AI086189, AI276499, AW058509, AI682025, AW004973, AW009042, AI367703, AI445623, AI241535, AA441932, N73089, AW295548, AI188497, F04870, F10561, W58482, Z41848, T35208, AA548624, AI094343, AA923598, AW440500, W76342, AW080667, AI720047, T17396, R37034, F22096, R39180, AA833987, AA197182, AA426126, AW363378, AI797280, AA196359, T19458, AI743371, AA090309, R34367, AA446271, T61317, AW407104, N71508, AA075086, AA383602, C21530, AI371957, AA192312, N22129, N91820, AA374751, AA213591, AA813578, H43284, H97310, C00318, T10425, T98391, AA832076, AI049609, AA740854, AA349688, AA369853, and AL035405.
HTECE62	897	523002	1 - 407	15 - 421	
HTECE61	898	789732	1 - 543	15 - 557	
HTECE51	899	870723	1 - 301	15 - 315	AI025190, AL137266, AC005071, AC005488, AC004878, and AC006014. AA804334, and AW007980.
HTECE39	900	650885	1 - 389	15 - 403	
HTECE31	901	508104	1 - 284	15 - 298	
HTECE08	902	960428	1 - 421	15 - 435	
HTECD94	903	527210	1 - 318	15 - 332	
HTECD88	904	527214	1 - 342	15 - 356	AA406427, H66890, H64867, H66639, H69191, AA693972, AA410436, AA931060, N38830, H48140, AI247909, AA251684, N23377, N76083, AA887276, T61107, AW328038, AI681235, AW328039, AA608986,
HTECD70	905	527203	1 - 324	15 - 338	
HTECD65	906	533795	1 - 328	15 - 342	
HTECD56	907	527209	1 - 178	15 - 192	
HTECD15	908	523029	1 - 402	15 - 416	
HTECC71	909	508142	1 - 370	15 - 384	AA406427, H66890, H64867, H66639, H69191, AA693972, AA410436, AA931060, N38830, H48140, AI247909, AA251684, N23377, N76083, AA887276, T61107, AW328038, AI681235, AW328039, AA608986,
HTECC45	910	508124	1 - 317	15 - 331	

HTECC26	911	508144				H72100, N71448, AA188574, C02442, H70867, R94076, AA394213, AA487534, T68446, AC005185, AL121877, AC006039, AL121578, AC006458, AC005544, AC005014, Z84481, AP000261, AP000100, AP000035, AC004696, AC002094, AC008040, AC005774, AC006157, AC005284, AL049834, AL080250, AC006150, AF048727, AL022393, AC004448, AC007001, AF129077, AF165147, AC008009, AC004202, AP000518, AC002383, AB023054, AP000692, AC003119, U91325, AC006355, AL031542, AC005853, Z69722, AL031315, AL035461, AF011889, Z83826, AC004975, AC008085, AL022318, AC004664, AC005862, Z76735, AC004746, AC007286, AP001101, U80460, U91324, AL133162, AP000075, Z97180, AC002531, AC002511, AC003034, AL135922, and U95738.
	912	678659				AA393147, and AA398551.
HTECC09			1 - 403	15 - 417		AA306529, AA306591, AA826008, AI089960, AA887528, AI333816, AA513786, AA524465, AI125407, AA541685, AA446158, AA315157, AI185832, AA603451, AI660483, AI871796, AI138696, AI563976, AI141745, AI479416, AI304867, AA938482, AI342761, AA281870, AA102814, AA586819, AA526476, AW157657, AI878833, C14084, AI815670, AI879393, C15292, AA931242, AA125855, W19566, AI081138, AA248470, AA070996, D59838, AW138570, AI660905, AA42677, D60576, AA776763, AI038860, AA527168, AI879973, H72163, AI096871, AA887522, AA535032, N29179, AA437187, C15125, AW163651, AA100697, AA070617, AA126067, AA682431, W21262, R58065, AI217985, W95562, H64391, H91983, AA352582, N53018, AA125841, AI356704, AA927737, AI336049, AA889266, AW272440, AA502617, AA431548, AI184304, AA833674, F35247, AA369535, W39436, AA281586, AA575968, W95435, AI056604, AI350076, C14543, AA878900, AA947125, W15344, AI537988, C15570, AI085201, AA732059, AI184964, AI569557, AI301035, AA429855, AI889555, AA513631, AI000301, AA592946, AA317358, AI797215, AA727271, AA758447, AA721039, AI339315, AA947500, AI149920, W37085, AA682224, AA962818, AA552223, C15228, AI073583, AI051738, AA737832, AA303269, AA548883, AA991817, AI869608, AA923511, AW297214, W07566, AI222563, AA991676, AI301328, AI376085, AI080573, AA364733, AI031902, W04779,
			1 - 353	15 - 367		

						AA878574, AA600861, AA779628, AA091291, AA322774, D81321, AI039006, D60527, AA782434, AI202852, H89937, AW192683, N80835, AA356010, AA301770, AA304243, AA129809, H91874, AI198092, D60707, T93983, N20273, AI271711, W24482, D60706, and AA369534.
HTECC08	913	960439	1 - 341	15 - 355		
HTECA44	914	508135	1 - 427	15 - 441		AW086066.
HTECA39	915	508132	1 - 408	15 - 422		
HTEBP54	916	728811	1 - 736	15 - 750		R62332, H17378, and R25901.
HTEBO43	917	715704	1 - 304	15 - 318		AI928432, AI291335, AI803224, AI298002, AI985197, AI924618, AA489696, AA489695, AI806154, AW138014, AI241232, AW291969, N36798, AA436451, AA765512, AA743624, AA020798, AA848065, AA436498, AI221817, AI768422, and AA015614.
HTEBM87	918	503275	1 - 278	15 - 292		AA383834, AA383833, AW117332, and AW268492.
HTEBL53	919	578544	1 - 355	15 - 369		AA383796.
HTEBJ02	920	921321	1 - 408	15 - 422		H73473, and AA383702.
HTEBH09	921	870732	1 - 560	15 - 574		AI204211, AW274576, AI285857, AA383617, AI394396, AA442838, AI218526, AI214386, AA781925, AA725598, AA758847, AI671527, and AI125254.
HTEAX06	922	960792	1 - 413	15 - 427		AW300891, AW182267, AI002121, AI393590, AW268430, AA812869, AI363725, AI937132, AI370331, AA431750, AA383228, C20655, and AI537879.
HTEAV22	923	679394	1 - 449	15 - 463		HI6258, AI362696, AA159083, AI337351, AI049674, H05276, AI963664, AA612853, AA421018, RS0945, AA398617, AI276451, AA868365, and AA383003.
HTEAU39	924	503295	1 - 428	15 - 442		R45446, AA994896, AI285099, AI419926, AI219508, AI650680, R41613, AA383142, AI264406, AI942371, and AC005752.
HTEAT17	925	667184	1 - 298	15 - 312		AA416657, AA394107, AA629341, AA382909, AI075928, AI150321, AI204602, AW022487, AA397912, AA862555, AI066604, and AA442269.
HTEAS02	926	921323	1 - 527	15 - 541		AI203924, AA383061, AI215017, and AA861908.
HTEAR93	927	503298	1 - 361	15 - 375		AA383056, and AA383057.
HTEAQ55	928	732562	1 - 1106	15 - 1120		AI979276, AW117497, AW269774, AA701653, W46209, AA778787, AW269767, AI218590, N20493, W28100, AA039403, AA781351,

						A1025502, A1696076, W26315, A1281715, AA088596, N25525, A1220590, AW136955, AA758981, AA406069, AA972182, A1634149, AA628118, A1819755, A1215556, AA039283, N33500, A1218587, W46210, AA382922, A1476428, A1766748, AA724549, AA723963, R84858, R85787, AW087598, AW275213, C20812, and AC004805.
HTEAJ96	929	503533	1 - 421	15 - 435		AA382756, and AA382755.
HTEAH75	930	503546	1 - 324	15 - 338		AA382618, and AA382617.
HTEAG47	931	503623	1 - 411	15 - 425		AA707221, H91075, AA677780, H90565, AA382495, AA382494, and A1825267.
HTEAG08	932	960469	1 - 322	15 - 336		AW298466, AA382538, AA504454, and AA382537.
HTEAB50	933	724751	1 - 310	15 - 324		AA459803, AA382330, AW084476, AW118229, AA770485, A1393130, and AA894604.
HTEAA04	934	925522	1 - 533	15 - 547		AA431127, AA432144, and AA382138.
HEPCB04	935	941270	1 - 512	15 - 526		A1917109, AW003912, A1080595, AA235033, AA235201, AW450977, A1969306, AA193652, AA193549, A1928801, R22829, T69554, AA588382, N94214, N80329, R17380, AL023581, AF153605, and AF151861.
HEPBO92	936	952996	1 - 427	15 - 441		W80428, A1281960, W58699, AA417821, A1191334, AA524259, A1140335, A1272028, A1198251, A1279567, A1077948, W58105, AA976989, A1279283, AA568684, N75444, A1768190, AA471035, A1042070, H27894, R69416, A1207043, A1093933, AA931805, AA057072, AA776787, A1356687, N89605, A1830795, H20193, A1125808, A1125797, A1160353, A1394538, A1336185, A1858974, A132347, A1268758, A1298093, A1298398, A1268851, A1191106, AA976789, A1184456, AW000778, AA479904, AA976567, A1184383, N80954, AA328860, AA482453, A1338345, A1042254, N68172, N80657, A1813413, N68196, A1343021, AA705334, AA931904, AA532627, AA721003, AA715390, W69319, AW327781, A1301403, W58698, W58215, N68260, AA481706, W05193, N54740, A1086220, AA159198, A1369601, A1074994, A1184042, AW439353, W69215, AW149380, H03721, H19993, H83921, H02830, AA428492, AW071418, N80631, R98136, H83779, R69545, A1800014, AA603925, H20384, H72739, T35392, A1026120, H50256, A1370680, A1554686, AA356398, AA765315, AW150959, AW008524, AA513681, AA481467, and R48307.

HEPBO85	937	783362	1 - 679	15 - 693	A1090010, AA779356, R70094, A1088640, R79670, R28363, R39498, and AF121177.
HEPAY26	938	825778	1 - 180	15 - 194	A1678727, A1373871, AA335883, R47985, A1915014, and AA586390.
HEPAX40	939	535627	1 - 726	15 - 740	A1888322, AA149051, AA149050, A1081764, A1985657, A1862905, A1082688, A1559607, AW151020, A1275490, A1824512, A1240781, AW294730, A1370307, A1925301, A1491857, H28424, H39903, D62631, A1956009, and AL137566.
HEPAX16	940	667665	1 - 473	15 - 487	A1216316, N95121, AA524146, AA826400, A1572953, AA576084, AA243582, AA693835, AA648272, AA830864, AA872868, A1083498, A1278286, R64633, A1919073, F25383, A1624649, A1380699, AW027102, R64632, AA975873, AA971324, and AL035416.
HEPAQ35	941	707533	1 - 520	15 - 534	T86787, N47173, AA335769, AA406114, A1560856, AA410382, and AA774453.
HEPAP34	942	703336	1 - 669	15 - 683	AA458879, AW138005, AA406623, A1749863, A1299810, A1968830, A1084067, A1749131, AA335721, A1473485, AA976661, AA464428, AA411695, AW130055, C03960, A1880337, A1904562, AA864979, AA781665, A1198298, AA430699, A1275029, AA706499, AW206841, C01121, and A1695779.
HEPAN05	943	932893	1 - 477	15 - 491	A1218711, A1918047, A1918977, A1288674, A1085618, A1139776, F29008, AA335421, A1929165, F35667, AC004751, and AC004646.
HEPAK04	944	933039	1 - 477	15 - 491	A1004158, AA335529, AA847893, A1262232, AW292700, A1950883, AA808598, AW183055, AA505961, AA478576, AA255751, A1468599, A1417159, A1678423, AW043579, A1333775, A1521274, AA009947, A1379044, A1089360, A1027938, AW173026, N49409, AA417796, AA173415, R94723, A1972464, W31503, H63962, A1703182, AW193647, A1741193, AA456887, AA470626, AA885985, D30922, and AC006557.
HEPAJ14	945	657440	1 - 231	15 - 245	H26683, and AA335271.
HEPAJ04	946	933091	1 - 353	15 - 367	A1219496, A1187819, AW085963, AA335263, AA669515, AC007993, and AC002094.
HEPAE58	947	509130	1 - 348	15 - 362	R46509, AA335475, AA335926, and Z63111.
HEPAE02	948	921389	1 - 211	15 - 225	AA484651, AA335440, and AC004887.
HEGBC03	949	922550	1 - 290	15 - 304	A1445299, AW005649, A1470184, AB032959, and AL021393.
HEGBB67	950	751233	1 - 340	15 - 354	AW295266, A1765278, A1261553, A1367242, A1050799, A1433693,

						AI672068, AI308137, AI769877, AW003759, AI201838, HI8343, AI761277, AI823875, R85423, HI8100, AI760769, AI984928, AW149699, H20325, R84272, AA860751, AI369859, AI262936, AI474901, AA013231, AA013325, and HI8141.
HEGBA01	951	915596	1 - 425	15 - 439		T51466, and AC006333.
HEGAX04	952	927260	1 - 522	15 - 536		AA236038.
HEGAQ01	953	789940	1 - 261	15 - 275		H54234, AL037663, W84821, AJ012221, AJ007014, and AL031319.
HEGAL55	954	731654	1 - 423	15 - 437		AI962879, AA133284, AI863307, AI679213, AA768727, AA417760, AI083774, H95609, AI538225, AW09962, AA516124, AA417846, AW196578, AW074110, AI168476, AI825102, and AI885413.
HEGAJ08	955	959216	1 - 557	15 - 571		AA059456, AA040649, R60003, AA058951, AI970861, AA662962, AW268083, and AA045527.
HEGAC02	956	918992	1 - 519	15 - 533		AA813370, and Z93016.
HEEAY84	957	782706	1 - 370	15 - 384		N77524.
HEEAX09	958	912065	1 - 400	15 - 414		AW305246, AA405462, and AA336099.
HEEAW40	959	710655	1 - 385	15 - 399		AA176878, AA984649, and AB009973.
HEEAP59	960	738892	1 - 401	15 - 415		AA083887.
HEEAM25	961	677599	1 - 771	15 - 785		AA086139, AI088145, AW131790, AI857700, AI283095, AI813629, AI917113, AI478664, AI919281, AI967944, AI499083, AI655215, AW136596, AI767765, AI825582, W16832, AA831238, AI381212, AW028578, Z19309, AA912593, AI497888, H86248, AA019370, and AF061261.
HEEAH94	962	794257	1 - 332	15 - 346		AI832117, and T60136.
HEEAH76	963	769950	1 - 503	15 - 517		T90469.
HEEAH57	964	734488	1 - 475	15 - 489		AA158378.
HEEAH16	965	661827	1 - 598	15 - 612		W94212.
HEEAG51	966	930810	1 - 430	15 - 444		T51329, R55106, AW298352, U73637, AF015416, and AF083108.
HEEAG12	967	724929	1 - 546	15 - 560		AA577763, AA633422, AL037129, AA400644, AI814562, AI951746, AA160713, AW273309, AI760380, AI829095, AI830606, AW410028, AA069839, AI762794, AA740152, AI079211, AI831826, AI436417, AA715294, AW248582, AI479090, AI446523, AI564707, AI580739, AI718353, AI114856, AI031714, AI979218, AW020139, AI927726, AI625558, AI803385, N63450, AI499665, AA609811, AL041488, AI559675, AA808909, AI805112, AA721567, AI356504, AW131446,

321

AL031430, AC005192, AL118497, AP000345, AL021394, AC006077, Z69705, AC005013, AC007372, AC005681, AC004754, AC004757, AL049837, AL109938, AC005667, AL024507, AF186194, AF020802, Z75746, AC005881, AC005530, AC002544, AC007666, AC006132, AB023056, AF165926, AC007999, L09706, AC000378, AC000052, AC005206, AL031671, Z83843, AP000555, AJ004799, AC002487, AL031391, AC006344, AC004019, AF019413, AC006539, AP000502, Z11740, AL109847, AP000514, AL049839, AB014080, AC004067, AP000520, AF117829, AP000687, AC005204, AC006039, AC004558, AJ229041, AL022721, AC007066, AC002295, AC006441, AC004206, AL096773, Z83826, Z83841, AC004887, AC005962, AL034394, Z94054, AC005694, AC004860, AC004167, AC003991, U91326, AC007687, AC006952, AL023875, AJ011930, AL117356, Z82976, AP000354, AL050321, Z98742, AC006222, Y18000, AC020663, AC003663, AC005570, AC008981, AL034421, AC002525, AC004448, AC004858, Z83844, AB023048, AL035407, AL022101, AP000511, AL133246, AL031685, AC006251, AL023575, AF109076, AC005006, AL135745, AJ003147, AF165147, AF109907, AC006008, AF050154, AC005529, AL133243, AC006427, AL049653, AL035458, AC004520, AL096703, AC005034, AC004021, AC006198, AC006236, AC005531, AL022332, AC006992, AC004922, AL035073, AC009731, Z98304, AL021877, AL079342, AF129077, AC007546, AC007860, AC004912, AC006449, AL035455, AC002299, AL121756, AL121653, AC006557, U92032, Z84489, AF053356, AC005510, AC004655, AL035681, AP000432, AC006121, AC004813, AL020995, AC005324, AF111169, AL031650, AC008282, AC005913, AC006011, AC005829, AL031594, AL022401, AL049776, AL133312, AC016027, AC004213, AL021918, AP000350, AP000457, AC005343, AL022400, AC007225, AC005668, AC002375, AC007172, Z93403, AL133245, Z93017, AL034402, AL035608, Z84487, AC005874, AF134471, AL022723, Z95889, AL136504, AF107885, AL133297, AL109758, AC000353, AC005828, AC004474, AL031602, AF134726, Z69710, AL121577, Z73900, AC007560, AL021938, AC006120, AC006026, AC008101, AC007376, AL021154, AF011889, AC002531, AB000879, AC005971, AB000882, AC002402, AC002455, L34079, AL020997, AC007387, AL137191,					
---	--	--	--	--	--

HEEAD13	968	470886	1 - 182	15 - 196	AC000134, AL135879, AL121790, Z95437, AL034430, AC005320, Z82203, AC005684, AP000506, Z82215, AC015853, AL008583, AC004973, AC004158, AC005832, AC005060, AC002996, AC016830, AL133304, AC003102, AC002536, AC009241, AF052041, AC006313, AL049539, AC007283, Z82196, AC005567, AC007298, AJ010395, AC004762, AL049757, and AL021397.
HEEAB40	969	710668	1 - 414	15 - 428	N44039. R08794, AI470646, AA506458, AA303007, AI002941, AI933534, AI691091, AI903462, AW380254, AA011026, AW021735, AW275510, AA493695, AA321168, AA455670, AW089101, AI311927, AA131035, AI933658, AA019312, AA635739, AW338179, AA676971, AI460009, AW004884, AA788982, AA188676, AI633390, AL045739, AI584186, AA679154, AI431240, AI469968, AA179944, AI888752, AI005388, AI872020, AI927741, AA834707, AA223174, AA358515, AA527209, AL042225, AA847515, F25733, AW193461, AA600869, AW022897, AA101689, AI268334, AI268336, AW276827, AL120343, AL046205, AA572713, AA584612, AI687343, AI249573, AI696595, R07234, AW023865, AW168618, AW270343, R68223, AW265009, C75026, AA467820, AI611569, AI611598, AL043009, AL045053, AA468244, AW020340, AI133164, AI345157, AI521632, AI246409, AA570385, AL037042, AW075998, AW193265, AA420998, AI350211, AW340844, AA421078, AI860020, AI953275, AA613345, AA279421, AI619997, AL119713, AW302903, AA720702, AW402237, AI149478, AI860013, AI962874, AI017251, AI110595, AA568494, AW102846, AW439562, AI754653, AI199137, AI110688, AI754658, AW104030, AA355083, F27407, N49368, AA580808, T77680, AA789192, AW169038, AA338904, AI271126, AA747070, AI500453, AW273218, AA662478, AW167374, AW178018, AW177870, AW131155, AA494089, AL038705, AA833896, AA833875, AA584167, AA577906, AI311684, T40308, AI932599, AI133297, AI744995, AI251082, AI631317, AI309643, N27584, AA837600, AW050726, AA468022, AW438643, AA834792, AI085719, AA480792, AA838190, AA640410, AA640430, AA357991, AC003070, AL034428, AL122020, Z93096, AC005660, AC009411, AC002426, AC006568, U82828, AC003009, Z85996, AP000350, AC005005, AL049843, AC004687, AP000556, AP000557,

AP000552, AC009516, AL034429, Z71183, AL023879, AL121825, AC004016, AP000351, AC005800, AC005753, AP000352, AC005155, AC006336, AC006350, AL080241, AL035587, AC005833, AC006236, AC007686, AC005771, AC005899, AL049760, AL022316, AP000553, AC003691, X55922, AC007114, AC004233, AL031228, Z85987, AF001552, AC007546, U91318, AL110292, AF001550, AP001056, AC000088, AC000071, AC005703, AL136295, AF002997, M87917, U04355, AC005512, Z84718, U18181, AC007225, AC004893, AL079295, AC007036, AC005071, AC005736, AC007536, AL008716, AC005091, AC005007, AF109907, AC008042, AF001298, AC004173, AC004397, AP000304, AC004192, AF000047, AC005233, AC006962, AL133382, AF003626, AC004975, AP000115, AF000504, AL008721, AL034420, L78833, AL022101, AL031767, Z84466, AC000025, AC004837, AC005519, AC005844, AC005527, AL132716, AL009172, AC005088, AC006017, AC004945, AC006120, AC003035, AF129756, AL031054, AC005539, AL109628, Z95114, AC007308, AC005529, AL035541, AC007263, AC004491, AC002368, AC005781, Z99755, AC005412, X87344, AC006254, AL031294, AL031055, AC005988, AC004525, AC002303, AL031730, AL031733, AF024533, AC005821, AL133404, AC007993, U91321, X98745, AP001045, Y07848, AC000026, AL034554, AC002059, U85195, AE000658, AC005738, AL031447, AC010206, AC006125, AC004081, M87926, AL031286, AF043945, AF064866, AC006007, AC004984, AC008012, AL133448, AL031075, AC003689, M17623, X66401, AL031295, AC004818, AC005209, AF001549, AC005479, U69639, AC007774, AL137682, U61238, U60970, U61224, U57833, AF184614, Z99754, AC007162, AC004652, AC005212, AC004242, AC004883, AL031667, AC003101, AC003046, AL109653, AL022331, AC004066, AC006942, AL133163, AC005906, U95090, AC006055, AC012384, AC006991, AP000240, AL079300, AC008545, AC004816, AL110164, AL096805, AL031276, AC003658, U78027, L81648, M87921, Z68285, AF030880, AF172277, AC005740, AB014078, AB004907, AB023052, AC004750, U73635, AC003690, U75931, Z81450, AP000302, AC005525, AC006127, AC006138, AF037338, AC005202, AC004755, AC005624, AC005568, Z69733, AC002499, Z70688, AF050154, AC007565, AC006277,					
---	--	--	--	--	--

						Z93024, AC005777, AC004643, AL049856, AC004209, Z70051, AC006139, AL080242, AC004696, AL121934, and AC002037.
HCDMF96	970	796196	1 - 418	15 - 432		AI459248, AI701427, AI023601, and N91037.
HCDME32	971	863374	1 - 593	15 - 607		AA405957, AA416555, T19219, AI134902, AI142134, AL119355, U46349, AL119457, AL043004, U46346, and AR066494.
HCDMC86	972	785134	1 - 316	15 - 330		AI675751, AA977468, AW183837, AI208676, AA401383, AI184678, AI016502, AA448192, and AA927251.
HCDMC25	973	677627	1 - 565	15 - 579		HI0593, and AI221385.
HCDMC23	974	675490	1 - 354	15 - 368		
HCDMC22	975	672815	1 - 228	15 - 242		AL119791, AI318280, AI611348, AW149236, AI252023, AI590830, AI567351, AI886753, AI866798, AL040241, AL038445, AI446373, AI285826, AI345745, AI446538, AI680498, AW268122, AI340603, AA572758, AL036631, AI288285, AW161579, AI312428, AI923989, AI567612, AI866770, AA012905, AI783504, AW163834, AW302965, AL036638, AI348854, AL040169, AI537677, AI802240, AL121463, AW088899, AI345347, AA420722, AW151138, AI538885, AI500659, AI570861, AI917252, AI648684, AI431424, AI499986, AI589267, F37471, AI500523, AI865906, AI246319, AI335426, AI590423, AI348777, AI457188, AI889168, AW132034, AW188382, AL036146, AA493647, AI633419, AW089572, AI926800, AI815232, AI249497, AW074993, AI349614, AW238730, AW268253, AA225339, AI312152, AI284131, AI873644, AW149227, AI345735, AI344785, AI627988, AI923370, AI569583, AL079963, AL038605, AI620284, AI254727, AA640779, AI349937, AI445992, AL120853, AI349645, AI874166, AL045620, AI500061, AI670009, AI433157, AI254042, AI702073, AI610402, AW087200, AI801793, AW022682, AI281773, AW105601, AI871709, AI823670, AI500662, AW073898, AI633125, AI698391, AI801325, AI340627, AI915291, AI916419, AI349772, AI627985, AI582932, AL048656, AA613907, AI521560, AI889189, AL040243, AL045500, AI621179, AW059713, AW269097, AI612885, AI888661, AI251221, AA833760, AI499263, AI284517, AW193134, AI500706, AL038565, AW167918, AW169604, AI862144, AI696626, AI866573, AI890806, AI554821, AA579232, AA635382, AI336495, AI955906, AW198144, AI610645, AI436429, AI950664, AI065027, AI309401, AW020693, AW118382, AL119863, AI343112, AL036980, AI348897,

AW026882, AI254226, AI689420, AL042627, AI440263, AI349598, AI950892, AI683585, AI539771, AI273843, AI866608, AI682841, AI539808, AI744256, AW302992, AI445237, AI497733, AL036274, AW084056, AI686877, AI446795, AI281779, AI434256, AW068845, W33163, AI933589, AI620639, AI867042, AI696819, AL038779, AI869367, AI889147, AL036403, AI468872, AI280661, AA528822, AI699011, AW025464, AI754897, AI537617, AI919345, AW088903, AI500077, AW169653, AI494201, AI758613, AW081255, AW152469, AI251830, AI635492, AI366549, AI636719, AI539153, AW151136, AI281800, AA974049, AL036396, AI918449, AL039086, AI682743, AI587121, AI570807, AI611743, AI679504, AW071349, AW071417, AW083804, AI889148, AW301300, AI684265, AI589993, AL036664, AW075207, AI349256, AL036802, AI753683, AW089272, AI277255, AI439601, AI699857, AW268072, AA804740, AA420758, AW075084, AI345608, AI270183, AI608936, AI364788, AI491776, AI334884, AI307543, AW160386, AI699865, AW130534, AF118090, AL050393, U42766, AL117460, AR011880, X70685, AL133565, I89947, AF104032, A08916, I48978, AF061943, A08913, AF090896, AF078844, A08910, A08909, AL049938, AF090901, AL117585, AL133557, I89931, U00763, AF113690, AF113694, AL137521, I03321, I49625, AL133016, AF097996, AF106862, AL137550, S78214, AF125949, AI2297, AL050138, E03348, AJ242859, AL117394, Y11254, AF017437, AF090943, AL049314, AF090900, AL050116, AL050146, AL117435, AF118094, AF118070, AF111851, AL110221, AL096744, AF113013, X82434, AL137557, AL122050, AL122093, AL133113, U35846, AL122121, AL049466, E02349, AL133606, AF026816, AF113019, AL110196, I33392, AF113699, AL050149, AL050277, I48979, A90832, L31396, X65873, L31397, AB019565, Y16645, AL137271, AL049452, AF113676, AF158248, A58524, A58523, AL080124, AL117583, A07647, X93495, AF113691, X72889, AL049464, S61953, AL137283, AF118064, AF067728, I17767, AF090903, AL110225, X98834, AL049283, X84990, AL050108, AF057300, AF057299, U72620, AL080060, U67958, AL049382, M30514, AL117457, AF125948, AL133568, AL133560, A93016, AL137463, AL122110, AF091084, AF090934, AF113677, I26207, X87582, AL050024, A77033, A77035,					
---	--	--	--	--	--

					AF087943, AL133640, AL137459, AF183393, AJ238278, E07108, U80742, A03736, X63574, AJ012755, AL137479, X96540, AL049300, A65341, AJ000937, AL133080, AL049430, I42402, Z82022, AR059958, AF026124, AF177401, AF079765, E07361, AL122049, AL137648, U91329, AL133093, AF079763, AL137538, Y09972, S68736, AF003737, AF113689, Y11587, AF146568, AL137527, A08912, AL122123, E05822, AL133098, AL133077, E15569, Y10655, I09360, AL080159, AL122098, AF017152, AL080127, AL133075, AL080137, L13297, I00734, AR038854, AL133104, AR038969, E00617, E00717, E00778, AL110280, E08263, E08264, AF119337, AL133067, AJ006417, AF061573, AL110159, AL137556, AF106827, AL133072, AL137560, A93350, U68387, X83508, AL133014, AR034821, AF111112, AF100781, AR000496, U39656, Z72491, AL133081, AF153205, Y14314, AF185576, E04233, U58996, L30117, AL117649, I66342, AL137526, AL096751, AF162270, AL110197, Z37987, AF016271, AF111849, AL137574, AL080074, AR054984, E08631, AF182215, AF067790, A18777, A08908, X92070, U96683, A45787, AL117440, U78525, AL137480, AL137476, S75997, AL137533, Y07905, AL133031, AF008439, AL049347, S36676, AF051325, A76335, AL050092, and AL137478.
HCDMC06	976	934663	1 - 364	15 - 378	AI249688, AW265688, AI077941, F00533, AA904275, AW341903, R70333, H71250, AI185394, AW380074, AL046746, AA779783, AI640411, AI287921, F23327, AA504878, AA640260, AW271904, AA177075, AA526193, AA593471, AI803809, AI446205, AA569190, AA381762, AA745356, AI205181, AW275719, AA847029, H82416, AA342189, AA657835, AA664604, AI536625, AI281474, AW408063, AI754037, AA310557, AW270768, AI915081, AI824541, AL039187, AI038304, AI569100, AW192599, AI754105, AA598927, AW131356, AI755214, R91827, AW157005, AI754567, AA262752, AI028510, AW008074, AI624528, AW383952, AI338426, AL120976, F00982, R70883, AI080307, AI570943, AA743811, AI872503, AA992126, AI291037, H91844, AW277174, AW069450, AI859438, AI580707, AI581486, AW268190, D58782, AA805841, AA666215, AI377413, H96518, AC006121, AC009248, AL034420, AC006044, AF107885, AC005089, Z93017, AL009181, AC007967, AC005071, AC004217,

AC000041, AC005971, Z99716, AP000553, AC004531, AF038458, U91326, AC002350, AC005037, AC008372, AC006285, Z84480, AC003101, AL035450, U02047, AC004253, AC005944, AL023803, U95739, U62317, AC016025, AC005740, AC005064, AC005562, U73649, AP000252, AL049776, AC005632, AC005516, AC002059, AC006211, AC000134, U91321, AC005730, AC006026, L48038, AC002398, AC007012, AC009516, AC019014, AL139054, AL132777, AL021394, L78833, AC002477, AC002544, AP000212, AP000134, AC006277, I34294, AC006064, U07000, AC006130, AC004797, AC007327, AL049589, AF178650, AL109939, AC006538, AP000106, AC007225, AC004975, AL021391, AC004633, AL031577, AC004000, AC005069, AC005726, AC005696, AL035410, Z82208, AL023807, AL096791, AC007363, AL022326, Z79997, AC007686, AC006449, AC005670, AP000692, AD000833, AL049692, AL121767, AC004883, AP000245, AL035045, AB001523, AL021368, AC002375, AC005664, AB020865, AC000026, AL022336, Z74617, AC005539, AC007242, AC007666, AC004757, AF222686, AL078611, AL024508, AP000115, AP000359, U85195, AL049745, AC005756, AL049757, AC004596, AC002310, AL031281, AC005988, AL031662, AC007308, AL022400, AC007387, AL035659, AE000658, AL080243, AL022165, AC004859, AC005755, AC006237, AC007785, Z93023, AP000348, AC004196, AC004765, Z83826, Z82201, AL031053, AL049709, AC009275, AC002073, AC004832, AC007450, AL031311, AC002041, AL049780, AC005924, AC004796, AL109827, AC005550, AC005488, AC006359, AC003661, AL021154, AC005681, AC006354, AC004848, AC002563, Z82176, AC005901, AC000052, AB023048, AL035610, AC007227, AL035458, AC005829, AP000966, AB020864, AC005878, AL022724, AL031848, AC007676, AC008072, AC006241, AC007784, AC002476, AC006965, AC005932, AC002377, AP000343, AC005914, AC000353, AL035420, AC004019, AC006166, AL049761, AC008055, AP000128, AP000206, AC002480, AC009263, U29953, AL008635, D87675, AL024498, AC005180, AC007221, AC010077, AL109628, AC005184, AC004913, AC007999, AP000030, AC005377, AC005899, AC007688, AC007066, AC006578, AL031297, AP000558, AJ010597, AL021366, AC005778, AC004148, AL035530, Z85986, AC004520, AC005962,					
---	--	--	--	--	--

HCDMB91	977	789551	1 - 330	15 - 344	AL049554, AF095901, AC006486, AC005536, Z82181, AC004003, Z82244, AC000075, AL035455, and AC004447.
					AA297443, AA564510, H01110, AA730795, W96277, AA020873, AA947369, AC005031, AL008719, U80017, AC005015, AC004996, AC002511, AC004655, AC002991, AC002477, AC004253, AC005231, AC002565, AC003665, AC006312, AC005837, AP000556, AL034379, AP000557, AP000552, AC006275, AP000247, AC004216, AC007919, AC005484, AC005529, AC002301, AC005821, AL031673, AC006449, AC000025, Z98742, AP000106, AL034421, AC000379, AC005527, AL049869, AC002404, AC002365, AC005924, AC005102, AC000003, AC016025, AL023807, AC002312, AC005081, AC003950, AL049757, AL109758, Z99774, AC004019, AC004531, AL135744, AC005288, AL022165, AC005071, AC007225, AL022721, AL109628, AL021878, AC002470, AL096701, AL050350, AC000353, AC005736, AF196969, AL021155, AC005730, AF053356, AC004125, AL080243, AC004702, AC000052, AC006121, AC004890, AC007151, AF196779, AC004967, AC005921, AC005520, AF129756, AF111168, AC007688, AC005911, AC002300, AP000514, AC004832, AC004477, AC007055, AC007637, AC002310, AC004098, AL023553, AC004910, AL031255, and AF111167.
HCDMB42	978	713300	1 - 230	15 - 244	AI525277, and AA079259.
HCDMB41	979	711996	1 - 563	15 - 577	
HCDMB27	980	682389	1 - 323	15 - 337	
HCDMB12	981	968918	1 - 613	15 - 627	AL134524, AI142134, AL038983, AL045328, AL037727, AL042898, AL047163, AL049018, AL038838, AL037343, AL039643, AL037436, AL037335, AL037323, AL037443, AL038532, AL044125, AL047012, AL040193, AL044162, AL037435, AL041347, AL040621, AL043538, AL043496, AL040464, AL038761, AL038822, AL043923, AL043814, AL041238, AL044186, AL040617, AL040463, AL047170, AL043845, AL041324, AL045327, AL044037, AL041635, AL040294, AL041098, AL047219, AL044064, AL041459, AL041577, AL047183, AL040625, AL045684, AL041752, AL042135, AL046850, AL040768, AL046994, AL040510, AL046914, AL043467, AL040052, AL040444, AL043677, AL040839, AL043492, AL041602, AL044074, AL041730, AL041523, AL043627, AL041374, AL043848, AL043570, AL134110, AL041163,

330

					A02136, A04664, A02135, A04663, I84553, I84554, E17098, I06859, A18050, A23334, A75888, I70384, A60111, A23633, AR007512, AR060234, A81878, AB025273, AR038855, A90655, D13316, A02712, A77094, A77095, A95051, A18053, A64973, Y17793, AR031566, I00682, A86792, A11245, A11624, A11623, E00609, A11178, E01007, I13349, A10361, I08396, AR043601, I03331, A93916, A85395, A70872, A85476, I44681, X83865, I19525, A84772, A84776, A84773, A84775, A84774, AR067731, AR037157, AR054109, AR067732, A58522, A91750, AR063812, M28262, I15718, AF149828, I05845, Y14219, I15717, S60422, I01995, E12615, A02710, AR035193, A92133, E14304, A07700, A13393, A13392, AR031488, I13521, I52048, A27396, I25027, AR027100, I49890, I44531, I28266, I21869, I26929, I44515, I26928, I26930, I26927, A91965, I44516, A70040, E16678, A82653, I08051, E16636, AF019249, A24783, A24782, A95117, AJ230935, AJ230972, A06631, A85203, A81671, A22734, AJ231028, I08395, A93931, A16035, I66495, I66494, I60241, I60242, I66498, I66497, I66496, I66486, I66487, AJ244007, AJ230902, AJ230845, I03669, AL133076, I03668, AR051957, AJ230951, A20699, E00696, E00697, E03813, I66482, AR009151, I66485, I66483, I66484, AR038066, AR027099, AJ231009, AJ230867, I33632, AR051651, AR051652, AR035975, AR035974, AR035977, AR035976, AR035978, E03654, AL133082, AR008429, AL133068, AR054723, A22739, AJ230996, A05993, A05991, and AL133020.
HCDMB08	982	958542	I - 255	15 - 269	AA719107.
HCDMB03	983	923316	I - 375	15 - 389	AL119691, A1305766, AW103758, A1284640, A1247199, AA634889, AA679532, A1345681, A1345675, AA584167, AA551552, A1345157, A1344812, A1473475, AW274346, AA747070, AW021207, AW072923, AL043009, AW069769, A1696962, AA515909, AA613203, AA551503, AW419262, AW264934, A1801482, AW265385, A1754336, AW088846, AA167055, AA580808, A1133164, A1334464, AW440545, A1754253, A1469968, AA493975, AL045526, AA683258, AA812281, AW193265, A1345418, A1457397, AW302903, H70994, A1888752, AA478355, A1687343, AA630362, AL038072, AW302013, AA521323, AA490183, A1350211, AW438643, A1872020, AA521399, A1859438, A1334443, N35896, AA303007, AA662225, AA515549, AL138396, A1270117,

332

					AC002543, AC005772, AC004381, AC000080, AC005300, AF077058, AL031229, Z86061, AC004966, AL049845, AC004751, Z95116, AC005041, AL034375, AC005341, AC004690, AC000120, AC005204, D83989, AC004020, AC004854, AL022477, AC005839, AL135744, L44140, AC006254, AC008044, U35114, AC005915, AC007225, AL033523, Z98200, AC009399, AL035071, AC002385, AC006023, AF015151, AC005886, AF000946, AC005593, AC005944, AJ246003, Z93020, AF130343, AC004990, AL109847, Z98050, AC005261, Z85987, AC016831, Z93929, AC004152, AC002550, U07562, AC005182, AC002369, AC007666, AC005154, AC007899, AC004894, AC003689, AC007371, AL121655, Z97635, AC004972, AC005256, and AC005779.
HCDMA20	984	669201	1 - 331	15 - 345	N62789, N62508, AI289289, N62494, AA936576, R52810, N49008, Z39305, R17666, F02223, H11727, R51380, N93902, and AL119444.

TABLE 4

Code	Description	Tissue	Organ	Cell Line	Disease	Vector
AR022	a Heart	a Heart				
AR023	a Liver	a Liver				
AR024	a mammary gland	a mammary gland				
AR025	a Prostate	a Prostate				
AR026	a small intestine	a small intestine				
AR027	a Stomach	a Stomach				
AR028	Blood B cells	Blood B cells				
AR029	Blood B cells activated	Blood B cells activated				
AR030	Blood B cells resting	Blood B cells resting				
AR031	Blood T cells activated	Blood T cells activated				
AR032	Blood T cells resting	Blood T cells resting				
AR033	brain	brain				
AR034	breast	breast				
AR035	breast cancer	breast cancer				
AR036	Cell Line CAOV3	Cell Line CAOV3				
AR037	cell line PA-1	cell line PA-1				
AR038	cell line transformed	cell line transformed				
AR039	colon	colon				
AR040	colon (9808co65R)	colon (9808co65R)				
AR041	colon (9809co15)	colon (9809co15)				
AR042	colon cancer	colon cancer				
AR043	colon cancer (9808co64R)	colon cancer (9808co64R)				
AR044	colon cancer 9809co14	colon cancer 9809co14				
AR045	corn clone 5	corn clone 5				
AR046	corn clone 6	corn clone 6				
AR047	corn clone2	corn clone2				
AR048	corn clone3	corn clone3				
AR049	Corn Clone4	Corn Clone4				
AR050	Donor II B Cells 24hrs	Donor II B Cells 24hrs				
AR051	Donor II B Cells 72hrs	Donor II B Cells 72hrs				
AR052	Donor II B-Cells 24 hrs.	Donor II B-Cells 24 hrs.				
AR053	Donor II B-Cells 72hrs	Donor II B-Cells 72hrs				
AR054	Donor II Resting B Cells	Donor II Resting B Cells				
AR055	Heart	Heart				
AR056	Human Lung (clonotech)	Human Lung (clonotech)				
AR057	Human Mammary (clonotech)	Human Mammary (clonotech)				
AR058	Human Thymus (clonotech)	Human Thymus (clonotech)				
AR059	Jurkat (unstimulated)	Jurkat (unstimulated)				
AR060	Kidney	Kidney				
AR061	Liver	Liver				

AR062	Liver (Clontech)	Liver (Clontech)				
AR063	Lymphocytes chronic lymphocytic leukaemia	Lymphocytes chronic lymphocytic leukaemia				
AR064	Lymphocytes diffuse large B cell lymphoma	Lymphocytes diffuse large B cell lymphoma				
AR065	Lymphocytes follicular lymphoma	Lymphocytes follicular lymphoma				
AR066	normal breast	normal breast				
AR067	Normal Ovarian (4004901)	Normal Ovarian (4004901)				
AR068	Normal Ovary 9508G045	Normal Ovary 9508G045				
AR069	Normal Ovary 9701G208	Normal Ovary 9701G208				
AR070	Normal Ovary 9806G005	Normal Ovary 9806G005				
AR071	Ovarian Cancer	Ovarian Cancer				
AR072	Ovarian Cancer (9702G001)	Ovarian Cancer (9702G001)				
AR073	Ovarian Cancer (9707G029)	Ovarian Cancer (9707G029)				
AR074	Ovarian Cancer (9804G011)	Ovarian Cancer (9804G011)				
AR075	Ovarian Cancer (9806G019)	Ovarian Cancer (9806G019)				
AR076	Ovarian Cancer (9807G017)	Ovarian Cancer (9807G017)				
AR077	Ovarian Cancer (9809G001)	Ovarian Cancer (9809G001)				
AR078	ovarian cancer 15799	ovarian cancer 15799				
AR079	Ovarian Cancer 17717AID	Ovarian Cancer 17717AID				
AR080	Ovarian Cancer 4004664B1	Ovarian Cancer 4004664B1				
AR081	Ovarian Cancer 4005315A1	Ovarian Cancer 4005315A1				
AR082	ovarian cancer 94127303	ovarian cancer 94127303				
AR083	Ovarian Cancer 96069304	Ovarian Cancer 96069304				
AR084	Ovarian Cancer 9707G029	Ovarian Cancer 9707G029				
AR085	Ovarian Cancer 9807G045	Ovarian Cancer 9807G045				
AR086	ovarian cancer 9809G001	ovarian cancer 9809G001				
AR087	Ovarian Cancer 9905C032RC	Ovarian Cancer 9905C032RC				
AR088	Ovarian cancer 9907 C00 3rd	Ovarian cancer 9907 C00 3rd				
AR089	Prostate	Prostate				
AR090	Prostate (clontech)	Prostate (clontech)				
AR091	prostate cancer	prostate cancer				
AR092	prostate cancer #15176	prostate cancer #15176				

AR093	prostate cancer #15509	prostate cancer #15509				
AR094	prostate cancer #15673	prostate cancer #15673				
AR095	Small Intestine (Clontech)	Small Intestine (Clontech)				
AR096	Spleen	Spleen				
AR097	Thymus T cells activated	Thymus T cells activated				
AR098	Thymus T cells resting	Thymus T cells resting				
AR099	Tonsil	Tonsil				
AR100	Tonsil germinal center centroblast	Tonsil germinal center centroblast				
AR101	Tonsil germinal center B cell	Tonsil germinal center B cell				
AR102	Tonsil lymph node	Tonsil lymph node				
AR103	Tonsil memory B cell	Tonsil memory B cell				
AR104	Whole Brain	Whole Brain				
AR105	Xenograft ES-2	Xenograft ES-2				
AR106	Xenograft SW626	Xenograft SW626				
H0009	Human Fetal Brain					Uni-ZAP XR
H0032	Human Prostate	Human Prostate	Prostate			Uni-ZAP XR
H0038	Human Testes	Human Testes	Testis			Uni-ZAP XR
H0040	Human Testes Tumor	Human Testes Tumor	Testis		disease	Uni-ZAP XR
H0046	Human Endometrial Tumor	Human Endometrial Tumor	Uterus		disease	Uni-ZAP XR
H0050	Human Fetal Heart	Human Fetal Heart	Heart			Uni-ZAP XR
H0063	Human Thymus	Human Thymus	Thymus			Uni-ZAP XR
H0090	Human T-Cell Lymphoma	T-Cell Lymphoma	T-Cell		disease	Uni-ZAP XR
H0124	Human Rhabdomyosarcoma	Human Rhabdomyosarcom a	Sk Muscle		disease	Uni-ZAP XR
H0150	Human Epididymus	Epididymis	Testis			Uni-ZAP XR
H0176	CAMA1Ee Cell Line	CAMA1Ee Cell Line	Breast	Cell Line		Uni-ZAP XR
H0179	Human Neutrophil	Human Neutrophil	Blood	Cell Line		Uni-ZAP XR
H0212	Human Prostate, subtracted	Human Prostate	Prostate			pBluescript
H0253	Human adult testis, large inserts	Human Adult Testis	Testis			Uni-ZAP XR
H0270	HPAS (human pancreas, subtracted)	Human Pancreas	Pancreas			Uni-ZAP XR
H0294	Amniotic Cells - TNF induced	Amniotic Cells - TNF induced	Placenta	Cell Line		Uni-ZAP XR
H0372	Human Testes	Human Testes	Testis			pCMVSPORT 1
H0392	H. Meningioma, M1	Human Meningioma	brain			pSport1
H0411	H Female Bladder, Adult	Human Female Adult Bladder	Bladder			pSport1
H0494	Keratinocyte	Keratinocyte				pCMVSPORT 2.0
H0521	Primary Dendritic Cells, lib 1	Primary Dendritic cells				pCMVSPORT 3.0
H0543	T cell helper II	Helper T cell				pCMVSPORT 3.0
H0549	H. Epididymus, caput	Human				Uni-ZAP XR

	& corpus	Epididymus, caput and corpus				
H0550	H. Epididymus, cauda	Human Epididymus, cauda				Uni-ZAP XR
H0553	Human Placenta	Human Placenta				pCMVSPORT 3.0
H0593	Olfactory epithelium;nasalcavity	Olfactory epithelium from roof of left nasal cavity				pCMVSPORT 3.0
H0616	Human Testes, Reexcision	Human Testes	Testis			Uni-ZAP XR
H0618	Human Adult Testes, Large Inserts, Reexcision	Human Adult Testis	Testis			Uni-ZAP XR
H0634	Human Testes Tumor, re-excision	Human Testes Tumor	Testis		disease	Uni-ZAP XR
H0670	Ovary, Cancer(4004650 A3): Well-Differentiated Micropapillary Serous Carcinoma	Ovarian Cancer - 4004650A3				pSport1
H0687	Human normal ovary(#9610G215)	Human normal ovary(#9610G215)	Ovary			pCMVSPORT 3.0
H0688	Human Ovarian Cancer(#9807G017)	Human Ovarian cancer(#9807G017),mRNA from Maura Ru				pCMVSPORT 3.0
S0042	Testes	Human Testes				ZAP Express
S0222	H. Frontal cortex,epileptic;re-excision	H. Brain, Frontal Cortex, Epileptic	Brain		disease	Uni-ZAP XR
S0274	PCMIX	PCMIX (Human Cerebellum)	Brain			PCRII
S0284	7TMCTT (Testis)	7TMCTP (Placenta)	Testis			PCRII
S0352	Larynx Carcinoma	Larynx carcinoma			disease	pSport1
S0398	Testis; normal	Testis; normal				pSport1
T0041	Jurkat T-cell G1 phase	Jurkat T-cell				pBluescript SK-
L0021	Human adult (K.Okubo)					
L0023	human adult testis					
L0070	Selected chromosome 21 cDNA library					
L0109	Human brain cDNA	brain				
L0151	Human testis (C. De Smet)	testis				
L0157	Human fetal brain (TFujiwara)		brain			
L0163	Human heart cDNA (YNakamura)		heart			
L0361	Stratagene ovary (#937217)		ovary			Bluescript SK
L0362	Stratagene ovarian cancer (#937219)					Bluescript SK-
L0363	NCI_CGAP_GC2	germ cell tumor				Bluescript SK-
L0366	Stratagene schizo brain S11	schizophrenic brain S-11 frontal				Bluescript SK-

		lobe				
L0369	NCI_CGAP_AA1	adrenal adenoma	adrenal gland			Bluescript SK-
L0371	NCI_CGAP_Br3	breast tumor	breast			Bluescript SK-
L0372	NCI_CGAP_Co12	colon tumor	colon			Bluescript SK-
L0380	NCI_CGAP_HN1	squamous cell carcinoma	lymph node			Bluescript SK-
L0381	NCI_CGAP_HN4	squamous cell carcinoma	pharynx			Bluescript SK-
L0438	normalized infant brain cDNA	total brain	brain			lafmid BA
L0439	Soares infant brain INIB		whole brain			Lafmid BA
L0455	Human retina cDNA randomly primed sublibrary	retina	eye			lambda gt10
L0470	BL29 Burkitt's lymphoma, Pascalis Sideras					lambda ZAP 2
L0483	Human pancreatic islet					Lambda ZAPII
L0485	STRATAGENE Human skeletal muscle cDNA library, cat. #936215.	skeletal muscle	leg muscle			Lambda ZAPII
L0517	NCI CGAP Pr1					pAMP10
L0518	NCI CGAP Pr2					pAMP10
L0519	NCI CGAP Pr3					pAMP10
L0522	NCI CGAP Kid1	kidney				pAMP10
L0532	NCI CGAP Thy1	thyroid				pAMP10
L0565	Normal Human Trabecular Bone Cells	Bone	Hip			pBluescript
L0587	Stratagene colon HT29 (#937221)					pBluescript SK-
L0588	Stratagene endothelial cell 937223					pBluescript SK-
L0589	Stratagene fetal retina 937202					pBluescript SK-
L0590	Stratagene fibroblast (#937212)					pBluescript SK-
L0591	Stratagene HeLa cell s3 937216					pBluescript SK-
L0592	Stratagene hNT neuron (#937233)					pBluescript SK-
L0593	Stratagene neuroepithelium (#937231)					pBluescript SK-
L0594	Stratagene neuroepithelium NT2RAMI 937234					pBluescript SK-
L0595	Stratagene NT2 neuronal precursor 937230	neuroepithelial cells	brain			pBluescript SK-
L0596	Stratagene colon (#937204)		colon			pBluescript SK-
L0597	Stratagene corneal stroma (#937222)		cornea			pBluescript SK-
L0599	Stratagene lung (#937210)		lung			pBluescript SK-

L0600	Weizmann Olfactory Epithelium	olfactory epithelium	nose			pBluescript SK-
L0601	Stratagene pancreas (#937208)		pancreas			pBluescript SK-
L0604	Stratagene muscle 937209	muscle	skeletal muscle			pBluescript SK-
L0605	Stratagene fetal spleen (#937205)	fetal spleen	spleen			pBluescript SK-
L0608	Stratagene lung carcinoma 937218	lung carcinoma	lung	NCI-H69		pBluescript SK-
L0617	Chromosome 22 exon					pBluescriptII KS+
L0618	Chromosome 9 exon					pBluescriptII KS+
L0637	NCI_CGAP_Brn53	three pooled meningiomas	brain			pCMV-SPORT6
L0646	NCI_CGAP_Co14	moderately-differentiated adenocarcinoma	colon			pCMV-SPORT6
L0649	NCI_CGAP_GU1	2 pooled high-grade transitional cell tumors	genitourinary tract			pCMV-SPORT6
L0655	NCI_CGAP_Lym12	lymphoma, follicular mixed small and large cell	lymph node			pCMV-SPORT6
L0659	NCI_CGAP_Pan1	adenocarcinoma	pancreas			pCMV-SPORT6
L0662	NCI_CGAP_Gas4	poorly differentiated adenocarcinoma with signet r	stomach			pCMV-SPORT6
L0663	NCI_CGAP_Ut2	moderately-differentiated endometrial adenocarcinoma	uterus			pCMV-SPORT6
L0664	NCI_CGAP_Ut3	poorly-differentiated endometrial adenocarcinoma,	uterus			pCMV-SPORT6
L0665	NCI_CGAP_Ut4	serous papillary carcinoma, high grade, 2 pooled t	uterus			pCMV-SPORT6
L0666	NCI_CGAP_Ut1	well-differentiated endometrial adenocarcinoma, 7	uterus			pCMV-SPORT6
L0697	Testis 1					PGEM 5zf(+)
L0698	Testis 2					PGEM 5zf(+)
L0717	Gessler Wilms tumor					pSPORT1
L0731	Soares_pregnant_uterus NbHPU		uterus			pT7T3-Pac
L0740	Soares melanocyte 2NbHM	melanocyte				pT7T3D (Pharmacia) with a modified polylinker
L0741	Soares adult brain N2b4HB55Y		brain			pT7T3D (Pharmacia) with a modified polylinker
L0742	Soares adult brain		brain			pT7T3D

	N2b5HB55Y					(Pharmacia) with a modified polylinker
L0743	Soares breast 2NbHBst		breast			pT7T3D (Pharmacia) with a modified polylinker
L0744	Soares breast 3NbHBst		breast			pT7T3D (Pharmacia) with a modified polylinker
L0745	Soares retina N2b4HR	retina	eye			pT7T3D (Pharmacia) with a modified polylinker
L0746	Soares retina N2b5HR	retina	eye			pT7T3D (Pharmacia) with a modified polylinker
L0747	Soares fetal heart_N bHH19W		heart			pT7T3D (Pharmacia) with a modified polylinker
L0748	Soares fetal liver spleen 1NFLS		Liver and Spleen			pT7T3D (Pharmacia) with a modified polylinker
L0749	Soares fetal liver_spl een_1NFLS_S1		Liver and Spleen			pT7T3D (Pharmacia) with a modified polylinker
L0750	Soares fetal lung_Nb HL19W		lung			pT7T3D (Pharmacia) with a modified polylinker
L0751	Soares ovary tumor NbHOT	ovarian tumor	ovary			pT7T3D (Pharmacia) with a modified polylinker
L0752	Soares parathyroid_tu mor_NbHPA	parathyroid tumor	parathyroid gland			pT7T3D (Pharmacia) with a modified polylinker
L0753	Soares pineal gland_ N3HPG		pineal gland			pT7T3D (Pharmacia) with a modified polylinker
L0754	Soares placenta Nb2HP		placenta			pT7T3D (Pharmacia) with a modified

L0755	Soares_placenta_8to9 weeks_2NbHP8to9W		placenta			polylinker pT7T3D (Pharmacia) with a modified polylinker
L0756	Soares_multiple_sclerosis_2NbHMSP	multiple sclerosis lesions				pT7T3D (Pharmacia) with a modified polylinker V TYPE
L0757	Soares_senescent_fibroblasts_NbHSF	senescent fibroblast				pT7T3D (Pharmacia) with a modified polylinker V TYPE
L0758	Soares_testis_NHT					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0759	Soares_total_fetus_Nb2HF8_9w					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0761	NCI_CGAP_CLL1	B-cell, chronic lymphocytic leukemia				pT7T3D-Pac (Pharmacia) with a modified polylinker
L0763	NCI_CGAP_Br2	breast				pT7T3D-Pac (Pharmacia) with a modified polylinker
L0764	NCI_CGAP_Co3	colon				pT7T3D-Pac (Pharmacia) with a modified polylinker
L0766	NCI_CGAP_GCB1	germinal center B cell				pT7T3D-Pac (Pharmacia) with a modified polylinker
L0767	NCI_CGAP_GC3	pooled germ cell tumors				pT7T3D-Pac (Pharmacia) with a modified polylinker
L0768	NCI_CGAP_GC4	pooled germ cell tumors				pT7T3D-Pac (Pharmacia) with a modified polylinker
L0769	NCI_CGAP_Brn25	anaplastic oligodendroglioma	brain			pT7T3D-Pac (Pharmacia) with a modified polylinker

L0770	NCI_CGAP_Brn23	glioblastoma (pooled)	brain			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0771	NCI_CGAP_Co8	adenocarcinoma	colon			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0772	NCI_CGAP_Co10	colon tumor RER+	colon			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0773	NCI_CGAP_Co9	colon tumor RER+	colon			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0774	NCI_CGAP_Kid3		kidney			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0775	NCI_CGAP_Kid5	2 pooled tumors (clear cell type)	kidney			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0776	NCI_CGAP_Lu5	carcinoid	lung			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0777	Soares_NhHMPu_S1	Pooled human melanocyte, fetal heart, and pregnant	mixed (see below)			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0779	Soares_NFL_T_GBC_S1		pooled			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0780	Soares_NSF_F8_9W_OT_PA_P_S1		pooled			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0783	NCI_CGAP_Pr22	normal prostate	prostate			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0787	NCI_CGAP_Sub1					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0788	NCI_CGAP_Sub2					pT7T3D-Pac (Pharmacia) with a

						modified polylinker
L0789	NCI_CGAP_Sub3					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0790	NCI_CGAP_Sub4					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0791	NCI_CGAP_Sub5					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0792	NCI_CGAP_Sub6					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0794	NCI_CGAP_GC6	pooled germ cell tumors				pT7T3D-Pac (Pharmacia) with a modified polylinker
L0796	NCI_CGAP_Brn50	medulloblastoma	brain			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0800	NCI_CGAP_Co16	colon tumor, RER+	colon			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0803	NCI_CGAP_Kid11		kidney			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0804	NCI_CGAP_Kid12	2 pooled tumors (clear cell type)	kidney			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0805	NCI_CGAP_Lu24	carcinoid	lung			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0806	NCI_CGAP_Lu19	squamous cell carcinoma, poorly differentiated (4	lung			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0807	NCI_CGAP_Ov18	fibrotheoma	ovary			pT7T3D-Pac (Pharmacia) with a modified polylinker

L0809	NCI_CGAP_Pr28		prostate			p17T3D-Pac (Pharmacia) with a modified polylinker
-------	---------------	--	----------	--	--	---

TABLE 5

OMIM Reference	Description
102770	Myoadenylate deaminase deficiency
104770	Amyloidosis, secondary, susceptibility to
107670	Apolipoprotein A-II deficiency
107910	Virilization, maternal and fetal, from placental aromatase deficiency
107910	Gynecomastia, familial, due to increased aromatase activity
109400	Basal cell nevus syndrome
109700	Hemodialysis-related amyloidosis
110700	Vivax malaria, susceptibility to
113721	Breast cancer
113900	Heart block, progressive familial, type I
114240	Muscular dystrophy, limb-girdle, type 2A, 253600
116806	Colorectal cancer
118485	Polycystic ovary syndrome with hyperandrogenemia
118504	Epilepsy, benign neonatal, type 1, 121200
118504	Epilepsy, nocturnal frontal lobe, 600513
120120	Epidermolysis bullosa dystrophica, dominant, 131750
120120	Epidermolysis bullosa dystrophica, recessive, 226600
120120	Epidermolysis bullosa, pretibial, 131850
120215	Ehlers-Danlos syndrome, type I, 130000
120215	Ehlers-Danlos syndrome, type II, 130010
120280	Stickler syndrome, type III
120280	Marshall syndrome, 154780
120436	Muir-Torre family cancer syndrome, 158320
120436	Turcot syndrome with glioblastoma, 276300
120436	Colorectal cancer, hereditary nonpolyposis, type 2
125270	Porphyria, acute hepatic
125270	Lead poisoning, susceptibility to
125852	Insulin-dependent diabetes mellitus-2
126340	Xeroderma pigmentosum, group D, 278730
126391	DNA ligase I deficiency
126452	Autonomic nervous system dysfunction
126452	[Novelty seeking personality]
126650	Chloride diarrhea, congenital, Finnish type, 214700
126650	Colon cancer
128100	Dystonia-1, torsion

130410	Glutaricaciduria, type IIB
131242	Shah-Waardenburg syndrome, 277580
132800	Basal cell carcinoma
132800	Epithelioma, self-healing, squamous 1, Ferguson-Smith type
133701	Exostoses, multiple, type 2
133780	Vitreoretinopathy, exudative, familial
134790	Hyperferritinemia-cataract syndrome, 600886
134797	Shprintzen-Goldberg syndrome, 182212
134797	Ectopia lentis, isolated
134797	Marfan syndrome, 154700
135940	Ichthyosis vulgaris, 146700
136350	Pfeiffer syndrome, 101600
137350	Amyloidosis, Finnish type, 105120
138320	Hemolytic anemia due to glutathione peroxidase deficiency
138570	Non-insulin dependent diabetes mellitus, susceptibility to
139320	Pituitary ACTH secreting adenoma
139320	Pseudohypoparathyroidism, type Ia, 103580
139320	Somatotrophinoma
139320	McCune-Albright polyostotic fibrous dysplasia, 174800
141900	Methemoglobinemias, beta-
141900	Sickle cell anemia
141900	Thalassemias, beta-
141900	Erythremias, beta-
141900	HPFH, deletion type
141900	Heinz body anemias, beta-
142000	Thalassemia due to Hb Lepore
142000	Thalassemia, delta-
142200	HPFH, nondeletion type A
142250	HPFH, nondeletion type G
142270	Hereditary persistence of fetal hemoglobin
145001	Hyperparathyroidism-jaw tumor syndrome
146790	Lupus nephritis, susceptibility to
147200	[Kappa light chain deficiency]
151400	Leukemia/lymphoma, B-cell, 1
151670	Hepatic lipase deficiency
152200	Coronary artery disease, susceptibility to
152445	Vohwinkel syndrome, 124500
152445	Erythrokeratoderma, progressive symmetric, 602036
152760	Hypogonadotropic hypogonadism due to GNRH deficiency, 227200
154276	Malignant hyperthermia susceptibility 3
155555	[Red hair/fair skin]
155555	UV-induced skin damage, vulnerability to
159001	Muscular dystrophy, limb-girdle, type 1B
160900	Myotonic dystrophy
166600	Osteopetrosis, AD, type II

167000	Ovarian cancer, serous
168468	Metaphyseal chondrodysplasia, Murk Jansen type, 156400
168500	Parietal foramina
170995	Zellweger syndrome-2
171650	Lysosomal acid phosphatase deficiency
173360	Thrombophilia due to excessive plasminogen activator inhibitor
173360	Hemorrhagic diathesis due to PAI1 deficiency
173370	Plasminogen activator deficiency
173850	Polio, susceptibility to
174000	Medullary cystic kidney disease, AD
176730	Diabetes mellitus, rare form
176730	Hyperproinsulinemia, familial
176730	MODY, one form
176930	Dysprothrombinemia
176930	Hypoprothrombinemia
178640	Pulmonary alveolar proteinosis, congenital, 265120
179755	Renal cell carcinoma, papillary, 1
180020	Retinal cone dystrophy-1
180100	Retinitis pigmentosa-1
182280	Small-cell cancer of lung
182860	Pyropoikilocytosis
182860	Spherocytosis, recessive
182860	Elliptocytosis-2
182900	Spherocytosis-2
185430	Atherosclerosis, susceptibility to
186855	Leukemia-2, T-cell acute lymphoblastic
188540	Hypothyroidism, nongoitrous
190020	Bladder cancer, 109800
190198	Leukemia, T-cell acute lymphoblastic
191100	Tuberous sclerosis-1
191290	Segawa syndrome, recessive
191315	Insensitivity to pain, congenital, with anhidrosis, 256800
192500	Jervell and Lange-Nielsen syndrome, 220400
192500	Long QT syndrome-1
194071	Wilms tumor, type 2
194071	Adrenocortical carcinoma, hereditary, 202300
204500	Ceroid-lipofuscinosis, neuronal 2, classic late infantile
215700	Citrullinemia
216900	Achromatopsia
223360	Dopamine-beta-hydroxylase deficiency
223900	Dysautonomia, familial
227650	Fanconi anemia, type A
230800	Gaucher disease
230800	Gaucher disease with cardiovascular calcification
231680	Glutaricaciduria, type IIA

232400	Glycogen storage disease IIIa
232400	Glycogen storage disease IIIb
247200	Miller-Dieker lissencephaly syndrome
253000	Mucopolysaccharidosis IVA
253800	Walker-Warburg syndrome, 236670
253800	Fukuyama type congenital muscular dystrophy
256850	Giant axonal neuropathy-1
258501	3-methylglutaconicaciduria, type III
266200	Anemia, hemolytic, due to PK deficiency
268900	[Sarcosinemia]
270800	Spastic paraplegia-5A
272800	Tay-Sachs disease
272800	[Hex A pseudodeficiency]
272800	GM2-gangliosidosis, juvenile, adult
276700	Tyrosinemia, type I
277700	Werner syndrome
278700	Xeroderma pigmentosum, group A
300000	Opitz G syndrome, type I
300066	Deafness, X-linked 6, sensorineural
300067	Subcortical laminar heterotopia, X-linked dominant
300067	Lissencephaly, X-linked
300077	Mental retardation, X-linked 29
300121	Subcortical laminar heterotopia, X-linked, 300067
300121	Lissencephaly, X-linked, 300067
300310	Agammaglobulinemia, type 2, X-linked
301201	Amelogenesis imperfecta-3, hypoplastic type
301220	Partington syndrome II
301835	Arts syndrome
302350	Nance-Horan syndrome
304050	Aicardi syndrome
304110	Craniofrontonasal dysplasia
306100	Gonadal dysgenesis, XY female type
309530	Mental retardation, X-linked 1, non-dysmorphic
309585	Mental retardation, X-linked, syndromic-6, with gynecomastia and obesity
311850	Phosphoribosyl pyrophosphate synthetase-related gout
312040	N syndrome, 310465
600040	Colorectal cancer
600059	Retinitis pigmentosa-13
600163	Long QT syndrome-3
600234	HMG-CoA synthase-2 deficiency
600309	Atrioventricular canal defect-1
600320	Insulin-dependent diabetes mellitus-5
600374	Bardet-Biedl syndrome 4
600617	Lipoid adrenal hyperplasia, 201710

600623	Prostate cancer, 176807
600811	Xeroderma pigmentosum, group E, DDB-negative subtype, 278740
600839	Bartter syndrome, 241200
600856	Beckwith-Wiedemann syndrome, 130650
600883	Diabetes mellitus, insulin-dependent, 8
600897	Cataract, zonular pulverulent-1, 116200
600958	Cardiomyopathy, familial hypertrophic, 4, 115197
600964	Refsum disease, adult, with increased pipecolicacidemia
601105	Pycnodysostosis, 265800
601412	Deafness, autosomal dominant 7
601414	Retinitis pigmentosa-18
601545	Lissencephaly-1
601652	Glaucoma 1A, primary open angle, juvenile-onset, 137750
601680	Distal arthrogryposis, type 2B
601691	Retinitis pigmentosa-19, 601718
601691	Stargardt disease-1, 248200
601691	Cone-rod dystrophy 3
601691	Fundus flavimaculatus with macular dystrophy, 248200
601718	Retinitis pigmentosa-19
601780	Ceroid-lipofuscinosis, neuronal-6, variant late infantile
601850	Retinitis pigmentosa-deafness syndrome
602025	Obesity/hyperinsulinism, susceptibility to
602026	Refsum disease, 266500
602078	Fibrosis of extraocular muscles, congenital, 2
602088	Nephronophthisis, infantile
602094	Lipodystrophy, familial partial
602099	Amyotrophic lateral sclerosis-5
602136	Refsum disease, infantile, 266510
602136	Zellweger syndrome-1, 214100
602136	Adrenoleukodystrophy, neonatal, 202370
602225	Cone-rod retinal dystrophy-2, 120970
602225	Leber congenital amaurosis, type III
602235	Epilepsy, benign, neonatal, type 1, 121200
602447	Coronary artery disease, susceptibility to
602491	Hyperlipidemia, familial combined, 1
602544	Parkinson disease, juvenile, type 2, 600116
602631	Rhabdomyosarcoma, 268210
602631	Breast Cancer
602782	Faisalabad histiocytosis
602783	Spastic paraplegia-7

Polynucleotide and Polypeptide Variants

[083] The present invention is also directed to variants of the testes associated polynucleotide sequence disclosed in SEQ ID NO:X or the complementary strand thereto, nucleotide sequences encoding the polypeptide of SEQ ID NO:Y, the nucleotide sequence of SEQ ID NO:X encoding the polypeptide sequence as defined in column 6 of Table 1A, nucleotide sequences encoding the polypeptide as defined in column 6 of Table 1A, the nucleotide sequence as defined in columns 8 and 9 of Table 2, nucleotide sequences encoding the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2, the nucleotide sequence as defined in column 6 of Table 1B, nucleotide sequences encoding the polypeptide encoded by the nucleotide sequence as defined in column 6 of Table 1B, the cDNA sequence contained in Clone ID NO:Z, and/or nucleotide sequences encoding a polypeptide encoded by the cDNA sequence contained in Clone ID NO:Z.

[084] The present invention also encompasses variants of the polypeptide sequence disclosed in SEQ ID NO:Y, a polypeptide sequence as defined in column 6 of Table 1A, a polypeptide sequence encoded by the polynucleotide sequence in SEQ ID NO:X, a polypeptide sequence encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2, a polypeptide sequence encoded by the nucleotide sequence as defined in column 6 of Table 1B, a polypeptide sequence encoded by the complement of the polynucleotide sequence in SEQ ID NO:X, and/or a polypeptide sequence encoded by the cDNA sequence contained in Clone ID NO:Z.

[085] "Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

[086] Thus, one aspect of the invention provides an isolated nucleic acid molecule comprising, or alternatively consisting of, a polynucleotide having a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence described in SEQ ID NO:X or contained in the cDNA sequence of Clone ID NO:Z; (b) a nucleotide sequence in SEQ ID NO:X or the cDNA in Clone ID NO:Z which encodes a mature testes associated polypeptide; (c) a nucleotide sequence in SEQ ID NO:X or the cDNA sequence of Clone ID NO:Z, which encodes a biologically active fragment

of a testes associated polypeptide; (d) a nucleotide sequence in SEQ ID NO:X or the cDNA sequence of Clone ID NO:Z, which encodes an antigenic fragment of a testes associated polypeptide; (e) a nucleotide sequence encoding a testes associated polypeptide having the complete amino acid sequence of SEQ ID NO:Y or the complete amino acid sequence encoded by the cDNA in Clone ID NO:Z; (f) a nucleotide sequence encoding a mature testes associated polypeptide of the amino acid sequence of SEQ ID NO:Y or the amino acid sequence encoded by the cDNA in Clone ID NO:Z; (g) a nucleotide sequence encoding a biologically active fragment of a testes associated polypeptide having the complete amino acid sequence of SEQ ID NO:Y or the complete amino acid sequence encoded by the cDNA in Clone ID NO:Z; (h) a nucleotide sequence encoding an antigenic fragment of a testes associated polypeptide having the complete amino acid sequence of SEQ ID NO:Y or the complete amino acid sequence encoded by the cDNA in Clone ID NO:Z; and (i) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g), or (h), above.

[087] The present invention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%, identical to, for example, any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g), (h), or (i) above, the nucleotide coding sequence in SEQ ID NO:X or the complementary strand thereto, the nucleotide coding sequence of the cDNA contained in Clone ID NO:Z or the complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding a polypeptide sequence encoded by the nucleotide sequence in SEQ ID NO:X, a polypeptide sequence encoded by the complement of the polynucleotide sequence in SEQ ID NO:X, a nucleotide sequence encoding the polypeptide encoded by the cDNA contained in Clone ID NO:Z, the nucleotide coding sequence in SEQ ID NO:X as defined in columns 8 and 9 of Table 2 or the complementary strand thereto, a nucleotide sequence encoding the polypeptide encoded by the nucleotide sequence in SEQ ID NO:X as defined in columns 8 and 9 of Table 2 or the complementary strand thereto, the nucleotide coding sequence in SEQ ID NO:B as defined in column 6 of Table 1B or the complementary strand thereto, a nucleotide sequence encoding the polypeptide encoded by the nucleotide sequence in

SEQ ID NO:B as defined in column 6 of Table 1B or the complementary strand thereto, the nucleotide sequence in SEQ ID NO:X encoding the polypeptide sequence as defined in column 6 of Table 1A or the complementary strand thereto, nucleotide sequences encoding a polypeptide as defined in column 6 of Table 1A or the complementary strand thereto, and/or polynucleotide fragments of any of these nucleic acid molecules (e.g., those fragments described herein). Polynucleotides which hybridize to the complement of these nucleic acid molecules under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention, as are polypeptides encoded by these polynucleotides and nucleic acids.

[088] In a preferred embodiment, the invention encompasses nucleic acid molecules which comprise, or alternatively, consist of a polynucleotide which hybridizes under stringent hybridization conditions, or alternatively, under lower stringency conditions, to a polynucleotide in (a), (b), (c), (d), (e), (f), (g), (h), or (i) above, as are polypeptides encoded by these polynucleotides. In another preferred embodiment, polynucleotides which hybridize to the complement of these nucleic acid molecules under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

[089] In another embodiment, the invention provides a purified protein comprising, or alternatively consisting of, a polypeptide having an amino acid sequence selected from the group consisting of: (a) the complete amino acid sequence of SEQ ID NO:Y or the complete amino acid sequence encoded by the cDNA in Clone ID NO:Z; (b) the amino acid sequence of a mature testes associated polypeptide having the amino acid sequence of SEQ ID NO:Y or the amino acid sequence encoded by the cDNA in Clone ID NO:Z; (c) the amino acid sequence of a biologically active fragment of a testes associated polypeptide having the complete amino acid sequence of SEQ ID NO:Y or the complete amino acid sequence encoded by the cDNA in Clone ID NO:Z; and (d) the amino acid sequence of an antigenic fragment of a testes associated polypeptide having the complete amino acid sequence of SEQ ID NO:Y or the complete amino acid sequence encoded by the cDNA in Clone ID NO:Z.

[090] The present invention is also directed to proteins which comprise, or alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%,

98%, 99% or 100%, identical to, for example, any of the amino acid sequences in (a), (b), (c), or (d), above, the amino acid sequence shown in SEQ ID NO:Y, the amino acid sequence encoded by the cDNA contained in Clone ID NO:Z, the amino acid sequence of the polypeptide encoded by the nucleotide sequence in SEQ ID NO:X as defined in columns 8 and 9 of Table 2, the amino acid sequence of the polypeptide encoded by the nucleotide sequence in SEQ ID NO:B as defined in column 6 of Table 1B, the amino acid sequence as defined in column 6 of Table 1A, an amino acid sequence encoded by the nucleotide sequence in SEQ ID NO:X, and an amino acid sequence encoded by the complement of the polynucleotide sequence in SEQ ID NO:X. Fragments of these polypeptides are also provided (e.g., those fragments described herein). Further proteins encoded by polynucleotides which hybridize to the complement of the nucleic acid molecules encoding these amino acid sequences under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention, as are the polynucleotides encoding these proteins.

[091] By a nucleic acid having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the nucleic acid is identical to the reference sequence except that the nucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a nucleic acid having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence referred to in Table 1A or 2 as the ORF (open reading frame), or any fragment specified, as described herein.

[092] As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject

sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245 (1990)). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is expressed as percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

[093] If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

[094] For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity

would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

[095] By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

[096] As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequence of a polypeptide referred to in Table 1A (e.g., an amino acid sequence identified in columns 5 or 6) or Table 2 (e.g., the amino acid sequence of the polypeptide encoded by the polynucleotide sequence defined in columns 8 and 9 of Table 2) or a fragment thereof, the amino acid sequence of the polypeptide encoded by the polynucleotide sequence in SEQ ID NO:B as defined in column 6 of Table 1B or a fragment thereof, the amino acid sequence of the polypeptide encoded by the nucleotide sequence in SEQ ID NO:X or a fragment thereof, or an amino acid sequence of the polypeptide encoded by cDNA contained in Clone ID NO:Z, or a fragment thereof, can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence

alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci.6:237-245 (1990)). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is expressed as percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

[097] If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C- terminal residues of the subject sequence.

[098] For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C- termini not matched/total number of residues in the query sequence) so 10% is subtracted from

the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

[0099] The polynucleotide variants of the invention may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, polypeptide variants in which less than 50, less than 40, less than 30, less than 20, less than 10, or 5-50, 5-25, 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

[0100] Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

[0101] Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the polypeptides of the present invention without substantial loss of biological function. As an example, the authors of Ron et

al., J. Biol. Chem. 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

[0102] Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem. 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

[0103] Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

[0104] Thus, the invention further includes polypeptide variants which show a functional activity (e.g., biological activity) of the polypeptides of the invention. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as to have little effect on activity.

[0105] The present application is directed to nucleic acid molecules at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the nucleic acid sequences disclosed herein, (e.g., encoding a polypeptide having the amino acid

sequence of an N and/or C terminal deletion), irrespective of whether they encode a polypeptide having functional activity. This is because even where a particular nucleic acid molecule does not encode a polypeptide having functional activity, one of skill in the art would still know how to use the nucleic acid molecule, for instance, as a hybridization probe or a polymerase chain reaction (PCR) primer. Uses of the nucleic acid molecules of the present invention that do not encode a polypeptide having functional activity include, *inter alia*, (1) isolating a gene or allelic or splice variants thereof in a cDNA library; (2) *in situ* hybridization (e.g., "FISH") to metaphase chromosomal spreads to provide precise chromosomal location of the gene, as described in Verma et al., Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York (1988); (3) Northern Blot analysis for detecting mRNA expression in specific tissues (e.g., normal testicular tissues or diseased testicular tissues); and (4) *in situ* hybridization (e.g., histochemistry) for detecting mRNA expression in specific tissues (e.g., normal testicular tissues or diseased testicular tissues).

[0106] Preferred, however, are nucleic acid molecules having sequences at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the nucleic acid sequences disclosed herein, which do, in fact, encode a polypeptide having functional activity. By a polypeptide having "functional activity" is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) protein of the invention. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a polypeptide of the invention for binding) to an anti-polypeptide of the invention antibody], immunogenicity (ability to generate antibody which binds to a specific polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide of the invention.

[0107] The functional activity of the polypeptides, and fragments, variants and derivatives of the invention, can be assayed by various methods.

[0108] For example, in one embodiment where one is assaying for the ability to bind or compete with full-length polypeptide of the present invention for binding to an anti-polypeptide of the invention antibody, various immunoassays known in the art can be used, including but not limited to, competitive and non-competitive assay

systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

[0109] In another embodiment, where a ligand is identified, or the ability of a polypeptide fragment, variant or derivative of the invention to multimerize is being evaluated, binding can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-reducing gel chromatography, protein affinity chromatography, and affinity blotting. See generally, Phizicky et al., *Microbiol. Rev.* 59:94-123 (1995). In another embodiment, the ability of physiological correlates of a polypeptide of the present invention to bind to a substrate(s) of the polypeptide of the invention can be routinely assayed using techniques known in the art.

[0110] In addition, assays described herein (see Examples) and otherwise known in the art may routinely be applied to measure the ability of polypeptides of the present invention and fragments, variants and derivatives thereof to elicit polypeptide related biological activity (either *in vitro* or *in vivo*). Other methods will be known to the skilled artisan and are within the scope of the invention.

[0111] Of course, due to the degeneracy of the genetic code, one of ordinary skill in the art will immediately recognize that a large number of the nucleic acid molecules having a sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to, for example, the nucleic acid sequence of the cDNA contained in Clone ID NO:Z, a nucleic acid sequence referred to in Table 1A (e.g., SEQ ID NO:X), a nucleic acid sequence disclosed in Table 2 (e.g., the nucleic acid sequence delineated in columns 8 and 9) or fragments thereof, will encode polypeptides "having functional

activity." In fact, since degenerate variants of any of these nucleotide sequences all encode the same polypeptide, in many instances, this will be clear to the skilled artisan even without performing the above described comparison assay. It will be further recognized in the art that, for such nucleic acid molecules that are not degenerate variants, a reasonable number will also encode a polypeptide having functional activity. This is because the skilled artisan is fully aware of amino acid substitutions that are either less likely or not likely to significantly effect protein function (e.g., replacing one aliphatic amino acid with a second aliphatic amino acid), as further described below.

[0112] For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," *Science* 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

[0113] The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

[0114] The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. See Cunningham et al., *Science* 244:1081-1085 (1989). The resulting mutant molecules can then be tested for biological activity.

[0115] As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains

are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly. Besides conservative amino acid substitutions, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitutions with one or more of the amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as, for example, an IgG Fc fusion region peptide, serum albumin (preferably human serum albumin) or a fragment or variant thereof, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

[0116] For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. See Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).

[0117] A further embodiment of the invention relates to polypeptides which comprise the amino acid sequence of a polypeptide having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions from a polypeptide sequence disclosed herein. Of course it is highly preferable for a polypeptide to have an amino acid sequence which comprises the amino acid sequence of a polypeptide of SEQ ID

NO:Y, an amino acid sequence encoded by SEQ ID NO:X, an amino acid sequence encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2, an amino acid sequence encoded by the complement of SEQ ID NO:X, and/or the amino acid sequence encoded by cDNA contained in Clone ID NO:Z which contains, in order of ever-increasing preference, at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions.

[0118] In specific embodiments, the polypeptides of the invention comprise, or alternatively, consist of, fragments or variants of a reference amino acid sequence selected from: (a) the amino acid sequence of SEQ ID NO:Y or fragments thereof (e.g., the mature form and/or other fragments described herein); (b) the amino acid sequence encoded by SEQ ID NO:X or fragments thereof; (c) the amino acid sequence encoded by the complement of SEQ ID NO:X or fragments thereof; (d) the amino acid sequence encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2 or fragments thereof; and (e) the amino acid sequence encoded by cDNA contained in Clone ID NO:Z or fragments thereof; wherein the fragments or variants have 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, amino acid residue additions, substitutions, and/or deletions when compared to the reference amino acid sequence. In preferred embodiments, the amino acid substitutions are conservative. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Polynucleotide and Polypeptide Fragments

[0119] The present invention is also directed to polynucleotide fragments of the polynucleotides (nucleic acids) of the invention. In the present invention, a "polynucleotide fragment" refers to a polynucleotide having a nucleic acid sequence which, for example: is a portion of the cDNA contained in Clone ID NO:Z or the complementary strand thereto; is a portion of the polynucleotide sequence encoding the polypeptide encoded by the cDNA contained in Clone ID NO:Z or the complementary strand thereto; is a portion of a polynucleotide sequence encoding the amino acid sequence encoded by the region of SEQ ID NO:X as defined in columns 8 and 9 of Table 2 or the complementary strand thereto; is a portion of the polynucleotide sequence of SEQ ID NO:X as defined in columns 8 and 9 of Table 2 or the complementary strand thereto; is a portion of the polynucleotide sequence in SEQ

403'

ID NO:X or the complementary strand thereto; is a polynucleotide sequence encoding a portion of the polypeptide of SEQ ID NO:Y; is a polynucleotide sequence encoding a portion of a polypeptide encoded by SEQ ID NO:X; is a polynucleotide sequence encoding a portion of a polypeptide encoded by the complement of the polynucleotide sequence in SEQ ID NO:X; is a portion of a polynucleotide sequence encoding the amino acid sequence encoded by the region of SEQ ID NO:B as defined in column 6 of Table 1B or the complementary strand thereto; or is a portion of the polynucleotide sequence of SEQ ID NO:B as defined in column 6 of Table 1B or the complementary strand thereto.

[0120] The polynucleotide fragments of the invention are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt, at least about 50 nt, at least about 75 nt, or at least about 150 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in Clone ID NO:Z, or the nucleotide sequence shown in SEQ ID NO:X or the complementary stand thereto. In this context "about" includes the particularly recited value or a value larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. These nucleotide fragments have uses that include, but are not limited to, as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., at least 160, 170, 180, 190, 200, 250, 500, 600, 1000, or 2000 nucleotides in length) are also encompassed by the invention.

[0121] Moreover, representative examples of polynucleotide fragments of the invention, comprise, or alternatively consist of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, 2001-2050, 2051-2100, 2101-2150, 2151-2200, 2201-2250, 2251-2300, 2301-2350, 2351-2400, 2401-2450, 2451-2500, 2501-2550, 2551-2600, 2601-2650, 2651-2700, 2701-2750, 2751-2800, 2801-2850, 2851-2900, 2901-2950, 2951-3000, 3001-3050, 3051-3100, 3101-3150, 3151-3200, 3201-3250, 3251-3300, 3301-3350, 3351-

3400, 3401-3450, 3451-3500, 3501-3550, 3551-3600, 3601-3650, 3651-3700, 3701-3750, 3751-3800, 3801-3850, 3851-3900, 3901-3950, 3951-4000, 4001-4050, 4051-4100, 4101-4150, 4151-4200, 4201-4250, 4251-4300, 4301-4350, 4351-4400, 4401-4450, 4451-4500, 4501-4550, 4551-4600, 4601-4650, 4651-4700, 4701-4750, 4751-4800, 4801-4850, 4851-4900, 4901-4950, 4951-5000, 5001-5050, 5051-5100, 5101-5150, 5151-5200, 5201-5250, 5251-5300, 5301-5350, 5351-5400, 5401-5450, 5451-5500, 5501-5550, 5551-5600, 5601-5650, 5651-5700, 5701-5750, 5751-5800, 5801-5850, 5851-5900, 5901-5950, 5951-6000, 6001-6050, 6051-6100, 6101-6150, 6151-6200, 6201-6250, 6251-6300, 6301-6350, 6351-6400, 6401-6450, 6451-6500, 6501-6550, 6551-6600, 6601-6650, 6651-6700, 6701-6750, 6751-6800, 6801-6850, 6851-6900, 6901-6950, 6951-7000, 7001-7050, 7051-7100, 7101-7150, 7151-7200, 7201-7250, 7251-7300 or 7301 to the end of SEQ ID NO:X, or the complementary strand thereto. In this context "about" includes the particularly recited range or a range larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has a functional activity (e.g., biological activity). More preferably, these polynucleotides can be used as probes or primers as discussed herein. Polynucleotides which hybridize to one or more of these polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

[0122] Further representative examples of polynucleotide fragments of the invention, comprise, or alternatively consist of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, 2001-2050, 2051-2100, 2101-2150, 2151-2200, 2201-2250, 2251-2300, 2301-2350, 2351-2400, 2401-2450, 2451-2500, 2501-2550, 2551-2600, 2601-2650, 2651-2700, 2701-2750, 2751-2800, 2801-2850, 2851-2900, 2901-2950, 2951-3000, 3001-3050, 3051-3100, 3101-3150, 3151-3200, 3201-3250, 3251-3300, 3301-3350, 3351-3400, 3401-3450, 3451-3500, 3501-3550, 3551-3600, 3601-3650, 3651-3700, 3701-

3750, 3751-3800, 3801-3850, 3851-3900, 3901-3950, 3951-4000, 4001-4050, 4051-4100, 4101-4150, 4151-4200, 4201-4250, 4251-4300, 4301-4350, 4351-4400, 4401-4450, 4451-4500, 4501-4550, 4551-4600, 4601-4650, 4651-4700, 4701-4750, 4751-4800, 4801-4850, 4851-4900, 4901-4950, 4951-5000, 5001-5050, 5051-5100, 5101-5150, 5151-5200, 5201-5250, 5251-5300, 5301-5350, 5351-5400, 5401-5450, 5451-5500, 5501-5550, 5551-5600, 5601-5650, 5651-5700, 5701-5750, 5751-5800, 5801-5850, 5851-5900, 5901-5950, 5951-6000, 6001-6050, 6051-6100, 6101-6150, 6151-6200, 6201-6250, 6251-6300, 6301-6350, 6351-6400, 6401-6450, 6451-6500, 6501-6550, 6551-6600, 6601-6650, 6651-6700, 6701-6750, 6751-6800, 6801-6850, 6851-6900, 6901-6950, 6951-7000, 7001-7050, 7051-7100, 7101-7150, 7151-7200, 7201-7250, 7251-7300 or 7301 to the end of the cDNA sequence contained in Clone ID NO:Z, or the complementary strand thereto. In this context "about" includes the particularly recited range or a range larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has a functional activity (e.g., biological activity). More preferably, these polynucleotides can be used as probes or primers as discussed herein. Polynucleotides which hybridize to one or more of these polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

[0123] Moreover, representative examples of polynucleotide fragments of the invention comprise, or alternatively consist of, a nucleic acid sequence comprising one, two, three, four, five, six, seven, eight, nine, ten, or more of the above described polynucleotide fragments of the invention in combination with a polynucleotide sequence delineated in Table 1B column 6. Additional, representative examples of polynucleotide fragments of the invention comprise, or alternatively consist of, a nucleic acid sequence comprising one, two, three, four, five, six, seven, eight, nine, ten, or more of the above described polynucleotide fragments of the invention in combination with a polynucleotide sequence that is the complementary strand of a sequence delineated in column 6 of Table 1B. In further embodiments, the above-described polynucleotide fragments of the invention comprise, or alternatively consist of, sequences delineated in Table 1B, column 6, and have a nucleic acid sequence

which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table 1B, column 5). In additional embodiments, the above-described polynucleotide fragments of the invention comprise, or alternatively consist of, sequences delineated in Table 1B, column 6, and have a nucleic acid sequence which is different from that published for the BAC clone identified as BAC ID NO:A (see Table 1B, column 4). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated Table 1B, column 6, and have a nucleic acid sequence which is different from that contained in the BAC clone identified as BAC ID NO:A (see Table 1B, column 4). Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides and polypeptides are also encompassed by the invention.

[0124] In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more fragments of the sequences delineated in column 6 of Table 1B, and the polynucleotide sequence of SEQ ID NO:X (e.g., as defined in Table 1B, column 2) or fragments or variants thereof. Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.

[0125] In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more fragments of the sequences delineated in column 6 of Table 1B which correspond to the same Clone ID NO:Z (see Table 1B, column 1), and the polynucleotide sequence of SEQ ID NO:X (e.g., as defined in Table 1A or 1B) or fragments or variants thereof. Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.

[0126] In further specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more fragments of the sequences delineated in the same row of column 6 of Table 1B, and the polynucleotide sequence of SEQ ID NO:X (e.g., as defined in Table

1A or 1B) or fragments or variants thereof. Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.

[0127] In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1B and the 5' 10 polynucleotides of the sequence of SEQ ID NO:X are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[0128] In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1B and the 5' 10 polynucleotides of a fragment or variant of the sequence of SEQ ID NO:X (e.g., as described herein) are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[0129] In further specific embodiments, polynucleotides of the invention comprise, or alternatively consist of a polynucleotide sequence in which the 3' 10 polynucleotides of a fragment or variant of the sequence of SEQ ID NO:X and the 5' 10 polynucleotides of the sequence of one of the sequences delineated in column 6 of Table 1B are directly contiguous. Nucleic acids which hybridize to the complement of

these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[0130] In specific embodiments, polynucleotides of the invention comprise, or alternatively consist of a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1B and the 5' 10 polynucleotides of another sequence in column 6 are directly contiguous. In preferred embodiments, the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1B is directly contiguous with the 5' 10 polynucleotides of the next sequential exon delineated in Table 1B, column 6. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[0131] In the present invention, a "polypeptide fragment" refers to an amino acid sequence which is a portion of that contained in SEQ ID NO:Y, a portion of an amino acid sequence encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2, a portion of an amino acid sequence encoded by the polynucleotide sequence of SEQ ID NO:X, a portion of an amino acid sequence encoded by the complement of the polynucleotide sequence in SEQ ID NO:X, and/or a portion of an amino acid sequence encoded by the cDNA contained in Clone ID NO:Z. Protein (polypeptide) fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of,

from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, 161-180, 181-200, 201-220, 221-240, 241-260, 261-280, 281-300, 301-320, 321-340, 341-360, 361-380, 381-400, 401-420, 421-440, 441-460, 461-480, 481-500, 501-520, 521-540, 541-560, 561-580, 581-600, 601-620, 621-640, 641-660, 661-680, 681-700, 701-720, 721-740, 741-760, 761-780, 781-800, 801-820, 821-840, 841-860, 861-880, 881-900, 901-920, 921-940, 941-960, 961-980, 981-1000, 1001-1020, 1021-1040, 1041-1060, 1061-1080, 1081-1100, 1101-1120, 1121-1140, 1141-1160, 1161-1180, 1181-1200, 1201-1220, 1221-1240, 1241-1260, 1261-1280, 1281-1300, 1301-1320, 1321-1340, 1341-1360, 1361-1380, 1381-1400, 1401-1420, 1421-1440, or 1441 to the end of the coding region. In a preferred embodiment, polypeptide fragments of the invention include, for example, fragments comprising, or alternatively consisting of, from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, 161-180, 181-200, 201-220, 221-240, 241-260, 261-280, 281-300, 301-320, 321-340, 341-360, 361-380, 381-400, 401-420, 421-440, 441-460, 461-480, 481-500, 501-520, 521-540, 541-560, 561-580, 581-600, 601-620, 621-640, 641-660, 661-680, 681-700, 701-720, 721-740, 741-760, 761-780, 781-800, 801-820, 821-840, 841-860, 861-880, 881-900, 901-920, 921-940, 941-960, 961-980, 981-1000, 1001-1020, 1021-1040, 1041-1060, 1061-1080, 1081-1100, 1101-1120, 1121-1140, 1141-1160, 1161-1180, 1181-1200, 1201-1220, 1221-1240, 1241-1260, 1261-1280, 1281-1300, 1301-1320, 1321-1340, 1341-1360, 1361-1380, 1381-1400, 1401-1420, 1421-1440, or 1441 to the end of the coding region of SEQ ID NO:Y. Moreover, polypeptide fragments of the invention may be at least about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges or values, or ranges or values larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes. Polynucleotides encoding these polypeptide fragments are also encompassed by the invention.

[0132] Even if deletion of one or more amino acids from the N-terminus of a protein results in modification or loss of one or more biological functions of the protein, other functional activities (e.g., biological activities, ability to multimerize, ability to bind a ligand) may still be retained. For example, the ability of shortened muteins to induce and/or bind to antibodies which recognize the complete or mature

forms of the polypeptides generally will be retained when less than the majority of the residues of the complete or mature polypeptide are removed from the N-terminus. Whether a particular polypeptide lacking N-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a mutain with a large number of deleted N-terminal amino acid residues may retain some biological or immunogenic activities. In fact, peptides composed of as few as six amino acid residues may often evoke an immune response.

[0133] Accordingly, polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions is preferred. Similarly, polynucleotides encoding these polypeptide fragments are also preferred.

[0134] The present invention further provides polypeptides having one or more residues deleted from the amino terminus of the amino acid sequence of a polypeptide disclosed herein (e.g., a polypeptide of SEQ ID NO:Y, a polypeptide encoded by the polynucleotide sequence contained in SEQ ID NO:X or the complement thereof, a polypeptide encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2, a polypeptide encoded by the portion of SEQ ID NO:B as defined in column 6 of Table 1B, and/or a polypeptide encoded by the cDNA contained in Clone ID NO:Z). In particular, N-terminal deletions may be described by the general formula $m-q$, where q is a whole integer representing the total number of amino acid residues in a polypeptide of the invention (e.g., the polypeptide disclosed in SEQ ID NO:Y, or the polypeptide encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2), and m is defined as any integer ranging from 2 to $q-6$. Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0135] The present invention further provides polypeptides having one or more residues from the carboxy terminus of the amino acid sequence of a polypeptide disclosed herein (e.g., a polypeptide of SEQ ID NO:Y, a polypeptide encoded by the polynucleotide sequence contained in SEQ ID NO:X, a polypeptide encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2, and/or a polypeptide encoded by the cDNA contained in Clone ID NO:Z). In particular, C-terminal deletions may be described by the general formula 1-n, where n is any whole integer ranging from 6 to q-1, and where n corresponds to the position of amino acid residue in a polypeptide of the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0136] In addition, any of the above described N- or C-terminal deletions can be combined to produce a N- and C-terminal deleted polypeptide. The invention also provides polypeptides having one or more amino acids deleted from both the amino and the carboxyl termini, which may be described generally as having residues m-n of a polypeptide encoded by SEQ ID NO:X (e.g., including, but not limited to, the preferred polypeptide disclosed as SEQ ID NO:Y and the polypeptide encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2), the cDNA contained in Clone ID NO:Z, and/or the complement thereof, where n and m are integers as described above. Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0137] Also as mentioned above, even if deletion of one or more amino acids from the C-terminus of a protein results in modification or loss of one or more biological functions of the protein, other functional activities (e.g., biological activities, ability to multimerize, ability to bind a ligand) may still be retained. For example the ability of the shortened mutein to induce and/or bind to antibodies which recognize the complete or mature forms of the polypeptide generally will be retained when less than the majority of the residues of the complete or mature polypeptide are removed from the C-terminus. Whether a particular polypeptide lacking C-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a mutein with a large number of deleted C-terminal amino acid residues may

retain some biological or immunogenic activities. In fact, peptides composed of as few as six amino acid residues may often evoke an immune response.

[0138] The present application is also directed to proteins containing polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a polypeptide sequence set forth herein. In preferred embodiments, the application is directed to proteins containing polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to polypeptides having the amino acid sequence of the specific N- and C-terminal deletions. Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0139] Any polypeptide sequence encoded by, for example, the polynucleotide sequences set forth as SEQ ID NO:X or the complement thereof, (presented, for example, in Tables 1A and 2), the cDNA contained in Clone ID NO:Z, or the polynucleotide sequence as defined in column 6 of Table 1B, may be analyzed to determine certain preferred regions of the polypeptide. For example, the amino acid sequence of a polypeptide encoded by a polynucleotide sequence of SEQ ID NO:X (e.g., the polypeptide of SEQ ID NO:Y and the polypeptide encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2) or the cDNA contained in Clone ID NO:Z may be analyzed using the default parameters of the DNASTAR computer algorithm (DNASTAR, Inc., 1228 S. Park St., Madison, WI 53715 USA; <http://www.dnastar.com/>).

[0140] Polypeptide regions that may be routinely obtained using the DNASTAR computer algorithm include, but are not limited to, Garnier-Robson alpha-regions, beta-regions, turn-regions, and coil-regions; Chou-Fasman alpha-regions, beta-regions, and turn-regions; Kyte-Doolittle hydrophilic regions and hydrophobic regions; Eisenberg alpha- and beta-amphipathic regions; Karplus-Schulz flexible regions; Emini surface-forming regions; and Jameson-Wolf regions of high antigenic index. Among highly preferred polynucleotides of the invention in this regard are those that encode polypeptides comprising regions that combine several structural features, such as several (e.g., 1, 2, 3 or 4) of the features set out above.

[0141] Additionally, Kyte-Doolittle hydrophilic regions and hydrophobic regions, Emini surface-forming regions, and Jameson-Wolf regions of high antigenic index (i.e., containing four or more contiguous amino acids having an antigenic index of

greater than or equal to 1.5, as identified using the default parameters of the Jameson-Wolf program) can routinely be used to determine polypeptide regions that exhibit a high degree of potential for antigenicity. Regions of high antigenicity are determined from data by DNASTAR analysis by choosing values which represent regions of the polypeptide which are likely to be exposed on the surface of the polypeptide in an environment in which antigen recognition may occur in the process of initiation of an immune response.

[0142] Preferred polypeptide fragments of the invention are fragments comprising, or alternatively, consisting of, an amino acid sequence that displays a functional activity (e.g. biological activity) of the polypeptide sequence of which the amino acid sequence is a fragment. By a polypeptide displaying a "functional activity" is meant a polypeptide capable of one or more known functional activities associated with a full-length protein, such as, for example, biological activity, antigenicity, immunogenicity, and/or multimerization, as described herein.

[0143] Other preferred polypeptide fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

[0144] In preferred embodiments, polypeptides of the invention comprise, or alternatively consist of, one, two, three, four, five or more of the antigenic fragments of the polypeptide of SEQ ID NO:Y, or portions thereof. Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0145] The present invention encompasses polypeptides comprising, or alternatively consisting of, an epitope of: the polypeptide sequence shown in SEQ ID NO:Y; a polypeptide sequence encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide sequence encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2; the polypeptide sequence encoded by the portion of SEQ ID NO:B as defined in column 6 of Table 1B or the complement thereto; the polypeptide sequence encoded by the cDNA contained in Clone ID NO:Z; or the polypeptide sequence encoded by a polynucleotide that hybridizes to the sequence of SEQ ID NO:X, the complement of the sequence of SEQ ID NO:X, the

complement of a portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2, or the cDNA sequence contained in Clone ID NO:Z under stringent hybridization conditions or alternatively, under lower stringency hybridization as defined *supra*. The present invention further encompasses polynucleotide sequences encoding an epitope of a polypeptide sequence of the invention (such as, for example, the sequence disclosed in SEQ ID NO:X, or a fragment thereof), polynucleotide sequences of the complementary strand of a polynucleotide sequence encoding an epitope of the invention, and polynucleotide sequences which hybridize to the complementary strand under stringent hybridization conditions or alternatively, under lower stringency hybridization conditions defined *supra*.

[0146] The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide encoding this polypeptide. An "immunogenic epitope," as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies described *infra*. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998- 4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross- reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

[0147] Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131- 5135 (1985) further described in U.S. Patent No. 4,631,211.)

[0148] In the present invention, antigenic epitopes preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30 amino acids. Preferred polypeptides comprising immunogenic or antigenic

epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in immunoassays. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe et al., Science 219:660-666 (1983)).

[0149] Non-limiting examples of epitopes of polypeptides that can be used to generate antibodies of the invention include a polypeptide comprising, or alternatively consisting of, at least one, two, three, four, five, six or more of the portion(s) of SEQ ID NO:Y specified in column 6 of Table 1A. These polypeptide fragments have been determined to bear antigenic epitopes of the proteins of the invention by the analysis of the Jameson-Wolf antigenic index which is included in the DNASTar suite of computer programs. By "comprise" it is intended that a polypeptide contains at least one, two, three, four, five, six or more of the portion(s) of SEQ ID NO:Y shown in column 6 of Table 1A, but it may contain additional flanking residues on either the amino or carboxyl termini of the recited portion. Such additional flanking sequences are preferably sequences naturally found adjacent to the portion; i.e., contiguous sequence shown in SEQ ID NO:Y. The flanking sequence may, however, be sequences from a heterologous polypeptide, such as from another protein described herein or from a heterologous polypeptide not described herein. In particular embodiments, epitope portions of a polypeptide of the invention comprise one, two, three, or more of the portions of SEQ ID NO:Y shown in column 6 of Table 1A. Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0150] Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. See, for instance, Sutcliffe et al., *supra*; Wilson et al., *supra*; Chow et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle et al., J. Gen. Virol. 66:2347-2354 (1985). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these immunogenic epitopes. The

polypeptides comprising one or more immunogenic epitopes may be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

[0151] Epitope-bearing polypeptides of the present invention may be used to induce antibodies according to methods well known in the art including, but not limited to, *in vivo* immunization, *in vitro* immunization, and phage display methods. See, e.g., Sutcliffe et al., *supra*; Wilson et al., *supra*, and Bittle et al., J. Gen. Virol., 66:2347-2354 (1985). If *in vivo* immunization is used, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a carrier using a linker such as maleimidobenzoyl- N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier- coupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 µg of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an immune response. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

[0152] As one of skill in the art will appreciate, and as discussed above, the polypeptides of the present invention (e.g., those comprising an immunogenic or antigenic epitope) can be fused to heterologous polypeptide sequences. For example, polypeptides of the present invention (including fragments or variants thereof), may be

fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination thereof and portions thereof, resulting in chimeric polypeptides. By way of another non-limiting example, polypeptides and/or antibodies of the present invention (including fragments or variants thereof) may be fused with albumin (including but not limited to recombinant human serum albumin or fragments or variants thereof (see, e.g., U.S. Patent No. 5,876,969, issued March 2, 1999, EP Patent 0 413 622, and U.S. Patent No. 5,766,883, issued June 16, 1998, herein incorporated by reference in their entirety)). In a preferred embodiment, polypeptides and/or antibodies of the present invention (including fragments or variants thereof) are fused with the mature form of human serum albumin (i.e., amino acids 1 – 585 of human serum albumin as shown in Figures 1 and 2 of EP Patent 0 322 094) which is herein incorporated by reference in its entirety. In another preferred embodiment, polypeptides and/or antibodies of the present invention (including fragments or variants thereof) are fused with polypeptide fragments comprising, or alternatively consisting of, amino acid residues 1-z of human serum albumin, where z is an integer from 369 to 419, as described in U.S. Patent 5,766,883 herein incorporated by reference in its entirety. Polypeptides and/or antibodies of the present invention (including fragments or variants thereof) may be fused to either the N- or C-terminal end of the heterologous protein (e.g., immunoglobulin Fc polypeptide or human serum albumin polypeptide). Polynucleotides encoding fusion proteins of the invention are also encompassed by the invention.

[0153] Such fusion proteins as those described above may facilitate purification and may increase half-life *in vivo*. This has been shown for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., Nature, 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the immune system has been demonstrated for antigens (e.g., insulin) conjugated to an FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO 96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion disulfide bonds have also been found to be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof

alone. See, e.g., Fountoulakis et al., J. Biochem., 270:3958-3964 (1995). Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin (HA) tag or flag tag) to aid in detection and purification of the expressed polypeptide. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991, Proc. Natl. Acad. Sci. USA 88:8972- 897). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni²⁺ nitriloacetic acid-agarose column and histidine-tagged proteins can be selectively eluted with imidazole-containing buffers.

Fusion Proteins

[0154] Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, polypeptides of the present invention which are shown to be secreted can be used as targeting molecules once fused to other proteins.

[0155] Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

[0156] In certain preferred embodiments, proteins of the invention are fusion proteins comprising an amino acid sequence that is an N and/or C- terminal deletion of a polypeptide of the invention. In preferred embodiments, the invention is directed to a fusion protein comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a polypeptide sequence of the invention. Polynucleotides encoding these proteins are also encompassed by the invention.

[0157] Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

[0158] As one of skill in the art will appreciate that, as discussed above, polypeptides of the present invention, and epitope-bearing fragments thereof, can be combined with heterologous polypeptide sequences. For example, the polypeptides of the present invention may be fused with heterologous polypeptide sequences, for example, the polypeptides of the present invention may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM) or portions thereof (CH1, CH2, CH3, and any combination thereof, including both entire domains and portions thereof), or albumin (including, but not limited to, native or recombinant human albumin or fragments or variants thereof (see, e.g., U.S. Patent No. 5,876,969, issued March 2, 1999, EP Patent 0 413 622, and U.S. Patent No. 5,766,883, issued June 16, 1998, herein incorporated by reference in their entirety)), resulting in chimeric polypeptides. For example, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties (EP-A 0232 262). Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. See, D. Bennett et al., *J. Molecular Recognition* 8:52-58 (1995); K. Johanson et al., *J. Biol. Chem.* 270:9459-9471 (1995).

[0159] Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a polypeptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., Cell 37:767 (1984).)

[0160] Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"), briefly described below, and further described herein. DNA shuffling may be employed to modulate the activities of polypeptides of the invention, such methods can be used to generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, Trends Biotechnol. 16(2):76-82 (1998); Hansson et al., J. Mol. Biol. 287:265-76 (1999); and Lorenzo and Blasco, Biotechniques 24(2):308-13 (1998); each of these patents and publications are hereby incorporated by reference in its entirety). In a preferred embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of a polynucleotide encoding a polypeptide of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc., of one or more heterologous molecules encoding a heterologous polypeptide.

[0161] Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

Recombinant and Synthetic Production of Polypeptides of the Invention

[0162] The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by synthetic

and recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

[0163] The polynucleotides of the invention may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged *in vitro* using an appropriate packaging cell line and then transduced into host cells.

[0164] The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli lac*, *trp*, *phoA* and *tac* promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

[0165] As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance, glutamine synthase, for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells (e.g., *Saccharomyces cerevisiae* or *Pichia pastoris* (ATCC Accession No. 201178)); insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, 293, NSO and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

[0166] Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems,

Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Preferred expression vectors for use in yeast systems include, but are not limited to pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalph, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, pPIC9K, and PAO815 (all available from Invitrogen, Carlsbad, CA). Other suitable vectors will be readily apparent to the skilled artisan.

[0167] Vectors which use glutamine synthase (GS) or DHFR as the selectable markers can be amplified in the presence of the drugs methionine sulfoximine or methotrexate, respectively. An advantage of glutamine synthase based vectors is the availability of cell lines (e.g., the murine myeloma cell line, NS0) which are glutamine synthase negative. Glutamine synthase expression systems can also function in glutamine synthase expressing cells (e.g., Chinese Hamster Ovary (CHO) cells) by providing additional inhibitor to prevent the functioning of the endogenous gene. A glutamine synthase expression system and components thereof are detailed in PCT publications: WO87/04462; WO86/05807; WO89/01036; WO89/10404; and WO91/06657 which are hereby incorporated in their entireties by reference herein. Additionally, glutamine synthase expression vectors can be obtained from Lonza Biologics, Inc. (Portsmouth, NH). Expression and production of monoclonal antibodies using a GS expression system in murine myeloma cells is described in Bebbington et al., *Bio/technology* 10:169(1992) and in Biblia and Robinson *Biotechnol. Prog.* 11:1 (1995) which are herein incorporated by reference.

[0168] The present invention also relates to host cells containing the above-described vector constructs described herein, and additionally encompasses host cells containing nucleotide sequences of the invention that are operably associated with one or more heterologous control regions (e.g., promoter and/or enhancer) using techniques known of in the art. The host cell can be a higher eukaryotic cell, such as a mammalian cell (e.g., a human derived cell), or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. A host strain may be chosen which modulates the expression of the inserted gene sequences, or modifies and processes the gene product in the specific fashion desired. Expression

from certain promoters can be elevated in the presence of certain inducers; thus expression of the genetically engineered polypeptide may be controlled. Furthermore, different host cells have characteristics and specific mechanisms for the translational and post-translational processing and modification (e.g., phosphorylation, cleavage) of proteins. Appropriate cell lines can be chosen to ensure the desired modifications and processing of the foreign protein expressed.

[0169] Introduction of the nucleic acids and nucleic acid constructs of the invention into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., *Basic Methods In Molecular Biology* (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

[0170] In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., testicular antigen coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with testes associated polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous testes associated polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous testes associated polynucleotide sequences via homologous recombination (see, e.g., U.S. Patent Number 5,641,670, issued June 24, 1997; International Publication Number WO 96/29411; International Publication Number WO 94/12650; Koller et al., *Proc. Natl. Acad. Sci. USA* 86:8932-8935 (1989); and Zijlstra et al., *Nature* 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

[0171] Polypeptides of the present invention can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including,

for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

[0172] In one embodiment, the yeast *Pichia pastoris* is used to express polypeptides of the invention in a eukaryotic system. *Pichia pastoris* is a methylotrophic yeast which can metabolize methanol as its sole carbon source. A main step in the methanol metabolization pathway is the oxidation of methanol to formaldehyde using O₂. This reaction is catalyzed by the enzyme alcohol oxidase. In order to metabolize methanol as its sole carbon source, *Pichia pastoris* must generate high levels of alcohol oxidase due, in part, to the relatively low affinity of alcohol oxidase for O₂. Consequently, in a growth medium depending on methanol as a main carbon source, the promoter region of one of the two alcohol oxidase genes (*AOX1*) is highly active. In the presence of methanol, alcohol oxidase produced from the *AOX1* gene comprises up to approximately 30% of the total soluble protein in *Pichia pastoris*. See, Ellis, S.B., *et al.*, *Mol. Cell. Biol.* 5:1111-21 (1985); Koutz, P.J., *et al.*, *Yeast* 5:167-77 (1989); Tschopp, J.F., *et al.*, *Nucl. Acids Res.* 15:3859-76 (1987). Thus, a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, under the transcriptional regulation of all or part of the *AOX1* regulatory sequence is expressed at exceptionally high levels in *Pichia* yeast grown in the presence of methanol.

[0173] In one example, the plasmid vector pPIC9K is used to express DNA encoding a polypeptide of the invention, as set forth herein, in a *Pichea* yeast system

essentially as described in "*Pichia* Protocols: Methods in Molecular Biology," D.R. Higgins and J. Cregg, eds. The Humana Press, Totowa, NJ, 1998. This expression vector allows expression and secretion of a polypeptide of the invention by virtue of the strong *AOX1* promoter linked to the *Pichia pastoris* alkaline phosphatase (PHO) secretory signal peptide (i.e., leader) located upstream of a multiple cloning site.

[0174] Many other yeast vectors could be used in place of pPIC9K, such as, pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalpha, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, and PAO815, as one skilled in the art would readily appreciate, as long as the proposed expression construct provides appropriately located signals for transcription, translation, secretion (if desired), and the like, including an in-frame AUG as required.

[0175] In another embodiment, high-level expression of a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, may be achieved by cloning the heterologous polynucleotide of the invention into an expression vector such as, for example, pGAPZ or pGAPZalpha, and growing the yeast culture in the absence of methanol.

[0176] In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

[0177] In addition, polypeptides of the invention can be chemically synthesized using techniques known in the art (e.g., see Creighton, 1983, *Proteins: Structures and Molecular Principles*, W.H. Freeman & Co., N.Y., and Hunkapiller et al., *Nature*, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a polypeptide can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid, α -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, g-Abu, e-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, b-alanine, fluoro-amino acids, designer amino acids such as b-methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

[0178] The invention encompasses polypeptides of the present invention which are differentially modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH_4 ; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

[0179] Additional post-translational modifications encompassed by the invention include, for example, e.g., N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of procaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

[0180] Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include iodine (^{121}I , ^{123}I , ^{125}I , ^{131}I), carbon (^{14}C), sulfur (^{35}S), tritium (^3H), indium (^{111}In , ^{112}In , $^{113\text{m}}\text{In}$, $^{115\text{m}}\text{In}$), technetium (^{99}Tc , $^{99\text{m}}\text{Tc}$), thallium (^{201}Tl), gallium (^{68}Ga , ^{67}Ga), palladium (^{103}Pd), molybdenum (^{99}Mo), xenon (^{133}Xe), fluorine (^{18}F), ^{153}Sm , ^{177}Lu , ^{159}Gd , ^{149}Pm , ^{140}La , ^{175}Yb , ^{166}Ho , ^{90}Y , ^{47}Sc , ^{186}Re , ^{188}Re , ^{142}Pr , ^{105}Rh , and ^{97}Ru .

[0181] In specific embodiments, a polypeptide of the present invention or fragment or variant thereof is attached to macrocyclic chelators that associate with radiometal ions, including but not limited to, ^{177}Lu , ^{90}Y , ^{166}Ho , and ^{153}Sm , to polypeptides. In a preferred embodiment, the radiometal ion associated with the macrocyclic chelators is ^{111}In . In another preferred embodiment, the radiometal ion associated with the macrocyclic chelator is ^{90}Y . In specific embodiments, the macrocyclic chelator is 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA). In other specific embodiments, DOTA is attached to an antibody of the invention or fragment thereof via a linker molecule. Examples of linker molecules useful for conjugating DOTA to a polypeptide are commonly known in the art - see, for example, DeNardo et al., Clin Cancer Res. 4(10):2483-90 (1998); Peterson et al., Bioconjug. Chem. 10(4):553-7 (1999); and Zimmerman et al, Nucl. Med. Biol. 26(8):943-50 (1999); which are hereby incorporated by reference in their entirety.

[0182] As mentioned, the testes associated proteins of the invention may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given testes associated polypeptide. testes associated polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic testes

associated polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth. Enzymol. 182:626-646 (1990); Rattan et al., Ann. N.Y. Acad. Sci. 663:48-62 (1992)).

[0183] Also provided by the invention are chemically modified derivatives of the polypeptides of the invention which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent No. 4,179,337). The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

[0184] The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or

lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog). For example, the polyethylene glycol may have an average molecular weight of about 200, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, 20,000, 25,000, 30,000, 35,000, 40,000, 50,000, 55,000, 60,000, 65,000, 70,000, 75,000, 80,000, 85,000, 90,000, 95,000, or 100,000 kDa.

[0185] As noted above, the polyethylene glycol may have a branched structure. Branched polyethylene glycols are described, for example, in U.S. Patent No. 5,643,575; Morpurgo et al., *Appl. Biochem. Biotechnol.* 56:59-72 (1996); Vorobjev et al., *Nucleosides Nucleotides* 18:2745-2750 (1999); and Caliceti et al., *Bioconjug. Chem.* 10:638-646 (1999), the disclosures of each of which are incorporated herein by reference.

[0186] The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those skilled in the art, such as, for example, the method disclosed in EP 0 401 384 (coupling PEG to G-CSF), herein incorporated by reference; see also Malik et al., *Exp. Hematol.* 20:1028-1035 (1992), reporting pegylation of GM-CSF using tresyl chloride. For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

[0187] As suggested above, polyethylene glycol may be attached to proteins via linkage to any of a number of amino acid residues. For example, polyethylene glycol can be linked to proteins via covalent bonds to lysine, histidine, aspartic acid,

glutamic acid, or cysteine residues. One or more reaction chemistries may be employed to attach polyethylene glycol to specific amino acid residues (e.g., lysine, histidine, aspartic acid, glutamic acid, or cysteine) of the protein or to more than one type of amino acid residue (e.g., lysine, histidine, aspartic acid, glutamic acid, cysteine and combinations thereof) of the protein.

[0188] One may specifically desire proteins chemically modified at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

[0189] As indicated above, pegylation of the proteins of the invention may be accomplished by any number of means. For example, polyethylene glycol may be attached to the protein either directly or by an intervening linker. Linkerless systems for attaching polyethylene glycol to proteins are described in Delgado et al., Crit. Rev. Thera. Drug Carrier Sys. 9:249-304 (1992); Francis et al., Intern. J. of Hematol. 68:1-18 (1998); U.S. Patent No. 4,002,531; U.S. Patent No. 5,349,052; WO 95/06058; and WO 98/32466, the disclosures of each of which are incorporated herein by reference.

[0190] One system for attaching polyethylene glycol directly to amino acid residues of proteins without an intervening linker employs tresylated MPEG, which is produced by the modification of monmethoxy polyethylene glycol (MPEG) using tresylchloride ($\text{ClSO}_2\text{CH}_2\text{CF}_3$). Upon reaction of protein with tresylated MPEG, polyethylene glycol is directly attached to amine groups of the protein. Thus, the

invention includes protein-polyethylene glycol conjugates produced by reacting proteins of the invention with a polyethylene glycol molecule having a 2,2,2-trifluoroethane sulphonyl group.

[0191] Polyethylene glycol can also be attached to proteins using a number of different intervening linkers. For example, U.S. Patent No. 5,612,460, the entire disclosure of which is incorporated herein by reference, discloses urethane linkers for connecting polyethylene glycol to proteins. Protein-polyethylene glycol conjugates wherein the polyethylene glycol is attached to the protein by a linker can also be produced by reaction of proteins with compounds such as MPEG-succinimidylsuccinate, MPEG activated with 1,1'-carbonyldiimidazole, MPEG-2,4,5-trichloropenylcarbonate, MPEG-p-nitrophenolcarbonate, and various MPEG-succinate derivatives. A number of additional polyethylene glycol derivatives and reaction chemistries for attaching polyethylene glycol to proteins are described in International Publication No. WO 98/32466, the entire disclosure of which is incorporated herein by reference. Pegylated protein products produced using the reaction chemistries set out herein are included within the scope of the invention.

[0192] The number of polyethylene glycol moieties attached to each protein of the invention (i.e., the degree of substitution) may also vary. For example, the pegylated proteins of the invention may be linked, on average, to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, or more polyethylene glycol molecules. Similarly, the average degree of substitution within ranges such as 1-3, 2-4, 3-5, 4-6, 5-7, 6-8, 7-9, 8-10, 9-11, 10-12, 11-13, 12-14, 13-15, 14-16, 15-17, 16-18, 17-19, or 18-20 polyethylene glycol moieties per protein molecule. Methods for determining the degree of substitution are discussed, for example, in Delgado et al., Crit. Rev. Thera. Drug Carrier Sys. 9:249-304 (1992).

[0193] The testes associated polypeptides of the invention can be recovered and purified from chemical synthesis and recombinant cell cultures by standard methods which include, but are not limited to, ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification. Well

known techniques for refolding protein may be employed to regenerate active conformation when the polypeptide is denatured during isolation and/or purification.

[0194] Testes associated polynucleotides and polypeptides may be used in accordance with the present invention for a variety of applications, particularly those that make use of the chemical and biological properties of testes associated antigens. Among these are applications in the detection, prevention, diagnosis and/or treatment of diseases associated with the testes, such as e.g., testicular cancer, tumors, cryptorchid testicle, varicocele, azoospermia, testicular cancers, and those described in the "Reproductive System Disorders" section below. Additional applications relate to diagnosis and to treatment of disorders of cells, tissues and organisms. These aspects of the invention are discussed further below.

[0195] In a preferred embodiment, polynucleotides expressed in a particular tissue type (see, e.g., Table 1A, column 7) are used to detect, diagnose, treat, prevent and/or prognose disorders associated with the tissue type.

[0196] The polypeptides of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present invention relates to monomers and multimers of the polypeptides of the invention, their preparation, and compositions (preferably, Therapeutics) containing them. In specific embodiments, the polypeptides of the invention are monomers, dimers, trimers or tetramers. In additional embodiments, the multimers of the invention are at least dimers, at least trimers, or at least tetramers.

[0197] Multimers encompassed by the invention may be homomers or heteromers. As used herein, the term homomer refers to a multimer containing only polypeptides corresponding to a protein of the invention (e.g., the amino acid sequence of SEQ ID NO:Y, an amino acid sequence encoded by SEQ ID NO:X or the complement of SEQ ID NO:X, the amino acid sequence encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2, and/or an amino acid sequence encoded by cDNA contained in Clone ID NO:Z (including fragments, variants, splice variants, and fusion proteins, corresponding to these as described herein)). These homomers may contain polypeptides having identical or different amino acid sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptides having an identical amino acid sequence. In another specific embodiment, a homomer

of the invention is a multimer containing polypeptides having different amino acid sequences. In specific embodiments, the multimer of the invention is a homodimer (e.g., containing two polypeptides having identical or different amino acid sequences) or a homotrimer (e.g., containing three polypeptides having identical and/or different amino acid sequences). In additional embodiments, the homomeric multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homotetramer.

[0198] As used herein, the term heteromer refers to a multimer containing two or more heterologous polypeptides (i.e., polypeptides of different proteins) in addition to the polypeptides of the invention. In a specific embodiment, the multimer of the invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

[0199] Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked by, for example, liposome formation. Thus, in one embodiment, multimers of the invention, such as, for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers of the invention, such as, for example, heterotrimers or heterotetramers, are formed when polypeptides of the invention contact antibodies to the polypeptides of the invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the invention are formed by covalent associations with and/or between the polypeptides of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence (e.g., that recited in SEQ ID NO:Y, encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2, and/or encoded by the cDNA contained in Clone ID NO:Z). In one instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the heterologous polypeptide sequence in a fusion protein. In one example, covalent associations are between the heterologous sequence

contained in a fusion protein of the invention (see, e.g., U.S. Patent Number 5,478,925). In a specific example, the covalent associations are between the heterologous sequence contained in a Fc fusion protein of the invention (as described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another protein that is capable of forming covalently associated multimers, such as for example, osteoprotegerin (see, e.g., International Publication NO: WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627 (hereby incorporated by reference). Proteins comprising multiple polypeptides of the invention separated by peptide linkers may be produced using conventional recombinant DNA technology.

[0200] Another method for preparing multimer polypeptides of the invention involves use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al., Science 240:1759, (1988)), and have since been found in a variety of different proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins of the invention are those described in PCT application WO 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide sequence that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture supernatant using techniques known in the art.

[0201] Trimeric polypeptides of the invention may offer the advantage of enhanced biological activity. Preferred leucine zipper moieties and isoleucine moieties are those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. (FEBS Letters 344:191, (1994)) and in U.S. patent application Ser. No. 08/446,922, hereby

incorporated by reference. Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric polypeptides of the invention.

[0202] In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention containing Flag® polypeptide sequence. In a further embodiment, proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti-Flag® antibody.

[0203] The multimers of the invention may be generated using chemical techniques known in the art. For example, polypeptides desired to be contained in the multimers of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., U.S. Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues located within the sequence of the polypeptides desired to be contained in the multimer (see, e.g., U.S. Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Further, polypeptides of the invention may be routinely modified by the addition of cysteine or biotin to the C-terminus or N-terminus of the polypeptide and techniques known in the art may be applied to generate multimers containing one or more of these modified polypeptides (see, e.g., U.S. Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, techniques known in the art may be applied to generate liposomes containing the polypeptide components desired to be contained in the multimer of the invention (see, e.g., U.S. Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

[0204] Alternatively, multimers of the invention may be generated using genetic engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see, e.g., U.S. Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are generated by ligating a polynucleotide sequence encoding a polypeptide of the

invention to a sequence encoding a linker polypeptide and then further to a synthetic polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., U.S. Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In another embodiment, recombinant techniques described herein or otherwise known in the art are applied to generate recombinant polypeptides of the invention which contain a transmembrane domain (or hydrophobic or signal peptide) and which can be incorporated by membrane reconstitution techniques into liposomes (see, e.g., U.S. Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Antibodies

[0205] Further polypeptides of the invention relate to antibodies and T-cell antigen receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of the invention (e.g., a polypeptide or fragment or variant of the amino acid sequence of SEQ ID NO:Y or a polypeptide encoded by the cDNA contained in Clone ID NO:Z, and/or an epitope, of the present invention) as determined by immunoassays well known in the art for assaying specific antibody-antigen binding. Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), intracellularly-made antibodies (i.e., intrabodies), and epitope-binding fragments of any of the above. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule. In preferred embodiments, the immunoglobulin molecules of the invention are IgG1. In other preferred embodiments, the immunoglobulin molecules of the invention are IgG4.

[0206] Most preferably the antibodies are human antigen-binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab' and F(ab')₂, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, ship rabbit, goat, guinea pig, camel, horse, or chicken. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described *infra* and, for example in, U.S. Patent No. 5,939,598 by Kucherlapati et al.

[0207] The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol. 147:60-69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., J. Immunol. 148:1547-1553 (1992).

[0208] Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention which they recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be specified as described herein, e.g., by N-terminal and C-terminal positions, or by size in contiguous amino acid residues, or listed in the Tables and Figures. Preferred epitopes of the invention include those shown in column 6 of Table 1A, as well as polynucleotides that encode these epitopes. Antibodies which specifically bind any epitope or polypeptide of the present invention may also be excluded. Therefore, the

present invention includes antibodies that specifically bind polypeptides of the present invention, and allows for the exclusion of the same.

[0209] Antibodies of the present invention may also be described or specified in terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of a polypeptide of the present invention are included. Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described herein). Antibodies of the present invention may also be described or specified in terms of their binding affinity to a polypeptide of the invention. Preferred binding affinities include those with a dissociation constant or K_d less than 5×10^{-2} M, 10^{-2} M, 5×10^{-3} M, 10^{-3} M, 5×10^{-4} M, 10^{-4} M, 5×10^{-5} M, 10^{-5} M, 5×10^{-6} M, 10^{-6} M, 5×10^{-7} M, 10^{-7} M, 5×10^{-8} M, 10^{-8} M, 5×10^{-9} M, 10^{-9} M, 5×10^{-10} M, 10^{-10} M, 5×10^{-11} M, 10^{-11} M, 5×10^{-12} M, 10^{-12} M, 5×10^{-13} M, 10^{-13} M, 5×10^{-14} M, 10^{-14} M, 5×10^{-15} M, or 10^{-15} M.

[0210] The invention also provides antibodies that competitively inhibit binding of an antibody to an epitope of the invention as determined by any method known in the art for determining competitive binding, for example, the immunoassays described herein. In preferred embodiments, the antibody competitively inhibits binding to the

epitope by at least 95%, at least 90%, at least 85 %, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50%.

[0211] Antibodies of the present invention may act as agonists or antagonists of the polypeptides of the present invention. For example, the present invention includes antibodies which disrupt the receptor/ligand interactions with the polypeptides of the invention either partially or fully. Preferably, antibodies of the present invention bind an antigenic epitope disclosed herein, or a portion thereof. The invention features both receptor-specific antibodies and ligand-specific antibodies. The invention also features receptor-specific antibodies which do not prevent ligand binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For example, receptor activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described *supra*). In specific embodiments, antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of the antibody.

[0212] The invention also features receptor-specific antibodies which both prevent ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand complex, and, preferably, do not specifically recognize the unbound receptor or the unbound ligand. Likewise, included in the invention are neutralizing antibodies which bind the ligand and prevent binding of the ligand to the receptor, as well as antibodies which bind the ligand, thereby preventing receptor activation, but do not prevent the ligand from binding the receptor. Further included in the invention are antibodies which activate the receptor. These antibodies may act as receptor agonists, i.e., potentiate or activate either all or a subset of the biological activities of the ligand-mediated receptor activation, for example, by inducing dimerization of the receptor. The antibodies may be specified as agonists, antagonists or inverse agonists for biological activities comprising the specific biological activities of the peptides of the invention disclosed herein. The above antibody agonists can be made using methods known in the art. See, e.g., PCT publication WO 96/40281; U.S. Patent No. 5,811,097; Deng et al., Blood 92(6):1981-1988 (1998); Chen et al., Cancer Res.

58(16):3668-3678 (1998); Harrop et al., J. Immunol. 161(4):1786-1794 (1998); Zhu et al., Cancer Res. 58(15):3209-3214 (1998); Yoon et al., J. Immunol. 160(7):3170-3179 (1998); Prat et al., J. Cell. Sci. 111(Pt2):237-247 (1998); Pitard et al., J. Immunol. Methods 205(2):177-190 (1997); Liautard et al., Cytokine 9(4):233-241 (1997); Carlson et al., J. Biol. Chem. 272(17):11295-11301 (1997); Taryman et al., Neuron 14(4):755-762 (1995); Muller et al., Structure 6(9):1153-1167 (1998); Bartunek et al., Cytokine 8(1):14-20 (1996) (which are all incorporated by reference herein in their entireties).

[0213] Antibodies of the present invention may be used, for example, to purify, detect, and target the polypeptides of the present invention, including both *in vitro* and *in vivo* diagnostic and therapeutic methods. For example, the antibodies have utility in immunoassays for qualitatively and quantitatively measuring levels of the polypeptides of the present invention in biological samples. See, e.g., Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); incorporated by reference herein in its entirety.

[0214] As discussed in more detail below, the antibodies of the present invention may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated (including covalent and non-covalent conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438; WO 89/12624; U.S. Patent No. 5,314,995; and EP 396,387; the disclosures of which are incorporated herein by reference in their entireties.

[0215] The antibodies of the invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical

modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

[0216] The antibodies of the present invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of-interest can be produced by various procedures well known in the art. For example, a polypeptide of the invention can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.

[0217] Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: *Monoclonal Antibodies and T-Cell Hybridomas* 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). The term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

[0218] Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art and are discussed in detail in the Examples. In a non-limiting example, mice can be immunized with a polypeptide of the invention or a cell expressing such peptide. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse

serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells, for example cells from cell line SP20 available from the ATCC. Hybridomas are selected and cloned by limited dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding a polypeptide of the invention. Ascites fluid, which generally contains high levels of antibodies, can be generated by immunizing mice with positive hybridoma clones.

[0219] Accordingly, the present invention provides methods of generating monoclonal antibodies as well as antibodies produced by the method comprising culturing a hybridoma cell secreting an antibody of the invention wherein, preferably, the hybridoma is generated by fusing splenocytes isolated from a mouse immunized with an antigen of the invention with myeloma cells and then screening the hybridomas resulting from the fusion for hybridoma clones that secrete an antibody able to bind a polypeptide of the invention.

[0220] Another well known method for producing both polyclonal and monoclonal human B cell lines is transformation using Epstein Barr Virus (EBV). Protocols for generating EBV-transformed B cell lines are commonly known in the art, such as, for example, the protocol outlined in Chapter 7.22 of Current Protocols in Immunology, Coligan et al., Eds., 1994, John Wiley & Sons, NY, which is hereby incorporated in its entirety by reference herein. The source of B cells for transformation is commonly human peripheral blood, but B cells for transformation may also be derived from other sources including, but not limited to, lymph nodes, tonsil, spleen, tumor tissue, and infected tissues. Tissues are generally made into single cell suspensions prior to EBV transformation. Additionally, steps may be taken to either physically remove or inactivate T cells (e.g., by treatment with cyclosporin A) in B cell-containing samples, because T cells from individuals seropositive for anti-EBV antibodies can suppress B cell immortalization by EBV.

[0221] In general, the sample containing human B cells is inoculated with EBV, and cultured for 3-4 weeks. A typical source of EBV is the culture supernatant of the B95-8 cell line (ATCC #VR-1492). Physical signs of EBV transformation can generally be seen towards the end of the 3-4 week culture period. By phase-contrast microscopy, transformed cells may appear large, clear, hairy and tend to aggregate in

tight clusters of cells. Initially, EBV lines are generally polyclonal. However, over prolonged periods of cell cultures, EBV lines may become monoclonal or polyclonal as a result of the selective outgrowth of particular B cell clones. Alternatively, polyclonal EBV transformed lines may be subcloned (e.g., by limiting dilution culture) or fused with a suitable fusion partner and plated at limiting dilution to obtain monoclonal B cell lines. Suitable fusion partners for EBV transformed cell lines include mouse myeloma cell lines (e.g., SP2/0, X63-Ag8.653), heteromyeloma cell lines (human x mouse; e.g., SPAM-8, SBC-H20, and CB-F7), and human cell lines (e.g., GM 1500, SKO-007, RPMI 8226, and KR-4). Thus, the present invention also provides a method of generating polyclonal or monoclonal human antibodies against polypeptides of the invention or fragments thereof, comprising EBV-transformation of human B cells.

[0222] Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')₂ fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments). F(ab')₂ fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain. For example, the antibodies of the present invention can also be generated using various phage display methods known in the art and as discussed in detail in the Examples (e.g., Example 10). In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., J. Immunol. Methods 182:41-50 (1995); Ames et al., J. Immunol. Methods 184:177-186

(1995); Kettleborough et al., Eur. J. Immunol. 24:952-958 (1994); Persic et al., Gene 187 9-18 (1997); Burton et al., Advances in Immunology 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

[0223] As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')₂ fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., BioTechniques 12(6):864-869 (1992); and Sawai et al., AJRI 34:26-34 (1995); and Better et al., Science 240:1041-1043 (1988) (said references incorporated by reference in their entireties).

[0224] Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston et al., Methods in Enzymology 203:46-88 (1991); Shu et al., PNAS 90:7995-7999 (1993); and Skerra et al., Science 240:1038-1040 (1988). For some uses, including *in vivo* use of antibodies in humans and *in vitro* detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Gillies et al., (1989) J. Immunol. Methods 125:191-202; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entirety. Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-

human species and a framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which are incorporated herein by reference in their entireties.) Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska. et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332).

[0225] Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety.

[0226] Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the human variable region, constant region, and diversity region may be introduced into mouse embryonic stem cells in addition to the human heavy and light chain genes. The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents

endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, *Int. Rev. Immunol.* 13:65-93 (1995). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; 5,939,598; 6,075,181 and 6,114,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

[0227] Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., *Bio/technology* 12:899-903 (1988)).

[0228] Further, antibodies to the polypeptides of the invention can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" polypeptides of the invention using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, *FASEB J.* 7(5):437-444; (1989) and Nissinoff, J. *Immunol.* 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide multimerization and/or binding of a polypeptide of the invention to a ligand can be used to generate anti-idiotypes that "mimic" the polypeptide multimerization and/or

binding domain and, as a consequence, bind to and neutralize polypeptide and/or its ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize polypeptide ligand/receptor. For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind its ligand(s)/receptor(s), and thereby block its biological activity. Alternatively, antibodies which bind to and enhance polypeptide multimerization and/or binding, and/or receptor/ligand multimerization, binding and/or signaling can be used to generate anti-idiotypes that function as agonists of a polypeptide of the invention and/or its ligand/receptor. Such agonistic anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens as agonists of the polypeptides of the invention or its ligand(s)/receptor(s). For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind its ligand(s)/receptor(s), and thereby promote or enhance its biological activity.

[0229] Intrabodies of the invention can be produced using methods known in the art, such as those disclosed and reviewed in Chen et al., *Hum. Gene Ther.* 5:595-601 (1994); Marasco, W.A., *Gene Ther.* 4:11-15 (1997); Rondon and Marasco, *Annu. Rev. Microbiol.* 51:257-283 (1997); Proba et al., *J. Mol. Biol.* 275:245-253 (1998); Cohen et al., *Oncogene* 17:2445-2456 (1998); Ohage and Steipe, *J. Mol. Biol.* 291:1119-1128 (1999); Ohage et al., *J. Mol. Biol.* 291:1129-1134 (1999); Wirtz and Steipe, *Protein Sci.* 8:2245-2250 (1999); Zhu et al., *J. Immunol. Methods* 231:207-222 (1999); and references cited therein.

Polynucleotides Encoding Antibodies

[0230] The invention further provides polynucleotides comprising a nucleotide sequence encoding an antibody of the invention and fragments thereof. The invention also encompasses polynucleotides that hybridize under stringent or alternatively, under lower stringency hybridization conditions, e.g., as defined *supra*, to polynucleotides that encode an antibody, preferably, that specifically binds to a polypeptide of the invention, preferably, an antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO:Y, to a polypeptide encoded by a portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2, and/or to a polypeptide encoded by the cDNA contained in Clone ID NO:Z.

[0231] The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. For example, if the nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., *BioTechniques* 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

[0232] Alternatively, a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

[0233] Once the nucleotide sequence and corresponding amino acid sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY and Ausubel et al., eds., 1998, *Current Protocols in Molecular Biology*, John Wiley & Sons, NY, which are both incorporated by reference herein in their entireties), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

[0234] In a specific embodiment, the amino acid sequence of the heavy and/or light chain variable domains may be inspected to identify the sequences of the

complementarity determining regions (CDRs) by methods that are well known in the art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using routine recombinant DNA techniques, one or more of the CDRs may be inserted within framework regions, e.g., into human framework regions to humanize a non-human antibody, as described *supra*. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., J. Mol. Biol. 278: 457-479 (1998) for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds a polypeptide of the invention. Preferably, as discussed *supra*, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.

[0235] In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., Proc. Natl. Acad. Sci. 81:851-855 (1984); Neuberger et al., Nature 312:604-608 (1984); Takeda et al., Nature 314:452-454 (1985)) by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. As described *supra*, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.

[0236] Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778; Bird, Science 242:423-42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region

via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in *E. coli* may also be used (Skerra et al., Science 242:1038- 1041 (1988)).

[0237] *Methods of Producing Antibodies*

[0238] The antibodies of the invention can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques. Methods of producing antibodies include, but are not limited to, hybridoma technology, EBV transformation, and other methods discussed herein as well as through the use recombinant DNA technology, as discussed below.

[0239] Recombinant expression of an antibody of the invention, or fragment, derivative or analog thereof, (e.g., a heavy or light chain of an antibody of the invention or a single chain antibody of the invention), requires construction of an expression vector containing a polynucleotide that encodes the antibody. Once a polynucleotide encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention, or a heavy or light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT Publication WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of

the antibody may be cloned into such a vector for expression of the entire heavy or light chain.

[0240] The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody of the invention. Thus, the invention includes host cells containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain thereof, or a single chain antibody of the invention, operably linked to a heterologous promoter. In preferred embodiments for the expression of double-chained antibodies, vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.

[0241] A variety of host-expression vector systems may be utilized to express the antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule of the invention in situ. These include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as *Escherichia coli*, and more preferably, eukaryotic cells, especially for the expression of whole recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For

example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., Gene 45:101 (1986); Cockett et al., Bio/Technology 8:2 (1990)).

[0242] In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an antibody molecule, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the E. coli expression vector pUR278 (Ruther et al., EMBO J. 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, Nucleic Acids Res. 13:3101-3109 (1985); Van Heeke & Schuster, J. Biol. Chem. 24:5503-5509 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

[0243] In an insect system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

[0244] In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome

(e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA 81:355-359 (1984)). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al., Methods in Enzymol. 153:51-544 (1987)).

[0245] In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell line such as, for example, CRL7030 and Hs578Bst.

[0246] For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to

grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.

[0247] A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817 (1980)) genes can be employed in tk-, hgp^rt- or ap^rt- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Natl. Acad. Sci. USA 77:357 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA 78:1527 (1981)); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 (Clinical Pharmacy 12:488-505; Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); TIB TECH 11(5):155-215 (1993)); and hyg^r, which confers resistance to hygromycin (Santerre et al., Gene 30:147 (1984)). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), Current Protocols in Human Genetics, John Wiley & Sons, NY (1994); Colberre-Garapin et al., J. Mol. Biol. 150:1 (1981), which are incorporated by reference herein in their entirety.

[0248] The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA

cloning, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will also increase (Crouse et al., Mol. Cell. Biol. 3:257 (1983)).

[0249] Vectors which use glutamine synthase (GS) or DHFR as the selectable markers can be amplified in the presence of the drugs methionine sulfoximine or methotrexate, respectively. An advantage of glutamine synthase based vectors are the availability of cell lines (e.g., the murine myeloma cell line, NS0) which are glutamine synthase negative. Glutamine synthase expression systems can also function in glutamine synthase expressing cells (e.g., Chinese Hamster Ovary (CHO) cells) by providing additional inhibitor to prevent the functioning of the endogenous gene. A glutamine synthase expression system and components thereof are detailed in PCT publications: WO87/04462; WO86/05807; WO89/01036; WO89/10404; and WO91/06657 which are incorporated in their entireties by reference herein. Additionally, glutamine synthase expression vectors that may be used according to the present invention are commercially available from suppliers, including, for example Lonza Biologics, Inc. (Portsmouth, NH). Expression and production of monoclonal antibodies using a GS expression system in murine myeloma cells is described in Bebbington et al., Bio/technology 10:169(1992) and in Biblia and Robinson Biotechnol. Prog. 11:1 (1995) which are incorporated in their entireties by reference herein.

[0250] The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, Nature 322:52 (1986); Kohler, Proc. Natl. Acad. Sci. USA 77:2197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

[0251] Once an antibody molecule of the invention has been produced by an animal, chemically synthesized, or recombinantly expressed, it may be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In addition, the antibodies of the present invention or fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

[0252] The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention. For example, antibodies may be used to target the polypeptides of the present invention to particular cell types, either *in vitro* or *in vivo*, by fusing or conjugating the polypeptides of the present invention to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in *in vitro* immunoassays and purification methods using methods known in the art. See e.g., Harbor et al., *supra*, and PCT publication WO 93/21232; EP 439,095; Naramura et al., *Immunol. Lett.* 39:91-99 (1994); U.S. Patent 5,474,981; Gillies et al., *PNAS* 89:1428-1432 (1992); Fell et al., *J. Immunol.* 146:2446-2452 (1991), which are incorporated by reference in their entireties.

[0253] The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the constant region, hinge region, CH1 domain, CH2 domain, and CH3 domain or any

combination of whole domains or portions thereof. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known in the art. See, e.g., U.S. Patent Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 91/06570; Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88:10535-10539 (1991); Zheng et al., J. Immunol. 154:5590-5600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11337- 11341 (1992) (said references incorporated by reference in their entireties).

[0254] As discussed, *supra*, the polypeptides corresponding to a polypeptide, polypeptide fragment, or a variant of SEQ ID NO:Y may be fused or conjugated to the above antibody portions to increase the *in vivo* half life of the polypeptides or for use in immunoassays using methods known in the art. Further, the polypeptides corresponding to SEQ ID NO:Y may be fused or conjugated to the above antibody portions to facilitate purification. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See EP 394,827; Traunecker et al., Nature 331:84-86 (1988). The polypeptides of the present invention fused or conjugated to an antibody having disulfide-linked dimeric structures (due to the IgG) may also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. See, for example, Fountoulakis et al., J. Biochem. 270:3958-3964 (1995). In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. See, for example, EP A 232,262. Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput

screening assays to identify antagonists of hIL-5. (See, Bennett et al., J. Molecular Recognition 8:52-58 (1995); Johanson et al., J. Biol. Chem. 270:9459-9471 (1995)).

[0255] Moreover, the antibodies or fragments thereof of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags useful for purification include, but are not limited to, the "HA" tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., Cell 37:767 (1984)) and the "flag" tag.

[0256] The present invention further encompasses antibodies or fragments thereof conjugated to a diagnostic or therapeutic agent. The antibodies can be used diagnostically to, for example, monitor the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the antibody (or fragment thereof) or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Patent No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention.

[0257] Further, an antibody or fragment thereof may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytotoxic agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example, ²¹³Bi. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicin,

doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis- dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

[0258] The conjugates of the invention can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, α -interferon, β -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF- α , TNF- β , AIM I (See, International Publication No. WO 97/33899), AIM II (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi *et al.*, *Int. Immunol.*, 6:1567-1574 (1994)), VEGI (See, International Publication No. WO 99/23105), a thrombotic agent or an anti- angiogenic agent, e.g., angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

[0259] Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

[0260] Techniques for conjugating such therapeutic moiety to antibodies are well known. See, for example., Arnon *et al.*, "Monoclonal Antibodies For

Immunotargeting Of Drugs In Cancer Therapy", in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", Immunol. Rev. 62:119-58 (1982).

[0261] Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which is incorporated herein by reference in its entirety.

[0262] An antibody, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can be used as a therapeutic.

Immunophenotyping

[0263] The antibodies of the invention may be utilized for immunophenotyping of cell lines and biological samples. Translation products of the genes of the present invention may be useful as cell specific markers, or more specifically as cellular markers that are differentially expressed at various stages of differentiation and/or maturation of particular cell types. Monoclonal antibodies directed against a specific epitope, or combination of epitopes, will allow for the screening of cellular populations expressing the marker. Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and include magnetic separation using antibody-coated magnetic beads, "panning" with antibody attached to a solid matrix (i.e., plate), and flow cytometry (See, e.g., U.S. Patent 5,985,660; and Morrison et al., Cell, 96:737-49 (1999)).

[0264] These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e. minimal residual disease

(MRD) in acute leukemic patients) and "non-self" cells in transplantations to prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

Assays For Antibody Binding

[0265] The antibodies of the invention may be assayed for immunospecific binding by any method known in the art. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, and protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

[0266] Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X- 100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1% Trasylol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (e.g., 1-4 hours) at 4° C, adding protein A and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 4° C, washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding

immunoprecipitation protocols see, e.g., Ausubel et al., eds., (1994), Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, section 10.16.1.

[0267] Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g., ³²P or ¹²⁵I) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e.g., Ausubel et al., eds., (1994), Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, section 10.8.1.

[0268] ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the coated well. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al., eds.,

(1994), Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, section 11.2.1.

[0269] The binding affinity of an antibody to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g., 3H or 125I) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of interest conjugated to a labeled compound (e.g., 3H or 125I) in the presence of increasing amounts of an unlabeled second antibody.

[0270] Antibodies of the invention may be characterized using immunocytochemistry methods on cells (e.g., mammalian cells, such as CHO cells) transfected with a vector enabling the expression of a testicular antigen or with vector alone using techniques commonly known in the art. Antibodies that bind testicular antigen transfected cells, but not vector-only transfected cells, are testicular antigen specific.

Therapeutic Uses

[0271] The present invention is further directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention (including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of a polypeptide of the invention, including, but not limited to, any one or more of the diseases, disorders, or conditions described herein. The treatment

and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

[0272] In a specific and preferred embodiment, the present invention is directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the diseases, disorders, or conditions of the testes, including, but not limited to, cryptorchid testicle, varicocele, azoospermia, testicular cancers, and those described in the "Reproductive System Disorders" section below. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention (e.g., antibodies directed to the full length protein expressed on the cell surface of a mammalian cell; antibodies directed to an epitope of a testes associated polypeptide of the invention (such as, a linear epitope (shown in Table 1A, column 6) or a conformational epitope), including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of a polypeptide of the invention, including, but not limited to, any one or more of the diseases, disorders, or conditions of the testes described herein. The treatment and/or prevention of diseases, disorders, or conditions of the testes associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

[0273] A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings

provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

[0274] The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

[0275] The antibodies of the invention may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment, human antibodies, fragments derivatives, analogs, or nucleic acids, are administered to a human patient for therapy or prophylaxis.

[0276] It is preferred to use high affinity and/or potent *in vivo* inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides of the invention, including fragments thereof. Preferred binding affinities include those with a dissociation constant or K_d less than 5×10^{-2} M, 10^{-2} M, 5×10^{-3} M, 10^{-3} M, 5×10^{-4} M, 10^{-4} M, 5×10^{-5} M, 10^{-5} M, 5×10^{-6} M, 10^{-6} M, 5×10^{-7} M, 10^{-7} M, 5×10^{-8} M, 10^{-8} M, 5×10^{-9} M, 10^{-9} M, 5×10^{-10} M, 10^{-10} M, 5×10^{-11} M, 10^{-11} M, 5×10^{-12} M, 10^{-12} M, 5×10^{-13} M, 10^{-13} M, 5×10^{-14} M, 10^{-14} M, 5×10^{-15} M, and 10^{-15} M.

Gene Therapy

[0277] In a specific embodiment, nucleic acids comprising sequences encoding antibodies or functional derivatives thereof, are administered to treat, inhibit or prevent a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention, by way of gene therapy. Gene therapy refers to therapy

performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect.

[0278] Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

[0279] For general reviews of the methods of gene therapy, see Goldspiel et al., *Clinical Pharmacy* 12:488-505 (1993); Wu and Wu, *Biotherapy* 3:87-95 (1991); Tolstoshev, *Ann. Rev. Pharmacol. Toxicol.* 32:573-596 (1993); Mulligan, *Science* 260:926-932 (1993); and Morgan and Anderson, *Ann. Rev. Biochem.* 62:191-217 (1993); May, *TIBTECH* 11(5):155-215 (1993). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1993); and Kriegler, *Gene Transfer and Expression, A Laboratory Manual*, Stockton Press, NY (1990).

[0280] In a preferred embodiment, the compound comprises nucleic acid sequences encoding an antibody, said nucleic acid sequences being part of expression vectors that express the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acid sequences have promoters operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue-specific. In another particular embodiment, nucleic acid molecules are used in which the antibody coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the antibody encoding nucleic acids (Koller and Smithies, *Proc. Natl. Acad. Sci. USA* 86:8932-8935 (1989); Zijlstra et al., *Nature* 342:435-438 (1989). In specific embodiments, the expressed antibody molecule is a single chain antibody; alternatively, the nucleic acid sequences include sequences encoding both the heavy and light chains, or fragments thereof, of the antibody.

[0281] Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid-carrying vectors, or indirect, in which case, cells are first transformed with the nucleic acids *in*

vitro, then transplanted into the patient. These two approaches are known, respectively, as *in vivo* or *ex vivo* gene therapy.

[0282] In a specific embodiment, the nucleic acid sequences are directly administered *in vivo*, where it is expressed to produce the encoded product. This can be accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted *in vivo* for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989)).

[0283] In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention are used. For example, a retroviral vector can be used (see Miller et al., Meth. Enzymol. 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al., Biotherapy 6:291-302 (1994), which describes the use of a

retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., *J. Clin. Invest.* 93:644-651 (1994); Kiem et al., *Blood* 83:1467-1473 (1994); Salmons and Gunzberg, *Human Gene Therapy* 4:129-141 (1993); and Grossman and Wilson, *Curr. Opin. in Genetics and Devel.* 3:110-114 (1993).

[0284] Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, *Current Opinion in Genetics and Development* 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., *Human Gene Therapy* 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., *Science* 252:431-434 (1991); Rosenfeld et al., *Cell* 68:143-155 (1992); Mastrangeli et al., *J. Clin. Invest.* 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., *Gene Therapy* 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.

[0285] Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., *Proc. Soc. Exp. Biol. Med.* 204:289-300 (1993); U.S. Patent No. 5,436,146).

[0286] Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

[0287] In this embodiment, the nucleic acid is introduced into a cell prior to administration *in vivo* of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection,

electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, Meth. Enzymol. 217:599-618 (1993); Cohen et al., Meth. Enzymol. 217:618-644 (1993); Cline, Pharmac. Ther. 29:69-92m (1985) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

[0288] The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.

[0289] Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

[0290] In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

[0291] In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered *in vivo* for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained *in vitro* can potentially be used in accordance with this embodiment of the present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson,

Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

[0292] In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by the presence or absence of an appropriate inducer of transcription.

Demonstration of Therapeutic or Prophylactic Activity

[0293] The compounds or pharmaceutical compositions of the invention are preferably tested *in vitro*, and then *in vivo* for the desired therapeutic or prophylactic activity, prior to use in humans. For example, *in vitro* assays to demonstrate the therapeutic or prophylactic utility of a compound or pharmaceutical composition include, the effect of a compound on a cell line or a patient tissue sample. The effect of the compound or composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, *in vitro* assays which can be used to determine whether administration of a specific compound is indicated, include *in vitro* cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.

Therapeutic/Prophylactic Administration and Composition

[0294] The invention provides methods of treatment, inhibition and prophylaxis by administration to a subject of an effective amount of a compound or pharmaceutical composition of the invention, preferably a polypeptide or antibody of the invention. In a preferred embodiment, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

[0295] Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above;

additional appropriate formulations and routes of administration can be selected from among those described herein below.

[0296] Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

[0297] In a specific embodiment, it may be desirable to administer the pharmaceutical compounds or compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

[0298] In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (see Langer, Science 249:1527-1533 (1990); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein

and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*)

[0299] In yet another embodiment, the compound or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, *supra*; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)). In another embodiment, polymeric materials can be used (see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., Macromol. Sci. Rev. Macromol. Chem. 23:61 (1983); see also Levy et al., Science 228:190 (1985); During et al., Ann. Neurol. 25:351 (1989); Howard et al., J.Neurosurg. 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, e.g., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, *supra*, vol. 2, pp. 115-138 (1984)).

[0300] Other controlled release systems are discussed in the review by Langer (Science 249:1527-1533 (1990)).

[0301] In a specific embodiment where the compound of the invention is a nucleic acid encoding a protein, the nucleic acid can be administered *in vivo* to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox- like peptide which is known to enter the nucleus (see e.g., Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

[0302] The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a compound, and a pharmaceutically acceptable carrier. In a specific embodiment, the term

"pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

[0303] In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry

lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

[0304] The compounds of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

[0305] The amount of the compound of the invention which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, *in vitro* assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from *in vitro* or animal model test systems.

[0306] For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

[0307] The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

Diagnosis and Imaging

[0308] Labeled antibodies, and derivatives and analogs thereof, which specifically bind to a polypeptide of interest can be used for diagnostic purposes to detect, diagnose, or monitor diseases, disorders, and/or conditions associated with the aberrant expression and/or activity of a polypeptide of the invention. The invention provides for the detection of aberrant expression of a polypeptide of interest, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of aberrant expression.

[0309] The invention provides a diagnostic assay for diagnosing a testicular disorder, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a particular disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

[0310] Antibodies of the invention can be used to assay protein levels in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen et al., J. Cell . Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine (^{125}I , ^{121}I), carbon (^{14}C), sulfur (^{35}S), tritium (^3H), indium (^{112}In), and technetium (^{99}Tc); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

[0311] One facet of the invention is the detection and diagnosis of a disease or disorder associated with aberrant expression of a polypeptide of interest in an animal, preferably a mammal and most preferably a human. A preferred embodiment of the invention is the detection and diagnosis of a disease or disorder of the testes associated with aberrant expression of a testicular antigen in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled molecule which specifically binds to the polypeptide of interest; b) waiting for a time interval following the administering for permitting the labeled molecule to preferentially concentrate at sites in the subject where the polypeptide is expressed (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled molecule in the subject, such that detection of labeled molecule above the background level indicates that the subject has a particular disease or disorder associated with aberrant expression of the polypeptide of interest. Background level can be determined by various methods including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

[0312] It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of $^{99\text{mTc}}$. The labeled antibody or antibody fragment will then preferentially

accumulate at the location of cells which contain the specific protein. *In vivo* tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982)).

[0313] Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5 to 20 days or 5 to 10 days.

[0314] In an embodiment, the method for diagnosing the disease or disorder, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

[0315] Presence of the labeled molecule can be detected in the patient using methods known in the art for *in vivo* scanning. These methods depend upon the type of label used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

[0316] In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Patent No. 5,441,050). In another embodiment, the molecule is labeled with a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patient using positron emission-tomography. In yet another embodiment, the molecule is labeled with a paramagnetic label and is detected in a patient using magnetic resonance imaging (MRI).

Kits

[0317] The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises an antibody of the invention, preferably a purified antibody, in one or more containers. In a specific embodiment, the kits of the present invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. Preferably, the kits of the present invention further comprise a control antibody which does not react with the polypeptide of interest. In another specific embodiment, the kits of the present invention contain a means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate).

[0318] In another specific embodiment of the present invention, the kit is a diagnostic kit for use in screening serum containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides. Such a kit may include a control antibody that does not react with the polypeptide of interest. Such a kit may include a substantially isolated polypeptide antigen comprising an epitope which is specifically immunoreactive with at least one anti-polypeptide antigen antibody. Further, such a kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or rhodamine which can be detected by flow cytometry). In specific embodiments, the kit may include a recombinantly produced or chemically synthesized polypeptide antigen. The polypeptide antigen of the kit may also be attached to a solid support.

[0319] In a more specific embodiment the detecting means of the above-described kit includes a solid support to which said polypeptide antigen is attached. Such a kit may also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to the polypeptide antigen can be detected by binding of the said reporter-labeled antibody.

[0320] In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The diagnostic kit includes a substantially isolated antibody specifically immunoreactive

with polypeptide or polynucleotide antigens, and means for detecting the binding of the polynucleotide or polypeptide antigen to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

[0321] In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the methods of the present invention. After binding with specific antigen antibody to the reagent and removing unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of bound anti-antigen antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate (Sigma, St. Louis, MO).

[0322] The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, 96-well plate or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group. Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

[0323] Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface-bound recombinant antigens, and a reporter-labeled anti-human antibody for detecting surface-bound anti-antigen antibody.

Uses of the Polynucleotides

- [0324] Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.
- [0325] The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome, thus each polynucleotide of the present invention can routinely be used as a chromosome marker using techniques known in the art. Table 1A, column 8 provides the chromosome location of some of the polynucleotides of the invention.
- [0326] Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably at least 15 bp (e.g., 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can optionally be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to SEQ ID NO:X will yield an amplified fragment.
- [0327] Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, preselection by hybridization to construct chromosome specific-cDNA libraries, and computer mapping techniques (See, e.g., Shuler, Trends Biotechnol 16:456-459 (1998) which is hereby incorporated by reference in its entirety).
- [0328] Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see

Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

[0329] For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes).

[0330] Thus, the present invention also provides a method for chromosomal localization which involves (a) preparing PCR primers from the polynucleotide sequences in Table 1A and/or Table 2 and SEQ ID NO:X and (b) screening somatic cell hybrids containing individual chromosomes.

[0331] The polynucleotides of the present invention would likewise be useful for radiation hybrid mapping, HAPPY mapping, and long range restriction mapping. For a review of these techniques and others known in the art, see, e.g. Dear, "Genome Mapping: A Practical Approach," IRL Press at Oxford University Press, London (1997); Aydin, J. Mol. Med. 77:691-694 (1999); Hacia et al., Mol. Psychiatry 3:483-492 (1998); Herrick et al., Chromosome Res. 7:409-423 (1999); Hamilton et al., Methods Cell Biol. 62:265-280 (2000); and/or Ott, J. Hered. 90:68-70 (1999), each of which is hereby incorporated by reference in its entirety.

[0332] Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library).) Column 9 of Table 1A provides an OMIM reference identification number of diseases associated with the cytologic band disclosed in column 8 of Table 1A, as determined using techniques described herein and by reference to Table 5. Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

[0333] Thus, once coinheritance is established, differences in a polynucleotide of the invention and the corresponding gene between affected and unaffected individuals can be examined. First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no

structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicate that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

[0334] Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using the polynucleotides of the invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker. Diagnostic and prognostic methods, kits and reagents encompassed by the present invention are briefly described below and more thoroughly elsewhere herein (see e.g., the sections labeled “Antibodies”, “Diagnostic Assays”, and “Methods for Detecting Testicular Disease, Including Cancer”).

[0335] Thus, the invention also provides a diagnostic method useful during diagnosis of a disorder, involving measuring the expression level of polynucleotides of the present invention in cells or body fluid from an individual and comparing the measured gene expression level with a standard level of polynucleotide expression level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a disorder. Additional non-limiting examples of diagnostic methods encompassed by the present invention are more thoroughly described elsewhere herein (see, e.g., Example 12).

[0336] In still another embodiment, the invention includes a kit for analyzing samples for the presence of proliferative and/or cancerous polynucleotides derived from a test subject, as further described herein. In a general embodiment, the kit includes at least one polynucleotide probe containing a nucleotide sequence that will specifically hybridize with a polynucleotide of the invention and a suitable container. In a specific embodiment, the kit includes two polynucleotide probes defining an internal region of the polynucleotide of the invention, where each probe has one strand containing a 31’mer-end internal to the region. In a further embodiment, the probes may be useful as primers for polymerase chain reaction amplification.

[0337] Where a diagnosis of a related disorder, including, for example, diagnosis of a tumor, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed polynucleotide of the invention expression will experience a worse clinical outcome relative to patients expressing the gene at a level nearer the standard level.

[0338] By "measuring the expression level of polynucleotides of the invention" is intended qualitatively or quantitatively measuring or estimating the level of the polypeptide of the invention or the level of the mRNA encoding the polypeptide of the invention in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the polypeptide level or mRNA level in a second biological sample). Preferably, the polypeptide level or mRNA level in the first biological sample is measured or estimated and compared to a standard polypeptide level or mRNA level, the standard being taken from a second biological sample obtained from an individual not having the related disorder or being determined by averaging levels from a population of individuals not having a related disorder. As will be appreciated in the art, once a standard polypeptide level or mRNA level is known, it can be used repeatedly as a standard for comparison.

[0339] By "biological sample" is intended any biological sample obtained from an individual, body fluid, cell line, tissue culture, or other source which contains polypeptide of the present invention or the corresponding mRNA. As indicated, biological samples include body fluids (such as semen, lymph, vaginal pool, sera, plasma, urine, synovial fluid and spinal fluid) which contain the polypeptide of the present invention, and tissue sources found to express the polypeptide of the present invention. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

[0340] The method(s) provided above may preferably be applied in a diagnostic method and/or kits in which polynucleotides and/or polypeptides of the invention are attached to a solid support. In one exemplary method, the support may be a "gene chip" or a "biological chip" as described in U.S. Patents 5,837,832, 5,874,219, and 5,856,174. Further, such a gene chip with polynucleotides of the invention attached

may be used to identify polymorphisms between the isolated polynucleotide sequences of the invention, with polynucleotides isolated from a test subject. The knowledge of such polymorphisms (i.e., their location, as well as, their existence) would be beneficial in identifying disease loci for many disorders, such as for example, in neural disorders, immune system disorders, muscular disorders, reproductive disorders, gastrointestinal disorders, pulmonary disorders, digestive disorders, cardiovascular disorders, renal disorders, proliferative disorders, and/or cancerous diseases and conditions. Such a method is described in U.S. Patents 5,858,659 and 5,856,104. The U.S. Patents referenced *supra* are hereby incorporated by reference in their entirety herein.

[0341] The present invention encompasses polynucleotides of the present invention that are chemically synthesized, or reproduced as peptide nucleic acids (PNA), or according to other methods known in the art. The use of PNAs would serve as the preferred form if the polynucleotides of the invention are incorporated onto a solid support, or gene chip. For the purposes of the present invention, a peptide nucleic acid (PNA) is a polyamide type of DNA analog and the monomeric units for adenine, guanine, thymine and cytosine are available commercially (Perceptive Biosystems). Certain components of DNA, such as phosphorus, phosphorus oxides, or deoxyribose derivatives, are not present in PNAs. As disclosed by Nielsen et al., *Science* 254:1497 (1991); and Egholm et al., *Nature* 365:666 (1993), PNAs bind specifically and tightly to complementary DNA strands and are not degraded by nucleases. In fact, PNA binds more strongly to DNA than DNA itself does. This is probably because there is no electrostatic repulsion between the two strands, and also the polyamide backbone is more flexible. Because of this, PNA/DNA duplexes bind under a wider range of stringency conditions than DNA/DNA duplexes, making it easier to perform multiplex hybridization. Smaller probes can be used than with DNA due to the strong binding. In addition, it is more likely that single base mismatches can be determined with PNA/DNA hybridization because a single mismatch in a PNA/DNA 15-mer lowers the melting point ($T_{sub.m}$) by 8°-20° C, vs. 4°-16° C for the DNA/DNA 15-mer duplex. Also, the absence of charge groups in PNA means that hybridization can be done at low ionic strengths and reduce possible interference by salt during the analysis.

[0342] The compounds of the present invention have uses which include, but are not limited to, detecting cancer in mammals. In particular the invention is useful during diagnosis of pathological cell proliferative neoplasias which include, but are not limited to: acute myelogenous leukemias including acute monocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute erythroleukemia, acute megakaryocytic leukemia, and acute undifferentiated leukemia, etc.; and chronic myelogenous leukemias including chronic myelomonocytic leukemia, chronic granulocytic leukemia, etc. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

[0343] The compounds of the present invention have preferred uses which include, but are not limited to, detecting testicular cancer in mammals. In particular the invention is useful during diagnosis of pathological cell proliferative neoplasias which include, but are not limited to: germ cell tumors (e.g., seminomas, embryonal cell carcinomas, teratocarcinomas, choriocarcinomas, and yolk sac tumors) and stromal tumors (e.g., Leydig cell tumors). Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

[0344] Pathological cell proliferative disorders are often associated with inappropriate activation of proto-oncogenes. (Germann, E. P. et al., "The Etiology of Acute Leukemia: Molecular Genetics and Viral Oncology," in Neoplastic Diseases of the Blood, Vol 1., Wiernik, P. H. et al. eds., 161-182 (1985)). Neoplasias are now believed to result from the qualitative alteration of a normal cellular gene product, or from the quantitative modification of gene expression by insertion into the chromosome of a viral sequence, by chromosomal translocation of a gene to a more actively transcribed region, or by some other mechanism. (Germann et al., *supra*) It is likely that mutated or altered expression of specific genes is involved in the pathogenesis of some leukemias, among other tissues and cell types. (Germann et al., *supra*) Indeed, the human counterparts of the oncogenes involved in some animal neoplasias have been amplified or translocated in some cases of human leukemia and carcinoma. (Germann et al., *supra*)

[0345] For example, c-myc expression is highly amplified in the non-lymphocytic leukemia cell line HL-60. When HL-60 cells are chemically induced to stop

proliferation, the level of c-myc is found to be downregulated. (International Publication Number WO 91/15580). However, it has been shown that exposure of HL-60 cells to a DNA construct that is complementary to the 5' end of c-myc or c-myb blocks translation of the corresponding mRNAs which downregulates expression of the c-myc or c-myb proteins and causes arrest of cell proliferation and differentiation of the treated cells. (International Publication Number WO 91/15580; Wickstrom et al., Proc. Natl. Acad. Sci. 85:1028 (1988); Anfossi et al., Proc. Natl. Acad. Sci. 86:3379 (1989)). However, the skilled artisan would appreciate the present invention's usefulness is not be limited to treatment, prevention, diagnosis and/or prognosis, of proliferative disorders of cells and tissues of hematopoietic origin, in light of the numerous cells and cell types of varying origins which are known to exhibit proliferative phenotypes. In preferred embodiments, the compounds and/or methods of the invention are used to treat, prevent, diagnose, and/or prognose, proliferative disorders of testicular cells and tissues.

[0346] In addition to the foregoing, a polynucleotide of the present invention can be used to control gene expression through triple helix formation or through antisense DNA or RNA. Antisense techniques are discussed, for example, in Okano, J. Neurochem. 56: 560 (1991); "Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance Lee et al., Nucleic Acids Research 6: 3073 (1979); Cooney et al., Science 241: 456 (1988); and Dervan et al., Science 251: 1360 (1991). Both methods rely on binding of the polynucleotide to a complementary DNA or RNA. For these techniques, preferred polynucleotides are usually oligonucleotides 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. The oligonucleotide described above can also be delivered to cells such that the antisense RNA or DNA may be expressed *in vivo* to inhibit production of

polypeptide of the present invention antigens. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat disease, and in particular, for the treatment of proliferative diseases and/or conditions. Non-limiting antisense and triple helix methods encompassed by the present invention are more thoroughly described elsewhere herein (see, e.g., the section labeled "Antisense and Ribozyme (Antagonists)").

[0347] Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell. Additional non-limiting examples of gene therapy methods encompassed by the present invention are more thoroughly described elsewhere herein (see, e.g., the sections labeled "Gene Therapy Methods" and Examples 16, 17 and 18).

[0348] The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

[0349] The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established

for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

[0350] Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, synovial fluid, amniotic fluid, breast milk, lymph, pulmonary sputum or surfactant, urine, fecal matter, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

[0351] There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers prepared from the sequences of the present invention, specific to tissues, including but not limited to, those sequences referred to in Table 1A. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination. Additional non-limiting examples of such uses are further described herein.

[0352] Because testicular antigens are found expressed in the testes, the polynucleotides of the present invention are also useful as hybridization probes for differential identification of the tissue(s) or cell type(s) present in a biological sample. Similarly, polypeptides and antibodies directed to polypeptides of the present invention are useful to provide immunological probes for differential identification of the tissue(s) (e.g., immunohistochemistry assays) or cell type(s) (e.g., immunocytochemistry assays). In a specific embodiment, the polynucleotides of the present invention are also useful as hybridization probes for differential identification of testicular tissue(s) or cell type(s) present in a biological sample. Similarly, polypeptides and antibodies directed to polypeptides of the present invention are

useful to provide immunological probes for differential identification of testicular tissue(s) (e.g., immunohistochemistry assays) or cell type(s) (e.g., immunocytochemistry assays). In addition, for a number of disorders of the above tissues or cells, significantly higher or lower levels of gene expression of the polynucleotides/polypeptides of the present invention may be detected in certain tissues (e.g., tissues expressing polypeptides and/or polynucleotides of the present invention, for example, normal testicular tissues or diseased testicular tissues, and/or those tissues/cells corresponding to the library source relating to a polynucleotide sequence of the invention as disclosed in column 7 of Table 1A, and/or cancerous and/or wounded tissues) or bodily fluids (e.g., semen, lymph, vaginal pool, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to a "standard" gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

[0353] Thus, the invention provides a diagnostic method of a disorder, which involves: (a) assaying gene expression level in cells or body fluid of an individual; (b) comparing the gene expression level with a standard gene expression level, whereby an increase or decrease in the assayed gene expression level compared to the standard expression level is indicative of a disorder.

[0354] In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

Uses of the Polypeptides

[0355] Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

[0356] Polypeptides and antibodies directed to polypeptides of the present invention are useful to provide immunological probes for differential identification of

the tissue(s) (e.g., immunohistochemistry assays such as, for example, ABC immunoperoxidase (Hsu et al., J. Histochem. Cytochem. 29:577-580 (1981)) or cell type(s) (e.g., immunocytochemistry assays).

[0357] Antibodies can be used to assay levels of polypeptides encoded by polynucleotides of the invention in a biological sample using classical immunohistological methods known to those of skill in the art (see, e.g., Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell. Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine (^{131}I , ^{125}I , ^{123}I , ^{121}I), carbon (^{14}C), sulfur (^{35}S), tritium (^3H), indium ($^{115\text{m}}\text{In}$, $^{113\text{m}}\text{In}$, ^{112}In , ^{111}In), and technetium (^{99}Tc , $^{99\text{m}}\text{Tc}$), thallium (^{201}Tl), gallium (^{68}Ga , ^{67}Ga), palladium (^{103}Pd), molybdenum (^{99}Mo), xenon (^{133}Xe), fluorine (^{18}F), ^{153}Sm , ^{177}Lu , ^{159}Gd , ^{149}Pm , ^{140}La , ^{175}Yb , ^{166}Ho , ^{90}Y , ^{47}Sc , ^{186}Re , ^{188}Re , ^{142}Pr , ^{105}Rh , ^{97}Ru ; luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

[0358] In addition to assaying levels of polypeptide of the present invention in a biological sample, proteins can also be detected *in vivo* by imaging. Antibody labels or markers for *in vivo* imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

[0359] A testicular antigen-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example, ^{131}I , ^{112}In , $^{99\text{m}}\text{Tc}$, (^{131}I , ^{125}I , ^{123}I , ^{121}I), carbon (^{14}C), sulfur (^{35}S), tritium (^3H), indium ($^{115\text{m}}\text{In}$, $^{113\text{m}}\text{In}$, ^{112}In , ^{111}In), and technetium (^{99}Tc , $^{99\text{m}}\text{Tc}$), thallium (^{201}Tl), gallium (^{68}Ga , ^{67}Ga), palladium (^{103}Pd), molybdenum (^{99}Mo), xenon (^{133}Xe), fluorine (^{18}F , ^{153}Sm , ^{177}Lu , ^{159}Gd , ^{149}Pm , ^{140}La , ^{175}Yb , ^{166}Ho , ^{90}Y , ^{47}Sc , ^{186}Re , ^{188}Re , ^{142}Pr , ^{105}Rh , ^{97}Ru), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously or

intraperitoneally) into the mammal to be examined for testicular disorders. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of ^{99m}Tc . The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which express the polypeptide encoded by a polynucleotide of the invention. *In vivo* tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments" (Chapter 13 in *Tumor Imaging: The Radiochemical Detection of Cancer*, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982)).

[0360] In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (e.g., polypeptides encoded by polynucleotides of the invention and/or antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

[0361] In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention in association with toxins or cytotoxic prodrugs.

[0362] In a preferred embodiment, the invention provides a method for the specific destruction of testicular cells (e.g., aberrant testicular cells, testicular neoplasm) by administering polypeptides of the invention (e.g., polypeptides encoded by polynucleotides of the invention and/or antibodies) in association with toxins or cytotoxic prodrugs. In another preferred embodiment the invention provides a method for the specific destruction of tissues/cells corresponding to the library source relating to a polynucleotide sequence of the invention as disclosed in column 7 of Table 1A by administering polypeptides of the invention in association with toxins or cytotoxic prodrugs.

[0363] By "toxin" is meant one or more compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. "Toxin" also includes a cytostatic or cytocidal agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example, ^{213}Bi , or other radioisotopes such as, for example, ^{103}Pd , ^{133}Xe , ^{131}I , ^{111}In , ^{68}Ge , ^{57}Co , ^{65}Zn , ^{85}Sr , ^{32}P , ^{35}S , ^{90}Y , ^{153}Sm , ^{153}Gd , ^{169}Yb , ^{51}Cr , ^{54}Mn , ^{75}Se , ^{113}Sn , $^{90}\text{Yttrium}$, ^{117}Tin , $^{186}\text{Rhenium}$, $^{166}\text{Holmium}$, and $^{188}\text{Rhenium}$; luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

[0364] In a specific embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention or antibodies of the invention in association with the radioisotope ^{90}Y . In another specific embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention or antibodies of the invention in association with the radioisotope ^{111}In . In a further specific embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention or antibodies of the invention in association with the radioisotope ^{131}I .

[0365] Techniques known in the art may be applied to label polypeptides of the invention (including antibodies). Such techniques include, but are not limited to, the use of bifunctional conjugating agents (see e.g., U.S. Patent Nos. 5,756,065; 5,714,631; 5,696,239; 5,652,361; 5,505,931; 5,489,425; 5,435,990; 5,428,139; 5,342,604; 5,274,119; 4,994,560; and 5,808,003; the contents of each of which are hereby incorporated by reference in its entirety).

[0366] Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression level of a polypeptide of the present invention in cells or body fluid of an individual; and (b) comparing the assayed polypeptide expression level with a standard polypeptide expression level, whereby an increase or decrease in the assayed polypeptide expression level compared to the standard expression level is indicative of a disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

[0367] Moreover, polypeptides of the present invention can be used to treat or prevent diseases or conditions of the testes such as, for example, cryptorchid testicle, varicocele, azoospermia, testicular cancers, and those described in the "Reproductive System Disorders" section below. In preferred embodiments, polynucleotides expressed in a particular tissue type (see, e.g., Table 1A, column 7) are used to diagnose, detect, prevent, treat and/or prognose disorders associated with the tissue type. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B, SOD, catalase, DNA repair proteins), to inhibit the activity of a polypeptide (e.g., an oncogene or tumor suppressor), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth inhibition, enhancement of the immune response to proliferative cells or tissues).

[0368] Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat disease (as described *supra*, and elsewhere herein). For example, administration of an antibody directed to a polypeptide of the present invention can bind, and/or neutralize the polypeptide, and/or reduce overproduction of the

polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

[0369] At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the biological activities described herein.

Diagnostic Assays

[0370] The compounds of the present invention are useful for diagnosis, treatment, prevention and/or prognosis of various testes related disorders in mammals, preferably humans. Such disorders include, but are not limited to, cryptorchid testicle, varicocele, azoospermia, testicular cancers, and those described in the "Reproductive System Disorders" section below. In preferred embodiments, polynucleotides expressed in a particular tissue type (see, e.g., Table 1A, column 7) are used to diagnose, detect, prevent, treat and/or prognose disorders associated with the tissue type.

[0371] Testicular antigens are expressed in the testes. For a number of testes-related disorders, substantially altered (increased or decreased) levels of testicular antigen gene expression can be detected in testicular tissue or other cells or bodily fluids (e.g., sera, plasma, urine, semen, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to a "standard" testicular antigen gene expression level, that is, the testicular antigen expression level in testicular tissues or bodily fluids from an individual not having the testicular disorder. Thus, the invention provides a diagnostic method useful during diagnosis of a testicular disorder, which involves measuring the expression level of the gene encoding the testes associated polypeptide in testicular tissue or other cells or body fluid from an individual and comparing the measured gene expression level with a standard testicular antigens gene expression level, whereby an increase or decrease in the gene expression level(s) compared to the standard is indicative of a testicular disorder.

[0372] In specific embodiments, the invention provides a diagnostic method useful during diagnosis of a disorder of a normal or diseased tissue/cell source corresponding to column 7 of Table 1A, which involves measuring the expression level of the coding sequence of a polynucleotide sequence associated with this tissue/cell source as disclosed in Table 1A in the tissue/cell source or other cells or body fluid from an individual and comparing the expression level of the coding sequence with a standard expression level of the coding sequence of a polynucleotide sequence, whereby an increase or decrease in the gene expression level(s) compared to the standard is indicative of a disorder of a normal or diseased tissue/cell source corresponding to column 7 of Table 1A.

[0373] In particular, it is believed that certain tissues in mammals with cancer of cells or tissue of the testes express significantly enhanced or reduced levels of normal or altered testicular antigen expression and mRNA encoding the testes associated polypeptide when compared to a corresponding "standard" level. Further, it is believed that enhanced or depressed levels of the testes associated polypeptide can be detected in certain body fluids (e.g., sera, plasma, urine, and spinal fluid) or cells or tissue from mammals with such a cancer when compared to sera from mammals of the same species not having the cancer.

[0374] For example, as disclosed herein, testes associated polypeptides of the invention are expressed in the testes. Accordingly, polynucleotides of the invention (e.g., polynucleotide sequences complementary to all or a portion of a testicular antigen mRNA nucleotide sequence of SEQ ID NO:X, nucleotide sequence encoding SEQ ID NO:Y, nucleotide sequence encoding a polypeptide encoded by SEQ ID NO:X and/or a nucleotide sequence delineated by columns 8 and 9 of Table 2) and antibodies (and antibody fragments) directed against the polypeptides of the invention may be used to quantitate or qualitate concentrations of cells of the testes expressing testicular antigens, preferably on their cell surfaces. These polynucleotides and antibodies additionally have diagnostic applications in detecting abnormalities in the level of testicular antigens gene expression, or abnormalities in the structure and/or temporal, tissue, cellular, or subcellular location of testicular antigens. These diagnostic assays may be performed *in vivo* or *in vitro*, such as, for example, on blood samples, biopsy tissue or autopsy tissue. In specific embodiments, polynucleotides and

antibodies of the invention are used to quantitate or qualitate tissues/cells corresponding to the library source disclosed in column 7 of Table 1A expressing the corresponding testicular sequence disclosed in the same row of Table 1A, preferably on their cell surface.

[0375] Thus, the invention provides a diagnostic method useful during diagnosis of a testicular disorder, including cancers, which involves measuring the expression level of the gene encoding the testicular antigen polypeptide in testicular tissue or other cells or body fluid from an individual and comparing the measured gene expression level with a standard testicular antigen gene expression level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a testicular disorder. In specific embodiments, polynucleotides and antibodies of the invention are used to quantitate or qualitate tissues/cells corresponding to the library source disclosed in column 7 of Table 1A expressing the corresponding testicular sequence disclosed in the same row of Table 1A, preferably on their cell surface.

[0376] Where a diagnosis of a disorder in the testes, including diagnosis of a tumor, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed testicular antigen gene expression will experience a worse clinical outcome relative to patients expressing the gene at a level nearer the standard level.

[0377] By "assaying the expression level of the gene encoding the testes associated polypeptide" is intended qualitatively or quantitatively measuring or estimating the level of the testicular antigen polypeptide or the level of the mRNA encoding the testicular antigen polypeptide in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the testes associated polypeptide level or mRNA level in a second biological sample). Preferably, the testicular antigen polypeptide expression level or mRNA level in the first biological sample is measured or estimated and compared to a standard testicular antigen polypeptide level or mRNA level, the standard being taken from a second biological sample obtained from an individual not having the disorder or being determined by averaging levels from a population of individuals not having a disorder of the testes. As will be appreciated in the art, once a standard testicular antigen polypeptide level or mRNA level is known, it can be used

repeatedly as a standard for comparison.

[0378] By "biological sample" is intended any biological sample obtained from an individual, cell line, tissue culture, or other source containing testicular antigen polypeptides (including portions thereof) or mRNA. As indicated, biological samples include body fluids (such as sera, plasma, urine, synovial fluid and spinal fluid) which contain cells expressing testicular antigen polypeptides, testicular tissue, and other tissue sources found to express the full length or fragments thereof of a testicular antigen. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

[0379] Total cellular RNA can be isolated from a biological sample using any suitable technique such as the single-step guanidinium-thiocyanate-phenol-chloroform method described in Chomczynski and Sacchi, *Anal. Biochem.* 162:156-159 (1987). Levels of mRNA encoding the testicular antigen polypeptides are then assayed using any appropriate method. These include Northern blot analysis, S1 nuclease mapping, the polymerase chain reaction (PCR), reverse transcription in combination with the polymerase chain reaction (RT-PCR), and reverse transcription in combination with the ligase chain reaction (RT-LCR).

[0380] The present invention also relates to diagnostic assays such as quantitative and diagnostic assays for detecting levels of testicular antigen polypeptides, in a biological sample (e.g., cells and tissues), including determination of normal and abnormal levels of polypeptides. Thus, for instance, a diagnostic assay in accordance with the invention for detecting over-expression of testicular antigens compared to normal control tissue samples may be used to detect the presence of tumors. Assay techniques that can be used to determine levels of a polypeptide, such as a testicular antigen polypeptide of the present invention in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays. Assaying testicular antigen polypeptide levels in a biological sample can occur using any art-known method.

[0381] Assaying testicular antigen polypeptide levels in a biological sample can occur using antibody-based techniques. For example, testicular antigen polypeptide

expression in tissues can be studied with classical immunohistological methods (Jalkanen et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell . Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting testicular antigen polypeptide gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (^{125}I , ^{121}I), carbon (^{14}C), sulfur (^{35}S), tritium (^3H), indium (^{112}In), and technetium ($^{99\text{m}}\text{Tc}$), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

[0382] The tissue or cell type to be analyzed will generally include those which are known, or suspected, to express the testicular antigen gene (such as, for example, cells of the testes or testicular cancer). The protein isolation methods employed herein may, for example, be such as those described in Harlow and Lane (Harlow, E. and Lane, D., 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York), which is incorporated herein by reference in its entirety. The isolated cells can be derived from cell culture or from a patient. The analysis of cells taken from culture may be a necessary step in the assessment of cells that could be used as part of a cell-based gene therapy technique or, alternatively, to test the effect of compounds on the expression of the testicular antigen gene.

[0383] For example, antibodies, or fragments of antibodies, such as those described herein, may be used to quantitatively or qualitatively detect the presence of testicular antigen gene products or conserved variants or peptide fragments thereof. This can be accomplished, for example, by immunofluorescence techniques employing a fluorescently labeled antibody coupled with light microscopic, flow cytometric, or fluorimetric detection.

[0384] In a preferred embodiment, antibodies, or fragments of antibodies directed to any one or all of the predicted epitope domains of the testicular antigen polypeptides (Shown in Table 1A, column 6) may be used to quantitatively or qualitatively detect the presence of testicular antigen gene products or conserved variants or peptide fragments thereof. This can be accomplished, for example, by immunofluorescence techniques employing a fluorescently labeled antibody coupled with light microscopic, flow cytometric, or fluorimetric detection.

[0385] In an additional preferred embodiment, antibodies, or fragments of antibodies directed to a conformational epitope of a testicular antigen may be used to quantitatively or qualitatively detect the presence of testicular antigen gene products or conserved variants or peptide fragments thereof. This can be accomplished, for example, by immunofluorescence techniques employing a fluorescently labeled antibody coupled with light microscopic, flow cytometric, or fluorimetric detection.

[0386] The antibodies (or fragments thereof), and/or testicular antigen polypeptides of the present invention may, additionally, be employed histologically, as in immunofluorescence, immunoelectron microscopy or non-immunological assays, for in situ detection of testicular antigen gene products or conserved variants or peptide fragments thereof. In situ detection may be accomplished by removing a histological specimen from a patient, and applying thereto a labeled antibody or testicular antigen polypeptide of the present invention. The antibody (or fragment thereof) or testicular antigen polypeptide is preferably applied by overlaying the labeled antibody (or fragment) onto a biological sample. Through the use of such a procedure, it is possible to determine not only the presence of the testicular antigen gene product, or conserved variants or peptide fragments, or testicular antigen polypeptide binding, but also its distribution in the examined tissue. Using the present invention, those of ordinary skill will readily perceive that any of a wide variety of histological methods (such as staining procedures) can be modified in order to achieve such in situ detection.

[0387] Immunoassays and non-immunoassays for testicular antigen gene products or conserved variants or peptide fragments thereof will typically comprise incubating a sample, such as a biological fluid, a tissue extract, freshly harvested cells, or lysates of cells which have been incubated in cell culture, in the presence of a detectably labeled antibody capable of binding testicular antigen gene products or conserved variants or peptide fragments thereof, and detecting the bound antibody by any of a number of techniques well-known in the art.

[0388] The biological sample may be brought in contact with and immobilized onto a solid phase support or carrier such as nitrocellulose, or other solid support which is capable of immobilizing cells, cell particles or soluble proteins. The support may then be washed with suitable buffers followed by treatment with the detectably

labeled anti- testicular antigen antibody or detectable testicular antigen polypeptide. The solid phase support may then be washed with the buffer a second time to remove unbound antibody or polypeptide. Optionally the antibody is subsequently labeled. The amount of bound label on solid support may then be detected by conventional means.

[0389] By "solid phase support or carrier" is intended any support capable of binding an antigen or an antibody. Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention. The support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to an antigen or antibody. Thus, the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc. Preferred supports include polystyrene beads. Those skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by use of routine experimentation.

[0390] The binding activity of a given lot of anti- testicular antigen antibody or testicular antigen polypeptide may be determined according to well known methods. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.

[0391] In addition to assaying testicular antigen polypeptide levels or polynucleotide levels in a biological sample obtained from an individual, testicular antigen polypeptide or polynucleotide can also be detected *in vivo* by imaging. For example, in one embodiment of the invention, testicular antigen polypeptide and/or anti- testicular antigen antibodies are used to image diseased cells of the testes, such as neoplasms. In another embodiment, testicular antigen polynucleotides of the invention (e.g., polynucleotides complementary to all or a portion of testicular antigen mRNA) and/or anti- testicular antigen antibodies (e.g., antibodies directed to any one or a combination of the epitopes of testicular antigens, antibodies directed to a conformational epitope of testicular antigens, antibodies directed to the full length

polypeptide expressed on the cell surface of a mammalian cell) are used to image diseased or neoplastic cells of the testes.

[0392] Antibody labels or markers for *in vivo* imaging of testicular antigen polypeptides include those detectable by X-radiography, NMR, MRI, CAT-scans or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma. Where *in vivo* imaging is used to detect enhanced levels of testicular antigen polypeptides for diagnosis in humans, it may be preferable to use human antibodies or "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using techniques described herein or otherwise known in the art. For example methods for producing chimeric antibodies are known in the art. See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).

[0393] Additionally, any testicular antigen polypeptides whose presence can be detected, can be administered. For example, testicular antigen polypeptides labeled with a radio-opaque or other appropriate compound can be administered and visualized *in vivo*, as discussed, above for labeled antibodies. Further such testicular antigen polypeptides can be utilized for *in vitro* diagnostic procedures.

[0394] A testicular antigen polypeptide-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example, ^{131}I , ^{112}In , $^{99\text{m}}\text{Tc}$), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously or intraperitoneally) into the mammal to be examined for a testicular disorder. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of

^{99m}Tc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain testicular antigen protein. *In vivo* tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments" (Chapter 13 in *Tumor Imaging: The Radiochemical Detection of Cancer*, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982)).

[0395] With respect to antibodies, one of the ways in which the anti- testicular antigen antibody can be detectably labeled is by linking the same to an enzyme and using the linked product in an enzyme immunoassay (EIA) (Voller, A., "The Enzyme Linked Immunosorbent Assay (ELISA)", 1978, Diagnostic Horizons 2:1-7, Microbiological Associates Quarterly Publication, Walkersville, MD); Voller et al., J. Clin. Pathol. 31:507-520 (1978); Butler, J.E., Meth. Enzymol. 73:482-523 (1981); Maggio, E. (ed.), 1980, Enzyme Immunoassay, CRC Press, Boca Raton, FL.; Ishikawa, E. et al., (eds.), 1981, Enzyme Immunoassay, Kigaku Shoin, Tokyo). The enzyme which is bound to the antibody will react with an appropriate substrate, preferably a chromogenic substrate, in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorimetric or by visual means. Enzymes which can be used to detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase. Additionally, the detection can be accomplished by colorimetric methods which employ a chromogenic substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.

[0396] Detection may also be accomplished using any of a variety of other immunoassays. For example, by radioactively labeling the antibodies or antibody fragments, it is possible to detect testicular antigens through the use of a radioimmunoassay (RIA) (see, for example, Weintraub, B., Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques, The

Endocrine Society, March, 1986, which is incorporated by reference herein). The radioactive isotope can be detected by means including, but not limited to, a gamma counter, a scintillation counter, or autoradiography.

[0397] It is also possible to label the antibody with a fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wave length, its presence can then be detected due to fluorescence. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, ophthaldehyde and fluorescamine.

[0398] The antibody can also be detectably labeled using fluorescence emitting metals such as ^{152}Eu , or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriaminepentacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).

[0399] The antibody also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

[0400] Likewise, a bioluminescent compound may be used to label the antibody of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in, which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

Methods for Detecting Testicular Disease, Including Cancer

[0401] In general, a testicular disease or cancer may be detected in a patient based on the presence of one or more testicular antigen proteins of the invention and/or polynucleotides encoding such proteins in a biological sample (for example, blood, sera, urine, and/or tumor biopsies) obtained from the patient. In other words, such proteins and/or polynucleotides may be used as markers to indicate the presence or absence of a testicular disease or disorder, including cancer. Cancers that may be

diagnosed, and/or prognosed using the compositions of the invention include but are not limited to, testicular cancer. In addition, such proteins and/or polynucleotides may be useful for the detection of other diseases and cancers, including cancers of tissues/cells corresponding to the library source disclosed in column 7 of Table 1A expressing the corresponding testicular sequence disclosed in the same row of Table 1A. The binding agents provided herein generally permit detection of the level of antigen that binds to the agent in the biological sample. Polynucleotide primers and probes may be used to detect the level of mRNA encoding testicular antigen polypeptides, which is also indicative of the presence or absence of a testicular disease or disorder, including cancer. In general, testicular antigen polypeptides should be present at a level that is at least three fold higher in diseased tissue than in normal tissue.

[0402] There are a variety of assay formats known to those of ordinary skill in the art for using a binding agent to detect polypeptide markers in a sample. See, e.g., Harlow and Lane, *supra*. In general, the presence or absence of a testicular disease in a patient may be determined by (a) contacting a biological sample obtained from a patient with a binding agent; (b) detecting in the sample a level of polypeptide that binds to the binding agent; and (c) comparing the level of polypeptide with a predetermined cut-off value.

[0403] In a preferred embodiment, the assay involves the use of binding agent immobilized on a solid support to bind to and remove the testicular antigen polypeptide of the invention from the remainder of the sample. The bound polypeptide may then be detected using a detection reagent that contains a reporter group and specifically binds to the binding agent/polypeptide complex. Such detection reagents may comprise, for example, a binding agent that specifically binds to the polypeptide or an antibody or other agent that specifically binds to the binding agent, such as an anti-immunoglobulin, protein G, protein A or a lectin. Alternatively, a competitive assay may be utilized, in which a polypeptide is labeled with a reporter group and allowed to bind to the immobilized binding agent after incubation of the binding agent with the sample. The extent to which components of the sample inhibit the binding of the labeled polypeptide to the binding agent is indicative of the reactivity of the sample with the immobilized binding agent. Suitable polypeptides for use within such

assays include testicular antigen polypeptides and portions thereof, or antibodies, to which the binding agent binds, as described above.

[0404] The solid support may be any material known to those of skill in the art to which testicular antigen polypeptides of the invention may be attached. For example, the solid support may be a test well in a microtiter plate or a nitrocellulose or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S. Patent No. 5,359,681. The binding agent may be immobilized on the solid support using a variety of techniques known to those of skill in the art, which are amply described in the patent and scientific literature. In the context of the present invention, the term "immobilization" refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the agent and functional groups on the support or may be a linkage by way of a cross-linking agent). Immobilization by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the binding agent, in a suitable buffer, with the solid support for the suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and about 1 day. In general, contacting a well of plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of binding agent ranging from about 10 ng to about 10 ug, and preferably about 100 ng to about 1 ug, is sufficient to immobilize an adequate amount of binding agent.

[0405] Covalent attachment of binding agent to a solid support may generally be achieved by first reacting the support with a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the binding agent. For example, the binding agent may be covalently attached to supports having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the binding partner (see, e.g., Pierce Immunotechnology Catalog and Handbook, 1991, at A12-A13).

Gene Therapy Methods

[0406] Also encompassed by the present invention are gene therapy methods for treating or preventing disorders, diseases and conditions. The gene therapy methods relate to the introduction of nucleic acid (DNA, RNA and antisense DNA or RNA) sequences into an animal to achieve expression of a testicular antigen of the present invention. This method requires a polynucleotide which codes for a polypeptide of the present invention operatively linked to a promoter and any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques are known in the art, see, for example, WO90/11092, which is herein incorporated by reference.

[0407] Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) comprising a promoter operably linked to a polynucleotide of the present invention ex vivo, with the engineered cells then being provided to a patient to be treated with the polypeptide of the present invention. Such methods are well-known in the art. For example, see Beldegrun, A., et al., J. Natl. Cancer Inst. 85: 207-216 (1993); Ferrantini, M. et al., Cancer Research 53: 1107-1112 (1993); Ferrantini, M. et al., J. Immunology 153: 4604-4615 (1994); Kaido, T., et al., Int. J. Cancer 60: 221-229 (1995); Ogura, H., et al., Cancer Research 50: 5102-5106 (1990); Santodonato, L., et al., Human Gene Therapy 7:1-10 (1996); Santodonato, L., et al., Gene Therapy 4:1246-1255 (1997); and Zhang, J.-F. et al., Cancer Gene Therapy 3: 31-38 (1996)), which are herein incorporated by reference. In one embodiment, the cells which are engineered are arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

[0408] As discussed in more detail below, the polynucleotide constructs can be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, and the like). The polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

[0409] In one embodiment, the polynucleotide of the present invention is delivered as a naked polynucleotide. The term "naked" polynucleotide, DNA or RNA refers to sequences that are free from any delivery vehicle that acts to assist, promote or

facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotide of the present invention can also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such methods are described, for example, in U.S. Patent Nos. 5,593,972, 5,589,466, and 5,580,859, which are herein incorporated by reference.

[0410] The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Appropriate vectors include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; pSVK3, pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

[0411] Any strong promoter known to those skilled in the art can be used for driving the expression of the polynucleotide sequence. Suitable promoters include adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoAI promoter; human globin promoters; viral thymidine kinase promoters, such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the b-actin promoter; and human growth hormone promoters. The promoter also may be the native promoter for the polynucleotide of the present invention.

[0412] Unlike other gene therapy techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

[0413] The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and

connective tissue. Interstitial space of the tissues comprises the intercellular, fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

[0414] For the naked nucleic acid sequence injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

[0415] The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked DNA constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

[0416] The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, and so-called "gene guns". These delivery methods are known in the art.

[0417] The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc. Such methods of delivery are known in the art.

[0418] In certain embodiments, the polynucleotide constructs are complexed in a liposome preparation. Liposomal preparations for use in the instant invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a tight charge complex can be formed between the cationic liposome and the polyanionic nucleic acid. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., Proc. Natl. Acad. Sci. USA (1987) 84:7413-7416, which is herein incorporated by reference); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA (1989) 86:6077-6081, which is herein incorporated by reference); and purified transcription factors (Debs et al., J. Biol. Chem. (1990) 265:10189-10192, which is herein incorporated by reference), in functional form.

[0419] Cationic liposomes are readily available. For example, N[1-2,3-dioleoyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are particularly useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y., (see, also, Felgner et al., Proc. Natl. Acad. Sci. USA (1987) 84:7413-7416, which is herein incorporated by reference). Other commercially available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

[0420] Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g. PCT Publication No. WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of DOTMA liposomes is explained in the literature, see, e.g., P. Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417, which is herein incorporated by reference. Similar methods can be used to prepare liposomes from other cationic lipid materials.

[0421] Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials. Such materials include phosphatidyl choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC),

dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

[0422] For example, commercially dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine (DOPE) can be used in various combinations to make conventional liposomes, with or without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas into a sonication vial. The sample is placed under a vacuum pump overnight and is hydrated the following day with deionized water. The sample is then sonicated for 2 hours in a capped vial, using a Heat Systems model 350 sonicator equipped with an inverted cup (bath type) probe at the maximum setting while the bath is circulated at 15EC. Alternatively, negatively charged vesicles can be prepared without sonication to produce multilamellar vesicles or by extrusion through nucleopore membranes to produce unilamellar vesicles of discrete size. Other methods are known and available to those of skill in the art.

[0423] The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred. The various liposome-nucleic acid complexes are prepared using methods well known in the art. See, e.g., Straubinger et al., *Methods of Immunology* (1983), 101:512-527, which is herein incorporated by reference. For example, MLVs containing nucleic acid can be prepared by depositing a thin film of phospholipid on the walls of a glass tube and subsequently hydrating with a solution of the material to be encapsulated. SUVs are prepared by extended sonication of MLVs to produce a homogeneous population of unilamellar liposomes. The material to be entrapped is added to a suspension of preformed MLVs and then sonicated. When using liposomes containing cationic lipids, the dried lipid film is resuspended in an appropriate solution such as sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and then the preformed liposomes are mixed directly with the DNA. The liposome and DNA form a very stable complex due to binding of the positively charged liposomes to the cationic DNA. SUVs find use with small nucleic acid

fragments. LUVs are prepared by a number of methods, well known in the art. Commonly used methods include Ca^{2+} -EDTA chelation (Papahadjopoulos et al., Biochim. Biophys. Acta (1975) 394:483; Wilson et al., Cell 17:77 (1979); ether injection (Deamer, D. and Bangham, A., Biochim. Biophys. Acta 443:629 (1976); Ostro et al., Biochem. Biophys. Res. Commun. 76:836 (1977); Fraley et al., Proc. Natl. Acad. Sci. USA 76:3348 (1979)); detergent dialysis (Enoch, H. and Strittmatter, P., Proc. Natl. Acad. Sci. USA 76:145 (1979)); and reverse-phase evaporation (REV) (Fraley et al., J. Biol. Chem. 255:10431 (1980); Szoka et al., Proc. Natl. Acad. Sci. USA 75:145 (1978); Schaefer-Ridder et al., Science 215:166 (1982)), which are herein incorporated by reference.

[0424] Generally, the ratio of DNA to liposomes will be from about 10:1 to about 1:10. Preferably, the ration will be from about 5:1 to about 1:5. More preferably, the ration will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.

[0425] U.S. Patent No. 5,676,954 (which is herein incorporated by reference) reports on the injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Patent Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication no. WO 94/9469 (which are herein incorporated by reference) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466, 5,693,622, 5,580,859, 5,703,055, and International Publication No. WO 94/9469 provide methods for delivering DNA-cationic lipid complexes to mammals.

[0426] In certain embodiments, cells are engineered, *ex vivo* or *in vivo*, using a retroviral particle containing RNA which comprises a sequence encoding a polypeptide of the present invention. Retroviruses from which the retroviral plasmid vectors may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

[0427] The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT-19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described

in Miller, Human Gene Therapy 1:5-14 (1990), which is incorporated herein by reference in its entirety. The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO_4 precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

[0428] The producer cell line generates infectious retroviral vector particles which include polynucleotide encoding a polypeptide of the present invention. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either *in vitro* or *in vivo*. The transduced eukaryotic cells will express a polypeptide of the present invention.

[0429] In certain other embodiments, cells are engineered, *ex vivo* or *in vivo*, with polynucleotide contained in an adenovirus vector. Adenovirus can be manipulated such that it encodes and expresses a polypeptide of the present invention, and at the same time is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Adenovirus expression is achieved without integration of the viral DNA into the host cell chromosome, thereby alleviating concerns about insertional mutagenesis. Furthermore, adenoviruses have been used as live enteric vaccines for many years with an excellent safety profile (Schwartz, et al., Am. Rev. Respir. Dis. 109:233-238 (1974)). Finally, adenovirus mediated gene transfer has been demonstrated in a number of instances including transfer of alpha-1-antitrypsin and CFTR to the lungs of cotton rats (Rosenfeld et al., Science 252:431-434 (1991); Rosenfeld et al., Cell 68:143-155 (1991)). Furthermore, extensive studies to attempt to establish adenovirus as a causative agent in human cancer were uniformly negative (Green et al., Proc. Natl. Acad. Sci. USA 76:6606 (1979)).

[0430] Suitable adenoviral vectors useful in the present invention are described, for example, in Kozarsky and Wilson, Curr. Opin. Genet. Devel. 3:499-503 (1993); Rosenfeld et al., Cell 68:143-155 (1992); Engelhardt et al., Human Genet. Ther. 4:759-769 (1993); Yang et al., Nature Genet. 7:362-369 (1994); Wilson et al., Nature 365:691-692 (1993); and U.S. Patent No. 5,652,224, which are herein incorporated by reference. For example, the adenovirus vector Ad2 is useful and can be grown in human 293 cells. These cells contain the E1 region of adenovirus and constitutively

express Ela and Elb, which complement the defective adenoviruses by providing the products of the genes deleted from the vector. In addition to Ad2, other varieties of adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

[0431] Preferably, the adenoviruses used in the present invention are replication deficient. Replication deficient adenoviruses require the aid of a helper virus and/or packaging cell line to form infectious particles. The resulting virus is capable of infecting cells and can express a polynucleotide of interest which is operably linked to a promoter, but cannot replicate in most cells. Replication deficient adenoviruses may be deleted in one or more of all or a portion of the following genes: Ela, Elb, E3, E4, E2a, or L1 through L5.

[0432] In certain other embodiments, the cells are engineered, *ex vivo* or *in vivo*, using an adeno-associated virus (AAV). AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, N., *Curr. Topics in Microbiol. Immunol.* 158:97 (1992)). It is also one of the few viruses that may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate, but space for exogenous DNA is limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678, 5,436,146, 5,474,935, 5,478,745, and 5,589,377.

[0433] For example, an appropriate AAV vector for use in the present invention will include all the sequences necessary for DNA replication, encapsidation, and host-cell integration. The polynucleotide construct is inserted into the AAV vector using standard cloning methods, such as those found in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press (1989). The recombinant AAV vector is then transfected into packaging cells which are infected with a helper virus, using any standard technique, including lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses. Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct. These viral particles are then used to transduce eukaryotic cells, either *ex vivo* or *in vivo*. The transduced cells will contain the

polynucleotide construct integrated into its genome, and will express a polypeptide of the invention.

[0434] Another method of gene therapy involves operably associating heterologous control regions and endogenous testicular antigen polynucleotide sequences (e.g., encoding a testicular antigen polypeptide of the present invention) via homologous recombination (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), which are herein incorporated by reference. This method involves the activation of a gene which is present in the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

[0435] Polynucleotide constructs are made, using standard techniques known in the art, which contain the promoter with targeting sequences flanking the promoter. Suitable promoters are described herein. The targeting sequence is sufficiently complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting sequence will be sufficiently near the 5' end of the desired endogenous polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

[0436] The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter. The amplified promoter and targeting sequences are digested and ligated together.

[0437] The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating agents, etc., described in more detail above. The P promoter-targeting sequence can be delivered by any method, included direct needle injection, intravenous injection,

topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

[0438] The promoter-targeting sequence construct is taken up by cells. Homologous recombination between the construct and the endogenous sequence takes place, such that an endogenous sequence is placed under the control of the promoter. The promoter then drives the expression of the endogenous sequence.

[0439] The polynucleotide encoding a polypeptide of the present invention may contain a secretory signal sequence that facilitates secretion of the protein. Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5' end of the coding region. The signal sequence may be homologous or heterologous to the testicular antigen polynucleotide of interest and may be homologous or heterologous to the cells to be transfected. Additionally, the signal sequence may be chemically synthesized using methods known in the art.

[0440] Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct needle injection, systemic injection, catheter infusion, biolistic injectors, particle accelerators (i.e., "gene guns"), gelfoam sponge depots, other commercially available depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid (tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated plasmid into the portal vein has resulted in gene expression of the foreign gene in the rat livers (Kaneda et al., Science 243:375 (1989)).

[0441] A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is administered by direct injection into or locally within the area of arteries. Administration of a composition locally within the area of arteries refers to injecting the composition centimeters and preferably, millimeters within arteries.

[0442] Another method of local administration is to contact a polynucleotide construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the

surface of tissue inside the wound or the construct can be injected into areas of tissue inside the wound.

[0443] Therapeutic compositions useful in systemic administration, include recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic administration comprise liposomes comprising ligands for targeting the vehicle to a particular site. In specific embodiments, suitable delivery vehicles for use with systemic administration comprise liposomes comprising polypeptides of the invention for targeting the vehicle to a particular site.

[0444] Preferred methods of systemic administration, include intravenous injection, aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad. Sci. USA 189:11277-11281, 1992, which is incorporated herein by reference). Oral delivery can be performed by complexing a polynucleotide construct of the present invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such as those known in the art. Topical delivery can be performed by mixing a polynucleotide construct of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.

[0445] Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the animal, the precise condition requiring treatment and its severity, and the route of administration. The frequency of treatments depends upon a number of factors, such as the amount of polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be determined by the attending physician or veterinarian.

[0446] Therapeutic compositions of the present invention can be administered to any animal, preferably to mammals and birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits sheep, cattle, horses and pigs, with humans being particularly preferred.

Biological Activities

[0447] Polynucleotides or polypeptides, or agonists or antagonists of the present invention, can be used in assays to test for one or more biological activities. If these polynucleotides or polypeptides, or agonists or antagonists of the present invention, do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides, and agonists or antagonists could be used to treat, prevent diagnose and/or prognose the associated disease.

[0448] The testicular antigen polynucleotides and polypeptides of the invention are predicted to have predominant expression in testicular tissues. Thus, the testicular antigens of the invention may be useful as therapeutic molecules. Each would be useful for diagnosis, detection, treatment and/or prevention of diseases or disorders of the testes, cryptorchid testicle, varicocele, azoospermia, testicular cancers, and those described in the "Reproductive System Disorders" section below.

[0449] In a preferred embodiment, polynucleotides of the invention (e.g., a nucleic acid sequence of SEQ ID NO:X or the complement thereof; or the cDNA sequence contained in Clone ID NO:Z, or fragments or variants thereof) and/or polypeptides of the invention (e.g., an amino acid sequence contained in SEQ ID NO:Y, an amino acid sequence encoded by SEQ ID NO:X, or the complement thereof, an amino acid sequence encoded by the cDNA sequence contained in Clone ID NO:Z and fragments or variants thereof as described herein) are useful for the diagnosis, detection, treatment, and/or prevention of diseases or disorders of the tissues/cells corresponding to the library source disclosed in column 7 of Table 1A expressing the corresponding testicular sequence disclosed in the same row of Table 1A. In certain embodiments, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to diagnose and/or prognose diseases and/or disorders associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 1A, column 7 (Tissue Distribution Library Code).

[0450] Particularly, the testicular antigens may be a useful therapeutic for testicular cancer. Treatment, diagnosis, detection, and/or prevention of testicular

disorders could be carried out using a testicular antigen or soluble form of a testicular antigen, a testicular antigen ligand, gene therapy, or ex vivo applications. Moreover, inhibitors of a testicular antigen, either blocking antibodies or mutant forms, could modulate the expression of the testicular antigen. These inhibitors may be useful to treat, diagnose, detect, and/or prevent diseases associated with the misregulation of a testicular antigen.

[0451] In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells (e.g., normal or diseased testicular cells) by administering polypeptides of the invention (e.g., testicular antigen polypeptides or anti- testicular antigen antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell (e.g., an aberrant testicular cell or testicular cancer cell). In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

[0452] In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of aberrant testicular cells, including, but not limited to, testicular tumor cells) by administering polypeptides of the invention (e.g., testicular antigen polypeptides or fragments thereof, or anti- testicular antigen antibodies) in association with toxins or cytotoxic prodrugs.

[0453] By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, cytotoxins (cytotoxic agents), or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. "Toxin" also includes a cytostatic or cytocidal agent, a therapeutic agent

or a radioactive metal ion, e.g., alpha-emitters such as, for example, ^{213}Bi , or other radioisotopes such as, for example, ^{103}Pd , ^{133}Xe , ^{131}I , ^{68}Ge , ^{57}Co , ^{65}Zn , ^{85}Sr , ^{32}P , ^{35}S , ^{90}Y , ^{153}Sm , ^{153}Gd , ^{169}Yb , ^{51}Cr , ^{54}Mn , ^{75}Se , ^{113}Sn , $^{90}\text{Yttrium}$, ^{117}Tin , $^{186}\text{Rhenium}$, $^{166}\text{Holmium}$, and $^{188}\text{Rhenium}$; luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

[0454] Techniques known in the art may be applied to label antibodies of the invention. Such techniques include, but are not limited to, the use of bifunctional conjugating agents (see e.g., U.S. Patent Nos. 5,756,065; 5,714,631; 5,696,239; 5,652,361; 5,505,931; 5,489,425; 5,435,990; 5,428,139; 5,342,604; 5,274,119; 4,994,560; and 5,808,003; the contents of each of which are hereby incorporated by reference in its entirety). A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis- dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

[0455] By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

[0456] It will be appreciated that conditions caused by a decrease in the standard or normal level of a testicular antigen activity in an individual, particularly disorders

of the testes, can be treated by administration of a testicular antigen polypeptide (e.g., such as, for example, the complete testicular antigen polypeptide, the soluble form of the extracellular domain of a testicular antigen polypeptide, or cells expressing the complete protein) or agonist. Thus, the invention also provides a method of treatment of an individual in need of an increased level of testicular antigen activity comprising administering to such an individual a pharmaceutical composition comprising an amount of an isolated testicular antigen polypeptide of the invention, or agonist thereof (e.g., an agonistic anti- testicular antigen antibody), effective to increase the testicular antigen activity level in such an individual.

[0457] It will also be appreciated that conditions caused by a increase in the standard or normal level of testicular antigen activity in an individual, particularly disorders of the testes, can be treated by administration of testicular antigen polypeptides (e.g., such as, for example, the complete testicular antigen polypeptide, the soluble form of the extracellular domain of a testicular antigen polypeptide, or cells expressing the complete protein) or antagonist (e.g., an antagonistic testicular antigen antibody). Thus, the invention also provides a method of treatment of an individual in need of an decreased level of testicular antigen activity comprising administering to such an individual a pharmaceutical composition comprising an amount of an isolated testicular antigen polypeptide of the invention, or antagonist thereof (e.g., an antagonistic anti- testicular antigen antibody), effective to decrease the testicular antigen activity level in such an individual.

[0458] More generally, polynucleotides, translation products and antibodies corresponding to this gene may be useful for the diagnosis, prognosis, prevention, and/or treatment of diseases and/or disorders associated with the following systems.

Reproductive System Disorders

[0459] The polynucleotides or polypeptides, or agonists or antagonists of the invention may be used for the diagnosis, treatment, or prevention of diseases and/or disorders of the reproductive system. Reproductive system disorders that can be treated by the compositions of the invention, include, but are not limited to, reproductive system injuries, infections, neoplastic disorders, congenital defects, and

diseases or disorders which result in infertility, complications with pregnancy, labor, or parturition, and postpartum difficulties.

[0460] Reproductive system disorders and/or diseases include diseases and/or disorders of the testes, including, but not limited to, testicular atrophy, testicular feminization, cryptorchism (unilateral and bilateral), anorchia, ectopic testis, epididymitis and orchitis (typically resulting from infections such as, for example, gonorrhea, mumps, tuberculosis, and syphilis), testicular torsion, vasitis nodosa, germ cell tumors (e.g., seminomas, embryonal cell carcinomas, teratocarcinomas, choriocarcinomas, yolk sac tumors, and teratomas), stromal tumors (e.g., Leydig cell tumors), hydrocele, hematocele, varicocele, spermatocele, inguinal hernia, and disorders of sperm production (e.g., immotile cilia syndrome, aspermia, asthenozoospermia, azoospermia, oligospermia, and teratozoospermia).

[0461] Reproductive system disorders also include, but are not limited to, disorders of the prostate gland, such as acute non-bacterial prostatitis, chronic non-bacterial prostatitis, acute bacterial prostatitis, chronic bacterial prostatitis, prostatodystonia, prostatosis, granulomatous prostatitis, malacoplakia, benign prostatic hypertrophy or hyperplasia, and prostate neoplastic disorders, including adenocarcinomas, transitional cell carcinomas, ductal carcinomas, and squamous cell carcinomas.

[0462] Additionally, the compositions of the invention may be useful in the diagnosis, treatment, and/or prevention of disorders or diseases of the penis and urethra, including, but not limited to, inflammatory disorders, such as balanoposthitis, balanitis xerotica obliterans, phimosis, paraphimosis, syphilis, herpes simplex virus, gonorrhea, non-gonococcal urethritis, chlamydia, mycoplasma, trichomonas, HIV, AIDS, Reiter's syndrome, condyloma acuminatum, condyloma latum, and pearly penile papules; urethral abnormalities, such as hypospadias, epispadias, and phimosis; premalignant lesions, including Erythroplasia of Queyrat, Bowen's disease, Bowenoid papulosis, giant condyloma of Buscke-Lowenstein, and verrucous carcinoma; penile cancers, including squamous cell carcinomas, carcinoma in situ, verrucous carcinoma, and disseminated penile carcinoma; urethral neoplastic disorders, including penile urethral carcinoma, bulbomembranous urethral carcinoma, and prostatic urethral

carcinoma; and erectile disorders, such as priapism, Peyronie's disease, erectile dysfunction, and impotence.

[0463] Moreover, diseases and/or disorders of the vas deferens include, but are not limited to, vasculitis and CBAVD (congenital bilateral absence of the vas deferens); additionally, the polynucleotides, polypeptides, and agonists or antagonists of the present invention may be used in the diagnosis, treatment, and/or prevention of diseases and/or disorders of the seminal vesicles, including but not limited to, hydatid disease, congenital chloride diarrhea, and polycystic kidney disease.

[0464] Other disorders and/or diseases of the male reproductive system that may be diagnosed, treated, and/or prevented with the compositions of the invention include, but are not limited to, Klinefelter's syndrome, Young's syndrome, premature ejaculation, diabetes mellitus, cystic fibrosis, Kartagener's syndrome, high fever, multiple sclerosis, and gynecomastia.

[0465] Further, the polynucleotides, polypeptides, and agonists or antagonists of the present invention may be used in the diagnosis, treatment, and/or prevention of diseases and/or disorders of the vagina and vulva, including, but not limited to, bacterial vaginosis, candida vaginitis, herpes simplex virus, chancroid, granuloma inguinale, lymphogranuloma venereum, scabies, human papillomavirus, vaginal trauma, vulvar trauma, adenosis, chlamydia vaginitis, gonorrhea, trichomonas vaginitis, condyloma acuminatum, syphilis, molluscum contagiosum, atrophic vaginitis, Paget's disease, lichen sclerosus, lichen planus, vulvodynia, toxic shock syndrome, vaginismus, vulvovaginitis, vulvar vestibulitis, and neoplastic disorders, such as squamous cell hyperplasia, clear cell carcinoma, basal cell carcinoma, melanomas, cancer of Bartholin's gland, and vulvar intraepithelial neoplasia.

[0466] Disorders and/or diseases of the uterus that may be diagnosed, treated, and/or prevented with the compositions of the invention include, but are not limited to, dysmenorrhea, retroverted uterus, endometriosis, fibroids, adenomyosis, anovulatory bleeding, amenorrhea, Cushing's syndrome, hydatidiform moles, Asherman's syndrome, premature menopause, precocious puberty, uterine polyps, dysfunctional uterine bleeding (e.g., due to aberrant hormonal signals), and neoplastic disorders, such as adenocarcinomas, leiomyosarcomas, and sarcomas. Additionally, the polypeptides, polynucleotides, or agonists or antagonists of the invention may be

useful as a marker or detector of, as well as in the diagnosis, treatment, and/or prevention of congenital uterine abnormalities, such as bicornuate uterus, septate uterus, simple unicornuate uterus, unicornuate uterus with a noncavitary rudimentary horn, unicornuate uterus with a non-communicating cavitary rudimentary horn, unicornuate uterus with a communicating cavitary horn, arcuate uterus, uterine didelphys, and T-shaped uterus.

[0467] Ovarian diseases and/or disorders that may be diagnosed, treated, and/or prevented with the compositions of the invention include, but are not limited to, anovulation, polycystic ovary syndrome (Stein-Leventhal syndrome), ovarian cysts, ovarian hypofunction, ovarian insensitivity to gonadotropins, ovarian overproduction of androgens, right ovarian vein syndrome, amenorrhea, hirsutism, and ovarian cancer (including, but not limited to, primary and secondary cancerous growth, Sertoli-Leydig tumors, endometrioid carcinoma of the ovary, ovarian papillary serous adenocarcinoma, ovarian mucinous adenocarcinoma, and Ovarian Krukenberg tumors).

[0468] Cervical diseases and/or disorders that may be diagnosed, treated, and/or prevented with the compositions of the invention include, but are not limited to, cervicitis, chronic cervicitis, mucopurulent cervicitis, cervical dysplasia, cervical polyps, Nabothian cysts, cervical erosion, cervical incompetence, and cervical neoplasms (including, for example, cervical carcinoma, squamous metaplasia, squamous cell carcinoma, adenosquamous cell neoplasia, and columnar cell neoplasia).

[0469] Additionally, diseases and/or disorders of the reproductive system that may be diagnosed, treated, and/or prevented with the compositions of the invention include, but are not limited to, disorders and/or diseases of pregnancy, including miscarriage and stillbirth, such as early abortion, late abortion, spontaneous abortion, induced abortion, therapeutic abortion, threatened abortion, missed abortion, incomplete abortion, complete abortion, habitual abortion, missed abortion, and septic abortion; ectopic pregnancy, anemia, Rh incompatibility, vaginal bleeding during pregnancy, gestational diabetes, intrauterine growth retardation, polyhydramnios, HELLP syndrome, abruptio placentae, placenta previa, hyperemesis, preeclampsia, eclampsia, herpes gestationis, and urticaria of pregnancy. Additionally, the polynucleotides,

polypeptides, and agonists or antagonists of the present invention may be used in the diagnosis, treatment, and/or prevention of diseases that can complicate pregnancy, including heart disease, heart failure, rheumatic heart disease, congenital heart disease, mitral valve prolapse, high blood pressure, anemia, kidney disease, infectious disease (e.g., rubella, cytomegalovirus, toxoplasmosis, infectious hepatitis, chlamydia, HIV, AIDS, and genital herpes), diabetes mellitus, Graves' disease, thyroiditis, hypothyroidism, Hashimoto's thyroiditis, chronic active hepatitis, cirrhosis of the liver, primary biliary cirrhosis, asthma, systemic lupus erythematosus, rheumatoid arthritis, myasthenia gravis, idiopathic thrombocytopenic purpura, appendicitis, ovarian cysts, gallbladder disorders, and obstruction of the intestine.

[0470] Complications associated with labor and parturition that may be diagnosed, treated, and/or prevented with the compositions of the invention include, but are not limited to, premature rupture of the membranes, pre-term labor, post-term pregnancy, postmaturity, labor that progresses too slowly, fetal distress (e.g., abnormal heart rate (fetal or maternal), breathing problems, and abnormal fetal position), shoulder dystocia, prolapsed umbilical cord, amniotic fluid embolism, and aberrant uterine bleeding.

[0471] Further, diseases and/or disorders of the postdelivery period, that may be diagnosed, treated, and/or prevented with the compositions of the invention, include, but are not limited to, endometritis, myometritis, parametritis, peritonitis, pelvic thrombophlebitis, pulmonary embolism, endotoxemia, pyelonephritis, saphenous thrombophlebitis, mastitis, cystitis, postpartum hemorrhage, and inverted uterus.

[0472] Other disorders and/or diseases of the female reproductive system that may be diagnosed, treated, and/or prevented by the polynucleotides, polypeptides, and agonists or antagonists of the present invention include, but are not limited to, Turner's syndrome, pseudohermaphroditism, premenstrual syndrome, pelvic inflammatory disease, pelvic congestion (vascular engorgement), frigidity, anorgasmia, dyspareunia, ruptured fallopian tube, and Mittelschmerz.

Immune Activity

[0473] Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, diagnosing and/or

prognosing diseases, disorders, and/or conditions of the immune system, by, for example, activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune diseases, disorders, and/or conditions may be genetic, somatic, such as cancer and some autoimmune diseases, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

[0474] In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to treat diseases and disorders of the immune system and/or to inhibit or enhance an immune response generated by cells associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 1A, column 7 (Tissue Distribution Library Code).

[0475] Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, diagnosing, and/or prognosing immunodeficiencies, including both congenital and acquired immunodeficiencies. Examples of B cell immunodeficiencies in which immunoglobulin levels B cell function and/or B cell numbers are decreased include: X-linked agammaglobulinemia (Bruton's disease), X-linked infantile agammaglobulinemia, X-linked immunodeficiency with hyper IgM, non X-linked immunodeficiency with hyper IgM, X-linked lymphoproliferative syndrome (XLP), agammaglobulinemia including congenital and acquired agammaglobulinemia, adult onset agammaglobulinemia, late-onset agammaglobulinemia, dysgammaglobulinemia, hypogammaglobulinemia, unspecified hypogammaglobulinemia, recessive agammaglobulinemia (Swiss type), Selective IgM deficiency, selective IgA deficiency, selective IgG subclass deficiencies, IgG subclass deficiency (with or without IgA deficiency), Ig deficiency with increased IgM, IgG and IgA deficiency with increased IgM, antibody deficiency with normal or elevated Igs, Ig heavy chain deletions, kappa chain deficiency, B cell lymphoproliferative disorder (BLPD),

common variable immunodeficiency (CVID), common variable immunodeficiency (CVI) (acquired), and transient hypogammaglobulinemia of infancy.

[0476] In specific embodiments, ataxia-telangiectasia or conditions associated with ataxia-telangiectasia are treated, prevented, diagnosed, and/or prognosing using the polypeptides or polynucleotides of the invention, and/or agonists or antagonists thereof.

[0477] Examples of congenital immunodeficiencies in which T cell and/or B cell function and/or number is decreased include, but are not limited to: DiGeorge anomaly, severe combined immunodeficiencies (SCID) (including, but not limited to, X-linked SCID, autosomal recessive SCID, adenosine deaminase deficiency, purine nucleoside phosphorylase (PNP) deficiency, Class II MHC deficiency (Bare lymphocyte syndrome), Wiskott-Aldrich syndrome, and ataxia telangiectasia), thymic hypoplasia, third and fourth pharyngeal pouch syndrome, 22q11.2 deletion, chronic mucocutaneous candidiasis, natural killer cell deficiency (NK), idiopathic CD4+ T-lymphocytopenia, immunodeficiency with predominant T cell defect (unspecified), and unspecified immunodeficiency of cell mediated immunity.

[0478] In specific embodiments, DiGeorge anomaly or conditions associated with DiGeorge anomaly are treated, prevented, diagnosed, and/or prognosed using polypeptides or polynucleotides of the invention, or antagonists or agonists thereof.

[0479] Other immunodeficiencies that may be treated, prevented, diagnosed, and/or prognosed using polypeptides or polynucleotides of the invention, and/or agonists or antagonists thereof, include, but are not limited to, chronic granulomatous disease, Chédiak-Higashi syndrome, myeloperoxidase deficiency, leukocyte glucose-6-phosphate dehydrogenase deficiency, X-linked lymphoproliferative syndrome (XLP), leukocyte adhesion deficiency, complement component deficiencies (including C1, C2, C3, C4, C5, C6, C7, C8 and/or C9 deficiencies), reticular dysgenesis, thymic aplasia, immunodeficiency with thymoma, severe congenital leukopenia, dysplasia with immunodeficiency, neonatal neutropenia, short limbed dwarfism, and Nezelof syndrome-combined immunodeficiency with Igs.

[0480] In a preferred embodiment, the immunodeficiencies and/or conditions associated with the immunodeficiencies recited above are treated, prevented,

diagnosed and/or prognosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

[0481] In a preferred embodiment polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used as an agent to boost immunoresponsiveness among immunodeficient individuals. In specific embodiments, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used as an agent to boost immunoresponsiveness among B cell and/or T cell immunodeficient individuals.

[0482] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, diagnosing and/or prognosing autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of polynucleotides and polypeptides of the invention that can inhibit an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

[0483] Autoimmune diseases or disorders that may be treated, prevented, diagnosed and/or prognosed by polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include, but are not limited to, one or more of the following: systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, multiple sclerosis, autoimmune thyroiditis, Hashimoto's thyroiditis, autoimmune hemolytic anemia, hemolytic anemia, thrombocytopenia, autoimmune thrombocytopenia purpura, autoimmune neonatal thrombocytopenia, idiopathic thrombocytopenia purpura, purpura (e.g., Henloch-Scoenlein purpura), autoimmunocytopenia, Goodpasture's syndrome, Pemphigus vulgaris, myasthenia gravis, Grave's disease (hyperthyroidism), and insulin-resistant diabetes mellitus.

[0484] Additional disorders that are likely to have an autoimmune component that may be treated, prevented, and/or diagnosed with the compositions of the invention include, but are not limited to, type II collagen-induced arthritis, antiphospholipid syndrome, dermatitis, allergic encephalomyelitis, myocarditis, relapsing polychondritis, rheumatic heart disease, neuritis, uveitis ophthalmia,

polyendocrinopathies, Reiter's Disease, Stiff-Man Syndrome, autoimmune pulmonary inflammation, autism, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disorders.

[0485] Additional disorders that are likely to have an autoimmune component that may be treated, prevented, diagnosed and/or prognosed with the compositions of the invention include, but are not limited to, scleroderma with anti-collagen antibodies (often characterized, e.g., by nucleolar and other nuclear antibodies), mixed connective tissue disease (often characterized, e.g., by antibodies to extractable nuclear antigens (e.g., ribonucleoprotein)), polymyositis (often characterized, e.g., by nonhistone ANA), pernicious anemia (often characterized, e.g., by antiparietal cell, microsomes, and intrinsic factor antibodies), idiopathic Addison's disease (often characterized, e.g., by humoral and cell-mediated adrenal cytotoxicity, infertility (often characterized, e.g., by antispermatozoal antibodies), glomerulonephritis (often characterized, e.g., by glomerular basement membrane antibodies or immune complexes), bullous pemphigoid (often characterized, e.g., by IgG and complement in basement membrane), Sjogren's syndrome (often characterized, e.g., by multiple tissue antibodies, and/or a specific nonhistone ANA (SS-B)), diabetes mellitus (often characterized, e.g., by cell-mediated and humoral islet cell antibodies), and adrenergic drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis) (often characterized, e.g., by beta-adrenergic receptor antibodies).

[0486] Additional disorders that may have an autoimmune component that may be treated, prevented, diagnosed and/or prognosed with the compositions of the invention include, but are not limited to, chronic active hepatitis (often characterized, e.g., by smooth muscle antibodies), primary biliary cirrhosis (often characterized, e.g., by mitochondria antibodies), other endocrine gland failure (often characterized, e.g., by specific tissue antibodies in some cases), vitiligo (often characterized, e.g., by melanocyte antibodies), vasculitis (often characterized, e.g., by Ig and complement in vessel walls and/or low serum complement), post-MI (often characterized, e.g., by myocardial antibodies), cardiomyopathy syndrome (often characterized, e.g., by myocardial antibodies), urticaria (often characterized, e.g., by IgG and IgM antibodies to IgE), atopic dermatitis (often characterized, e.g., by IgG and IgM antibodies to IgE), asthma

(often characterized, e.g., by IgG and IgM antibodies to IgE), and many other inflammatory, granulomatous, degenerative, and atrophic disorders.

[0487] In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prevented, diagnosed and/or prognosed using for example, antagonists or agonists, polypeptides or polynucleotides, or antibodies of the present invention. In a specific preferred embodiment, rheumatoid arthritis is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

[0488] In another specific preferred embodiment, systemic lupus erythematosus is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred embodiment, idiopathic thrombocytopenia purpura is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

[0489] In another specific preferred embodiment IgA nephropathy is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

[0490] In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prevented, diagnosed and/or prognosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

[0491] In preferred embodiments, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a immunosuppressive agent(s).

[0492] Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, prognosing, and/or diagnosing diseases, disorders, and/or conditions of hematopoietic cells. Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with a decrease in certain (or many)

types hematopoietic cells, including but not limited to, leukopenia, neutropenia, anemia, and thrombocytopenia. Alternatively, Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with an increase in certain (or many) types of hematopoietic cells, including but not limited to, histiocytosis.

[0493] Allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated, prevented, diagnosed and/or prognosed using polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof. Moreover, these molecules can be used to treat, prevent, prognose, and/or diagnose anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

[0494] Additionally, polypeptides or polynucleotides of the invention, and/or agonists or antagonists thereof, may be used to treat, prevent, diagnose and/or prognose IgE-mediated allergic reactions. Such allergic reactions include, but are not limited to, asthma, rhinitis, and eczema. In specific embodiments, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate IgE concentrations in vitro or in vivo.

[0495] Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention have uses in the diagnosis, prognosis, prevention, and/or treatment of inflammatory conditions. For example, since polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists of the invention may inhibit the activation, proliferation and/or differentiation of cells involved in an inflammatory response, these molecules can be used to prevent and/or treat chronic and acute inflammatory conditions. Such inflammatory conditions include, but are not limited to, for example, inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome), ischemia-reperfusion injury, endotoxin lethality, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, over production of cytokines (e.g., TNF or IL-1.), respiratory disorders (e.g., asthma and allergy); gastrointestinal disorders (e.g., inflammatory

bowel disease); cancers (e.g., gastric, ovarian, lung, bladder, liver, and breast); CNS disorders (e.g., multiple sclerosis; ischemic brain injury and/or stroke, traumatic brain injury, neurodegenerative disorders (e.g., Parkinson's disease and Alzheimer's disease); AIDS-related dementia; and prion disease); cardiovascular disorders (e.g., atherosclerosis, myocarditis, cardiovascular disease, and cardiopulmonary bypass complications); as well as many additional diseases, conditions, and disorders that are characterized by inflammation (e.g., hepatitis, rheumatoid arthritis, gout, trauma, pancreatitis, sarcoidosis, dermatitis, renal ischemia-reperfusion injury, Grave's disease, systemic lupus erythematosus, diabetes mellitus, and allogenic transplant rejection).

[0496] Because inflammation is a fundamental defense mechanism, inflammatory disorders can effect virtually any tissue of the body. Accordingly, polynucleotides, polypeptides, and antibodies of the invention, as well as agonists or antagonists thereof, have uses in the treatment of tissue-specific inflammatory disorders, including, but not limited to, adrenalitis, alveolitis, angiocholecystitis, appendicitis, balanitis, blepharitis, bronchitis, bursitis, carditis, cellulitis, cervicitis, cholecystitis, chorditis, cochlitis, colitis, conjunctivitis, cystitis, dermatitis, diverticulitis, encephalitis, endocarditis, esophagitis, eustachitis, fibrositis, folliculitis, gastritis, gastroenteritis, gingivitis, glossitis, hepatosplenitis, keratitis, labyrinthitis, laryngitis, lymphangitis, mastitis, media otitis, meningitis, metritis, mucitis, myocarditis, myositis, myringitis, nephritis, neuritis, orchitis, osteochondritis, otitis, pericarditis, peritendonitis, peritonitis, pharyngitis, phlebitis, poliomyelitis, prostatitis, pulpitis, retinitis, rhinitis, salpingitis, scleritis, sclerochoroiditis, scrotitis, sinusitis, spondylitis, steatitis, stomatitis, synovitis, syringitis, tendonitis, tonsillitis, urethritis, and vaginitis.

[0497] In specific embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, are useful to diagnose, prognose, prevent, and/or treat organ transplant rejections and graft-versus-host disease. Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. Polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, that inhibit an immune response, particularly the activation, proliferation,

differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD. In specific embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, that inhibit an immune response, particularly the activation, proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing experimental allergic and hyperacute xenograft rejection.

[0498] In other embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, are useful to diagnose, prognose, prevent, and/or treat immune complex diseases, including, but not limited to, serum sickness, post streptococcal glomerulonephritis, polyarteritis nodosa, and immune complex-induced vasculitis.

[0499] Polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the invention can be used to treat, detect, and/or prevent infectious agents. For example, by increasing the immune response, particularly increasing the proliferation activation and/or differentiation of B and/or T cells, infectious diseases may be treated, detected, and/or prevented. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may also directly inhibit the infectious agent (refer to section of application listing infectious agents, etc), without necessarily eliciting an immune response.

[0500] In another embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a vaccine adjuvant that enhances immune responsiveness to an antigen. In a specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance tumor-specific immune responses.

[0501] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance anti-viral immune responses. Anti-viral immune responses that may be enhanced using the compositions of the invention as an adjuvant, include virus and virus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to

enhance an immune response to a virus, disease, or symptom selected from the group consisting of: AIDS, meningitis, Dengue, EBV, and hepatitis (e.g., hepatitis B). In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of: HIV/AIDS, respiratory syncytial virus, Dengue, rotavirus, Japanese B encephalitis, influenza A and B, parainfluenza, measles, cytomegalovirus, rabies, Junin, Chikungunya, Rift Valley Fever, herpes simplex, and yellow fever.

[0502] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance anti-bacterial or anti-fungal immune responses. Anti-bacterial or anti-fungal immune responses that may be enhanced using the compositions of the invention as an adjuvant, include bacteria or fungus and bacteria or fungus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: tetanus, Diphtheria, botulism, and meningitis type B.

[0503] In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: *Vibrio cholerae*, *Mycobacterium leprae*, *Salmonella typhi*, *Salmonella paratyphi*, *Meisseria meningitidis*, *Streptococcus pneumoniae*, Group B streptococcus, *Shigella spp.*, Enterotoxigenic *Escherichia coli*, Enterohemorrhagic *E. coli*, and *Borrelia burgdorferi*.

[0504] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance anti-parasitic immune responses. Anti-parasitic immune responses that may be enhanced using the compositions of the invention as an adjuvant, include parasite and parasite associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a parasite. In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to Plasmodium (malaria) or Leishmania.

- [0505] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may also be employed to treat infectious diseases including silicosis, sarcoidosis, and idiopathic pulmonary fibrosis; for example, by preventing the recruitment and activation of mononuclear phagocytes.
- [0506] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an antigen for the generation of antibodies to inhibit or enhance immune mediated responses against polypeptides of the invention.
- [0507] In one embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are administered to an animal (e.g., mouse, rat, rabbit, hamster, guinea pig, pigs, micro-pig, chicken, camel, goat, horse, cow, sheep, dog, cat, non-human primate, and human, most preferably human) to boost the immune system to produce increased quantities of one or more antibodies (e.g., IgG, IgA, IgM, and IgE), to induce higher affinity antibody production and immunoglobulin class switching (e.g., IgG, IgA, IgM, and IgE), and/or to increase an immune response.
- [0508] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a stimulator of B cell responsiveness to pathogens.
- [0509] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an activator of T cells.
- [0510] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent that elevates the immune status of an individual prior to their receipt of immunosuppressive therapies.
- [0511] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to induce higher affinity antibodies.
- [0512] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to increase serum immunoglobulin concentrations.

- [0513] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to accelerate recovery of immunocompromised individuals.
- [0514] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to boost immunoresponsiveness among aged populations and/or neonates.
- [0515] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an immune system enhancer prior to, during, or after bone marrow transplant and/or other transplants (e.g., allogeneic or xenogeneic organ transplantation). With respect to transplantation, compositions of the invention may be administered prior to, concomitant with, and/or after transplantation. In a specific embodiment, compositions of the invention are administered after transplantation, prior to the beginning of recovery of T-cell populations. In another specific embodiment, compositions of the invention are first administered after transplantation after the beginning of recovery of T cell populations, but prior to full recovery of B cell populations.
- [0516] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to boost immunoresponsiveness among individuals having an acquired loss of B cell function. Conditions resulting in an acquired loss of B cell function that may be ameliorated or treated by administering the polypeptides, antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are not limited to, HIV Infection, AIDS, bone marrow transplant, and B cell chronic lymphocytic leukemia (CLL).
- [0517] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to boost immunoresponsiveness among individuals having a temporary immune deficiency. Conditions resulting in a temporary immune deficiency that may be ameliorated or treated by administering the polypeptides, antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are not limited to, recovery from viral infections (e.g., influenza), conditions associated with malnutrition, recovery from infectious mononucleosis, or conditions associated with stress, recovery from measles, recovery from blood transfusion, and recovery from surgery.

- [0518] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a regulator of antigen presentation by monocytes, dendritic cells, and/or B-cells. In one embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention enhance antigen presentation or antagonizes antigen presentation in vitro or in vivo. Moreover, in related embodiments, said enhancement or antagonism of antigen presentation may be useful as an anti-tumor treatment or to modulate the immune system.
- [0519] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to direct an individual's immune system towards development of a humoral response (i.e. TH2) as opposed to a TH1 cellular response.
- [0520] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means to induce tumor proliferation and thus make it more susceptible to anti-neoplastic agents. For example, multiple myeloma is a slowly dividing disease and is thus refractory to virtually all anti-neoplastic regimens. If these cells were forced to proliferate more rapidly their susceptibility profile would likely change.
- [0521] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a stimulator of B cell production in pathologies such as AIDS, chronic lymphocyte disorder and/or Common Variable Immunodeficiency.
- [0522] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for generation and/or regeneration of lymphoid tissues following surgery, trauma or genetic defect. In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used in the pretreatment of bone marrow samples prior to transplant.
- [0523] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a gene-based therapy for genetically inherited disorders resulting in immuno-incompetence/immunodeficiency such as observed among SCID patients.

- [0524] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of activating monocytes/macrophages to defend against parasitic diseases that effect monocytes such as Leishmania.
- [0525] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of regulating secreted cytokines that are elicited by polypeptides of the invention.
- [0526] In another embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used in one or more of the applications described herein, as they may apply to veterinary medicine.
- [0527] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of blocking various aspects of immune responses to foreign agents or self. Examples of diseases or conditions in which blocking of certain aspects of immune responses may be desired include autoimmune disorders such as lupus, and arthritis, as well as immunoresponsiveness to skin allergies, inflammation, bowel disease, injury and diseases/disorders associated with pathogens.
- [0528] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for preventing the B cell proliferation and Ig secretion associated with autoimmune diseases such as idiopathic thrombocytopenic purpura, systemic lupus erythematosus and multiple sclerosis.
- [0529] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an inhibitor of B and/or T cell migration in endothelial cells. This activity disrupts tissue architecture or cognate responses and is useful, for example in disrupting immune responses, and blocking sepsis.
- [0530] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for chronic hypergammaglobulinemia evident in such diseases as monoclonal gammopathy of undetermined significance (MGUS), Waldenstrom's disease, related idiopathic monoclonal gammopathies, and plasmacytomas.

- [0531] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be employed for instance to inhibit polypeptide chemotaxis and activation of macrophages and their precursors, and of neutrophils, basophils, B lymphocytes and some T-cell subsets, e.g., activated and CD8 cytotoxic T cells and natural killer cells, in certain autoimmune and chronic inflammatory and infective diseases. Examples of autoimmune diseases are described herein and include multiple sclerosis, and insulin-dependent diabetes.
- [0532] The polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may also be employed to treat idiopathic hyper-eosinophilic syndrome by, for example, preventing eosinophil production and migration.
- [0533] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used to enhance or inhibit complement mediated cell lysis.
- [0534] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used to enhance or inhibit antibody dependent cellular cytotoxicity.
- [0535] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may also be employed for treating atherosclerosis, for example, by preventing monocyte infiltration in the artery wall.
- [0536] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be employed to treat adult respiratory distress syndrome (ARDS).
- [0537] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be useful for stimulating wound and tissue repair, stimulating angiogenesis, and/or stimulating the repair of vascular or lymphatic diseases or disorders. Additionally, agonists and antagonists of the invention may be used to stimulate the regeneration of mucosal surfaces.
- [0538] In a specific embodiment, polynucleotides or polypeptides, and/or agonists thereof are used to diagnose, prognose, treat, and/or prevent a disorder characterized by primary or acquired immunodeficiency, deficient serum immunoglobulin

production, recurrent infections, and/or immune system dysfunction. Moreover, polynucleotides or polypeptides, and/or agonists thereof may be used to treat or prevent infections of the joints, bones, skin, and/or parotid glands, blood-borne infections (e.g., sepsis, meningitis, septic arthritis, and/or osteomyelitis), autoimmune diseases (e.g., those disclosed herein), inflammatory disorders, and malignancies, and/or any disease or disorder or condition associated with these infections, diseases, disorders and/or malignancies) including, but not limited to, CVID, other primary immune deficiencies, HIV disease, CLL, recurrent bronchitis, sinusitis, otitis media, conjunctivitis, pneumonia, hepatitis, meningitis, herpes zoster (e.g., severe herpes zoster), and/or pneumocystis carinii. Other diseases and disorders that may be prevented, diagnosed, prognosed, and/or treated with polynucleotides or polypeptides, and/or agonists of the present invention include, but are not limited to, HIV infection, HTLV-BLV infection, lymphopenia, phagocyte bactericidal dysfunction anemia, thrombocytopenia, and hemoglobinuria.

[0539] In another embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention are used to treat, and/or diagnose an individual having common variable immunodeficiency disease ("CVID"; also known as "acquired agammaglobulinemia" and "acquired hypogammaglobulinemia") or a subset of this disease.

[0540] In a specific embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to diagnose, prognose, prevent, and/or treat cancers or neoplasms including immune cell or immune tissue-related cancers or neoplasms. Examples of cancers or neoplasms that may be prevented, diagnosed, or treated by polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include, but are not limited to, acute myelogenous leukemia, chronic myelogenous leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphocytic leukemia (ALL) Chronic lymphocyte leukemia, plasmacytomas, multiple myeloma, Burkitt's lymphoma, EBV-transformed diseases, and/or diseases and disorders described in the section entitled "Hyperproliferative Disorders" elsewhere herein.

- [0541] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for decreasing cellular proliferation of Large B-cell Lymphomas.
- [0542] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of decreasing the involvement of B cells and Ig associated with Chronic Myelogenous Leukemia.
- [0543] In specific embodiments, the compositions of the invention are used as an agent to boost immunoresponsiveness among B cell immunodeficient individuals, such as, for example, an individual who has undergone a partial or complete splenectomy.
- [0544] Antagonists of the invention include, for example, binding and/or inhibitory antibodies, antisense nucleic acids, ribozymes or soluble forms of the polypeptides of the present invention (e.g., Fc fusion protein; see, e.g., Example 9). Agonists of the invention include, for example, binding or stimulatory antibodies, and soluble forms of the polypeptides (e.g., Fc fusion proteins; see, e.g., Example 9). Polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be employed in a composition with a pharmaceutically acceptable carrier, e.g., as described herein.
- [0545] In another embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are administered to an animal (including, but not limited to, those listed above, and also including transgenic animals) incapable of producing functional endogenous antibody molecules or having an otherwise compromised endogenous immune system, but which is capable of producing human immunoglobulin molecules by means of a reconstituted or partially reconstituted immune system from another animal (see, e.g., published PCT Application Nos. WO98/24893, WO/9634096, WO/9633735, and WO/9110741). Administration of polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention to such animals is useful for the generation of monoclonal antibodies against the polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention.

Blood-Related Disorders

[0546] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate hemostatic (the stopping of bleeding) or thrombolytic (clot dissolving) activity. For example, by increasing hemostatic or thrombolytic activity, polynucleotides or polypeptides, and/or agonists or antagonists of the present invention could be used to treat or prevent blood coagulation diseases, disorders, and/or conditions (e.g., afibrinogenemia, factor deficiencies, hemophilia), blood platelet diseases, disorders, and/or conditions (e.g., thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment or prevention of heart attacks (infarction), strokes, or scarring.

[0547] In specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to prevent, diagnose, prognose, and/or treat thrombosis, arterial thrombosis, venous thrombosis, thromboembolism, pulmonary embolism, atherosclerosis, myocardial infarction, transient ischemic attack, unstable angina. In specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used for the prevention of occlusion of saphenous grafts, for reducing the risk of periprocedural thrombosis as might accompany angioplasty procedures, for reducing the risk of stroke in patients with atrial fibrillation including nonrheumatic atrial fibrillation, for reducing the risk of embolism associated with mechanical heart valves and or mitral valves disease. Other uses for the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention, include, but are not limited to, the prevention of occlusions in extracorporeal devices (e.g., intravascular canulas, vascular access shunts in hemodialysis patients, hemodialysis machines, and cardiopulmonary bypass machines).

[0548] In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to prevent, diagnose, prognose, and/or treat diseases and disorders of the blood and/or blood forming organs associated with the tissue(s) in which the polypeptide of the

invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 1A, column 7 (Tissue Distribution Library Code).

[0549] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate hematopoietic activity (the formation of blood cells). For example, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to increase the quantity of all or subsets of blood cells, such as, for example, erythrocytes, lymphocytes (B or T cells), myeloid cells (e.g., basophils, eosinophils, neutrophils, mast cells, macrophages) and platelets. The ability to decrease the quantity of blood cells or subsets of blood cells may be useful in the prevention, detection, diagnosis and/or treatment of anemias and leukopenias described below. Alternatively, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to decrease the quantity of all or subsets of blood cells, such as, for example, erythrocytes, lymphocytes (B or T cells), myeloid cells (e.g., basophils, eosinophils, neutrophils, mast cells, macrophages) and platelets.. The ability to decrease the quantity of blood cells or subsets of blood cells may be useful in the prevention, detection, diagnosis and/or treatment of leukocytoses, such as, for example eosinophilia.

[0550] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to prevent, treat, or diagnose blood dyscrasia.

[0551] Anemias are conditions in which the number of red blood cells or amount of hemoglobin (the protein that carries oxygen) in them is below normal. Anemia may be caused by excessive bleeding, decreased red blood cell production, or increased red blood cell destruction (hemolysis). The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing anemias. Anemias that may be treated prevented or diagnosed by the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include iron deficiency anemia, hypochromic anemia, microcytic anemia, chlorosis, hereditary sideroblastic anemia, idiopathic acquired sideroblastic anemia, red cell aplasia, megaloblastic anemia (e.g., pernicious anemia, (vitamin B12 deficiency) and folic acid deficiency anemia), aplastic anemia,

hemolytic anemias (e.g., autoimmune hemolytic anemia, microangiopathic hemolytic anemia, and paroxysmal nocturnal hemoglobinuria). The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing anemias associated with diseases including but not limited to, anemias associated with systemic lupus erythematosus, cancers, lymphomas, chronic renal disease, and enlarged spleens. The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing anemias arising from drug treatments such as anemias associated with methyl dopa, dapsone, and/or sulfadiazine. Additionally, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing anemias associated with abnormal red blood cell architecture including but not limited to, hereditary spherocytosis, hereditary elliptocytosis, glucose-6-phosphate dehydrogenase deficiency, and sickle cell anemia.

[0552] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing hemoglobin abnormalities, (e.g., those associated with sickle cell anemia, hemoglobin C disease, hemoglobin S-C disease, and hemoglobin E disease). Additionally, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating thalassemias, including, but not limited to major and minor forms of alpha-thalassemia and beta-thalassemia.

[0553] In another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating bleeding disorders including, but not limited to, thrombocytopenia (e.g., idiopathic thrombocytopenic purpura, and thrombotic thrombocytopenic purpura), Von Willebrand's disease, hereditary platelet disorders (e.g., storage pool disease such as Chediak-Higashi and Hermansky-Pudlak syndromes, thromboxane A2 dysfunction, thrombasthenia, and Bernard-Soulier syndrome), hemolytic-uremic syndrome, hemophilias such as hemophilia A or Factor VII deficiency and Christmas disease or Factor IX deficiency, Hereditary

Hemorrhagic Telangiectasia, also known as Rendu-Osler-Weber syndrome, allergic purpura (Henoch Schonlein purpura) and disseminated intravascular coagulation.

[0554] The effect of the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention on the clotting time of blood may be monitored using any of the clotting tests known in the art including, but not limited to, whole blood partial thromboplastin time (PTT), the activated partial thromboplastin time (aPTT), the activated clotting time (ACT), the recalcified activated clotting time, or the Lee-White Clotting time.

[0555] Several diseases and a variety of drugs can cause platelet dysfunction. Thus, in a specific embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating acquired platelet dysfunction such as platelet dysfunction accompanying kidney failure, leukemia, multiple myeloma, cirrhosis of the liver, and systemic lupus erythematosus as well as platelet dysfunction associated with drug treatments, including treatment with aspirin, ticlopidine, nonsteroidal anti-inflammatory drugs (used for arthritis, pain, and sprains), and penicillin in high doses.

[0556] In another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders characterized by or associated with increased or decreased numbers of white blood cells. Leukopenia occurs when the number of white blood cells decreases below normal. Leukopenias include, but are not limited to, neutropenia and lymphocytopenia. An increase in the number of white blood cells compared to normal is known as leukocytosis. The body generates increased numbers of white blood cells during infection. Thus, leukocytosis may simply be a normal physiological parameter that reflects infection. Alternatively, leukocytosis may be an indicator of injury or other disease such as cancer. Leukocytoses, include but are not limited to, eosinophilia, and accumulations of macrophages. In specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating leukopenia. In other specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present

invention may be useful in diagnosing, prognosing, preventing, and/or treating leukocytosis

[0557] Leukopenia may be a generalized decreased in all types of white blood cells, or may be a specific depletion of particular types of white blood cells. Thus, in specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating decreases in neutrophil numbers, known as neutropenia. Neutropenias that may be diagnosed, prognosed, prevented, and/or treated by the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include, but are not limited to, infantile genetic agranulocytosis, familial neutropenia, cyclic neutropenia, neutropenias resulting from or associated with dietary deficiencies (e.g., vitamin B 12 deficiency or folic acid deficiency), neutropenias resulting from or associated with drug treatments (e.g., antibiotic regimens such as penicillin treatment, sulfonamide treatment, anticoagulant treatment, anticonvulsant drugs, anti-thyroid drugs, and cancer chemotherapy), and neutropenias resulting from increased neutrophil destruction that may occur in association with some bacterial or viral infections, allergic disorders, autoimmune diseases, conditions in which an individual has an enlarged spleen (e.g., Felty syndrome, malaria and sarcoidosis), and some drug treatment regimens.

[0558] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating lymphocytopenias (decreased numbers of B and/or T lymphocytes), including, but not limited lymphocytopenias resulting from or associated with stress, drug treatments (e.g., drug treatment with corticosteroids, cancer chemotherapies, and/or radiation therapies), AIDS infection and/or other diseases such as, for example, cancer, rheumatoid arthritis, systemic lupus erythematosus, chronic infections, some viral infections and/or hereditary disorders (e.g., DiGeorge syndrome, Wiskott-Aldrich Syndrome, severe combined immunodeficiency, ataxia telangiectasia).

[0559] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders associated with macrophage

numbers and/or macrophage function including, but not limited to, Gaucher's disease, Niemann-Pick disease, Letterer-Siwe disease and Hand-Schuller-Christian disease.

[0560] In another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders associated with eosinophil numbers and/or eosinophil function including, but not limited to, idiopathic hypereosinophilic syndrome, eosinophilia-myalgia syndrome, and Hand-Schuller-Christian disease.

[0561] In yet another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating leukemias and lymphomas including, but not limited to, acute lymphocytic (lymphoblastic) leukemia (ALL), acute myeloid (myelocytic, myelogenous, myeloblastic, or myelomonocytic) leukemia, chronic lymphocytic leukemia (e.g., B cell leukemias, T cell leukemias, Sezary syndrome, and Hairy cell leukemia), chronic myelocytic (myeloid, myelogenous, or granulocytic) leukemia, Hodgkin's lymphoma, non-hodgkin's lymphoma, Burkitt's lymphoma, and mycosis fungoides.

[0562] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders of plasma cells including, but not limited to, plasma cell dyscrasias, monoclonal gammaopathies, monoclonal gammopathies of undetermined significance, multiple myeloma, macroglobulinemia, Waldenstrom's macroglobulinemia, cryoglobulinemia, and Raynaud's phenomenon.

[0563] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing myeloproliferative disorders, including but not limited to, polycythemia vera, relative polycythemia, secondary polycythemia, myelofibrosis, acute myelofibrosis, agnogenic myeloid metaplasia, thrombocythemia, (including both primary and secondary thrombocythemia) and chronic myelocytic leukemia.

- [0564] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as a treatment prior to surgery, to increase blood cell production.
- [0565] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to enhance the migration, phagocytosis, superoxide production, antibody dependent cellular cytotoxicity of neutrophils, eosinophils and macrophages.
- [0566] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to increase the number of stem cells in circulation prior to stem cells pheresis. In another specific embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to increase the number of stem cells in circulation prior to platelet pheresis.
- [0567] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to increase cytokine production.
- [0568] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in preventing, diagnosing, and/or treating primary hematopoietic disorders.

Hyperproliferative Disorders

- [0569] Testes associated polynucleotides or polypeptides, or agonists or antagonists thereof, can be used to treat, prevent, diagnose and/or prognose hyperproliferative diseases, disorders, and/or conditions, including neoplasms.
- [0570] In a specific embodiment, testes associated polynucleotides or polypeptides, or agonists or antagonists thereof, can be used to treat, prevent, and/or diagnose hyperproliferative diseases, disorders, and/or conditions of the testes.
- [0571] In a preferred embodiment, testes associated polynucleotides or polypeptides, or agonists or antagonists thereof, can be used to treat, prevent, and/or diagnose testes neoplasms.
- [0572] Testes associated polynucleotides or polypeptides, or agonists or antagonists of the invention, may inhibit the proliferation of the disorder through direct

or indirect interactions. Alternatively, testes associated polynucleotides or polypeptides, or agonists or antagonists thereof, may proliferate other cells, which can inhibit the hyperproliferative disorder.

[0573] For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative diseases, disorders, and/or conditions can be treated, prevented, and/or diagnosed. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating, preventing, and/or diagnosing hyperproliferative diseases, disorders, and/or conditions, such as a chemotherapeutic agent.

[0574] Examples of hyperproliferative diseases, disorders, and/or conditions that can be treated, prevented, and/or diagnosed by testes associated polynucleotides or polypeptides, or agonists or antagonists thereof, include, but are not limited to neoplasms located in the: prostate, colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

[0575] Similarly, other hyperproliferative disorders can also be treated or detected by polynucleotides or polypeptides, or agonists or antagonists of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: Acute Childhood Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Adrenocortical Carcinoma, Adult (Primary) Hepatocellular Cancer, Adult (Primary) Liver Cancer, Adult Acute Lymphocytic Leukemia, Adult Acute Myeloid Leukemia, Adult Hodgkin's Disease, Adult Hodgkin's Lymphoma, Adult Lymphocytic Leukemia, Adult Non-Hodgkin's Lymphoma, Adult Primary Liver Cancer, Adult Soft Tissue Sarcoma, AIDS-Related Lymphoma, AIDS-Related Malignancies, Anal Cancer, Astrocytoma, Bile Duct Cancer, Bladder Cancer, Bone Cancer, Brain Stem Glioma, Brain Tumors, Breast Cancer, Cancer of the Renal Pelvis and Ureter, Central Nervous System (Primary) Lymphoma, Central Nervous System Lymphoma, Cerebellar Astrocytoma, Cerebral Astrocytoma, Cervical Cancer, Childhood (Primary) Hepatocellular Cancer,

Childhood (Primary) Liver Cancer, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Brain Stem Glioma, Childhood Cerebellar Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Extracranial Germ Cell Tumors, Childhood Hodgkin's Disease, Childhood Hodgkin's Lymphoma, Childhood Hypothalamic and Visual Pathway Glioma, Childhood Lymphoblastic Leukemia, Childhood Medulloblastoma, Childhood Non-Hodgkin's Lymphoma, Childhood Pineal and Supratentorial Primitive Neuroectodermal Tumors, Childhood Primary Liver Cancer, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma, Childhood Visual Pathway and Hypothalamic Glioma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Colon Cancer, Cutaneous T-Cell Lymphoma, Endocrine Pancreas Islet Cell Carcinoma, Endometrial Cancer, Ependymoma, Epithelial Cancer, Esophageal Cancer, Ewing's Sarcoma and Related Tumors, Exocrine Pancreatic Cancer, Extracranial Germ Cell Tumor, Extragonadal Germ Cell Tumor, Extrahepatic Bile Duct Cancer, Eye Cancer, Female Breast Cancer, Gaucher's Disease, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Tumors, Germ Cell Tumors, Gestational Trophoblastic Tumor, Hairy Cell Leukemia, Head and Neck Cancer, Hepatocellular Cancer, Hodgkin's Disease, Hodgkin's Lymphoma, Hypergammaglobulinemia, Hypopharyngeal Cancer, Intestinal Cancers, Intraocular Melanoma, Islet Cell Carcinoma, Islet Cell Pancreatic Cancer, Kaposi's Sarcoma, Kidney Cancer, Laryngeal Cancer, Lip and Oral Cavity Cancer, Liver Cancer, Lung Cancer, Lymphoproliferative Disorders, Macroglobulinemia, Male Breast Cancer, Malignant Mesothelioma, Malignant Thymoma, Medulloblastoma, Melanoma, Mesothelioma, Metastatic Occult Primary Squamous Neck Cancer, Metastatic Primary Squamous Neck Cancer, Metastatic Squamous Neck Cancer, Multiple Myeloma, Multiple Myeloma/Plasma Cell Neoplasm, Myelodysplastic Syndrome, Myelogenous Leukemia, Myeloid Leukemia, Myeloproliferative Disorders, Nasal Cavity and Paranasal Sinus Cancer, Nasopharyngeal Cancer, Neuroblastoma, Non-Hodgkin's Lymphoma During Pregnancy, Nonmelanoma Skin Cancer, Non-Small Cell Lung Cancer, Occult Primary Metastatic Squamous Neck Cancer, Oropharyngeal Cancer, Osteo-/Malignant Fibrous Sarcoma, Osteosarcoma/Malignant Fibrous Histiocytoma, Osteosarcoma/Malignant Fibrous Histiocytoma of Bone, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor,

Ovarian Low Malignant Potential Tumor, Pancreatic Cancer, Paraproteinemias, Purpura, Parathyroid Cancer, Penile Cancer, Pheochromocytoma, Pituitary Tumor, Plasma Cell Neoplasm/Multiple Myeloma, Primary Central Nervous System Lymphoma, Primary Liver Cancer, Prostate Cancer, Rectal Cancer, Renal Cell Cancer, Renal Pelvis and Ureter Cancer, Retinoblastoma, Rhabdomyosarcoma, Salivary Gland Cancer, Sarcoidosis Sarcomas, Sezary Syndrome, Skin Cancer, Small Cell Lung Cancer, Small Intestine Cancer, Soft Tissue Sarcoma, Squamous Neck Cancer, Stomach Cancer, Supratentorial Primitive Neuroectodermal and Pineal Tumors, T-Cell Lymphoma, Testicular Cancer, Thymoma, Thyroid Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Transitional Renal Pelvis and Ureter Cancer, Trophoblastic Tumors, Ureter and Renal Pelvis Cell Cancer, Urethral Cancer, Uterine Cancer, Uterine Sarcoma, Vaginal Cancer, Visual Pathway and Hypothalamic Glioma, Vulvar Cancer, Waldenstrom's Macroglobulinemia, Wilms' Tumor, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

[0576] In another preferred embodiment, polynucleotides or polypeptides, or agonists or antagonists of the present invention are used to diagnose, prognose, prevent, and/or treat premalignant conditions and to prevent progression to a neoplastic or malignant state, including but not limited to those disorders described above. Such uses are indicated in conditions known or suspected of preceding progression to neoplasia or cancer, in particular, where non-neoplastic cell growth consisting of hyperplasia, metaplasia, or most particularly, dysplasia has occurred (for review of such abnormal growth conditions, see Robbins and Angell, 1976, Basic Pathology, 2d Ed., W. B. Saunders Co., Philadelphia, pp. 68-79.)

[0577] Hyperplasia is a form of controlled cell proliferation, involving an increase in cell number in a tissue or organ, without significant alteration in structure or function. Hyperplastic disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, angiofollicular mediastinal lymph node hyperplasia, angiolymphoid hyperplasia with eosinophilia, atypical melanocytic hyperplasia, basal cell hyperplasia, benign giant lymph node hyperplasia, cementum hyperplasia, congenital adrenal hyperplasia, congenital sebaceous hyperplasia, cystic hyperplasia, cystic hyperplasia of the breast, denture hyperplasia,

ductal hyperplasia, endometrial hyperplasia, fibromuscular hyperplasia, focal epithelial hyperplasia, gingival hyperplasia, inflammatory fibrous hyperplasia, inflammatory papillary hyperplasia, intravascular papillary endothelial hyperplasia, nodular hyperplasia of prostate, nodular regenerative hyperplasia, pseudoepitheliomatous hyperplasia, senile sebaceous hyperplasia, and verrucous hyperplasia.

[0578] Metaplasia is a form of controlled cell growth in which one type of adult or fully differentiated cell substitutes for another type of adult cell. Metaplastic disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, agnogenic myeloid metaplasia, apocrine metaplasia, atypical metaplasia, autoparenchymatous metaplasia, connective tissue metaplasia, epithelial metaplasia, intestinal metaplasia, metaplastic anemia, metaplastic ossification, metaplastic polyps, myeloid metaplasia, primary myeloid metaplasia, secondary myeloid metaplasia, squamous metaplasia, squamous metaplasia of amnion, and symptomatic myeloid metaplasia.

[0579] Dysplasia is frequently a forerunner of cancer, and is found mainly in the epithelia; it is the most disorderly form of non-neoplastic cell growth, involving a loss in individual cell uniformity and in the architectural orientation of cells. Dysplastic cells often have abnormally large, deeply stained nuclei, and exhibit pleomorphism. Dysplasia characteristically occurs where there exists chronic irritation or inflammation. Dysplastic disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, anhidrotic ectodermal dysplasia, anterofacial dysplasia, asphyxiating thoracic dysplasia, atrioidigital dysplasia, bronchopulmonary dysplasia, cerebral dysplasia, cervical dysplasia, chondroectodermal dysplasia, cleidocranial dysplasia, congenital ectodermal dysplasia, craniodiaphysial dysplasia, craniocarpotarsal dysplasia, craniometaphysial dysplasia, dentin dysplasia, diaphysial dysplasia, ectodermal dysplasia, enamel dysplasia, encephalo-ophthalmic dysplasia, dysplasia epiphysialis hemimelia, dysplasia epiphysialis multiplex, dysplasia epiphysialis punctata, epithelial dysplasia, faciodigitogenital dysplasia, familial fibrous dysplasia of jaws, familial

white folded dysplasia, fibromuscular dysplasia, fibrous dysplasia of bone, florid osseous dysplasia, hereditary renal-retinal dysplasia, hidrotic ectodermal dysplasia, hypohidrotic ectodermal dysplasia, lymphopenic thymic dysplasia, mammary dysplasia, mandibulofacial dysplasia, metaphysial dysplasia, Mondini dysplasia, monostotic fibrous dysplasia, mucoepithelial dysplasia, multiple epiphysial dysplasia, oculoauriculovertebral dysplasia, oculodentodigital dysplasia, oculovertbral dysplasia, odontogenic dysplasia, ophthalmomandibulomelic dysplasia, periapical cemental dysplasia, polyostotic fibrous dysplasia, pseudoachondroplastic spondyloepiphysial dysplasia, retinal dysplasia, septo-optic dysplasia, spondyloepiphysial dysplasia, and ventriculoradial dysplasia.

[0580] Additional pre-neoplastic disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, benign dysproliferative disorders (e.g., benign tumors, fibrocystic conditions, tissue hypertrophy, intestinal polyps, colon polyps, and esophageal dysplasia), leukoplakia, keratoses, Bowen's disease, Farmer's Skin, solar cheilitis, and solar keratosis.

[0581] In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to diagnose and/or prognose disorders associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 1A, 7 (Tissue Distribution Library Code).

[0582] In another embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat cancers and neoplasms, including, but not limited to those described herein. In a further preferred embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat acute myelogenous leukemia.

[0583] Additionally, polynucleotides, polypeptides, and/or agonists or antagonists of the invention may affect apoptosis, and therefore, would be useful in treating a number of diseases associated with increased cell survival or the inhibition of apoptosis. For example, diseases associated with increased cell survival or the

inhibition of apoptosis that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection.

[0584] In preferred embodiments, polynucleotides, polypeptides, and/or agonists or antagonists of the invention are used to inhibit growth, progression, and/or metastasis of cancers, in particular those listed above.

[0585] Additional diseases or conditions associated with increased cell survival that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell

carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, emangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

[0586] Diseases associated with increased apoptosis that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, cerebellar degeneration and brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

[0587] Hyperproliferative diseases and/or disorders that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include, but are not limited to, neoplasms located in the liver, abdomen, bone, breast, digestive system, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous system (central and peripheral), lymphatic system, pelvis, skin, soft tissue, spleen, thorax, and urogenital tract.

[0588] Similarly, other hyperproliferative disorders can also be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention. Examples of such hyperproliferative disorders include,

but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstrom's macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

[0589] One preferred embodiment utilizes polynucleotides of the present invention to inhibit aberrant cellular division, by gene therapy using the present invention, and/or protein fusions or fragments thereof.

[0590] Thus, the present invention provides a method for treating cell proliferative diseases, disorders, and/or conditions by inserting into an abnormally proliferating cell a polynucleotide of the present invention, wherein said polynucleotide represses said cell proliferation, disease, disorder, and/or condition.

[0591] In a preferred embodiment, the present invention provides a method for treating cell proliferative diseases, disorders and/or conditions of the testes by inserting into a cell, a polynucleotide of the present invention, wherein said polynucleotide represses said cell proliferation, disease and/or disorder.

[0592] Another embodiment of the present invention provides a method of treating cell-proliferative diseases, disorders, and/or conditions in individuals comprising administration of one or more active gene copies of the present invention to an abnormally proliferating cell or cells. In a preferred embodiment, polynucleotides of the present invention is a DNA construct comprising a recombinant expression vector effective in expressing a DNA sequence encoding said polynucleotides. In another preferred embodiment of the present invention, the DNA construct encoding the polynucleotides of the present invention is inserted into cells to be treated utilizing a retrovirus, or more preferably an adenoviral vector (see, e.g., G J. Nabel, et. al., PNAS 96: 324-326 (1999), which is hereby incorporated by reference). In a most preferred embodiment, the viral vector is defective and will not transform non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the polynucleotides of the present invention inserted into proliferating cells either alone, or in combination with or fused to other polynucleotides, can then be modulated via an external stimulus (i.e., magnetic, specific small molecule, chemical, or drug administration, etc.), which acts upon the promoter upstream of said polynucleotides to induce expression of the encoded protein product. As such the beneficial

therapeutic affect of the present invention may be expressly modulated (i.e., to increase, decrease, or inhibit expression of the present invention) based upon said external stimulus.

[0593] Polynucleotides of the present invention may be useful in repressing expression of oncogenic genes or antigens. By "repressing expression of the oncogenic genes " is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the normal function of the protein.

[0594] For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any other method described throughout the specification. The polynucleotide of the present invention may be delivered by known gene delivery systems such as, but not limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature 320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference. In order to specifically deliver or transfect cells which are abnormally proliferating and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as described in the art and elsewhere herein) delivery system known to those of skill in the art. Since host DNA replication is required for retroviral DNA to integrate and the retrovirus will be unable to self replicate due to the lack of the retrovirus genes needed for its life cycle. Utilizing such a retroviral delivery system for polynucleotides of the present invention will target said gene and constructs to abnormally proliferating cells and will spare the non-dividing normal cells.

[0595] The polynucleotides of the present invention may be delivered directly to cell proliferative disorder/disease sites in internal organs, body cavities and the like by use of imaging devices used to guide an injecting needle directly to the disease site.

The polynucleotides of the present invention may also be administered to disease sites at the time of surgical intervention.

[0596] By "cell proliferative disease" is meant any human or animal disease or disorder, affecting any one or any combination of organs, cavities, or body parts, which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

[0597] Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of the treated cells. Moreover, it is possible to administer more than one of the polynucleotide of the present invention simultaneously to the same site. By "biologically inhibiting" is meant partial or total growth inhibition as well as decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of the present invention on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

[0598] The present invention is further directed to antibody-based therapies which involve administering of anti-polypeptides and anti-polynucleotide antibodies to a mammalian, preferably human, patient for treating one or more of the described diseases, disorders, and/or conditions. Methods for producing anti-polypeptides and anti-polynucleotide antibodies polyclonal and monoclonal antibodies are described in detail elsewhere herein. Such antibodies may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

[0599] A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g., as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

- [0600] In particular, the antibodies, fragments and derivatives of the present invention are useful for treating a subject having or developing cell proliferative and/or differentiation diseases, disorders, and/or conditions as described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate thereof.
- [0601] The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors, for example, which serve to increase the number or activity of effector cells which interact with the antibodies.
- [0602] It is preferred to use high affinity and/or potent *in vivo* inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of diseases, disorders, and/or conditions related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides, including fragments thereof. Preferred binding affinities include those with a dissociation constant or K_d less than $5 \times 10^{-6}M$, $10^{-6}M$, $5 \times 10^{-7}M$, $10^{-7}M$, $5 \times 10^{-8}M$, $10^{-8}M$, $5 \times 10^{-9}M$, $10^{-9}M$, $5 \times 10^{-10}M$, $10^{-10}M$, $5 \times 10^{-11}M$, $10^{-11}M$, $5 \times 10^{-12}M$, $10^{-12}M$, $5 \times 10^{-13}M$, $10^{-13}M$, $5 \times 10^{-14}M$, $10^{-14}M$, $5 \times 10^{-15}M$, and $10^{-15}M$.
- [0603] Moreover, testes antigen polypeptides of the present invention or fragments thereof, are useful in inhibiting the angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in combination with other polypeptides directly or indirectly, as described elsewhere herein. In a most preferred embodiment, said anti-angiogenesis effect may be achieved indirectly, for example, through the inhibition of hematopoietic, tumor-specific cells, such as tumor-associated macrophages (see, e.g., Joseph IB, et al. J Natl Cancer Inst, 90(21):1648-53 (1998), which is hereby incorporated by reference). Antibodies directed to polypeptides or polynucleotides of the present invention may also result in inhibition of angiogenesis directly, or indirectly (see, e.g., Witte L, et al., Cancer Metastasis Rev. 17(2):155-61 (1998), which is hereby incorporated by reference)).
- [0604] Polypeptides, including protein fusions, of the present invention, or fragments thereof may be useful in inhibiting proliferative cells or tissues through the

induction of apoptosis. Said polypeptides may act either directly, or indirectly to induce apoptosis of proliferative cells and tissues, for example in the activation of a death-domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1), TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (see, e.g., Schulze-Osthoff K, et.al., Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference). Moreover, in another preferred embodiment of the present invention, said polypeptides may induce apoptosis through other mechanisms, such as in the activation of other proteins which will activate apoptosis, or through stimulating the expression of said proteins, either alone or in combination with small molecule drugs or adjuvants, such as apoptonin, galectins, thioredoxins, antiinflammatory proteins (See for example, Mutat. Res. 400(1-2):447-55 (1998), Med Hypotheses.50(5):423-33 (1998), Chem. Biol. Interact. Apr 24;111-112:23-34 (1998), J. Mo. Med. 76(6):402-12 (1998), Int. J. Tissue React. 20(1):3-15 (1998), which are all hereby incorporated by reference).

[0605] Polypeptides, including protein fusions to, or fragments thereof, of the present invention are useful in inhibiting the metastasis of proliferative cells or tissues. Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewhere herein, or indirectly, such as activating the expression of proteins known to inhibit metastasis, for example alpha 4 integrins, (See, e.g., Curr Top Microbiol Immunol 1998;231:125-41, which is hereby incorporated by reference). Such therapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

[0606] In another embodiment, the invention provides a method of delivering compositions containing the polypeptides of the invention (e.g., compositions containing polypeptides or anti- testes antigen polypeptide antibodies associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells expressing the polypeptide of the present invention. testes antigen polypeptides or anti- testes antigen polypeptide antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions.

[0607] Polypeptides, protein fusions to, or fragments thereof, of the present invention are useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present invention 'vaccinated' the immune response to respond to proliferative antigens and immunogens, or indirectly, such as in activating the expression of proteins known to enhance the immune response (e.g. chemokines), to said antigens and immunogens.

Urinary System Disorders

[0608] Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose disorders of the urinary system, including but not limited to disorders of the renal system, bladder, ureters, and urethra. Renal disorders include, but are not limited to, kidney failure, nephritis, blood vessel disorders of kidney, metabolic and congenital kidney disorders, urinary disorders of the kidney, autoimmune disorders, sclerosis and necrosis, electrolyte imbalance, and kidney cancers.

[0609] Kidney failure diseases include, but are not limited to, acute kidney failure, chronic kidney failure, atheroembolic renal failure, and end-stage renal disease. Inflammatory diseases of the kidney include acute glomerulonephritis, postinfectious glomerulonephritis, rapidly progressive glomerulonephritis, nephrotic syndrome, membranous glomerulonephritis, familial nephrotic syndrome, membranoproliferative glomerulonephritis I and II, mesangial proliferative glomerulonephritis, chronic glomerulonephritis, acute tubulointerstitial nephritis, chronic tubulointerstitial nephritis, acute post-streptococcal glomerulonephritis (PSGN), pyelonephritis, lupus nephritis, chronic nephritis, interstitial nephritis, and post-streptococcal glomerulonephritis.

[0610] Blood vessel disorders of the kidneys include, but are not limited to, kidney infarction, atheroembolic kidney disease, cortical necrosis, malignant nephrosclerosis, renal vein thrombosis, renal underperfusion, renal ischemia-reperfusion, renal artery embolism, and renal artery stenosis. Kidney disorders resulting from urinary tract problems include, but are not limited to, pyelonephritis, hydronephrosis, urolithiasis

(renal lithiasis, nephrolithiasis), reflux nephropathy, urinary tract infections, urinary retention, and acute or chronic unilateral obstructive uropathy.

[0611] Metabolic and congenital disorders of the kidneys include, but are not limited to, renal tubular acidosis, renal glycosuria, nephrogenic diabetes insipidus, cystinuria, Fanconi's syndrome, vitamin D-resistant rickets, Hartnup disease, Bartter's syndrome, Liddle's syndrome, polycystic kidney disease, medullary cystic disease, medullary sponge kidney, Alport's syndrome, nail-patella syndrome, congenital nephrotic syndrome, CRUSH syndrome, horseshoe kidney, diabetic nephropathy, nephrogenic diabetes insipidus, analgesic nephropathy, kidney stones, and membranous nephropathy. Kidney disorders resulting from an autoimmune response include, but are not limited to, systemic lupus erythematosus (SLE), Goodpasture syndrome, IgA nephropathy, and IgM mesangial proliferative glomerulonephritis.

[0612] Sclerotic or necrotic disorders of the kidney include, but are not limited to, glomerulosclerosis, diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), necrotizing glomerulonephritis, and renal papillary necrosis. Kidneys may also develop carcinomas, including, but not limited to, hypernephroma, nephroblastoma, renal cell cancer, transitional cell cancer, squamous cell cancer, and Wilm's tumor.

[0613] Kidney disorders may also result in electrolyte imbalances, including, but not limited to, nephrocalcinosis, pyuria, edema, hydronephritis, proteinuria, hyponatremia, hypernatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypophosphatemia, and hyperphosphatemia.

[0614] Bladder disorders include, but are not limited to, benign prostatic hyperplasia (BPH), interstitial cystitis (IC), prostatitis, proteinuria, urinary tract infections, urinary incontinence, urinary retention. Disorders of the ureters and urethra include, but are not limited to, acute or chronic unilateral obstructive uropathy. The bladder, ureters, and urethra may also develop carcinomas, including, but not limited to, superficial bladder cancer, invasive bladder cancer, carcinoma of the ureter, and urethra cancers.

[0615] Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials,

osmotic pumps, oral or suppositorial solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides may be administered as part of a Therapeutic, described in more detail below. Methods of delivering polynucleotides are described in more detail herein.

Cardiovascular Disorders

[0616] Polynucleotides or polypeptides, or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose cardiovascular disorders, including, but not limited to, peripheral artery disease, such as limb ischemia.

[0617] Cardiovascular disorders include cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral arteriovenous malformations, congenital heart defects, pulmonary atresia, and Scimitar Syndrome. Congenital heart defects include aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart, dextrocardia, patent ductus arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, total anomalous pulmonary venous connection, hypoplastic left heart syndrome, and heart septal defects, such as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, atrioventricular canal defect, trilogly of Fallot, ventricular heart septal defects.

[0618] Cardiovascular disorders also include heart disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac arrest, sudden cardiac death, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous), pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy

complications, Scimitar Syndrome, diastolic dysfunction, enlarged heart, heart block, J-curve phenomenon, rheumatic heart disease, Marfan syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

[0619] Arrhythmias include sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

[0620] Heart valve disease include aortic valve insufficiency, aortic valve stenosis, heart murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, tricuspid valve stenosis, and bicuspid aortic valve.

[0621] Myocardial diseases include alcoholic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, Barth syndrome, myocardial reperfusion injury, and myocarditis.

[0622] Myocardial ischemias include coronary disease, such as angina pectoris, Prinzmetal's angina, unstable angina, coronary aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary vasospasm, myocardial infarction and myocardial stunning.

[0623] Cardiovascular diseases also include vascular diseases such as aneurysms, angiodysplasia, angiomas, bacillary angiomatosis, Hippiel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular disorders, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, erythromelalgia,

hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension (shock), ischemia, peripheral vascular diseases, phlebitis, superficial phlebitis, pulmonary veno-occlusive disease, chronic obstructive pulmonary disease, Buerger's disease, Raynaud's disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome, superior vena cava syndrome, telangiectasia, atacia telangiectasia, hereditary hemorrhagic telangiectasia, deep vein thrombosis, varicocele, varicose veins, varicose ulcer, vasculitis, and venous insufficiency.

[0624] Aneurysms include dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart aneurysms, and iliac aneurysms.

[0625] Arterial occlusive diseases include arteriosclerosis, arteriolosclerosis, atherosclerosis, intermittent claudication, carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

[0626] Cerebrovascular disorders include carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural hematoma, subarachnoid hemorrhage, cerebral infarction, cerebral ischemia (including transient), subclavian steal syndrome, periventricular leukomalacia, vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

[0627] Embolisms include air embolisms, amniotic fluid embolisms, cholesterol embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and thromboembolisms. Thrombosis include coronary thrombosis, hepatic vein thrombosis, deep vein thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.

[0628] Ischemia includes cerebral ischemia, ischemic colitis, silent ischemia, compartment syndromes, anterior compartment syndrome, myocardial ischemia, reperfusion injuries, and peripheral limb ischemia. Vasculitis includes aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome, mucocutaneous lymph node

syndrome, thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura, allergic cutaneous vasculitis, and Wegener's granulomatosis.

[0629] Cardiovascular diseases can also occur due to electrolyte imbalances that include, but are not limited to hyponatremia, hypernatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypophosphatemia, and hyperphosphatemia. Neoplasm and/or cancers of the cardiovascular system include, but are not limited to, myxomas, fibromas, and rhabdomyomas.

[0630] Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppositorial solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides may be administered as part of a Therapeutic, described in more detail below. Methods of delivering polynucleotides are described in more detail herein.

Respiratory Disorders

[0631] Polynucleotides or polypeptides, or agonists or antagonists of the present invention may be used to treat, prevent, diagnose, and/or prognose diseases and/or disorders of the respiratory system.

[0632] Diseases and disorders of the respiratory system include, but are not limited to, nasal vestibulitis, nonallergic rhinitis (e.g., acute rhinitis, chronic rhinitis, atrophic rhinitis, vasomotor rhinitis), nasal polyps, and sinusitis, juvenile angiofibromas, cancer of the nose and juvenile papillomas, vocal cord polyps, nodules (singer's nodules), contact ulcers, vocal cord paralysis, laryngoceles, pharyngitis (e.g., viral and bacterial), tonsillitis, tonsillar cellulitis, parapharyngeal abscess, laryngitis, laryngoceles, and throat cancers (e.g., cancer of the nasopharynx, tonsil cancer, larynx cancer), lung cancer (e.g., squamous cell carcinoma, small cell (oat cell) carcinoma, large cell carcinoma, and adenocarcinoma), allergic disorders (eosinophilic pneumonia, hypersensitivity pneumonitis (e.g., extrinsic allergic alveolitis, allergic interstitial pneumonitis, organic dust pneumoconiosis, allergic bronchopulmonary

aspergillosis, asthma, Wegener's granulomatosis (granulomatous vasculitis), Goodpasture's syndrome)), pneumonia (e.g., bacterial pneumonia (e.g., *Streptococcus pneumoniae* (pneumococcal pneumonia), *Staphylococcus aureus* (staphylococcal pneumonia), Gram-negative bacterial pneumonia (caused by, e.g., *Klebsiella* and *Pseudomonas spp.*), *Mycoplasma pneumoniae* pneumonia, *Hemophilus influenzae* pneumonia, *Legionella pneumophila* (Legionnaires' disease), and *Chlamydia psittaci* (Psittacosis)), and viral pneumonia (e.g., influenza, chickenpox (varicella).

[0633] Additional diseases and disorders of the respiratory system include, but are not limited to bronchiolitis, polio (poliomyelitis), croup, respiratory syncytial viral infection, mumps, erythema infectiosum (fifth disease), roseola infantum, progressive rubella panencephalitis, german measles, and subacute sclerosing panencephalitis), fungal pneumonia (e.g., Histoplasmosis, Coccidioidomycosis, Blastomycosis, fungal infections in people with severely suppressed immune systems (e.g., cryptococcosis, caused by *Cryptococcus neoformans*; aspergillosis, caused by *Aspergillus spp.*; candidiasis, caused by *Candida*; and mucormycosis)), *Pneumocystis carinii* (pneumocystis pneumonia), atypical pneumonias (e.g., *Mycoplasma* and *Chlamydia spp.*), opportunistic infection pneumonia, nosocomial pneumonia, chemical pneumonitis, and aspiration pneumonia, pleural disorders (e.g., pleurisy, pleural effusion, and pneumothorax (e.g., simple spontaneous pneumothorax, complicated spontaneous pneumothorax, tension pneumothorax)), obstructive airway diseases (e.g., asthma, chronic obstructive pulmonary disease (COPD), emphysema, chronic or acute bronchitis), occupational lung diseases (e.g., silicosis, black lung (coal workers' pneumoconiosis), asbestosis, berylliosis, occupational asthma, byssinosis, and benign pneumoconioses), Infiltrative Lung Disease (e.g., pulmonary fibrosis (e.g., fibrosing alveolitis, usual interstitial pneumonia), idiopathic pulmonary fibrosis, desquamative interstitial pneumonia, lymphoid interstitial pneumonia, histiocytosis X (e.g., Letterer-Siwe disease, Hand-Schüller-Christian disease, eosinophilic granuloma), idiopathic pulmonary hemosiderosis, sarcoidosis and pulmonary alveolar proteinosis), Acute respiratory distress syndrome (also called, e.g., adult respiratory distress syndrome), edema, pulmonary embolism, bronchitis (e.g., viral, bacterial), bronchiectasis, atelectasis, lung abscess (caused by, e.g., *Staphylococcus aureus* or *Legionella pneumophila*), and cystic fibrosis.

Anti-Angiogenesis Activity

- [0634] The naturally occurring balance between endogenous stimulators and inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad *et al.*, *Cell* 56:345-355 (1989). In those rare instances in which neovascularization occurs under normal physiological conditions, such as wound healing, organ regeneration, embryonic development, and female reproductive processes, angiogenesis is stringently regulated and spatially and temporally delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes pathologic and sustains progression of many neoplastic and non-neoplastic diseases. A number of serious diseases are dominated by abnormal neovascularization including solid tumor growth and metastases, arthritis, some types of eye disorders, and psoriasis. See, e.g., reviews by Moses *et al.*, *Biotech.* 9:630-634 (1991); Folkman *et al.*, *N. Engl. J. Med.*, 333:1757-1763 (1995); Auerbach *et al.*, *J. Microvasc. Res.* 29:401-411 (1985); Folkman, *Advances in Cancer Research*, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-203 (1985); Patz, *Am. J. Ophthalmol.* 94:715-743 (1982); and Folkman *et al.*, *Science* 221:719-725 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, *Science* 235:442-447 (1987).
- [0635] The present invention provides for treatment of diseases or disorders associated with neovascularization by administration of the polynucleotides and/or polypeptides of the invention, as well as agonists or antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the invention include, but are not limited to, malignancies, solid tumors, and cancers described herein and otherwise known in the art (for a review of such disorders, see Fishman *et al.*, *Medicine*, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the present invention provides a method of treating an angiogenesis-related disease and/or disorder, comprising administration to an individual in need thereof a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist of the

invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety of additional methods in order to therapeutically treat a cancer or tumor. Cancers which may be treated with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors, including prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma; Kaposi's sarcoma; leiomyosarcoma; non-small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example, polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically, in order to treat cancers such as skin cancer, head and neck tumors, breast tumors, and Kaposi's sarcoma.

[0636] Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists may be delivered directly into the tumor, or near the tumor site, via injection or a catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.

[0637] Polynucleotides, polypeptides, antagonists and/or agonists may be useful in treating other disorders, besides cancers, which involve angiogenesis. These disorders include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound granulation;

Crohn's disease; and atherosclerosis.

[0638] For example, within one aspect of the present invention methods are provided for treating hypertrophic scars and keloids, comprising the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

[0639] Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists of the invention are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of hypertrophic scars and keloids (e.g., burns), and is preferably initiated after the proliferative phase has had time to progress (approximately 14 days after the initial injury), but before hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroplasia and macular degeneration.

[0640] Moreover, ocular disorders associated with neovascularization which can be treated with the polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman *et al.*, *Am. J. Ophthalmol.* 85:704-710 (1978) and Gartner *et al.*, *Surv. Ophthalmol.* 22:291-312 (1978).

[0641] Thus, within one aspect of the present invention methods are provided for treating neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue, which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in

a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of disorders can result in corneal neovascularization, including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause), toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

[0642] Within particularly preferred embodiments of the invention, may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in eyedrop form. The solution or suspension may be prepared in its pure form and administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer, which binds to cornea. Within further embodiments, the anti-angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a high probability of inducing an angiogenic response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent complications.

[0643] Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance. The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the cornea from the advancing blood vessels. This method may also be utilized shortly after a corneal insult in order to prophylactically prevent corneal neovascularization. In this situation, the material could be injected in the perilimbic cornea interspersed between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary

invasion of transplanted corneas. In a sustained-release form, injections might only be required 2-3 times per year. A steroid could also be added to the injection solution to reduce inflammation resulting from the injection itself.

[0644] Within another aspect of the present invention, methods are provided for treating neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat early forms of neovascular glaucoma. Within other embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided for treating proliferative diabetic retinopathy, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

[0645] Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide, polypeptide, antagonist and/or agonist in the retina. Preferably, this treatment should be initiated prior to the acquisition of severe disease requiring photocoagulation.

[0646] Within another aspect of the present invention, methods are provided for treating retrolental fibroplasia, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreal injection and/or via intraocular implants.

[0647] Additionally, disorders which can be treated with the polynucleotides, polypeptides, agonists and/or antagonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome, pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

[0648] Moreover, disorders and/or states, which can be treated, prevented, diagnosed and/or prognosed with the polynucleotides, polypeptides, agonists and/or agonists of the invention include, but are not limited to, solid tumors, blood born tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, and uveitis, delayed wound healing, endometriosis, vasculogenesis, granulations, hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, plaque neovascularization, telangiectasia, hemophilic joints, angiofibroma fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth control agent by preventing vascularization required for embryo implantation controlling menstruation, diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (*Rochela minalia quintosa*), ulcers (*Helicobacter pylori*), Bartonellosis and bacillary angiomatosis.

[0649] In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and fertilization have occurred, thus providing an effective method of birth control, possibly a "morning after" method. Polynucleotides, polypeptides, agonists and/or agonists may also be used in controlling menstruation or administered as either a peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

[0650] Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch granulomas.

[0651] Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present invention a compositions (in the form of, for example, a spray or film) may be utilized to coat or spray an area prior to removal of a tumor, in order to isolate normal surrounding tissues from malignant tissue, and/or to prevent the spread of disease to

surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes, which have been coated with anti-angiogenic compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the invention a surgical mesh laden with an anti-angiogenic composition may be utilized during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

[0652] Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide, agonist and/or agonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied after hepatic resections for malignancy, and after neurosurgical operations.

[0653] Within one aspect of the present invention, polynucleotides, polypeptides, agonists and/or agonists may be administered to the resection margin of a wide variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

[0654] The polynucleotides, polypeptides, agonists and/or agonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator

Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

[0655] Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

[0656] Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

[0657] Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

[0658] A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26 (1991)); Sulphated Polysaccharide Peptidoglycan Complex (SP- PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-

3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326 (1992)); Chymostatin (Tomkinson et al., Biochem J. 286:475-480 (1992)); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557 (1990)); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446 (1987)); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664 (1987)); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312-316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxyaminoimidazole; and metalloproteinase inhibitors such as BB94.

Musculoskeletal System Disorders

- [0659] Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose disorders of the musculoskeletal system, including but not limited to, disorders of the bone, joints, ligaments, tendons, bursa, muscle, and/or neoplasms and cancers associated with musculoskeletal tissue.
- [0660] Diseases or disorders of the bone include, but are not limited to, Albers-Schönberg disease, bowlegs, heel spurs, Köhler's bone disease, knock-knees, Legg-Calvé-Perthes disease, Marfan's syndrome, mucopolysaccharidoses, Osgood-Schlatter disease, osteochondroses, osteochondrodysplasia, osteomyelitis, osteopetroses, osteoporosis (postmenopausal, senile, and juvenile), Paget's disease, Scheuermann's disease, scoliosis, Sever's disease, and patellofemoral stress syndrome.
- [0661] Joint diseases or disorders include, but are not limited to, ankylosing spondylitis, Behçet's syndrome, CREST syndrome, Ehlers-Danlos syndrome, infectious arthritis, discoid lupus erythematosus, systemic lupus erythematosus, Lyme disease, osteoarthritis, psoriatic arthritis, relapsing polychondritis, Reiter's syndrome, rheumatoid arthritis (adult and juvenile), scleroderma, and Still's disease.
- [0662] Diseases or disorders affecting ligaments, tendons, or bursa include, but are not limited to, ankle sprain, bursitis, posterior Achilles tendon bursitis (Haglund's

deformity), anterior Achilles tendon bursitis (Albert's disease), tendinitis, tenosynovitis, popliteus tendinitis, Achilles tendinitis, medial or lateral epicondylitis, rotator cuff tendinitis, spasmodic torticollis, and fibromyalgia syndrome.

[0663] Muscle diseases or disorders include, but are not limited to, Becker's muscular dystrophy, Duchenne's muscular dystrophy, Landouzy-Dejerine muscular dystrophy, Leyden-Möbius muscular dystrophy, Erb's muscular dystrophy, Charcot's joints, dermatomyositis, gout, pseudogout, glycogen storage diseases, Pompe's disease, mitochondrial myopathy, periodic paralysis, polymyalgia rheumatica, polymyositis, Steinert's disease, Thomsen's disease, anterolateral and posteromedial shin splints, posterior femoral muscle strain, and fibromyositis.

[0664] Musculoskeletal tissue may also develop cancers and/or neoplasms that include, but are not limited to, osteochondroma, benign chondroma, chondroblastoma, chondromyxoid fibroma, osteoid osteoma, giant cell tumor, multiple myeloma, osteosarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's tumor, and malignant lymphoma of bone.

Neural Activity and Neurological Diseases

[0665] The polynucleotides, polypeptides and agonists or antagonists of the invention may be used for the diagnosis and/or treatment of diseases, disorders, damage or injury of the brain and/or nervous system. Nervous system disorders that can be treated with the compositions of the invention (e.g., polypeptides, polynucleotides, and/or agonists or antagonists), include, but are not limited to, nervous system injuries, and diseases or disorders which result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated in a patient (including human and non-human mammalian patients) according to the methods of the invention, include but are not limited to, the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems: (1) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia; (2) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries; (3)

malignant lesions, in which a portion of the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous system tissue; (4) infectious lesions, in which a portion of the nervous system is destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, or syphilis; (5) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to, degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis (ALS); (6) lesions associated with nutritional diseases or disorders, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including, but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar degeneration; (7) neurological lesions associated with systemic diseases including, but not limited to, diabetes (diabetic neuropathy, Bell's palsy), systemic lupus erythematosus, carcinoma, or sarcoidosis; (8) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (9) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including, but not limited to, multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

[0666] In one embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of hypoxia. In a further preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of cerebral hypoxia. According to this embodiment, the compositions of the invention are used to treat or prevent neural cell injury associated with cerebral hypoxia. In one non-exclusive aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention, are used to treat or prevent neural cell injury associated with cerebral ischemia. In another non-

exclusive aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with cerebral infarction.

[0667] In another preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with a stroke. In a specific embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent cerebral neural cell injury associated with a stroke.

[0668] In another preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with a heart attack. In a specific embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent cerebral neural cell injury associated with a heart attack.

[0669] The compositions of the invention which are useful for treating or preventing a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons. For example, and not by way of limitation, compositions of the invention which elicit any of the following effects may be useful according to the invention: (1) increased survival time of neurons in culture either in the presence or absence of hypoxia or hypoxic conditions; (2) increased sprouting of neurons in culture or *in vivo*; (3) increased production of a neuron-associated molecule in culture or *in vivo*, e.g., choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or (4) decreased symptoms of neuron dysfunction *in vivo*. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may routinely be measured using a method set forth herein or otherwise known in the art, such as, for example, in Zhang *et al.*, *Proc Natl Acad Sci USA* 97:3637-42 (2000) or in Arakawa *et al.*, *J. Neurosci.*, 10:3507-15 (1990); increased sprouting of neurons may be detected by methods known in the art, such as, for example, the methods set forth in Pestronk *et al.*, *Exp. Neurol.*, 70:65-82 (1980), or Brown *et al.*, *Ann. Rev. Neurosci.*, 4:17-42 (1981); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., using techniques known in the art and depending on the molecule to be measured; and

motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability.

[0670] In specific embodiments, motor neuron disorders that may be treated according to the invention include, but are not limited to, disorders such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as disorders that selectively affect neurons such as amyotrophic lateral sclerosis, and including, but not limited to, progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motorsensory Neuropathy (Charcot-Marie-Tooth Disease).

[0671] Further, polypeptides or polynucleotides of the invention may play a role in neuronal survival; synapse formation; conductance; neural differentiation, etc. Thus, compositions of the invention (including polynucleotides, polypeptides, and agonists or antagonists) may be used to diagnose and/or treat or prevent diseases or disorders associated with these roles, including, but not limited to, learning and/or cognition disorders. The compositions of the invention may also be useful in the treatment or prevention of neurodegenerative disease states and/or behavioural disorders. Such neurodegenerative disease states and/or behavioral disorders include, but are not limited to, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, compositions of the invention may also play a role in the treatment, prevention and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders.

[0672] Additionally, polypeptides, polynucleotides and/or agonists or antagonists of the invention, may be useful in protecting neural cells from diseases, damage, disorders, or injury, associated with cerebrovascular disorders including, but not limited to, carotid artery diseases (e.g., carotid artery thrombosis, carotid stenosis, or

Moyamoya Disease), cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis (e.g., carotid artery thrombosis, sinus thrombosis, or Wallenberg's Syndrome), cerebral hemorrhage (e.g., epidural or subdural hematoma, or subarachnoid hemorrhage), cerebral infarction, cerebral ischemia (e.g., transient cerebral ischemia, Subclavian Steal Syndrome, or vertebrobasilar insufficiency), vascular dementia (e.g., multi-infarct), leukomalacia, periventricular, and vascular headache (e.g., cluster headache or migraines).

[0673] In accordance with yet a further aspect of the present invention, there is provided a process for utilizing polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, for therapeutic purposes, for example, to stimulate neurological cell proliferation and/or differentiation. Therefore, polynucleotides, polypeptides, agonists and/or antagonists of the invention may be used to treat and/or detect neurologic diseases. Moreover, polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used as a marker or detector of a particular nervous system disease or disorder.

[0674] Examples of neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include brain diseases, such as metabolic brain diseases which includes phenylketonuria such as maternal phenylketonuria, pyruvate carboxylase deficiency, pyruvate dehydrogenase complex deficiency, Wernicke's Encephalopathy, brain edema, brain neoplasms such as cerebellar neoplasms which include infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms, supratentorial neoplasms, canavan disease, cerebellar diseases such as cerebellar ataxia which include spinocerebellar degeneration such as ataxia telangiectasia, cerebellar dyssynergia, Friederich's Ataxia, Machado-Joseph Disease, olivopontocerebellar atrophy, cerebellar neoplasms such as infratentorial neoplasms, diffuse cerebral sclerosis such as encephalitis periaxialis, globoid cell leukodystrophy, metachromatic leukodystrophy and subacute sclerosing panencephalitis.

[0675] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention

include cerebrovascular disorders (such as carotid artery diseases which include carotid artery thrombosis, carotid stenosis and Moyamoya Disease), cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis such as carotid artery thrombosis, sinus thrombosis and Wallenberg's Syndrome, cerebral hemorrhage such as epidural hematoma, subdural hematoma and subarachnoid hemorrhage, cerebral infarction, cerebral ischemia such as transient cerebral ischemia, Subclavian Steal Syndrome and vertebrobasilar insufficiency, vascular dementia such as multi-infarct dementia, periventricular leukomalacia, vascular headache such as cluster headache and migraine.

[0676] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include dementia such as AIDS Dementia Complex, presenile dementia such as Alzheimer's Disease and Creutzfeldt-Jakob Syndrome, senile dementia such as Alzheimer's Disease and progressive supranuclear palsy, vascular dementia such as multi-infarct dementia, encephalitis which include encephalitis periaxialis, viral encephalitis such as epidemic encephalitis, Japanese Encephalitis, St. Louis Encephalitis, tick-borne encephalitis and West Nile Fever, acute disseminated encephalomyelitis, meningoencephalitis such as uveomeningoencephalitic syndrome, Postencephalitic Parkinson Disease and subacute sclerosing panencephalitis, encephalomalacia such as periventricular leukomalacia, epilepsy such as generalized epilepsy which includes infantile spasms, absence epilepsy, myoclonic epilepsy which includes MERRF Syndrome, tonic-clonic epilepsy, partial epilepsy such as complex partial epilepsy, frontal lobe epilepsy and temporal lobe epilepsy, post-traumatic epilepsy, status epilepticus such as Epilepsia Partialis Continua, and Hallervorden-Spatz Syndrome.

[0677] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include hydrocephalus such as Dandy-Walker Syndrome and normal pressure hydrocephalus, hypothalamic diseases such as hypothalamic neoplasms, cerebral malaria, narcolepsy which includes cataplexy, bulbar poliomyelitis, cerebri pseudotumor, Rett Syndrome, Reye's Syndrome, thalamic diseases, cerebral

toxoplasmosis, intracranial tuberculoma and Zellweger Syndrome, central nervous system infections such as AIDS Dementia Complex, Brain Abscess, subdural empyema, encephalomyelitis such as Equine Encephalomyelitis, Venezuelan Equine Encephalomyelitis, Necrotizing Hemorrhagic Encephalomyelitis, Visna, and cerebral malaria.

[0678] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include meningitis such as arachnoiditis, aseptic meningitis such as viral meningitis which includes lymphocytic choriomeningitis, Bacterial meningitis which includes Haemophilus Meningitis, Listeria Meningitis, Meningococcal Meningitis such as Waterhouse-Friderichsen Syndrome, Pneumococcal Meningitis and meningeal tuberculosis, fungal meningitis such as Cryptococcal Meningitis, subdural effusion, meningoencephalitis such as uvemeningoencephalitic syndrome, myelitis such as transverse myelitis, neurosyphilis such as tabes dorsalis, poliomyelitis which includes bulbar poliomyelitis and postpoliomyelitis syndrome, prion diseases (such as Creutzfeldt-Jakob Syndrome, Bovine Spongiform Encephalopathy, Gerstmann-Straussler Syndrome, Kuru, Scrapie), and cerebral toxoplasmosis.

[0679] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include central nervous system neoplasms such as brain neoplasms that include cerebellar neoplasms such as infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms and supratentorial neoplasms, meningeal neoplasms, spinal cord neoplasms which include epidural neoplasms, demyelinating diseases such as Canavan Diseases, diffuse cerebral scleriosis which includes adrenoleukodystrophy, encephalitis periaxialis, globoid cell leukodystrophy, diffuse cerebral sclerosis such as metachromatic leukodystrophy, allergic encephalomyelitis, necrotizing hemorrhagic encephalomyelitis, progressive multifocal leukoencephalopathy, multiple sclerosis, central pontine myelinolysis, transverse myelitis, neuromyelitis optica, Scrapie, Swayback, Chronic Fatigue Syndrome, Visna, High Pressure Nervous Syndrome, Meningism, spinal cord diseases such as amyotonia congenita, amyotrophic lateral sclerosis, spinal muscular atrophy such as Werdnig-Hoffmann Disease, spinal cord compression, spinal cord neoplasms

such as epidural neoplasms, syringomyelia, Tabes Dorsalis, Stiff-Man Syndrome, mental retardation such as Angelman Syndrome, Cri-du-Chat Syndrome, De Lange's Syndrome, Down Syndrome, Gangliosidoses such as gangliosidoses G(M1), Sandhoff Disease, Tay-Sachs Disease, Hartnup Disease, homocystinuria, Laurence-Moon- Biedl Syndrome, Lesch-Nyhan Syndrome, Maple Syrup Urine Disease, mucopolipidosis such as fucosidosis, neuronal ceroid-lipofuscinosis, oculocerebrorenal syndrome, phenylketonuria such as maternal phenylketonuria, Prader-Willi Syndrome, Rett Syndrome, Rubinstein-Taybi Syndrome, Tuberous Sclerosis, WAGR Syndrome, nervous system abnormalities such as holoprosencephaly, neural tube defects such as anencephaly which includes hydrangencephaly, Arnold-Chairi Deformity, encephalocele, meningocele, meningomyelocele, spinal dysraphism such as spina bifida cystica and spina bifida occulta.

[0680] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include hereditary motor and sensory neuropathies which include Charcot-Marie Disease, Hereditary optic atrophy, Refsum's Disease, hereditary spastic paraplegia, Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies such as Congenital Analgesia and Familial Dysautonomia, Neurologic manifestations (such as agnosia that include Gerstmann's Syndrome, Amnesia such as retrograde amnesia, apraxia, neurogenic bladder, cataplexy, communicative disorders such as hearing disorders that includes deafness, partial hearing loss, loudness recruitment and tinnitus, language disorders such as aphasia which include agraphia, anomia, broca aphasia, and Wernicke Aphasia, Dyslexia such as Acquired Dyslexia, language development disorders, speech disorders such as aphasia which includes anomia, broca aphasia and Wernicke Aphasia, articulation disorders, communicative disorders such as speech disorders which include dysarthria, echolalia, mutism and stuttering, voice disorders such as aphonia and hoarseness, decerebrate state, delirium, fasciculation, hallucinations, meningism, movement disorders such as angelman syndrome, ataxia, athetosis, chorea, dystonia, hypokinesia, muscle hypotonia, myoclonus, tic, torticollis and tremor, muscle hypertonia such as muscle rigidity such as stiff-man syndrome, muscle spasticity, paralysis such as facial paralysis which includes Herpes Zoster Oticus, Gastroparesis, Hemiplegia, ophthalmoplegia such as diplopia, Duane's

Syndrome, Horner's Syndrome, Chronic progressive external ophthalmoplegia such as Kearns Syndrome, Bulbar Paralysis, Tropical Spastic Paraparesis, Paraplegia such as Brown-Sequard Syndrome, quadriplegia, respiratory paralysis and vocal cord paralysis, paresis, phantom limb, taste disorders such as ageusia and dysgeusia, vision disorders such as amblyopia, blindness, color vision defects, diplopia, hemianopsia, scotoma and subnormal vision, sleep disorders such as hypersomnia which includes Kleine-Levin Syndrome, insomnia, and somnambulism, spasm such as trismus, unconsciousness such as coma, persistent vegetative state and syncope and vertigo, neuromuscular diseases such as amyotonia congenita, amyotrophic lateral sclerosis, Lambert-Eaton Myasthenic Syndrome, motor neuron disease, muscular atrophy such as spinal muscular atrophy, Charcot-Marie Disease and Werdnig-Hoffmann Disease, Postpoliomyelitis Syndrome, Muscular Dystrophy, Myasthenia Gravis, Myotonia Atrophica, Myotonia Confenita, Nemaline Myopathy, Familial Periodic Paralysis, Multiplex Paramyoclonus, Tropical Spastic Paraparesis and Stiff-Man Syndrome, peripheral nervous system diseases such as acrodynia, amyloid neuropathies, autonomic nervous system diseases such as Adie's Syndrome, Barre-Lieou Syndrome, Familial Dysautonomia, Horner's Syndrome, Reflex Sympathetic Dystrophy and Shy-Drager Syndrome, Cranial Nerve Diseases such as Acoustic Nerve Diseases such as Acoustic Neuroma which includes Neurofibromatosis 2, Facial Nerve Diseases such as Facial Neuralgia, Melkersson-Rosenthal Syndrome, ocular motility disorders which includes amblyopia, nystagmus, oculomotor nerve paralysis, ophthalmoplegia such as Duane's Syndrome, Horner's Syndrome, Chronic Progressive External Ophthalmoplegia which includes Kearns Syndrome, Strabismus such as Esotropia and Exotropia, Oculomotor Nerve Paralysis, Optic Nerve Diseases such as Optic Atrophy which includes Hereditary Optic Atrophy, Optic Disk Drusen, Optic Neuritis such as Neuromyelitis Optica, Papilledema, Trigeminal Neuralgia, Vocal Cord Paralysis, Demyelinating Diseases such as Neuromyelitis Optica and Swayback, and Diabetic neuropathies such as diabetic foot.

[0681] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include nerve compression syndromes such as carpal tunnel syndrome, tarsal tunnel syndrome, thoracic outlet syndrome such as cervical rib syndrome, ulnar nerve

compression syndrome, neuralgia such as causalgia, cervico-brachial neuralgia, facial neuralgia and trigeminal neuralgia, neuritis such as experimental allergic neuritis, optic neuritis, polyneuritis, polyradiculoneuritis and radiculities such as polyradiculitis, hereditary motor and sensory neuropathies such as Charcot-Marie Disease, Hereditary Optic Atrophy, Refsum's Disease, Hereditary Spastic Paraplegia and Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies which include Congenital Analgesia and Familial Dysautonomia, POEMS Syndrome, Sciatica, Gustatory Sweating and Tetany).

Endocrine Disorders

[0682] Polynucleotides or polypeptides, or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose disorders and/or diseases related to hormone imbalance, and/or disorders or diseases of the endocrine system.

[0683] Hormones secreted by the glands of the endocrine system control physical growth, sexual function, metabolism, and other functions. Disorders may be classified in two ways: disturbances in the production of hormones, and the inability of tissues to respond to hormones. The etiology of these hormone imbalance or endocrine system diseases, disorders or conditions may be genetic, somatic, such as cancer and some autoimmune diseases, acquired (e.g., by chemotherapy, injury or toxins), or infectious. Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention can be used as a marker or detector of a particular disease or disorder related to the endocrine system and/or hormone imbalance.

[0684] Endocrine system and/or hormone imbalance and/or diseases encompass disorders of uterine motility including, but not limited to: complications with pregnancy and labor (e.g., pre-term labor, post-term pregnancy, spontaneous abortion, and slow or stopped labor); and disorders and/or diseases of the menstrual cycle (e.g., dysmenorrhea and endometriosis).

[0685] Endocrine system and/or hormone imbalance disorders and/or diseases include disorders and/or diseases of the pancreas, such as, for example, diabetes mellitus, diabetes insipidus, congenital pancreatic agenesis, pheochromocytoma-islet cell tumor syndrome; disorders and/or diseases of the adrenal glands such as, for

example, Addison's Disease, corticosteroid deficiency, virilizing disease, hirsutism, Cushing's Syndrome, hyperaldosteronism, pheochromocytoma; disorders and/or diseases of the pituitary gland, such as, for example, hyperpituitarism, hypopituitarism, pituitary dwarfism, pituitary adenoma, panhypopituitarism, acromegaly, gigantism; disorders and/or diseases of the thyroid, including but not limited to, hyperthyroidism, hypothyroidism, Plummer's disease, Graves' disease (toxic diffuse goiter), toxic nodular goiter, thyroiditis (Hashimoto's thyroiditis, subacute granulomatous thyroiditis, and silent lymphocytic thyroiditis), Pendred's syndrome, myxedema, cretinism, thyrotoxicosis, thyroid hormone coupling defect, thymic aplasia, Hurthle cell tumours of the thyroid, thyroid cancer, thyroid carcinoma, Medullary thyroid carcinoma; disorders and/or diseases of the parathyroid, such as, for example, hyperparathyroidism, hypoparathyroidism; disorders and/or diseases of the hypothalamus.

[0686] In addition, endocrine system and/or hormone imbalance disorders and/or diseases may also include disorders and/or diseases of the testes or ovaries, including cancer. Other disorders and/or diseases of the testes or ovaries further include, for example, ovarian cancer, polycystic ovary syndrome, Klinefelter's syndrome, vanishing testes syndrome (bilateral anorchia), congenital absence of Leydig's cells, cryptorchidism, Noonan's syndrome, myotonic dystrophy, capillary haemangioma of the testis (benign), neoplasias of the testis and neo-testis.

[0687] Moreover, endocrine system and/or hormone imbalance disorders and/or diseases may also include disorders and/or diseases such as, for example, polyglandular deficiency syndromes, pheochromocytoma, neuroblastoma, multiple Endocrine neoplasia, and disorders and/or cancers of endocrine tissues.

[0688] In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to diagnose, prognose, prevent, and/or treat endocrine diseases and/or disorders associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 1A, column 7 (Tissue Distribution Library Code).

Gastrointestinal Disorders

- [0689] Polynucleotides or polypeptides, or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose gastrointestinal disorders, including inflammatory diseases and/or conditions, infections, cancers (e.g., intestinal neoplasms (carcinoid tumor of the small intestine, non-Hodgkin's lymphoma of the small intestine, small bowel lymphoma)), and ulcers, such as peptic ulcers.
- [0690] Gastrointestinal disorders include dysphagia, odynophagia, inflammation of the esophagus, peptic esophagitis, gastric reflux, submucosal fibrosis and stricturing, Mallory-Weiss lesions, leiomyomas, lipomas, epidermal cancers, adeocarcinomas, gastric retention disorders, gastroenteritis, gastric atrophy, gastric/stomach cancers, polyps of the stomach, autoimmune disorders such as pernicious anemia, pyloric stenosis, gastritis (bacterial, viral, eosinophilic, stress-induced, chronic erosive, atrophic, plasma cell, and Ménétrier's), and peritoneal diseases (e.g., chyloperitoneum, hemoperitoneum, mesenteric cyst, mesenteric lymphadenitis, mesenteric vascular occlusion, panniculitis, neoplasms, peritonitis, pneumoperitoneum, bubphrenic abscess).
- [0691] Gastrointestinal disorders also include disorders associated with the small intestine, such as malabsorption syndromes, distension, irritable bowel syndrome, sugar intolerance, celiac disease, duodenal ulcers, duodenitis, tropical sprue, Whipple's disease, intestinal lymphangiectasia, Crohn's disease, appendicitis, obstructions of the ileum, Meckel's diverticulum, multiple diverticula, failure of complete rotation of the small and large intestine, lymphoma, and bacterial and parasitic diseases (such as Traveler's diarrhea, typhoid and paratyphoid, cholera, infection by Roundworms (*Ascariasis lumbricoides*), Hookworms (*Ancylostoma duodenale*), Threadworms (*Enterobius vermicularis*), Tapeworms (*Taenia saginata*, *Echinococcus granulosus*, *Diphyllobothrium spp.*, and *T. solium*).
- [0692] Liver diseases and/or disorders include intrahepatic cholestasis (alagille syndrome, biliary liver cirrhosis), fatty liver (alcoholic fatty liver, reye syndrome), hepatic vein thrombosis, hepatolenticular degeneration, hepatomegaly, hepatopulmonary syndrome, hepatorenal syndrome, portal hypertension (esophageal and gastric varices), liver abscess (amebic liver abscess), liver cirrhosis (alcoholic, biliary and experimental), alcoholic liver diseases (fatty liver, hepatitis, cirrhosis),

parasitic (hepatic echinococcosis, fascioliasis, amebic liver abscess), jaundice (hemolytic, hepatocellular, and cholestatic), cholestasis, portal hypertension, liver enlargement, ascites, hepatitis (alcoholic hepatitis, animal hepatitis, chronic hepatitis (autoimmune, hepatitis B, hepatitis C, hepatitis D, drug induced), toxic hepatitis, viral human hepatitis (hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E), Wilson's disease, granulomatous hepatitis, secondary biliary cirrhosis, hepatic encephalopathy, portal hypertension, varices, hepatic encephalopathy, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular adenoma, hemangiomas, bile stones, liver failure (hepatic encephalopathy, acute liver failure), and liver neoplasms (angiomyolipoma, calcified liver metastases, cystic liver metastases, epithelial tumors, fibrolamellar hepatocarcinoma, focal nodular hyperplasia, hepatic adenoma, hepatobiliary cystadenoma, hepatoblastoma, hepatocellular carcinoma, hepatoma, liver cancer, liver hemangioendothelioma, mesenchymal hamartoma, mesenchymal tumors of liver, nodular regenerative hyperplasia, benign liver tumors (Hepatic cysts [Simple cysts, Polycystic liver disease, Hepatobiliary cystadenoma, Choledochal cyst], Mesenchymal tumors [Mesenchymal hamartoma, Infantile hemangioendothelioma, Hemangioma, Peliosis hepatis, Lipomas, Inflammatory pseudotumor, Miscellaneous], Epithelial tumors [Bile duct epithelium (Bile duct hamartoma, Bile duct adenoma), Hepatocyte (Adenoma, Focal nodular hyperplasia, Nodular regenerative hyperplasia)]), malignant liver tumors [hepatocellular, hepatoblastoma, hepatocellular carcinoma, cholangiocellular, cholangiocarcinoma, cystadenocarcinoma, tumors of blood vessels, angiosarcoma, Kaposi's sarcoma, hemangioendothelioma, other tumors, embryonal sarcoma, fibrosarcoma, leiomyosarcoma, rhabdomyosarcoma, carcinosarcoma, teratoma, carcinoid, squamous carcinoma, primary lymphoma]), peliosis hepatis, erythrohepatic porphyria, hepatic porphyria (acute intermittent porphyria, porphyria cutanea tarda), Zellweger syndrome).

[0693] Pancreatic diseases and/or disorders include acute pancreatitis, chronic pancreatitis (acute necrotizing pancreatitis, alcoholic pancreatitis), neoplasms (adenocarcinoma of the pancreas, cystadenocarcinoma, insulinoma, gastrinoma, and glucagonoma, cystic neoplasms, islet-cell tumors, pancreoblastoma), and other pancreatic diseases (e.g., cystic fibrosis, cyst (pancreatic pseudocyst, pancreatic fistula, insufficiency)).

[0694] Gallbladder diseases include gallstones (cholelithiasis and choledocholithiasis), postcholecystectomy syndrome, diverticulosis of the gallbladder, acute cholecystitis, chronic cholecystitis, bile duct tumors, and mucocele.

[0695] Diseases and/or disorders of the large intestine include antibiotic-associated colitis, diverticulitis, ulcerative colitis, acquired megacolon, abscesses, fungal and bacterial infections, anorectal disorders (e.g., fissures, hemorrhoids), colonic diseases (colitis, colonic neoplasms [colon cancer, adenomatous colon polyps (e.g., villous adenoma), colon carcinoma, colorectal cancer], colonic diverticulitis, colonic diverticulosis, megacolon [Hirschsprung disease, toxic megacolon]; sigmoid diseases [proctocolitis, sigmoid neoplasms]), constipation, Crohn's disease, diarrhea (infantile diarrhea, dysentery), duodenal diseases (duodenal neoplasms, duodenal obstruction, duodenal ulcer, duodenitis), enteritis (enterocolitis), HIV enteropathy, ileal diseases (ileal neoplasms, ileitis), immunoproliferative small intestinal disease, inflammatory bowel disease (ulcerative colitis, Crohn's disease), intestinal atresia, parasitic diseases (anisakiasis, balantidiasis, blastocystis infections, cryptosporidiosis, dientamoebiasis, amebic dysentery, giardiasis), intestinal fistula (rectal fistula), intestinal neoplasms (cecal neoplasms, colonic neoplasms, duodenal neoplasms, ileal neoplasms, intestinal polyps, jejunal neoplasms, rectal neoplasms), intestinal obstruction (afferent loop syndrome, duodenal obstruction, impacted feces, intestinal pseudo-obstruction [cecal volvulus], intussusception), intestinal perforation, intestinal polyps (colonic polyps, gardner syndrome, peutz-jeghers syndrome), jejunal diseases (jejunal neoplasms), malabsorption syndromes (blind loop syndrome, celiac disease, lactose intolerance, short bowel syndrome, tropical sprue, whipple's disease), mesenteric vascular occlusion, pneumatosis cystoides intestinalis, protein-losing enteropathies (intestinal lymphagiectasis), rectal diseases (anus diseases, fecal incontinence, hemorrhoids, proctitis, rectal fistula, rectal prolapse, rectocele), peptic ulcer (duodenal ulcer, peptic esophagitis, hemorrhage, perforation, stomach ulcer, Zollinger-Ellison syndrome), postgastrectomy syndromes (dumping syndrome), stomach diseases (e.g., achlorhydria, duodenogastric reflux (bile reflux), gastric antral vascular ectasia, gastric fistula, gastric outlet obstruction, gastritis (atrophic or hypertrophic), gastroparesis, stomach dilatation, stomach diverticulum, stomach neoplasms (gastric cancer, gastric polyps, gastric adenocarcinoma, hyperplastic gastric polyp), stomach rupture, stomach

ulcer, stomach volvulus), tuberculosis, visceroptosis, vomiting (e.g., hematemesis, hyperemesis gravidarum, postoperative nausea and vomiting) and hemorrhagic colitis.

[0696] Further diseases and/or disorders of the gastrointestinal system include biliary tract diseases, such as, gastroschisis, fistula (e.g., biliary fistula, esophageal fistula, gastric fistula, intestinal fistula, pancreatic fistula), neoplasms (e.g., biliary tract neoplasms, esophageal neoplasms, such as adenocarcinoma of the esophagus, esophageal squamous cell carcinoma, gastrointestinal neoplasms, pancreatic neoplasms, such as adenocarcinoma of the pancreas, mucinous cystic neoplasm of the pancreas, pancreatic cystic neoplasms, pancreatoblastoma, and peritoneal neoplasms), esophageal disease (e.g., bullous diseases, candidiasis, glycogenic acanthosis, ulceration, barrett esophagus varices, atresia, cyst, diverticulum (e.g., Zenker's diverticulum), fistula (e.g., tracheoesophageal fistula), motility disorders (e.g., CREST syndrome, deglutition disorders, achalasia, spasm, gastroesophageal reflux), neoplasms, perforation (e.g., Boerhaave syndrome, Mallory-Weiss syndrome), stenosis, esophagitis, diaphragmatic hernia (e.g., hiatal hernia); gastrointestinal diseases, such as, gastroenteritis (e.g., cholera morbus, norwalk virus infection), hemorrhage (e.g., hematemesis, melena, peptic ulcer hemorrhage), stomach neoplasms (gastric cancer, gastric polyps, gastric adenocarcinoma, stomach cancer)), hernia (e.g., congenital diaphragmatic hernia, femoral hernia, inguinal hernia, obturator hernia, umbilical hernia, ventral hernia), and intestinal diseases (e.g., cecal diseases (appendicitis, cecal neoplasms)).

Developmental and Inherited Disorders

[0697] Polynuceotides or polypeptides, or agonists or antagonists of the present invention may be used to treat, prevent, diagnose, and/or prognose diseases associated with mixed fetal tissues, including, but not limited to, developmental and inherited disorders or defects of the nervous system, musculoskeletal system, excretory system, cardiovascular system, hematopoietic system, gastrointestinal system, reproductive system, and respiratory system. Compositions of the present invention may also be used to treat, prevent, diagnose, and/or prognose developmental and inherited disorders or defects associated with, but not limited to, skin, hair, visual, and auditory tissues, metabolism. Additionally, the compositions of the invention may be useful in

the diagnosis, treatment, and/or prevention of disorders or diseases associated with, but not limited to, chromosomal or genetic abnormalities and hyperproliferation or neoplasia.

[0698] Disorders or defects of the nervous system associated with developmental or inherited abnormalities that may be diagnosed, treated, and/or prevented with the compositions of the invention include, but are not limited to, adrenoleukodystrophy, agenesis of corpus callosum, Alexander disease, anencephaly, Angelman syndrome, Arnold-Chiari deformity, Batten disease, Canavan disease, cephalic disorders, Charcot-Marie-Tooth disease, encephalocele, Friedreich's ataxia, Gaucher's disease, Gorlin syndrome, Hallervorden-Spatz disease, hereditary spastic paraplegia, Huntington disease, hydranencephaly, hydrocephalus, Joubert syndrome, Lesch-Nyhan syndrome, leukodystrophy, Menkes disease, microcephaly, Niemann-Pick Type C1, neurofibromatosis, porencephaly, progeria, proteus syndrome, Refsum disease, spina bifida, Sturge-Weber syndrome, Tay-Sachs disease, tuberous sclerosis, and von Hippel-Lindau disease.

[0699] Developmental and inherited disorders resulting in disorders or defects of the musculoskeletal system that may be diagnosed, treated, and/or prevented with the compositions of the invention include, but are not limited to, achondroplasia, atlanto-occipital fusion, arthrogryposis multiplex congenita, autosomal recessive muscular dystrophy, Becker's muscular dystrophy, cerebral palsy, choanal atresia, cleft lip, cleft palate, clubfoot, congenital amputation, congenital dislocation of the hip, congenital torticollis, congenital scoliosis, dopa-responsive dystonia, Duchenne muscular dystrophy, early-onset generalized dystonia, femoral torsion, Gorlin syndrome, hypophosphatasia, Klippel-Feil syndrome, knee dislocation, myoclonic dystonia, myotonic dystrophy, nail-patella syndrome, osteogenesis imperfecta, paroxysmal dystonia, progeria, prune-belly syndrome, rapid-onset dystonia parkinsonism, scoliosis, syndactyly, Treacher Collins' syndrome, velocardiofacial syndrome, and X-linked dystonia-parkinsonism.

[0700] Developmental or hereditary disorders or defects of the excretory system that may be diagnosed, treated, and/or prevented with the compositions of the invention include, but are not limited to, Alport's syndrome, Bartter's syndrome, bladder diverticula, bladder exstrophy, cystinuria, epispadias, Fanconi's syndrome,

Hartnup disease, horseshoe kidney, hypospadias, kidney agenesis, kidney ectopia, kidney malrotation, Liddle's syndrome, medullary cystic disease, medullary sponge, multicystic kidney, kidney polycystic kidney disease, nail-patella syndrome, Potter's syndrome, urinary tract flow obstruction, vitamin D-resistant rickets, and Wilm's tumor.

[0701] Cardiovascular disorders or defects of developmental or hereditary origin that may be diagnosed, treated, and/or prevented with the compositions of the invention include, but are not limited to, aortic valve stenosis, atrial septal defects, artioventricular (A-V) canal defect, bicuspid aortic valve, coarctation of the aorta, dextrocardia, Ebstein's anomaly, Eisenmenger's complex, hypoplastic left heart syndrome, Marfan syndrome, patent ductus arteriosus, progeria, pulmonary atresia, pulmonary valve stenosis, subaortic stenosis, tetralogy of fallot, total anomalous pulmonary venous (P-V) connection, transposition of the great arteries, tricuspid atresia, truncus arteriosus, ventricular septal defects. Developmental or inherited disorders resulting in disorders involving the hematopoietic system that may be diagnosed, treated, and/or prevented with the compositions of the invention include, but not limited to, Bernard-Soulier syndrome, Chédiak-Higashi syndrome, hemophilia, Hermansky-Pudlak syndrome, sickle cell anemia, storage pool disease, thromboxane A2 dysfunction, thrombasthenia, and von Willebrand's disease.

[0702] The compositions of the invention may also be used to diagnose, treat, and/or prevent developmental and inherited disorders resulting in disorders or defects of the gastrointestinal system, including, but not limited to, anal atresia, biliary atresia, esophageal atresia, diaphragmatic hernia, Hirschsprung's disease, Meckel's diverticulum, oligohydramnios, omphalocele, polyhydramnios, porphyria, situs inversus viscera. Developmental or inherited disorders resulting in metabolic disorders that may be diagnosed, treated, and/or prevented with the compositions of the invention include, but are not limited to, alpha-1 antitrypsin deficiency, cystic fibrosis, hemochromatosis, lysosomal storage disease, phenylketonuria, Wilson's disease, and Zellweger syndrome.

[0703] Disorders of the reproductive system that are developmentally or hereditary related that may also be diagnosed, treated, and/or prevented with the compositions of the invention include, but are not limited to, androgen insensitivity syndrome,

ambiguous genitalia, autosomal sex reversal, congenital adrenal hyperplasia, gonadoblastoma, ovarian germ cell cancer, pseudohermaphroditism, true hermaphroditism, undescended testis, XX male syndrome, and XY female type gonadal dysgenesis. The compositions of the invention may also be used to diagnose, treat, and/or prevent developmental or inherited respiratory defects including, but not limited to, askin tumor, azygos lobe, congenital diaphragmatic hernia, congenital lobar emphysema, cystic adenomatoid malformation, lobar emphysema, hyaline membrane disease, and pectus excavatum.

[0704] Developmental or inherited disorders may also result from chromosomal or genetic aberration that may be diagnosed, treated, and/or prevented with the compositions of the invention including, but not limited to, 4p- syndrome, cri du chat syndrome, Digeorge syndrome, Down's syndrome, Edward's syndrome, fragile X syndrome, Klinefelter's syndrome, Patau's syndrome, Prader-Willi syndrome, progeria, Turner's syndrome, triple X syndrome, and XYY syndrome. Other developmental disorders that can be diagnosed, treated, and/or prevented with the compositions of the invention, include, but are not limited to, fetal alcohol syndrome, and can be caused by environmental factors surrounding the developing fetus.

[0705] The compositions of the invention may further be able to be used to diagnose, treat, and/or prevent errors in development or a genetic disposition that may result in hyperproliferative disorders or neoplasms, including, but not limited to, acute childhood lymphoblastic leukemia, askin tumor, Beckwith-Wiedemann syndrome, childhood acute myeloid leukemia, childhood brain stem glioma, childhood cerebellar astrocytoma, childhood extracranial germ cell tumors childhood (primary), gonadoblastoma, hepatocellular cancer, childhood Hodgkin's disease, childhood Hodgkin's lymphoma, childhood hypothalamic and visual pathway glioma, childhood (primary) liver cancer, childhood lymphoblastic leukemia, childhood medulloblastoma, childhood non-Hodgkin's lymphoma, childhood pineal and supratentorial primitive neuroectodermal tumors, childhood primary liver cancer, childhood rhabdomyosarcoma, childhood soft tissue sarcoma, Gorlin syndrome, familial multiple endocrine neoplasia type I, neuroblastoma, ovarian germ cell cancer, pheochromocytoma, retinoblastoma, and Wilm's tumor.

[0706] Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppository solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides may be administered as part of a Therapeutic, described in more detail below. Methods of delivering polynucleotides are described in more detail herein.

Diseases at the Cellular Level

[0707] Diseases associated with increased cell survival or the inhibition of apoptosis that could be treated, prevented, diagnosed and/or prognosed using polynucleotides or polypeptides, as well as antagonists or agonists of the present invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection.

[0708] In preferred embodiments, polynucleotides, polypeptides, and/or antagonists of the invention are used to inhibit growth, progression, and/or metastasis of cancers, in particular those [listed above] involving testes tissues.

[0709] Additional diseases or conditions associated with increased cell survival that could be treated or detected by polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to, progression, and/or

metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma; pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

[0710] Diseases associated with increased apoptosis that could be treated, prevented, diagnosed, and/or prognosed using polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, include, but are not limited to, AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestasis (bile duct injury) and liver

cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

Wound Healing and Epithelial Cell Proliferation

[0711] In accordance with yet a further aspect of the present invention, there is provided a process for utilizing polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, for therapeutic purposes, for example, to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and healing of dermal wounds. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may be clinically useful in stimulating wound healing including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and antimetabolites. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to promote dermal reestablishment subsequent to dermal loss.

[0712] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to increase the adherence of skin grafts to a wound bed and to stimulate re-epithelialization from the wound bed. The following are types of grafts that polynucleotides or polypeptides, agonists or antagonists of the present invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts, autodermic graft, autoepdermic grafts, avacular grafts, Blair-Brown grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft, epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-Thiersch graft, omenpal graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. Polynucleotides or polypeptides, as well as agonists or

antagonists of the present invention, can be used to promote skin strength and to improve the appearance of aged skin.

[0713] It is believed that polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intestine, and large intestine. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could promote proliferation of epithelial cells such as sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. Polynucleotides or polypeptides, agonists or antagonists of the present invention, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

[0714] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may have a cytoprotective effect on the small intestine mucosa. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

[0715] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could further be used in full regeneration of skin in full and partial thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat glands, and sebaceous glands), treatment of other skin defects such as psoriasis. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could also be used to treat gastric and duodenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly. Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases, which result in destruction of the mucosal surface of the small or large

intestine, respectively. Thus, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with polynucleotides or polypeptides, agonists or antagonists of the present invention, is expected to have a significant effect on the production of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to treat diseases associate with the under expression.

[0716] Moreover, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to prevent and heal damage to the lungs due to various pathological states. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could stimulate proliferation and differentiation and promote the repair of alveoli and brochiolar epithelium to prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of aveoli, and inhalation injuries, i.e., resulting from smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated using polynucleotides or polypeptides, agonists or antagonists of the present invention. Also, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to stimulate the proliferation of and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary displasia, in premature infants.

[0717] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could stimulate the proliferation and differentiation of hepatocytes and, thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic substances (i.e., acetaminophen, carbon tetraholoride and other hepatotoxins known in the art).

[0718] In addition, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where

some islet cell function remains, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to maintain the islet function so as to alleviate, delay or prevent permanent manifestation of the disease. Also, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

Infectious Disease

[0719] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

[0720] Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention. Examples of viruses, include, but are not limited to Examples of viruses, include, but are not limited to the following DNA and RNA viruses and viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papiloma virus, Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, respiratory syncytial virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), Japanese B encephalitis,

Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat patients nonresponsive to one or more other commercially available hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat AIDS.

[0721] Similarly, bacterial and fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following Gram-Negative and Gram-positive bacteria, bacterial families, and fungi: Actinomyces (e.g., Norcardia), Acinetobacter, *Cryptococcus neoformans*, Aspergillus, Bacillaceae (e.g., *Bacillus anthracis*), Bacteroides (e.g., *Bacteroides fragilis*), Blastomycosis, Bordetella, Borrelia (e.g., *Borrelia burgdorferi*), Brucella, Candidia, Campylobacter, Chlamydia, Clostridium (e.g., *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Clostridium tetani*), Coccidioides, Corynebacterium (e.g., *Corynebacterium diphtheriae*), Cryptococcus, Dermatocycoses, *E. coli* (e.g., Enterotoxigenic *E. coli* and Enterohemorrhagic *E. coli*), Enterobacter (e.g., *Enterobacter aerogenes*), Enterobacteriaceae (Klebsiella, Salmonella (e.g., *Salmonella typhi*, *Salmonella enteritidis*, *Salmonella typhi*), Serratia, Yersinia, Shigella), Erysipelothrix, Haemophilus (e.g., *Haemophilus influenza* type B), Helicobacter, Legionella (e.g., *Legionella pneumophila*), Leptospira, Listeria (e.g., *Listeria monocytogenes*), Mycoplasma, Mycobacterium (e.g., *Mycobacterium leprae* and *Mycobacterium tuberculosis*), Vibrio (e.g., *Vibrio cholerae*), Neisseriaceae (e.g., *Neisseria gonorrhea*, *Neisseria meningitidis*), Pasteurellaceae, Proteus, Pseudomonas (e.g., *Pseudomonas aeruginosa*), Rickettsiaceae, Spirochetes (e.g., Treponema spp.,

Leptospira spp., *Borrelia* spp.), *Shigella* spp., *Staphylococcus* (e.g., *Staphylococcus aureus*), *Meningioccus*, *Pneumococcus* and *Streptococcus* (e.g., *Streptococcus pneumoniae* and Groups A, B, and C *Streptococci*), and *Ureaplasmas*. These bacterial, parasitic, and fungal families can cause diseases or symptoms, including, but not limited to: antibiotic-resistant infections, bacteremia, endocarditis, septicemia, eye infections (e.g., conjunctivitis), uveitis, tuberculosis, gingivitis, bacterial diarrhea, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, dental caries, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, dysentery, paratyphoid fever, food poisoning, *Legionella* disease, chronic and acute inflammation, erythema, yeast infections, typhoid, pneumonia, gonorrhea, meningitis (e.g., meningitis types A and B), chlamydia, syphilis, diphtheria, leprosy, brucellosis, peptic ulcers, anthrax, spontaneous abortions, birth defects, pneumonia, lung infections, ear infections, deafness, blindness, lethargy, malaise, vomiting, chronic diarrhea, Crohn's disease, colitis, vaginosis, sterility, pelvic inflammatory diseases, candidiasis, paratuberculosis, tuberculosis, lupus, botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections, nosocomial infections. Polynucleotides or polypeptides, agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, agonists or antagonists of the invention are used to treat: tetanus, diphtheria, botulism, and/or meningitis type B.

[0722] Moreover, parasitic agents causing disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Schistosoma, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas and Sporozoans (e.g., *Plasmodium virax*, *Plasmodium falciparum*, *Plasmodium malariae* and *Plasmodium ovale*). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections

(e.g., AIDS related), malaria, pregnancy complications, and toxoplasmosis. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose malaria.

[0723] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

Regeneration

[0724] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

[0725] Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

[0726] Moreover, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention could also be used prophylactically in an effort to avoid

damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

[0727] Similarly, nerve and brain tissue could also be regenerated by using polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotides or polypeptides, as well as agonists or antagonists of the present invention.

Chemotaxis

[0728] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

[0729] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

[0730] It is also contemplated that polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention could be used as an inhibitor of chemotaxis.

Binding Activity

[0731] A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

[0732] Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

[0733] Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

[0734] The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

[0735] Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product

mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

[0736] Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

[0737] Additionally, the receptor to which the polypeptide of the present invention binds can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., Current Protocols in Immun., 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the polypeptides, for example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labeled. The polypeptides can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase.

[0738] Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

[0739] As an alternative approach for receptor identification, the labeled polypeptides can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

[0740] Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be employed to modulate the activities of the polypeptide of the present invention thereby effectively generating agonists and antagonists of the polypeptide of the present invention. *See generally*, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458, and Patten, P. A., et al., *Curr. Opinion Biotechnol.* 8:724-33 (1997); Harayama, S. *Trends Biotechnol.* 16(2):76-82 (1998); Hansson L. O., et al., *J. Mol. Biol.* 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. *Biotechniques* 24(2):308-13 (1998); each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of polynucleotides and corresponding polypeptides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired molecule by homologous, or site-specific, recombination. In another embodiment, polynucleotides and corresponding polypeptides may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptide of the present invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecules are family members. In further preferred embodiments, the heterologous molecule is a growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs), nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-derived neurotrophic factor (GDNF).

[0741] Other preferred fragments are biologically active fragments of the polypeptide of the present invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

[0742] Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention. An example of such an assay comprises combining a mammalian fibroblast cell, the polypeptide of the present invention, the compound to be screened and $^3\text{[H]}$ thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the compound to determine if the compound stimulates proliferation by determining the uptake of $^3\text{[H]}$ thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography which measures the incorporation of $^3\text{[H]}$ thymidine. Both agonist and antagonist compounds may be identified by this procedure.

[0743] In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured. Alternatively, the response of a known second messenger system following interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase, ion channels or phosphoinositide hydrolysis.

[0744] All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptides of the invention from suitably manipulated cells or tissues.

[0745] Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a candidate binding compound with a polypeptide of the present invention; and (b)

determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the present invention, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

Targeted Delivery

[0746] In another embodiment, the invention provides a method of delivering compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

[0747] As discussed herein, polypeptides or antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (including antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

[0748] In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in association with toxins or cytotoxic prodrugs.

[0749] By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced

endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

Drug Screening

[0750] Further contemplated is the use of the polypeptides of the present invention, or the polynucleotides encoding these polypeptides, to screen for molecules which modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected compound(s) suspected of having antagonist or agonist activity, and assaying the activity of these polypeptides following binding.

[0751] This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the present invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and a polypeptide of the present invention.

[0752] Thus, the present invention provides methods of screening for drugs or any other agents which affect activities mediated by the polypeptides of the present invention. These methods comprise contacting such an agent with a polypeptide of the present invention or a fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically

labeled. Following incubation, free agent is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the present invention.

[0753] Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present invention, and is described in great detail in European Patent Application 84/03564, published on September 13, 1984, which is incorporated herein by reference herein. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptides of the present invention and washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

[0754] This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the present invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

Antisense And Ribozyme (Antagonists)

[0755] In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to cDNA sequences contained in cDNA Clone ID NO:Z identified for example, in Table 1A. In one embodiment, antisense sequence is generated internally, by the organism, in another embodiment, the antisense sequence is separately administered (see, for example, O'Connor, J., Neurochem. 56:560 (1991). Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for example, in Okano, J., Neurochem. 56:560

(1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance, Lee et al., Nucleic Acids Research 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

[0756] For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These experiments were performed *in vitro* by incubating cells with the oligoribonucleotide. A similar procedure for *in vivo* use is described in WO 91/15580. Briefly, a pair of oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoRI site on the 5' end and a HindIII site on the 3' end. Next, the pair of oligonucleotides is heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS HCl pH 7.5, 10mM MgCl₂, 10mM dithiothreitol (DTT) and 0.2 mM ATP) and then ligated to the EcoRI/Hind III site of the retroviral vector PMV7 (WO 91/15580).

[0757] For example, the 5' coding portion of a polynucleotide that encodes the polypeptide of the present invention may be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the receptor. The antisense RNA oligonucleotide hybridizes to the mRNA *in vivo* and blocks translation of the mRNA molecule into receptor polypeptide.

[0758] In one embodiment, the antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the antisense nucleic acid. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in

vertebrate cells. Expression of the sequence encoding the polypeptide of the present invention or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, *Nature* 29:304-310 (1981)), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., *Cell* 22:787-797 (1980)), the herpes thymidine promoter (Wagner et al., *Proc. Natl. Acad. Sci. U.S.A.* 78:1441-1445 (1981)), the regulatory sequences of the metallothionein gene (Brinster, et al., *Nature* 296:39-42 (1982)), etc.

[0759] The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of the present invention. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the hybridizing nucleic acid, the more base mismatches with a RNA it may contain and still form a stable duplex (or triplex as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

[0760] Oligonucleotides that are complementary to the 5' end of the message, e.g., the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., 1994, *Nature* 372:333-335. Thus, oligonucleotides complementary to either the 5'- or 3'- non- translated, non-coding regions of polynucleotide sequences described herein could be used in an antisense approach to inhibit translation of endogenous mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to

mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5', 3'- or coding region of mRNA of the present invention, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

[0761] The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., 1989, Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556; Lemaitre et al., 1987, Proc. Natl. Acad. Sci. 84:648-652; PCT Publication No. WO88/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication No. WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., 1988, BioTechniques 6:958-976) or intercalating agents. (See, e.g., Zon, 1988, Pharm. Res. 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

[0762] The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine,

2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

[0763] The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.

[0764] In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

[0765] In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., 1987, Nucl. Acids Res. 15:6625-6641). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue et al., 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue et al., 1987, FEBS Lett. 215:327-330).

[0766] Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (1988, Nucl. Acids Res. 16:3209), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451), etc.

[0767] While antisense nucleotides complementary to the coding region sequence could be used, those complementary to the transcribed untranslated region are most preferred.

[0768] Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published October 4, 1990; Sarver et al, Science 247:1222-1225 (1990). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs,

the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, Nature 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within the nucleotide sequence of SEQ ID NO:X. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the mRNA; i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

[0769] As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells which express *in vivo*. DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous messages and inhibit translation. Since ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

[0770] Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or prevent abnormal cellular growth and proliferation, for example, in tumor formation or growth.

[0771] The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular cataract surgery. Prevention of the mitogenic activity of the polypeptides of the present invention may also be desirous in cases such as restenosis after balloon angioplasty.

[0772] The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

[0773] The antagonist/agonist may also be employed to treat the diseases described herein.

[0774] Thus, the invention provides a method of treating disorders or diseases, including but not limited to the disorders or diseases listed throughout this application, associated with overexpression of a polynucleotide of the present invention by administering to a patient (a) an antisense molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention.

Binding Peptides and Other Molecules

[0775] The invention also encompasses screening methods for identifying polypeptides and nonpolypeptides that bind testicular antigen polypeptides, and the testicular antigen binding molecules identified thereby. These binding molecules are useful, for example, as agonists and antagonists of the testicular antigen polypeptides. Such agonists and antagonists can be used, in accordance with the invention, in the therapeutic embodiments described in detail, below.

[0776] This method comprises the steps of:
contacting testicular antigen polypeptides or testicular antigen-like polypeptides with a plurality of molecules; and
identifying a molecule that binds the testicular antigen polypeptides or testicular antigen-like polypeptides.

[0777] The step of contacting the testicular antigen polypeptides or testicular antigen-like polypeptides with the plurality of molecules may be effected in a number of ways. For example, one may contemplate immobilizing the testicular antigen polypeptides or testicular antigen-like polypeptides on a solid support and bringing a solution of the plurality of molecules in contact with the immobilized testicular antigen polypeptides or testicular antigen-like polypeptides. Such a procedure would be akin to an affinity chromatographic process, with the affinity matrix being comprised of the immobilized testicular antigen polypeptides or testicular antigen-like polypeptides. The molecules having a selective affinity for the testicular antigen polypeptides or testicular antigen-like polypeptides can then be purified by affinity selection. The nature of the solid support, process for attachment of the testicular

antigen polypeptides or testicular antigen-like polypeptides to the solid support, solvent, and conditions of the affinity isolation or selection are largely conventional and well known to those of ordinary skill in the art.

[0778] Alternatively, one may also separate a plurality of polypeptides into substantially separate fractions comprising a subset of or individual polypeptides. For instance, one can separate the plurality of polypeptides by gel electrophoresis, column chromatography, or like method known to those of ordinary skill for the separation of polypeptides. The individual polypeptides can also be produced by a transformed host cell in such a way as to be expressed on or about its outer surface (e.g., a recombinant phage). Individual isolates can then be "probed" by the testicular antigen polypeptides or testicular antigen-like polypeptides, optionally in the presence of an inducer should one be required for expression, to determine if any selective affinity interaction takes place between the testicular antigen polypeptides or testicular antigen-like polypeptides and the individual clone. Prior to contacting the testicular antigen polypeptides or testicular antigen-like polypeptides with each fraction comprising individual polypeptides, the polypeptides could first be transferred to a solid support for additional convenience. Such a solid support may simply be a piece of filter membrane, such as one made of nitrocellulose or nylon. In this manner, positive clones could be identified from a collection of transformed host cells of an expression library, which harbor a DNA construct encoding a polypeptide having a selective affinity for testicular antigen polypeptides or testicular antigen-like polypeptides. Furthermore, the amino acid sequence of the polypeptide having a selective affinity for the testicular antigen polypeptides or testicular antigen-like polypeptides can be determined directly by conventional means or the coding sequence of the DNA encoding the polypeptide can frequently be determined more conveniently. The primary sequence can then be deduced from the corresponding DNA sequence. If the amino acid sequence is to be determined from the polypeptide itself, one may use microsequencing techniques. The sequencing technique may include mass spectroscopy.

[0779] In certain situations, it may be desirable to wash away any unbound testicular antigen polypeptides or testicular antigen-like polypeptides, or alternatively, unbound polypeptides, from a mixture of the testicular antigen polypeptides or

testicular antigen-like polypeptides and the plurality of polypeptides prior to attempting to determine or to detect the presence of a selective affinity interaction. Such a wash step may be particularly desirable when the testicular antigen polypeptides or testicular antigen-like polypeptides or the plurality of polypeptides is bound to a solid support.

[0780] The plurality of molecules provided according to this method may be provided by way of diversity libraries, such as random or combinatorial peptide or nonpeptide libraries which can be screened for molecules that specifically bind testicular antigen polypeptides. Many libraries are known in the art that can be used, e.g., chemically synthesized libraries, recombinant (e.g., phage display libraries), and *in vitro* translation-based libraries. Examples of chemically synthesized libraries are described in Fodor et al., 1991, Science 251:767-773; Houghten et al., 1991, Nature 354:84-86; Lam et al., 1991, Nature 354:82-84; Medynski, 1994, Bio/Technology 12:709-710; Gallop et al., 1994, J. Medicinal Chemistry 37(9):1233-1251; Ohlmeyer et al., 1993, Proc. Natl. Acad. Sci. USA 90:10922-10926; Erb et al., 1994, Proc. Natl. Acad. Sci. USA 91:11422-11426; Houghten et al., 1992, Biotechniques 13:412; Jayawickreme et al., 1994, Proc. Natl. Acad. Sci. USA 91:1614-1618; Salmon et al., 1993, Proc. Natl. Acad. Sci. USA 90:11708-11712; PCT Publication No. WO 93/20242; and Brenner and Lerner, 1992, Proc. Natl. Acad. Sci. USA 89:5381-5383.

[0781] Examples of phage display libraries are described in Scott and Smith, 1990, Science 249:386-390; Devlin et al., 1990, Science, 249:404-406; Christian, R. B., et al., 1992, J. Mol. Biol. 227:711-718; Lenstra, 1992, J. Immunol. Meth. 152:149-157; Kay et al., 1993, Gene 128:59-65; and PCT Publication No. WO 94/18318 dated Aug. 18, 1994.

[0782] *In vitro* translation-based libraries include but are not limited to those described in PCT Publication No. WO 91/05058 dated Apr. 18, 1991; and Mattheakis et al., 1994, Proc. Natl. Acad. Sci. USA 91:9022-9026.

[0783] By way of examples of nonpeptide libraries, a benzodiazepine library (see e.g., Bunin et al., 1994, Proc. Natl. Acad. Sci. USA 91:4708-4712) can be adapted for use. Peptoid libraries (Simon et al., 1992, Proc. Natl. Acad. Sci. USA 89:9367-9371) can also be used. Another example of a library that can be used, in which the amide functionalities in peptides have been permethylated to generate a chemically

transformed combinatorial library, is described by Ostresh et al. (1994, Proc. Natl. Acad. Sci. USA 91:11138-11142).

[0784] The variety of non-peptide libraries that are useful in the present invention is great. For example, Ecker and Crooke, 1995, Bio/Technology 13:351-360 list benzodiazepines, hydantoins, piperazinediones, biphenyls, sugar analogs, beta-mercaptoketones, arylacetic acids, acylpiperidines, benzopyrans, cubanes, xanthines, aminimides, and oxazolones as among the chemical species that form the basis of various libraries.

[0785] Non-peptide libraries can be classified broadly into two types: decorated monomers and oligomers. Decorated monomer libraries employ a relatively simple scaffold structure upon which a variety functional groups is added. Often the scaffold will be a molecule with a known useful pharmacological activity. For example, the scaffold might be the benzodiazepine structure.

[0786] Non-peptide oligomer libraries utilize a large number of monomers that are assembled together in ways that create new shapes that depend on the order of the monomers. Among the monomer units that have been used are carbamates, pyrrolinones, and morpholinos. Peptoids, peptide-like oligomers in which the side chain is attached to the alpha amino group rather than the alpha carbon, form the basis of another version of non-peptide oligomer libraries. The first non-peptide oligomer libraries utilized a single type of monomer and thus contained a repeating backbone. Recent libraries have utilized more than one monomer, giving the libraries added flexibility.

[0787] Screening the libraries can be accomplished by any of a variety of commonly known methods. See, e.g., the following references, which disclose screening of peptide libraries: Parmley and Smith, 1989, Adv. Exp. Med. Biol. 251:215-218; Scott and Smith, 1990, Science 249:386-390; Fowlkes et al., 1992; BioTechniques 13:422-427; Oldenburg et al., 1992, Proc. Natl. Acad. Sci. USA 89:5393-5397; Yu et al., 1994, Cell 76:933-945; Staudt et al., 1988, Science 241:577-580; Bock et al., 1992, Nature 355:564-566; Tuerk et al., 1992, Proc. Natl. Acad. Sci. USA 89:6988-6992; Ellington et al., 1992, Nature 355:850-852; U.S. Pat. No. 5,096,815, U.S. Pat. No. 5,223,409, and U.S. Pat. No. 5,198,346, all to Ladner et al.; Rebar and Pabo, 1993, Science 263:671-673; and CT Publication No. WO 94/18318.

[0788] In a specific embodiment, screening to identify a molecule that binds testicular antigen polypeptides can be carried out by contacting the library members with a testicular antigen polypeptides or testicular antigen-like polypeptides immobilized on a solid phase and harvesting those library members that bind to the testicular antigen polypeptides or testicular antigen-like polypeptides. Examples of such screening methods, termed "panning" techniques are described by way of example in Parmley and Smith, 1988, *Gene* 73:305-318; Fowlkes et al., 1992, *BioTechniques* 13:422-427; International Publication No. WO 94/18318; and in references cited herein.

[0789] In another embodiment, the two-hybrid system for selecting interacting proteins in yeast (Fields and Song, 1989, *Nature* 340:245-246; Chien et al., 1991, *Proc. Natl. Acad. Sci. USA* 88:9578-9582) can be used to identify molecules that specifically bind to testicular antigen polypeptides or testicular antigen-like polypeptides.

[0790] Where the testicular antigen binding molecule is a polypeptide, the polypeptide can be conveniently selected from any peptide library, including random peptide libraries, combinatorial peptide libraries, or biased peptide libraries. The term "biased" is used herein to mean that the method of generating the library is manipulated so as to restrict one or more parameters that govern the diversity of the resulting collection of molecules, in this case peptides.

[0791] Thus, a truly random peptide library would generate a collection of peptides in which the probability of finding a particular amino acid at a given position of the peptide is the same for all 20 amino acids. A bias can be introduced into the library, however, by specifying, for example, that a lysine occur every fifth amino acid or that positions 4, 8, and 9 of a decapeptide library be fixed to include only arginine. Clearly, many types of biases can be contemplated, and the present invention is not restricted to any particular bias. Furthermore, the present invention contemplates specific types of peptide libraries, such as phage displayed peptide libraries and those that utilize a DNA construct comprising a lambda phage vector with a DNA insert.

[0792] As mentioned above, in the case of a testicular antigen binding molecule that is a polypeptide, the polypeptide may have about 6 to less than about 60 amino acid residues, preferably about 6 to about 10 amino acid residues, and most preferably,

about 6 to about 22 amino acids. In another embodiment, a testicular antigen binding polypeptide has in the range of 15-100 amino acids, or 20-50 amino acids.

[0793] The selected testicular antigen binding polypeptide can be obtained by chemical synthesis or recombinant expression. s

Other Activities

[0794] A polypeptide, polynucleotide, agonist, or antagonist of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-vascularization of ischemic tissues due to various disease conditions such as thrombosis, arteriosclerosis, and other cardiovascular conditions. The polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed to stimulate angiogenesis and limb regeneration, as discussed above.

[0795] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed for treating wounds due to injuries, burns, post-operative tissue repair, and ulcers since they are mitogenic to various cells of different origins, such as fibroblast cells and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

[0796] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed to stimulate neuronal growth and to treat and prevent neuronal damage which occurs in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's disease, Parkinson's disease, and AIDS-related complex. A polypeptide, polynucleotide, agonist, or antagonist of the present invention may have the ability to stimulate chondrocyte growth; therefore, they may be employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts.

[0797] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may be also be employed to prevent skin aging due to sunburn by stimulating keratinocyte growth.

[0798] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed for preventing hair loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, a

polypeptide, polynucleotide, agonist, or antagonist of the present invention may be employed to stimulate growth and differentiation of hematopoietic cells and bone marrow cells when used in combination with other cytokines.

[0799] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed to maintain organs before transplantation or for supporting cell culture of primary tissues. A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

[0800] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

[0801] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, a polypeptide, polynucleotide, agonist, or antagonist of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

[0802] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, circadian rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

[0803] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

[0804] The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit,

goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

Other Preferred Embodiments

[0805] Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, the nucleotide sequence as defined in column 4 of Table 1A or columns 8 and 9 of Table 2 or the complementary strand thereto, and/or cDNA contained in Clone ID NO:Z.

[0806] Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of the portion of SEQ ID NO:X as defined in column 4, "ORF (From-To)", in Table 1A.

[0807] Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of the portion of SEQ ID NO:X as defined in columns 8 and 9, "NT From" and "NT To" respectively, in Table 2.

[0808] Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, the nucleotide sequence as defined in column 4 of Table 1A or columns 8 and 9 of Table 2 or the complementary strand thereto, and/or cDNA contained in Clone ID NO:Z.

[0809] Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, the nucleotide sequence as defined in column 4 of Table 1A or columns 8 and 9 of Table 2 or the complementary strand thereto, and/or cDNA contained in Clone ID NO:Z.

- [0810] A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of the portion of SEQ ID NO:X defined in column 4, "ORF (From-To)", in Table 1A.
- [0811] A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of the portion of SEQ ID NO:X defined in columns 8 and 9, "NT From" and "NT To", respectively, in Table 2.
- [0812] A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, the nucleotide sequence as defined in column 4 of Table 1A or columns 8 and 9 of Table 2 or the complementary strand thereto, and/or cDNA contained in Clone ID NO:Z.
- [0813] Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, the nucleotide sequence as defined in column 4 of Table 1A or columns 8 and 9 of Table 2 or the complementary strand thereto, and/or cDNA contained in Clone ID NO:Z, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.
- [0814] Also preferred is a composition of matter comprising a DNA molecule which comprises the cDNA contained in Clone ID NO:Z.
- [0815] Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides of the cDNA sequence contained in Clone ID NO:Z.
- [0816] Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of an open reading frame sequence encoded by cDNA contained in Clone ID NO:Z.
- [0817] Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by cDNA contained in Clone ID NO:Z.

- [0818] A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by cDNA contained in Clone ID NO:Z.
- [0819] A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by cDNA contained in Clone ID NO:Z.
- [0820] A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; the nucleotide sequence as defined in column 4 of Table 1A or columns 8 and 9 of Table 2 or the complementary strand thereto; and a nucleotide sequence encoded by cDNA contained in Clone ID NO:Z; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.
- [0821] Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.
- [0822] A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; the nucleotide sequence as defined in column 4 of

Table 1A or columns 8 and 9 of Table 2 or the complementary strand thereto; and a nucleotide sequence of the cDNA contained in Clone ID NO:Z.

[0823] The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

[0824] Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; the nucleotide sequence as defined in column 4 of Table 1A or columns 8 and 9 of Table 2 or the complementary strand thereto; or the cDNA contained in Clone ID NO:Z which encodes a protein, wherein the method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; the nucleotide sequence as defined in column 4 of Table 1A or columns 8 and 9 of Table 2 or the complementary strand thereto; and a nucleotide sequence of cDNA contained in Clone ID NO:Z.

[0825] The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

[0826] Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; the nucleotide sequence as defined in column 4 of Table 1A or columns 8 and 9 of Table 2 or the complementary strand

thereto; and a nucleotide sequence encoded by cDNA contained in Clone ID NO:Z. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

[0827] Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a DNA microarray or "chip" of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 100, 150, 200, 250, 300, 500, 1000, 2000, 3000, or 4000 nucleotide sequences, wherein at least one sequence in said DNA microarray or "chip" is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1A; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA "Clone ID" in Table 1A.

[0828] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and/or a polypeptide encoded by cDNA contained in Clone ID NO:Z.

[0829] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and/or a polypeptide encoded by cDNA contained in Clone ID NO:Z.

[0830] Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and/or a polypeptide encoded by cDNA contained in Clone ID NO:Z.

[0831] Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto;

the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and/or a polypeptide encoded by cDNA contained in Clone ID NO:Z.

[0832] Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a polypeptide encoded by contained in Clone ID NO:Z

[0833] Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a portion of said polypeptide encoded by cDNA contained in Clone ID NO:Z; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and/or the polypeptide sequence of SEQ ID NO:Y.

[0834] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of a polypeptide encoded by the cDNA contained in Clone ID NO:Z.

[0835] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of a polypeptide encoded by cDNA contained in Clone ID NO:Z.

[0836] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of a polypeptide encoded by the cDNA contained in Clone ID NO:Z.

[0837] Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: a polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and a polypeptide encoded by the cDNA contained in Clone ID NO:Z.

[0838] Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a

sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: a polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and a polypeptide encoded by the cDNA contained in Clone ID NO:Z; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

[0839] Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: a polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and a polypeptide encoded by the cDNA contained in Clone ID NO:Z.

[0840] Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

[0841] Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and a polypeptide encoded by the cDNA contained in Clone ID NO:Z.

[0842] Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide

molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

[0843] Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a nucleic acid sequence identified in Table 1A or Table 2 encoding a polypeptide, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and a polypeptide encoded by the cDNA contained in Clone ID NO:Z.

[0844] In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

[0845] Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and a polypeptide encoded by the cDNA contained in Clone ID NO:Z.

[0846] Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

[0847] Also preferred is a polypeptide molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as

defined in columns 8 and 9 of Table 2; and a polypeptide encoded by the cDNA contained in Clone ID NO:Z.

[0848] Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

[0849] Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a human protein comprising an amino acid sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and a polypeptide encoded by the cDNA contained in Clone ID NO:Z. The isolated polypeptide produced by this method is also preferred.

[0850] Also preferred is a method of treatment of an individual in need of an increased level of a protein activity, which method comprises administering to such an individual a Therapeutic comprising an amount of an isolated polypeptide, polynucleotide, immunogenic fragment or analogue thereof, binding agent, antibody, or antigen binding fragment of the claimed invention effective to increase the level of said protein activity in said individual.

[0851] Also preferred is a method of treatment of an individual in need of a decreased level of a protein activity, which method comprised administering to such an individual a Therapeutic comprising an amount of an isolated polypeptide, polynucleotide, immunogenic fragment or analogue thereof, binding agent, antibody, or antigen binding fragment of the claimed invention effective to decrease the level of said protein activity in said individual.

[0852] Also preferred is a method of treatment of an individual in need of a specific delivery of toxic compositions to diseased cells (e.g., tumors, leukemias or lymphomas), which method comprises administering to such an individual a

Therapeutic comprising an amount of an isolated polypeptide of the invention, including, but not limited to a binding agent, or antibody of the claimed invention that are associated with toxin or cytotoxic prodrugs.

[0853] Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

TABLE 6

ATCC Deposits	Deposit Date	ATCC Designation Number
LP01, LP02, LP03, LP04, LP05, LP06, LP07, LP08, LP09, LP10, LP11,	May-20-97	209059, 209060, 209061, 209062, 209063, 209064, 209065, 209066, 209067, 209068, 209069
LP12	Jan-12-98	209579
LP13	Jan-12-98	209578
LP14	Jul-16-98	203067
LP15	Jul-16-98	203068
LP16	Feb-1-99	203609
LP17	Feb-1-99	203610
LP20	Nov-17-98	203485
LP21	Jun-18-99	PTA-252
LP22	Jun-18-99	PTA-253
LP23	Dec-22-99	PTA-1081

Examples

Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

[0854] Each Clone ID NO:Z is contained in a plasmid. Table 7 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The following correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 7 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited Plasmid</u>
Lambda Zap	pBluescript (pBS)
Uni-Zap XR	pBluescript (pBS)
Zap Express	pBK
lafmid BA	plafmid BA
pSport1	pSport1
pCMVSPORT 2.0	pCMVSPORT 2.0
pCMVSPORT 3.0	pCMVSPORT 3.0
pCR [®] 2.1	pCR [®] 2.1

[0855] Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK⁺, SK⁻, KS⁺ and KS⁻. The S and K refers to the orientation of the polylinker to the T7 and T3 primer

sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the fl origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the fl ori generates sense strand DNA and in the other, antisense.

[0856] Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR[®]2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the vector sequences identified for the particular clone in Table 7, as well as the corresponding plasmid vector sequences designated above.

[0857] The deposited material in the sample assigned the ATCC Deposit Number cited by reference to Tables 1, 2, 6 and 7 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each Clone ID NO:Z.

TABLE 7

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HUKA HUKB HUKC HUKD HUKF HUKG	Human Uterine Cancer	Lambda ZAP II	LP01
HCNA HCNB	Human Colon	Lambda Zap II	LP01
HFFA	Human Fetal Brain, random primed	Lambda Zap II	LP01
HTWA	Resting T-Cell	Lambda ZAP II	LP01
HBQA	Early Stage Human Brain, random primed	Lambda ZAP II	LP01
HLMB HLMF HLMG HLMH	breast lymph node CDNA library	Lambda ZAP II	LP01

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HLMJ HLMJ HLMM HLMN			
HCQA HCQB	human colon cancer	Lamda ZAP II	LP01
HMEA HMEC HMED HMEE HMEF HMEG HMEI HMEJ HMEK HMEL	Human Microvascular Endothelial Cells, fract. A	Lambda ZAP II	LP01
HUSA HUSC	Human Umbilical Vein Endothelial Cells, fract. A	Lambda ZAP II	LP01
HLQA HLQB	Hepatocellular Tumor	Lambda ZAP II	LP01
HHGA HHGB HHGC HHGD	Hemangiopericytoma	Lambda ZAP II	LP01
HSMD	Human Striatum Depression, re-rescue	Lambda ZAP II	LP01
HUSH	H Umbilical Vein Endothelial Cells, frac A, re-excision	Lambda ZAP II	LP01
HSGS	Salivary gland, subtracted	Lambda ZAP II	LP01
HFXA HFXB HFXC HFXD HFXE HFXF HFXG HFXH	Brain frontal cortex	Lambda ZAP II	LP01
HPQA HPQB HPQC	PERM TF274	Lambda ZAP II	LP01
HFXJ HFXK	Brain Frontal Cortex, re-excision	Lambda ZAP II	LP01
HCWA HCWB HCWC HCWD HCWE HCWF HCWG HCWH HCWI HCWJ HCWK	CD34 positive cells (Cord Blood)	ZAP Express	LP02
HCUA HCUB HCUC	CD34 depleted Buffy Coat (Cord Blood)	ZAP Express	LP02
HRSM	A-14 cell line	ZAP Express	LP02
HRSA	A1-CELL LINE	ZAP Express	LP02
HCUD HCUE HCUF HCUG HCUH HCUI	CD34 depleted Buffy Coat (Cord Blood), re-excision	ZAP Express	LP02
HBXE HBXF HBXG	H. Whole Brain #2, re-excision	ZAP Express	LP02
HRLM	L8 cell line	ZAP Express	LP02
HBXA HBXB HBXC HBXD	Human Whole Brain #2 - Oligo dT > 1.5Kb	ZAP Express	LP02
HUDA HUDB HUDC	Testes	ZAP Express	LP02
HHTM HHTN HHTO	H. hypothalamus, frac A; re-excision	ZAP Express	LP02
HHTL	H. hypothalamus, frac A	ZAP Express	LP02
HASA HASD	Human Adult Spleen	Uni-ZAP XR	LP03
HFKC HFKD HFKE HFKF HFKG	Human Fetal Kidney	Uni-ZAP XR	LP03
HE8A HE8B HE8C HE8D HE8E HE8F HE8M HE8N	Human 8 Week Whole Embryo	Uni-ZAP XR	LP03
HGBA HGBD HGBE HGBF HGBG HGBH HGBI	Human Gall Bladder	Uni-ZAP XR	LP03
HLHA HLHB HLHC HLHD HLHE HLHF HLHG HLHH HLHQ	Human Fetal Lung III	Uni-ZAP XR	LP03
HPMA HPMB HPMC HPMD HPME HPMF HPMG HPMH	Human Placenta	Uni-ZAP XR	LP03
HPRA HPRB HPRC HPRD	Human Prostate	Uni-ZAP XR	LP03
HSIA HSIC HSID HSIE	Human Adult Small Intestine	Uni-ZAP XR	LP03
HTEA HTEB HTEC HTED HTEE HTEF HTEG HTEH HTEI HTEJ HTEK	Human Testes	Uni-ZAP XR	LP03
HTPA HTPB HTPC HTPD HTPE	Human Pancreas Tumor	Uni-ZAP XR	LP03
HTTA HTTB HTTC HTTD HTTE HTTF	Human Testes Tumor	Uni-ZAP XR	LP03
HAPA HAPB HAPC HAPM	Human Adult Pulmonary	Uni-ZAP XR	LP03
HETA HETB HETC HETD HETE	Human Endometrial Tumor	Uni-ZAP XR	LP03

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HETF HETG HETH HETI			
HHFB HHFC HHFD HHFE HHFF HHFG HHFH HHFI	Human Fetal Heart	Uni-ZAP XR	LP03
HHPB HHPC HHPD HHPE HHPF HHPG HHPH	Human Hippocampus	Uni-ZAP XR	LP03
HCE1 HCE2 HCE3 HCE4 HCE5 HCEB HCEC HCED HCEE HCEF HCEG	Human Cerebellum	Uni-ZAP XR	LP03
HUVB HUVC HUVD HUVE	Human Umbilical Vein, Endo. remake	Uni-ZAP XR	LP03
HSTA HSTB HSTC HSTD	Human Skin Tumor	Uni-ZAP XR	LP03
HTAA HTAB HTAC HTAD HTAE	Human Activated T-Cells	Uni-ZAP XR	LP03
HFEA HFEB HFEC	Human Fetal Epithelium (Skin)	Uni-ZAP XR	LP03
HJPA HJPB HJPC HJPD	HUMAN JURKAT MEMBRANE BOUND POLYSOMES	Uni-ZAP XR	LP03
HESA	Human epithelioid sarcoma	Uni-Zap XR	LP03
HLTA HLTB HLTC HLTD HLTE HLTF	Human T-Cell Lymphoma	Uni-ZAP XR	LP03
HFTA HFTB HFTC HFTD	Human Fetal Dura Mater	Uni-ZAP XR	LP03
HRDA HRDB HRDC HRDD HRDE HRDF	Human Rhabdomyosarcoma	Uni-ZAP XR	LP03
HCAA HCAB HCAC	Cem cells cyclohexamide treated	Uni-ZAP XR	LP03
HRGA HRGB HRGC HRGD	Raji Cells, cyclohexamide treated	Uni-ZAP XR	LP03
HSUA HSUB HSUC HSUM	Supt Cells, cyclohexamide treated	Uni-ZAP XR	LP03
HT4A HT4C HT4D	Activated T-Cells, 12 hrs.	Uni-ZAP XR	LP03
HE9A HE9B HE9C HE9D HE9E HE9F HE9G HE9H HE9M HE9N	Nine Week Old Early Stage Human	Uni-ZAP XR	LP03
HATA HATB HATC HATD HATE	Human Adrenal Gland Tumor	Uni-ZAP XR	LP03
HT5A	Activated T-Cells, 24 hrs.	Uni-ZAP XR	LP03
HFGA HFGM	Human Fetal Brain	Uni-ZAP XR	LP03
HNEA HNEB HNEC HNED HNEE	Human Neutrophil	Uni-ZAP XR	LP03
HBGB HBGD	Human Primary Breast Cancer	Uni-ZAP XR	LP03
HBNA HBNB	Human Normal Breast	Uni-ZAP XR	LP03
HCAS	Cem Cells, cyclohexamide treated, subtra	Uni-ZAP XR	LP03
HHPS	Human Hippocampus, subtracted	pBS	LP03
HKCS HKCU	Human Colon Cancer, subtracted	pBS	LP03
HRGS	Raji cells, cyclohexamide treated, subtracted	pBS	LP03
HSUT	Supt cells, cyclohexamide treated, differentially expressed	pBS	LP03
HT4S	Activated T-Cells, 12 hrs, subtracted	Uni-ZAP XR	LP03
HCDA HCDB HCDC HCDD HCDE	Human Chondrosarcoma	Uni-ZAP XR	LP03
HOAA HOAB HOAC	Human Osteosarcoma	Uni-ZAP XR	LP03
HTLA HTLB HTLC HTLD HTLE HTLF	Human adult testis, large inserts	Uni-ZAP XR	LP03
HLMA HLMD HLMD	Breast Lymph node cDNA library	Uni-ZAP XR	LP03
H6EA H6EB H6EC	HL-60, PMA 4H	Uni-ZAP XR	LP03
HTXA HTXB HTXC HTXD HTXE HTXF HTXG HTXH	Activated T-Cell (12hs)/Thiouridine labelledEco	Uni-ZAP XR	LP03
HNFA HNFB HNFC HNFD HNFE HNFF HNFG HNFH HNFJ	Human Neutrophil, Activated	Uni-ZAP XR	LP03

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HTOB HTOC	HUMAN TONSILS, FRACTION 2	Uni-ZAP XR	LP03
HMGB	Human OB MG63 control fraction I	Uni-ZAP XR	LP03
HOPB	Human OB HOS control fraction I	Uni-ZAP XR	LP03
HORB	Human OB HOS treated (10 nM E2) fraction I	Uni-ZAP XR	LP03
HSVA HSVB HSVC	Human Chronic Synovitis	Uni-ZAP XR	LP03
HROA	HUMAN STOMACH	Uni-ZAP XR	LP03
HBJA HBJB HBJC HBJD HBJE HBJF HBJG HBJH HBJI HBJJ HBJK	HUMAN B CELL LYMPHOMA	Uni-ZAP XR	LP03
HCRA HCRB HCRC	human corpus colosum	Uni-ZAP XR	LP03
HODA HODB HODC HODD	human ovarian cancer	Uni-ZAP XR	LP03
HDSA	Dermatofibrosarcoma Protuberance	Uni-ZAP XR	LP03
HMWA HMWB HMWC HMWD HMWE HMWF HMWG HMWH HMWI HMWJ	Bone Marrow Cell Line (RS4;11)	Uni-ZAP XR	LP03
HSOA	stomach cancer (human)	Uni-ZAP XR	LP03
HERA	SKIN	Uni-ZAP XR	LP03
HMDA	Brain-medulloblastoma	Uni-ZAP XR	LP03
HGLA HGLB HGLD	Glioblastoma	Uni-ZAP XR	LP03
HEAA	H. Atrophic Endometrium	Uni-ZAP XR	LP03
HBCA HBCB	H. Lymph node breast Cancer	Uni-ZAP XR	LP03
HPWT	Human Prostate BPH, re-excision	Uni-ZAP XR	LP03
HFVG HFVH HFVI	Fetal Liver, subtraction II	pBS	LP03
HNFI	Human Neutrophils, Activated, re-excision	pBS	LP03
HBMB HBMC HBMD	Human Bone Marrow, re-excision	pBS	LP03
HKML HKMM HKMN	H. Kidney Medulla, re-excision	pBS	LP03
HKIX HKIY	H. Kidney Cortex, subtracted	pBS	LP03
HADT	H. Amygdala Depression, subtracted	pBS	LP03
H6AS	HL-60, untreated, subtracted	Uni-ZAP XR	LP03
H6ES	HL-60, PMA 4H, subtracted	Uni-ZAP XR	LP03
H6BS	HL-60, RA 4h, Subtracted	Uni-ZAP XR	LP03
H6CS	HL-60, PMA 1d, subtracted	Uni-ZAP XR	LP03
HTXJ HTXK	Activated T-cell(12h)/Thiouridine-re-excision	Uni-ZAP XR	LP03
HMSA HMSB HMSC HMSD HMSE HMSF HMSG HMSH HMSI HMSJ HMSK	Monocyte activated	Uni-ZAP XR	LP03
HAGA HAGB HAGC HAGD HAGE HAGF	Human Amygdala	Uni-ZAP XR	LP03
HSRA HSRB HSRE	STROMAL -OSTEOCLASTOMA	Uni-ZAP XR	LP03
HSRD HSRF HSRG HSRH	Human Osteoclastoma Stromal Cells - unamplified	Uni-ZAP XR	LP03
HSQA HSQB HSQC HSQD HSQE HSQF HSQG	Stromal cell TF274	Uni-ZAP XR	LP03
HSKA HSKB HSKC HSKD HSKE HSKF HSKZ	Smooth muscle, serum treated	Uni-ZAP XR	LP03
HSLA HSLB HSLC HSLD HSLE HSLF HSLG	Smooth muscle, control	Uni-ZAP XR	LP03
HSDA HSDD HSDE HSDF HSDG HSDH	Spinal cord	Uni-ZAP XR	LP03

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HPWS	Prostate-BPH subtracted II	pBS	LP03
HSKW HSKX HSKY	Smooth Muscle- HASTE normalized	pBS	LP03
HFPB HFPC HFPD	H. Frontal cortex,epileptic;re-excision	Uni-ZAP XR	LP03
HSDI HSDJ HSDK	Spinal Cord, re-excision	Uni-ZAP XR	LP03
HSKN HSKO	Smooth Muscle Serum Treated, Norm	pBS	LP03
HSKG HSKH HSKI	Smooth muscle, serum induced,re-exc	pBS	LP03
HFCB HFCB HFCC HFCD HFCE HFCF	Human Fetal Brain	Uni-ZAP XR	LP04
HPTA HPTB HPTD	Human Pituitary	Uni-ZAP XR	LP04
HTHB HTHC HTHD	Human Thymus	Uni-ZAP XR	LP04
HE6B HE6C HE6D HE6E HE6F HE6G HE6S	Human Whole Six Week Old Embryo	Uni-ZAP XR	LP04
HSSA HSSB HSSC HSSD HSSE HSSF HSSG HSSH HSSI HSSJ HSSK	Human Synovial Sarcoma	Uni-ZAP XR	LP04
HE7T	7 Week Old Early Stage Human, subtracted	Uni-ZAP XR	LP04
HEPA HEPB HEPC	Human Epididymus	Uni-ZAP XR	LP04
HSNA HSNB HSNC HSNM HSNM	Human Synovium	Uni-ZAP XR	LP04
HPFB HPFC HPFD HPFE	Human Prostate Cancer, Stage C fraction	Uni-ZAP XR	LP04
HE2A HE2D HE2E HE2H HE2I HE2M HE2N HE2O	12 Week Old Early Stage Human	Uni-ZAP XR	LP04
HE2B HE2C HE2F HE2G HE2P HE2Q	12 Week Old Early Stage Human, II	Uni-ZAP XR	LP04
HPTS HPTT HPTU	Human Pituitary, subtracted	Uni-ZAP XR	LP04
HAUA HAUB HAUC	Amniotic Cells - TNF induced	Uni-ZAP XR	LP04
HAQA HAQB HAQC HAQD	Amniotic Cells - Primary Culture	Uni-ZAP XR	LP04
HWTA HWTB HWTC	wilm's tumor	Uni-ZAP XR	LP04
HBSD	Bone Cancer, re-excision	Uni-ZAP XR	LP04
HSGB	Salivary gland, re-excision	Uni-ZAP XR	LP04
HSJA HSJB HSJC	Smooth muscle-ILb induced	Uni-ZAP XR	LP04
HSXA HSXB HSXC HSXD	Human Substantia Nigra	Uni-ZAP XR	LP04
HSJA HSJB HSJC	Smooth muscle, IL1b induced	Uni-ZAP XR	LP04
HOUA HOUB HOUC HOUD HOUE	Adipocytes	Uni-ZAP XR	LP04
HPWA HPWB HPWC HPWD HPWE	Prostate BPH	Uni-ZAP XR	LP04
HELA HELB HELC HELD HELE HELF HELG HELH	Endothelial cells-control	Uni-ZAP XR	LP04
HEMA HEMB HEMC HEMD HEME HEMF HEMG HEMH	Endothelial-induced	Uni-ZAP XR	LP04
HBIA HBIB HBIC	Human Brain, Striatum	Uni-ZAP XR	LP04
HHSB HHSB HHSC HHSD HHSE	Human Hypothalamus,Schizophrenia	Uni-ZAP XR	LP04
HNGA HNGB HNGC HNGD HNGE HNGF HNGG HNGH HNGI HNGJ	neutrophils control	Uni-ZAP XR	LP04
HNHA HNHB HNHC HNHD HNHE HNHF HNHG HNHH HNHI HNHI	Neutrophils IL-1 and LPS induced	Uni-ZAP XR	LP04
HSDB HSDC	STRIATUM DEPRESSION	Uni-ZAP XR	LP04
HHPT	Hypothalamus	Uni-ZAP XR	LP04

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HSAT HSAU HSAV HSAW HSAX HSAY HSAZ	Anergic T-cell	Uni-ZAP XR	LP04
HBMS HBMT HBMU HBMV HBMW HBMX	Bone marrow	Uni-ZAP XR	LP04
HOEA HOEB HOEC HOED HOEE HOEF HOEJ	Osteoblasts	Uni-ZAP XR	LP04
HAIA HAIB HAIC HAID HAIE HAIF	Epithelial-TNF α and INF induced	Uni-ZAP XR	LP04
HTGA HTGB HTGC HTGD	Apoptotic T-cell	Uni-ZAP XR	LP04
HMCA HMCB HMCC HMCD HMCE	Macrophage-oxLDL	Uni-ZAP XR	LP04
HMAA HMAB HMAL HMAD HMAE HMAF HMAG	Macrophage (GM-CSF treated)	Uni-ZAP XR	LP04
HPHA	Normal Prostate	Uni-ZAP XR	LP04
HPIA HPIB HPIC	LNCAP prostate cell line	Uni-ZAP XR	LP04
HPJA HPJB HPJC	PC3 Prostate cell line	Uni-ZAP XR	LP04
HOSE HOSF HOSG	Human Osteoclastoma, re-excision	Uni-ZAP XR	LP04
HTGE HTGF	Apoptotic T-cell, re-excision	Uni-ZAP XR	LP04
HMAJ HMAK	H Macrophage (GM-CSF treated), re-excision	Uni-ZAP XR	LP04
HACB HACC HACD	Human Adipose Tissue, re-excision	Uni-ZAP XR	LP04
HFPA	H. Frontal Cortex, Epileptic	Uni-ZAP XR	LP04
HFAA HFAB HFAC HFAD HFAE	Alzheimers, spongy change	Uni-ZAP XR	LP04
HFAM	Frontal Lobe, Dementia	Uni-ZAP XR	LP04
HMIA HMIB HMIC	Human Manic Depression Tissue	Uni-ZAP XR	LP04
HTSA HTSE HTSF HTSG HTSH	Human Thymus	pBS	LP05
HPBA HPBB HPBC HPBD HPBE	Human Pineal Gland	pBS	LP05
HSAA HSAB HSAC	HSA 172 Cells	pBS	LP05
HSBA HSBB HSBC HSBM	HSC172 cells	pBS	LP05
HJAA HJAB HJAC HJAD	Jurkat T-cell G1 phase	pBS	LP05
HJBA HJBB HJBC HJBD	Jurkat T-Cell, S phase	pBS	LP05
HAFA HAFB	Aorta endothelial cells + TNF- α	pBS	LP05
HAWA HAWB HAWC	Human White Adipose	pBS	LP05
HTNA HTNB	Human Thyroid	pBS	LP05
HONA	Normal Ovary, Premenopausal	pBS	LP05
HARA HARB	Human Adult Retina	pBS	LP05
HLJA HLJB	Human Lung	pCMVSPORT 1	LP06
HOFM HOFN HOFO	H. Ovarian Tumor, II, OV5232	pCMVSPORT 2.0	LP07
HOGA HOGB HOGC	OV 10-3-95	pCMVSPORT 2.0	LP07
HCGL	CD34+cells, II	pCMVSPORT 2.0	LP07
HDLA	Hodgkin's Lymphoma I	pCMVSPORT 2.0	LP07
HDTA HDTB HDTC HDTD HDTE	Hodgkin's Lymphoma II	pCMVSPORT 2.0	LP07
HKAA HKAB HKAC HKAD HKA E HKAF HKAG HKAH	Keratinocyte	pCMVSPORT2.0	LP07
HCIM	CAPFINDER, Crohn's Disease, lib 2	pCMVSPORT 2.0	LP07
HKAL	Keratinocyte, lib 2	pCMVSPORT2.0	LP07
HKAT	Keratinocyte, lib 3	pCMVSPORT2.0	LP07
HNDA	Nasal polyps	pCMVSPORT2.0	LP07
HDRA	H. Primary Dendritic Cells, lib 3	pCMVSPORT2.0	LP07

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HOHA HOHB HOHC	Human Osteoblasts II	pCMVSPORT2.0	LP07
HLDA HLDB HLDC	Liver, Hepatoma	pCMVSPORT3.0	LP08
HLDN HLDO HLDP	Human Liver, normal	pCMVSPORT3.0	LP08
HMTA	pBMC stimulated w/ poly I/C	pCMVSPORT3.0	LP08
HNTA	NTERA2, control	pCMVSPORT3.0	LP08
HDP A HDPB HDP C HDPD HDPF HDPG HDPH HDPI HDPJ HDPK	Primary Dendritic Cells, lib 1	pCMVSPORT3.0	LP08
HDPM HDPN HDPO HDPP	Primary Dendritic cells, frac 2	pCMVSPORT3.0	LP08
HMUA HMUB HMUC	Myeloid Progenitor Cell Line	pCMVSPORT3.0	LP08
HHEA HHEB HHEC HHED	T Cell helper I	pCMVSPORT3.0	LP08
HHEM HHEN HHEO HHEP	T cell helper II	pCMVSPORT3.0	LP08
HEQA HEQB HEQC	Human endometrial stromal cells	pCMVSPORT3.0	LP08
HJMA HJMB	Human endometrial stromal cells- treated with progesterone	pCMVSPORT3.0	LP08
HSWA HSWB HSWC	Human endometrial stromal cells- treated with estradiol	pCMVSPORT3.0	LP08
HSYA HSYB HSYC	Human Thymus Stromal Cells	pCMVSPORT3.0	LP08
HLWA HLWB HLWC	Human Placenta	pCMVSPORT3.0	LP08
HRAA HRAB HRAC	Rejected Kidney, lib 4	pCMVSPORT3.0	LP08
HMTM	PCR, pBMC I/C treated	PCR II	LP09
HMJA	H. Meningioma, M6	pSport 1	LP10
HMKA HMKB HMKC HMKD HMKE	H. Meningioma, M1	pSport 1	LP10
HUSG HUSI	Human umbilical vein endothelial cells, IL-4 induced	pSport 1	LP10
HUSX HUSY	Human Umbilical Vein Endothelial Cells, uninduced	pSport 1	LP10
HOFA	Ovarian Tumor I, OV5232	pSport 1	LP10
HCFA HCFB HCFC HCFD	T-Cell PHA 16 hrs	pSport 1	LP10
HCFL HCFM HCFN HCFO	T-Cell PHA 24 hrs	pSport 1	LP10
HADA HADC HADD HADE HADG HADH	Human Adipose	pSport 1	LP10
HOVA HOVB HOVC	Human Ovary	pSport 1	LP10
HTWB HTWC HTWD HTWE HTWF	Resting T-Cell Library, II	pSport 1	LP10
HMMA	Spleen metastatic melanoma	pSport 1	LP10
HLYA HLYB HLYC HLYD HLYE	Spleen, Chronic lymphocytic leukemia	pSport 1	LP10
HCGA	CD34+ cell, I	pSport 1	LP10
HEOM HEON	Human Eosinophils	pSport 1	LP10
HTDA	Human Tonsil, Lib 3	pSport 1	LP10
HSPA	Salivary Gland, Lib 2	pSport 1	LP10
HCHA HCHB HCHC	Breast Cancer cell line, MDA 36	pSport 1	LP10
HCHM HCHN	Breast Cancer Cell line, angiogenic	pSport 1	LP10
HCIA	Crohn's Disease	pSport 1	LP10
HDAA HDAB HDAC	HEL cell line	pSport 1	LP10
HABA	Human Astrocyte	pSport 1	LP10
HUFA HUFB HUFC	Ulcerative Colitis	pSport 1	LP10
HNTM	NTERA2 + retinoic acid, 14 days	pSport 1	LP10
HDQA	Primary Dendritic cells, CapFinder2, frac 1	pSport 1	LP10

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HDQM	Primary Dendritic Cells, CapFinder, frac 2	pSport 1	LP10
HLDX	Human Liver, normal,	pSport 1	LP10
HULA HULB HULC	Human Dermal Endothelial Cells, untreated	pSport1	LP10
HUMA	Human Dermal Endothelial cells, treated	pSport1	LP10
HCJA	Human Stromal Endometrial fibroblasts, untreated	pSport1	LP10
HCJM	Human Stromal endometrial fibroblasts, treated w/ estradiol	pSport1	LP10
HEDA	Human Stromal endometrial fibroblasts, treated with progesterone	pSport1	LP10
HFNA	Human ovary tumor cell OV350721	pSport1	LP10
HKGA HKGB HKGC HKGD	Merkel Cells	pSport1	LP10
HISA HISB HISC	Pancreas Islet Cell Tumor	pSport1	LP10
HLSA	Skin, burned	pSport1	LP10
HBZA	Prostate, BPH, Lib 2	pSport 1	LP10
HBZS	Prostate BPH, Lib 2, subtracted	pSport 1	LP10
HFIA HFIB HFIC	Synovial Fibroblasts (control)	pSport 1	LP10
HFII HFII HFII	Synovial hypoxia	pSport 1	LP10
HFTT HFII HFIV	Synovial IL-1/TNF stimulated	pSport 1	LP10
HGCA	Mesangial cell, frac 1	pSport1	LP10
HMVA HMVB HMVC	Bone Marrow Stromal Cell, untreated	pSport1	LP10
HFIX HFII HFIZ	Synovial Fibroblasts (II/TNF), subt	pSport1	LP10
HFOX HFOY HFOZ	Synovial hypoxia-RSF subtracted	pSport1	LP10
HMQA HMQB HMQC HMQD	Human Activated Monocytes	Uni-ZAP XR	LP11
HLIA HLIB HLIC	Human Liver	pCMVSPORT 1	LP012
HHBA HHBB HHBC HHBD HHBE	Human Heart	pCMVSPORT 1	LP012
HBBA HBBB	Human Brain	pCMVSPORT 1	LP012
HLJA HLJB HLJC HLJD HLJE	Human Lung	pCMVSPORT 1	LP012
HOGA HOGB HOGC	Ovarian Tumor	pCMVSPORT 2.0	LP012
HTJM	Human Tonsils, Lib 2	pCMVSPORT 2.0	LP012
HAMF HAMG	KMH2	pCMVSPORT 3.0	LP012
HABA HAJB HAJC	L428	pCMVSPORT 3.0	LP012
HWBA HWBB HWBC HWBD HWBE	Dendritic cells, pooled	pCMVSPORT 3.0	LP012
HWAA HWAB HWAC HWAD HWAE	Human Bone Marrow, treated	pCMVSPORT 3.0	LP012
HYAA HYAB HYAC	B Cell lymphoma	pCMVSPORT 3.0	LP012
HWHG HWHH HWHI	Healing groin wound, 6.5 hours post incision	pCMVSPORT 3.0	LP012
HWHP HWHQ HWHR	Healing groin wound; 7.5 hours post incision	pCMVSPORT 3.0	LP012
HARM	Healing groin wound - zero hr post-incision (control)	pCMVSPORT 3.0	LP012
HBIM	Olfactory epithelium; nasalcavity	pCMVSPORT 3.0	LP012
HWDA	Healing Abdomen wound; 70&90 min post incision	pCMVSPORT 3.0	LP012
HWEA	Healing Abdomen Wound; 15 days post incision	pCMVSPORT 3.0	LP012
HWJA	Healing Abdomen Wound; 21&29 days	pCMVSPORT 3.0	LP012

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HNAL	Human Tongue, frac 2	pSport1	LP012
HMJA	H. Meningima, M6	pSport1	LP012
HMKA HMKB HMKC HMKD HMKE	H. Meningima, M1	pSport1	LP012
HOFA	Ovarian Tumor 1, OV5232	pSport1	LP012
HCFA HCFB HCFC HCFC	T-Cell PHA 16 hrs	pSport1	LP012
HCFL HCFM HCFN HCFO	T-Cell PHA 24 hrs	pSport1	LP012
HMMA HMMB HMMC	Spleen metastatic melanoma	pSport1	LP012
HTDA	Human Tonsil, Lib 3	pSport1	LP012
HDBA	Human Fetal Thymus	pSport1	LP012
HDDA	Pericardium	pSport1	LP012
HBZA	Prostate, BPH, Lib 2	pSport1	LP012
HWCA	Larynx tumor	pSport1	LP012
HWKA	Normal lung	pSport1	LP012
HSMB	Bone marrow stroma, treated	pSport1	LP012
HBHM	Normal trachea	pSport1	LP012
HLFC	Human Larynx	pSport1	LP012
HLRB	Siebben Polyposis	pSport1	LP012
HNIA	Mammary Gland	pSport1	LP012
HNJB	Palate carcinoma	pSport1	LP012
HNKA	Palate normal	pSport1	LP012
HMZA	Pharynx carcinoma	pSport1	LP012
HABG	Cheek Carcinoma	pSport1	LP012
HMZM	Pharynx Carcinoma	pSport1	LP012
HDRM	Larynx Carcinoma	pSport1	LP012
HVAA	Pancreas normal PCA4 No	pSport1	LP012
HICA	Tongue carcinoma	pSport1	LP012
HUKA HUKB HUKC HUKD HUKF	Human Uterine Cancer	Lambda ZAP II	LP013
HFFA	Human Fetal Brain, random primed	Lambda ZAP II	LP013
HTUA	Activated T-cell labeled with 4-thioluri	Lambda ZAP II	LP013
HBQA	Early Stage Human Brain, random primed	Lambda ZAP II	LP013
HMEB	Human microvascular Endothelial cells, fract. B	Lambda ZAP II	LP013
HUSH	Human Umbilical Vein Endothelial cells, fract. A, re-excision	Lambda ZAP II	LP013
HLQC HLQD	Hepatocellular tumor, re-excision	Lambda ZAP II	LP013
HTWJ HTWK HTWL	Resting T-cell, re-excision	Lambda ZAP II	LP013
HF6S	Human Whole 6 week Old Embryo (II), subt	pBluescript	LP013
HHPS	Human Hippocampus, subtracted	pBluescript	LP013
HL1S	LNCAP, differential expression	pBluescript	LP013
HLHS HLHT	Early Stage Human Lung, Subtracted	pBluescript	LP013
HSUS	Supt cells, cyclohexamide treated, subtracted	pBluescript	LP013
HSUT	Supt cells, cyclohexamide treated, differentially expressed	pBluescript	LP013
HSDS	H. Striatum Depression, subtracted	pBluescript	LP013
HPTZ	Human Pituitary, Subtracted VII	pBluescript	LP013
HSDX	H. Striatum Depression, subt II	pBluescript	LP013
HSDZ	H. Striatum Depression, subt	pBluescript	LP013

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HPBA HPBB HPBC HPBD HPBE	Human Pineal Gland	pBluescript SK-	LP013
HRTA	Colorectal Tumor	pBluescript SK-	LP013
HSBA HSBB HSBC HSBM	HSC172 cells	pBluescript SK-	LP013
HJAA HJAB HJAC HJAD	Jurkat T-cell G1 phase	pBluescript SK-	LP013
HJBA HJBB HJBC HJBD	Jurkat T-cell, S1 phase	pBluescript SK-	LP013
HTNA HTNB	Human Thyroid	pBluescript SK-	LP013
HAHA HAHB	Human Adult Heart	Uni-ZAP XR	LP013
HE6A	Whole 6 week Old Embryo	Uni-ZAP XR	LP013
HFCA HFCB HFCC HFCD HFCE	Human Fetal Brain	Uni-ZAP XR	LP013
HFKE HFKE HFKE HFKE HFKE	Human Fetal Kidney	Uni-ZAP XR	LP013
HGBA HGBD HGBE HGBF HGBG	Human Gall Bladder	Uni-ZAP XR	LP013
HPRA HPRB HPRC HPRD	Human Prostate	Uni-ZAP XR	LP013
HTEA HTEB HTEC HTEH HTEE	Human Testes	Uni-ZAP XR	LP013
HTTA HTTB HTTC HTTD HTTE	Human Testes Tumor	Uni-ZAP XR	LP013
HYBA HYBB	Human Fetal Bone	Uni-ZAP XR	LP013
HFLA	Human Fetal Liver	Uni-ZAP XR	LP013
HHFB HHFC HHFD HHFE HHFF	Human Fetal Heart	Uni-ZAP XR	LP013
HUVB HUVB HUVB HUVB	Human Umbilical Vein, End. remake	Uni-ZAP XR	LP013
HTHB HTHC HTHD	Human Thymus	Uni-ZAP XR	LP013
HSTA HSTB HSTC HSTD	Human Skin Tumor	Uni-ZAP XR	LP013
HTAA HTAB HTAC HTAD HTAE	Human Activated T-cells	Uni-ZAP XR	LP013
HFEA HFEB HFEC	Human Fetal Epithelium (skin)	Uni-ZAP XR	LP013
HJPA HJPB HJPC HJPD	Human Jurkat Membrane Bound Polysomes	Uni-ZAP XR	LP013
HESA	Human Epithelioid Sarcoma	Uni-ZAP XR	LP013
HALS	Human Adult Liver, Subtracted	Uni-ZAP XR	LP013
HFTA HFTB HFTC HFTD	Human Fetal Dura Mater	Uni-ZAP XR	LP013
HCAA HCAB HCAC	Cem cells, cyclohexamide treated	Uni-ZAP XR	LP013
HRGA HRGB HRGC HRGD	Raji Cells, cyclohexamide treated	Uni-ZAP XR	LP013
HE9A HE9B HE9C HE9D HE9E	Nine Week Old Early Stage Human	Uni-ZAP XR	LP013
HSFA	Human Fibrosarcoma	Uni-ZAP XR	LP013
HATA HATB HATC HATD HATE	Human Adrenal Gland Tumor	Uni-ZAP XR	LP013
HTRA	Human Trachea Tumor	Uni-ZAP XR	LP013
HE2A HE2D HE2E HE2H HE2I	12 Week Old Early Stage Human	Uni-ZAP XR	LP013
HE2B HE2C HE2F HE2G HE2P	12 Week Old Early Stage Human, II	Uni-ZAP XR	LP013
HNEA HNEB HNEC HNEH HNEE	Human Neutrophil	Uni-ZAP XR	LP013
HBGA	Human Primary Breast Cancer	Uni-ZAP XR	LP013
HPTS HPTT HPTU	Human Pituitary, subtracted	Uni-ZAP XR	LP013
HMQA HMQB HMQC HMQD	Human Activated Monocytes	Uni-ZAP XR	LP013
HOAA HOAB HOAC	Human Osteosarcoma	Uni-ZAP XR	LP013
HTOA HTOD HTOE HTOF HTOG	human tonsils	Uni-ZAP XR	LP013
HMGB	Human OB MG63 control fraction I	Uni-ZAP XR	LP013
HOPB	Human OB HOS control fraction I	Uni-ZAP XR	LP013
HOQB	Human OB HOS treated (1 nM E2) fraction I	Uni-ZAP XR	LP013
HAUA HAUB HAUC	Amniotic Cells - TNF induced	Uni-ZAP XR	LP013
HAQA HAQB HAQC HAQD	Amniotic Cells - Primary Culture	Uni-ZAP XR	LP013
HROA HROC	HUMAN STOMACH	Uni-ZAP XR	LP013
HBJA HBJB HBJC HBJD HBJE	HUMAN B CELL LYMPHOMA	Uni-ZAP XR	LP013
HODA HODB HODC HODD	human ovarian cancer	Uni-ZAP XR	LP013

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HCPA	Corpus Callosum	Uni-ZAP XR	LP013
HSOA	stomach cancer (human)	Uni-ZAP XR	LP013
HERA	SKIN	Uni-ZAP XR	LP013
HMDA	Brain-medulloblastoma	Uni-ZAP XR	LP013
HGLA HGLB HGLD	Glioblastoma	Uni-ZAP XR	LP013
HWTA HWTB HWTC	wilm's tumor	Uni-ZAP XR	LP013
HEAA	H. Atrophic Endometrium	Uni-ZAP XR	LP013
HAPN HAPO HAPP HAPQ HAPR	Human Adult Pulmonary;re-excision	Uni-ZAP XR	LP013
HLTG HLTH	Human T-cell lymphoma;re-excision	Uni-ZAP XR	LP013
HAHC HAHD HAHE	Human Adult Heart;re-excision	Uni-ZAP XR	LP013
HAGA HAGB HAGC HAGD HAGE	Human Amygdala	Uni-ZAP XR	LP013
HSJA HSJB HSJC	Smooth muscle-ILb induced	Uni-ZAP XR	LP013
HSJA HSJB HSJC	Smooth muscle, IL1b induced	Uni-ZAP XR	LP013
HPWA HPWB HPWC HPWD HPWE	Prostate BPH	Uni-ZAP XR	LP013
HPIA HPIB HPIC	LNCAP prostate cell line	Uni-ZAP XR	LP013
HPJA HPJB HPJC	PC3 Prostate cell line	Uni-ZAP XR	LP013
HBJA	Bone Marrow Stroma, TNF&LPS ind	Uni-ZAP XR	LP013
HMCF HMCG HMCH HMCI HMCJ	Macrophage-oxLDL; re-excision	Uni-ZAP XR	LP013
HAGG HAGH HAGI	Human Amygdala;re-excision	Uni-ZAP XR	LP013
HACA	H. Adipose Tissue	Uni-ZAP XR	LP013
HKFB	K562 + PMA (36 hrs);re-excision	ZAP Express	LP013
HCWT HCWU HCWV	CD34 positive cells (cord blood);re-ex	ZAP Express	LP013
HBWA	Whole brain	ZAP Express	LP013
HBXA HBXB HBXC HBXD	Human Whole Brain #2 - Oligo dT > 1.5Kb	ZAP Express	LP013
HAVM	Temporal cortex-Alzheimer	pT-Adv	LP014
HAVT	Hippocampus, Alzheimer Subtracted	pT-Adv	LP014
HHAS	CHME Cell Line	Uni-ZAP XR	LP014
HAJR	Larynx normal	pSport 1	LP014
HWLE HWLF HWLG HWLH	Colon Normal	pSport 1	LP014
HCRM HCRN HCRO	Colon Carcinoma	pSport 1	LP014
HWLI HWLJ HWLK	Colon Normal	pSport 1	LP014
HWLQ HWLR HWLS HWLT	Colon Tumor	pSport 1	LP014
HBFM	Gastrocnemius Muscle	pSport 1	LP014
HBOD HBOE	Quadriceps Muscle	pSport 1	LP014
HBKD HBKE	Soleus Muscle	pSport 1	LP014
HCCM	Pancreatic Langerhans	pSport 1	LP014
HWGA	Larynx carcinoma	pSport 1	LP014
HWGM HWGN	Larynx carcinoma	pSport 1	LP014
HWLA HWLB HWLC	Normal colon	pSport 1	LP014
HWLM HWLN	Colon Tumor	pSport 1	LP014
HVAM HVAN HVAO	Pancreas Tumor	pSport 1	LP014
HWGQ	Larynx carcinoma	pSport 1	LP014
HAQM HAQN	Salivary Gland	pSport 1	LP014
HASM	Stomach; normal	pSport 1	LP014
HBCM	Uterus; normal	pSport 1	LP014
HCDM	Testis; normal	pSport 1	LP014
HDJM	Brain; normal	pSport 1	LP014

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HEFM	Adrenal Gland, normal	pSport 1	LP014
HBAA	Rectum normal	pSport 1	LP014
HFDM	Rectum tumour	pSport 1	LP014
HGAM	Colon, normal	pSport 1	LP014
HHMM	Colon, tumour	pSport 1	LP014
HCLB HCLC	Human Lung Cancer	Lambda Zap II	LP015
HRLA	L1 Cell line	ZAP Express	LP015
HHAM	Hypothalamus, Alzheimer's	pCMV Sport 3.0	LP015
HKBA	Ku 812F Basophils Line	pSport 1	LP015
HS2S	Saos2, Dexamethosome Treated	pSport 1	LP016
HA5A	Lung Carcinoma A549 TNFalpha activated	pSport 1	LP016
HTFM	TF-1 Cell Line GM-CSF Treated	pSport 1	LP016
HYAS	Thyroid Tumour	pSport 1	LP016
HUTS	Larynx Normal	pSport 1	LP016
HXOA	Larynx Tumor	pSport 1	LP016
HEAH	Ea.hy.926 cell line	pSport 1	LP016
HINA	Adenocarcinoma Human	pSport 1	LP016
HRMA	Lung Mesothelium	pSport 1	LP016
HLCL	Human Pre-Differentiated Adipocytes	Uni-Zap XR	LP017
HS2A	Saos2 Cells	pSport 1	LP020
HS2I	Saos2 Cells; Vitamin D3 Treated	pSport 1	LP020
HUCM	CHME Cell Line, untreated	pSport 1	LP020
HEPN	Aryepiglottis Normal	pSport 1	LP020
HPSN	Sinus Piniformis Tumour	pSport 1	LP020
HNSA	Stomach Normal	pSport 1	LP020
HNSM	Stomach Tumour	pSport 1	LP020
HNLA	Liver Normal Met5No	pSport 1	LP020
HUTA	Liver Tumour Met 5 Tu	pSport 1	LP020
HOCN	Colon Normal	pSport 1	LP020
HOCT	Colon Tumor	pSport 1	LP020
HTNT	Tongue Tumour	pSport 1	LP020
HLXN	Larynx Normal	pSport 1	LP020
HLXT	Larynx Tumour	pSport 1	LP020
HTYN	Thymus	pSport 1	LP020
HPLN	Placenta	pSport 1	LP020
HTNG	Tongue Normal	pSport 1	LP020
HZAA	Thyroid Normal (SDCA2 No)	pSport 1	LP020
HWES	Thyroid Thyroiditis	pSport 1	LP020
HFHD	Ficoll Human Stromal Cells, 5Fu treated	pTrip1Ex2	LP021
HFHM, HFHN	Ficoll Human Stromal Cells, Untreated	pTrip1Ex2	LP021
HPCI	Hep G2 Cells, lambda library	lambda Zap-CMV XR	LP021
HBCA, HBCB, HBCC	H. Lymph node breast Cancer	Uni-ZAP XR	LP021
HCOK	Chondrocytes	pSPORT1	LP022
HDCA, HDCB, HDCC	Dendritic Cells From CD34 Cells	pSPORT1	LP022
HDMA, HDMB	CD40 activated monocyte dendritic cells	pSPORT1	LP022
HDDM, HDDN, HDDO	LPS activated derived dendritic cells	pSPORT1	LP022

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HPCR	Hep G2 Cells, PCR library	lambda Zap-CMV XR	LP022
HAAA, HAAB, HAAC	Lung, Cancer (400513A3): Invasive Poorly Differentiated Lung Adenocarcinoma	pSPORT1	LP022
HIPA, HIPB, HIPC	Lung, Cancer (4005163 B7): Invasive, Poorly Diff. Adenocarcinoma, Metastatic	pSPORT1	LP022
HOOH, HOOI	Ovary; Cancer: (4004562 B6) Papillary Serous Cystic Neoplasm, Low Malignant Pot	pSPORT1	LP022
HIDA	Lung, Normal: (400513 B1)	pSPORT1	LP022
HUJA,HUJB,HUJC,HUJD,HUJE	B-Cells	pCMVSPORT 3.0	LP022
HNOA,HNOB,HNOC,HNOD	Ovary, Normal: (9805C040R)	pSPORT1	LP022
HNLM	Lung, Normal: (400513 B1)	pSPORT1	LP022
HSCL	Stromal Cells	pSPORT1	LP022
HAAX	Lung, Cancer: (400513 A3) Invasive Poorly-differentiated Metastatic lung adenocarcinoma	pSPORT1	LP022
HUUA,HUUB,HUUC,HUUD	B-cells (unstimulated)	pTrip1Ex2	LP022
HWWA,HWWB,HWWC,HWWD, HWWE,HWWF,HWWG	B-cells (stimulated)	pSPORT1	LP022
HCCC	Colon, Cancer: (9808C064R)	pCMVSPORT 3.0	LP023
HPDO HPDP HPDQ HPDR HPD	Ovary, Cancer (9809C332): Poorly differentiated adenocarcinoma	pSport 1	LP023
HPCO HPCP HPCQ HPCT	Ovary, Cancer (15395A1F): Grade II Papillary Carcinoma	pSport 1	LP023
HOCM HOCO HOCF HOCQ	Ovary, Cancer: (15799A1F) Poorly differentiated carcinoma	pSport 1	LP023
HCBM HCBN HCBO	Breast, Cancer: (4004943 A5)	pSport 1	LP023
HNBT HNBU HNBV	Breast, Normal: (4005522B2)	pSport 1	LP023
HBCP HBCQ	Breast, Cancer: (4005522 A2)	pSport 1	LP023
HBCJ	Breast, Cancer: (9806C012R)	pSport 1	LP023
HSAM HSAN	Stromal cells 3.88	pSport 1	LP023
HVCA HVCB HVCC HVCD	Ovary, Cancer: (4004332 A2)	pSport 1	LP023
HSCK HSEN HSEO	Stromal cells (HBM3.18)	pSport 1	LP023
HSCP HSCQ	stromal cell clone 2.5	pSport 1	LP023
HUXA	Breast Cancer: (4005385 A2)	pSport 1	LP023
HCOM HCON HCOO HCOP HCOQ	Ovary, Cancer (4004650 A3): Well-Differentiated Micropapillary Serous Carcinoma	pSport 1	LP023
HBNM	Breast, Cancer: (9802C020E)	pSport 1	LP023
HVVA HVVB HVVC HVVD HVVE	Human Bone Marrow, treated	pSport 1	LP023

[0858] Two nonlimiting examples are provided below for isolating a particular clone from the deposited sample of plasmid cDNAs cited for that clone in Table 7. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to the nucleotide sequence of SEQ ID NO:X.

[0859] Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with ^{32}P - γ -ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

[0860] Alternatively, two primers of 17-20 nucleotides derived from both ends of the nucleotide sequence of SEQ ID NO:X are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 μl of reaction mixture with 0.5 μg of the above cDNA template. A convenient reaction mixture is 1.5-5 mM MgCl_2 , 0.01% (w/v) gelatin, 20 μM each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

[0861] Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for

generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

[0862] Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

[0863] This above method starts with total RNA isolated from the desired source, although poly-A⁺ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

[0864] This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide

[0865] A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the sequence corresponding to SEQ ID NO:X according to the method described in Example 1. (See also, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edn., (1989), Cold Spring Harbor Laboratory Press).

Example 3: Tissue specific expression analysis

- [0866] The Human Genome Sciences, Inc. (HGS) database is derived from sequencing tissue and/or disease specific cDNA libraries. Libraries generated from a particular tissue are selected and the specific tissue expression pattern of EST groups or assembled contigs within these libraries is determined by comparison of the expression patterns of those groups or contigs within the entire database. ESTs and assembled contigs which show tissue specific expression are selected.
- [0867] The original clone from which the specific EST sequence was generated, or in the case of an assembled contig, the clone from which the 5' most EST sequence was generated, is obtained from the catalogued library of clones and the insert amplified by PCR using methods known in the art. The PCR product is denatured and then transferred in 96 or 384 well format to a nylon membrane (Schleicher and Scheull) generating an array filter of tissue specific clones. Housekeeping genes, maize genes, and known tissue specific genes are included on the filters. These targets can be used in signal normalization and to validate assay sensitivity. Additional targets are included to monitor probe length and specificity of hybridization.
- [0868] Radioactively labeled hybridization probes are generated by first strand cDNA synthesis per the manufacturer's instructions (Life Technologies) from mRNA/RNA samples prepared from the specific tissue being analyzed (e.g., testes, testicular cancer, prostate, prostate cancer, ovarian, ovarian cancer, etc.). The hybridization probes are purified by gel exclusion chromatography, quantitated, and hybridized with the array filters in hybridization bottles at 65°C overnight. The filters are washed under stringent conditions and signals are captured using a Fuji phosphorimager.
- [0869] Data is extracted using AIS software and following background subtraction, signal normalization is performed. This includes a normalization of filter-wide expression levels between different experimental runs. Genes that are differentially expressed in the tissue of interest are identified.

Example 4: Chromosomal Mapping of the Polynucleotides

[0870] An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions: 30 seconds, 95°C; 1 minute, 56°C; 1 minute, 70°C. This cycle is repeated 32 times followed by one 5 minute cycle at 70°C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions are analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

Example 5: Bacterial Expression of a Polypeptide

[0871] A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

[0872] The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^r).

Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

[0873] Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

[0874] Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4°C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

[0875] Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8. The column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

[0876] The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4° C or frozen at -80° C.

[0877] In addition to the above expression vector, the present invention further includes an expression vector, called pHE4a (ATCC Accession Number 209645, deposited on February 25, 1998) which contains phage operator and promoter elements operatively linked to a polynucleotide of the present invention. This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an *E. coli* origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter and operator sequences are made synthetically.

[0878] DNA can be inserted into the pHE4a by restricting the vector with *NdeI* and *XbaI*, *BamHI*, *XhoI*, or *Asp718*, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for *NdeI* (5' primer) and *XbaI*, *BamHI*, *XhoI*, or *Asp718* (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

[0879] The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

Example 6: Purification of a Polypeptide from an Inclusion Body

[0880] The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10°C.

[0881] Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM

Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

[0882] The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

[0883] The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.

[0884] Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.

[0885] To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 µm membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

[0886] Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under

constant A₂₈₀ monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

[0887] The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 µg of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System

[0888] In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

[0889] Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

[0890] Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon, is amplified using the PCR protocol described in

Example 1. If a naturally occurring signal sequence is used to produce the polypeptide of the present invention, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

[0891] The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

[0892] The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

[0893] The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

[0894] Five µg of a plasmid containing the polynucleotide is co-transfected with 1.0 µg of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One µg of BaculoGold™ virus DNA and 5 µg of the plasmid are mixed in a sterile well of a microtiter plate containing 50 µl of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 µl Lipofectin plus 90 µl Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27° C. The transfection solution is then removed from

the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27° C for four days.

[0895] After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 μ l of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4° C.

[0896] To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 μ Ci of 35 S-methionine and 5 μ Ci 35 S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

[0897] Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

Example 8: Expression of a Polypeptide in Mammalian Cells

[0898] The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

[0899] Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

[0900] Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as DHFR, gpt, neomycin, or hygromycin allows the identification and isolation of the transfected cells.

[0901] The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the

mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

[0902] Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

[0903] Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

[0904] A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If a naturally occurring signal sequence is used to produce the polypeptide of the present invention, the vector does not need a second signal peptide. Alternatively, if a naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., International Publication No. WO 96/34891.)

[0905] The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

[0906] The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

[0907] Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five μ g of the expression plasmid pC6 or pC4 is cotransfected with 0.5 μ g of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 μ M, 2 μ M, 5 μ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 μ M. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

Example 9: Protein Fusions

[0908] The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the halflife time *in vivo*. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the

following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

[0909] Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

[0910] For example, if pC4 (ATCC Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

[0911] If the naturally occurring signal sequence is used to produce the polypeptide of the present invention, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., International Publication No. WO 96/34891.)

Human IgG Fc region:

```
GGGATCCGGAGCCCAAATCTTCTGACAAACTCACACATGCCACCGTGC
CCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCTCTTCCCCCAAAA
CCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTG GTG
GTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGA
CGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTAC
AACAGCACGTACCGTGTGGTCAGCGTCCTACCGTCCTGCACCAGGACTGG
CTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAAC
CCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCAC
AGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTC
AGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGTGGAG
TGGGAGAGCAATGGGCAGCCGGAACAACACTACAAGACCACGCCTCCCGT
GCTGGACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTGGACAA
```

GAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGG
CTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAAT
GAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO: 1)

Example 10: Production of an Antibody from a Polypeptide

Hybridoma Technology

[0912] The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing polypeptide of the present invention are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of polypeptide of the present invention is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

[0913] Monoclonal antibodies specific for polypeptide of the present invention are prepared using hybridoma technology (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized with polypeptide of the present invention or, more preferably, with a secreted polypeptide of the present invention-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

[0914] The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981)). The hybridoma

cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide of the present invention.

[0915] Alternatively, additional antibodies capable of binding to polypeptide of the present invention can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the polypeptide of the present invention-specific antibody can be blocked by polypeptide of the present invention. Such antibodies comprise anti-idiotypic antibodies to the polypeptide of the present invention-specific antibody and are used to immunize an animal to induce formation of further polypeptide of the present invention-specific antibodies.

[0916] For *in vivo* use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric and humanized antibodies are known in the art and are discussed herein. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., International Publication No. WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

Isolation Of Antibody Fragments Directed Against Polypeptide of the Present Invention From A Library Of scFvs

[0917] Naturally occurring V-genes isolated from human PBLs are constructed into a library of antibody fragments which contain reactivities against polypeptide of the present invention to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein by reference in its entirety).

[0918] *Rescue of the Library.* A library of scFvs is constructed from the RNA of human PBLs as described in International Publication No. WO 92/01047. To rescue

phage displaying antibody fragments, approximately 10^9 *E. coli* harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 µg/ml of ampicillin (2xTY-AMP-GLU) and grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to inoculate 50 ml of 2xTY-AMP-GLU, 2×10^8 TU of delta gene 3 helper (M13 delta gene III, see International Publication No. WO 92/01047) are added and the culture incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY containing 100 µg/ml ampicillin and 50 µg/ml kanamycin and grown overnight. Phage are prepared as described in International Application No. WO 92/01047.

[0919] M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III particles are made by growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37°C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in 300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY-AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and concentrated from the culture medium by two PEG-precipitations (Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 µm filter (Minisart NML; Sartorius) to give a final concentration of approximately 10^{13} transducing units/ml (ampicillin-resistant clones).

[0920] *Panning of the Library.* Immunotubes (Nunc) are coated overnight in PBS with 4 ml of either 100 µg/ml or 10 µg/ml of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately 10^{13} TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to

infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose and 100 µg/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification with tube-washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

[0921] *Characterization of Binders.* Eluted phage from the 3rd and 4th rounds of selection are used to infect E. coli HB 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with 10 pg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., International Application No. WO 92/01047) and then by sequencing. These ELISA positive clones may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

Example 11: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide

[0922] RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X; and/or the nucleotide sequence of the cDNA contained in Clone ID NO:Z. Suggested PCR conditions consist of 35 cycles at 95 degrees C for 30 seconds; 60-120 seconds at 52-58 degrees C; and 60-120 seconds at 70 degrees C, using buffer solutions described in Sidransky et al., Science 252:706 (1991).

[0923] PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase (Epicentre

Technologies). The intron-exon boundaries of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations are then cloned and sequenced to validate the results of the direct sequencing.

[0924] PCR products are cloned into T-tailed vectors as described in Holton et al., *Nucleic Acids Research*, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

[0925] Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson et al., *Methods Cell Biol.* 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

[0926] Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson et al., *Genet. Anal. Tech. Appl.*, 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

Example 12: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample

[0927] A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

[0928] For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

[0929] The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbound polypeptide.

[0930] Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbound conjugate.

[0931] Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

Example 13: Formulation

[0932] The invention also provides methods of treatment and/or prevention of diseases or disorders (such as, for example, any one or more of the diseases or disorders disclosed herein) by administration to a subject of an effective amount of a Therapeutic. By therapeutic is meant polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or antibodies thereto, in combination with a pharmaceutically acceptable carrier type (e.g., a sterile carrier).

[0933] The Therapeutic will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the Therapeutic alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

[0934] As a general proposition, the total pharmaceutically effective amount of the Therapeutic administered parenterally per dose will be in the range of about 1 μ g/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the Therapeutic is typically administered at a dose rate of about 1 μ g/kg/hour to about 50 μ g/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

[0935] Therapeutics can be administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

[0936] Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

[0937] Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics include suitable polymeric materials (such as, for example, semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules), suitable hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).

[0938] Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., *Biopolymers* 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (Langer et al., *J. Biomed. Mater. Res.* 15:167-277 (1981), and Langer, *Chem. Tech.* 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., *Id.*) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988).

[0939] Sustained-release Therapeutics also include liposomally entrapped Therapeutics of the invention (*see generally*, Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317 -327 and 353-365 (1989)). Liposomes containing the Therapeutic are prepared by methods known per se: DE 3,218,121; Epstein et al., *Proc. Natl. Acad. Sci. (USA)* 82:3688-3692 (1985); Hwang et al., *Proc. Natl. Acad. Sci.(USA)* 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than

about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal Therapeutic.

[0940] In yet an additional embodiment, the Therapeutics of the invention are delivered by way of a pump (*see* Langer, *supra*; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)).

[0941] Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

[0942] For parenteral administration, in one embodiment, the Therapeutic is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to the Therapeutic.

[0943] Generally, the formulations are prepared by contacting the Therapeutic uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

[0944] The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar

alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

[0945] The Therapeutic is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

[0946] Any pharmaceutical used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutics generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

[0947] Therapeutics ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Therapeutic solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized Therapeutic using bacteriostatic Water-for-Injection.

[0948] The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the Therapeutics of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the Therapeutics may be employed in conjunction with other therapeutic compounds.

[0949] The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, alum, alum plus deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG (e.g., THERACYS®), MPL and nonviable preparations of *Corynebacterium parvum*. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be

administered with the Therapeutics of the invention include, but are not limited to, Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diphtheria, hepatitis A, hepatitis B, haemophilus influenzae B, whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

[0950] The Therapeutics of the invention may be administered alone or in combination with other therapeutic agents. Therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not limited to, chemotherapeutic agents, antibiotics, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, and/or therapeutic treatments described below. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

[0951] In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and/or protease inhibitors (PIs). NRTIs that may be administered in combination with the

Therapeutics of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™ (didanosine/ddI), HIVID™ (zalcitabine/ddC), ZERIT™ (stavudine/d4T), EPIVIR™ (lamivudine/3TC), and COMBIVIR™ (zidovudine/lamivudine). NNRTIs that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, VIRAMUNE™ (nevirapine), RESCRIPTOR™ (delavirdine), and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, CRIXIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.

[0952] Additional NRTIs include LODENOSINE™ (F-ddA; an acid-stable adenosine NRTI; Triangle/Abbott); COVIRACIL™ (emtricitabine/FTC; structurally related to lamivudine (3TC) but with 3- to 10-fold greater activity *in vitro*; Triangle/Abbott); dOTC (BCH-10652, also structurally related to lamivudine but retains activity against a substantial proportion of lamivudine-resistant isolates; Biochem Pharma); Adefovir (refused approval for anti-HIV therapy by FDA; Gilead Sciences); PREVEON® (Adefovir Dipivoxil, the active prodrug of adefovir; its active form is PMEA-pp); TENOFOVIR™ (bis-POC PMPA, a PMPA prodrug; Gilead); DAPD/DXG (active metabolite of DAPD; Triangle/Abbott); D-D4FC (related to 3TC, with activity against AZT/3TC-resistant virus); GW420867X (Glaxo Wellcome); ZIAGEN™ (abacavir/159U89; Glaxo Wellcome Inc.); CS-87 (3'azido-2',3'-dideoxyuridine; WO 99/66936); and S-acyl-2-thioethyl (SATE)-bearing prodrug forms of β -L-FD4C and β -L-FddC (WO 98/17281).

[0953] Additional NNRTIs include COACTINON™ (Emvirine/MKC-442, potent NNRTI of the HEPT class; Triangle/Abbott); CAPRAVIRINE™ (AG-1549/S-1153, a next generation NNRTI with activity against viruses containing the K103N mutation; Agouron); PNU-142721 (has 20- to 50-fold greater activity than its predecessor delavirdine and is active against K103N mutants; Pharmacia & Upjohn); DPC-961 and

DPC-963 (second-generation derivatives of efavirenz, designed to be active against viruses with the K103N mutation; DuPont); GW-420867X (has 25-fold greater activity than HBY097 and is active against K103N mutants; Glaxo Wellcome); CALANOLIDE A (naturally occurring agent from the latex tree; active against viruses containing either or both the Y181C and K103N mutations); and Propolis (WO 99/49830).

[0954] Additional protease inhibitors include LOPINAVIR™ (ABT378/r; Abbott Laboratories); BMS-232632 (an azapeptide; Bristol-Myers Squibb); TIPRANAVIR™ (PNU-140690, a non-peptic dihydropyrone; Pharmacia & Upjohn); PD-178390 (a nonpeptidic dihydropyrone; Parke-Davis); BMS 232632 (an azapeptide; Bristol-Myers Squibb); L-756,423 (an indinavir analog; Merck); DMP-450 (a cyclic urea compound; Avid & DuPont); AG-1776 (a peptidomimetic with *in vitro* activity against protease inhibitor-resistant viruses; Agouron); VX-175/GW-433908 (phosphate prodrug of amprenavir; Vertex & Glaxo Wellcome); CGP61755 (Ciba); and AGENERASE™ (amprenavir; Glaxo Wellcome Inc.).

[0955] Additional antiretroviral agents include fusion inhibitors/gp41 binders. Fusion inhibitors/gp41 binders include T-20 (a peptide from residues 643-678 of the HIV gp41 transmembrane protein ectodomain which binds to gp41 in its resting state and prevents transformation to the fusogenic state; Trimeris) and T-1249 (a second-generation fusion inhibitor; Trimeris).

[0956] Additional antiretroviral agents include fusion inhibitors/chemokine receptor antagonists. Fusion inhibitors/chemokine receptor antagonists include CXCR4 antagonists such as AMD 3100 (a bicyclam), SDF-1 and its analogs, and ALX40-4C (a cationic peptide), T22 (an 18 amino acid peptide; Trimeris) and the T22 analogs T134 and T140; CCR5 antagonists such as RANTES (9-68), AOP-RANTES, NNY-RANTES, and TAK-779; and CCR5/CXCR4 antagonists such as NSC 651016 (a distamycin analog). Also included are CCR2B, CCR3, and CCR6 antagonists. Chemokine receptor agonists such as RANTES, SDF-1, MIP-1 α , MIP-1 β , etc., may also inhibit fusion.

[0957] Additional antiretroviral agents include integrase inhibitors. Integrase inhibitors include dicaffeoylquinic (DFQA) acids; L-chicoric acid (a dicaffeoyltartaric (DCTA) acid); quinalizarin (QLC) and related anthraquinones; ZINTEVIR™ (AR 177,

an oligonucleotide that probably acts at cell surface rather than being a true integrase inhibitor; Arondex); and naphthols such as those disclosed in WO 98/50347.

[0958] Additional antiretroviral agents include hydroxyurea-like compounds such as BCX-34 (a purine nucleoside phosphorylase inhibitor; Biocryst); ribonucleotide reductase inhibitors such as DIDOX™ (Molecules for Health); inosine monophosphate dehydrogenase (IMPDH) inhibitors such as VX-497 (Vertex); and mycopholic acids such as CellCept (mycophenolate mofetil; Roche).

[0959] Additional antiretroviral agents include inhibitors of viral integrase, inhibitors of viral genome nuclear translocation such as arylene bis(methylketone) compounds; inhibitors of HIV entry such as AOP-RANTES, NNY-RANTES, RANTES-IgG fusion protein, soluble complexes of RANTES and glycosaminoglycans (GAG), and AMD-3100; nucleocapsid zinc finger inhibitors such as dithiane compounds; targets of HIV Tat and Rev; and pharmacoenhancers such as ABT-378.

[0960] Other antiretroviral therapies and adjunct therapies include cytokines and lymphokines such as MIP-1 α , MIP-1 β , SDF-1 α , IL-2, PROLEUKIN™ (aldesleukin/L2-7001; Chiron), IL-4, IL-10, IL-12, and IL-13; interferons such as IFN- α 2a; antagonists of TNFs, NF κ B, GM-CSF, M-CSF, and IL-10; agents that modulate immune activation such as cyclosporin and prednisone; vaccines such as Remune™ (HIV Immunogen), APL 400-003 (Apollon), recombinant gp120 and fragments, bivalent (B/E) recombinant envelope glycoprotein, rgp120CM235, MN rgp120, SF-2 rgp120, gp120/soluble CD4 complex, Delta JR-FL protein, branched synthetic peptide derived from discontinuous gp120 C3/C4 domain, fusion-competent immunogens, and Gag, Pol, Nef, and Tat vaccines; gene-based therapies such as genetic suppressor elements (GSEs; WO 98/54366), and intrakines (genetically modified CC chemokines targeted to the ER to block surface expression of newly synthesized CCR5 (Yang *et al.*, *PNAS* 94:11567-72 (1997); Chen *et al.*, *Nat. Med.* 3:1110-16 (1997)); antibodies such as the anti-CXCR4 antibody 12G5, the anti-CCR5 antibodies 2D7, 5C7, PA8, PA9, PA10, PA11, PA12, and PA14, the anti-CD4 antibodies Q4120 and RPA-T4, the anti-CCR3 antibody 7B11, the anti-gp120 antibodies 17b, 48d, 447-52D, 257-D, 268-D and 50.1, anti-Tat antibodies, anti-TNF- α antibodies, and monoclonal antibody 33A; aryl hydrocarbon (AH) receptor agonists and antagonists such as TCDD, 3,3',4,4',5-pentachlorobiphenyl, 3,3',4,4'-tetrachlorobiphenyl, and α -naphthoflavone

(WO 98/30213); and antioxidants such as γ -L-glutamyl-L-cysteine ethyl ester (γ -GCE; WO 99/56764).

[0961] In a further embodiment, the Therapeutics of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered with the Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

[0962] In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™, FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™, KETOCONAZOLE™, ACYCLOVIR™, FAMCICOLVIR™, PYRIMETHAMINE™, LEUCOVORIN™, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™ (sargramostim/GM-CSF). In a specific embodiment, Therapeutics of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat or prevent an opportunistic *Pneumocystis carinii* pneumonia infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat or prevent an opportunistic *Mycobacterium avium* complex infection. In another specific embodiment, Therapeutics of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or prevent an opportunistic *Mycobacterium tuberculosis* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with FLUCONAZOLE™, ITRACONAZOLE™, and/or

KETOCONAZOLE™ to prophylactically treat or prevent an opportunistic fungal infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any combination with PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent an opportunistic *Toxoplasma gondii* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial infection.

[0963] In a further embodiment, the Therapeutics of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered with the Therapeutics of the invention include, but are not limited to, amoxicillin, beta-lactamases, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, ciprofloxacin, erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rapamycin, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-sulfamthoxazole, and vancomycin.

[0964] In other embodiments, Therapeutics of the invention are administered in combination with immunosuppressive agents. Immunosuppressive agents that may be administered in combination with the Therapeutics of the invention include, but are not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other immunosuppressive agents that act by suppressing the function of responding T cells. Other immunosuppressive agents that may be administered in combination with the Therapeutics of the invention include, but are not limited to, prednisolone, methotrexate, thalidomide, methoxsalen, rapamycin, leflunomide, mizoribine (BREDININ™), brequinar, deoxyspergualin, and azaspirane (SKF 105685), ORTHOCLONE OKT® 3 (muromonab-CD3), SANDIMMUNE™, NEORAL™, SANGDYA™ (cyclosporine), PROGRAF® (FK506, tacrolimus), CELLCEPT® (mycophenolate motefil, of which the active metabolite is mycophenolic acid), IMURAN™ (azathioprine), glucocorticosteroids, adrenocortical steroids such as

DELTAONE™ (prednisone) and HYDELTRASOL™ (prednisolone), FOLEX™ and MEXATE™ (methotrexate), OXSORALEN-ULTRA™ (methoxsalen) and RAPAMUNE™ (sirolimus). In a specific embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation.

[0965] In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations. Intravenous immune globulin preparations that may be administered with the Therapeutics of the invention include, but not limited to, GAMMAR™, IVEEGAM™, SANDOGLOBULIN™, GAMMAGARD S/D™, ATGAM™ (antithymocyte globulin), and GAMIMUNE™. In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow transplant).

[0966] In certain embodiments, the Therapeutics of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the Therapeutics of the invention include, but are not limited to, corticosteroids (e.g. betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone), nonsteroidal anti-inflammatory drugs (e.g., diclofenac, diflunisal, etodolac, fenoprofen, floctafenine, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tenoxicam, tiaprofenic acid, and tolmetin.), as well as antihistamines, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

[0967] In an additional embodiment, the compositions of the invention are administered alone or in combination with an anti-angiogenic agent. Anti-angiogenic agents that may be administered with the compositions of the invention include, but

are not limited to, Angiostatin (Entremed, Rockville, MD), Troponin-1 (Boston Life Sciences, Boston, MA), anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel (Taxol), Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, VEGI, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

[0968] Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

[0969] Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

[0970] Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

[0971] A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include, but are not limited to, platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, (1991)); Sulphated

Polysaccharide Peptidoglycan Complex (SP- PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., *J. Bio. Chem.* 267:17321-17326, (1992)); Chymostatin (Tomkinson et al., *Biochem J.* 286:475-480, (1992)); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., *Nature* 348:555-557, (1990)); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, *J. Clin. Invest.* 79:1440-1446, (1987)); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., *J. Biol. Chem.* 262(4):1659-1664, (1987)); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4- chloroanthronilic acid disodium or "CCA"; (Takeuchi et al., *Agents Actions* 36:312-316, (1992)); and metalloproteinase inhibitors such as BB94.

[0972] Additional anti-angiogenic factors that may also be utilized within the context of the present invention include Thalidomide, (Celgene, Warren, NJ); Angiostatic steroid; AGM-1470 (H. Brem and J. Folkman *J Pediatr. Surg.* 28:445-51 (1993)); an integrin alpha v beta 3 antagonist (C. Storgard et al., *J Clin. Invest.* 103:47-54 (1999)); carboxynaminolimidazole; Carboxyamidotriazole (CAI) (National Cancer Institute, Bethesda, MD); Conbretastatin A-4 (CA4P) (OXiGENE, Boston, MA); Squalamine (Magainin Pharmaceuticals, Plymouth Meeting, PA); TNP-470, (Tap Pharmaceuticals, Deerfield, IL); ZD-0101 AstraZeneca (London, UK); APRA (CT2584); Benefin, Byrostatin-1 (SC339555); CGP-41251 (PKC 412); CM101; Dexrazoxane (ICRF187); DMXAA; Endostatin; Flavopridiol; Genestein; GTE; ImmTher; Iressa (ZD1839); Octreotide (Somatostatin); Panretin; Penacillamine; Photopoint; PI-88; Prinomastat (AG-3340) Purlytin; Suradista (FCE26644); Tamoxifen (Nolvadex); Tazarotene; Tetrathiomolybdate; Xeloda (Capecitabine); and 5-Fluorouracil.

[0973] Anti-angiogenic agents that may be administered in combination with the compounds of the invention may work through a variety of mechanisms including, but not limited to, inhibiting proteolysis of the extracellular matrix, blocking the function of endothelial cell-extracellular matrix adhesion molecules, by antagonizing the

function of angiogenesis inducers such as growth factors, and inhibiting integrin receptors expressed on proliferating endothelial cells. Examples of anti-angiogenic inhibitors that interfere with extracellular matrix proteolysis and which may be administered in combination with the compositions of the invention include, but are not limited to, AG-3340 (Agouron, La Jolla, CA), BAY-12-9566 (Bayer, West Haven, CT), BMS-275291 (Bristol Myers Squibb, Princeton, NJ), CGS-27032A (Novartis, East Hanover, NJ), Marimastat (British Biotech, Oxford, UK), and Metastat (Aeterna, St-Foy, Quebec). Examples of anti-angiogenic inhibitors that act by blocking the function of endothelial cell-extracellular matrix adhesion molecules and which may be administered in combination with the compositions of the invention include, but are not limited to, EMD-121974 (Merck KgaA Darmstadt, Germany) and Vitaxin (Ixsys, La Jolla, CA/Medimmune, Gaithersburg, MD). Examples of anti-angiogenic agents that act by directly antagonizing or inhibiting angiogenesis inducers and which may be administered in combination with the compositions of the invention include, but are not limited to, Angiozyme (Ribozyme, Boulder, CO), Anti-VEGF antibody (Genentech, S. San Francisco, CA), PTK-787/ZK-225846 (Novartis, Basel, Switzerland), SU-101 (Sugen, S. San Francisco, CA), SU-5416 (Sugen/ Pharmacia Upjohn, Bridgewater, NJ), and SU-6668 (Sugen). Other anti-angiogenic agents act to indirectly inhibit angiogenesis. Examples of indirect inhibitors of angiogenesis which may be administered in combination with the compositions of the invention include, but are not limited to, IM-862 (Cytran, Kirkland, WA), Interferon-alpha, IL-12 (Roche, Nutley, NJ), and Pentosan polysulfate (Georgetown University, Washington, DC).

[0974] In particular embodiments, the use of compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of an autoimmune disease, such as for example, an autoimmune disease described herein.

[0975] In a particular embodiment, the use of compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of arthritis. In a more particular embodiment, the use of compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of rheumatoid arthritis.

[0976] In another embodiment, the polynucleotides encoding a polypeptide of the present invention are administered in combination with an angiogenic protein, or polynucleotides encoding an angiogenic protein. Examples of angiogenic proteins that may be administered with the compositions of the invention include, but are not limited to, acidic and basic fibroblast growth factors, VEGF-1, VEGF-2, VEGF-3, epidermal growth factor alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin-like growth factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

[0977] In additional embodiments, compositions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to alkylating agents such as nitrogen mustards (for example, Mechlorethamine, cyclophosphamide, Cyclophosphamide Ifosfamide, Melphalan (L-sarcosine), and Chlorambucil), ethylenimines and methylmelamines (for example, Hexamethylmelamine and Thiotepa), alkyl sulfonates (for example, Busulfan), nitrosoureas (for example, Carmustine (BCNU), Lomustine (CCNU), Semustine (methyl-CCNU), and Streptozocin (streptozotocin)), triazines (for example, Dacarbazine (DTIC; dimethyltriazenoimidazolecarboxamide)), folic acid analogs (for example, Methotrexate (amethopterin)), pyrimidine analogs (for example, Fluorouracil (5-fluorouracil; 5-FU), Floxuridine (fluorodeoxyuridine; FudR), and Cytarabine (cytosine arabinoside)), purine analogs and related inhibitors (for example, Mercaptopurine (6-mercaptopurine; 6-MP), Thioguanine (6-thioguanine; TG), and Pentostatin (2'-deoxycoformycin)), vinca alkaloids (for example, Vinblastine (VLB, vinblastine sulfate) and Vincristine (vincristine sulfate)), epipodophyllotoxins (for example, Etoposide and Teniposide), antibiotics (for example, Dactinomycin (actinomycin D), Daunorubicin (daunomycin; rubidomycin), Doxorubicin, Bleomycin, Plicamycin (mithramycin), and Mitomycin (mitomycin C), enzymes (for example, L-Asparaginase), biological response modifiers (for example, Interferon-alpha and interferon-alpha-2b), platinum coordination compounds (for example, Cisplatin (cis-DDP) and Carboplatin), anthracenedione (Mitoxantrone), substituted ureas (for example, Hydroxyurea), methylhydrazine derivatives (for example, Procarbazine (N-

methylhydrazine; MIH), adrenocorticosteroids (for example, Prednisone), progestins (for example, Hydroxyprogesterone caproate, Medroxyprogesterone, Medroxyprogesterone acetate, and Megestrol acetate), estrogens (for example, Diethylstilbestrol (DES), Diethylstilbestrol diphosphate, Estradiol, and Ethinyl estradiol), antiestrogens (for example, Tamoxifen), androgens (Testosterone propionate, and Fluoxymesterone), antiandrogens (for example, Flutamide), gonadotropin-releasing hormone analogs (for example, Leuprolide), other hormones and hormone analogs (for example, methyltestosterone, estramustine, estramustine phosphate sodium, chlorotrianisene, and testolactone), and others (for example, dicarbazine, glutamic acid, and mitotane).

[0978] In one embodiment, the compositions of the invention are administered in combination with one or more of the following drugs: infliximab (also known as Remicade™ Centocor, Inc.), Trocade (Roche, RO-32-3555), Leflunomide (also known as Arava™ from Hoechst Marion Roussel), Kineret™ (an IL-1 Receptor antagonist also known as Anakinra from Amgen, Inc.).

[0979] In a specific embodiment, compositions of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or combination of one or more of the components of CHOP. In one embodiment, the compositions of the invention are administered in combination with anti-CD20 antibodies, human monoclonal anti-CD20 antibodies. In another embodiment, the compositions of the invention are administered in combination with anti-CD20 antibodies and CHOP, or anti-CD20 antibodies and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. In a specific embodiment, compositions of the invention are administered in combination with Rituximab. In a further embodiment, compositions of the invention are administered with Rituximab and CHOP, or Rituximab and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. In a specific embodiment, compositions of the invention are administered in combination with tositumomab. In a further embodiment, compositions of the invention are administered with tositumomab and CHOP, or tositumomab and any combination of one or more of the components of

CHOP, particularly cyclophosphamide and/or prednisone. The anti-CD20 antibodies may optionally be associated with radioisotopes, toxins or cytotoxic prodrugs.

[0980] In another specific embodiment, the compositions of the invention are administered in combination Zevalin™. In a further embodiment, compositions of the invention are administered with Zevalin™ and CHOP, or Zevalin™ and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. Zevalin™ may be associated with one or more radisotopes. Particularly preferred isotopes are ⁹⁰Y and ¹¹¹In.

[0981] In an additional embodiment, the Therapeutics of the invention are administered in combination with cytokines. Cytokines that may be administered with the Therapeutics of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha. In another embodiment, Therapeutics of the invention may be administered with any interleukin, including, but not limited to, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

[0982] In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the Therapeutics of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), OPG, and neutrokin-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-IBB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms CD154, CD70, and CD153.

[0983] In an additional embodiment, the Therapeutics of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as disclosed in European Patent Number EP-282317; Placental Growth Factor (PlGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PlGF-2), as disclosed in Hauser et al., Growth Factors, 4:259-268 (1993); Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2 (VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent Number DE19639601. The above mentioned references are herein incorporated by reference in their entireties.

[0984] In an additional embodiment, the Therapeutics of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth Factors that may be administered with the Therapeutics of the invention include, but are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

[0985] In an additional embodiment, the Therapeutics of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention include, but are not limited to, granulocyte macrophage colony stimulating factor (GM-CSF) (sargramostim, LEUKINE™, PROKINE™), granulocyte colony stimulating factor (G-CSF) (filgrastim, NEUPOGEN™), macrophage colony

stimulating factor (M-CSF, CSF-1) erythropoietin (epoetin alfa, EPOGEN™, PROCRIT™), stem cell factor (SCF, c-kit ligand, steel factor), megakaryocyte colony stimulating factor, PIXY321 (a GMCSF/IL-3 fusion protein), interleukins, especially any one or more of IL-1 through IL-12, interferon-gamma, or thrombopoietin.

[0986] In certain embodiments, Therapeutics of the present invention are administered in combination with adrenergic blockers, such as, for example, acebutolol, atenolol, betaxolol, bisoprolol, carteolol, labetalol, metoprolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol.

[0987] In another embodiment, the Therapeutics of the invention are administered in combination with an antiarrhythmic drug (e.g., adenosine, amiodarone, bretylium, digitalis, digoxin, digitoxin, diltiazem, disopyramide, esmolol, flecainide, lidocaine, mexiletine, moricizine, phenytoin, procainamide, N-acetyl procainamide, propafenone, propranolol, quinidine, sotalol, tocainide, and verapamil).

[0988] In another embodiment, the Therapeutics of the invention are administered in combination with diuretic agents, such as carbonic anhydrase-inhibiting agents (e.g., acetazolamide, dichlorphenamide, and methazolamide), osmotic diuretics (e.g., glycerin, isosorbide, mannitol, and urea), diuretics that inhibit $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ symport (e.g., furosemide, bumetanide, azosemide, piretanide, tripamide, ethacrynic acid, muzolimine, and torsemide), thiazide and thiazide-like diuretics (e.g., bendroflumethiazide, benzthiazide, chlorothiazide, hydrochlorothiazide, hydroflumethiazide, methyclothiazide, polythiazide, trichormethiazide, chlorthalidone, indapamide, metolazone, and quinethazone), potassium sparing diuretics (e.g., amiloride and triamterene), and mineralcorticoid receptor antagonists (e.g., spironolactone, canrenone, and potassium canrenoate).

[0989] In one embodiment, the Therapeutics of the invention are administered in combination with treatments for endocrine and/or hormone imbalance disorders. Treatments for endocrine and/or hormone imbalance disorders include, but are not limited to, ^{127}I , radioactive isotopes of iodine such as ^{131}I and ^{123}I ; recombinant growth hormone, such as HUMATROPE™ (recombinant somatropin); growth hormone analogs such as PROTROPIN™ (somatrem); dopamine agonists such as PARLODEL™ (bromocriptine); somatostatin analogs such as SANDOSTATIN™ (octreotide); gonadotropin preparations such as PREGNYL™, A.P.L.™ and

PROFASI™ (chorionic gonadotropin (CG)), PERGONAL™ (menotropins), and METRODIN™ (urofollitropin (uFSH)); synthetic human gonadotropin releasing hormone preparations such as FACTREL™ and LUTREPULSE™ (gonadorelin hydrochloride); synthetic gonadotropin agonists such as LUPRON™ (leuprolide acetate), SUPPRELIN™ (histrelin acetate), SYNAREL™ (nafarelin acetate), and ZOLADEX™ (goserelin acetate); synthetic preparations of thyrotropin-releasing hormone such as RELEFACT TRH™ and THYPINONE™ (protirelin); recombinant human TSH such as THYROGEN™; synthetic preparations of the sodium salts of the natural isomers of thyroid hormones such as L-T₄™, SYNTHROID™ and LEVOTHROID™ (levothyroxine sodium), L-T₃™, CYTOMEL™ and TRIOSTAT™ (liothyroine sodium), and THYROLAR™ (liotrix); antithyroid compounds such as 6-*n*-propylthiouracil (propylthiouracil), 1-methyl-2-mercaptoimidazole and TAPAZOLE™ (methimazole), NEO-MERCAZOLE™ (carbimazole); beta-adrenergic receptor antagonists such as propranolol and esmolol; Ca²⁺ channel blockers; dexamethasone and iodinated radiological contrast agents such as TELEPAQUE™ (iopanoic acid) and ORAGRAFIN™ (sodium ipodate); estrogens or conjugated estrogens such as ESTRACE™ (estradiol), ESTINYL™ (ethinyl estradiol), PREMARIN™, ESTRATAB™, ORTHO-EST™, OGEN™ and estropipate (estrone), ESTROVIS™ (quinestrol), ESTRADERM™ (estradiol), DELESTROGEN™ and VALERGEN™ (estradiol valerate), DEPO-ESTRADIOL CYPIONATE™ and ESTROJECT LA™ (estradiol cypionate); antiestrogens such as NOLVADEX™ (tamoxifen), SEROPHENE™ and CLOMID™ (clomiphene); progestins such as DURALUTIN™ (hydroxyprogesterone caproate), MPA™ and DEPO-PROVERA™ (medroxyprogesterone acetate), PROVERA™ and CYCRIN™ (MPA), MEGACE™ (megestrol acetate), NORLUTIN™ (norethindrone), and NORLUTATE™ and AYGESTIN™ (norethindrone acetate); progesterone implants such as NORPLANT SYSTEM™ (subdermal implants of norgestrel); antiprogestins such as RU 486™ (mifepristone); hormonal contraceptives such as ENOVID™ (norethynodrel plus mestranol), PROGESTASERT™ (intrauterine device that releases progesterone), LOESTRIN™, BREVICON™, MODICON™, GENORA™, NELONA™,

NORINYL™, OVACON-35™ and OVACON-50™ (ethinyl estradiol/norethindrone), LEVLEN™, NORDETTE™, TRI-LEVLEN™ and TRIPHASIL-21™ (ethinyl estradiol/levonorgestrel) LO/OVRAL™ and OVRAL™ (ethinyl estradiol/norgestrel), DEMULEN™ (ethinyl estradiol/ethynodiol diacetate), NORINYL™, ORTHO-NOVUM™, NORETHIN™, GENORA™, and NELOVA™ (norethindrone/mestranol), DESOGEN™ and ORTHO-CEPT™ (ethinyl estradiol/desogestrel), ORTHO-CYCLEN™ and ORTHO-TRICYCLEN™ (ethinyl estradiol/norgestimate), MICRONOR™ and NOR-QD™ (norethindrone), and OVRETTE™ (norgestrel); testosterone esters such as methenolone acetate and testosterone undecanoate; parenteral and oral androgens such as TESTOJECT-50™ (testosterone), TESTEX™ (testosterone propionate), DELATESTRYL™ (testosterone enanthate), DEPO-TESTOSTERONE™ (testosterone cypionate), DANOCRINE™ (danazol), HALOTESTIN™ (fluoxymesterone), ORETON METHYL™, TESTRED™ and VIRILON™ (methyltestosterone), and OXANDRIN™ (oxandrolone); testosterone transdermal systems such as TESTODERM™; androgen receptor antagonist and 5-alpha-reductase inhibitors such as ANDROCUR™ (cyproterone acetate), EULEXIN™ (flutamide), and PROSCAR™ (finasteride); adrenocorticotrophic hormone preparations such as CORTROSYN™ (cosyntropin); adrenocortical steroids and their synthetic analogs such as ACLOVATE™ (alclometasone dipropionate), CYCLOCORT™ (amcinonide), BECLOVENT™ and VANCERIL™ (beclomethasone dipropionate), CELESTONE™ (betamethasone), BENISONE™ and UTICORT™ (betamethasone benzoate), DIPROSONE™ (betamethasone dipropionate), CELESTONE PHOSPHATE™ (betamethasone sodium phosphate), CELESTONE SOLUSPAN™ (betamethasone sodium phosphate and acetate), BETA-VAL™ and VALISONE™ (betamethasone valerate), TEMOVATE™ (clobetasol propionate), CLODERM™ (clocortolone pivalate), CORTEF™ and HYDROCORTONE™ (cortisol (hydrocortisone)), HYDROCORTONE ACETATE™ (cortisol (hydrocortisone) acetate), LOCOID™ (cortisol (hydrocortisone) butyrate), HYDROCORTONE PHOSPHATE™ (cortisol (hydrocortisone) sodium phosphate), A-HYDROCORT™ and SOLU CORTEF™ (cortisol (hydrocortisone) sodium succinate), WESTCORT™

(cortisol (hydrocortisone) valerate), CORTISONE ACETATE™ (cortisone acetate), DESOWEN™ and TRIDESILON™ (desonide), TOPICORT™ (desoximetasone), DECADRON™ (dexamethasone), DECADRON LA™ (dexamethasone acetate), DECADRON PHOSPHATE™ and HEXADROL PHOSPHATE™ (dexamethasone sodium phosphate), FLORONE™ and MAXIFLOR™ (diflorasone diacetate), FLORINEF ACETATE™ (fludrocortisone acetate), AEROBID™ and NASALIDE™ (flunisolide), FLUONID™ and SYNALAR™ (fluocinolone acetonide), LIDEX™ (fluocinonide), FLUOR-OP™ and FML™ (fluorometholone), CORDRAN™ (flurandrenolide), HALOG™ (halcinonide), HMS LIZUIFILM™ (medrysone), MEDROL™ (methylprednisolone), DEPO-MEDROL™ and MEDROL ACETATE™ (methylprednisone acetate), A-METHAPRED™ and SOLUMEDROL™ (methylprednisolone sodium succinate), ELOCON™ (mometasone furoate), HALDRONE™ (paramethasone acetate), DELTA-CORTEF™ (prednisolone), ECONOPRED™ (prednisolone acetate), HYDELTRASOL™ (prednisolone sodium phosphate), HYDELTRA-T.B.A™ (prednisolone tebutate), DELTASONE™ (prednisone), ARISTOCORT™ and KENACORT™ (triamcinolone), KENALOG™ (triamcinolone acetonide), ARISTOCORT™ and KENACORT DIACETATE™ (triamcinolone diacetate), and ARISTOSPAN™ (triamcinolone hexacetonide); inhibitors of biosynthesis and action of adrenocortical steroids such as CYTADREN™ (aminoglutethimide), NIZORAL™ (ketoconazole), MODRASTANE™ (trilostane), and METOPIRONE™ (metyrapone); bovine, porcine or human insulin or mixtures thereof; insulin analogs; recombinant human insulin such as HUMULIN™ and NOVOLIN™; oral hypoglycemic agents such as ORAMIDE™ and ORINASE™ (tolbutamide), DIABINESE™ (chlorpropamide), TOLAMIDE™ and TOLINASE™ (tolazamide), DYMELOR™ (acetoexamide), glibenclamide, MICRONASE™, DIBETA™ and GLYNASE™ (glyburide), GLUCOTROL™ (glipizide), and DIAMICRON™ (gliclazide), GLUCOPHAGE™ (metformin), ciglitazone, pioglitazone, and alpha-glucosidase inhibitors; bovine or porcine glucagon; somatostatins such as SANDOSTATIN™ (octreotide); and diazoxides such as PROGLYCEM™ (diazoxide).

[0990] In one embodiment, the Therapeutics of the invention are administered in combination with treatments for uterine motility disorders. Treatments for uterine motility disorders include, but are not limited to, estrogen drugs such as conjugated estrogens (e.g., PREMARIN® and ESTRATAB®), estradiols (e.g., CLIMARA® and ALORA®), estropipate, and chlorotrianisene; progestin drugs (e.g., AMEN® (medroxyprogesterone), MICRONOR® (norethidrone acetate), PROMETRIUM® progesterone, and megestrol acetate); and estrogen/progesterone combination therapies such as, for example, conjugated estrogens/medroxyprogesterone (e.g., PREMPRO™ and PREMPHASE®) and norethindrone acetate/ethinyl estradiol (e.g., FEMHRT™).

[0991] In an additional embodiment, the Therapeutics of the invention are administered in combination with drugs effective in treating iron deficiency and hypochromic anemias, including but not limited to, ferrous sulfate (iron sulfate, FEOSOL™), ferrous fumarate (e.g., FEOSTAT™), ferrous gluconate (e.g., FERGON™), polysaccharide-iron complex (e.g., NIFEREX™), iron dextran injection (e.g., INFED™), cupric sulfate, pyroxidine, riboflavin, Vitamin B₁₂, cyanocobalamin injection (e.g., REDISOL™, RUBRAMIN PC™), hydroxocobalamin, folic acid (e.g., FOLVITE™), leucovorin (folinic acid, 5-CHOH4PteGlu, citrovorum factor) or WELLCOVORIN (Calcium salt of leucovorin), transferrin or ferritin.

[0992] In certain embodiments, the Therapeutics of the invention are administered in combination with agents used to treat psychiatric disorders. Psychiatric drugs that may be administered with the Therapeutics of the invention include, but are not limited to, antipsychotic agents (e.g., chlorpromazine, chlorprothixene, clozapine, fluphenazine, haloperidol, loxapine, mesoridazine, molindone, olanzapine, perphenazine, pimozide, quetiapine, risperidone, thioridazine, thiothixene, trifluoperazine, and triflupromazine), antimanic agents (e.g., carbamazepine, divalproex sodium, lithium carbonate, and lithium citrate), antidepressants (e.g., amitriptyline, amoxapine, bupropion, citalopram, clomipramine, desipramine, doxepin, fluvoxamine, fluoxetine, imipramine, isocarboxazid, maprotiline, mirtazapine, nefazodone, nortriptyline, paroxetine, phenelzine, protriptyline, sertraline, tranylcypromine, trazodone, trimipramine, and venlafaxine), antianxiety agents (e.g., alprazolam, buspirone, chlordiazepoxide, clorazepate, diazepam, halazepam,

lorazepam, oxazepam, and prazepam), and stimulants (e.g., d-amphetamine, methylphenidate, and pemoline).

[0993] In other embodiments, the Therapeutics of the invention are administered in combination with agents used to treat neurological disorders. Neurological agents that may be administered with the Therapeutics of the invention include, but are not limited to, antiepileptic agents (e.g., carbamazepine, clonazepam, ethosuximide, phenobarbital, phenytoin, primidone, valproic acid, divalproex sodium, felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, zonisamide, diazepam, lorazepam, and clonazepam), antiparkinsonian agents (e.g., levodopa/carbidopa, selegiline, amantidine, bromocriptine, pergolide, ropinirole, pramipexole, benzotropine; biperiden; ethopropazine; procyclidine; trihexyphenidyl, tolcapone), and ALS therapeutics (e.g. riluzole).

[0994] In another embodiment, Therapeutics of the invention are administered in combination with vasodilating agents and/or calcium channel blocking agents. Vasodilating agents that may be administered with the Therapeutics of the invention include, but are not limited to, Angiotensin Converting Enzyme (ACE) inhibitors (e.g., papaverine, isoxsuprine, benazepril, captopril, cilazapril, enalapril, enalaprilat, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, spirapril,trandolapril, and nylidrin), and nitrates (e.g., isosorbide dinitrate, isosorbide mononitrate, and nitroglycerin). Examples of calcium channel blocking agents that may be administered in combination with the Therapeutics of the invention include, but are not limited to amlodipine, bepridil, diltiazem, felodipine, flunarizine, isradipine, nicardipine, nifedipine, nimodipine, and verapamil.

[0995] In additional embodiments, the Therapeutics of the invention are administered in combination with other therapeutic or prophylactic regimens, such as, for example, radiation therapy.

Example 14: Method of Treating Decreased Levels of the Polypeptide

[0996] The present invention relates to a method for treating an individual in need of an increased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically

effective amount of an agonist of the invention (including polypeptides of the invention). Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of a polypeptide of the present invention in an individual can be treated by administering the agonist or antagonist of the present invention. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a Therapeutic comprising an amount of the agonist or antagonist to increase the activity level of the polypeptide in such an individual.

[0997] For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the agonist or antagonist for six consecutive days. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 13.

Example 15: Method of Treating Increased Levels of the Polypeptide

[0998] The present invention also relates to a method of treating an individual in need of a decreased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an antagonist of the invention (including polypeptides and antibodies of the invention).

[0999] In one example, antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, due to a variety of etiologies, such as cancer.

[01000] For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 13.

Example 16: Method of Treatment Using Gene Therapy-Ex Vivo

- [01001] One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37 degree C for approximately one week.
- [01002] At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.
- [01003] pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.
- [01004] The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.
- [01005] The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with

10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

[01006] Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

[01007] The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

Example 17: Gene Therapy Using Endogenous Genes Corresponding To Polynucleotides of the Invention

[01008] Another method of gene therapy according to the present invention involves operably associating the endogenous polynucleotide sequence of the invention with a promoter via homologous recombination as described, for example, in U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA, 86:8932-8935 (1989); and Zijlstra et al., Nature, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

[01009] Polynucleotide constructs are made which contain a promoter and targeting sequences, which are homologous to the 5' non-coding sequence of endogenous polynucleotide sequence, flanking the promoter. The targeting sequence will be sufficiently near the 5' end of the polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination. The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter.

[01010] The amplified promoter and the amplified targeting sequences are digested with the appropriate restriction enzymes and subsequently treated with calf intestinal phosphatase. The digested promoter and digested targeting sequences are added together in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The construct is size fractionated on an agarose gel, then purified by phenol extraction and ethanol precipitation.

[01011] In this Example, the polynucleotide constructs are administered as naked polynucleotides via electroporation. However, the polynucleotide constructs may also be administered with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, precipitating agents, etc. Such methods of delivery are known in the art.

[01012] Once the cells are transfected, homologous recombination will take place which results in the promoter being operably linked to the endogenous polynucleotide sequence. This results in the expression of polynucleotide corresponding to the polynucleotide in the cell. Expression may be detected by immunological staining, or any other method known in the art.

[01013] Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining

cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 5 mM KCl, 0.7 mM Na₂ HPO₄, 6 mM dextrose). The cells are recentrifuged, the supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains approximately 3X10⁶ cells/ml. Electroporation should be performed immediately following resuspension.

[01014] Plasmid DNA is prepared according to standard techniques. For example, to construct a plasmid for targeting to the locus corresponding to the polynucleotide of the invention, plasmid pUC18 (MBI Fermentas, Amherst, NY) is digested with HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3' end. Two non-coding sequences are amplified via PCR: one non-coding sequence (fragment 1) is amplified with a HindIII site at the 5' end and an Xba site at the 3' end; the other non-coding sequence (fragment 2) is amplified with a BamHI site at the 5' end and a HindIII site at the 3' end. The CMV promoter and the fragments (1 and 2) are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; fragment 1 - XbaI; fragment 2 - BamHI) and ligated together. The resulting ligation product is digested with HindIII, and ligated with the HindIII-digested pUC18 plasmid.

[01015] Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap (Bio-Rad). The final DNA concentration is generally at least 120 µg/ml. 0.5 ml of the cell suspension (containing approximately 1.5X10⁶ cells) is then added to the cuvette, and the cell suspension and DNA solutions are gently mixed. Electroporation is performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960 µF and 250-300 V, respectively. As voltage increases, cell survival decreases, but the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of approximately 14-20 mSec should be observed.

[01016] Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following

day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

[01017] The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a patient as described above.

Example 18: Method of Treatment Using Gene Therapy - In Vivo

[01018] Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to (i.e., associated with) a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata et al., *Cardiovasc. Res.* 35(3):470-479 (1997); Chao et al., *Pharmacol. Res.* 35(6):517-522 (1997); Wolff, *Neuromuscul. Disord.* 7(5):314-318 (1997); Schwartz et al., *Gene Ther.* 3(5):405-411 (1996); Tsurumi et al., *Circulation* 94(12):3281-3290 (1996) (incorporated herein by reference).

[01019] The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

[01020] The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in

Felgner P.L. et al. (1995) Ann. NY Acad. Sci. 772:126-139 and Abdallah B. et al. (1995) Biol. Cell 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

[01021] The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapy techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

[01022] The polynucleotide construct can be delivered to the interstitial space of tissues within an animal, including muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

[01023] For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the

tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

[01024] The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

[01025] Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

[01026] After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 μ m cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be used to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

Example 19: Transgenic Animals

[01027] The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, e.g., baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

[01028] Any technique known in the art may be used to introduce the transgene (i.e., polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, e.g., Ulmer et al., Science 259:1745 (1993)); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

[01029] Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

[01030] The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but

not all their cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

[01031] Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

[01032] Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate

lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

[01033] Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Example 20: Knock-Out Animals

[01034] Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (See e.g., Smithies et al., *Nature* 317:230-234 (1985); Thomas & Capecchi, *Cell* 51:503-512 (1987); Thompson et al., *Cell* 5:313-321 (1989); each of which is incorporated by reference herein in its entirety.) For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (e.g., see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely

adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

[01035] In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e.g., knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

[01036] Alternatively, the cells can be incorporated into a matrix and implanted in the body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

[01037] When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an

exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

[01038] Transgenic and “knock-out” animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

***Example 21: Assays Detecting Stimulation or Inhibition of B cell
Proliferation and Differentiation***

[01039] Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may impart a positive stimulus that allows a B-lineage cell to continue its programmed development, or a negative stimulus that instructs the cell to arrest its current developmental pathway. To date, numerous stimulatory and inhibitory signals have been found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL10, IL-13, IL-14 and IL-15. Interestingly, these signals are by themselves weak effectors but can, in combination with various co-stimulatory proteins, induce activation, proliferation, differentiation, homing, tolerance and death among B cell populations.

[01040] One of the best studied classes of B-cell co-stimulatory proteins is the TNF-superfamily. Within this family CD40, CD27, and CD30 along with their respective ligands CD154, CD70, and CD153 have been found to regulate a variety of immune responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of proliferation and differentiation. Listed below are two assays designed to allow for the detection of the differentiation, proliferation, or inhibition of B-cell populations and their precursors.

[01041] *In vitro* Assay- Agonists or antagonists of the invention can be assessed for its ability to induce activation, proliferation, differentiation or inhibition and/or death

in B-cell populations and their precursors. The activity of the agonists or antagonists of the invention on purified human tonsillar B cells, measured qualitatively over the dose range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed *Staphylococcus aureus* Cowan I (SAC) or immobilized anti-human IgM antibody as the priming agent. Second signals such as IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. Novel synergizing agents can be readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).

[01042] Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added 10^5 B-cells suspended in culture medium (RPMI 1640 containing 10% FBS, 5×10^{-5} M 2ME, 100U/ml penicillin, 10ug/ml streptomycin, and 10^{-5} dilution of SAC) in a total volume of 150ul. Proliferation or inhibition is quantitated by a 20h pulse (1uCi/well) with 3 H-thymidine (6.7 Ci/mM) beginning 72h post factor addition. The positive and negative controls are IL2 and medium respectively.

[01043] *In Vivo* Assay- BALB/c mice are injected (i.p.) twice per day with buffer only, or 2 mg/Kg of agonists or antagonists of the invention, or truncated forms thereof. Mice receive this treatment for 4 consecutive days, at which time they are sacrificed and various tissues and serum collected for analyses. Comparison of H&E sections from normal spleens and spleens treated with agonists or antagonists of the invention identify the results of the activity of the agonists or antagonists on spleen cells, such as the diffusion of peri-arterial lymphatic sheaths, and/or significant increases in the nucleated cellularity of the red pulp regions, which may indicate the activation of the differentiation and proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to determine whether any physiological changes to splenic cells, such as splenic disorganization, are due to increased B-cell representation within loosely defined B-cell zones that infiltrate established T-cell regions.

- [01044] Flow cytometric analyses of the spleens from mice treated with agonist or antagonist is used to indicate whether the agonists or antagonists specifically increases the proportion of ThB+, CD45R(B220)dull B cells over that which is observed in control mice.
- [01045] Likewise, a predicted consequence of increased mature B-cell representation *in vivo* is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are compared between buffer and agonists or antagonists-treated mice.
- [01046] The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 22: T Cell Proliferation Assay

- [01047] A CD3-induced proliferation assay is performed on PBMCs and is measured by the uptake of ³H-thymidine. The assay is performed as follows. Ninety-six well plates are coated with 100 µl/well of mAb to CD3 (HIT3a, Pharmingen) or isotype-matched control mAb (B33.1) overnight at 4 degrees C (1 µg/ml in .05M bicarbonate buffer, pH 9.5), then washed three times with PBS. PBMC are isolated by F/H gradient centrifugation from human peripheral blood and added to quadruplicate wells (5 x 10⁴/well) of mAb coated plates in RPMI containing 10% FCS and P/S in the presence of varying concentrations of agonists or antagonists of the invention (total volume 200 ul). Relevant protein buffer and medium alone are controls. After 48 hr. culture at 37 degrees C, plates are spun for 2 min. at 1000 rpm and 100 µl of supernatant is removed and stored -20 degrees C for measurement of IL-2 (or other cytokines) if effect on proliferation is observed. Wells are supplemented with 100 ul of medium containing 0.5 uCi of ³H-thymidine and cultured at 37 degrees C for 18-24 hr. Wells are harvested and incorporation of ³H-thymidine used as a measure of proliferation. Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation. Control antibody which

does not induce proliferation of T cells is used as the negative control for the effects of agonists or antagonists of the invention.

[01048] The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 23: Effect of Agonists or Antagonists of the Invention on the Expression of MHC Class II, Costimulatory and Adhesion Molecules and Cell Differentiation of Monocytes and Monocyte-Derived Human Dendritic Cells

[01049] Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and MHC class II antigens). Treatment with activating factors, such as TNF- α , causes a rapid change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FC γ RII, upregulation of CD83). These changes correlate with increased antigen-presenting capacity and with functional maturation of the dendritic cells.

[01050] FACS analysis of surface antigens is performed as follows. Cells are treated 1-3 days with increasing concentrations of agonist or antagonist of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

[01051] Effect on the production of cytokines. Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune responses. IL-12 strongly influences the development of Th1 helper T-cell immune

response, and induces cytotoxic T and NK cell function. An ELISA is used to measure the IL-12 release as follows. Dendritic cells ($10^6/\text{ml}$) are treated with increasing concentrations of agonists or antagonists of the invention for 24 hours. LPS (100 ng/ml) is added to the cell culture as positive control. Supernatants from the cell cultures are then collected and analyzed for IL-12 content using commercial ELISA kit (e.g., R & D Systems (Minneapolis, MN)). The standard protocols provided with the kits are used.

[01052] Effect on the expression of MHC Class II, costimulatory and adhesion molecules. Three major families of cell surface antigens can be identified on monocytes: adhesion molecules, molecules involved in antigen presentation, and Fc receptor. Modulation of the expression of MHC class II antigens and other costimulatory molecules, such as B7 and ICAM-1, may result in changes in the antigen presenting capacity of monocytes and ability to induce T cell activation. Increased expression of Fc receptors may correlate with improved monocyte cytotoxic activity, cytokine release and phagocytosis.

[01053] FACS analysis is used to examine the surface antigens as follows. Monocytes are treated 1-5 days with increasing concentrations of agonists or antagonists of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

[01054] Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or alternatively, decrease monocyte survival) are known in the art and may routinely be applied to determine whether a molecule of the invention functions as an inhibitor or activator of monocytes. Agonists or antagonists of the invention can be screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified from single donor leukopacks (American Red

Cross, Baltimore, MD) by centrifugation through a Histopaque gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal elutriation.

[01055] Monocyte Survival Assay. Human peripheral blood monocytes progressively lose viability when cultured in absence of serum or other stimuli. Their death results from internally regulated processes (apoptosis). Addition to the culture of activating factors, such as TNF-alpha dramatically improves cell survival and prevents DNA fragmentation. Propidium iodide (PI) staining is used to measure apoptosis as follows. Monocytes are cultured for 48 hours in polypropylene tubes in serum-free medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative control), and in the presence of varying concentrations of the compound to be tested. Cells are suspended at a concentration of 2×10^6 /ml in PBS containing PI at a final concentration of 5 µg/ml, and then incubated at room temperature for 5 minutes before FACScan analysis. PI uptake has been demonstrated to correlate with DNA fragmentation in this experimental paradigm.

[01056] Effect on cytokine release. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the release of cytokines after stimulation. An ELISA to measure cytokine release is performed as follows. Human monocytes are incubated at a density of 5×10^5 cells/ml with increasing concentrations of agonists or antagonists of the invention and under the same conditions, but in the absence of agonists or antagonists. For IL-12 production, the cells are primed overnight with IFN (100 U/ml) in the presence of agonist or antagonist of the invention. LPS (10 ng/ml) is then added. Conditioned media are collected after 24h and kept frozen until use. Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then performed using a commercially available ELISA kit (e.g., R & D Systems (Minneapolis, MN)) and applying the standard protocols provided with the kit.

[01057] Oxidative burst. Purified monocytes are plated in 96-w plate at 2×10^5 cell/well. Increasing concentrations of agonists or antagonists of the invention are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640 + 10%

FCS, glutamine and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is removed from the wells. To the macrophage monolayers, 0.2 ml per well of phenol red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red and 19 U/ml of HRPO) is added, together with the stimulant (200 nM PMA). The plates are incubated at 37°C for 2 hours and the reaction is stopped by adding 20 μ l 1N NaOH per well. The absorbance is read at 610 nm. To calculate the amount of H₂O₂ produced by the macrophages, a standard curve of a H₂O₂ solution of known molarity is performed for each experiment.

[01058] The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 24: Biological Effects of Agonists or Antagonists of the Invention

Astrocyte and Neuronal Assays.

[01059] Agonists or antagonists of the invention, expressed in *Escherichia coli* and purified as described above, can be tested for activity in promoting the survival, neurite outgrowth, or phenotypic differentiation of cortical neuronal cells and for inducing the proliferation of glial fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for the bioassay is based on the prevalent expression of FGF-1 and FGF-2 in cortical structures and on the previously reported enhancement of cortical neuronal survival resulting from FGF-2 treatment. A thymidine incorporation assay, for example, can be used to elucidate an agonist or antagonist of the invention's activity on these cells.

[01060] Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) on cortical or hippocampal neurons *in vitro* have demonstrated increases in both neuron survival and neurite outgrowth (Walicke et al., "Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension." Proc. Natl. Acad. Sci. USA 83:3012-3016. (1986), assay herein incorporated by reference in its

entirety). However, reports from experiments done on PC-12 cells suggest that these two responses are not necessarily synonymous and may depend on not only which FGF is being tested but also on which receptor(s) are expressed on the target cells. Using the primary cortical neuronal culture paradigm, the ability of an agonist or antagonist of the invention to induce neurite outgrowth can be compared to the response achieved with FGF-2 using, for example, a thymidine incorporation assay.

Fibroblast and endothelial cell assays.

[01061] Human lung fibroblasts are obtained from Clonetics (San Diego, CA) and maintained in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from Cell Applications (San Diego, CA). For proliferation assays, the human lung fibroblasts and dermal microvascular endothelial cells can be cultured at 5,000 cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium. After replacing the medium with fresh 0.1% BSA medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, CA) is added to each well to a final concentration of 10%. The cells are incubated for 4 hr. Cell viability is measured by reading in a CytoFluor fluorescence reader. For the PGE₂ assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or agonists or antagonists of the invention with or without IL-1 α for 24 hours. The supernatants are collected and assayed for PGE₂ by EIA kit (Cayman, Ann Arbor, MI). For the IL-6 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or with or without agonists or antagonists of the invention IL-1 α for 24 hours. The supernatants are collected and assayed for IL-6 by ELISA kit (Endogen, Cambridge, MA).

[01062] Human lung fibroblasts are cultured with FGF-2 or agonists or antagonists of the invention for 3 days in basal medium before the addition of Alamar Blue to assess effects on growth of the fibroblasts. FGF-2 should show a stimulation at 10 - 2500 ng/ml which can be used to compare stimulation with agonists or antagonists of the invention.

Parkinson Models.

[01063] The loss of motor function in Parkinson's disease is attributed to a deficiency of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic projection neurons. An animal model for Parkinson's that has been extensively characterized involves the systemic administration of 1-methyl-4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP^+) and released. Subsequently, MPP^+ is actively accumulated in dopaminergic neurons by the high-affinity reuptake transporter for dopamine. MPP^+ is then concentrated in mitochondria by the electrochemical gradient and selectively inhibits nicotinamide adenine disphosphate: ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and eventually generating oxygen radicals.

[01064] It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has trophic activity towards nigral dopaminergic neurons (Ferrari et al., Dev. Biol. 1989). Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam implants in the striatum results in the near complete protection of nigral dopaminergic neurons from the toxicity associated with MPTP exposure (Otto and Unsicker, J. Neuroscience, 1990).

[01065] Based on the data with FGF-2, agonists or antagonists of the invention can be evaluated to determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic neuronal survival *in vitro* and it can also be tested *in vivo* for protection of dopaminergic neurons in the striatum from the damage associated with MPTP treatment. The potential effect of an agonist or antagonist of the invention is first examined *in vitro* in a dopaminergic neuronal cell culture paradigm. The cultures are prepared by dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm² on polyorthinine-laminin coated glass coverslips. The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium containing hormonal supplements (N1). The cultures are fixed with paraformaldehyde after 8 days *in vitro* and are processed for tyrosine hydroxylase, a specific marker for dopaminergic neurons, immunohistochemical staining. Dissociated

cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the factors are also added at that time.

[01066] Since the dopaminergic neurons are isolated from animals at gestation day 14, a developmental time which is past the stage when the dopaminergic precursor cells are proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons would represent an increase in the number of dopaminergic neurons surviving *in vitro*. Therefore, if an agonist or antagonist of the invention acts to prolong the survival of dopaminergic neurons, it would suggest that the agonist or antagonist may be involved in Parkinson's Disease.

[01067] The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 25: The Effect of Agonists or Antagonists of the Invention on the Growth of Vascular Endothelial Cells

[01068] On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at 2×10^4 cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16 units/ml heparin, and 50 units/ml endothelial cell growth supplements (ECGS, Biotechnology, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8 units/ml heparin. An agonist or antagonist of the invention, and positive controls, such as VEGF and basic FGF (bFGF) are added, at varying concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is determined with a Coulter Counter.

[01069] An increase in the number of HUVEC cells indicates that the compound of the invention may proliferate vascular endothelial cells, while a decrease in the number of HUVEC cells indicates that the compound of the invention inhibits vascular endothelial cells.

[01070] The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to

test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 26: Rat Corneal Wound Healing Model

[01071] This animal model shows the effect of an agonist or antagonist of the invention on neovascularization. The experimental protocol includes:

Making a 1-1.5 mm long incision from the center of cornea into the stromal layer.

Inserting a spatula below the lip of the incision facing the outer corner of the eye.

Making a pocket (its base is 1-1.5 mm from the edge of the eye).

Positioning a pellet, containing 50ng- 5ug of an agonist or antagonist of the invention, within the pocket.

Treatment with an agonist or antagonist of the invention can also be applied topically to the corneal wounds in a dosage range of 20mg - 500mg (daily treatment for five days).

[01072] The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 27: Diabetic Mouse and Glucocorticoid-Impaired Wound Healing Models

Diabetic db+/db+ Mouse Model.

[01073] To demonstrate that an agonist or antagonist of the invention accelerates the healing process, the genetically diabetic mouse model of wound healing is used. The full thickness wound healing model in the db+/db+ mouse is a well characterized, clinically relevant and reproducible model of impaired wound healing. Healing of the diabetic wound is dependent on formation of granulation tissue and re-epithelialization rather than contraction (Gartner, M.H. et al., J. Surg. Res. 52:389 (1992); Greenhalgh, D.G. et al., Am. J. Pathol. 136:1235 (1990)).

- [01074] The diabetic animals have many of the characteristic features observed in Type II diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal heterozygous (db+/-m) littermates. Mutant diabetic (db+/db+) mice have a single autosomal recessive mutation on chromosome 4 (db+) (Coleman et al. Proc. Natl. Acad. Sci. USA 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria. Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin levels, and suppressed cell-mediated immunity (Mandel et al., J. Immunol. 120:1375 (1978); Debray-Sachs, M. et al., Clin. Exp. Immunol. 51(1):1-7 (1983); Leiter et al., Am. J. of Pathol. 114:46-55 (1985)). Peripheral neuropathy, myocardial complications, and microvascular lesions, basement membrane thickening and glomerular filtration abnormalities have been described in these animals (Norido, F. et al., Exp. Neurol. 83(2):221-232 (1984); Robertson et al., Diabetes 29(1):60-67 (1980); Giacomelli et al., Lab Invest. 40(4):460-473 (1979); Coleman, D.L., Diabetes 31 (Suppl):1-6 (1982)). These homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to human type II diabetes (Mandel et al., J. Immunol. 120:1375-1377 (1978)).
- [01075] The characteristics observed in these animals suggests that healing in this model may be similar to the healing observed in human diabetes (Greenhalgh, et al., Am. J. of Pathol. 136:1235-1246 (1990)).
- [01076] Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic (db+/-m) heterozygous littermates are used in this study (Jackson Laboratories). The animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study. Animals are individually housed and received food and water ad libitum. All manipulations are performed using aseptic techniques. The experiments are conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.
- [01077] Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D.B., J. Exp. Med. 172:245-251 (1990)). Briefly, on the day of wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and iodine. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-

thickness wound is then created using a Keyes tissue punch. Immediately following wounding, the surrounding skin is gently stretched to eliminate wound expansion. The wounds are left open for the duration of the experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

[01078] Wounds are visually examined and photographed at a fixed distance at the day of surgery and at two day intervals thereafter. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

[01079] An agonist or antagonist of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

[01080] Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology and immunohistochemistry. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

[01081] Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are evaluated: 1) Vehicle placebo control, 2) untreated group, and 3) treated group.

[01082] Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total square area of the wound. Contraction is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm², the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

[01083] Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using a Reichert-Jung microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds are used to assess whether the healing process and the morphologic appearance of the repaired skin is altered by treatment

with an agonist or antagonist of the invention. This assessment included verification of the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, re-epithelialization and epidermal maturity (Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)). A calibrated lens micrometer is used by a blinded observer.

[01084] Tissue sections are also stained immunohistochemically with a polyclonal rabbit anti-human keratin antibody using ABC Elite detection system. Human skin is used as a positive tissue control while non-immune IgG is used as a negative control. Keratinocyte growth is determined by evaluating the extent of reepithelialization of the wound using a calibrated lens micrometer.

[01085] Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon cancer served as a positive tissue control and human brain tissue is used as a negative tissue control. Each specimen included a section with omission of the primary antibody and substitution with non-immune mouse IgG. Ranking of these sections is based on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting slight proliferation to the higher side reflecting intense proliferation.

[01086] Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

Steroid Impaired Rat Model

[01087] The inhibition of wound healing by steroids has been well documented in various *in vitro* and *in vivo* systems (Wahl, Glucocorticoids and Wound healing. In: Anti-Inflammatory Steroid Action: Basic and Clinical Aspects. 280-302 (1989); Wahl *et al.*, *J. Immunol.* 115: 476-481 (1975); Werb *et al.*, *J. Exp. Med.* 147:1684-1694 (1978)). Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular permeability (Ebert *et al.*, *An. Intern. Med.* 37:701-705 (1952)), fibroblast proliferation, and collagen synthesis (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish phenomenon in rats (Beck *et al.*, *Growth*

Factors. 5: 295-304 (1991); Haynes et al., J. Clin. Invest. 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989); Pierce et al., Proc. Natl. Acad. Sci. USA 86: 2229-2233 (1989)).

[01088] To demonstrate that an agonist or antagonist of the invention can accelerate the healing process, the effects of multiple topical applications of the agonist or antagonist on full thickness excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

[01089] Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and are 9 weeks old at the beginning of the study. The healing response of rats is impaired by the systemic administration of methylprednisolone (17mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and received food and water *ad libitum*. All manipulations are performed using aseptic techniques. This study is conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

[01090] The wounding protocol is followed according to section A, above. On the day of wounding, animals are anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue punch. The wounds are left open for the duration of the experiment. Applications of the testing materials are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

[01091] Wounds are visually examined and photographed at a fixed distance at the day of wounding and at the end of treatment. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

[01092] The agonist or antagonist of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

[01093] Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

[01094] Three groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) treated groups.

[01095] Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total area of the wound. Closure is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm², the corresponding size of the dermal punch. Calculations are made using the following formula:

$$\frac{[\text{Open area on day 8}] - [\text{Open area on day 1}]}{[\text{Open area on day 1}]}$$

[01096] Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using an Olympus microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds allows assessment of whether the healing process and the morphologic appearance of the repaired skin is improved by treatment with an agonist or antagonist of the invention. A calibrated lens micrometer is used by a blinded observer to determine the distance of the wound gap.

[01097] Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

[01098] The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 28: Lymphadema Animal Model

- [01099] The purpose of this experimental approach is to create an appropriate and consistent lymphedema model for testing the therapeutic effects of an agonist or antagonist of the invention in lymphangiogenesis and re-establishment of the lymphatic circulatory system in the rat hind limb. Effectiveness is measured by swelling volume of the affected limb, quantification of the amount of lymphatic vasculature, total blood plasma protein, and histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly, the chronic progress of the edema is followed for up to 3-4 weeks.
- [01100] Prior to beginning surgery, blood sample is drawn for protein concentration analysis. Male rats weighing approximately ~350g are dosed with Pentobarbital. Subsequently, the right legs are shaved from knee to hip. The shaved area is swabbed with gauze soaked in 70% EtOH. Blood is drawn for serum total protein testing. Circumference and volumetric measurements are made prior to injecting dye into paws after marking 2 measurement levels (0.5 cm above heel, at mid-pt of dorsal paw). The intradermal dorsum of both right and left paws are injected with 0.05 ml of 1% Evan's Blue. Circumference and volumetric measurements are then made following injection of dye into paws.
- [01101] Using the knee joint as a landmark, a mid-leg inguinal incision is made circumferentially allowing the femoral vessels to be located. Forceps and hemostats are used to dissect and separate the skin flaps. After locating the femoral vessels, the lymphatic vessel that runs along side and underneath the vessel(s) is located. The main lymphatic vessels in this area are then electrically coagulated or suture ligated.
- [01102] Using a microscope, muscles in back of the leg (near the semitendinosus and adductors) are bluntly dissected. The popliteal lymph node is then located. The 2 proximal and 2 distal lymphatic vessels and distal blood supply of the popliteal node are then ligated by suturing. The popliteal lymph node, and any accompanying adipose tissue, is then removed by cutting connective tissues.
- [01103] Care is taken to control any mild bleeding resulting from this procedure. After lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ

Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving a gap of ~0.5 cm around the leg. Skin also may be anchored by suturing to underlying muscle when necessary.

- [01104] To avoid infection, animals are housed individually with mesh (no bedding). Recovering animals are checked daily through the optimal edematous peak, which typically occurred by day 5-7. The plateau edematous peak are then observed. To evaluate the intensity of the lymphedema, the circumference and volumes of 2 designated places on each paw before operation and daily for 7 days are measured. The effect of plasma proteins on lymphedema is determined and whether protein analysis is a useful testing perimeter is also investigated. The weights of both control and edematous limbs are evaluated at 2 places. Analysis is performed in a blind manner.
- [01105] Circumference Measurements: Under brief gas anesthetic to prevent limb movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people and those 2 readings are averaged. Readings are taken from both control and edematous limbs.
- [01106] Volumetric Measurements: On the day of surgery, animals are anesthetized with Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under brief halothane anesthetic (rapid immobilization and quick recovery), and both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then dipped into instrument to each marked level, then measured by Buxco edema software(Chen/Victor). Data is recorded by one person, while the other is dipping the limb to marked area.
- [01107] Blood-plasma protein measurements: Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and Ca^{2+} comparison.
- [01108] Limb Weight Comparison: After drawing blood, the animal is prepared for tissue collection. The limbs are amputated using a quillitine, then both experimental and control legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.
- [01109] Histological Preparations: The transverse muscle located behind the knee (popliteal) area is dissected and arranged in a metal mold, filled with freezeGel, dipped into cold methylbutane, placed into labeled sample bags at - 80EC until sectioning. Upon sectioning, the muscle is observed under fluorescent microscopy for lymphatics..

[01110] The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 29: Suppression of TNF alpha-induced adhesion molecule expression by a Agonist or Antagonist of the Invention

[01111] The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

[01112] Tumor necrosis factor alpha (TNF-a), a potent proinflammatory cytokine, is a stimulator of all three CAMs on endothelial cells and may be involved in a wide variety of inflammatory responses, often resulting in a pathological outcome.

[01113] The potential of an agonist or antagonist of the invention to mediate a suppression of TNF-a induced CAM expression can be examined. A modified ELISA assay which uses ECs as a solid phase absorbent is employed to measure the amount of CAM expression on TNF-a treated ECs when co-stimulated with a member of the FGF family of proteins.

[01114] To perform the experiment, human umbilical vein endothelial cell (HUVEC) cultures are obtained from pooled cord harvests and maintained in growth medium (EGM-2; Clonetics, San Diego, CA) supplemented with 10% FCS and 1% penicillin/streptomycin in a 37 degree C humidified incubator containing 5% CO₂. HUVECs are seeded in 96-

well plates at concentrations of 1×10^4 cells/well in EGM medium at 37 degree C for 18-24 hrs or until confluent. The monolayers are subsequently washed 3 times with a serum-free solution of RPMI-1640 supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, and treated with a given cytokine and/or growth factor(s) for 24 h at 37 degree C. Following incubation, the cells are then evaluated for CAM expression.

[01115] Human Umbilical Vein Endothelial cells (HUVECs) are grown in a standard 96 well plate to confluence. Growth medium is removed from the cells and replaced with 90 μ l of 199 Medium (10% FBS). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10 μ l volumes). Plates are incubated at 37 degree C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100 μ l of 0.1% paraformaldehyde-PBS(with Ca^{++} and Mg^{++}) is added to each well. Plates are held at 4°C for 30 min.

[01116] Fixative is then removed from the wells and wells are washed 1X with PBS(+Ca,Mg)+0.5% BSA and drained. Do not allow the wells to dry. Add 10 μ l of diluted primary antibody to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10 μ g/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA.

[01117] Then add 20 μ l of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution) to each well and incubated at 37°C for 30 min. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA. 1 tablet of p-Nitrophenol Phosphate pNPP is dissolved in 5 ml of glycine buffer (pH 10.4). 100 μ l of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer: $1:5,000 (10^0) > 10^{-0.5} > 10^{-1} > 10^{-1.5}$. 5 μ l of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 μ l of pNPP reagent must then be added to each of the standard wells. The plate must be incubated at 37°C for 4h. A volume of 50 μ l of 3M NaOH is added to all wells. The results are quantified on a plate reader at 405 nm. The background subtraction option is used on blank wells filled with glycine buffer only. The template is set up to indicate the concentration of AP-conjugate in each standard well [5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

[01118] The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 30: Production Of Polypeptide of the Invention For High-Throughput Screening Assays

[01119] The following protocol produces a supernatant containing polypeptide of the present invention to be tested. This supernatant can then be used in the Screening Assays described in Examples 32-41.

[01120] First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

[01121] Plate 293T cells (do not carry cells past P+20) at 2×10^5 cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

[01122] The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 8-10, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well.

As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

[01123] Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37 degree C for 6 hours.

[01124] While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or HGS CHO-5 media (116.6 mg/L of CaCl₂ (anhyd); 0.00130 mg/L CuSO₄·5H₂O; 0.050 mg/L of Fe(NO₃)₃·9H₂O; 0.417 mg/L of FeSO₄·7H₂O; 311.80 mg/L of KCl; 28.64 mg/L of MgCl₂; 48.84 mg/L of MgSO₄; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO₃; 62.50 mg/L of NaH₂PO₄·H₂O; 71.02 mg/L of Na₂HPO₄; .4320 mg/L of ZnSO₄·7H₂O; .002 mg/L of Arachidonic Acid ; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitic Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine-H₂O; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL-H₂O; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-H₂O; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2H₂O; and 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of

Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; 0.680 mg/L of Vitamin B₁₂; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal Acetate. Adjust osmolarity to 327 mOsm) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

[01125] The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37 degree C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

[01126] On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 32-39.

[01127] It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide of the present invention directly (e.g., as a secreted protein) or by polypeptide of the present invention inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

Example 31: Construction of GAS Reporter Construct

[01128] One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-

sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

[01129] GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

[01130] The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

[01131] The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xaa-Trp-Ser (SEQ ID NO:2)).

[01132] Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

[01133] Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using

GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

<u>Ligand</u>	<u>tyk2</u>	<u>JAKs</u>			<u>STATS</u>	<u>GAS(elements) or ISRE</u>
		<u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>		
<u>IFN family</u>						
IFN-a/B	+	+	-	-	1,2,3	ISRE
IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
Il-10	+	?	?	-	1,3	
<u>gp130 family</u>						
IL-6 (Pleiotrohic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
Il-11(Pleiotrohic)	?	+	?	?	1,3	
OnM(Pleiotrohic)	?	+	+	?	1,3	
LIF(Pleiotrohic)	?	+	+	?	1,3	
CNTF(Pleiotrohic)	-/+	+	+	?	1,3	
G-CSF(Pleiotrohic)	?	+	?	?	1,3	
IL-12(Pleiotrohic)	+	-	+	+	1,3	
<u>g-C family</u>						
IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1=IFP >>Ly6)(IgH)
IL-7 (lymphocytes)	-	+	-	+	5	GAS
IL-9 (lymphocytes)	-	+	-	+	5	GAS
IL-13 (lymphocyte)	-	+	?	?	6	GAS
IL-15	?	+	?	+	5	GAS
<u>gp140 family</u>						
IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
IL-5 (myeloid)	-	-	+	-	5	GAS
GM-CSF (myeloid)	-	-	+	-	5	GAS
<u>Growth hormone family</u>						
GH	?	-	+	-	5	GAS(B-
PRL	?	+/-	+	-	1,3,5	
EPO	?	-	+	-	5	
CAS>IRF1=IFP>>Ly6)						
<u>Receptor Tyrosine Kinases</u>						
EGF	?	+	+	-	1,3	GAS (IRF1)
PDGF	?	+	+	-	1,3	
CSF-1	?	+	+	-	1,3	GAS (not IRF1)

[01134] To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 32-33, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., *Immunity* 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

5':GCGCCTCGAGATTTCCTCCGAAATCTAGATTTCCTCCGAAATGATTTCCTCCGAAATGATTTCCTCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO: 3)

[01135] The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTGTCAAAGCCTAGGC:3' (SEQ ID NO: 4)

[01136] PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

5':CTCGAGATTTCCTCCGAAATCTAGATTTCCTCCGAAATGATTTCCTCCGAAATGATTTCCTCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCTAACTCCGCCCATCCCGCCCTAACTCCGCCAGTTCCGCCATTCTCCGCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAGCTT:3' (SEQ ID NO: 5)

[01137] With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be used instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol

acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

[01138] The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

[01139] Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 32-33.

[01140] Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 34 and 35. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

Example 32: High-Throughput Screening Assay for T-cell Activity.

[01141] The following protocol is used to assess T-cell activity by identifying factors, and determining whether supernate containing a polypeptide of the invention proliferates and/or differentiates T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 31. Thus, factors that increase SEAP

activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

[01142] Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

[01143] Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

[01144] During the incubation period, count cell concentration, spin down the required number of cells (10^7 per transfection), and resuspend in OPTI-MEM to a final concentration of 10^7 cells/ml. Then add 1ml of 1×10^7 cells in OPTI-MEM to T25 flask and incubate at 37 degree C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

[01145] The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentamicin, and 1% Pen-Strep. These cells are treated with supernatants containing polypeptide of the present invention or polypeptide of the present invention induced polypeptides as produced by the protocol described in Example 30.

[01146] On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

- [01147] Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).
- [01148] After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.
- [01149] The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at -20 degree C until SEAP assays are performed according to Example 36. The plates containing the remaining treated cells are placed at 4 degree C and serve as a source of material for repeating the assay on a specific well if desired.
- [01150] As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.
- [01151] The above protocol may be used in the generation of both transient, as well as stable, transfected cells, which would be apparent to those of skill in the art.

Example 33: High-Throughput Screening Assay Identifying Myeloid Activity

- [01152] The following protocol is used to assess myeloid activity of polypeptide of the present invention by determining whether polypeptide of the present invention proliferates and/or differentiates myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 31. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

[01153] To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 31, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest 2×10^7 U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

[01154] Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 1 mM MgCl_2 , and 675 uM CaCl_2 . Incubate at 37 degrees C for 45 min.

[01155] Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37 degree C for 36 hr.

[01156] The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

[01157] These cells are tested by harvesting 1×10^8 cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of 5×10^5 cells/ml. Plate 200 ul cells per well in the 96-well plate (or 1×10^5 cells/well).

[01158] Add 50 ul of the supernatant prepared by the protocol described in Example 30. Incubate at 37 degree C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 36.

Example 34: High-Throughput Screening Assay Identifying Neuronal Activity.

[01159] When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes,

EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed by polypeptide of the present invention.

[01160] Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells by polypeptide of the present invention can be assessed.

[01161] The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO: 6)

5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO: 7)

[01162] Using the GAS:SEAP/Neo vector produced in Example 31, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

[01163] To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

[01164] PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is

done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

[01165] Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 30. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

[01166] To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

[01167] The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as 5×10^5 cells/ml.

[01168] Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to 1×10^5 cells/well). Add 50 ul supernatant produced by Example 30, 37 degree C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 36.

Example 35: High-Throughput Screening Assay for T-cell Activity

[01169] NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-KB regulates the expression of genes involved in immune cell activation, control of

apoptosis (NF- KB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

[01170] In non-stimulated conditions, NF- KB is retained in the cytoplasm with I- KB (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and degraded, causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- KB include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.

[01171] Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-KB promoter element are used to screen the supernatants produced in Example 30. Activators or inhibitors of NF-KB would be useful in treating, preventing, and/or diagnosing diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation of NF-KB, such as rheumatoid arthritis.

[01172] To construct a vector containing the NF-KB promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF-KB binding site (GGGGACTTTCCC) (SEQ ID NO: 8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC
TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO: 9)

[01173] The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5':GCGGCAAGCTTTTGGCAAAGCCTAGGC:3' (SEQ ID NO: 4)

[01174] PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene) Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCC
ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCC
ATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGA

CTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCTCGGCCTCTGAGCTAT
TCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGC
TT:3' (SEQ ID NO: 10)

[01175] Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

[01176] In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP cassette is removed from the above NF-KB/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

[01177] Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 32. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 32. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

Example 36: Assay for SEAP Activity

[01178] As a reporter molecule for the assays described in Examples 32-35, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

[01179] Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 ul of 2.5x dilution buffer into Optiplates containing 35 ul of a supernatant. Seal the plates with a plastic sealer and incubate at 65 degree C for 30 min. Separate the Optiplates to avoid uneven heating.

[01180] Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 ml Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the

Table below). Add 50 ul Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on a luminometer, thus one should treat 5 plates at each time and start the second set 10 minutes later.

[01181] Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

[01182] Reaction Buffer Formulation:

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25

36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

Example 37: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability

[01183] Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

[01184] The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

[01185] For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO₂ incubator for 20

hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

[01186] A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37 degrees C in a CO₂ incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

[01187] For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to $2-5 \times 10^6$ cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37 degrees C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1×10^6 cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley Cell Wash with 200 ul, followed by an aspiration step to 100 ul final volume.

[01188] For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

[01189] To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event caused by the a molecule, either polypeptide of the present invention or a molecule induced by polypeptide of the present invention, which has resulted in an increase in the intracellular Ca^{++} concentration.

Example 38: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity

[01190] The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth

factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

[01191] Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

[01192] Because of the wide range of known factors capable of stimulating tyrosine kinase activity, identifying whether polypeptide of the present invention or a molecule induced by polypeptide of the present invention is capable of activating tyrosine kinase signal transduction pathways is of interest. Therefore, the following protocol is designed to identify such molecules capable of activating the tyrosine kinase signal transduction pathways.

[01193] Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4 degree C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

[01194] To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyn plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 30, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na₃VO₄, 2 mM Na₄P₂O₇ and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN)) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4°C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4 degree C at 16,000 x g.

[01195] Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

[01196] Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

[01197] The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg₂⁺ (5mM ATP/50mM MgCl₂), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl₂, 5 mM MnCl₂, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate (1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30 degree C for 2 min. Initiate the reaction by adding 10ul of the control enzyme or the filtered supernatant.

[01198] The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mm EDTA and place the reactions on ice.

[01199] Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37 degree C for 20 min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase (anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37 degree C for one hour. Wash the well as above.

[01200] Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

***Example 39: High-Throughput Screening Assay Identifying
Phosphorylation Activity***

[01201] As a potential alternative and/or complement to the assay of protein tyrosine kinase activity described in Example 38, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

[01202] Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against

Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4 degree C until use.

[01203] A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 30 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

[01204] After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation by polypeptide of the present invention or a molecule induced by polypeptide of the present invention.

Example 40: Assay for the Stimulation of Bone Marrow CD34+ Cell Proliferation

[01205] This assay is based on the ability of human CD34+ to proliferate in the presence of hematopoietic growth factors and evaluates the ability of isolated polypeptides expressed in mammalian cells to stimulate proliferation of CD34+ cells.

[01206] It has been previously shown that most mature precursors will respond to only a single signal. More immature precursors require at least two signals to respond. Therefore, to test the effect of polypeptides on hematopoietic activity of a wide range of progenitor cells, the assay contains a given polypeptide in the presence or absence of other hematopoietic growth factors. Isolated cells are cultured for 5 days in the

presence of Stem Cell Factor (SCF) in combination with tested sample. SCF alone has a very limited effect on the proliferation of bone marrow (BM) cells, acting in such conditions only as a "survival" factor. However, combined with any factor exhibiting stimulatory effect on these cells (e.g., IL-3), SCF will cause a synergistic effect. Therefore, if the tested polypeptide has a stimulatory effect on hematopoietic progenitors, such activity can be easily detected. Since normal BM cells have a low level of cycling cells, it is likely that any inhibitory effect of a given polypeptide, or agonists or antagonists thereof, might not be detected. Accordingly, assays for an inhibitory effect on progenitors is preferably tested in cells that are first subjected to *in vitro* stimulation with SCF+IL+3, and then contacted with the compound that is being evaluated for inhibition of such induced proliferation.

[01207] Briefly, CD34+ cells are isolated using methods known in the art. The cells are thawed and resuspended in medium (QBSF 60 serum-free medium with 1% L-glutamine (500ml) Quality Biological, Inc., Gaithersburg, MD Cat# 160-204-101). After several gentle centrifugation steps at 200 x g, cells are allowed to rest for one hour. The cell count is adjusted to 2.5×10^5 cells/ml. During this time, 100 μ l of sterile water is added to the peripheral wells of a 96-well plate. The cytokines that can be tested with a given polypeptide in this assay is rhSCF (R&D Systems, Minneapolis, MN, Cat# 255-SC) at 50 ng/ml alone and in combination with rhSCF and rhIL-3 (R&D Systems, Minneapolis, MN, Cat# 203-ML) at 30 ng/ml. After one hour, 10 μ l of prepared cytokines, 50 μ l of the supernatants prepared in Example 30 (supernatants at 1:2 dilution = 50 μ l) and 20 μ l of diluted cells are added to the media which is already present in the wells to allow for a final total volume of 100 μ l. The plates are then placed in a 37°C/5% CO₂ incubator for five days.

[01208] Eighteen hours before the assay is harvested, 0.5 μ Ci/well of [3H] Thymidine is added in a 10 μ l volume to each well to determine the proliferation rate. The experiment is terminated by harvesting the cells from each 96-well plate to a filtermat using the Tomtec Harvester 96. After harvesting, the filtermats are dried, trimmed and placed into OmniFilter assemblies consisting of one OmniFilter plate and one OmniFilter Tray. 60 μ l Microscint is added to each well and the plate sealed with TopSeal-A press-on sealing film. A bar code 15 sticker is affixed to the first plate for

counting. The sealed plates are then loaded and the level of radioactivity determined via the Packard Top Count and the printed data collected for analysis. The level of radioactivity reflects the amount of cell proliferation.

[01209] The studies described in this example test the activity of a given polypeptide to stimulate bone marrow CD34+ cell proliferation. One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof. As a nonlimiting example, potential antagonists tested in this assay would be expected to inhibit cell proliferation in the presence of cytokines and/or to increase the inhibition of cell proliferation in the presence of cytokines and a given polypeptide. In contrast, potential agonists tested in this assay would be expected to enhance cell proliferation and/or to decrease the inhibition of cell proliferation in the presence of cytokines and a given polypeptide.

[01210] The ability of a gene to stimulate the proliferation of bone marrow CD34+ cells indicates that polynucleotides and polypeptides corresponding to the gene are useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections above, and elsewhere herein.

***Example 41: Assay for Extracellular Matrix Enhanced Cell Response
(EMECCR)***

[01211] The objective of the Extracellular Matrix Enhanced Cell Response (EMECCR) assay is to identify gene products (e.g., isolated polypeptides) that act on the hematopoietic stem cells in the context of the extracellular matrix (ECM) induced signal.

[01212] Cells respond to the regulatory factors in the context of signal(s) received from the surrounding microenvironment. For example, fibroblasts, and endothelial and epithelial stem cells fail to replicate in the absence of signals from the ECM. Hematopoietic stem cells can undergo self-renewal in the bone marrow, but not in *in vitro* suspension culture. The ability of stem cells to undergo self-renewal *in vitro* is

dependent upon their interaction with the stromal cells and the ECM protein fibronectin (fn). Adhesion of cells to fn is mediated by the $\alpha_5\beta_1$ and $\alpha_4\beta_1$ integrin receptors, which are expressed by human and mouse hematopoietic stem cells. The factor(s) which integrate with the ECM environment and are responsible for stimulating stem cell self-renewal have not yet been identified. Discovery of such factors should be of great interest in gene therapy and bone marrow transplant applications

[01213] Briefly, polystyrene, non tissue culture treated, 96-well plates are coated with fn fragment at a coating concentration of $0.2 \mu\text{g}/\text{cm}^2$. Mouse bone marrow cells are plated (1,000 cells/well) in 0.2 ml of serum-free medium. Cells cultured in the presence of IL-3 (5 ng/ml) + SCF (50 ng/ml) would serve as the positive control, conditions under which little self-renewal but pronounced differentiation of the stem cells is to be expected. Gene products of the invention (e.g., including, but not limited to, polynucleotides and polypeptides of the present invention, and supernatants produced in Example 30), are tested with appropriate negative controls in the presence and absence of SCF(5.0 ng/ml), where test factor supernatants represent 10% of the total assay volume. The plated cells are then allowed to grow by incubating in a low oxygen environment (5% CO_2 , 7% O_2 , and 88% N_2) tissue culture incubator for 7 days. The number of proliferating cells within the wells is then quantitated by measuring thymidine incorporation into cellular DNA. Verification of the positive hits in the assay will require phenotypic characterization of the cells, which can be accomplished by scaling up of the culture system and using appropriate antibody reagents against cell surface antigens and FACScan.

[01214] One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

[01215] If a particular polypeptide of the present invention is found to be a stimulator of hematopoietic progenitors, polynucleotides and polypeptides corresponding to the gene encoding said polypeptide may be useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and "Infectious Disease"

sections above, and elsewhere herein. The gene product may also be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

[01216] Additionally, the polynucleotides and/or polypeptides of the gene of interest and/or agonists and/or antagonists thereof, may also be employed to inhibit the proliferation and differentiation of hematopoietic cells and therefore may be employed to protect bone marrow stem cells from chemotherapeutic agents during chemotherapy. This antiproliferative effect may allow administration of higher doses of chemotherapeutic agents and, therefore, more effective chemotherapeutic treatment.

[01217] Moreover, polynucleotides and polypeptides corresponding to the gene of interest may also be useful for the treatment and diagnosis of hematopoietic related disorders such as, for example, anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

Example 42: Human Dermal Fibroblast and Aortic Smooth Muscle Cell Proliferation

[01218] The polypeptide of interest is added to cultures of normal human dermal fibroblasts (NHDF) and human aortic smooth muscle cells (AoSMC) and two co-assays are performed with each sample. The first assay examines the effect of the polypeptide of interest on the proliferation of normal human dermal fibroblasts (NHDF) or aortic smooth muscle cells (AoSMC). Aberrant growth of fibroblasts or smooth muscle cells is a part of several pathological processes, including fibrosis, and restenosis. The second assay examines IL6 production by both NHDF and SMC. IL6 production is an indication of functional activation. Activated cells will have increased production of a number of cytokines and other factors, which can result in a proinflammatory or immunomodulatory outcome. Assays are run with and without co-TNF α stimulation, in order to check for costimulatory or inhibitory activity.

- [01219] Briefly, on day 1, 96-well black plates are set up with 1000 cells/well (NHDF) or 2000 cells/well (AoSMC) in 100 μ l culture media. NHDF culture media contains: Clonetics FB basal media, 1mg/ml hFGF, 5mg/ml insulin, 50mg/ml gentamycin, 2%FBS, while AoSMC culture media contains Clonetics SM basal media, 0.5 μ g/ml hEGF, 5mg/ml insulin, 1 μ g/ml hFGF, 50mg/ml gentamycin, 50 μ g/ml Amphotericin B, 5%FBS. After incubation at 37°C for at least 4-5 hours culture media is aspirated and replaced with growth arrest media. Growth arrest media for NHDF contains fibroblast basal media, 50mg/ml gentamycin, 2% FBS, while growth arrest media for AoSMC contains SM basal media, 50mg/ml gentamycin, 50 μ g/ml Amphotericin B, 0.4% FBS. Incubate at 37 °C until day 2.
- [01220] On day 2, serial dilutions and templates of the polypeptide of interest are designed such that they always include media controls and known-protein controls. For both stimulation and inhibition experiments, proteins are diluted in growth arrest media. For inhibition experiments, TNFa is added to a final concentration of 2ng/ml (NHDF) or 5ng/ml (AoSMC). Add 1/3 vol media containing controls or polypeptides of the present invention and incubate at 37 degrees C/5% CO₂ until day 5.
- [01221] Transfer 60 μ l from each well to another labeled 96-well plate, cover with a plate-sealer, and store at 4 degrees C until Day 6 (for IL6 ELISA). To the remaining 100 μ l in the cell culture plate, aseptically add Alamar Blue in an amount equal to 10% of the culture volume (10 μ l). Return plates to incubator for 3 to 4 hours. Then measure fluorescence with excitation at 530nm and emission at 590nm using the CytoFluor. This yields the growth stimulation/inhibition data.
- [01222] On day 5, the IL6 ELISA is performed by coating a 96 well plate with 50-100 ul/well of Anti-Human IL6 Monoclonal antibody diluted in PBS, pH 7.4, incubate ON at room temperature.
- [01223] On day 6, empty the plates into the sink and blot on paper towels. Prepare Assay Buffer containing PBS with 4% BSA. Block the plates with 200 μ l/well of Pierce Super Block blocking buffer in PBS for 1-2 hr and then wash plates with wash buffer (PBS, 0.05% Tween-20). Blot plates on paper towels. Then add 50 μ l/well of diluted Anti-Human IL-6 Monoclonal, Biotin-labeled antibody at 0.50 mg/ml. Make

dilutions of IL-6 stock in media (30, 10, 3, 1, 0.3, 0 ng/ml). Add duplicate samples to top row of plate. Cover the plates and incubate for 2 hours at RT on shaker.

[01224] Plates are washed with wash buffer and blotted on paper towels. Dilute EU-labeled Streptavidin 1:1000 in Assay buffer, and add 100 μ l/well. Cover the plate and incubate 1 h at RT. Plates are again washed with wash buffer and blotted on paper towels.

[01225] Add 100 μ l/well of Enhancement Solution. Shake for 5 minutes. Read the plate on the Wallac DELFIA Fluorometer. Readings from triplicate samples in each assay were tabulated and averaged.

[01226] A positive result in this assay suggests AoSMC cell proliferation and that the polypeptide of the present invention may be involved in dermal fibroblast proliferation and/or smooth muscle cell proliferation. A positive result also suggests many potential uses of polypeptides, polynucleotides, agonists and/or antagonists of the polynucleotide/polypeptide of the present invention which gives a positive result. For example, inflammation and immune responses, wound healing, and angiogenesis, as detailed throughout this specification. Particularly, polypeptides of the present invention and polynucleotides of the present invention may be used in wound healing and dermal regeneration, as well as the promotion of vasculogenesis, both of the blood vessels and lymphatics. The growth of vessels can be used in the treatment of, for example, cardiovascular diseases. Additionally, antagonists of polypeptides and polynucleotides of the invention may be useful in treating diseases, disorders, and/or conditions which involve angiogenesis by acting as an anti-vascular agent (e.g., anti-angiogenesis). These diseases, disorders, and/or conditions are known in the art and/or are described herein, such as, for example, malignancies, solid tumors, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular

adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis. Moreover, antagonists of polypeptides and polynucleotides of the invention may be useful in treating anti-hyperproliferative diseases and/or anti-inflammatory known in the art and/or described herein.

[01227] One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

***Example 43: Cellular Adhesion Molecule (CAM) Expression
on Endothelial Cells***

[01228] The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

[01229] Briefly, endothelial cells (e.g., Human Umbilical Vein Endothelial cells (HUVECs)) are grown in a standard 96 well plate to confluence, growth medium is removed from the cells and replaced with 100 µl of 199 Medium (10% fetal bovine serum (FBS)). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10 µl volumes). Plates are then incubated at 37°C for either 5 h

(selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100 μ l of 0.1% paraformaldehyde-PBS(with Ca^{++} and Mg^{++}) is added to each well. Plates are held at 4°C for 30 min. Fixative is removed from the wells and wells are washed 1X with PBS(+Ca,Mg) + 0.5% BSA and drained. 10 μ l of diluted primary antibody is added to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10 μ g/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed three times with PBS(+Ca,Mg) + 0.5% BSA. 20 μ l of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution, referred to herein as the working dilution) are added to each well and incubated at 37°C for 30 min. Wells are washed three times with PBS(+Ca,Mg)+0.5% BSA. Dissolve 1 tablet of p-Nitrophenol Phosphate pNPP per 5 ml of glycine buffer (pH 10.4). 100 μ l of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer: 1:5,000 (10^0) > $10^{-0.5}$ > 10^{-1} > $10^{-1.5}$. 5 μ l of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 μ l of pNPP reagent is then added to each of the standard wells. The plate is incubated at 37°C for 4h. A volume of 50 μ l of 3M NaOH is added to all wells. The plate is read on a plate reader at 405 nm using the background subtraction option on blank wells filled with glycine buffer only. Additionally, the template is set up to indicate the concentration of AP-conjugate in each standard well [5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

Example 44: Alamar Blue Endothelial Cells Proliferation Assay

[01230] This assay may be used to quantitatively determine protein mediated inhibition of bFGF-induced proliferation of Bovine Lymphatic Endothelial Cells (LECs), Bovine Aortic Endothelial Cells (BAECs) or Human Microvascular Uterine Myometrial Cells (UTMECs). This assay incorporates a fluorometric growth indicator based on detection of metabolic activity. A standard Alamar Blue Proliferation Assay

is prepared in EGM-2MV with 10 ng /ml of bFGF added as a source of endothelial cell stimulation. This assay may be used with a variety of endothelial cells with slight changes in growth medium and cell concentration. Dilutions of the protein batches to be tested are diluted as appropriate. Serum-free medium (GIBCO SFM) without bFGF is used as a non-stimulated control and Angiostatin or TSP-1 are included as a known inhibitory controls.

[01231] Briefly, LEC, BAECs or UTMECs are seeded in growth media at a density of 5000 to 2000 cells/well in a 96 well plate and placed at 37degrees C overnight. After the overnight incubation of the cells, the growth media is removed and replaced with GIBCO EC-SFM. The cells are treated with the appropriate dilutions of the protein of interest or control protein sample(s) (prepared in SFM) in triplicate wells with additional bFGF to a concentration of 10 ng/ ml. Once the cells have been treated with the samples, the plate(s) is/are placed back in the 37° C incubator for three days. After three days 10 ml of stock alamar blue (Biosource Cat# DAL1100) is added to each well and the plate(s) is/are placed back in the 37°C incubator for four hours. The plate(s) are then read at 530nm excitation and 590nm emission using the CytoFluor fluorescence reader. Direct output is recorded in relative fluorescence units.

[01232] Alamar blue is an oxidation-reduction indicator that both fluoresces and changes color in response to chemical reduction of growth medium resulting from cell growth. As cells grow in culture, innate metabolic activity results in a chemical reduction of the immediate surrounding environment. Reduction related to growth causes the indicator to change from oxidized (non-fluorescent blue) form to reduced (fluorescent red) form (i.e., stimulated proliferation will produce a stronger signal and inhibited proliferation will produce a weaker signal and the total signal is proportional to the total number of cells as well as their metabolic activity). The background level of activity is observed with the starvation medium alone. This is compared to the output observed from the positive control samples (bFGF in growth medium) and protein dilutions.

Example 45: Detection of Inhibition of a Mixed Lymphocyte Reaction

[01233] This assay can be used to detect and evaluate inhibition of a Mixed Lymphocyte Reaction (MLR) by gene products (e.g., isolated polypeptides). Inhibition of a MLR may be due to a direct effect on cell proliferation and viability, modulation of costimulatory molecules on interacting cells, modulation of adhesiveness between lymphocytes and accessory cells, or modulation of cytokine production by accessory cells. Multiple cells may be targeted by these polypeptides since the peripheral blood mononuclear fraction used in this assay includes T, B and natural killer lymphocytes, as well as monocytes and dendritic cells.

[01234] Polypeptides of interest found to inhibit the MLR may find application in diseases associated with lymphocyte and monocyte activation or proliferation. These include, but are not limited to, diseases such as asthma, arthritis, diabetes, inflammatory skin conditions, psoriasis, eczema, systemic lupus erythematosus, multiple sclerosis, glomerulonephritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, arteriosclerosis, cirrhosis, graft vs. host disease, host vs. graft disease, hepatitis, leukemia and lymphoma.

[01235] Briefly, PBMCs from human donors are purified by density gradient centrifugation using Lymphocyte Separation Medium (LSM[®], density 1.0770 g/ml, Organon Teknika Corporation, West Chester, PA). PBMCs from two donors are adjusted to 2×10^6 cells/ml in RPMI-1640 (Life Technologies, Grand Island, NY) supplemented with 10% FCS and 2 mM glutamine. PBMCs from a third donor is adjusted to 2×10^5 cells/ml. Fifty microliters of PBMCs from each donor is added to wells of a 96-well round bottom microtiter plate. Dilutions of test materials (50 μ l) is added in triplicate to microtiter wells. Test samples (of the protein of interest) are added for final dilution of 1:4; rhuIL-2 (R&D Systems, Minneapolis, MN, catalog number 202-IL) is added to a final concentration of 1 μ g/ml; anti-CD4 mAb (R&D Systems, clone 34930.11, catalog number MAB379) is added to a final concentration of 10 μ g/ml. Cells are cultured for 7-8 days at 37°C in 5% CO₂, and 1 μ C of [³H] thymidine is added to wells for the last 16 hrs of culture. Cells are harvested and thymidine incorporation determined using a Packard TopCount. Data is expressed as the mean and standard deviation of triplicate determinations.

[01236] Samples of the protein of interest are screened in separate experiments and compared to the negative control treatment, anti-CD4 mAb, which inhibits proliferation of lymphocytes and the positive control treatment, IL-2 (either as recombinant material or supernatant), which enhances proliferation of lymphocytes.

[01237] One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

Example 46: Assays for Protease Activity

[01238] The following assay may be used to assess protease activity of the polypeptides of the invention.

[01239] Gelatin and casein zymography are performed essentially as described (Heusen et al., Anal. Biochem., 102:196-202 (1980); Wilson et al., Journal of Urology, 149:653-658 (1993)). Samples are run on 10% polyacryamide/0.1% SDS gels containing 1% gelatin or casein, soaked in 2.5% triton at room temperature for 1 hour, and in 0.1M glycine, pH 8.3 at 37°C 5 to 16 hours. After staining in amido black areas of proteolysis appear as clear areas against the blue-black background. Trypsin (Sigma T8642) is used as a positive control.

[01240] Protease activity is also determined by monitoring the cleavage of n-a-benzoyl-L-arginine ethyl ester (BAEE) (Sigma B-4500. Reactions are set up in (25mM NaPO₄, 1mM EDTA, and 1mM BAEE), pH 7.5. Samples are added and the change in adsorbance at 260nm is monitored on the Beckman DU-6 spectrophotometer in the time-drive mode. Trypsin is used as a positive control.

[01241] Additional assays based upon the release of acid-soluble peptides from casein or hemoglobin measured as adsorbance at 280 nm or colorimetrically using the Folin method are performed as described in Bergmeyer, et al., Methods of Enzymatic Analysis, 5 (1984). Other assays involve the solubilization of chromogenic substrates (Ward, Applied Science, 251-317 (1983).

Example 47: Identifying Serine Protease Substrate Specificity

[01242] Methods known in the art or described herein may be used to determine the substrate specificity of the polypeptides of the present invention having serine protease activity. A preferred method of determining substrate specificity is by the use of positional scanning synthetic combinatorial libraries as described in GB 2 324 529 (incorporated herein in its entirety).

Example 48: Ligand Binding Assays

[01243] The following assay may be used to assess ligand binding activity of the polypeptides of the invention.

[01244] Ligand binding assays provide a direct method for ascertaining receptor pharmacology and are adaptable to a high throughput format. The purified ligand for a polypeptide is radiolabeled to high specific activity (50-2000 Ci/mmol) for binding studies. A determination is then made that the process of radiolabeling does not diminish the activity of the ligand towards its polypeptide. Assay conditions for buffers, ions, pH and other modulators such as nucleotides are optimized to establish a workable signal to noise ratio for both membrane and whole cell polypeptide sources. For these assays, specific polypeptide binding is defined as total associated radioactivity minus the radioactivity measured in the presence of an excess of unlabeled competing ligand. Where possible, more than one competing ligand is used to define residual nonspecific binding.

Example 49: Functional Assay in *Xenopus* Oocytes

[01245] Capped RNA transcripts from linearized plasmid templates encoding the polypeptides of the invention are synthesized *in vitro* with RNA polymerases in accordance with standard procedures. *In vitro* transcripts are suspended in water at a final concentration of 0.2 mg/ml. Ovarian lobes are removed from adult female toads, Stage V defolliculated oocytes are obtained, and RNA transcripts (10 ng/oocyte) are

injected in a 50 nl bolus using a microinjection apparatus. Two electrode voltage clamps are used to measure the currents from individual *Xenopus oocytes* in response polypeptides and polypeptide agonist exposure. Recordings are made in Ca^{2+} free Barth's medium at room temperature. The *Xenopus* system can be used to screen known ligands and tissue/cell extracts for activating ligands.

Example 50: Microphysiometric Assays

[01246] Activation of a wide variety of secondary messenger systems results in extrusion of small amounts of acid from a cell. The acid formed is largely as a result of the increased metabolic activity required to fuel the intracellular signaling process. The pH changes in the media surrounding the cell are very small but are detectable by the CYTOSENSOR microphysiometer (Molecular Devices Ltd., Menlo Park, Calif.). The CYTOSENSOR is thus capable of detecting the activation of polypeptide which is coupled to an energy utilizing intracellular signaling pathway.

Example 51: Extract/Cell Supernatant Screening

[01247] A large number of mammalian receptors exist for which there remains, as yet, no cognate activating ligand (agonist). Thus, active ligands for these receptors may not be included within the ligands banks as identified to date. Accordingly, the polypeptides of the invention can also be functionally screened (using calcium, cAMP, microphysiometer, oocyte electrophysiology, etc., functional screens) against tissue extracts to identify its natural ligands. Extracts that produce positive functional responses can be sequentially subfractionated until an activating ligand is isolated and identified.

Example 52: Calcium and cAMP Functional Assays

[01248] Seven transmembrane receptors which are expressed in HEK 293 cells have been shown to be coupled functionally to activation of PLC and calcium mobilization and/or cAMP stimulation or inhibition. Basal calcium levels in the HEK 293 cells in receptor-transfected or vector control cells were observed to be in the normal, 100 nM to 200 nM, range. HEK 293 cells expressing recombinant receptors are loaded with fura 2 and in a single day >150 selected ligands or tissue/cell extracts are evaluated for agonist induced calcium mobilization. Similarly, HEK 293 cells expressing recombinant receptors are evaluated for the stimulation or inhibition of cAMP production using standard cAMP quantitation assays. Agonists presenting a calcium transient or cAMP fluctuation are tested in vector control cells to determine if the response is unique to the transfected cells expressing receptor.

Example 53: ATP-binding assay

[01249] The following assay may be used to assess ATP-binding activity of polypeptides of the invention.

[01250] ATP-binding activity of the polypeptides of the invention may be detected using the ATP-binding assay described in U.S. Patent 5,858,719, which is herein incorporated by reference in its entirety. Briefly, ATP-binding to polypeptides of the invention is measured via photoaffinity labeling with 8-azido-ATP in a competition assay. Reaction mixtures containing 1 mg/ml of the ABC transport protein of the present invention are incubated with varying concentrations of ATP, or the non-hydrolyzable ATP analog adenylyl-5'-imidodiphosphate for 10 minutes at 4°C. A mixture of 8-azido-ATP (Sigma Chem. Corp., St. Louis, MO.) plus 8-azido-ATP (³²P-ATP) (5 mCi/μmol, ICN, Irvine CA.) is added to a final concentration of 100 μM and 0.5 ml aliquots are placed in the wells of a porcelain spot plate on ice. The plate is irradiated using a short wave 254 nm UV lamp at a distance of 2.5 cm from the plate for two one-minute intervals with a one-minute cooling interval in between. The reaction is stopped by addition of dithiothreitol to a final concentration of 2mM. The incubations are subjected to SDS-PAGE electrophoresis, dried, and autoradiographed. Protein bands corresponding to the particular polypeptides of the invention are

excised, and the radioactivity quantified. A decrease in radioactivity with increasing ATP or adenyly-5'-imidodiphosphate provides a measure of ATP affinity to the polypeptides.

Example 54: Small Molecule Screening

[01251] This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and polypeptide of the invention.

[01252] Thus, the present invention provides methods of screening for drugs or any other agents which affect activities mediated by the polypeptides of the invention. These methods comprise contacting such an agent with a polypeptide of the invention or fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically labeled. Following incubation, free agent is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the invention.

[01253] Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the invention, and is described in great detail in European Patent Application 84/03564, published on September 13, 1984, which is herein incorporated by reference in its entirety. Briefly stated, large numbers of different small molecule test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are

reacted with polypeptides of the invention and washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

[01254] This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

Example 55: Phosphorylation Assay

[01255] In order to assay for phosphorylation activity of the polypeptides of the invention, a phosphorylation assay as described in U.S. Patent 5,958,405 (which is herein incorporated by reference) is utilized. Briefly, phosphorylation activity may be measured by phosphorylation of a protein substrate using gamma-labeled ^{32}P -ATP and quantitation of the incorporated radioactivity using a gamma radioisotope counter. The polypeptides of the invention are incubated with the protein substrate, ^{32}P -ATP, and a kinase buffer. The ^{32}P incorporated into the substrate is then separated from free ^{32}P -ATP by electrophoresis, and the incorporated ^{32}P is counted and compared to a negative control. Radioactivity counts above the negative control are indicative of phosphorylation activity of the polypeptides of the invention.

Example 56: Detection of Phosphorylation Activity (Activation) of the Polypeptides of the Invention in the Presence of Polypeptide Ligands

[01256] Methods known in the art or described herein may be used to determine the phosphorylation activity of the polypeptides of the invention. A preferred method of

determining phosphorylation activity is by the use of the tyrosine phosphorylation assay as described in U.S. Patent 5,817,471 (incorporated herein by reference).

Example 57: Identification Of Signal Transduction Proteins That Interact With Polypeptides Of The Present Invention

[01257] The purified polypeptides of the invention are research tools for the identification, characterization and purification of additional signal transduction pathway proteins or receptor proteins. Briefly, labeled receptor PTK polypeptide is useful as a reagent for the purification of molecules with which it interacts. In one embodiment of affinity purification, receptor PTK polypeptide is covalently coupled to a chromatography column. Cell-free extract derived from putative target cells, such as carcinoma tissues, is passed over the column, and molecules with appropriate affinity bind to the receptor PTK polypeptides, or specific phosphotyrosine-recognition domains thereof. The receptor PTK polypeptide interacting protein-complex is recovered from the column, dissociated, and the recovered molecule subjected to N-terminal protein sequencing. This amino acid sequence is then used to identify the captured molecule or to design degenerate oligonucleotide probes for cloning the relevant gene from an appropriate cDNA library.

Example 58: IL-6 Bioassay

[01258] To test the proliferative effects of the polypeptides of the invention, the IL-6 Bioassay as described by Marz *et al.* is utilized (*Proc. Natl. Acad. Sci., U.S.A.*, 95:3251-56 (1998), which is herein incorporated by reference). Briefly, IL-6 dependent B9 murine cells are washed three times in IL-6 free medium and plated at a concentration of 5,000 cells per well in 50 μ l, and 50 μ l of the IL-6-like polypeptide is added. After 68 hrs. at 37°C, the number of viable cells is measured by adding the tetrazolium salt thiazolyl blue (MTT) and incubating for a further 4 hrs. at 37°C. B9 cells are lysed by SDS and optical density is measured at 570 nm. Controls containing

IL-6 (positive) and no cytokine (negative) are utilized. Enhanced proliferation in the test sample(s) relative to the negative control is indicative of proliferative effects mediated by polypeptides of the invention.

Example 59: Support of Chicken Embryo Neuron Survival

[01259] To test whether sympathetic neuronal cell viability is supported by polypeptides of the invention, the chicken embryo neuronal survival assay of Senaldi *et al* is utilized (*Proc. Natl. Acad. Sci., U.S.A.*, 96:11458-63 (1998), which is herein incorporated by reference). Briefly, motor and sympathetic neurons are isolated from chicken embryos, resuspended in L15 medium (with 10% FCS, glucose, sodium selenite, progesterone, conalbumin, putrescine, and insulin; Life Technologies, Rockville, MD.) and Dulbecco's modified Eagles medium [with 10% FCS, glutamine, penicillin, and 25 mM Hepes buffer (pH 7.2); Life Technologies, Rockville, MD.], respectively, and incubated at 37°C in 5% CO₂ in the presence of different concentrations of the purified IL-6-like polypeptide, as well as a negative control lacking any cytokine. After 3 days, neuron survival is determined by evaluation of cellular morphology, and through the use of the colorimetric assay of Mosmann (Mossmann, T., *J. Immunol. Methods*, 65:55-63 (1983)). Enhanced neuronal cell viability as compared to the controls lacking cytokine is indicative of the ability of the inventive purified IL-6-like polypeptide(s) to enhance the survival of neuronal cells.

Example 60: Assay for Phosphatase Activity

[01260] The following assay may be used to assess serine/threonine phosphatase (PTPase) activity of the polypeptides of the invention.

[01261] In order to assay for serine/threonine phosphatase (PTPase) activity, assays can be utilized which are widely known to those skilled in the art. For example, the serine/threonine phosphatase (PSPase) activity is measured using a PSPase assay kit from New England Biolabs, Inc. Myelin basic protein (MyBP), a substrate for PSPase, is phosphorylated on serine and threonine residues with cAMP-dependent Protein

Kinase in the presence of [^{32}P]ATP. Protein serine/threonine phosphatase activity is then determined by measuring the release of inorganic phosphate from ^{32}P -labeled MyBP.

Example 61: Interaction of Serine/Threonine Phosphatases with other Proteins

[01262] The polypeptides of the invention with serine/threonine phosphatase activity as determined in Example 60 are research tools for the identification, characterization and purification of additional interacting proteins or receptor proteins, or other signal transduction pathway proteins. Briefly, labeled polypeptide(s) of the invention is useful as a reagent for the purification of molecules with which it interacts. In one embodiment of affinity purification, polypeptide of the invention is covalently coupled to a chromatography column. Cell-free extract derived from putative target cells, such as neural or liver cells, is passed over the column, and molecules with appropriate affinity bind to the polypeptides of the invention. The polypeptides of the invention -complex is recovered from the column, dissociated, and the recovered molecule subjected to N-terminal protein sequencing. This amino acid sequence is then used to identify the captured molecule or to design degenerate oligonucleotide probes for cloning the relevant gene from an appropriate cDNA library.

Example 62: Assaying for Heparanase Activity

[01263] In order to assay for heparanase activity of the polypeptides of the invention, the heparanase assay described by Vlodavsky et al is utilized (Vlodavsky, I., et al., Nat. Med., 5:793-802 (1999)). Briefly, cell lysates, conditioned media or intact cells (1×10^6 cells per 35-mm dish) are incubated for 18 hrs at 37°C , pH 6.2-6.6, with ^{35}S -labeled ECM or soluble ECM derived peak I proteoglycans. The incubation medium is centrifuged and the supernatant is analyzed by gel filtration on a Sepharose CL-6B column (0.9 x 30 cm). Fractions are eluted with PBS and their radioactivity is

measured. Degradation fragments of heparan sulfate side chains are eluted from Sepharose 6B at $0.5 < K_{av} < 0.8$ (peak II). Each experiment is done at least three times. Degradation fragments corresponding to "peak II," as described by Vlodavsky et al., is indicative of the activity of the polypeptides of the invention in cleaving heparan sulfate.

Example 63: Immobilization of biomolecules

[01264] This example provides a method for the stabilization of polypeptides of the invention in non-host cell lipid bilayer constructs (see, e.g., Bieri et al., Nature Biotech 17:1105-1108 (1999), hereby incorporated by reference in its entirety herein) which can be adapted for the study of polypeptides of the invention in the various functional assays described above. Briefly, carbohydrate-specific chemistry for biotinylation is used to confine a biotin tag to the extracellular domain of the polypeptides of the invention, thus allowing uniform orientation upon immobilization. A 50uM solution of polypeptides of the invention in washed membranes is incubated with 20 mM NaIO₄ and 1.5 mg/ml (4mM) BACH or 2 mg/ml (7.5mM) biotin-hydrazide for 1 hr at room temperature (reaction volume, 150ul). Then the sample is dialyzed (Pierce Slidealizer Cassett, 10 kDa cutoff; Pierce Chemical Co., Rockford IL) at 4C first for 5 h, exchanging the buffer after each hour, and finally for 12 h against 500 ml buffer R (0.15 M NaCl, 1 mM MgCl₂, 10 mM sodium phosphate, pH7). Just before addition into a cuvette, the sample is diluted 1:5 in buffer ROG50 (Buffer R supplemented with 50 mM octylglucoside).

Example 64: TAQMAN

[01265] Quantitative PCR (QPCR). Total RNA from cells in culture are extracted by Trizol separation as recommended by the supplier (LifeTechnologies). (Total RNA is treated with DNase I (Life Technologies) to remove any contaminating genomic

DNA before reverse transcription.) Total RNA (50 ng) is used in a one-step, 50ul, RT-QPCR, consisting of Taqman Buffer A (Perkin-Elmer; 50 mM KCl/10 mM Tris, pH 8.3), 5.5 mM MgCl₂, 240 μM each dNTP, 0.4 units RNase inhibitor(Promega), 8%glycerol, 0.012% Tween-20, 0.05% gelatin, 0.3uM primers, 0.1uM probe, 0.025units Amplitaq Gold (Perkin-Elmer) and 2.5 units Superscript II reverse transcriptase (Life Technologies). As a control for genomic contamination, parallel reactions are setup without reverse transcriptase. The relative abundance of (unknown) and 18S RNAs are assessed by using the Applied Biosystems Prism 7700 Sequence Detection System (Livak, K. J., Flood, S. J., Marmaro, J., Giusti, W. & Deetz, K. (1995) PCR Methods Appl. 4, 357-362). Reactions are carried out at 48°C for 30 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15s, 60°C for 1 min. Reactions are performed in triplicate.

[01266] Primers (f & r) and FRET probes sets are designed using Primer Express Software (Perkin-Elmer). Probes are labeled at the 5'-end with the reporter dye 6-FAM and on the 3'-end with the quencher dye TAMRA (Biosource International, Camarillo, CA or Perkin-Elmer).

Example 65: Assays for Metalloproteinase Activity

[01267] Metalloproteinases (EC 3.4.24.-) are peptide hydrolases which use metal ions, such as Zn²⁺, as the catalytic mechanism. Metalloproteinase activity of polypeptides of the present invention can be assayed according to the following methods.

Proteolysis of alpha-2-macroglobulin

[01268] To confirm protease activity, purified polypeptides of the invention are mixed with the substrate alpha-2-macroglobulin (0.2 unit/ml; Boehringer Mannheim, Germany) in 1x assay buffer (50 mM HEPES, pH 7.5, 0.2 M NaCl, 10 mM CaCl₂, 25 μM ZnCl₂ and 0.05% Brij-35) and incubated at 37°C for 1-5 days. Trypsin is used as positive control. Negative controls contain only alpha-2-macroglobulin in assay buffer. The samples are collected and boiled in SDS-PAGE sample buffer containing 5% 2-

mercaptoethanol for 5-min, then loaded onto 8% SDS-polyacrylamide gel. After electrophoresis the proteins are visualized by silver staining. Proteolysis is evident by the appearance of lower molecular weight bands as compared to the negative control.

Inhibition of alpha-2-macroglobulin proteolysis by inhibitors of metalloproteinases

[01269] Known metalloproteinase inhibitors (metal chelators (EDTA, EGTA, AND HgCl_2), peptide metalloproteinase inhibitors (TIMP-1 and TIMP-2), and commercial small molecule MMP inhibitors) are used to characterize the proteolytic activity of polypeptides of the invention. The three synthetic MMP inhibitors used are: MMP inhibitor I, [IC_{50} = 1.0 μM against MMP-1 and MMP-8; IC_{50} = 30 μM against MMP-9; IC_{50} = 150 μM against MMP-3]; MMP-3 (stromelysin-1) inhibitor I [IC_{50} = 5 μM against MMP-3], and MMP-3 inhibitor II [K_i = 130 nM against MMP-3]; inhibitors available through Calbiochem, catalog # 444250, 444218, and 444225, respectively). Briefly, different concentrations of the small molecule MMP inhibitors are mixed with purified polypeptides of the invention (50 $\mu\text{g}/\text{ml}$) in 22.9 μl of 1x HEPES buffer (50 mM HEPES, pH 7.5, 0.2 M NaCl, 10 mM CaCl_2 , 25 μM ZnCl_2 and 0.05%Brij-35) and incubated at room temperature (24 °C) for 2-hr, then 7.1 μl of substrate alpha-2-macroglobulin (0.2 unit/ml) is added and incubated at 37°C for 20-hr. The reactions are stopped by adding 4x sample buffer and boiled immediately for 5 minutes. After SDS-PAGE, the protein bands are visualized by silver stain.

Synthetic Fluorogenic Peptide Substrates Cleavage Assay

[01270] The substrate specificity for polypeptides of the invention with demonstrated metalloproteinase activity can be determined using synthetic fluorogenic peptide substrates (purchased from BACHEM Bioscience Inc). Test substrates include, M-1985, M-2225, M-2105, M-2110, and M-2255. The first four are MMP substrates and the last one is a substrate of tumor necrosis factor- α (TNF- α) converting enzyme (TACE). All the substrates are prepared in 1:1 dimethyl sulfoxide (DMSO) and water. The stock solutions are 50-500 μM . Fluorescent assays are performed by using a Perkin Elmer LS 50B luminescence spectrometer equipped with a constant temperature water bath. The excitation λ is 328 nm and the emission λ is 393 nm.

Briefly, the assay is carried out by incubating 176 μ l 1x HEPES buffer (0.2 M NaCl, 10 mM CaCl_2 , 0.05% Brij-35 and 50 mM HEPES, pH 7.5) with 4 μ l of substrate solution (50 μ M) at 25 °C for 15 minutes, and then adding 20 μ l of a purified polypeptide of the invention into the assay cuvet. The final concentration of substrate is 1 μ M. Initial hydrolysis rates are monitored for 30-min.

Example 66: Characterization of the cDNA contained in a deposited plasmid

[01271] The size of the cDNA insert contained in a deposited plasmid may be routinely determined using techniques known in the art, such as PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the cDNA sequence. For example, two primers of 17-30 nucleotides derived from each end of the cDNA (i.e., hybridizable to the absolute 5' nucleotide or the 3' nucleotide end of the sequence of SEQ ID NO:X, respectively) are synthesized and used to amplify the cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 μ l of reaction mixture with 0.5 μ g of the above cDNA template. A convenient reaction mixture is 1.5-5 mM MgCl_2 , 0.01% (w/v) gelatin, 20 μ M each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94 degree C for 1 min; annealing at 55 degree C for 1 min; elongation at 72 degree C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

[01272] Use of the above methodologies and/or other methodologies known in the art generates fragments from the clone corresponding to the approximate fragments described in Table 8, below. Accordingly, Table 8 provides a physical characterization of certain clones encompassed by the invention. The first column provides the unique clone identifier, "Clone ID NO:Z", for cDNA clones of the invention, as described in Table 1A. The second column provides the approximate size of the cDNA insert contained in the corresponding cDNA clone.

TABLE 8

Clone ID NO:Z	cDNA Insert Size:
H7MDD72	700
HEGAZ61	600
HEPBA39	700
HEPCU32	1500
HTECA32	800
HTEHC47	700
HTLIV78	700
HTTCT34	600
HTEPE35	700

[01273] It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

[01274] The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. In addition, the CD-ROM copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties. The specification and Sequence Listing of each of the following U.S. applications are herein incorporated by reference in their entirety: Application No. 60/179,065, filed on 31-Jan-2000; Application No. 60/180,628, filed on 04-Feb-2000; Application No. 60/214,886, filed on 28-Jun-2000; Application No. 60/217,487, filed on 11-Jul-2000; Application No.

60/225,758, filed on 14-Aug-2000; Application No. 60/220,963, filed on 26-Jul-2000; Application No. 60/217,496, filed on 11-Jul-2000; Application No. 60/225,447, filed on 14-Aug-2000; Application No. 60/218,290, filed on 14-Jul-2000; Application No. 60/225,757, filed on 14-Aug-2000; Application No. 60/226,868, filed on 22-Aug-2000; Application No. 60/216,647, filed on 07-Jul-2000; Application No. 60/225,267, filed on 14-Aug-2000; Application No. 60/216,880, filed on 07-Jul-2000; Application No. 60/225,270, filed on 14-Aug-2000; Application No. 60/251,869, filed on 08-Dec-2000; Application No. 60/235,834, filed on 27-Sep-2000; Application No. 60/234,274, filed on 21-Sep-2000; Application No. 60/234,223, filed on 21-Sep-2000; Application No. 60/228,924, filed on 30-Aug-2000; Application No. 60/224,518, filed on 14-Aug-2000; Application No. 60/236,369, filed on 29-Sep-2000; Application No. 60/224,519, filed on 14-Aug-2000; Application No. 60/220,964, filed on 26-Jul-2000; Application No. 60/241,809, filed on 20-Oct-2000; Application No. 60/249,299, filed on 17-Nov-2000; Application No. 60/236,327, filed on 29-Sep-2000; Application No. 60/241,785, filed on 20-Oct-2000; Application No. 60/244,617, filed on 01-Nov-2000; Application No. 60/225,268, filed on 14-Aug-2000; Application No. 60/236,368, filed on 29-Sep-2000; Application No. 60/251,856, filed on 08-Dec-2000; Application No. 60/251,868, filed on 08-Dec-2000; Application No. 60/229,344, filed on 01-Sep-2000; Application No. 60/234,997, filed on 25-Sep-2000; Application No. 60/229,343, filed on 01-Sep-2000; Application No. 60/229,345, filed on 01-Sep-2000; Application No. 60/229,287, filed on 01-Sep-2000; Application No. 60/229,513, filed on 05-Sep-2000; Application No. 60/231,413, filed on 08-Sep-2000; Application No. 60/229,509, filed on 05-Sep-2000; Application No. 60/236,367, filed on 29-Sep-2000; Application No. 60/237,039, filed on 02-Oct-2000; Application No. 60/237,038, filed on 02-Oct-2000; Application No. 60/236,370, filed on 29-Sep-2000; Application No. 60/236,802, filed on 02-Oct-2000; Application No. 60/237,037, filed on 02-Oct-2000; Application No. 60/237,040, filed on 02-Oct-2000; Application No. 60/240,960, filed on 20-Oct-2000; Application No. 60/239,935, filed on 13-Oct-2000; Application No. 60/239,937, filed on 13-Oct-2000; Application No. 60/241,787, filed on 20-Oct-2000; Application No. 60/246,474, filed on 08-Nov-2000; Application No. 60/246,532, filed on 08-Nov-2000; Application No. 60/249,216, filed on 17-Nov-2000; Application No. 60/249,210, filed

on 17-Nov-2000; Application No. 60/226,681, filed on 22-Aug-2000; Application No. 60/225,759, filed on 14-Aug-2000; Application No. 60/225,213, filed on 14-Aug-2000; Application No. 60/227,182, filed on 22-Aug-2000; Application No. 60/225,214, filed on 14-Aug-2000; Application No. 60/235,836, filed on 27-Sep-2000; Application No. 60/230,438, filed on 06-Sep-2000; Application No. 60/215,135, filed on 30-Jun-2000; Application No. 60/225,266, filed on 14-Aug-2000; Application No. 60/249,218, filed on 17-Nov-2000; Application No. 60/249,208, filed on 17-Nov-2000; Application No. 60/249,213, filed on 17-Nov-2000; Application No. 60/249,212, filed on 17-Nov-2000; Application No. 60/249,207, filed on 17-Nov-2000; Application No. 60/249,245, filed on 17-Nov-2000; Application No. 60/249,244, filed on 17-Nov-2000; Application No. 60/249,217, filed on 17-Nov-2000; Application No. 60/249,211, filed on 17-Nov-2000; Application No. 60/249,215, filed on 17-Nov-2000; Application No. 60/249,264, filed on 17-Nov-2000; Application No. 60/249,214, filed on 17-Nov-2000; Application No. 60/249,297, filed on 17-Nov-2000; Application No. 60/232,400, filed on 14-Sep-2000; Application No. 60/231,242, filed on 08-Sep-2000; Application No. 60/232,081, filed on 08-Sep-2000; Application No. 60/232,080, filed on 08-Sep-2000; Application No. 60/231,414, filed on 08-Sep-2000; Application No. 60/231,244, filed on 08-Sep-2000; Application No. 60/233,064, filed on 14-Sep-2000; Application No. 60/233,063, filed on 14-Sep-2000; Application No. 60/232,397, filed on 14-Sep-2000; Application No. 60/232,399, filed on 14-Sep-2000; Application No. 60/232,401, filed on 14-Sep-2000; Application No. 60/241,808, filed on 20-Oct-2000; Application No. 60/241,826, filed on 20-Oct-2000; Application No. 60/241,786, filed on 20-Oct-2000; Application No. 60/241,221, filed on 20-Oct-2000; Application No. 60/246,475, filed on 08-Nov-2000; Application No. 60/231,243, filed on 08-Sep-2000; Application No. 60/233,065, filed on 14-Sep-2000; Application No. 60/232,398, filed on 14-Sep-2000; Application No. 60/234,998, filed on 25-Sep-2000; Application No. 60/246,477, filed on 08-Nov-2000; Application No. 60/246,528, filed on 08-Nov-2000; Application No. 60/246,525, filed on 08-Nov-2000; Application No. 60/246,476, filed on 08-Nov-2000; Application No. 60/246,526, filed on 08-Nov-2000; Application No. PT172, filed on 17-Nov-2000; Application No. 60/246,527, filed on 08-Nov-2000; Application No. 60/246,523, filed

on 08-Nov-2000; Application No. 60/246,524, filed on 08-Nov-2000; Application No. 60/246,478, filed on 08-Nov-2000; Application No. 60/246,609, filed on 08-Nov-2000; Application No. 60/246,613, filed on 08-Nov-2000; Application No. 60/249,300, filed on 17-Nov-2000; Application No. 60/249,265, filed on 17-Nov-2000; Application No. 60/246,610, filed on 08-Nov-2000; Application No. 60/246,611, filed on 08-Nov-2000; Application No. 60/230,437, filed on 06-Sep-2000; Application No. 60/251,990, filed on 08-Dec-2000; Application No. 60/251,988, filed on 05-Dec-2000; Application No. 60/251,030, filed on 05-Dec-2000; Application No. 60/251,479, filed on 06-Dec-2000; Application No. PJ005, filed on 05-Dec-2000; Application No. PJ006, filed on 01-Dec-2000; Application No. 60/251,989, filed on 08-Dec-2000; Application No. 60/250,391, filed on 01-Dec-2000; and Application No. 60/254,097, filed on 11-Dec-2000.

[01275] Moreover, the microfiche copy and the corresponding computer readable form of the Sequence Listing of U.S. Application Serial No. 60/179,065, and the hard copy of and the corresponding computer readable form of the Sequence Listing of U.S. Application Serial No. 60/180,628 are also incorporated herein by reference in their entireties.

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: center;">May 20, 1997</div>			Accession Number <div style="text-align: center;">209059</div>		
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)					
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)					
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
For receiving Office use only		For International Bureau use only			
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution <i>(including postal code and country)</i> 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: center;">May 20, 1997</div>			Accession Number <div style="text-align: center;">209060</div>		
C. ADDITIONAL INDICATIONS <i>(leave blank if not applicable)</i> This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE <i>(if the indications are not for all designated States)</i> Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>					
E. SEPARATE FURNISHING OF INDICATIONS <i>(leave blank if not applicable)</i>					
The indications listed below will be submitted to the international Bureau later <i>(specify the general nature of the indications e.g., "Accession Number of Deposit")</i>					
For receiving Office use only		For International Bureau use only			
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: center;">May 20, 1997</div>			Accession Number <div style="text-align: center;">209061</div>		
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)					
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)					
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
	For receiving Office use only			For International Bureau use only	
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: center;">May 20, 1997</div>			Accession Number <div style="text-align: center;">209062</div>		
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)					
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)					
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
	For receiving Office use only			For International Bureau use only	
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: center;">May 20, 1997</div>			Accession Number <div style="text-align: center;">209063</div>		
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)					
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). Continued on additional sheets					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)					
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
	For receiving Office use only			For International Bureau use only	
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)			
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.			
B. IDENTIFICATION OF DEPOSIT		Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution: American Type Culture Collection			
Address of depositary institution <i>(including postal code and country)</i> 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit <div style="text-align: center;">May 20, 1997</div>		Accession Number <div style="text-align: center;">209064</div>	
C. ADDITIONAL INDICATIONS <i>(leave blank if not applicable)</i>		This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE <i>(if the indications are not for all designated States)</i> Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>			
E. SEPARATE FURNISHING OF INDICATIONS <i>(leave blank if not applicable)</i>			
The indications listed below will be submitted to the international Bureau later <i>(specify the general nature of the indications e.g., "Accession Number of Deposit")</i>			
For receiving Office use only		For International Bureau use only	
<input type="checkbox"/> This sheet was received with the international application		<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer		Authorized officer	

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: center;">May 20, 1997</div>			Accession Number <div style="text-align: center;">209065</div>		
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)					
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). Continued on additional sheets					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)					
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
For receiving Office use only		For International Bureau use only			
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: center;">May 20, 1997</div>			Accession Number <div style="text-align: center;">209066</div>		
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)					
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)					
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
For receiving Office use only		For International Bureau use only			
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: right;">May 20, 1997</div>			Accession Number <div style="text-align: right;">209067</div>		
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)					
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)					
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
For receiving Office use only		For International Bureau use only			
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: center;">May 20, 1997</div>			Accession Number <div style="text-align: center;">209068</div>		
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). Continued on additional sheets					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)					
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
For receiving Office use only		For International Bureau use only			
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: right;">May 20, 1997</div>			Accession Number <div style="text-align: right;">209069</div>		
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)					
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)					
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
For receiving Office use only		For International Bureau use only			
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: center;">January 12, 1998</div>			Accession Number <div style="text-align: center;">209579</div>		
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). Continued on additional sheets					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
For receiving Office use only		For International Bureau use only			
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: center;">January 12, 1998</div>			Accession Number <div style="text-align: center;">209578</div>		
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)					
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). Continued on additional sheets					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)					
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
For receiving Office use only		For International Bureau use only			
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: center;">July 16, 1998</div>			Accession Number <div style="text-align: center;">203067</div>		
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (If the indications are not for all designated States)					
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). Continued on additional sheets					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)					
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
For receiving Office use only		For International Bureau use only			
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: center;">July 16, 1998</div>			Accession Number <div style="text-align: center;">203068</div>		
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)					
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)					
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
For receiving Office use only		For International Bureau use only			
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution <i>(including postal code and country)</i> 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: center;">February 1, 1999</div>			Accession Number <div style="text-align: center;">203609</div>		
C. ADDITIONAL INDICATIONS <i>(leave blank if not applicable)</i> This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE <i>(if the indications are not for all designated States)</i> Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). Continued on additional sheets					
E. SEPARATE FURNISHING OF INDICATIONS <i>(leave blank if not applicable)</i>					
The indications listed below will be submitted to the international Bureau later <i>(specify the general nature of the indications e.g., "Accession Number of Deposit")</i>					
For receiving Office use only		For International Bureau use only			
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: center;">February 1, 1999</div>			Accession Number <div style="text-align: center;">203610</div>		
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)					
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). Continued on additional sheets					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)					
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
For receiving Office use only		For International Bureau use only			
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: center;">November 17, 1998</div>			Accession Number <div style="text-align: center;">203485</div>		
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)					
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). Continued on additional sheets					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)					
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
For receiving Office use only		For International Bureau use only			
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: center;">June 18, 1999</div>			Accession Number <div style="text-align: center;">PTA-252</div>		
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)					
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). Continued on additional sheets					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)					
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
For receiving Office use only		For International Bureau use only			
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: center;">June 18, 1999</div>			Accession Number <div style="text-align: center;">PTA-253</div>		
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)					
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). Continued on additional sheets					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)					
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
For receiving Office use only		For International Bureau use only			
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: center;">December 22, 1999</div>			Accession Number <div style="text-align: center;">PTA-1081</div>		
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)					
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). Continued on additional sheets					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)					
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
For receiving Office use only		For International Bureau use only			
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at page 11, paragraph [025].					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: center;">October 5, 2000</div>			Accession Number <div style="text-align: center;">PTA-2574</div>		
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)					
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). Continued on additional sheets					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)					
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
For receiving Office use only		For International Bureau use only			
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at page 11, paragraph [025].					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution <i>(including postal code and country)</i> 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: center;">October 5, 2000</div>			Accession Number <div style="text-align: center;">PTA-2575</div>		
C. ADDITIONAL INDICATIONS <i>(leave blank if not applicable)</i> This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE <i>(if the indications are not for all designated States)</i> Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>					
E. SEPARATE FURNISHING OF INDICATIONS <i>(leave blank if not applicable)</i>					
The indications listed below will be submitted to the international Bureau later <i>(specify the general nature of the indications e.g., "Accession Number of Deposit")</i>					
For receiving Office use only		For International Bureau use only			
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at page 11, paragraph [025].					
B. IDENTIFICATION OF DEPOSIT <div style="float: right;">Further deposits are identified on an additional sheet <input checked="" type="checkbox"/></div>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: center;">January 5, 2001</div>			Accession Number <div style="text-align: center;">(HGS reference code TS-1)</div>		
C. ADDITIONAL INDICATIONS (leave blank if not applicable) <div style="text-align: right;">This information is continued on an additional sheet <input type="checkbox"/></div>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)					
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)					
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
For receiving Office use only		For International Bureau use only			
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at page 11, paragraph [025].					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: center;">January 5, 2001</div>			Accession Number <div style="text-align: center;">(HGS reference code TS-2)</div>		
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)					
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)					
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
For receiving Office use only		For International Bureau use only			
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at page 11, paragraph [025].					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution <i>(including postal code and country)</i> 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: center;">January 5, 2001</div>			Accession Number <div style="text-align: center;">(HGS reference code AC-1)</div>		
C. ADDITIONAL INDICATIONS <i>(leave blank if not applicable)</i> This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE <i>(if the indications are not for all designated States)</i>					
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). Continued on additional sheets					
E. SEPARATE FURNISHING OF INDICATIONS <i>(leave blank if not applicable)</i>					
The indications listed below will be submitted to the international Bureau later <i>(specify the general nature of the indications e.g., "Accession Number of Deposit")</i>					
For receiving Office use only		For International Bureau use only			
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)					
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description at page 11, paragraph [025].					
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit <div style="text-align: center;">January 5, 2001</div>			Accession Number <div style="text-align: center;">(HGS reference code AC-2)</div>		
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>					
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)					
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>					
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)					
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
For receiving Office use only		For International Bureau use only			
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

ATCC Deposit No.: 209059, 209060, 209061, 209062, 209063, 209064, 209065, 209066, 209067, 209068, 209069, 209579, 209578, 203067, 203068, 203609, 203610, 203485, PTA-252, PTA-253, PTA-1081, PTA-2574, PTA-2575, TS-1, TS-2, AC-1, AC-2

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

ATCC Deposit No.: 209059, 209060, 209061, 209062, 209063, 209064, 209065, 209066, 209067, 209068, 209069, 209579, 209578, 203067, 203068, 203609, 203610, 203485, PTA-252, PTA-253, PTA-1081, PTA-2574, PTA-2575, TS-1, TS-2, AC-1, AC-2

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

What Is Claimed Is:

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
 - (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence contained in Clone ID NO:Z, which is hybridizable to SEQ ID NO:X;
 - (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence contained in cDNA Clone ID NO:Z, which is hybridizable to SEQ ID NO:X;
 - (c) a polynucleotide encoding a polypeptide fragment of a polypeptide encoded by SEQ ID NO:X or a polypeptide fragment encoded by the cDNA sequence contained in cDNA Clone ID NO:Z, which is hybridizable to SEQ ID NO:X;
 - (d) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence contained in cDNA Clone ID NO:Z, which is hybridizable to SEQ ID NO:X;
 - (e) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence contained in cDNA Clone ID NO:Z, which is hybridizable to SEQ ID NO:X;
 - (f) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence contained in cDNA Clone ID NO:Z, which is hybridizable to SEQ ID NO:X, having biological activity;
 - (g) a polynucleotide which is a variant of SEQ ID NO:X;
 - (h) a polynucleotide which is an allelic variant of SEQ ID NO:X;
 - (i) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
 - (j) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.
2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a protein.

3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence contained in cDNA Clone ID NO:Z, which is hybridizable to SEQ ID NO:X.

4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence contained in cDNA Clone ID NO:Z, which is hybridizable to SEQ ID NO:X.

5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

9. A recombinant host cell produced by the method of claim 8.

10. The recombinant host cell of claim 9 comprising vector sequences.

11. An isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence selected from the group consisting of:

(a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence contained in cDNA Clone ID NO:Z;

(b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence contained in cDNA Clone ID NO:Z, having biological activity;

- (c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence contained in cDNA Clone ID NO:Z;
- (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence contained in cDNA Clone ID NO:Z;
- (e) a full length protein of SEQ ID NO:Y or the encoded sequence contained in cDNA Clone ID NO:Z;
- (f) a variant of SEQ ID NO:Y;
- (g) an allelic variant of SEQ ID NO:Y; or
- (h) a species homologue of the SEQ ID NO:Y.

12. The isolated polypeptide of claim 11, wherein the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:

- (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and
- (b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

- (a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

(a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

22. A method of identifying an activity in a biological assay, wherein the method comprises:

(a) expressing SEQ ID NO:X in a cell;

(b) isolating the supernatant;

(c) detecting an activity in a biological assay; and

identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

24. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11.